FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Nunes, RP
   Hirai, FE
   Barroso, LF
   Badaro, E
   Novais, E
   Rodrigues, EB
   Maia, M
   Magalhaes, O
   Farah, ME
AF Nunes, Renata Portella
   Hirai, Flavio Eduardo
   Barroso, Leticia Fernandes
   Badaro, Emmerson
   Novais, Eduardo
   Rodrigues, Eduardo Buchele
   Maia, Mauricio
   Magalhaes, Octaviano, Jr.
   Farah, Michel Eid
TI Effectiveness of monthly and fortnightly anti-VEGF treatments for
   age-related macular degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration; Retina; Bevacizumab; Ranibizumab; Clinical trial
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB AVASTIN;
   RANIBIZUMAB; TRIAL
AB Purpose: To study the efficacy and safety of treatments with ranibizumab and bevacizumab for exudative age-related macular degeneration. Methods: A parallel randomized clinical trial was conducted to compare the efficacy and safety of three regimens (bevacizumab every month, bevacizumab every 2 weeks, and ranibizumab every month), followed by as-needed retreatments, for 1 year, in previously untreated individuals with age-related macular degeneration. The primary outcome was change in visual acuity and in central macular thickness after 1 year of follow-up. Subjects were assigned randomly to one of the three groups in a 1:1:1 ratio, and investigators and examiners were blinded to the randomization results. Results: We included 15 patients in each group. After 1 year of follow-up, we found statistically significant improvements in visual acuity and central macular thickness reduction in all groups. However, we found no statistically significant differences between the three groups. Conclusions: The bi-weekly follow-up was effective and we found no significant differences in efficacy or safety between the treatments with ranibizumab and bevacizumab.
C1 [Nunes, Renata Portella; Hirai, Flavio Eduardo; Barroso, Leticia Fernandes; Badaro, Emmerson; Novais, Eduardo; Rodrigues, Eduardo Buchele; Maia, Mauricio; Magalhaes, Octaviano, Jr.; Farah, Michel Eid] Univ Fed Sao Paulo, Escola Paulista Med, Dept Ophthalmol & Visual Sci, Sao Paulo, SP, Brazil.
RP Nunes, RP (corresponding author), Inst Olhos Florianopolis, Rua Presidente Coutinho 579-501, BR-88015231 Florianopolis, SC, Brazil.
EM reportellanunes@gmail.com
RI Hirai, Flavio E/G-3583-2012; Farah, Michel Eid E/F-3285-2012; Maia,
   Mauricio/I-5892-2015
OI Hirai, Flavio E/0000-0002-5757-4254; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [558868/2009-6]; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2010/15451-0]; CAPESCAPES [BEX1059/12-2]
FX This study was supported by CNPq (558868/2009-6), FAPESP (2010/15451-0),
   and CAPES (BEX1059/12-2).
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V365, P2237
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin DF, 2014, JAMA-J AM MED ASSOC, V311, P1491
   Martin DF, 2015, JAMA OPHTHALMOL, V133, P363
   Martin DF, 2012, J COMP EFFECT RES, V1, P485
   Martin DF, 2015, JAMA OPHTHALMOL, V133, P726
   Martin DF, 2011, NEW ENGL J MED, V364, P1966
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2007, NEW ENGL J MED, V356, P749
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROSENFELD PJ, 2005, OPHTHAL SURG LAS IM, V36, P270
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1409
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Valmaggia C, 2009, KLIN MONATSBL AUGENH, V226, P294, DOI 10.1055/s-0028-1109298
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   2010, EYE LOND, V24, P1708, DOI DOI 10.1038/EYE.2010.147
   2013, OPHTHALMOLOGY, V120, P1719
   2011, EYE LOND, V25, P820, DOI DOI 10.1038/EYE.2011.16
   2012, OPHTHALMOLOGY, V119, P1508
   2011, CLIN EXP OPHTHALMOL, V39, P718, DOI DOI 10.1111/J.1442-9071.2011.02703.X
   2005, OPHTHALMIC SURG LASE, V36, P331
   2013, LANCET, V382, P1258, DOI DOI 10.1016/S0140-6736(13)61501-9
NR 38
TC 1
Z9 1
U1 0
U2 1
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAY-JUN
PY 2019
VL 82
IS 3
BP 225
EP 232
DI 10.5935/0004-2749.20190043
PG 8
WC Ophthalmology
SC Ophthalmology
GA HY4UO
UT WOS:000468123600011
PM 30810619
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Vianello, S
   de Souza, GS
   Maia, M
   Belfort, R
   Dias, JRD
AF Vianello, Silvana
   de Souza, Glaucio Silva
   Maia, Mauricio
   Belfort, Rubens, Jr.
   de Oliveira Dias, Joao Rafael
TI Ocular Findings in Yellow Fever Infection
SO JAMA OPHTHALMOLOGY
LA English
DT Article
AB IMPORTANCE Yellow fever virus (YFV) is a reemerging, potentially lethal arboviral disease that has been occurring recently in Africa and South America. Poor levels of immunization have facilitated the viral spread in southeastern Brazil, leading to an unprecedented outbreak that started in late 2016. Although human cases have been linked to sylvatic mosquitoes, the concern is that YFV may spread to urban centers infested with Aedes aegypti and Aedes albopictus mosquitoes and start a true urban cycle.
   OBJECTiVE To describe the ocular findings in patients with acute YFV infection.
   DESIGN, SETTING, PARTICIPANTS Two adults with an acute YFV infection in southeastern Brazil underwent an ophthalmologic and ocular ultrasonographic examination in early 2018.
   MAIN OUTCOMES AND MEASURES Ocular findings in patients with acute YFV infection.
   RESULTS Both patients presented with increased choroidal thickness bilaterally seen on ocular ultrasonography. A man in his late 50s who had not been vaccinated previously also presented with bilateral, midperipheral, 360 degrees choroidal detachment and yellowish subretinal lesions. After clinical deterioration and liver transplant, the man died. A woman in her early 30s who had been vaccinated previously for YFV presented with increased retinal venous congestion bilaterally. She was discharged with mild conjunctival chemosis and icterus.
   CONCLUSIONS AND RELEVANCE These reports describe different patterns of ocular findings associated with YFV acute infection. However, the exact mechanism involved in the retinal and choroidal findings remains unclear.
C1 [Vianello, Silvana] Ctr Estudo Visao, Juiz De Fora, MG, Brazil.
   [Vianello, Silvana; Maia, Mauricio; Belfort, Rubens, Jr.; de Oliveira Dias, Joao Rafael] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, Paulista Med Sch, Pedro Toledo St 781,Second Floor, BR-04023062 Sao Paulo, SP, Brazil.
   [de Souza, Glaucio Silva] Santa Casa Misericordia Juiz de Fora, Dept Gen Surg, Juiz De Fora, MG, Brazil.
   [Maia, Mauricio] Brazilian Inst Fight Blindness Assis & Presidente, Sao Paulo, Brazil.
RP Dias, JRD (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, Paulista Med Sch, Pedro Toledo St 781,Second Floor, BR-04023062 Sao Paulo, SP, Brazil.
EM dias_joaor@yahoo.com.br
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR Barrett ADT, 2016, NEW ENGL J MED, V375, P301, DOI 10.1056/NEJMp1606997
   Biancardi AL, 2019, OCUL IMMUNOL INFLAMM, V27, P521, DOI 10.1080/09273948.2018.1510529
   Brazilian Ministry of Health, FEBR AM MIN SAUD AT
   Cardoso JD, 2010, EMERG INFECT DIS, V16, P1918, DOI 10.3201/eid1612.100608
   Evandro Chagas Institute, I EV CHAG DET VIR FE
   Klitting R, 2018, GENES-BASEL, V9, DOI 10.3390/genes9060291
   Lucey D, 2016, JAMA-J AM MED ASSOC, V315, P2661, DOI 10.1001/jama.2016.6606
   Maggio E, 2016, GRAEF ARCH CLIN EXP, V254, P545, DOI 10.1007/s00417-015-3176-y
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Norrby E, 2007, J EXP MED, V204, P2779, DOI 10.1084/jem.20072290
   Pan American Health Organization, 2017, BRAZ WORKS CONTR YEL
   Possas C, 2018, MEM I OSWALDO CRUZ, V113, P1, DOI 10.1590/0074-02760170361
   Romano AP, 2014, PLOS NEGLECT TROP D, V8, pe2740, DOI [10.1371/journal.pntd.OOO2740, DOI 10.1371/J0URNAL.PNTD.0002]
   ROSS RW, 1950, ANN TROP MED PARASIT, V44, P351, DOI 10.1080/00034983.1950.11685460
NR 14
TC 1
Z9 1
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2019
VL 137
IS 3
BP 300
EP 304
DI 10.1001/jamaophthalmol.2018.6408
PG 5
WC Ophthalmology
SC Ophthalmology
GA HO8LL
UT WOS:000461203100019
PM 30629101
OA Green Published
DA 2020-12-15
ER

PT J
AU Palacios, RM
   de Carvalho, ACM
   Maia, M
   Caiado, RR
   Camilo, DAG
   Farah, ME
AF Palacios, Renato Menezes
   Maia de Carvalho, Andre Correa
   Maia, Mauricio
   Caiado, Rafael Ramos
   Gardim Camilo, Danilo Aedo
   Farah, Michel Eid
TI An experimental and clinical study on the initial experiences of
   Brazilian vitreoretinal surgeons with heads-up surgery
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Heads-up; 3D; Microscopy; Digital integration; Ergonomics; Technical
   feasibility; Resolution; Field of view; Educational value; Depth
   perception; Color filters
ID OPTICAL COHERENCE TOMOGRAPHY
AB PurposeTo evaluate the initial experiences of several vitreoretinal surgeons in Brazil, both experienced and beginners, with a three-dimensional (3D) system, and to report the advantages and disadvantages of this technology. We also report surgical manipulations performed using the heads-up method in porcine eyes. For full-thickness idiopathic macular holes (MHs), we analyzed the times required for pars plana vitrectomy (PPV) and internal limiting membrane (ILM) rhexis by using traditional microscopy and 3D system, and to evaluate anatomical surgical results.MethodsDuring experimental vitreoretinal surgery on porcine eyes, two retinal surgeons applied the heads-up method. In clinical surgery, 14 retinal surgeons performed almost all types of vitreoretinal surgeries in association with facectomy, Ahmed glaucoma valve implant, or minimally invasive glaucoma surgery using an iStent (R). The Ngenuity (R) 3D Visualization System was digitally integrated with intraoperative optical coherence tomography, the Verion Image-Guided System, and an endoscope (with a modified GoPro (R) camera). To compare the 3D system with traditional microscopy, ergonomics, educational value, image sharpness, depth perception, field of view, advantages and disadvantages, and technical feasibility were assessed using a questionnaire. One year later, the 14 surgeons answered the same questionnaire again, in order to assess whether they became more comfortable or not with 3D. For treating MHs, four surgeons (surgeon 1, fellows 1, 2, 3) performed the total of 40 surgeries. Each one performed 10 surgeries (5 with traditional microscopy and 5 with 3D visualization). The completion time for PPV and ILM rhexis were determined by using both methods.ResultsIn porcine eyes, disabling the color channels allowed better visualization of the ILM, either with Brilliant Blue G (BBG), indocyanine green chorioangiography (ICG), or acai dye; transillumination through the sclera was also better without a color channel, but visualization of the peripheral vitreous was better with a blue channel. Regarding clinical experience, the questionnaire responses showed that the respondents generally favored the heads-up method compared with traditional microscopy (p<0.05); however, despite a slightly higher average score, the 3D system was not statistically significantly preferred in terms of technical feasibility (p=0.1814). Answering again the same questionnaire 1year later, the 14 surgeons felt more comfortable with 3D (p<0.05). The type of surgery benefitting most from the 3D system was peeling of the ILM or epiretinal membrane (p<0.001), and that receiving the least benefit was anterior segment surgery (p<0.001). In addition, surgeons did not report benefits of color channels, preferring to disable it (p<0.001). Comparisons between the average time for full PPV and ILM rhexis by using the two methods were non-significant, neither in each individual case of 3D surgery for each surgeon. Surgeon 1 had always been faster than his fellows. Thirty-six (90%) full-thickness MHs were successfully closed with one surgery.ConclusionsThe 3D system was preferred to traditional microscopy. The 3D system was especially helpful for certain specific types of surgeries and served as an educational tool, having reduced illumination and allowing precise focusing. Concerning MH surgery, heads-up method was similar to traditional microscopy regarding length of time and anatomical surgical results.
   As a digital platform, it will be amenable to constant upgrades and may ultimately become the new standard for ophthalmic surgery.
C1 [Palacios, Renato Menezes; Maia de Carvalho, Andre Correa; Maia, Mauricio; Caiado, Rafael Ramos; Gardim Camilo, Danilo Aedo; Farah, Michel Eid] Univ Fed Sao Paulo, Dept Ophthalmol Retina, Sao Paulo, Brazil.
RP Palacios, RM (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol Retina, Sao Paulo, Brazil.
EM renatompalacios@hotmail.com
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091
CR Adam MK, 2017, RETINA-J RET VIT DIS, V37, P1746, DOI 10.1097/IAE.0000000000001420
   Allen CH, 2015, RETINA TODAY, V10, P76
   Berrocal M, 2016, INSERT RETINA TODAY, V3, P4
   Charles S, 2017, RETINA TODAY, V12, P48
   Charles S, 2018, EUROTIMES, V23, P4
   Charles S, 2008, RETINA-J RET VIT DIS, V28, P1, DOI 10.1097/IAE.0b013e318156e015
   Chow DR, 2017, EURETINA M SEP 8 BAR
   Coppola Michele, 2017, Int J Retina Vitreous, V3, P46, DOI 10.1186/s40942-017-0099-2
   De Smet MD, 2005, RETINA-J RET VIT DIS, V25, P976, DOI 10.1097/00006982-200512000-00004
   Desai URT, 2004, AM SOC RET SPEC ANN
   Dhimitri KC, 2005, AM J OPHTHALMOL, V139, P179, DOI 10.1016/j.ajo.2004.06.091
   Eckardt C, 2014, FRANKF RET M MARCH 1
   Eckardt C, 2016, RETINA-J RET VIT DIS, V36, P137, DOI 10.1097/IAE.0000000000000689
   Ehlers JP, 2014, RETINA-J RET VIT DIS, V34, P1341, DOI 10.1097/IAE.0000000000000123
   Ehlers JP, 2014, CURR OPIN OPHTHALMOL, V25, P221, DOI 10.1097/ICU.0000000000000044
   Elhofi AH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001618
   Kitchens JW, 2011, ARCH OPHTHALMOL-CHIC, V129, P949, DOI 10.1001/archophthalmol.2011.165
   Marra Kyle V, 2013, J Ophthalmic Vis Res, V8, P282
   Olsen TW, 2011, AM J OPHTHALMOL, V151, P287, DOI 10.1016/j.ajo.2010.08.026
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Saheb H, 2014, BRIT J OPHTHALMOL, V98, P19, DOI 10.1136/bjophthalmol-2012-302951
   Saheb H, 2012, CURR OPIN OPHTHALMOL, V23, P96, DOI 10.1097/ICU.0b013e32834ff1e7
   Skinner Cassandra C, 2018, Retin Cases Brief Rep, V12, P257, DOI 10.1097/ICB.0000000000000486
   Stem MS, 2017, RETINA TODAY, V12, P44
   Webers VSC, 2017, J CATARACT REFR SURG, V43, P781, DOI 10.1016/j.jcrs.2017.03.041
   Weinstock RJ, 2011, CATARACT REFRACT SUR, V66, P8
   Wykoff CC, 2010, OPHTHAL SURG LAS IM, V41, P7, DOI 10.3928/15428877-20091230-01
   Yoshihiro Y, 2016, RETINA TODAY, V11, P54
NR 28
TC 4
Z9 6
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2019
VL 257
IS 3
BP 473
EP 483
DI 10.1007/s00417-019-04246-w
PG 11
WC Ophthalmology
SC Ophthalmology
GA HM9FR
UT WOS:000459788800005
PM 30645695
DA 2020-12-15
ER

PT J
AU Caiado, RR
   Peris, C
   Rodrigues, EB
   Farah, ME
   Maia, A
   Magalhaes, O
   Novais, E
   Lima, AS
   Maia, M
AF Caiado, Rafael R.
   Peris, Cristiane
   Rodrigues, Eduardo B.
   Farah, Michel Eid
   Maia, Andre
   Magalhaes, Octaviano
   Novais, Eduardo
   Lima-Filho, Acacio Souza
   Maia, Mauricio
TI A new dye based on anthocyanins from the acai fruit (Euterpe oleracea)
   for chromovitrectomy in humans: clinical trial results
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Acai dye; Internal limiting membrane; Pars plana vitrectomy; Posterior
   hyaloid; Toxicity
ID INTERNAL LIMITING MEMBRANE; INDOCYANINE GREEN INJECTION; BRILLIANT BLUE
   G; MACULAR HOLE; VITAL DYES; ISCEV STANDARD; REMOVAL; SURGERY; LUTEIN
AB PurposeTo test the applicability of the acai dye at a 25% concentration for identifying the posterior hyaloids and internal limiting membranes (ILMs) during pars plana vitrectomy (PPV) in human eyes with macular holes (MHs).MethodsThis study included 25 patients with chronic idiopathic MHs. The exclusion criteria included glaucoma, previous significant ocular conditions, and previous ocular surgeries except uncomplicated cataract. Ten surgeons performed 23-gauge four-port PPV, phacoemulsification, posterior hyaloid detachment, ILM peeling guided by dye staining, and perfluoropropane injection. The patients remained prone for 5days postoperatively. The patients were evaluated postoperatively after 1, 30, and 180days. The surgeons completed a questionnaire regarding the dye's staining abilities.ResultsThe posterior hyaloids and ILMs stained purple in all eyes. The final best-corrected visual acuity improved significantly (p<0.001) from preoperatively (1.370.29) to 180days postoperatively (1.05 +/- 0.43). The MHs closed in 76% of eyes.Conclusion The acai dye at a 25% concentration identified posterior hyaloids and ILMs during PPVs in humans. Dye toxicity was unlikely.
C1 [Caiado, Rafael R.; Peris, Cristiane; Rodrigues, Eduardo B.; Farah, Michel Eid; Maia, Andre; Magalhaes, Octaviano; Novais, Eduardo; Lima-Filho, Acacio Souza; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, 781 Pedro Toledo St,2nd Floor, BR-04039032 Sao Paulo, Brazil.
   [Lima-Filho, Acacio Souza] Ophthalmos Pharmaceut Ind, Sao Paulo, Brazil.
   [Maia, Mauricio] Assis Presidente Prudente, Brazilian Inst Fight Blindness, Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, 781 Pedro Toledo St,2nd Floor, BR-04039032 Sao Paulo, Brazil.; Maia, M (corresponding author), Assis Presidente Prudente, Brazilian Inst Fight Blindness, Sao Paulo, Brazil.
EM maiamauricio@terra.com.br
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015; Maia,
   Mauricio/Z-1042-2019; de Souza Lima Filho, Acacio Alves/C-7189-2012
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091; Alves
   de Souza Lima Filho, Acacio/0000-0003-1802-9592
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brasilia,
   BrazilNational Council for Scientific and Technological Development
   (CNPq) [CNPq- 402718/2013-5]; Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo, Sao Paulo, BrazilFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [FAPESP - 2014/07686-8]
FX This study was funded by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq- 402718/2013-5), Brasilia, Brazil,
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP -
   2014/07686-8), YSao Paulo, Brazil.
CR Badaro E, 2014, GRAEF ARCH CLIN EXP, V252, P1071, DOI 10.1007/s00417-013-2539-5
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Caiado RR, 2017, CURR EYE RES, V42, P1185, DOI 10.1080/02713683.2017.1297995
   Caiado Rafael Ramos, 2014, Rev. bras.oftalmol., V73, P363, DOI 10.5935/0034-7280.20140076
   Chatziralli IP, 2018, RETINA-J RET VIT DIS, V38, P870, DOI 10.1097/IAE.0000000000001959
   Chen J, 2013, RETINA-J RET VIT DIS, V33, P89, DOI 10.1097/IAE.0b013e3182618a6d
   De Rosso VV, 2008, FREE RADICAL RES, V42, P885, DOI 10.1080/10715760802506349
   Del Pozo-Insfran D, 2004, J AGR FOOD CHEM, V52, P1539, DOI 10.1021/jf035189n
   Eckardt C, 1997, OPHTHALMOLOGE, V94, P545, DOI 10.1007/s003470050156
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Gandorfer A, 2001, AM J OPHTHALMOL, V132, P431, DOI 10.1016/S0002-9394(01)01087-X
   Henrich PB, 2011, INVEST OPHTH VIS SCI, V52, P4345, DOI 10.1167/iovs.10-6972
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Kahkonen MP, 2003, J AGR FOOD CHEM, V51, P628, DOI 10.1021/jf025551i
   Lim JW, 2010, CLIN OPHTHALMOL, V4, P689
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Maia M, 2009, BRIT J OPHTHALMOL, V93, P1687, DOI 10.1136/bjo.2008.151597
   Maia M, 2014, RETINA-J RET VIT DIS, V34, P262, DOI 10.1097/IAE.0b013e3182a0b7f4
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   Mester V, 2000, AM J OPHTHALMOL, V129, P769, DOI 10.1016/S0002-9394(00)00358-5
   Peris CS, 2013, J OCUL PHARMACOL TH, V29, P746, DOI 10.1089/jop.2013.0003
   Peris CS, 2018, J OPHTHALMOL, P1
   Rahman MM, 2006, FREE RADICAL RES, V40, P993, DOI 10.1080/10715760600815322
   Rizzo S, 2017, OSLI RETINA, V48, P62, DOI 10.3928/23258160-20161219-09
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Rodrigues EB, 2010, AM J OPHTHALMOL, V149, P265, DOI 10.1016/j.ajo.2009.08.020
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Schauss AG, 2006, J AGR FOOD CHEM, V54, P8604, DOI 10.1021/jf0609779
   Tari SR, 2007, RETINA-J RET VIT DIS, V27, P567, DOI 10.1097/IAE.0b013e31802ea53d
   Yuen D, 2009, AM J OPHTHALMOL, V147, P251, DOI 10.1016/j.ajo.2008.08.031
NR 33
TC 1
Z9 1
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2019
VL 257
IS 3
BP 517
EP 528
DI 10.1007/s00417-018-04204-y
PG 12
WC Ophthalmology
SC Ophthalmology
GA HM9FR
UT WOS:000459788800009
PM 30607553
DA 2020-12-15
ER

PT J
AU Passos, RM
   Belucio-Neto, J
   Xavier, CO
   Novais, EA
   Maia, M
   Farah, ME
AF Passos, Renato M.
   Belucio-Neto, Jose
   Xavier, Camilla O.
   Novais, Eduardo A.
   Maia, Mauricio
   Farah, Michel Eid
TI Comparison of 577-nm Multispot and Standard Single-Spot Photocoagulation
   for Diabetic Retinopathy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Diabetic retinopathy; Multispot laser; Panretinal photocoagulation;
   Standard photocoagulation
ID PANRETINAL PHOTOCOAGULATION; YELLOW LASER; INTRAVITREOUS RANIBIZUMAB;
   RETINAL PHOTOCOAGULATION; SCANNING LASER; PAIN RESPONSE; WAVELENGTH;
   EFFICACY; 532-NM
AB Objective: To compare two different laser strategies of panretinal photocoagulation for diabetic retinopathy. Methods: Single-center, randomized study including 41 eyes treated with 577-nm multispot laser with a 20-ms pulse duration (group 1) or a 532-nm single-spot laser with a 100-ms pulse duration (group 2). The outcomes included best-corrected visual acuity (BCVA) and imaging changes at baseline, 6 and 12 months, laser parameters, and results of subjective pain analysis. Results: At 12 months, the treatments did not differ significantly in BCVA, central retinal thicknesses (CRTs), improved macular edema, vitreomacular interface changes, patient-reported pain scores, or angiographic responses. Group 1 had significantly fewer treatment sessions but used more laser spots (p < 0.001). Conclusion: The multispot laser required fewer applications with more spots delivered to compensate for lower fluency, showing similar patient tolerance to single-spot laser. Both groups maintained the initial visual acuities and CRTs; about 50% of cases had vitreomacular interface changes and improved macular edema, with similar angiographic improvements after 12 months. (C) 2018 S. Karger AG, Basel
C1 [Passos, Renato M.; Belucio-Neto, Jose; Xavier, Camilla O.; Novais, Eduardo A.; Maia, Mauricio; Farah, Michel Eid] Fed Univ Sao Paulo UNIFESP, Dept Ophthalmol, Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, 781 Pedro Toledo St,2nd Floor, BR-04039032 Sao Paulo, Brazil.
EM maiamauricio@terra.com.br
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091
CR Al-Hussainy S, 2008, EYE, V22, P96, DOI 10.1038/sj.eye.6703026
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x
   Blumenkranz MS, 2006, RETINA-J RET VIT DIS, V26, P370, DOI 10.1097/00006982-200603000-00024
   CHAPPELOW A, AM J OPHTHALMOL, DOI DOI 10.1097/IAE.0B013E3181C70127
   Chappelow AV, 2012, AM J OPHTHALMOL, V153, P137, DOI 10.1016/j.ajo.2011.05.035
   DIABETIC R, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI DOI 10.1016/S0140-6736(17)31193-5
   EARLY T, GROUP
   FRIBERG TR, 1995, LASER SURG MED, V16, P380, DOI 10.1002/lsm.1900160409
   Gonzalez-Saldivar G, 2017, OSLI RETINA, V48, P902, DOI 10.3928/23258160-20171030-05
   Gross JG, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI 10.1001/jama.2015.15217
   Hirano T, 2014, OPHTHALMIC RES, V51, P204, DOI 10.1159/000357918
   Hutton DW, 2017, JAMA OPHTHALMOL, V135, P576, DOI 10.1001/jamaophthalmol.2017.0837
   Kim JY, 2015, GRAEF ARCH CLIN EXP, V253, P2129, DOI 10.1007/s00417-015-2965-7
   KWON Y, KOREAN J OPHTHALMOL, P577, DOI DOI 10.3928/15428877-20120426-05
   Lin J, 2016, OPHTHALMOLOGY, V123, P1912, DOI 10.1016/j.ophtha.2016.05.037
   MAINSTER MA, 1986, OPHTHALMOLOGY, V93, P952
   MAINSTER MA, OPHTHALMOLOGY
   Melzack R, 2013, WALL MELZACKS TXB PA, P301
   Mirshahi A, 2013, GRAEF ARCH CLIN EXP, V251, P1103, DOI 10.1007/s00417-012-2167-5
   Muqit MMK, 2010, ARCH OPHTHALMOL-CHIC, V128, P525, DOI 10.1001/archophthalmol.2010.60
   Muqit MMK, 2010, ARCH OPHTHALMOL-CHIC, V128, P448, DOI 10.1001/archophthalmol.2010.36
   MUQIT MM, PASCAL, P20, DOI DOI 10.3928/23258160-20171030-05
   Nagpal M, 2010, RETINA-J RET VIT DIS, V30, P452, DOI 10.1097/IAE.0b013e3181c70127
   Palanker D, 2011, RETINA-J RET VIT DIS, V31, P1664, DOI 10.1097/IAE.0b013e3182115679
   S Sadda, 2013, RETINA, P969
   Sebag J, 2017, GRAEF ARCH CLIN EXP, V255, P421, DOI 10.1007/s00417-016-3527-3
   Sivaprasad S, 2017, LANCET, V389, P2193, DOI 10.1016/S0140-6736(17)31193-5
   Sramek CK, 2012, OPHTHAL SURG LAS IM, V43, P341, DOI 10.3928/15428877-20120426-05
   VOGEL M, 1989, GRAEF ARCH CLIN EXP, V227, P277, DOI 10.1007/BF02172762
   Yadav NK, 2015, EYE, V29, P258, DOI 10.1038/eye.2014.315
NR 31
TC 0
Z9 0
U1 1
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2019
VL 241
IS 4
BP 202
EP 210
DI 10.1159/000493280
PG 9
WC Ophthalmology
SC Ophthalmology
GA HV7CG
UT WOS:000466138500005
PM 30332674
DA 2020-12-15
ER

PT J
AU Mello, P
   Andrade, G
   Maia, A
   Maia, M
   Neto, LB
   Neto, AM
   Brasil, OM
   Minelli, E
   Dalloul, C
   Iglicki, M
AF Mello Filho, Paulo
   Andrade, Gabriel
   Maia, Andre
   Maia, Mauricio
   Biccas Neto, Laurentino
   Muralha Neto, Acacio
   Brasil, Oswaldo Moura
   Minelli, Eduardo
   Dalloul, Claudio
   Iglicki, Matias
TI Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex)
   in Patients with Diabetic Macular Edema: A Real-World Experience
SO OPHTHALMOLOGICA
LA English
DT Article
DE Anti-vascular endothelial growth factor; Diabetic macular edema; Drug
   delivery; Vascular endothelial growth factor
ID TRIAMCINOLONE ACETONIDE; BEVACIZUMAB; RETINOPATHY; RANIBIZUMAB;
   AFLIBERCEPT; PREVALENCE; EFFICACY; 3-YEAR
AB Introduction: There are few real-life studies on the intravitreal 0.7-mg dexamethasone implant for the treatment of diabetic macular edema (DME) conducted in Latin America. We aimed to assess the effectiveness and safety of this implant in clinical practice. Methods: Twenty-seven centers from Brazil and one from Argentina provided information on patients with DME treated with Ozurdex. The efficacy outcome variables were best-corrected visual acuity (BCVA) in Snellen and central retinal thickness (CRT). Safety was assessed by the elevation in intraocular pressure (IOP), occurrence of cataracts, and adverse events. Results: A total of 329 eyes (both treated cases and naive eyes) from 282 patients underwent treatment. The time since diagnosis of DME ranged from 1 to 156 months. The median BCVA was 0.7 log-MAR/50 letters at baseline and 0.3 logMAR/70 letters after treatment (both p < 0.001). Median CRT values decreased from 425 mu m at baseline to 270 mu m after treatment (p < 0.001). Increases in IOP of at least 10 mm Hg were observed in 7.4% of eyes, and 4% of eyes had cataract evolution. No cases of endophthalmitis were reported. Conclusion: These real-life results suggest that the intravitreal dexamethasone implant is effective and safe for eyes with DME. (C) 2018 S. Karger AG, Basel.
C1 [Mello Filho, Paulo; Andrade, Gabriel; Maia, Andre; Maia, Mauricio; Biccas Neto, Laurentino] Univ Fed Sao Paulo, Dept Ophthalmol, Botucatu St 821, BR-04024000 Sao Paulo, SP, Brazil.
   [Muralha Neto, Acacio] Univ Estado Rio De Janeiro, Dept Ophthalmol, Rio De Janeiro, Brazil.
   [Brasil, Oswaldo Moura] Brazilian Inst Ophthalmol, Rio De Janeiro, Brazil.
   [Minelli, Eduardo] HCLOE Clin, Sao Paulo, Brazil.
   [Dalloul, Claudio] DOlhos Hosp, Sao Jose Do Rio Preto, Brazil.
   [Iglicki, Matias] Retina Private Off, Buenos Aires, DF, Argentina.
RP Andrade, G (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Botucatu St 821, BR-04024000 Sao Paulo, SP, Brazil.
EM drgabrielandrade@gmail.com
RI Neto, Laurentino Biccas/AAP-3887-2020; Andrade, Gabriel/AAV-3155-2020;
   Maia, Mauricio/I-5892-2015
OI Neto, Laurentino Biccas/0000-0003-2047-3983; Andrade,
   Gabriel/0000-0002-5881-8126; Maia, Mauricio/0000-0002-7034-8091
CR Alshahrani ST, 2016, RETINA-J RET VIT DIS, V36, P131, DOI 10.1097/IAE.0000000000000616
   Bertoldi AD, 2013, GLOBALIZATION HEALTH, V9, DOI 10.1186/1744-8603-9-62
   Bonnin S, 2015, EUR J OPHTHALMOL, V25, P448, DOI 10.5301/ejo.5000581
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Ciulla TA, 2014, EXPERT OPIN PHARMACO, V15, P953, DOI 10.1517/14656566.2014.896899
   Isaac DLC, 2012, ACTA OPHTHALMOL, V90, P56, DOI 10.1111/j.1755-3768.2009.01817.x
   Dugel PU, 2015, CLIN OPHTHALMOL, V9, P1321, DOI 10.2147/OPTH.S79948
   Medeiros MD, 2014, OPHTHALMOLOGICA, V231, P141, DOI 10.1159/000356413
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   Gillies MC, 2010, CLIN EXP OPHTHALMOL, V38, P605, DOI 10.1111/j.1442-9071.2010.02341.x
   Gillies MC, 1995, OPHTHALMOLOGY, V102, P7
   Gonzalez VH, 2016, AM J OPHTHALMOL, V172, P72, DOI 10.1016/j.ajo.2016.09.012
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Grover D, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005656.pub2
   Guigou S, 2015, OPHTHALMOLOGICA, V233, P169, DOI 10.1159/000381356
   Gupta PC, 2016, EYE, V30, P1650, DOI 10.1038/eye.2016.191
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   International Diabetes Federation, 2015, IDF DIABETES ATLAS
   Jimenez-Gomez B, 2015, Arch Soc Esp Oftalmol, V90, P421, DOI 10.1016/j.oftal.2015.01.006
   Escobar-Barranco JJ, 2015, OPHTHALMOLOGICA, V233, P176, DOI 10.1159/000371770
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Klafke A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2123-5
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P7
   Lam WC, 2015, CLIN OPHTHALMOL, V9, P1255, DOI 10.2147/OPTH.S80500
   Paccola L, 2008, BRIT J OPHTHALMOL, V92, P76, DOI 10.1136/bjo.2007.129122
   Querques G, 2016, J OCUL PHARMACOL TH, V32, P383, DOI 10.1089/jop.2016.0010
   Romero-Aroca P, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/2156273
   Ross EL, 2016, JAMA OPHTHALMOL, V134, P888, DOI 10.1001/jamaophthalmol.2016.1669
   Virgili G, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub4
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
NR 31
TC 20
Z9 21
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2019
VL 241
IS 1
BP 9
EP 16
DI 10.1159/000492132
PG 8
WC Ophthalmology
SC Ophthalmology
GA HF4CE
UT WOS:000454180000002
PM 30408801
DA 2020-12-15
ER

PT J
AU Liu, LN
   Xu, KY
   Li, J
   Maia, M
   Mathieu, M
   Elliott, R
   Yang, JH
   Nijem, I
   Kaur, S
AF Liu, Luna
   Xu, Keyang
   Li, Jenny
   Maia, Mauricio
   Mathieu, Mary
   Elliott, Rebecca
   Yang, Jihong
   Nijem, Ihsan
   Kaur, Surinder
TI Optimizing hybrid LC-MS/MS binding conditions is critical: impact of
   biotransformation on quantification of trastuzumab
SO BIOANALYSIS
LA English
DT Article
DE biotherapeutics; biotransformation; capture format; deamidation;
   enrichment; HER2 ECD; hybrid ligand binding LC-MS; isomerization;
   quantification; trastuzumab
ID IN-VIVO; IMMUNOAFFINITY-ENRICHMENT; BIOANALYTICAL STRATEGIES;
   THERAPEUTIC ANTIBODIES; MONOCLONAL-ANTIBODIES; ASSAY; MS; QUANTITATION;
   PROTEINS; PEPTIDE
AB Background: Hybrid ligand-binding (LB) LC-MS/MS protein quantitative assays involve a LB step for analyte enrichment that has less stringent requirements than the conventional LB assays. Results: Herceptin (TM)(trastuzumab) binding to HER2 extracellular domain was evaluated using on-bead and off-bead capture formats. The two formats yielded significantly different trastuzumab concentrations in human and monkey serum pharmacokinetic samples. Biotransformations, including deamidation of asparagine and isomerization of aspartic acid near the complementarity-determining regions of trastuzumab, had a profound impact on the LB step for analyte enrichment and trastuzumab quantification. Conclusion: Quantitative measurements were profoundly impacted by LB conditions in a hybrid LB LC-MS/MS protein assay due to biotransformations. Therefore, similar to conventional LB assays, binding conditions should be carefully evaluated during assay development.
C1 [Liu, Luna; Xu, Keyang; Li, Jenny; Maia, Mauricio; Elliott, Rebecca; Yang, Jihong; Nijem, Ihsan; Kaur, Surinder] Genentech Inc, Dept BioAnalyt Sci, 1 DNA Way, San Francisco, CA 94080 USA.
   [Mathieu, Mary] Genentech Inc, Dept Antibody Engn, 1 DNA Way, San Francisco, CA 94080 USA.
RP Xu, KY (corresponding author), Genentech Inc, Dept BioAnalyt Sci, 1 DNA Way, San Francisco, CA 94080 USA.
EM xu.keyang@gene.com
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR Becker J, 2012, BIOANALYSIS, V4, P281, DOI [10.4155/BIO.11.319, 10.4155/bio.11.319]
   Bults P, 2016, ANAL CHEM, V88, P1871, DOI 10.1021/acs.analchem.5b04276
   Chappell DL, 2014, BIOANALYSIS, V6, P1843, DOI 10.4155/bio.14.145
   Ewles M, 2016, BIOANALYSIS, V8, P2565, DOI 10.4155/bio-2016-0197
   Furlong MT, 2012, BIOMED CHROMATOGR, V26, P1024, DOI 10.1002/bmc.2759
   Harris RJ, 2001, J CHROMATOGR B, V752, P233, DOI 10.1016/S0378-4347(00)00548-X
   Heinrich J, 2015, BIOANALYSIS, V7, P3057, DOI 10.4155/bio.15.218
   Huang LH, 2005, ANAL CHEM, V77, P1432, DOI 10.1021/ac0494174
   Iwamoto N, 2017, J PHARMACEUT BIOMED, V145, P33, DOI 10.1016/j.jpba.2017.06.032
   Jenkins R, 2015, AAPS J, V17, P1, DOI 10.1208/s12248-014-9685-5
   Jiang H, 2013, ANAL CHEM, V85, P9859, DOI 10.1021/ac402420v
   Jordan G, 2017, BIOANALYSIS, V9, P1705, DOI 10.4155/bio-2017-0158
   Kaur S, 2014, US, Patent No. 8679767
   Kaur S, 2016, BIOANALYSIS, V8, P1565, DOI 10.4155/bio-2016-0117
   Kaur S, 2013, BIOANALYSIS, V5, P201, DOI [10.4155/bio.12.299, 10.4155/BIO.12.299]
   Lassman ME, 2014, CLIN CHEM, V60, P1217, DOI 10.1373/clinchem.2014.222455
   Li HY, 2012, ANAL CHEM, V84, P1267, DOI 10.1021/ac202792n
   Mehl JT, 2016, BIOANALYSIS, V8, P1611, DOI 10.4155/bio-2016-0035
   Peng K, 2014, MABS-AUSTIN, V6, P1500, DOI 10.4161/mabs.36208
   Staack RF, 2011, BIOANALYSIS, V3, P523, DOI 10.4155/BIO.11.16
   Xu KY, 2014, BIOANALYSIS, V6, P1781, DOI 10.4155/bio.14.142
   Xu KY, 2013, BIOANALYSIS, V5, P1057, DOI [10.4155/BIO.13.66, 10.4155/bio.13.66]
   Xu K, 2011, ANAL BIOCHEM, V412, P56, DOI 10.1016/j.ab.2011.01.004
   Zhang YJ, 2014, BIOANALYSIS, V6, P1827, DOI 10.4155/bio.14.128
NR 24
TC 8
Z9 8
U1 1
U2 6
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1757-6180
EI 1757-6199
J9 BIOANALYSIS
JI Bioanalysis
PD NOV
PY 2018
VL 10
IS 22
BP 1819
EP 1831
DI 10.4155/bio-2018-0196
PG 13
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA HD3FH
UT WOS:000452399800004
PM 30325201
DA 2020-12-15
ER

PT J
AU Roizenblatt, M
   Naranjit, N
   Maia, M
   Gehlbach, PL
AF Roizenblatt, Marina
   Naranjit, Nara
   Maia, Mauricio
   Gehlbach, Peter L.
TI The Question of a Role for Statins in Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; atherosclerotic disease; cholesterol;
   retina; statins
ID REDUCTASE INHIBITORS STATINS; UNESTERIFIED CHOLESTEROL;
   APOLIPOPROTEIN-B; NATIONAL-HEALTH; BASAL DEPOSITS; GROWTH-FACTOR;
   PROGRESSION; METABOLISM; RETINA; RISK
AB Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in patients over the age of 65 years in industrialized countries. Epidemiologic studies suggest that high dietary fat intake is a risk factor for the development and progression of both vascular and retinal disease. These, and other associations, suggest a hypothesis linking elevated cholesterol and AMD progression. It follows, therefore, that cholesterol-lowering medications, such as statins, may influence the onset and progression of AMD. However, the findings have been inconclusive as to whether statins play a role in AMD. Due to the significant public health implications of a potential inhibitory effect of statins on the onset and progression of AMD, it is important to continually evaluate emerging findings germane to this question.
C1 [Roizenblatt, Marina; Naranjit, Nara; Gehlbach, Peter L.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Roizenblatt, Marina; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, BR-04023062 Sao Paulo, Brazil.
   [Roizenblatt, Marina; Maia, Mauricio] Univ Fed Sao Paulo, Paulista Med Sch, Dept Ophthalmol, Vis Inst,IPEPO, BR-04038032 Sao Paulo, Brazil.
RP Gehlbach, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
EM maroizenb@gmail.com; nnaranj2@jhmi.edu; maiamauricio@terra.com.br;
   pgelbach@jhmi.edu
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
FU Lemann Foundation; Instituto de Visao-IPEPO, Sao Paulo, Brazil; Research
   to Prevent Blindness, New York, New York, USAResearch to Prevent
   Blindness (RPB); J. Willard and Alice S. Marriott Foundation; Gale
   Trust; CNPq-National Council for Scientific and Technological
   Development, Brasilia, DF, BrazilNational Council for Scientific and
   Technological Development (CNPq)
FX (M.R.) Lemann Foundation, Instituto de Visao-IPEPO, Sao Paulo, Brazil.
   (P.G.) Research to Prevent Blindness, New York, New York, USA, and gifts
   by the J. Willard and Alice S. Marriott Foundation, the Gale Trust, Herb
   Ehlers, Bill Wilbur, Rajandre Shaw, Don Feiner and Maggie Feiner, Helen
   Nassif and Ronald Stiff. (M.M.) CNPq-National Council for Scientific and
   Technological Development, Brasilia, DF, Brazil.
CR Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Albert A, 2016, CHEM PHYS LIPIDS, V199, P94, DOI 10.1016/j.chemphyslip.2016.04.008
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Barathi VA, 2014, INVEST OPHTH VIS SCI, V55, P460, DOI 10.1167/iovs.13-11636
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   Blum A, 2009, ATHEROSCLEROSIS, V203, P325, DOI 10.1016/j.atherosclerosis.2008.08.022
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brautbar A, 2011, NAT REV CARDIOL, V8, P253, DOI 10.1038/nrcardio.2011.2
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Cavelier C, 2006, BBA-MOL CELL BIOL L, V1761, P655, DOI 10.1016/j.bbalip.2006.04.012
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Dryja TP, 2016, JAMA OPHTHALMOL, V134, P1281, DOI 10.1001/jamaophthalmol.2016.3031
   Eandi CM, 2016, EUR J PHARMACOL, V787, P78, DOI 10.1016/j.ejphar.2016.03.002
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fong DS, 2010, AM J OPHTHALMOL, V149, P955, DOI 10.1016/j.ajo.2009.12.037
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Funatsu T, 2001, ATHEROSCLEROSIS, V157, P107, DOI 10.1016/S0021-9150(00)00714-0
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JB, 2016, J LIPID RES, V57, P258, DOI 10.1194/jlr.M064469
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   Machalinska Anna, 2013, Klin Oczna, V115, P74
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Martini E., 1991, VALUTAZIONE EFFETTI, V117
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Ostadal P, 2012, EXP CLIN CARDIOL, V17, P227
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rader DJ, 2000, MOL MED TODAY, V6, P170, DOI 10.1016/S1357-4310(00)01673-7
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Roizenblatt M., 2018, INSIGHT, V43, P5
   Saadane A, 2016, J BIOL CHEM, V291, P20427, DOI 10.1074/jbc.M116.744656
   Sackett Catherine Stewart, 2002, Insight, V27, P5
   Saeed MU, 2013, CLIN OPHTHALMOL, V7, P533, DOI 10.2147/OPTH.S31016
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Terai N, 2011, ACTA OPHTHALMOL, V89, pE500, DOI 10.1111/j.1755-3768.2011.02154.x
   Tian B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02407-7
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Tsao SW, 2013, DRUG AGING, V30, P205, DOI 10.1007/s40266-013-0061-4
   Tserentsoodol N, 2006, MOL VIS, V12, P18
   Tserentsoodol N, 2006, MOL VIS, V12, pe33
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Wilkinson-Berka JL, 2004, CURR PHARM DESIGN, V10, P3331, DOI 10.2174/1381612043383142
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
NR 86
TC 4
Z9 4
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2018
VL 19
IS 11
AR 3688
DI 10.3390/ijms19113688
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA HC0ZM
UT WOS:000451528500404
PM 30469381
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Wong, TY
   Sun, J
   Kawasaki, R
   Ruamviboonsuk, P
   Gupta, N
   Lansingh, V
   Maia, M
   Mathenge, W
   Moreker, S
   Muqit, MMK
   Resnikoff, S
   Verdaguer, J
   Zhao, PQ
   Ferris, F
   Aiello, LP
   Taylor, HR
AF Wong, Tien Y.
   Sun, Jennifer
   Kawasaki, Ryo
   Ruamviboonsuk, Paisan
   Gupta, Neeru
   Lansingh, Van Charles
   Maia, Mauricio
   Mathenge, Wanjiku
   Moreker, Sunil
   Muqit, Mahi M. K.
   Resnikoff, Serge
   Verdaguer, Juan
   Zhao, Peiquan
   Ferris, Frederick
   Aiello, Lloyd P.
   Taylor, Hugh R.
TI Guidelines on Diabetic Eye Care The International Council of
   Ophthalmology Recommendations for Screening, Follow-up, Referral, and
   Treatment Based on Resource Settings
SO OPHTHALMOLOGY
LA English
DT Review
ID COHERENCE TOMOGRAPHIC ANGIOGRAPHY; MAJOR RISK-FACTORS; PANRETINAL
   PHOTOCOAGULATION; MICROVASCULAR DENSITY; GLOBAL PREVALENCE;
   CATARACT-SURGERY; OLDER-PEOPLE; LOW-INCOME; RETINOPATHY; MANAGEMENT
AB Diabetes mellitus (DM) is a global epidemic and affects populations in both developing and developed countries, with differing health care and resource levels. Diabetic retinopathy (DR) is a major complication of DM and a leading cause of vision loss in working middle-aged adults. Vision loss from DR can be prevented with broad-level public health strategies, but these need to be tailored to a country's and population's resource setting. Designing DR screening programs, with appropriate and timely referral to facilities with trained eye care professionals, and using cost-effective treatment for vision-threatening levels of DR can prevent vision loss. The International Council of Ophthalmology Guidelines for Diabetic Eye Care 2017 summarize and offer a comprehensive guide for DR screening, referral and follow-up schedules for DR, and appropriate management of vision-threatening DR, including diabetic macular edema (DME) and proliferative DR, for countries with high-and low-or intermediate-resource settings. The guidelines include updated evidence on screening and referral criteria, the minimum requirements for a screening vision and retinal examination, follow-up care, and management of DR and DME, including laser photocoagulation and appropriate use of intravitreal anti-vascular endothelial growth factor inhibitors and, in specific situations, intravitreal corticosteroids. Recommendations for management of DR in patients during pregnancy and with concomitant cataract also are included. The guidelines offer suggestions for monitoring outcomes and indicators of success at a population level. (C) 2018 by the American Academy of Ophthalmology.
C1 [Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Wong, Tien Y.] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Sun, Jennifer; Aiello, Lloyd P.] Harvard Med Sch, Beetham Eye Inst, Joslin Diabet Ctr, Boston, MA USA.
   [Sun, Jennifer] Harvard Med Sch, Dept Ophthalmol, Boston, MA USA.
   [Kawasaki, Ryo] Yamagata Univ, Grad Sch Med Sci, Dept Publ Hlth, Yamagata, Japan.
   [Ruamviboonsuk, Paisan] Rajavithi Hosp, Dept Ophthalmol, Bangkok, Thailand.
   [Gupta, Neeru] Univ Toronto, St Michaels Hosp, Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Gupta, Neeru] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Lansingh, Van Charles] Help Me See, Queretaro, Mexico.
   [Lansingh, Van Charles] Inst Mexicano Oftalmol, Queretaro, Mexico.
   [Maia, Mauricio] Univ Fed Sao Paulo, Escola Paulista Med, Dept Ophthalmol & Visual Sci, Sao Paulo, Brazil.
   [Mathenge, Wanjiku] Rwanda Int Inst Ophthalmol, Kigali, Rwanda.
   [Mathenge, Wanjiku] Dr Agarwals Eye Hosp, Kigali, Rwanda.
   [Moreker, Sunil] MGM Hosp, Apollo, Seven Hills,Cumballa Hill, Bombay, Maharashtra, India.
   [Muqit, Mahi M. K.] NIHR Moorfields Biomed Res Ctr BRC, Vitreoretinal Serv, Moorfields Eye Hosp, London, England.
   [Resnikoff, Serge] Univ New South Wales, Brien Holden Vis Inst, Sydney, NSW, Australia.
   [Resnikoff, Serge] Univ New South Wales, SOVS, Sydney, NSW, Australia.
   [Verdaguer, Juan] Los Andes Univ, Los Andes Ophthalmol Fdn, Santiago, Chile.
   [Zhao, Peiquan] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Ferris, Frederick] NEI, NIH, Bethesda, MD 20892 USA.
   [Taylor, Hugh R.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
RP Wong, TY (corresponding author), Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM wong.tien.yin@snec.com.sg
RI Sun, Jennifer K/AAP-2734-2020; Kawasaki, Ryo/H-9716-2019; Resnikoff,
   Serge/N-2355-2019; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015; MATHENGE, WANJIKU/W-3993-2019; Wong, Tien
   Y/AAC-9724-2020; Lansingh, Van/C-8672-2018
OI Sun, Jennifer K/0000-0003-0915-6303; Resnikoff,
   Serge/0000-0002-5866-4446; Maia, Mauricio/0000-0002-7034-8091; Maia,
   Mauricio/0000-0002-7034-8091; Wong, Tien Y/0000-0002-8448-1264; Ferris,
   Frederick/0000-0002-4933-0639; Kawasaki, Ryo/0000-0002-7492-6303;
   Lansingh, Van/0000-0002-0090-4195; Muqit, Mahiul/0000-0003-1161-3956;
   Gupta, Neeru/0000-0001-8141-7710
FU STaR Award, National Medical Research Council, Singapore; GenentechRoche
   HoldingGenentech; Eleven Biotherapeutics; Vindico Medical Education;
   Kalvista; MerckMerck & Company; AllerganAllergan; Kowa;
   NovartisNovartis; Regeneron; BayerBayer AG; Senju; RocheRoche Holding;
   Predictive Analytics Group Pty. Ltd; Office Future Co.
FX The author(s) have made the following disclosure(s): T.Y.W.: Financial
   support - the STaR Award, National Medical Research Council, Singapore,
   which funded the drafting and preparation of the manuscript.r J.S.:
   Financial support - Genentech, Eleven Biotherapeutics, Vindico Medical
   Education, Kalvista, Merck, Allergan, Kowa, Novartis, Regeneron, Bayer;
   Nonfinancial support - Optovue, Boston Micromachines, Genentech,
   Novartis, Regeneron, Novo Nordisk, Adaptive Sensory Technologies.r R.K.:
   Financial support and Advisory board - Bayer, Novartis, Senju, Roche,
   Predictive Analytics Group Pty. Ltd, Office Future Co.; Financial
   support - Bayer, Novartis, Senju.r P.R.: Financial support - Novartis,
   Bayer, Allergan.
CR Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Augustin AJ, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0148-2
   Bandello F, 2016, EUR J OPHTHALMOL, V26, P252, DOI 10.5301/ejo.5000736
   Beagley J, 2014, DIABETES RES CLIN PR, V103, P150, DOI 10.1016/j.diabres.2013.11.001
   Beran D, 2006, LANCET, V368, P1689, DOI 10.1016/S0140-6736(06)69704-3
   Bradley PD, 2016, INVEST OPHTH VIS SCI, V57, P626, DOI 10.1167/iovs.15-18034
   Bragge P, 2011, ARCH OPHTHALMOL-CHIC, V129, P435, DOI 10.1001/archophthalmol.2010.319
   Bressler NM, 2014, JAMA OPHTHALMOL, V132, P168, DOI 10.1001/jamaophthalmol.2013.6426
   Bressler NM, 2011, NEW ENGL J MED, V365, P1520, DOI 10.1056/NEJMct0908432
   Burgess PI, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-157
   Chan JCN, 2009, JAMA-J AM MED ASSOC, V301, P2129, DOI 10.1001/jama.2009.726
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Cunha-Vaz J, 2014, OPHTHALMOLOGY, V121, P1892, DOI 10.1016/j.ophtha.2014.04.019
   Das T, 2016, INDIAN J OPHTHALMOL, V64, P14, DOI 10.4103/0301-4738.178142
   Durbin MK, 2017, JAMA OPHTHALMOL, V135, P370, DOI 10.1001/jamaophthalmol.2017.0080
   FERRIS FL, 1993, JAMA-J AM MED ASSOC, V269, P1290, DOI 10.1001/jama.269.10.1290
   Fong DS, 2007, ARCH OPHTHALMOL-CHIC, V125, P469
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Gakidou E, 2011, B WORLD HEALTH ORGAN, V89, P172, DOI 10.2471/BLT.10.080820
   Goh James Kang Hao, 2016, J Diabetes Sci Technol, V10, P282, DOI 10.1177/1932296816629491
   Gross JG, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI 10.1001/jama.2015.15217
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Haddad NMN, 2014, SEMIN OPHTHALMOL, V29, P329, DOI 10.3109/08820538.2014.959197
   Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470
   Hooper P, 2014, OPHTHALMOLOGICA, V231, P2, DOI 10.1159/000354548
   Horton MB, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0813-8
   Horton MB, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0814-7
   Jani PD, 2017, JAMA OPHTHALMOL, V135, P706, DOI 10.1001/jamaophthalmol.2017.1150
   Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017
   Jones S, 2010, DIABETIC MED, V27, P249, DOI 10.1111/j.1464-5491.2009.02870.x
   Martinez-Zapata MJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008721.pub2
   Kim AY, 2016, INVEST OPHTH VIS SCI, V57, pOCT362, DOI 10.1167/iovs.15-18904
   Klein R, 2009, OPHTHALMOLOGY, V116, P497, DOI 10.1016/j.ophtha.2008.10.016
   Leasher JL, 2016, DIABETES CARE, V39, P1643, DOI 10.2337/dc15-2171
   Mathenge W, 2014, OPHTHAL EPIDEMIOL, V21, P169, DOI 10.3109/09286586.2014.903982
   Mbanya JCN, 2010, LANCET, V375, P2254, DOI 10.1016/S0140-6736(10)60550-8
   Mitchell P, 2014, AM J OPHTHALMOL, V157, P505, DOI 10.1016/j.ajo.2013.11.012
   Mohamed QA, 2016, BMJ CLIN EVID, V2016
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Morrison JL, 2016, CLIN EXP OPHTHALMOL, V44, P321, DOI 10.1111/ceo.12760
   Muqit MMK, 2011, EYE, V25, P1447, DOI 10.1038/eye.2011.188
   Owolabi M, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2016-000105
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Rajavi Zhale, 2016, J Ophthalmic Vis Res, V11, P394
   Relhan N, 2017, CURR OPIN OPHTHALMOL, V28, P205, DOI 10.1097/ICU.0000000000000362
   Resnikoff S, 2012, BRIT J OPHTHALMOL, V96, P783, DOI 10.1136/bjophthalmol-2011-301378
   ROHAN TE, 1989, BMJ-BRIT MED J, V299, P1198, DOI 10.1136/bmj.299.6709.1198
   Sabanayagam C, 2016, OPHTHAL EPIDEMIOL, V23, P209, DOI 10.1080/09286586.2016.1193618
   Samara WA, 2017, OPHTHALMOLOGY, V124, P235, DOI 10.1016/j.ophtha.2016.10.008
   Sattar N, 2015, LANCET DIABETES ENDO, V3, P1004, DOI 10.1016/S2213-8587(15)00326-5
   Scanlon PH, 2008, J MED SCREEN, V15, P1, DOI 10.1258/jms.2008.008015
   Shah AS, 2010, CURR OPIN OPHTHALMOL, V21, P4, DOI 10.1097/ICU.0b013e328333e9c1
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Shannon H, 2000, NEW ENGL J MED, V342, P381
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Shi LL, 2015, BRIT J OPHTHALMOL, V99, P823, DOI 10.1136/bjophthalmol-2014-305631
   Silva PS, 2015, JAMA OPHTHALMOL, V133, P525, DOI 10.1001/jamaophthalmol.2015.0333
   Sivaprasad S, 2017, LANCET, V389, P2193, DOI 10.1016/S0140-6736(17)31193-5
   Sloan FA, 2007, CANC CONTROL OPPORTU
   Solomon SD, 2017, DIABETES CARE, V40, P412, DOI 10.2337/dc16-2641
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Tan GS, 2017, LANCET DIABETES ENDO, V5, P143, DOI 10.1016/S2213-8587(16)30052-3
   Ting DSW, 2017, JAMA OPHTHALMOL, V135, P306, DOI 10.1001/jamaophthalmol.2016.5877
   Ting DSW, 2016, CLIN EXP OPHTHALMOL, V44, P260, DOI 10.1111/ceo.12696
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   Wang LZZ, 2017, BRIT J OPHTHALMOL, V101, P1352, DOI 10.1136/bjophthalmol-2016-310002
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Werfalli M, 2016, LANCET DIABETES ENDO, V4, P72, DOI 10.1016/S2213-8587(15)00363-0
   WHO Study on global AGEing and adult health (SAGE) World Health Organization, HLTH STAT INF SYST
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wong TY, 2009, DIABETES CARE, V32, P2307, DOI 10.2337/dc09-0615
   Wong TY, 2016, JAMA-J AM MED ASSOC, V316, P2366, DOI 10.1001/jama.2016.17563
   Wong TY, 2006, AM J OPHTHALMOL, V141, P446, DOI 10.1016/j.ajo.2005.08.063
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yip CH, 2007, EXPERT REV ANTICANC, V7, P1095, DOI 10.1586/14737140.7.8.1095
   Yoon KH, 2006, LANCET, V368, P1681, DOI 10.1016/S0140-6736(06)69703-1
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   Zhang XP, 2008, DIABETES CARE, V31, P1748, DOI 10.2337/dc08-0572
   Ziemssen F, 2016, OPHTHALMOLOGE, V113, P623, DOI 10.1007/s00347-016-0315-8
NR 81
TC 79
Z9 83
U1 4
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2018
VL 125
IS 10
BP 1608
EP 1622
DI 10.1016/j.ophtha.2018.04.007
PG 15
WC Ophthalmology
SC Ophthalmology
GA GU1IF
UT WOS:000445012100028
PM 29776671
OA Bronze
DA 2020-12-15
ER

PT J
AU Lowe, J
   Wakshull, E
   Shek, T
   Chuntharapai, A
   Elliott, R
   Rusit, J
   Maia, M
AF Lowe, John
   Wakshull, Eric
   Shek, Theresa
   Chuntharapai, Anan
   Elliott, Rebecca
   Rusit, Jeriza
   Maia, Mauricio
TI Development and validation of a novel semi-homogenous clinical assay for
   quantitation of Ranibizumab in human serum
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE ELISA pharmacokinetic; Ultra-sensitive; Validation; Clinical;
   Intraocular administration
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; MYOPIC CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB AVASTIN; RETINAL VEIN
   OCCLUSION; CRYSTAL-STRUCTURE; FACTOR THERAPY; DEGENERATION; VEGF;
   PHARMACOKINETICS
AB Ranibizumab (Lucentis (R)), a humanized antigen-binding fragment (Fab) monoclonal antibody that blocks VEGF-A activity, is currently approved for the treatment of several retinal degenerative diseases. The assessment of drug pharmacokinetics (PK) is essential for evaluating exposure as it relates to drug safety and efficacy. For drugs administered intravitreally, systemic drug levels during the course of clinical studies are typically 100 to 1000 fold lower than those of similar therapeutics dosed intravenously, posing a significant bioanalytical challenge for PK measurements. Thus, the development of a highly-sensitive assay for measuring pg/mL levels of ranibizumab in patients' sera after intravitreal administration was needed to support clinical studies. In this report, we describe the development of a novel method that utilizes a high-affinity murine monoclonal anti-ranibizumab-VEGF-complexes antibody (MARA) reagent to measure ranibizumab in human serum. The assay format utilizes a semi-homogeneous solution phase step using a monoclonal antibody (the MARA) that binds specifically to the ranibizumab-VEGF complex, but not to either alone. This unique reagent exhibited low non-specific binding and high selectivity, increasing signal-to-noise readouts and maximizing assay sensitivity. The resulting MARA enzyme-linked immunosorbent assay (ELISA) has a lower limit of quantification of 15 pg/mL in human serum. In the assay, serum samples are incubated overnight with a mixture containing biotinylated-VEGF and MARA, which form a three-molecule complex with ranibizumab in the sample. These complexes are then captured onto streptavidin-coated wells, followed by enzymatic detection using a horseradish peroxidase-labeled-anti-murine antibody reagent and a colorimetric reaction. The assay conditions were optimized to allow for quantitative detection of "total" ranibizumab levels in serum. The assay was fully validated, establishing its high tolerance to sample matrix, as well as its suitable specificity, accuracy, dilution linearity, as well as intra- and inter-assay precision. The MARA ELISA's novel and unique approach has resulted in a considerably more sensitive ranibizumab PK assay compared to earlier versions of this assay. The MARA ELISA has been used for PK measurements in multiple ranibizumab studies, supporting this drug's life-cycle management and related preclinical and clinical-development studies.
C1 [Lowe, John; Wakshull, Eric; Elliott, Rebecca; Maia, Mauricio] Genentech Inc, Dept BioAnalyt Sci, MS 471a,One DNA Way, San Francisco, CA 94080 USA.
   [Shek, Theresa; Chuntharapai, Anan] Genentech Inc, Dept Prot Engn, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA.
   [Rusit, Jeriza] Genentech Inc, Dept Business Management & Commun, San Francisco, CA 94080 USA.
   [Chuntharapai, Anan] Bristol Myers Squibb, Biol Lead Discovery Dept, Redwood City, CA USA.
RP Maia, M (corresponding author), Genentech Inc, Dept BioAnalyt Sci, MS 471a,One DNA Way, San Francisco, CA 94080 USA.
EM mmaia@gene.com
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
FU Genentech, Inc.Roche HoldingGenentech
FX Funding was provided by Genentech, Inc.
CR Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Cutroneo PM, 2017, DRUG SAFETY, V40, P1131, DOI 10.1007/s40264-017-0553-y
   Deeks ED, 2014, BIODRUGS, V28, P403, DOI 10.1007/s40259-014-0102-5
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Fischer SK, 2015, AAPS J, V17, P93, DOI 10.1208/s12248-014-9682-8
   Food and Drug Administration, 2015, AN PROC METH VAL DRU
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gross JG, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI 10.1001/jama.2015.15217
   Gupta N, 2013, OPEN OPHTHALMOL J, V7, P4, DOI 10.2174/1874364101307010004
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Iacono P, 2015, ACTA OPHTHALMOL, V93, pE519, DOI 10.1111/aos.12677
   Kaiser PK, 2007, INT J CLIN PRACT, V61, P501, DOI 10.1111/j.1742-1241.2007.01299.x
   Kang-Mieler JJ, 2014, EXPERT OPIN DRUG DEL, V11, P1647, DOI 10.1517/17425247.2014.935338
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kong LK, 2016, INVEST OPHTH VIS SCI, V57, P1649, DOI 10.1167/iovs.15-18528
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lowe J, 2010, J PHARMACEUT BIOMED, V52, P680, DOI 10.1016/j.jpba.2010.01.048
   Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6
   Pennock S, 2012, MOL CELL BIOL, V32, P1955, DOI 10.1128/MCB.06668-11
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Roman K., 2015, RETINA TODAY, P81
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubio RG, 2014, RETIN TODAY, V8, P78
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Smith AG, 2016, DEV OPHTHALMOL, V55, P246, DOI 10.1159/000431200
   Sohn HJ, 2011, AM J OPHTHALMOL, V152, P686, DOI 10.1016/j.ajo.2011.03.033
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Wu LT, 2008, RETINA-J RET VIT DIS, V28, P212, DOI 10.1097/IAE.0b013e3181619bee
   Wu ZH, 2016, INT J OPHTHALMOL-CHI, V9, P63, DOI 10.18240/ijo.2016.01.11
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
   Zhang Y, 2014, OPHTHALMOLOGY, V121, P2237, DOI 10.1016/j.ophtha.2014.05.012
NR 46
TC 5
Z9 5
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
EI 1872-7905
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD OCT
PY 2018
VL 461
BP 44
EP 52
DI 10.1016/j.jim.2018.05.007
PG 9
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA GV0AX
UT WOS:000445719500006
PM 29772250
DA 2020-12-15
ER

PT J
AU Dias, JRD
   Ventura, CV
   Freitas, BD
   Prazeres, J
   Ventura, LO
   Bravo, V
   Aleman, T
   Ko, AI
   Zin, A
   Belfort, R
   Maia, M
AF de Oliveira Dias, Joao Rafael
   Ventura, Camila V.
   Freitas, Bruno de Paula
   Prazeres, Juliana
   Ventura, Liana O.
   Bravo-Filho, Vasco
   Aleman, Tomas
   Ko, Albert Icksang
   Zin, Andrea
   Belfort, Rubens, Jr.
   Maia, Mauricio
CA Zika Virus Study Grp
TI Zika and the Eye: Pieces of a Puzzle
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
ID WEST-NILE-VIRUS; OPTICAL COHERENCE TOMOGRAPHY; ASYMPTOMATIC
   BLOOD-DONORS; SEXUAL TRANSMISSION; YELLOW-FEVER; OPHTHALMIC
   MANIFESTATIONS; NEUTRALIZING ANTIBODIES; INVASIVE MOSQUITOS; INTERIM
   GUIDANCE; FRENCH-POLYNESIA
AB Zika virus (ZIKV) is an arbovirus mainly transmitted to humans by mosquitoes from Aedes genus. Other ways of transmission include the perinatal and sexual routes, blood transfusion, and laboratory exposure. Although the first human cases were registered in 1952 in African countries, outbreaks were only reported since 2007, when entire Pacific islands were affected. In March 2015, the first cases of ZIKV acute infection were notified in Brazil and, to date, 48 countries and territories in the Americas have confirmed local mosquito-borne transmission of ZIKV. Until 2015, ZIKV infection was thought to only cause asymptomatic or mild exanthematous febrile infections. However, after explosive ZIKV outbreaks in Polynesia and Latin American countries, it was confirmed that ZIKV could also lead to Guillain-Barre syndrome and congenital birth abnormalities. These abnormalities, which can include neurologic, ophthalmologic, audiologic, and skeletal findings, are now considered congenital Zika syndrome (CZS). Brain abnormalities in CZS include cerebral calcifications, malformations of cortical development, ventriculomegaly, lissencephaly, hypoplasia of the cerebellum and brainstem. The ocular findings, which are present in up to 70% of infants with CZS, include iris coloboma, lens subluxation, cataract, congenital glaucoma, and especially posterior segment findings. Loss of retinal pigment epithelium, the presence of a thin choroid, a perivascular choroidal inflammatory infiltrate, and atrophic changes within the optic nerve were seen in histologic analyses of eyes from deceased fetuses. To date, there is no ZIKV licensed vaccines or antiviral therapies are available for treatment. Preventive measures include individual protection from mosquito bites, control of mosquito populations and the use of barriers measures such as condoms during sexual intercourse or sexual abstinence for couples either at risk or after confirmed infection. A literature review based on studies that analyzed ocular findings in mothers and infants with CZS, with or without microcephaly, was conducted and a theoretical pathophysiologic explanation for ZIKV-ocular abnormalities was formulated.
C1 [de Oliveira Dias, Joao Rafael; Ventura, Camila V.; Freitas, Bruno de Paula; Prazeres, Juliana; Ventura, Liana O.; Belfort, Rubens, Jr.; Maia, Mauricio] Univ Fed Sao Paulo, Vis Inst, Dept Ophthalmol, Paulista Med Sch, Sao Paulo, Brazil.
   [Ventura, Camila V.; Ventura, Liana O.; Bravo-Filho, Vasco] Altino Ventura Fdn, Recife, PE, Brazil.
   [Ventura, Camila V.; Ventura, Liana O.; Bravo-Filho, Vasco] HOPE Eye Hosp, Recife, PE, Brazil.
   [Freitas, Bruno de Paula] Roberto Santos Gen Hosp, Dept Ophthalmol, Salvador, BA, Brazil.
   [Aleman, Tomas] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Ctr Adv Med,Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Ko, Albert Icksang] Fundacao Oswaldo Cruz, Goncalo Moniz Res Ctr, Salvador, BA, Brazil.
   [Ko, Albert Icksang] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
   [Zin, Andrea] Fundacao Oswaldo Cruz, Clin Res Unit, Fernandes Figueira Inst, Rio De Janeiro, Brazil.
   [Maia, Mauricio] Brazilian Inst Fight Blindness Assts & Presidente, Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Pedro de Toledo St 781,2nd Floor, BR-04023062 Sao Paulo, SP, Brazil.
EM mmaia@unifesp.br
RI Ventura, Liana Vieira O/N-6151-2018; Ko, Albert Icksang/P-2343-2015;
   Maia, Mauricio/I-5892-2015; Ventura, Camila V/N-2654-2018; Bravo-Filho,
   Vasco/N-6993-2018
OI Ventura, Liana Vieira O/0000-0001-6529-6883; Ko, Albert
   Icksang/0000-0001-9023-2339; Maia, Mauricio/0000-0002-7034-8091;
   Ventura, Camila V/0000-0002-2927-4684; Bravo-Filho,
   Vasco/0000-0003-4460-3236
CR Aagaard KM, 2017, SCI REP-UK, V7, DOI 10.1038/srep41389
   Adibi JJ, 2016, LANCET, V387, P1587, DOI 10.1016/S0140-6736(16)00650-4
   Akoua-Koffi C, 2001, B SOC PATHOL EXOT, V94, P227
   Aleman TS, 2017, JAMA OPHTHALMOL, V135, P1069, DOI 10.1001/jamaophthalmol.2017.3292
   Alpert SG, 2003, AM J OPHTHALMOL, V136, P733, DOI 10.1016/S0002-9394(03)00452-5
   Alpuche-Lazcano SP, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020053
   Althouse BM, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005055
   Alvarado MG, 2017, ARCH PATHOL LAB MED, V141, P26, DOI 10.5858/arpa.2016-0382-RA
   Aubry M, 2017, EMERG INFECT DIS, V23, P669, DOI 10.3201/eid2304.161549
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   Berthet N, 2014, VECTOR-BORNE ZOONOT, V14, P862, DOI 10.1089/vbz.2014.1607
   Besnard M, 2016, EURO SURVEILL, V21
   Bingham AM, 2016, MMWR-MORBID MORTAL W, V65, P475, DOI 10.15585/mmwr.mm6518e2
   Bogoch II, 2016, LANCET INFECT DIS, V16, P1237, DOI 10.1016/S1473-3099(16)30270-5
   Bonafede L, 2015, INVEST OPHTH VIS SCI, V56, P7875, DOI 10.1167/iovs.15-17857
   Bonaldo MC, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004816
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Buechler CR, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00392-16
   Bueno MG, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005073
   Busch MP, 2008, J INFECT DIS, V198, P984, DOI 10.1086/591467
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Centers for Diasease Control and Prevention, 2017, MORB MORT WEEK REP M
   Centers for Disease Control and Prevention, 2014, ZIK VIR TRANSM RISKS
   Centers for Disease Control and Prevention, 2016, CFDCAP ZIK VIR
   Centers for Disease Control and Prevention, 2018, ZIK CAS US
   CLARKE DH, 1958, AM J TROP MED HYG, V7, P561, DOI 10.4269/ajtmh.1958.7.561
   Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   Cordeiro MT, 2016, J INFECT DIS, V214, P1897, DOI 10.1093/infdis/jiw477
   Coura JR, 2006, MEM I OSWALDO CRUZ, V101, P229, DOI 10.1590/S0074-02762006000300001
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   Dang J, 2016, CELL STEM CELL, V19, P258, DOI 10.1016/j.stem.2016.04.014
   de Caires LC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02790-9
   de Miranda HA, 2016, OPHTHALMOLOGY, V123, P1788, DOI 10.1016/j.ophtha.2016.05.001
   Campos AGD, 2016, ARQ BRAS OFTALMOL, V79, P400, DOI 10.5935/0004-2749.20160112
   de Noronha L, 2016, MEM I OSWALDO CRUZ, V111, P287, DOI 10.1590/0074-02760160085
   de Oliveira Dias Joao Rafael, 2018, Retin Cases Brief Rep, V12, P382, DOI 10.1097/ICB.0000000000000518
   de Paula Freitas B., 2017, OPHTHALMOLOGY
   Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3
   Diallo D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109442
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Duong V, 2015, P NATL ACAD SCI USA, V112, P14688, DOI 10.1073/pnas.1508114112
   Dupont-Rouzeyrol M, 2016, LANCET, V387, P1051, DOI 10.1016/S0140-6736(16)00624-3
   Dupont-Rouzeyrol M, 2015, EMERG INFECT DIS, V21, P381, DOI 10.3201/eid2102.141553
   Epelboin Y, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005933
   European Centre for Disease Prevention and Control (ECDC), 2017, ZIK TRANSM
   European Centre for Disease Prevention and Control (ECDC), 2017, ZIK VIR TRANSM LIST
   FAGBAMI AH, 1979, J HYG-CAMBRIDGE, V83, P213, DOI 10.1017/S0022172400025997
   Favoretto S., 2016, 1 DETECTION ZIKA VIR
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Fernandez M. P., 2017, JAMA OPHTHALMOLOGY
   Food and Drug Administration, 2016, ZIK VIR EM US AUTH
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   Frank C, 2016, EUROPEAN COMMUNICABL, V2016, P21, DOI DOI 10.2807/1560-7917
   Freitas BP, 2016, JAMA OPHTHALMOL
   Freitas BDP, 2017, OPHTHALMOLOGY, V124, P407, DOI 10.1016/j.ophtha.2016.10.004
   FUNG JC, 1985, ANN CLIN LAB SCI, V15, P204
   Furtado JM, 2016, NEW ENGL J MED, V375, P394, DOI 10.1056/NEJMc1603618
   Gake B, 2017, BRAZ J INFECT DIS, V21, P481, DOI 10.1016/j.bjid.2017.03.018
   Gallian P, 2017, BLOOD, V129, P263, DOI 10.1182/blood-2016-09-737981
   Gardner L, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005487
   Gardner LM, 2016, LANCET INFECT DIS, V16, P522, DOI 10.1016/S1473-3099(16)00176-6
   Garg S, 2009, RETINA-J RET VIT DIS, V29, P631, DOI 10.1097/IAE.0b013e318198d8de
   Gasperi G., 2014, PLOS NEGLECTED TROP, V6, pe1836
   Gatherer D, 2016, J GEN VIROL, V97, P269, DOI 10.1099/jgv.0.000381
   Goldenberg D, 2013, GRAEF ARCH CLIN EXP, V251, P2037, DOI 10.1007/s00417-013-2334-3
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Grard G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002681
   Gratz NG, 2004, MED VET ENTOMOL, V18, P215, DOI 10.1111/j.0269-283X.2004.00513.x
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   Hamer DH, 2014, ANN INTERN MED, V161, P827, DOI 10.7326/M14-1958
   Harrower J, 2016, EMERG INFECT DIS, V22, P1855, DOI 10.3201/eid2210.160951
   Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006
   Intergrowth-21st Fetal, 2017, PRETERM NEWBORN APPL
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   JAN C, 1978, B SOC PATHOL EXOT, V71, P140
   Johansson MA, 2016, NEW ENGL J MED, V375, P1, DOI 10.1056/NEJMp1605367
   Kodati S, 2017, LANCET, V389, P125, DOI 10.1016/S0140-6736(16)32518-1
   Kostyuchenko VA, 2016, NATURE, V533, P425, DOI 10.1038/nature17994
   Kraemer MUG, 2015, ELIFE, V4, DOI 10.7554/eLife.08347
   Krow-Lucal ER, 2017, EMERG INFECT DIS, V23, P841, DOI 10.3201/eid2305.161715
   Kuno G, 2007, ARCH VIROL, V152, P687, DOI 10.1007/s00705-006-0903-z
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanciotti RS, 2016, EMERG INFECT DIS, V22, P933, DOI 10.3201/eid2205.160065
   Leder K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185689
   Lindsey NP, 2015, MMWR-MORBID MORTAL W, V64, P929, DOI 10.15585/mmwr.mm6434a1
   MacNamara F., 1952, ANN REPORT, P1951
   Mani RS, 2016, NATL MED J INDIA, V29, P339
   MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411
   Marcondes CB, 2016, REV SOC BRAS MED TRO, V49, P4, DOI 10.1590/0037-8682-0220-2015
   Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000
   Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2
   MCCRAE AWR, 1982, T ROY SOC TROP MED H, V76, P552, DOI 10.1016/0035-9203(82)90161-4
   Medlock JM, 2015, LANCET INFECT DIS, V15, P721, DOI 10.1016/S1473-3099(15)70091-5
   Medlock JM, 2012, VECTOR-BORNE ZOONOT, V12, P435, DOI 10.1089/vbz.2011.0814
   Mehrjardi MZ, 2017, JPN J RADIOL, V35, P41, DOI 10.1007/s11604-016-0599-2
   Mehrjardi MZ, 2017, VIROLOGY AUCKL, V8
   Miner JJ, 2016, CELL REP, V16, P3208, DOI 10.1016/j.celrep.2016.08.079
   Ministerio da Saude do Brasil, 2016, MIN SAUD BRAS B
   Ministerio da Saude do Brasil, 2017, MIN SAUD BRAS B EP, V48
   Ministerio da Saude do Brasil, 2016, NFORM EP 47 SEMANA E
   Mladinich M. C., 2017, ZIKA VIRUS PERSISTEN
   Mlalcar J., 2016, ENGL J MED, V374, P951
   MONLUN E, 1993, B SOC PATHOL EXOT, V86, P21
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Moreira-Soto A, 2018, MSPHERE, V3, DOI [10.1128/mSphere.00523-17, 10.1128/msphere.00523-17]
   Morris G., 2017, MOL NEUROBIOL
   Motta IJF, 2016, NEW ENGL J MED, V375, P1101, DOI 10.1056/NEJMc1607262
   Mousson L, 2005, GENET RES, V86, P1, DOI 10.1017/S0016672305007627
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Musso D, 2015, EMERG INFECT DIS, V21, P1887, DOI 10.3201/eid2110.151125
   Mysorekar IU, 2016, NEW ENGL J MED, V375, P481, DOI 10.1056/NEJMcibr1605445
   van den Pol AN, 2017, J NEUROSCI, V37, P2161, DOI 10.1523/JNEUROSCI.3124-16.2017
   Nogueira ML, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14047
   OEHLER E, 2013, EUROSURVEILLANCE, V2014, P19, DOI DOI 10.2807/1560-7917.ES2014.19.9.20720
   OLSON JG, 1983, ANN TROP MED PARASIT, V77, P131, DOI 10.1080/00034983.1983.11811687
   OLSON JG, 1981, T ROY SOC TROP MED H, V75, P389, DOI 10.1016/0035-9203(81)90100-0
   Paixao ES, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000530
   Pan American Health Organization/World Health Organization, 2016, ZIK VIR INF STEP STE
   Parke DW, 2016, OPHTHALMOLOGY, V123, P2432, DOI 10.1016/j.ophtha.2016.06.039
   Petersen EE, 2016, MMWR-MORBID MORTAL W, V65, P315, DOI 10.15585/mmwr.mm6512e2
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Pinto VL, 2015, ACTA MEDICA PORT, V28, P760, DOI 10.20344/amp.6929
   POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   Rajah MM, 2016, ACS INFECT DIS, V2, P763, DOI 10.1021/acsinfecdis.6b00161
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Reuters, 2016, BRAZ REP ZIK INF BLO
   Rigau-Perez JG, 1998, LANCET, V352, P971, DOI 10.1016/S0140-6736(97)12483-7
   Ritter JM, 2017, ARCH PATHOL LAB MED, V141, P49, DOI 10.5858/arpa.2016-0397-SA
   Roach T, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0824-7
   Robbiani DF, 2017, CELL, V169, P597, DOI 10.1016/j.cell.2017.04.024
   Robin Y., 1978, B SOC PATHOL EXOT, V68, P249
   Rochlin I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060874
   Rosenberg AZ, 2017, ARCH PATHOL LAB MED, V141, P43, DOI 10.5858/arpa.2016-0401-OA
   Roth A., 2014, EURO SURVEILL, V16
   Saiz JC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01554
   Salam AP, 2017, EMERG INFECT DIS, V23, P1922, DOI 10.3201/eid2311.171049
   SALUZZO JF, 1981, B SOC PATHOL EXOT, V74, P490
   Salvo MA, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006210
   Sampathkumar P, 2016, MAYO CLIN PROC, V91, P514, DOI 10.1016/j.mayocp.2016.02.017
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Schaffner F, 2013, CLIN MICROBIOL INFEC, V19, P685, DOI 10.1111/1469-0691.12189
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Schwartz DA, 2017, ARCH PATHOL LAB MED, V141, P68, DOI 10.5858/arpa.2016-0343-OA
   Secretaria de Estado de Saude do Estado de Sao Paulo, 2016, DISTR CAS NOT CONF F
   Sheridan MA, 2017, P NATL ACAD SCI USA, V114, pE1587, DOI 10.1073/pnas.1616097114
   Simonin Y, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005821
   Singh PK, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92340
   Slavov SN, 2016, BRAZ J MED BIOL RES, V49, DOI 10.1590/1414-431X20165420
   Slavov SN, 2017, TRANSFUSION, V57, P2897, DOI 10.1111/trf.14322
   SMITHBURN KC, 1952, J IMMUNOL, V69, P223
   Subissi L, 2017, INT J INFECT DIS, V65, P116, DOI 10.1016/j.ijid.2017.10.009
   Sun Lisa L, 2012, Digit J Ophthalmol, V18, P1, DOI 10.5693/djo.02.2012.04.001
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
   Tognarelli J., 2015, ARCH VIROL, P665
   van den Berg B, 2014, NAT REV NEUROL, V10, P469, DOI 10.1038/nrneurol.2014.121
   van der Linden V, 2016, MMWR-MORBID MORTAL W, V65, P1343, DOI 10.15585/mmwr.mm6547e2
   van der Linden V, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3899
   Van Kerkhove MD, 2016, LANCET GLOB HEALTH, V4, pE911, DOI 10.1016/S2214-109X(16)30255-8
   Vega-Rua A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059716
   Ventura CV, 2016, JAMA OPHTHALMOL, V134, P1420, DOI 10.1001/jamaophthalmol.2016.4283
   Ventura CV, 2016, OSLI RETINA, V47, P952, DOI 10.3928/23258160-20161004-09
   Ventura CV, 2016, JAMA OPHTHALMOL, V134, P912, DOI 10.1001/jamaophthalmol.2016.1784
   Ventura CV, 2016, LANCET, V387, P2502, DOI 10.1016/S0140-6736(16)30776-0
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   Ventura CV, 2014, ARQ BRAS OFTALMOL, V77, P300, DOI 10.5935/0004-2749.20140076
   Ventura L. O., 2017, J AAPOS
   Ventura LO, 2017, J AAPOS, V21, P295, DOI 10.1016/j.jaapos.2017.04.003
   Vercosa I, 2017, J AAPOS, V21, P300, DOI 10.1016/j.jaapos.2017.05.024
   Villarroel PMS, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006239
   Vorou R, 2016, INT J INFECT DIS, V48, P85, DOI 10.1016/j.ijid.2016.05.014
   Wang L, 2016, CELL HOST MICROBE, V19, P561, DOI 10.1016/j.chom.2016.04.006
   Weaver SC, 2009, INFECT GENET EVOL, V9, P523, DOI 10.1016/j.meegid.2009.02.003
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   WHO, 2016, INT GUID
   WHO/Institut Pasteur/ISARIC/CONSISE, 2017, STAND PROT CROSS SEC
   Wolfe ND, 2001, AM J TROP MED HYG, V64, P310, DOI 10.4269/ajtmh.2001.64.310
   World Health Organization, 2018, HIST ZIK VIR
   World Health Organization, 2017, ZIK SIT REP
   World Health Organization, 2016, ZIK SIT REP ZIK VIR
   World Health Organization, 2016, WHO STAT 1 M INT HLT
   World Health Organization, 2017, INF TRAV VIS ZIK AFF
   World Health Organization (WHO), 2016, ZIK VIR VECT RISK SP
   Yepez JB, 2017, JAMA OPHTHALMOL, V135, P440, DOI 10.1001/jamaophthalmol.2017.0561
   Zhao HY, 2016, CELL, V166, P1016, DOI 10.1016/j.cell.2016.07.020
   Zhao ZY, 2017, INVEST OPHTH VIS SCI, V58, P4355, DOI 10.1167/iovs.17-22016
   Zhu Z, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.48
   Zin AA, 2017, JAMA PEDIATR, V171, P847, DOI 10.1001/jamapediatrics.2017.1474
NR 195
TC 9
Z9 9
U1 0
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2018
VL 66
BP 85
EP 106
DI 10.1016/j.preteyeres.2018.04.004
PG 22
WC Ophthalmology
SC Ophthalmology
GA GW6ZN
UT WOS:000447113700004
PM 29698814
DA 2020-12-15
ER

PT J
AU Wakshull, E
   Avery, R
   Maia, M
AF Wakshull, Eric
   Avery, Robert
   Maia, Mauricio
TI Comments on Assays Used to Measure VEGF in the Presence of Anti-VEGF
   Therapeutics
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Letter
C1 [Wakshull, Eric; Maia, Mauricio] Genentech Inc, San Francisco, CA 94080 USA.
   [Avery, Robert] Calif Retina Consultants, Santa Barbara, CA USA.
RP Wakshull, E (corresponding author), Genentech Inc, San Francisco, CA 94080 USA.
EM wakshull.eric@gene.com
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Jampol LM, 2018, OPHTHALMOLOGY, V125, P1054, DOI 10.1016/j.ophtha.2018.01.019
   Takahashi H, 2016, INVEST OPHTH VIS SCI, V57, P462, DOI 10.1167/iovs.15-18245
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
NR 7
TC 1
Z9 1
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2018
VL 59
IS 10
BP 4106
EP 4106
DI 10.1167/iovs.18-24792
PG 1
WC Ophthalmology
SC Ophthalmology
GA GP9ZB
UT WOS:000441273800034
PM 30098197
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Alves, BQ
   Brasil, OFM
   Espinhosa, CT
   Japiassu, RM
   Goncalves, MB
   Magalhaes, O
   Maia, A
   Cardoso, EB
   Serraino, P
   Alezzandrinni, A
   Maia, M
AF Alves, Bruno Queiroz
   Moura Brasil, Oswaldo Ferreira
   Espinhosa, Cristiano Toesca
   Japiassu, Ricardo Miguel
   Goncalves, Mariana Batista
   Magalhaes Junior, Octaviano
   Maia, Andre
   Cardoso, Emmerson Badar
   Serraino, Paula
   Alezzandrinni, Arturo
   Maia, Mauricio
TI Combined Femtosecond Laser-Assisted Cataract Surgery and Small-Gauge
   Pars Plana Vitrectomy Using Different Devices: A New Trend for
   Vitreoretinal Surgery?
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
CY APR 29-MAY 03, 2018
CL Honolulu, HI
SP Assoc Res Vis & Ophthalmol
C1 [Alves, Bruno Queiroz; Moura Brasil, Oswaldo Ferreira; Espinhosa, Cristiano Toesca; Japiassu, Ricardo Miguel; Goncalves, Mariana Batista; Magalhaes Junior, Octaviano; Maia, Andre; Cardoso, Emmerson Badar; Maia, Mauricio] Univ Fed Sao Paulo, Ophthalmol, Sao Paulo, SP, Brazil.
   [Serraino, Paula; Alezzandrinni, Arturo] Univ Buenos Aires, Buenos Aires, DF, Argentina.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2018
VL 59
IS 9
MA 5921
PG 7
WC Ophthalmology
SC Ophthalmology
GA GR8CB
UT WOS:000442932807060
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Goncalves, MB
   Alves, BQ
   Moura, R
   Magalhaes, O
   Maia, A
   Belfort, R
   Avila, M
   Zas, M
   Saravia, MJ
   Lousas, M
   Wu, L
   Arevalo, JF
   Pacheco, KD
   Farah, ME
   Rodriguez, FJ
   Maia, M
AF Goncalves, Mariana Batista
   Alves, Bruno Queiroz
   Moura, Raphael
   Magalhaes Junior, Octaviano
   Maia, Andre
   Belfort, Rubens, Jr.
   Avila, Marcos
   Zas, Marcelo
   Saravia, Mario J.
   Lousas, Marcia
   Wu, Lihteh
   Arevalo, J. Fernando
   Pacheco, Katia Delalibera
   Farah, Michel Eid
   Rodriguez, Francisco J.
   Maia, Mauricio
TI Intravitreal Dexamethasone Implant Migration into the Anterior Chamber:
   A Multicenter Study from the Pan-American Collaborative Retina Study
   Group
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
CY APR 29-MAY 03, 2018
CL Honolulu, HI
SP Assoc Res Vis & Ophthalmol
C1 [Goncalves, Mariana Batista; Alves, Bruno Queiroz; Moura, Raphael; Magalhaes Junior, Octaviano; Maia, Andre; Belfort, Rubens, Jr.; Farah, Michel Eid; Maia, Mauricio] Univ Fed Sao Paulo, Ophthalmol, Sao Paulo, SP, Brazil.
   [Avila, Marcos] Univ Fed Goias, Goiania, Go, Brazil.
   [Zas, Marcelo] Univ Buenos Aires, Buenos Aires, DF, Argentina.
   [Saravia, Mario J.; Lousas, Marcia] Univ Austral, Buenos Aires, DF, Argentina.
   [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Arevalo, J. Fernando] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Pacheco, Katia Delalibera] Vis Eye Hosp, Brazilian Ctr, Brasilia, DF, Brazil.
   [Rodriguez, Francisco J.] Fdn Oftalmol Nacl, Bogota, Colombia.
RI Farah, Michel Eid E/F-3285-2012; Zas, Marcelo/AAF-2679-2020; Maia,
   Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2018
VL 59
IS 9
MA 390
PG 7
WC Ophthalmology
SC Ophthalmology
GA GR7XS
UT WOS:000442912501030
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Ishioka, P
   Maia, M
   Rodrigues, SB
   Lellis, RF
   Hirata, SH
AF Ishioka, P.
   Maia, M.
   Rodrigues, S. B.
   Lellis, R. F.
   Hirata, S. H.
TI In vivo Confocal Laser Microscopy for monitoring of actinic keratosis
   treatment: a comparison with histopathologic assessment after treatment
   with topical 5% 5-fluorouracil
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; BASAL-CELL CARCINOMA; FOLLOW-UP; FIELD
   CANCERIZATION; TREATMENT ALGORITHM; HUMAN SKIN; 0.5-PERCENT;
   FLUOROURACIL; MANAGEMENT; EFFICACY
AB Background Histological examination is the gold standard for actinic keratosis diagnosis; however, it is not always a feasible approach. Reflectance confocal microscopy (RCM) is a non-invasive technique that may be an alternative for monitoring actinic keratoses treatment response. Topical 5-fluorouracil is indicated for actinic keratosis multiple lesions and for field cancerization treatment.
   Objectives To assess the RCM accuracy, sensibility and specificity for actinic keratosis, considering as a gold standard the histopathological examination; as well as to evaluate the efficacy of 5% 5-fluorouracil treatment.
   Methods This is a prospective study in actinic keratosis patients between August 2014 and November 2015. RCM analyses were performed in one randomly selected actinic keratosis lesion of the upper limbs by two independent observers before and after 5% 5-fluorouracil treatment. At the end of treatment and with clinical bleaching of treated lesions, histological examination was performed by two pathologists.
   Results A total of 50 lesions were enroled, and 40 lesions presented complete clinical bleaching after treatment and were included in the final analysis. Accuracy, sensibility and specificity means among observers were 83.8%, 84.6% and 83.3%, respectively. After 5-fluorouracil treatment, actinic keratosis was diagnosed in 45.0% (observer 1) and 32.5% (observer 2) of subjects according to RCM and in 32.5% of subjects according to histological examination. Considering RCM observers diagnosis, the concordance was substantial (k 0.637, P<0.001). 5-fluorouracil led to a reduction in 55.0%-67.5% of actinic keratoses according to RCM analysis.
   Conclusion This study allows to validate RCM as a non-invasive method capable of monitoring actinic keratosis therapeutic response to 5-fluorouracil, presenting efficacy comparable to histological examination. Additionally, the results suggest that 5-fluorouracil may be a satisfactory option for therapeutic control of this condition.
C1 [Ishioka, P.; Hirata, S. H.] Univ Fed Sao Paulo, Sao Paulo, SP, Brazil.
   [Ishioka, P.; Maia, M.; Rodrigues, S. B.; Lellis, R. F.] Santa Casa de Misericordia Sao Paulo, Sao Paulo, SP, Brazil.
RP Ishioka, P (corresponding author), Univ Fed Sao Paulo, Sao Paulo, SP, Brazil.; Ishioka, P (corresponding author), Santa Casa de Misericordia Sao Paulo, Sao Paulo, SP, Brazil.
EM pishioka@uol.com.br
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR Abhishek Kumar, 2015, J Cutan Aesthet Surg, V8, P239, DOI 10.4103/0974-2077.172206
   Aghassi D, 2000, J AM ACAD DERMATOL, V43, P42, DOI 10.1067/mjd.2000.105565
   Ardigo M, 2016, BRIT J DERMATOL, V175, P364, DOI 10.1111/bjd.14516
   Askew DA, 2009, INT J DERMATOL, V48, P453, DOI 10.1111/j.1365-4632.2009.04045.x
   Braakhuis BJM, 2003, CANCER RES, V63, P1727
   Ceilley RI, 2012, J DERMATOL TREAT, V23, P83, DOI 10.3109/09546634.2010.507704
   Costa C, 2015, J DERMATOL CASE REP, V9, P28, DOI 10.3315/jdcr.2015.1199
   Dreno B, 2014, J EUR ACAD DERMATOL, V28, P1141, DOI 10.1111/jdv.12434
   Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137
   FROST CA, 1994, BRIT J DERMATOL, V131, P455
   Ghita MA, 2016, ONCOL LETT, V11, P3019, DOI 10.3892/ol.2016.4354
   Glogau RG, 2000, J AM ACAD DERMATOL, V42, pS23, DOI 10.1067/mjd.2000.103339
   GOETTE DK, 1981, J AM ACAD DERMATOL, V4, P633, DOI 10.1016/S0190-9622(81)80196-X
   Guitera P, 2013, JAMA DERMATOL, V149, P692, DOI 10.1001/jamadermatol.2013.2301
   Gupta AK, 2013, BRIT J DERMATOL, V169, P250, DOI 10.1111/bjd.12343
   Gupta AK, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004415.pub2
   Huerta-Brogeras M, 2012, ARCH DERMATOL, V148, P1159, DOI 10.1001/archdermatol.2012.1060
   Ishioka P, 2015, AN BRAS DERMATOL, V90, P426, DOI 10.1590/abd1806-4841.20153437
   Ishioka P, 2009, CAD SAUDE PUBLICA, V25, P964
   Jafari SMS, 2016, BRIT J DERMATOL, V175, P375, DOI 10.1111/bjd.14517
   Jiyad Z, 2017, ACTA DERM-VENEREOL, V97, P351, DOI 10.2340/00015555-2539
   Jorizzo J, 2002, CUTIS, V70, P335
   Krawtchenko N, 2007, BRIT J DERMATOL, V157, P34, DOI 10.1111/j.1365-2133.2007.08271.x
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lee JH, 2014, J DERMATOL, V41, P487, DOI 10.1111/1346-8138.12282
   Lee KC, 2011, ACTA DERM-VENEREOL, V91, P101, DOI 10.2340/00015555-0972
   Levy S, 2001, CLIN THER, V23, P901, DOI 10.1016/S0149-2918(01)80077-1
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Longo C, 2014, J AM ACAD DERMATOL, V71, P716, DOI 10.1016/j.jaad.2014.04.067
   Loven K, 2002, CLIN THER, V24, P990, DOI 10.1016/S0149-2918(02)80012-1
   Maier T, 2015, BRIT J DERMATOL, V172, P816, DOI 10.1111/bjd.13304
   Malvehy J, 2016, J EUR ACAD DERMATOL, V30, P258, DOI 10.1111/jdv.13445
   Malvehy J, 2015, ACTA DERM-VENEREOL, V95, P45, DOI 10.2340/00015555-1860
   Meijer BUGA, 2007, CONTACT DERMATITIS, V57, P58, DOI 10.1111/j.1600-0536.2007.01079.x
   Micali G, 2014, J AM ACAD DERMATOL, V70
   Micali G, 2014, J AM ACAD DERMATOL, V70, DOI 10.1016/j.jaad.2013.12.037
   Moore AY, 2009, J DERMATOL TREAT, V20, P328, DOI 10.3109/09546630902789326
   Moy R L, 2000, J Am Acad Dermatol, V42, P8
   NeittaanmakiPerttu N., 2015, DIAGNOSIS TREATMENT
   Nieves D, 2015, EXPERT REV PHARM OUT, V15, P539, DOI 10.1586/14737167.2015.995171
   Parikh R, 2008, INDIAN J OPHTHALMOL, V56, P45, DOI 10.4103/0301-4738.37595
   Ponsford M W, 1983, Australas J Dermatol, V24, P79, DOI 10.1111/j.1440-0960.1983.tb00256.x
   Rajadhyaksha M, 1999, J INVEST DERMATOL, V113, P293, DOI 10.1046/j.1523-1747.1999.00690.x
   RAJADHYAKSHA M, 1995, J INVEST DERMATOL, V104, P946, DOI 10.1111/1523-1747.ep12606215
   Richtig E, 2010, J EUR ACAD DERMATOL, V24, P293, DOI 10.1111/j.1468-3083.2009.03410.x
   Rishpon A, 2009, ARCH DERMATOL, V145, P766, DOI 10.1001/archdermatol.2009.134
   Robins P, 2002, CUTIS, V70, P4
   Roewert-Huber J, 2007, BRIT J DERMATOL, V157, P18, DOI 10.1111/j.1365-2133.2007.08267.x
   Rosen T, 2013, J AM ACAD DERMATOL, V68, pS2, DOI 10.1016/j.jaad.2012.09.052
   Ruini C, 2016, LASER MED SCI, V31, P1727, DOI 10.1007/s10103-016-2043-3
   Salasche SJ, 2000, J AM ACAD DERMATOL, V42, pS4, DOI 10.1067/mjd.2000.103342
   Samrao A, 2013, AM J CLIN DERMATOL, V14, P273, DOI 10.1007/s40257-013-0023-y
   Siegel JA, 2017, BRIT J DERMATOL, V177, P350, DOI 10.1111/bjd.14852
   Stockfleth E, 2008, EUR J DERMATOL, V18, P651, DOI 10.1684/ejd.2008.0514
   THOMPSON SC, 1993, NEW ENGL J MED, V329, P1147, DOI 10.1056/NEJM199310143291602
   Ulrich M, 2007, BRIT J DERMATOL, V156, P13, DOI 10.1111/j.1365-2133.2007.07865.x
   Ulrich M, 2010, DERMATOLOGY, V220, P15, DOI 10.1159/000254893
   Ulrich M, 2008, DERMATOL SURG, V34, P610, DOI 10.1111/j.1524-4725.2007.34117.x
   Ulrich M, 2015, DERMATOLOGY, V230, P193, DOI 10.1159/000370148
   Vale SM, 2017, PHARMACOECONOMICS, V35, P177, DOI 10.1007/s40273-016-0462-4
   Venna SS, 2005, ARCH DERMATOL, V141, P507, DOI 10.1001/archderm.141.4.507
   Weinstock MA, 2009, J AM ACAD DERMATOL, V61, P207, DOI 10.1016/j.jaad.2009.02.022
   Werner RN, 2015, J EUR ACAD DERMATOL, V29, P2069, DOI 10.1111/jdv.13180
   Wojcik R, 2016, J MED ECON, V20, P1
   Yentzer B, 2009, ARCH DERMATOL, V145, P203, DOI 10.1001/archdermatol.2008.562
NR 65
TC 3
Z9 3
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
EI 1468-3083
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
PD JUL
PY 2018
VL 32
IS 7
BP 1155
EP 1163
DI 10.1111/jdv.14716
PG 9
WC Dermatology
SC Dermatology
GA GK5XH
UT WOS:000436252800045
PM 29178474
DA 2020-12-15
ER

PT J
AU Sancho, KFCB
   Zett, C
   Goncalves, I
   Morales, MC
   Maia, M
   Neto, RBM
AF Castelo Branco Sancho, Karlos Frederico
   Zett, Claudio
   Goncalves Junior, Iran
   Morales, Melina Correia
   Maia, Mauricio
   Mattos Neto, Rubens Belfort
TI Effects of oral propranolol for circumscribed choroidal hemangioma
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Hemangioma; Choroid neoplasms; Propranolol; Indocyanine green;
   Tomography; optical coherence
ID STURGE-WEBER SYNDROME; INFANTILE HEMANGIOMAS; THERAPY; DIFFUSE
AB Purpose: We aimed to evaluate the effects of oral propranolol for circumscribed choroidal hemangioma. Methods: In this prospective, longitudinal interventional study, we administered oral propranolol at a dosage of 1.5 mg/kg/day to five patients with circumscribed choroidal hemangioma. We then evaluated visual acuity, binocular indirect ophthalmoscopy, optical coherence tomography, optical coherence tomography angiography, fluorescein and indocyanine green angiography, and ocular ultrasonography at regular intervals and compared changes from the baseline assessments. Results: No clinical or diagnostic changes were observed in the sizes of the circumscribed choroidal hemangiomas during treatment. Complications due to the hemangioma were reduced in the first four months of treatment, followed by maintenance, before worsening in the subsequent three months. Conclusions: The study showed that oral propranolol at a dose of 1.5 mg/kg/day did not offer effective monotherapy in the treatment of circumscribed choroidal hemangioma.
C1 [Castelo Branco Sancho, Karlos Frederico; Zett, Claudio; Morales, Melina Correia; Maia, Mauricio; Mattos Neto, Rubens Belfort] Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Sao Paulo, SP, Brazil.
   [Zett, Claudio] Pontificia Univ Catolica Valparaiso, Valparaiso, Chile.
   [Goncalves Junior, Iran] Univ Fed Sao Paulo, Dept Cardiol, Hosp Sao Paulo, Sao Paulo, SP, Brazil.
RP Neto, RBM (corresponding author), Rua Augusta 2529, BR-01413000 Sao Paulo, SP, Brazil.
EM rubens@belfort.med.br
RI Belfort, Rubens/AAD-5416-2020; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR Arevalo JF, 2011, ARCH OPHTHALMOL-CHIC, V129, P1373, DOI 10.1001/archophthalmol.2011.294
   Balasubramaniam SC, 2017, RETINA-J RET VIT DIS, V37, P1134, DOI 10.1097/IAE.0000000000001317
   Berry Morgan, 2017, J Optom, V10, P79, DOI 10.1016/j.optom.2015.12.006
   Causse S, 2013, BRIT J DERMATOL, V169, P125, DOI 10.1111/bjd.12417
   Cennamo G, 2017, EYE, V31, P906, DOI 10.1038/eye.2017.14
   Dave Tarjani, 2016, Retin Cases Brief Rep, V10, P11, DOI 10.1097/ICB.0000000000000165
   Ji Y, 2015, BRIT J DERMATOL, V172, P24, DOI 10.1111/bjd.13388
   Ji Y, 2016, BRIT J DERMATOL, V174, P464
   Ji Y, 2012, ANN SURG, V256, P146
   Ji Y, 2015, ANN SURG, V261, pE52, DOI 10.1097/SLA.0000000000000450
   Karimi Saeed, 2015, J Ophthalmic Vis Res, V10, P320, DOI 10.4103/2008-322X.170353
   Krema H, 2013, JAMA OPHTHALMOL, V131, P681, DOI 10.1001/jamaophthalmol.2013.2879
   Kumar MG, 2015, PEDIATR DERMATOL, V32, P171, DOI 10.1111/pde.12435
   Naseripour M, 2018, RETINA-J RET VIT DIS, V38, P1024, DOI 10.1097/IAE.0000000000001616
   Sanz-Marco E, 2011, CASE REP OPHTHALM, V2, P84, DOI 10.1159/000325142
   Shields JA, 2008, INTRAOCULAR TUMORS A, P230
   Tanabe H, 2013, JAMA OPHTHALMOL, V131, P1617, DOI 10.1001/jamaophthalmol.2013.5669
   Thapa R, 2013, EUR J OPHTHALMOL, V23, P922, DOI 10.5301/ejo.5000322
   Tsipursky MS, 2011, SURV OPHTHALMOL, V56, P68, DOI 10.1016/j.survophthal.2010.08.002
   WITSCHEL H, 1976, Survey of Ophthalmology, V20, P415, DOI 10.1016/0039-6257(76)90067-9
   Zhang L, 2013, INT J CLIN EXP MED, V6, P342
NR 21
TC 0
Z9 0
U1 0
U2 3
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAY-JUN
PY 2018
VL 81
IS 3
BP 171
EP 176
DI 10.5935/0004-2749.20180037
PG 6
WC Ophthalmology
SC Ophthalmology
GA GJ8QH
UT WOS:000435654400002
PM 29924188
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Alves, BD
   Brasil, OFM
   Espinhosa, CT
   Japiassu, RM
   Goncalves, MB
   Magalhaes, O
   Maia, A
   Badaro, E
   Serraino, P
   Alezzandrinni, A
   Maia, M
AF Alves, Bruno de Queiroz
   Moura Brasil, Oswaldo Ferreira
   Espinhosa, Cristiano Toesca
   Japiassu, Ricardo Miguel
   Goncalves, Mariana Batista
   Magalhaes Junior, Otaviano
   Maia, Andre
   Badaro, Emmerson
   Serraino, Paula
   Alezzandrinni, Arturo
   Maia, Mauricio
TI Combined Femtosecond Laser-Assisted Cataract Surgery and Small-Gauge
   Pars Plana Vitrectomy Using Different Devices: A New Trend for
   Vitreoretinal Surgery?
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Review
ID PHACOEMULSIFICATION
AB BACKGROUND AND OBJECTIVE: To report the efficacy, safety, and benefits of femtosecond laser-assisted cataract surgery (FLACS) combined with sutureless 23-gauge pars plana vitrectomy (PPV).
   PATIENTS AND METHODS: This multicenter, retrospective study evaluated patient records and videos of 43 cases with retinal pathologies and cataract who underwent the combined procedure.
   RESULTS: In 44.2% and 55.8% of cases, respectively, the LenSx Laser (femtosecond machine; Alcon, Fort Worth, TX) and the Constellation (vitreous cutter; Alcon, Fort Worth, TX), and the Victus (femtosecond machine; Bausch + Lomb, Rochester, NY) and Stellaris PC (vitreous cutter; Bausch + Lomb, Rochester, NY) were used. No complications developed during capsulorrhexis, even without a red fundus reflex, retrobulbar block, or scleral indentation. Foldable intraocular lenses remained stable in the capsular bag during the vitreoretinal surgeries and postoperative visits. The mean times of femtosecond phacoemulsification, vitreoretinal surgery, and total surgery were 22.9 minutes +/- 4.7 minutes, 43.1 minutes +/- 9.8 minutes, and 65.3 minutes +/- 8.6 minutes, respectively.
   CONCLUSION: This emerging technology is safe and offers several potential benefits for the success of the combined procedure.
C1 [Alves, Bruno de Queiroz; Moura Brasil, Oswaldo Ferreira; Espinhosa, Cristiano Toesca; Japiassu, Ricardo Miguel; Goncalves, Mariana Batista; Magalhaes Junior, Otaviano; Maia, Andre; Badaro, Emmerson; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Serraino, Paula; Alezzandrinni, Arturo] Univ Buenos Aires, Inst Oftalmol Alta Complejidad, Buenos Aires, DF, Argentina.
   [Maia, Mauricio] Brazilian Inst Fight Blindness INBRACE, Assis & Presidente Prudente, Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, 822 Botucatu St, BR-06023062 Vila Clementino, Brazil.
EM retina@femanet.com.br
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo. Sao Paulo,
   BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brasilia,
   BrazilNational Council for Scientific and Technological Development
   (CNPq); Jose Berrocal Award (Panamerican Vitreoretinal Society, Puerto
   Rico)
FX Publication of this article was supported by Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo. Sao Paulo, Brazil; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico, Brasilia, Brazil; and Jose
   Berrocal Award 2013 (Panamerican Vitreoretinal Society, Puerto Rico).
CR Friedman NJ, 2011, J CATARACT REFR SURG, V37, P1189, DOI 10.1016/j.jcrs.2011.04.022
   Heath G, 2010, EYE LOND, V24, P2214
   KOENIG SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P1101, DOI 10.1001/archopht.1992.01080200081029
   Li WS, 2009, ACTA OPHTHALMOL, V87, P896, DOI 10.1111/j.1755-3768.2008.01383.x
   Martin AI, 2014, CURR OPIN OPHTHALMOL, V25, P71, DOI 10.1097/ICU.0000000000000018
   Nagy Z, 2009, J REFRACT SURG, V25, P1053, DOI 10.3928/1081597X-20091117-04
   Palanker DV, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001305
   Pardo-Munoz A, 2006, EUR J OPHTHALMOL, V16, P52
   Rahman R, 2002, J CATARACT REFR SURG, V28, P1607, DOI 10.1016/S0886-3350(02)01212-9
   Uy HS, 2012, CURR OPIN OPHTHALMOL, V23, P33, DOI 10.1097/ICU.0b013e32834cd622
NR 10
TC 2
Z9 2
U1 0
U2 4
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAY
PY 2018
VL 49
IS 5
BP 374
EP 379
DI 10.3928/23258160-20180501-13
PG 6
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA GG9DF
UT WOS:000433000200013
PM 29772050
DA 2020-12-15
ER

PT J
AU Chhablani, J
   Paulose, RM
   Lasave, AF
   Wu, L
   Carpentier, C
   Maia, M
   Lujan, S
   Rojas, S
   Serrano, M
   Berrocal, MH
   Arevalo, JF
AF Chhablani, Jay
   Paulose, Remya Mareen
   Lasave, Andres F.
   Wu, Lihteh
   Carpentier, Cristian
   Maia, Mauricio
   Lujan, Silvio
   Rojas, Sergio
   Serrano, Martin
   Berrocal, Maria H.
   Arevalo, J. Fernando
TI Intravitreal bevacizumab monotherapy in myopic choroidal
   neovascularisation: 5-year outcomes for the PAN-American Collaborative
   Retina Study Group
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE choroidal neovascularization; anti-VEGF; myopia; bevacizumab
ID MACULAR DEGENERATION; PATHOLOGICAL MYOPIA; RANIBIZUMAB; SECONDARY
AB Purpose To report the long-term anatomical and visual outcomes of intravitreal bevacizumab (IVB) monotherapy in naive choroidal neovascularisation (CNV) caused by myopia.
   Methods Retrospective analysis of naive CNV secondary to myopia that underwent antivascular endothelial growth factor monotherapy was performed. Collected data included demographic details, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were resolution of CNV activity at the last visit. Secondary outcomes included change in visual acuity, number of injections and adverse events.
   Results Thirty-three eyes of 31 subjects with a mean age of 51.4816.4 years were included. The mean follow-up was 66.47 months. 27 eyes had type 2 CNV and the rest seven eyes had type 1 CNV. The mean number of IVB injections per eye was 4.9. Mean visual acuity at baseline reduced from 0.65 +/- 0.33logMAR units (Snellen equivalent=20/89) to 0.73 +/- 0.50logMAR units (20/107) at final follow-up (p=0.003). The mean central macular thickness decreased from 309.31 +/- 86 mu m at baseline to 267.5 +/- 70.89 mu m at the last visit (p=0.03). However, visual acuity was maintained (+/- 1line of baseline) in 13 eyes (39.4%), 2line improvement in nine (27.3%) eyes and more than two lines worsening in 11 eyes (33.3%). Foveal atrophy was observed at baseline and last visit in 6 (12.5%) and 14 (29.1%), respectively (p=0.007). No systemic adverse events were observed.
   Conclusion IVB monotherapy is safe and effective for long-term treatment of CNV secondary to myopia in real life.
C1 [Chhablani, Jay; Paulose, Remya Mareen] LV Prasad Eye Inst, Hyderabad, Andhra Pradesh, India.
   [Lasave, Andres F.] Clin Privada Ojos, Retina & Vitreous Serv, Mar Del Plata, Buenos Aires, Argentina.
   [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Carpentier, Cristian] Los Andes Univ, Fdn Oftalmol Los Andes, Santiago, Chile.
   [Maia, Mauricio] Fed Univ Sao Paulo UNIFESP, Retina Div, Dept Ophthalmol & Visual Sci, Sao Paulo, Brazil.
   [Lujan, Silvio] MACULA D&T Diagnost Tratamiento & Rehabil Visual, Lima, Peru.
   [Rojas, Sergio] Fdn Hosp Nuestra Senora Luz, Mexico City, DF, Mexico.
   [Serrano, Martin] Ctr Caracas, Clin Oftalmol, Caracas, Venezuela.
   [Serrano, Martin] Arevalo Coutinho Fdn Res Ophthalmol, Caracas, Venezuela.
   [Berrocal, Maria H.] Univ Puerto Rico, Dept Ophthalmol, San Juan, PR 00936 USA.
   [Arevalo, J. Fernando] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
RP Arevalo, JF (corresponding author), Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St,Maumenee 708, Baltimore, MD 21287 USA.
EM arevalojf@jhmi.edu
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Lasave, Andres/0000-0002-9602-9769
CR Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Brue C, 2016, EYE, V30, P139, DOI 10.1038/eye.2015.199
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   CURTIN BJ, 1971, AM J OPHTHALMOL, V71, P42, DOI 10.1016/0002-9394(71)91092-0
   Gharbiya M, 2010, CLIN TER, V161, pE87
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P589, DOI 10.1016/j.ophtha.2014.10.001
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gupta B, 2010, EYE, V24, P203, DOI 10.1038/eye.2009.201
   HAMPTON GR, 1983, OPHTHALMOLOGY, V90, P923
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P3721, DOI 10.1167/iovs.09-3493
   Ikuno Y, 2010, AM J OPHTHALMOL, V149, P140, DOI 10.1016/j.ajo.2009.08.008
   Leveziel N, 2012, INVEST OPHTH VIS SCI, V53, P5004, DOI 10.1167/iovs.12-9538
   Maguire MG, 2016, OPHTHALMOLOGY
   Marano F, 2000, GRAEF ARCH CLIN EXP, V238, P760, DOI 10.1007/s004170000186
   Nakanishi H, 2011, EYE, V25, P375, DOI 10.1038/eye.2010.226
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   Parodi MB, 2013, RETINA-J RET VIT DIS, V33, P953, DOI 10.1097/IAE.0b013e318275397c
   Prabhu VV, 2011, INDIAN J OPHTHALMOL, V59, P306, DOI 10.4103/0301-4738.82000
   Ruiz-Moreno JM, 2010, GRAEF ARCH CLIN EXP, V248, P937, DOI 10.1007/s00417-010-1340-y
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Yadav NK, 2009, EYE, V23, P1872, DOI 10.1038/eye.2008.370
   Yoshida T, 2003, OPHTHALMOLOGY, V110, P1297, DOI 10.1016/S0161-6420(03)00461-5
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 25
TC 4
Z9 4
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2018
VL 102
IS 4
BP 455
EP 459
DI 10.1136/bjophthalmol-2017-310411
PG 5
WC Ophthalmology
SC Ophthalmology
GA GC4DD
UT WOS:000429732500007
PM 28814417
DA 2020-12-15
ER

PT J
AU Mansour, AM
   Sheheitli, H
   Kucukerdonmez, C
   Sisk, RA
   Moura, R
   Moschos, MM
   Lima, LH
   Al-Shaar, L
   Arevalo, JF
   Maia, M
   Foster, RE
   Kayikcioglu, O
   Kozak, I
   Kurup, S
   Zegarra, H
   Gallego-Pinazo, R
   Hamam, RN
   Bejjani, RA
   Cinar, E
   Erakgun, ET
   Kimura, A
   Teixeira, A
AF Mansour, Ahmad M.
   Sheheitli, Huda
   Kucukerdonmez, Cem
   Sisk, Robert A.
   Moura, Raphael
   Moschos, Marilita M.
   Lima, Luiz H.
   Al-Shaar, Laila
   Fernando Arevalo, J.
   Maia, Mauricio
   Foster, Robert E.
   Kayikcioglu, Ozcan
   Kozak, Igor
   Kurup, Shree
   Zegarra, Hernando
   Gallego-Pinazo, Roberto
   Hamam, Rola N.
   Bejjani, Riad A.
   Cinar, Esat
   Erakgun, Ethem T.
   Kimura, Alan
   Teixeira, Anderson
TI INTRAVITREAL DEXAMETHASONE IMPLANT IN RETINITIS PIGMENTOSA-RELATED
   CYSTOID MACULAR EDEMA
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE cystoid macular edema; dexamethasone implant; intraocular pressure;
   retinitis pigmentosa
ID OPTICAL COHERENCE TOMOGRAPHY; TRIAMCINOLONE ACETONIDE; VISUAL-ACUITY;
   ASSOCIATION; MANAGEMENT; SECONDARY
AB Purpose: To report the clinical outcome after intravitreal dexamethasone implant in patients with retinitis pigmentosa and cystoid macular edema.
   Methods: Multicenter retrospective case series of eyes with retinitis pigmentosa and cystoid macular edema that underwent intravitreal dexamethasone implant. Primary outcome measures were best-corrected visual acuity in LogMAR and central macular thickness. Statistical analyses used two-tailed comparison with Wilcoxon signed-rank test.
   Results: There were a total of 45 eyes from 34 patients with a mean age of 32.7 years (range 16-57) and mean follow-up of 15.5 +/- 13.0 months. At Month 3 after the first injection, mean initial best-corrected visual acuity improved from 0.61 +/- 0.38 (20/81) to 0.37 +/- 0.16 (20/47) (P = 0.012), whereas mean central macular thickness (mu m) decreased from 506 +/- 288 mu m to 311.7 +/- 71.6 mu m (P < 0.001) and mean intraocular pressure increased from 15.7 +/- 2.3 mmHg to 19.8 +/- 11.0 mmHg (P = 0.01). Fourteen eyes had multiple injections (1-7 reinjections) at a mean interval of 6 months. Treatment effect was durable with multiple injections, but with seven eyes developing visually significant cataracts.
   Conclusion: Best-corrected visual acuity improved up to 4 months in around half of the eyes. Eyes that benefited the most were pseudophakic, steroid nonresponsive, with large initial central macular thickness, and profuse fluorescein dye leakage.
C1 [Mansour, Ahmad M.] Rafic Hariri Univ Hosp, Dept Ophthalmol, Beirut, Lebanon.
   [Mansour, Ahmad M.; Sheheitli, Huda; Hamam, Rola N.] Amer Univ Beirut, Dept Ophthalmol, Beirut 1136044, Lebanon.
   [Kucukerdonmez, Cem; Cinar, Esat] Izmir Univ, Fac Med, Dept Ophthalmol, Izmir, Turkey.
   [Sisk, Robert A.; Foster, Robert E.] Univ Cincinnati, Cincinnati Eye Inst, Dept Ophthalmol, Cincinnati, OH USA.
   [Moura, Raphael; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Moschos, Marilita M.] Univ Athens, Dept Ophthalmol, Athens, Greece.
   [Lima, Luiz H.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Al-Shaar, Laila] Amer Univ Beirut, Med Ctr, Vasc Med Program, Beirut, Lebanon.
   [Fernando Arevalo, J.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Kayikcioglu, Ozcan] Celal Bayar Univ, Dept Ophthalmol, Manisa, Turkey.
   [Kozak, Igor] King Khalid Eye Specialist Hosp, Div Vitreoretinal Dis & Surg, Riyadh, Saudi Arabia.
   [Kurup, Shree] Wake Forest Univ, Dept Ophthalmol, Winston Salem, NC 27109 USA.
   [Zegarra, Hernando] Retina Associates Cleveland, Beachwood, OH USA.
   [Gallego-Pinazo, Roberto] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Valencia, Spain.
   [Bejjani, Riad A.] Hotel Dieu France, Dept Ophthalmol, Beirut, Lebanon.
   [Erakgun, Ethem T.] Ekol Eye Hosp, Dept Ophthalmol, Izmir, Turkey.
   [Kimura, Alan] Univ Colorado, Dept Ophthalmol, Aurora, CO USA.
   [Teixeira, Anderson] Univ Catolica Brasilia, Sch Med, Brasilia, DF, Brazil.
RP Mansour, AM (corresponding author), Amer Univ Beirut, Dept Ophthalmol, Beirut 1136044, Lebanon.
EM ammansourmd@gmail.com
RI Kozak, Igor/AAC-4645-2019; Lima, Luiz H/V-4940-2017; Maia,
   Mauricio/I-5892-2015; cinar, esat/AAE-4755-2019; Hamam, Rola/K-7454-2019
OI Lima, Luiz H/0000-0001-7304-909X; Maia, Mauricio/0000-0002-7034-8091;
   Al-Shaar, Laila/0000-0003-2774-3464
CR Adamus G, 2012, MOL VIS, V18, P2323
   Ahn SJ, 2014, OPHTHAL SURG LAS IM, V45, P160, DOI 10.3928/23258160-20140131-03
   Alhassan M, 2013, GRAEF ARCH CLIN EXP, V251, P2827, DOI 10.1007/s00417-013-2447-8
   Artunay O, 2009, J OCUL PHARMACOL TH, V25, P545, DOI 10.1089/jop.2009.0089
   Barge S, 2013, CASE REP OPHTHALMOL, DOI 10.1155/2013/591681
   Buchaim G, 2013, ARQ BRAS OFTALMOL, V76, P377, DOI 10.1590/S0004-27492013000600013
   Chung H, 2006, RETINA-J RET VIT DIS, V26, P922, DOI 10.1097/01.iae.0000250008.83779.23
   Guadagni V, 2015, PROG RETIN EYE RES, V48, P62, DOI 10.1016/j.preteyeres.2015.06.005
   Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014
   Heckenlively JR, 1999, AM J OPHTHALMOL, V127, P565, DOI 10.1016/S0002-9394(98)00446-2
   Kim JE, 2006, RETINA-J RET VIT DIS, V26, P1094, DOI 10.1097/01.iae.0000254897.86389.a5
   Kim YJ, 2013, INVEST OPHTH VIS SCI, V54, P1303, DOI 10.1167/iovs.12-10149
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Liew G, 2015, INVEST OPHTH VIS SCI, V56, P1531, DOI 10.1167/iovs.14-15995
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Minnella AM, 2006, EUR J OPHTHALMOL, V16, P883
   Ozdemir H, 2005, ACTA OPHTHALMOL SCAN, V83, P248, DOI 10.1111/j.1600-0420.2005.00395.x
   Patil L, 2014, EYE, V28, P449, DOI 10.1038/eye.2013.314
   Saatci AO, 2013, CASE REP OPHTHALM, V4, P53, DOI 10.1159/000350544
   Sacchetti M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/737053
   Sandberg MA, 2005, INVEST OPHTH VIS SCI, V46, P3349, DOI 10.1167/iovs.04-1383
   Saraiva VS, 2003, OPHTHALMIC SUR LA IM, V34, P398
   Scorolli L, 2007, ARCH OPHTHALMOL-CHIC, V125, P759, DOI 10.1001/archopht.125.6.759
   Siqueira RC, 2013, BONE MARROW TRANSPL, V48, P612, DOI 10.1038/bmt.2012.185
   Srour M, 2013, GRAEF ARCH CLIN EXP, V251, P1501, DOI 10.1007/s00417-012-2249-4
   Urban Kathleen E, 2009, Retin Cases Brief Rep, V3, P47, DOI 10.1097/ICB.0b013e318150d705
   Wang CG, 2006, ADV EXP MED BIOL, V572, P309
   Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006
NR 28
TC 7
Z9 7
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2018
VL 38
IS 2
BP 416
EP 423
PG 8
WC Ophthalmology
SC Ophthalmology
GA GB0KQ
UT WOS:000428735400030
PM 28221257
DA 2020-12-15
ER

PT J
AU Deng, R
   Wang, YH
   Maia, M
   Burgess, T
   McBride, JM
   Liao, XC
   Tavel, JA
   Hanley, WD
AF Deng, Rong
   Wang, Yehong
   Maia, Mauricio
   Burgess, Tracy
   McBride, Jacqueline M.
   Liao, X. Charlene
   Tavel, Jorge A.
   Hanley, William D.
TI Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination
   of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a
   Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk
   Kidney Transplant Recipients
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE RG7667; cytomegalovirus; kidney transplantation; monoclonal antibodies;
   pharmacokinetics
ID STAGE RENAL-DISEASE; IMMUNE GLOBULIN; LIVER-TRANSPLANTATION;
   HEALTHY-VOLUNTEERS; ENDOTHELIAL-CELLS; ORAL GANCICLOVIR; DOUBLE-BLIND;
   CMV DISEASE; SAFETY; VIRUS
AB RG7667, a novel combination of two anticytomegalovirus (anti-CMV) monoclonal IgG1 antibodies (MCMV5322A and MCMV3068A), was designed to block CMV entry into host cells. It was developed as a potential therapy for preventing CMV infection and disease in transplant recipients. RG7667 was assessed for preventing CMV infection in a phase 2a trial with CMV-seronegative recipients of kidney transplants from CMV-seropositive donors. The patients received 4 intravenous doses of RG7667 (10 mg/kg of body weight of each antibody, n = 60) or placebo (n = 60) at the time of the transplant and at 1, 4, and 8 weeks after the transplant. Serum samples were collected for pharmacokinetic (PK) analysis and antidrug antibody (ADA) evaluation. To guide future dose selection, the relationships between RG7667 exposure and pharmacological activity were evaluated. MCMV5322A and MCMV3068A exposures were confirmed in all RG7667-treated patients. Mean clearances for MCMV5322A and MCMV3068A were 2.97 and 2.65 ml/day/kg, respectively, and the terminal half-lives of MCMV5322A and MCMV3068A were 26.9 and 27.4 days, respectively. The ADA incidence was low and was not associated with lower drug exposure. Patients with RG7667 or component antibody exposures greater than the respective median values had a lower incidence of viremia at 12 weeks and 24 weeks after transplantation and a longer delayed time to detectable CMV viremia than patients with exposures less than the median values. MCMV5322A and MCMV3068A exhibited expected IgG1 PK profiles in high-risk kidney transplant recipients, consistent with the earlier PK behavior of RG7667 in healthy subjects. Higher drug exposure was associated with better anti-CMV pharmacological activity. (This study has been registered at ClinicalTrials. gov under identifier NCT01753167.)
C1 [Deng, Rong; Wang, Yehong; Maia, Mauricio; Burgess, Tracy; McBride, Jacqueline M.; Liao, X. Charlene; Tavel, Jorge A.; Hanley, William D.] Genentech Inc, San Francisco, CA 94080 USA.
   [Liao, X. Charlene] Immune Onc Therapeut Inc, Palo Alto, CA USA.
RP Deng, R (corresponding author), Genentech Inc, San Francisco, CA 94080 USA.
EM deng.rong@gene.com
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
FU Genentech, Inc.Roche HoldingGenentech
FX This study was supported by Genentech, Inc. Editing and writing
   assistance was provided by Deborah Solymar (Genentech, Inc.) and funded
   by Genentech, Inc.
CR AULITZKY WE, 1991, J INFECT DIS, V163, P1344, DOI 10.1093/infdis/163.6.1344
   Bai S, 2012, CLIN PHARMACOKINET, V51, P119, DOI 10.2165/11596370-000000000-00000
   Both L, 2013, VACCINE, V31, P1553, DOI 10.1016/j.vaccine.2013.01.025
   Castro M, 2001, P AN M AM SOC CLIN, V20, p233b
   Chung RT, 2013, AM J TRANSPLANT, V13, P1047, DOI 10.1111/ajt.12083
   DROBYSKI WR, 1991, TRANSPLANTATION, V51, P1190, DOI 10.1097/00007890-199106000-00009
   Falagas ME, 1997, CLIN TRANSPLANT, V11, P432
   Fouts AE, 2014, P NATL ACAD SCI USA, V111, P8209, DOI 10.1073/pnas.1404653111
   Garnier-Viougeat N, 2007, NEPHROL DIAL TRANSPL, V22, P975, DOI 10.1093/ndt/gfl664
   Griffiths PD, 2011, LANCET, V377, P1256, DOI 10.1016/S0140-6736(11)60136-0
   Gupta NK, 2003, BLOOD, V102, p298B
   Gupta P, 2016, MABS-AUSTIN, V8, P991, DOI 10.1080/19420862.2016.1167294
   Hahn G, 2004, J VIROL, V78, P10023, DOI 10.1128/JVI.78.18.10023-10033.2004
   Hodson EM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003774.pub4
   Husain S, 2009, TRANSPL IMMUNOL, V21, P1, DOI 10.1016/j.trim.2008.12.004
   Ishida JH, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01794-16
   Ishida JH, 2015, ANTIMICROB AGENTS CH, V59, P4919, DOI 10.1128/AAC.00523-15
   Jillella AP, 2002, AM J HEMATOL, V71, P219, DOI 10.1002/ajh.10213
   Leav BA, 2010, J HEPATOL, V52, pS118, DOI 10.1016/S0168-8278(10)60283-8
   Lim JJ, 2016, ANTIMICROB AGENTS CH, V60, P5437, DOI 10.1128/AAC.00607-16
   McKeage K, 2002, DRUGS, V62, P209, DOI 10.2165/00003495-200262010-00008
   METSELAAR HJ, 1987, TRANSPL P, V19, P4063
   Paya C, 2004, AM J TRANSPLANT, V4, P611, DOI 10.1111/j.1600-6143.2004.00382.x
   Ramanan P, 2013, INFECT CHEMOTHER, V45, P260, DOI 10.3947/ic.2013.45.3.260
   Razonable RR, 2001, J INFECT DIS, V184, P1461, DOI 10.1086/324516
   Saylor C, 2009, VACCINE, V27, pG38, DOI 10.1016/j.vaccine.2009.09.105
   SNYDMAN DR, 1984, TRANSPLANTATION, V38, P553, DOI 10.1097/00007890-198411000-00026
   SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703
   Snydman DR., 2001, TRANSPL INFECT DI S2, V3, pS6
   Thariat J, 2008, J CLIN ONCOL, V26, P4223, DOI 10.1200/JCO.2008.18.7674
   Wang D, 2005, P NATL ACAD SCI USA, V102, P18153, DOI 10.1073/pnas.0509201102
   Wang D, 2005, J VIROL, V79, P10330, DOI 10.1128/JVI.79.16.10330-10338.2005
   Wille PT, 2010, J VIROL, V84, P2585, DOI 10.1128/JVI.02249-09
NR 33
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD FEB
PY 2018
VL 62
IS 2
AR e01108-17
DI 10.1128/AAC.01108-17
PG 12
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA FT9AF
UT WOS:000423443600021
PM 29133549
OA Green Published, Bronze
DA 2020-12-15
ER

PT J
AU Peris, CS
   Caiado, RR
   Lima, AAS
   Rodrigues, EB
   Farah, ME
   Goncalves, MB
   Alves, BD
   Urushima, JGP
   Ragazzi, R
   Maia, M
AF Peris, Cristiane S.
   Caiado, Rafael R.
   Souza Lima-Filho, Acacio Alves
   Rodrigues, Eduardo B.
   Farah, Michel Eid
   Goncalves, Mariana Batista
   Alves, Bruno de Queiroz
   Palma Urushima, Joao Guilherme
   Ragazzi, Raul
   Maia, Mauricio
TI Analysis of Anthocyanins Extracted from the Acai Fruit (Euterpe
   oleracea): A Potential Novel Vital Dye for Chromovitrectomy
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Purpose. To classify and quantify anthocyanins in a vital dye extracted from the acai fruit (Euterpe oleracea), adjust pH and osmolarity, and perform lyophilization to develop a new chromovitrectomy dye. Methods. Three dye concentrations 10%, 25%, and 35% (equivalent to 100, 250, and 350 mg of lyophilized acai fruit pulp extract samples) were evaluated when diluted in 1 ml of phosphate-buffered solution (pH 7 and 300 mOsm). The dye was analyzed by mass spectrometry and high-performance liquid chromatography (HPLC) to identify and quantify anthocyanins molecules. Results. The pH and osmolarity correction and lyophilization were performed without damaging the anthocyanin molecular structure. Mass spectrometry confirmed the presence of five anthocyanins in the three concentrations of the dye. Cyanidin-3-O-glucoside was the major anthocyanin found. HPLC showed that the concentration of anthocyanin wars similar, independent of the dye concentration tested. Conclusions. Lyophilization and the correction of pH and osmolarity (7.00 and 300 mOsm, resp.) were performed successfully. Five anthocyanins are present in the dye from the acai fruit. The major anthocyanin is cyanidin-3-O-glucoside. Independent of the dye concentration tested, the anthocyanin concentration was similar. Standardized chemical characteristics of this new dye may allow its use during chromovitrectomy in humans.
C1 [Peris, Cristiane S.; Caiado, Rafael R.; Souza Lima-Filho, Acacio Alves; Rodrigues, Eduardo B.; Farah, Michel Eid; Goncalves, Mariana Batista; Alves, Bruno de Queiroz; Palma Urushima, Joao Guilherme; Ragazzi, Raul; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Botucatu St,816 Vila Clementino, BR-04023062 Sao Paulo, Brazil.
   [Souza Lima-Filho, Acacio Alves; Ragazzi, Raul] Ophthalmos SA, Brigadeiro Luis Antonio Ave,4830 Jardim Paulista, BR-01401002 Sao Paulo, SP, Brazil.
   [Maia, Mauricio] Brazilian Inst Fight Blindness, Otto Ribeiro Ave,901 Jardim Paulista, BR-19814470 Assis, SP, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Botucatu St,816 Vila Clementino, BR-04023062 Sao Paulo, Brazil.; Maia, M (corresponding author), Brazilian Inst Fight Blindness, Otto Ribeiro Ave,901 Jardim Paulista, BR-19814470 Assis, SP, Brazil.
EM maiamauricio@terra.com.br
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012; de Souza
   Lima Filho, Acacio Alves/C-7189-2012; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Alves de
   Souza Lima Filho, Acacio/0000-0003-1802-9592; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brasilia,
   BrazilNational Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Sao Paulo,
   BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Pan-American Association of Ophthalmology/Pan-American Ophthalmological
   Foundation, Paul Kayser Global Award, Arlington, Texas
FX This work was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, Brasilia, Brazil; Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo, Sao Paulo, Brazil; and Pan-American
   Association of Ophthalmology/Pan-American Ophthalmological Foundation,
   Paul Kayser Global Award, Arlington, Texas. The authors are grateful to
   Rubens Belfort Jr., M.D., Ph.D., for donating supplies for the
   development of this study and to Paulo Schor, M.D., Ph.D., for support
   regarding application for financial support at Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico, Brasilia, Brazil.
CR Caiado RR, 2017, CURR EYE RES, V42, P1185, DOI 10.1080/02713683.2017.1297995
   Carvalho AV, 2017, J SCI FOOD AGR, V97, P1467, DOI 10.1002/jsfa.7886
   Chen J, 2013, RETINA-J RET VIT DIS, V33, P89, DOI 10.1097/IAE.0b013e3182618a6d
   Cretu GC, 2014, FOOD CHEM, V146, P104, DOI 10.1016/j.foodchem.2013.09.038
   Darnet S, 2011, FOOD RES INT, V44, P2107, DOI 10.1016/j.foodres.2010.12.039
   Yamaguchi KKD, 2015, FOOD CHEM, V179, P137, DOI 10.1016/j.foodchem.2015.01.055
   Del Pozo-Insfran D, 2004, J AGR FOOD CHEM, V52, P1539, DOI 10.1021/jf035189n
   Costa EDF, 2009, INVEST OPHTH VIS SCI, V50, P385, DOI 10.1167/iovs.08-2285
   Gallori S, 2004, CHROMATOGRAPHIA, V59, P739, DOI 10.1365/s10337-004-0305-x
   Peris CS, 2013, J OCUL PHARMACOL TH, V29, P746, DOI 10.1089/jop.2013.0003
   Rogez H., 2000, ACAI PREPARO COMPOSI
   Rufino MDM, 2011, FOOD RES INT, V44, P2100, DOI 10.1016/j.foodres.2010.09.011
   Yanagi Y, 2006, BRIT J OPHTHALMOL, V90, P229, DOI 10.1136/bjo.2005.076711
NR 13
TC 1
Z9 1
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2018
VL 2018
AR 6830835
DI 10.1155/2018/6830835
PG 9
WC Medicine, Research & Experimental; Ophthalmology
SC Research & Experimental Medicine; Ophthalmology
GA GP0MP
UT WOS:000440504500001
PM 30116632
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Freitas, BD
   Zin, A
   Ko, A
   Maia, M
   Ventura, CV
   Belfort, R
AF Freitas, Bruno de Paula
   Zin, Andrea
   Ko, Albert
   Maia, Mauricio
   Ventura, Camila V.
   Belfort, Rubens, Jr.
TI Anterior-Segment Ocular Findings and Microphthalmia in Congenital Zika
   Syndrome
SO OPHTHALMOLOGY
LA English
DT Editorial Material
ID VIRUS
C1 [Freitas, Bruno de Paula] Hosp Geral Roberto Santos, Dept Ophthalmol, Salvador, BA, Brazil.
   [Freitas, Bruno de Paula; Maia, Mauricio; Ventura, Camila V.; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Vis Inst, Sao Paulo, Brazil.
   [Freitas, Bruno de Paula; Maia, Mauricio; Ventura, Camila V.; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Dept Ophthalmol, Rua Botucatu 821,1st Floor, BR-04023062 Sao Paulo, Brazil.
   [Zin, Andrea] Fundacao Oswaldo Cruz, Inst Fernandes Figueira, Clin Res Unit, Rio De Janeiro, Brazil.
   [Ko, Albert] Fundacao Oswaldo Cruz, Goncalo Moniz Res Ctr, Salvador, BA, Brazil.
   [Ko, Albert] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
   [Ventura, Camila V.] Altino Ventura Fdn, Recife, PE, Brazil.
RP Belfort, R (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Rua Botucatu 821,1st Floor, BR-04023062 Sao Paulo, Brazil.
EM prof.belfort@clinicabelfort.com.br
RI Ventura, Camila V/N-2654-2018; Maia, Mauricio/I-5892-2015; Ko, Albert
   Icksang/P-2343-2015
OI Ventura, Camila V/0000-0002-2927-4684; Maia,
   Mauricio/0000-0002-7034-8091; Ko, Albert Icksang/0000-0001-9023-2339
CR Freitas BDP, 2017, OPHTHALMOLOGY, V124, P407, DOI 10.1016/j.ophtha.2016.10.004
   Meaney-Delman D, 2016, OBSTET GYNECOL, V128, P724, DOI 10.1097/AOG.0000000000001625
   Prazeres J, 2016, BRAZIL JAMA OPHTHALM, V134, P529, DOI [10.1001/jamaophthalmol.2016.0267, DOI 10.1001/JAMA0PHTHALM0L.2016.0267]
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
NR 5
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2017
VL 124
IS 12
BP 1876
EP 1878
PG 3
WC Ophthalmology
SC Ophthalmology
GA FM9JZ
UT WOS:000415586000031
PM 28676282
DA 2020-12-15
ER

PT J
AU Zhong, ZDD
   Clements-Egan, A
   Gorovits, B
   Maia, M
   Sumner, G
   Theobald, V
   Wu, YL
   Rajadhyaksha, M
AF Zhong, Zhandong Don
   Clements-Egan, Adrienne
   Gorovits, Boris
   Maia, Mauricio
   Sumner, Giane
   Theobald, Valerie
   Wu, Yuling
   Rajadhyaksha, Manoj
TI Drug Target Interference in Immunogenicity Assays: Recommendations and
   Mitigation Strategies
SO AAPS JOURNAL
LA English
DT Article
DE anti-drug antibody; immunogenicity; mitigation; neutralizing antibody;
   target interference
ID MONOCLONAL-ANTIBODY THERAPEUTICS; RHEUMATOID-FACTOR INTERFERENCE;
   BIOTECHNOLOGY PRODUCTS; HOST ANTIBODIES; PROTEIN; RESPONSES; ELISA;
   IDENTIFICATION; INHIBITION; VALIDATION
AB Sensitive and specific methodology is required for the detection and characterization of anti-drug antibodies (ADAs). High-quality ADA data enables the evaluation of potential impact of ADAs on the drug pharmacokinetic profile, patient safety, and efficacious response to the drug. Immunogenicity assessments are typically initiated at early stages in preclinical studies and continue throughout the drug development program. One of the potential bioanalytical challenges encountered with ADA testing is the need to identify and mitigate the interference mediated by the presence of soluble drug target. A drug target, when present at sufficiently high circulating concentrations, can potentially interfere with the performance of ADA and neutralizing antibody (NAb) assays, leading to either false-positive or, in some cases, false-negative ADA and NAb assay results. This publication describes various mechanisms of assay interference by soluble drug target, as well as strategies to recognize and mitigate such target interference. Pertinent examples are presented to illustrate the impact of target interference on ADA and NAb assays as well as several mitigation strategies, including the use of anti-target antibodies, soluble versions of the receptors, target-binding proteins, lectins, and solid-phase removal of targets. Furthermore, recommendations for detection and mitigation of such interference in different formats of ADA and NAb assays are provided.
C1 [Zhong, Zhandong Don] Amgen Inc, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
   [Clements-Egan, Adrienne] Janssen Res & Dev LLC, Janssen Biotherapeut, Spring House, PA USA.
   [Gorovits, Boris] Pfizer Inc, BioMed Design, Andover, MA USA.
   [Maia, Mauricio] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
   [Sumner, Giane; Rajadhyaksha, Manoj] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.
   [Theobald, Valerie] Shire Pharmaceut, Lexington, MA USA.
   [Wu, Yuling] MedImmune, Gaithersburg, MD USA.
RP Zhong, ZDD (corresponding author), Amgen Inc, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
EM zhongz@amgen.com
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR Araujo J, 2011, J PHARMACEUT BIOMED, V55, P1041, DOI 10.1016/j.jpba.2011.03.008
   Bourdage JS, 2007, J IMMUNOL METHODS, V327, P10, DOI 10.1016/j.jim.2007.07.004
   Buttel IC, 2011, BIOLOGICALS, V39, P100, DOI 10.1016/j.biologicals.2011.01.006
   Butterfield AM, 2010, BIOANALYSIS, V2, P1961, DOI [10.4155/bio.10.136, 10.4155/BIO.10.136]
   Carrasco-Triguero M, 2012, BIOANALYSIS, V4, P2013, DOI [10.4155/BIO.12.165, 10.4155/bio.12.165]
   Chen KG, 2013, J IMMUNOL METHODS, V394, P22, DOI 10.1016/j.jim.2013.04.011
   Committe for Medicinal Product for Human Use (CHMP), 2016, EMEACHMPBMWP14327200
   Dai S, 2014, AAPS J, V16, P464, DOI 10.1208/s12248-014-9581-z
   Gupta S, 2011, J PHARMACEUT BIOMED, V55, P878, DOI 10.1016/j.jpba.2011.03.038
   Jacques S, 2015, AAPS ANN M ORL FL
   Koren E, 2008, J IMMUNOL METHODS, V333, P1, DOI 10.1016/j.jim.2008.01.001
   Lee JW, 2011, AAPS J, V13, P99, DOI 10.1208/s12248-011-9251-3
   Li JA, 2011, J PHARMACEUT BIOMED, V54, P286, DOI 10.1016/j.jpba.2010.08.022
   Liao K, 2017, J IMMUNOL METHODS, V441, P15, DOI 10.1016/j.jim.2016.11.010
   Lofgren JA, 2006, J IMMUNOL METHODS, V308, P101, DOI 10.1016/j.jim.2005.10.007
   Mikulskis A, 2011, J IMMUNOL METHODS, V365, P38, DOI 10.1016/j.jim.2010.11.011
   Mire-Sluis AR, 2004, J IMMUNOL METHODS, V289, P1, DOI 10.1016/j.jim.2004.06.002
   Neubert H, 2008, ANAL CHEM, V80, P6907, DOI 10.1021/ac8005439
   Patton A, 2005, J IMMUNOL METHODS, V304, P189, DOI 10.1016/j.jim.2005.06.014
   Rispens T, 2013, J PHARMACEUT BIOMED, V85, P179, DOI 10.1016/j.jpba.2013.07.022
   Sanchez S, 2011, J PHARMACEUT BIOMED, V55, P1265, DOI 10.1016/j.jpba.2011.03.029
   Schwickart M, 2014, J IMMUNOL METHODS, V403, P52, DOI 10.1016/j.jim.2013.11.018
   Shankar G, 2008, J PHARMACEUT BIOMED, V48, P1267, DOI 10.1016/j.jpba.2008.09.020
   Sickert D, 2008, J IMMUNOL METHODS, V334, P29, DOI 10.1016/j.jim.2008.01.010
   Sim SL, 2012, J BIOTECHNOL, V157, P315, DOI 10.1016/j.jbiotec.2011.09.028
   Smith HW, 2007, REGUL TOXICOL PHARM, V49, P230, DOI 10.1016/j.yrtph.2007.07.005
   Tatarewicz S, 2010, J IMMUNOL METHODS, V357, P10, DOI 10.1016/j.jim.2010.03.012
   Wang YMC, 2012, PHARM RES-DORDR, V29, P3384, DOI 10.1007/s11095-012-0833-2
   Weeraratne DK, 2013, J IMMUNOL METHODS, V396, P44, DOI 10.1016/j.jim.2013.07.010
   Wu B, 2016, AAPS J
   Wu YL, 2015, AAPS J, V17, P1417, DOI 10.1208/s12248-015-9798-5
   Zhong ZDD, 2010, J IMMUNOL METHODS, V355, P21, DOI 10.1016/j.jim.2010.02.008
   Zoghbi J, 2015, J IMMUNOL METHODS, V426, P62, DOI 10.1016/j.jim.2015.08.002
NR 33
TC 15
Z9 15
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1550-7416
J9 AAPS J
JI AAPS J.
PD NOV
PY 2017
VL 19
IS 6
BP 1564
EP 1575
DI 10.1208/s12248-017-0148-7
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA FM5FR
UT WOS:000415057700003
PM 29063411
OA Other Gold
DA 2020-12-15
ER

PT J
AU Freitas, BD
   Ventura, CV
   Maia, M
   Belfort, R
AF Freitas, Bruno de Paula
   Ventura, Camila V.
   Maia, Mauricio
   Belfort, Rubens, Jr.
TI Zika virus and the eye
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE congenital Zika syndrome; ocular findings; Zika virus
ID INFECTION; INFANTS; BRAZIL; CLINICIAN
AB Purpose of review
   The aim of this study was to review the ocular findings related to the Zika virus (ZIKV) based on the main studies published to date, describe the patterns of the lesions and risk factors, and identify the public health implications and scientific importance of this emerging disease.
   Recent findings
   In most studies, the ZIKV seems related to congenital ocular lesions and most mothers reported mild symptoms during the first pregnancy trimester. Five fundus patterns were seen most often: macular chorioretinal atrophy, chorioretinal atrophy elsewhere, focal pigmentary changes in the macular region, optic nerve abnormalities and combined types. A few studies have suggested that the ZIKV might damage the anterior segment of these babies' eyes. Few reports have described the ocular complications seen in adults during the acute infection, including conjunctivitis, iridocyclitis and chorioretinitis.
   Summary
   Infants with congenital Zika syndrome might have vision-threatening fundus abnormalities. Although the full spectrum of ocular lesions caused by the ZIKV infection is not yet determined, a distinctive new disease has been observed. Recognition of these lesions by ophthalmologists can help ensure appropriate etiologic evaluation and clinical investigation to define the range of anomalies in an affected infant and determine essential follow-up and ongoing care.
C1 [Freitas, Bruno de Paula; Ventura, Camila V.; Maia, Mauricio; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Vis Inst, Paulista Med Sch, Dept Ophthalmol, Sao Paulo, Brazil.
   [Freitas, Bruno de Paula] Hosp Geral Roberto Santos, Dept Ophthalmol, Salvador, BA, Brazil.
   [Ventura, Camila V.] Altino Ventura Fdn, Dept Ophthalmol, Recife, PE, Brazil.
   [Ventura, Camila V.] HOPE Eye Hosp, Dept Ophthalmol, Recife, PE, Brazil.
RP Freitas, BD (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Rua Botucatu 821,1st Floor, BR-04023062 Sao Paulo, SP, Brazil.
EM brunodepaulafreitas@hotmail.com
RI Ventura, Camila V/N-2654-2018; Maia, Mauricio/I-5892-2015
OI Ventura, Camila V/0000-0002-2927-4684; Maia,
   Mauricio/0000-0002-7034-8091
CR Adibi JJ, 2016, LANCET, V387, P1587, DOI 10.1016/S0140-6736(16)00650-4
   Chan JFW, 2016, J INFECTION, V72, P507, DOI 10.1016/j.jinf.2016.02.011
   de Miranda HA, 2016, OPHTHALMOLOGY, V123, P1788, DOI 10.1016/j.ophtha.2016.05.001
   de Oliveira Dias JR, 2017, RETIN CASES BRIEF RE
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   Freitas BP, 2016, JAMA OPHTHALMOL
   Freitas BDP, 2017, OPHTHALMOLOGY, V124, P407, DOI 10.1016/j.ophtha.2016.10.004
   Furtado JM, 2016, NEW ENGL J MED, V375, P394, DOI 10.1056/NEJMc1603618
   Kodati S, 2017, LANCET, V389, P125, DOI 10.1016/S0140-6736(16)32518-1
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Parke DW, 2016, OPHTHALMOLOGY, V123, P2432, DOI 10.1016/j.ophtha.2016.06.039
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Pinto VL, 2015, ACTA MEDICA PORT, V28, P760, DOI 10.20344/amp.6929
   Sampathkumar P, 2016, MAYO CLIN PROC, V91, P514, DOI 10.1016/j.mayocp.2016.02.017
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   van der Linden V, 2016, MMWR-MORBID MORTAL W, V65, P1343, DOI 10.15585/mmwr.mm6547e2
   Ventura CV, 2016, JAMA OPHTHALMOL, V134, P1420, DOI 10.1001/jamaophthalmol.2016.4283
   Ventura CV, 2016, JAMA OPHTHALMOL, V134, P912, DOI 10.1001/jamaophthalmol.2016.1784
   Ventura CV, 2016, LANCET, V387, P2502, DOI 10.1016/S0140-6736(16)30776-0
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   Vorou R, 2016, INT J INFECT DIS, V48, P85, DOI 10.1016/j.ijid.2016.05.014
   Yepez JB, 2017, JAMA OPHTHALMOL, V135, P440, DOI 10.1001/jamaophthalmol.2017.0561
NR 25
TC 17
Z9 17
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD NOV
PY 2017
VL 28
IS 6
BP 595
EP 599
DI 10.1097/ICU.0000000000000420
PG 5
WC Ophthalmology
SC Ophthalmology
GA FQ3GP
UT WOS:000418245600008
PM 28795959
DA 2020-12-15
ER

PT J
AU Aleman, TS
   Ventura, CV
   Cavalcanti, MM
   Serrano, LW
   Traband, A
   Nti, AA
   Gois, AL
   Bravo-Filho, V
   Martins, TT
   Nichols, CW
   Maia, M
   Belfort, R
AF Aleman, Tomas S.
   Ventura, Camila V.
   Cavalcanti, Milena M.
   Serrano, Leona W.
   Traband, Anastasia
   Nti, Akosua A.
   Gois, Adriana L.
   Bravo-Filho, Vasco
   Martins, Thayze T.
   Nichols, Charles W.
   Maia, Mauricio
   Belfort, Rubens
TI Quantitative Assessment of Microstructural Changes of the Retina in
   Infants With Congenital Zika Syndrome
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; HUMAN FOVEAL DEVELOPMENT; VIRUS-INFECTION;
   NEURAL PROGENITORS; OCULAR FINDINGS; BRAZIL; BRAIN; MACULOPATHY;
   MUTATIONS; ORGANOIDS
AB IMPORTANCE A better pathophysiologic understanding of the neurodevelopmental abnormalities observed in neonates exposed in utero to Zika virus (ZIKV) is needed to develop treatments. The retina as an extension of the diencephalon accessible to in vivo microcopy with spectral-domain optical coherence tomography (SD-OCT) can provide an insight into the pathophysiology of congenital Zika syndrome (CZS).
   OBJECTIVE To quantify the microstructural changes of the retina in CZS and compare these changes with those of cobalamin C (cblC) deficiency, a disease with potential retinal maldevelopment.
   DESIGN, SETTING, AND PARTICIPANTS This case series included 8 infants with CZS and 8 individuals with cblC deficiency. All patients underwent ophthalmologic evaluation at 2 university teaching hospitals and SD-OCT imaging in at least 1 eye. Patients with cblC deficiency were homozygous or compound heterozygotes for mutations in the methylmalonic aciduria and homocystinuria type C (MMACHC) gene. Data were collected from January 1 to March 17, 2016, for patients with CZS and from May 4, 2015, to April 23, 2016, for patients with cblC deficiency.
   MAIN OUTCOMES AND MEASURES The SD-OCT cross-sections were segmented using automatic segmentation algorithms embedded in the SD-OCT systems. Each retinal layer thickness was measured at critical eccentricities using the position of the signal peaks and troughs on longitudinal reflectivity profiles.
   RESULTS Eight infants with CZS (5 girls and 3 boys; age range, 3-5 months) and 8 patients with cblC deficiency (3 girls and 5 boys; age range, 4 months to 15 years) were included in the analysis. All 8 patients with CZS had foveal abnormalities in the analyzed eyes (8 eyes), including discontinuities of the ellipsoid zone, thinning of the central retina with increased backscatter, and severe structural disorganization, with 3 eyes showing macular pseudocolobomas. Pericentral retina with normal lamination showed a thinned (< 30% of normal thickness) ganglion cell layer (GCL) that colocalized in 7 of 8 eyes with a normal photoreceptor layer. The inner nuclear layer was normal or had borderline thinning. The central retinal degeneration was similar to that of cblC deficiency.
   CONCLUSIONS AND RELEVANCE Congenital Zika syndrome showed a central retinal degeneration with severe GCL loss, borderline inner nuclear layer thinning, and less prominent photoreceptor loss. The findings provide the first, to date, in vivo evidence in humans for possible retinal maldevelopment with a predilection for retinal GCL loss in CZS, consistent with a murine model of the disease and suggestive of in utero depletion of this neuronal population as a consequence of Zika virus infection.
C1 [Aleman, Tomas S.; Serrano, Leona W.; Traband, Anastasia; Nti, Akosua A.; Nichols, Charles W.] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Ctr Adv Med,Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Ventura, Camila V.; Gois, Adriana L.; Bravo-Filho, Vasco; Martins, Thayze T.] Altino Ventura Fdn, Dept Ophthalmol, Recife, PE, Brazil.
   [Ventura, Camila V.; Gois, Adriana L.; Bravo-Filho, Vasco; Martins, Thayze T.] HOPE Eye Hosp, Dept Ophthalmol, Recife, PE, Brazil.
   [Ventura, Camila V.; Maia, Mauricio; Belfort, Rubens] Univ Fed Sao Paulo, Dept Ophthalmol, Paulista Med Sch, Sao Paulo, Brazil.
   [Cavalcanti, Milena M.] Altino Ventura Fdn, Rehabil Ctr Menina Olhos, Recife, PE, Brazil.
RP Aleman, TS (corresponding author), Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Perelman Ctr Adv Med, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM aleman@mail.med.upenn.edu
RI Maia, Mauricio/I-5892-2015; Filho, Vasco/N-6993-2018; Ventura, Camila
   V/N-2654-2018
OI Maia, Mauricio/0000-0002-7034-8091; Filho, Vasco/0000-0003-4460-3236;
   Ventura, Camila V/0000-0002-2927-4684; Gois, Adriana/0000-0001-5542-1097
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [NEI-K12EY015398-10,
   R01-EY025287]; Hope for Vision; Foundation Fighting Blindness;
   Pennsylvania Lions Sight Conservation; National Council for Scientific
   and Technological Development of BrazilNational Council for Scientific
   and Technological Development (CNPq)
FX This study was supported by grants NEI-K12EY015398-10 and R01-EY025287
   from the National Institutes of Health, Hope for Vision, the Foundation
   Fighting Blindness, the Pennsylvania Lions Sight Conservation, and the
   National Council for Scientific and Technological Development of Brazil.
CR Alvarado MG, 2017, ARCH PATHOL LAB MED, V141, P26, DOI 10.5858/arpa.2016-0382-RA
   Bonafede L, 2015, INVEST OPHTH VIS SCI, V56, P7875, DOI 10.1167/iovs.15-17857
   Cideciyan AV, 2013, HUM GENE THER, V24, P993, DOI 10.1089/hum.2013.153
   Culjat M, 2016, CLIN INFECT DIS, V63, P805, DOI 10.1093/cid/ciw324
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Dang J, 2016, CELL STEM CELL, V19, P258, DOI 10.1016/j.stem.2016.04.014
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   de Miranda HA, 2016, OPHTHALMOLOGY, V123, P1788, DOI 10.1016/j.ophtha.2016.05.001
   Campos AGD, 2016, ARQ BRAS OFTALMOL, V79, P400, DOI 10.5935/0004-2749.20160112
   de Oliveira Dias Joao Rafael, 2018, Retin Cases Brief Rep, V12, P382, DOI 10.1097/ICB.0000000000000518
   Drasdo N, 2007, VISION RES, V47, P2901, DOI 10.1016/j.visres.2007.01.007
   Dubis AM, 2012, ARCH OPHTHALMOL-CHIC, V130, P1291, DOI 10.1001/archophthalmol.2012.2270
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   Freitas BD, 2016, JAMA OPHTHALMOL, V134, P529, DOI 10.1001/jamaophthalmol.2016.0267
   Hendrickson A, 2006, EXP EYE RES, V83, P920, DOI 10.1016/j.exer.2006.04.017
   Henry CR, 2017, JAMA OPHTHALMOL, V135, P386, DOI 10.1001/jamaophthalmol.2017.0098
   Huang YJ, 1998, INVEST OPHTH VIS SCI, V39, P2405
   Jampol LM, 2016, JAMA OPHTHALMOL, V134, P946, DOI 10.1001/jamaophthalmol.2016.1307
   Kodati S, 2017, LANCET, V389, P125, DOI 10.1016/S0140-6736(16)32518-1
   Koenekoop RK, 2012, NAT GENET, V44, P1035, DOI 10.1038/ng.2356
   Li HD, 2016, CELL STEM CELL, V19, P593, DOI 10.1016/j.stem.2016.08.005
   Lucchese G, 2016, AUTOIMMUN REV, V15, P801, DOI 10.1016/j.autrev.2016.03.020
   Maldonado RS, 2011, OPHTHALMOLOGY, V118, P2315, DOI 10.1016/j.ophtha.2011.05.028
   Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2
   Miner JJ, 2016, CELL REP, V16, P3208, DOI 10.1016/j.celrep.2016.08.079
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   van den Pol AN, 2017, J NEUROSCI, V37, P2161, DOI 10.1523/JNEUROSCI.3124-16.2017
   Ostergaard P, 2012, AM J HUM GENET, V90, P356, DOI 10.1016/j.ajhg.2011.12.018
   Paixao ES, 2016, AM J PUBLIC HEALTH, V106, P606, DOI 10.2105/AJPH.2016.303112
   Parke DW, 2016, OPHTHALMOLOGY, V123, P2432, DOI 10.1016/j.ophtha.2016.06.039
   Provis JM, 2013, PROG RETIN EYE RES, V35, P63, DOI 10.1016/j.preteyeres.2013.01.005
   Qian XY, 2016, CELL, V165, P1238, DOI 10.1016/j.cell.2016.04.032
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Roach T, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0824-7
   SALOMAO SR, 1995, INVEST OPHTH VIS SCI, V36, P657
   Schwartz DA, 2017, ARCH PATHOL LAB MED, V141, P18, DOI [10.5858/arpa.2016-0429-ED, 10.5858/arpa.2016-04]
   Schwartz DA, 2017, ARCH PATHOL LAB MED, V141, P68, DOI 10.5858/arpa.2016-0343-OA
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Vajzovic L, 2012, AM J OPHTHALMOL, V154, P779, DOI 10.1016/j.ajo.2012.05.004
   Ventura CV, 2016, JAMA OPHTHALMOL, V134, P1420, DOI 10.1001/jamaophthalmol.2016.4283
   Ventura CV, 2016, OSLI RETINA, V47, P952, DOI 10.3928/23258160-20161004-09
   Ventura CV, 2016, LANCET, V387, P2502, DOI 10.1016/S0140-6736(16)30776-0
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   Wong Chee Wai, 2019, Retin Cases Brief Rep, V13, P171, DOI 10.1097/ICB.0000000000000552
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Zhang FR, 2016, NUCLEIC ACIDS RES, V44, P8610, DOI [10.1093/nar/gkw765, 10]
NR 47
TC 17
Z9 17
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD OCT
PY 2017
VL 135
IS 10
BP 1069
EP 1076
DI 10.1001/jamaophthalmol.2017.3292
PG 8
WC Ophthalmology
SC Ophthalmology
GA FJ6LL
UT WOS:000412869200016
PM 28880978
OA Green Published
DA 2020-12-15
ER

PT J
AU Avery, RL
   Castellarin, AA
   Steinle, NC
   Dhoot, DS
   Pieramici, DJ
   See, R
   Couvillion, S
   Nasir, MA
   Rabena, MD
   Maia, M
   Van Everen, S
   Le, K
   Hanley, WD
AF Avery, Robert L.
   Castellarin, Alessandro A.
   Steinle, Nathan C.
   Dhoot, Dilsher S.
   Pieramici, Dante J.
   See, Robert
   Couvillion, Stephen
   Nasir, Ma'an A.
   Rabena, Melvin D.
   Maia, Mauricio
   Van Everen, Sherri
   Le, Kha
   Hanley, William D.
TI SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL
   AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; diabetic macular edema;
   pharmacokinetics; retinal vein occlusion
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; INTRAOCULAR
   PHARMACOKINETICS; MONOCLONAL-ANTIBODIES; PLASMA-LEVELS; SERUM VEGF;
   IN-VITRO; DEGENERATION; INJECTION; THERAPY
AB Purpose: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO).
   Methods: Prospective, open-label, nonrandomized clinical trial of patients with AMD, DME, or RVO who were antivascular endothelial growth factor (VEGF) naive or had not received anti-VEGF for >= 4 months. Patients received 3 monthly intravitreal injections of aflibercept 2.0 mg, bevacizumab 1.25 mg, or ranibizumab (0.5 mg for AMD/RVO, 0.3 mg for DME). The main outcome measures were serum PKs and plasma free-VEGF concentrations after the first and third injections.
   Results: A total of 151 patients were included. In AMD/DME/RVO, systemic exposure to each drug was highest with bevacizumab, then aflibercept, and lowest with ranibizumab. Ranibizumab cleared from the bloodstream more quickly than bevacizumab or aflibercept. Aflibercept treatment resulted in the greatest reductions in plasma free-VEGF relative to baseline levels, whereas ranibizumab treatment resulted in the smallest decreases in plasma free-VEGF.
   Conclusion: The three anti-VEGF treatments examined in this analysis demonstrated notable differences in systemic PKs. Generally, the reduction in plasma free-VEGF levels correlated with elevated levels of circulating anti-VEGF agents, with the reduction in free-VEGF levels greatest with aflibercept and least with ranibizumab.
C1 [Avery, Robert L.; Castellarin, Alessandro A.; Steinle, Nathan C.; Dhoot, Dilsher S.; Pieramici, Dante J.; See, Robert; Couvillion, Stephen; Nasir, Ma'an A.; Rabena, Melvin D.] Calif Retina Consultants, 525 East Micheltorena St,Suite A, Santa Barbara, CA 93103 USA.
   [Maia, Mauricio; Van Everen, Sherri; Le, Kha; Hanley, William D.] Genentech Inc, San Francisco, CA 94080 USA.
RP Avery, RL (corresponding author), Calif Retina Consultants, 525 East Micheltorena St,Suite A, Santa Barbara, CA 93103 USA.
EM bobave@gmail.com
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
FU Genentech, Inc.Roche HoldingGenentech
FX The authors thank Ai Ping Lee and Xin Wang for assistance with data
   reconciliation and analysis. Third-party medical writing and editorial
   assistance was provided by Emma A. Platt, PharmD, at Envision Scientific
   Solutions, and funded by Genentech, Inc.
CR Aguilar-Mahecha A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038290
   [Anonymous], 2014, LUCENTIS RANIBIZUMAB
   [Anonymous], 2016, EYLEA AFL INJ INTR I
   Avery RL, 2016, OPHTHALMOLOGY, V123, pE14, DOI 10.1016/j.ophtha.2015.08.031
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Avery RL, 2012, J AAPOS, V16, P2, DOI 10.1016/j.jaapos.2011.11.002
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2014, INVEST OPHTH VIS SCI, V55
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Enders P, 2015, RETINA-J RET VIT DIS, V35, P454, DOI 10.1097/IAE.0000000000000320
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gu XY, 2014, CURR EYE RES, V39, P518, DOI 10.3109/02713683.2013.848899
   Gunsilius E, 2000, ONCOLOGY-BASEL, V58, P169, DOI 10.1159/000012095
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirose M, 2014, CLIN OPHTHALMOL, V8, P2301, DOI 10.2147/OPTH.S74888
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kong LK, 2015, INVEST OPHTH VIS SCI, V56, P956, DOI 10.1167/iovs.14-15842
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lien RY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148019
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mody M, 1999, TRANSFUSION MED, V9, P147
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Morin J, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3218
   Narayanan R, 2015, BRIT J OPHTHALMOL, V99, P954, DOI 10.1136/bjophthalmol-2014-306543
   Nepomuceno AB, 2013, AM J OPHTHALMOL, V156, P502, DOI 10.1016/j.ajo.2013.04.026
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park SJ, 2015, EYE, V29, P561, DOI 10.1038/eye.2014.329
   Rajendram R, 2012, ARCH OPHTHALMOL-CHIC, V130, P972, DOI 10.1001/archophthalmol.2012.393
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Scott L, 2014, INVEST OPHTH VIS SCI, V55
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Ternant D, 2005, EXPERT OPIN BIOL TH, V5, pS37, DOI 10.1517/14712598.5.1.S37
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zhang XY, 2014, INT J OPHTHALMOL-CHI, V7, P355, DOI 10.3980/j.issn.2222-3959.2014.02.30
   Zhang Y, 2014, OPHTHALMOLOGY, V121, P2237, DOI 10.1016/j.ophtha.2014.05.012
NR 60
TC 82
Z9 84
U1 2
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2017
VL 37
IS 10
BP 1847
EP 1858
DI 10.1097/IAE.0000000000001493
PG 12
WC Ophthalmology
SC Ophthalmology
GA FI1GH
UT WOS:000411680300016
PM 28106709
OA Green Published
DA 2020-12-15
ER

PT J
AU Neto, HO
   Regatieri, CV
   Nobrega, MJ
   Muccioli, C
   Casella, AM
   Andrade, RE
   Maia, M
   Kniggendorf, V
   Ferreira, M
   Branco, AC
   Belfort, R
AF Neto, Hermelino O.
   Regatieri, Caio V.
   Nobrega, Mario J.
   Muccioli, Cristina
   Casella, Antonio M.
   Andrade, Rafael E.
   Maia, Mauricio
   Kniggendorf, Vinicius
   Ferreira, Magno
   Branco, Andre C.
   Belfort, Rubens, Jr.
TI Multicenter, Randomized Clinical Trial to Assess the Effectiveness of
   Intravitreal Injections of Bevacizumab, Triamcinolone, or Their
   Combination in the Treatment of Diabetic Macular Edema
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID INTRAOCULAR-PRESSURE; RISK-FACTORS; RANIBIZUMAB; ACETONIDE; RETINOPATHY;
   AFLIBERCEPT; EFFICACY; VEGF
AB BACKGROUND AND OBJECTIVE: To evaluate the efficacy of combined bevacizumab-triamcinolone intravitreal injection in the treatment of diabetic macular edema (DME) compared to monotherapy.
   PATIENTS AND METHODS: At eight clinical sites, 111 patients with DME were randomly assigned to receive an intravitreal injection of bevacizumab (Avastin; Genentech, South San Francisco, CA), triamcinolone (Ophthalmos Pharmaceutical Industry, Sao Paulo-SP, Brazil), or their combination. The primary outcome was visual acuity (VA) at 6 months' follow-up.
   RESULTS: The average number of injections was 3.2 in the bevacizumab group, 2.4 in the combined group, and 2.1 in the triamcinolone group. All groups presented with improvements in VA (P < .001); however, no differences between groups were observed (P =.436). Mean reduction in central retinal thickness was statistically different only between the triamcinolone and bevacizumab groups (P < .015).
   CONCLUSION: Mono-or combination therapy was effective for DME treatment. No synergistic effects were observed; however, triamcinolone alone or a drug combination may reduce the number of injections required when compared to bevacizumab alone.
C1 [Neto, Hermelino O.; Regatieri, Caio V.; Muccioli, Cristina; Maia, Mauricio; Kniggendorf, Vinicius; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Dept Ophthalmol, Rua Botucatu 821,1o Andar, BR-04023062 Sao Paulo, SP, Brazil.
   [Neto, Hermelino O.] Feira Santana Eye Hosp, CLIHON, Salvador, Brazil.
   [Maia, Mauricio] Brazilian Inst Fight Blindness Assis & Presidente, Dept Ophthalmol, Sao Paulo, Brazil.
   [Nobrega, Mario J.] Sadalla Amin Gahnem Eye Hosp, Joinville, SC, Brazil.
   [Casella, Antonio M.] Univ Estadual Londrina, Dept Ophthalmol, Londrina, Parana, Brazil.
   [Andrade, Rafael E.] Beira Rio Eye Hosp, Itabuna, Bahia, Brazil.
   [Ferreira, Magno] Univ Fed Uberlandia, Uberlandia, MG, Brazil.
   [Branco, Andre C.] Univ Fed Bahia, Salvador, Brazil.
RP Regatieri, CV (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Rua Botucatu 821,1o Andar, BR-04023062 Sao Paulo, SP, Brazil.
EM caiore@gmail.com
RI Maia, Mauricio/I-5892-2015; Regatieri, Caio/G-8152-2014
OI Maia, Mauricio/0000-0002-7034-8091; Regatieri, Caio/0000-0003-1511-8696
FU Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP)
FX This work was supported in part by Sao Paulo Research Foundation.
CR Abu El-Asrar AM, 2012, MIDDLE EAST AFR J OP, V19, P70, DOI 10.4103/0974-9233.92118
   Alasil T, 2010, OPHTHALMOLOGY, V117, P2379, DOI 10.1016/j.ophtha.2010.03.051
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Aref AA, 2015, JAMA OPHTHALMOL, V133, P1022, DOI 10.1001/jamaophthalmol.2015.1823
   Bakri SJ, 2005, EYE, V19, P686, DOI 10.1038/sj.eye.6701602
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Behl T, 2015, PHARMACOL RES, V99, P137, DOI 10.1016/j.phrs.2015.05.013
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Chae JB, 2012, EYE, V26, P479, DOI 10.1038/eye.2011.310
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Elman MJ, 2012, OPHTHALMOLOGY, V119, P2312, DOI 10.1016/j.ophtha.2012.08.022
   Gavin JR, 1999, DIABETES CARE, V22, pS5
   Im L, 2008, J GLAUCOMA, V17, P128, DOI 10.1097/IJG.0b013e31814b9948
   Inoue M, 2004, AM J OPHTHALMOL, V138, P1046, DOI 10.1016/j.ajo.2004.05.028
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1447, DOI 10.1016/j.ophtha.2008.06.015
   Kamppeter BA, 2008, OPHTHALMOLOGY, V115, P1372, DOI 10.1016/j.ophtha.2008.01.019
   Kook D, 2008, RETINA-J RET VIT DIS, V28, P1053, DOI 10.1097/IAE.0b013e318176de48
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Lam DSC, 2009, RETINA-J RET VIT DIS, V29, P292, DOI 10.1097/IAE.0b013e31819a2d61
   Lang GE, 2012, OPHTHALMOLOGICA, V227, P21, DOI 10.1159/000337156
   Marey HM, 2011, CLIN OPHTHALMOL, V5, P1011, DOI 10.2147/OPTH.S22103
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Michaelides M., 2010, OPHTHALMOLOGY, V117
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Otani T, 2010, RETINA-J RET VIT DIS, V30, P774, DOI 10.1097/IAE.0b013e3181c2e0d6
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Rangasamy S, 2012, MIDDLE EAST AFR J OP, V19, P52, DOI 10.4103/0974-9233.92116
   Romero-Aroca P, 2013, WORLD J DIABETES, V4, P165, DOI 10.4239/wjd.v4.i5.165
   Vasconcelos-Santos DV, 2008, RETINA-J RET VIT DIS, V28, P573, DOI 10.1097/IAE.0b013e31816079e8
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
NR 34
TC 9
Z9 10
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2017
VL 48
IS 9
BP 734
EP 740
DI 10.3928/23258160-20170829-08
PG 7
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA FN5TY
UT WOS:000416072300007
PM 28902334
DA 2020-12-15
ER

PT J
AU Lucatto, LFA
   Magalhaes, O
   Prazeres, JMB
   Ferreira, AM
   Oliveira, RA
   Moraes, NS
   Hirai, FE
   Maia, M
AF Adami Lucatto, Luiz Filipe
   Magalhaes-Junior, Octaviano
   Prazeres, Juliana M. B.
   Ferreira, Adriano M.
   Oliveira, Ramon A.
   Moraes, Nilva S.
   Hirai, Flavio E.
   Maia, Mauricio
TI Incidence of anterior segment neovascularization during intravitreal
   treatment for macular edema secondary to central retinal vein occlusion
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Neovascularization; Pathologic; Bevacizumab; Retinal vein occlusion;
   Macular edema; Glaucoma; Neovascular
ID ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB TREATMENT; TRIAL;
   ELECTRORETINOGRAPHY; TRIAMCINOLONE; RANIBIZUMAB; AVASTIN
AB Purpose: To analyze the effects of injections of intravitreal triamcinolone acetonide (IVTA) and intravitreal bevacizumab (IVB) on the incidence rates of anterior segment neovascularization (ASN) and neovascular glaucoma (NVG) in patients with macular edema secondary to central retinal vein occlusion (CRVO).
   Methods: In this prospective, randomized, double-masked, sham-controlled study, 35 patients with macular edema following CRVO were randomized to intravitreal bevacizumab, intravitreal triamcinolone acetonide, or sham injections during the first 6 months of the study. The primary outcome was the incidence rate of ASN at month 6. The secondary outcomes were the mean changes from baseline in best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography over time to month 12.
   Results: ASN developed in 8 (22.86%) eyes, including 5 (62.50%) eyes in the sham group and 3 (37.50%) eyes in the IVTA group, during 12 months of follow-up (p=0.009). BCVA differed significantly (p<0.05) among the groups only at month 1. CFT did not differ significantly (p<0.05) among the groups over 12 months. NVG required surgery and developed in one eye despite laser treatment.
   Conclusion: Early treatment with intravitreal antivascular endothelial growth factor therapy decreases the rates of ASN and NVG after CRVO.
C1 [Adami Lucatto, Luiz Filipe; Magalhaes-Junior, Octaviano; Prazeres, Juliana M. B.; Ferreira, Adriano M.; Oliveira, Ramon A.; Moraes, Nilva S.; Hirai, Flavio E.; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, SP, Brazil.
RP Lucatto, LFA (corresponding author), Univ Fed Sao Paulo, Rua Botucatu 821, BR-04023062 Sao Paulo, SP, Brazil.
EM filipeadami@yahoo.com.br
RI Maia, Mauricio/I-5892-2015; Hirai, Flavio E/G-3583-2012; Ferreira,
   Adriano Menis/AAO-3396-2020
OI Maia, Mauricio/0000-0002-7034-8091; Hirai, Flavio E/0000-0002-5757-4254;
   
CR Boyd SR, 2002, ARCH OPHTHALMOL-CHIC, V120, P1644
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   BRESNICK GH, 1988, ARCH OPHTHALMOL-CHIC, V106, P324
   BRETON ME, 1989, OPHTHALMOLOGY, V96, P1343
   Cheung N, 2008, INVEST OPHTH VIS SCI, V49, P4297, DOI 10.1167/iovs.08-1826
   Clarkson JC, 1997, ARCH OPHTHALMOL-CHIC, V115, P486
   Clarkson JC, 1997, ARCH OPHTHALMOL-CHIC, V115, P1275
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1425
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1434
   Ehlers JP, 2011, SURV OPHTHALMOL, V56, P281, DOI 10.1016/j.survophthal.2010.11.006
   Felinski EA, 2005, CURR EYE RES, V30, P949, DOI 10.1080/02713680500263598
   Ferrara DC, 2007, AM J OPHTHALMOL, V144, P864, DOI 10.1016/j.ajo.2007.07.038
   Figueroa MS, 2010, BRIT J OPHTHALMOL, V94, P1052, DOI 10.1136/bjo.2009.173732
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   HAYREH SS, 1990, GRAEF ARCH CLIN EXP, V228, P201, DOI 10.1007/BF00920022
   Hayreh SS, 2003, OPHTHALMOLOGICA, V217, P167, DOI 10.1159/000068980
   HAYREH SS, 1983, OPHTHALMOLOGY, V90, P488
   HAYREH SS, 1989, GRAEF ARCH CLIN EXP, V227, P549, DOI 10.1007/BF02169451
   Heier JS, 2012, OPHTHALMOLOGY, V119, P802, DOI 10.1016/j.ophtha.2011.12.005
   Ip MS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1101, DOI 10.1001/archophthalmol.2009.234
   Klein R, 2000, Trans Am Ophthalmol Soc, V98, P133
   MATSUI Y, 1994, GRAEF ARCH CLIN EXP, V232, P75, DOI 10.1007/BF00171667
   Matsumoto Y, 2007, RETINA-J RET VIT DIS, V27, P426, DOI 10.1097/IAE.0b013e31804a7af2
   Pe'er J, 1998, OPHTHALMOLOGY, V105, P412, DOI 10.1016/S0161-6420(98)93020-2
   Rabena MD, 2007, RETINA-J RET VIT DIS, V27, P419, DOI 10.1097/IAE.0b013e318030e77e
   Ramezani A, 2006, GRAEF ARCH CLIN EXP, V244, P1601, DOI 10.1007/s00417-006-0348-9
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2010.01.060, 10.1016/j.ophtha.2009.07.017]
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   SABATES R, 1983, ARCH OPHTHALMOL-CHIC, V101, P232
   Spandau UHM, 2006, ACTA OPHTHALMOL SCAN, V84, P555, DOI 10.1111/j.1600-0420.2006.00740.x
NR 31
TC 2
Z9 2
U1 0
U2 2
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAR-APR
PY 2017
VL 80
IS 2
BP 97
EP 103
DI 10.5935/0004-2749.20170024
PG 7
WC Ophthalmology
SC Ophthalmology
GA EX5AR
UT WOS:000403248600008
PM 28591282
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Freitas, BDP
   Ko, AI
   Khouri, R
   Mayoral, M
   Henriques, DF
   Maia, M
   Belfort, R
AF Freitas, Bruno De Paula
   Ko, Albert I.
   Khouri, Ricardo
   Mayoral, Monica
   Henriques, Daniele Freitas
   Maia, Mauricio
   Belfort, Rubens, Jr.
TI Glaucoma and Congenital Zika Syndrome
SO OPHTHALMOLOGY
LA English
DT Editorial Material
ID VIRUS-INFECTION
C1 [Freitas, Bruno De Paula; Mayoral, Monica] Hosp Geral Roberto Santos, Dept Ophthalmol, Salvador, BA, Brazil.
   [Freitas, Bruno De Paula; Maia, Mauricio; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Paulista Med Sch, Vis Inst, Dept Ophthalmol, Sao Paulo, SP, Brazil.
   [Ko, Albert I.; Khouri, Ricardo] Fundacao Oswaldo Cruz, Goncalo Moniz Res Ctr, Salvador, BA, Brazil.
   [Ko, Albert I.] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
   [Henriques, Daniele Freitas] Minist Hlth, Evandro Chagas Inst, Dept Arbovirol & Hemorrhag Fevers, Ananindeua, Brazil.
RP Belfort, R (corresponding author), Univ Fed Sao Paulo, Paulista Med Sch, Dept Ophthalmol, Rua Botucatu,821, BR-04023062 Sao Paulo, SP, Brazil.
EM prof.belfort@clinicabelfort.com.br
RI Ko, Albert Icksang/P-2343-2015; Maia, Mauricio/I-5892-2015; Khouri,
   Ricardo/M-3184-2018
OI Ko, Albert Icksang/0000-0001-9023-2339; Maia,
   Mauricio/0000-0002-7034-8091; Khouri, Ricardo/0000-0001-5664-4436
CR Furtado JM, 2016, NEW ENGL J MED, V375, P394, DOI 10.1056/NEJMc1603618
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Prazeres J, 2016, BRAZIL JAMA OPHTHALM, V134, P529, DOI [10.1001/jamaophthalmol.2016.0267, DOI 10.1001/JAMA0PHTHALM0L.2016.0267]
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
NR 5
TC 22
Z9 22
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2017
VL 124
IS 3
BP 407
EP 408
PG 2
WC Ophthalmology
SC Ophthalmology
GA EQ1SB
UT WOS:000397848800040
PM 27914834
DA 2020-12-15
ER

PT J
AU Benzekri, R
   Belfort, R
   Ventura, CV
   Freitas, BDP
   Maia, M
   Leite, M
   Labetoulle, M
   Rousseau, A
AF Benzekri, R.
   Belfort, R., Jr.
   Ventura, C. V.
   Freitas, B. de Paula
   Maia, M.
   Leite, M.
   Labetoulle, M.
   Rousseau, A.
TI Ocular manifestations of Zika virus: What we do and do not know
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA French
DT Review
DE Zika; Virus; Microcephaly; Maculopathy; Uveitis; Conjunctivitis;
   Epidemics
ID INTERIM GUIDANCE; INFECTION; TRANSMISSION; BRAZIL; INFANTS;
   PATHOGENESIS; SPECIFICITY; MICRONESIA; EPIDEMIC; OUTBREAK
AB Zika virus (ZIKV) disease outbreak, which was declared by the end of 2015 inBrazil, has become the largest one to date. Being reported in the Americas and in certain islands of the Pacific, it has the potential to spread worldwide. Although ZIKV infections are mostly self-limiting and/or asymptomatic in the healthy adult, they are responsible for devastating congenital neurologic malformations ZIKV (mainly microcephaly) when contracted during the first months of pregnancy. Ocular manifestations during the acute adult infection include conjunctivitis and more rarely ocular inflammation. Congenital infection is associated with chorioretinal atrophy pigment mottling of the retina retinal vasculature abnormalities and optic nerve atrophy. Therefore, complete ophthalmological evaluation is recommended for suspected congenital infections. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Benzekri, R.; Leite, M.; Labetoulle, M.; Rousseau, A.] Univ Paris Sud, Hop Bicetre, Assistance Publ Hop Paris, Serv Ophtalmol,DHU Vis & Handicap, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.
   [Belfort, R., Jr.; Ventura, C. V.; Maia, M.] Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Paulista Sch Med, Sao Paulo, Brazil.
   [Belfort, R., Jr.; Ventura, C. V.; Maia, M.] Vis Inst, Sao Paulo, Brazil.
   [Ventura, C. V.] Altino Ventura Fdn, Recife, PE, Brazil.
   [Ventura, C. V.] Pernambucos Eye Hosp HOPE, Dept Ophthalmol, Recife, PE, Brazil.
   [Freitas, B. de Paula] Hosp Geral Roberto Santos, Dept Ophthalmol, Salvador, BA, Brazil.
   [Labetoulle, M.; Rousseau, A.] Commissariat Energie Atom & Energies Alternat, Immunol Infect Virales & Malad Autoimmunes, UMR 1184, Fontenay Aux Roses, France.
RP Rousseau, A (corresponding author), Univ Paris Sud, Hop Bicetre, Assistance Publ Hop Paris, Serv Ophtalmol,DHU Vis & Handicap, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.; Rousseau, A (corresponding author), Commissariat Energie Atom & Energies Alternat, Immunol Infect Virales & Malad Autoimmunes, UMR 1184, Fontenay Aux Roses, France.
EM antoine.rousseau@aphp.fr
RI Maia, Mauricio/Z-1042-2019; Ventura, Camila V/N-2654-2018; Maia,
   Mauricio/I-5892-2015; Rousseau, Antoine/A-6667-2018
OI Maia, Mauricio/0000-0002-7034-8091; Ventura, Camila
   V/0000-0002-2927-4684; Maia, Mauricio/0000-0002-7034-8091; BENZEKRI,
   Reda/0000-0002-4599-9909
CR Alera MT, 2015, EMERG INFECT DIS, V21, P722, DOI 10.3201/eid2104.141707
   Bogoch II, 2016, LANCET INFECT DIS, V16, P1237, DOI 10.1016/S1473-3099(16)30270-5
   Buathong R, 2015, AM J TROP MED HYG, V93, P380, DOI 10.4269/ajtmh.15-0022
   Carlson CJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004968
   Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6
   Chan JFW, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.99
   Cordeiro MT, 2016, LANCET, V387, P1811, DOI 10.1016/S0140-6736(16)30253-7
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   de Miranda HA, 2016, OPHTHALMOLOGY, V123, P1788, DOI 10.1016/j.ophtha.2016.05.001
   de Oliveira Dias JR, 2017, RETIN CASES BRIEF RE
   de Paula Freitas B, 2016, OPHTHALMOLOGY
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   DICK GWA, 1953, T ROY SOC TROP MED H, V47, P13, DOI 10.1016/0035-9203(53)90021-2
   Dirlikov E, 2016, MMWR-MORBID MORTAL W, V65, P910, DOI 10.15585/mmwr.mm6534e1
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Freitas BD, 2016, JAMA OPHTHALMOL, V134, P529, DOI 10.1001/jamaophthalmol.2016.0267
   Furtado JM, 2016, NEW ENGL J MED, V375, P394, DOI 10.1056/NEJMc1603618
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Gornet ME, 2016, SEMIN REPROD MED, V34, P285, DOI 10.1055/s-0036-1592312
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Heukelbach J, 2016, J INFECT DEV COUNTR, V10, P116, DOI 10.3855/jidc.8217
   Hulo C, 2011, NUCLEIC ACIDS RES, V39, pD576, DOI 10.1093/nar/gkq901
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Marcondes CB, 2016, REV SOC BRAS MED TRO, V49, P4, DOI 10.1590/0037-8682-0220-2015
   Mawson AR, 2016, BIORESEARCH OPEN ACC, V5, P171, DOI 10.1089/biores.2016.0004
   Miner JJ, 2016, CELL REP, V16, P3208, DOI 10.1016/j.celrep.2016.08.079
   Munoz LS, 2016, SEMIN REPROD MED, V34, P273, DOI 10.1055/s-0036-1592066
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Pan American Health Organization (PAHO), 2016, ZIK VIR INF
   Parke DW, 2016, OPHTHALMOLOGY, V123, P2432, DOI 10.1016/j.ophtha.2016.06.039
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   Rasool N, 2016, JAMA OPHTHALMOL, V134, P1200, DOI 10.1001/jamaophthalmol.2016.2398
   Rousseau A, 2015, J FR OPHTALMOL, V38, P758, DOI 10.1016/j.jfo.2015.06.002
   Russell K, 2016, MMWR-MORBID MORTAL W, V65, P870, DOI 10.15585/mmwr.mm6533e2
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Ventura C. V, 2016, ARQ BRAS OFTALMOL, V79
   Ventura CV, 2016, JAMA OPHTHALMOL, V134, P1420, DOI 10.1001/jamaophthalmol.2016.4283
   Ventura CV, 2016, JAMA OPHTHALMOL, V134, P912, DOI 10.1001/jamaophthalmol.2016.1784
   Ventura CV, 2016, LANCET, V387, P2502, DOI 10.1016/S0140-6736(16)30776-0
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   Zambrano H, 2016, AM J TROP MED HYG, V95, P894, DOI 10.4269/ajtmh.16-0323
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 49
TC 2
Z9 2
U1 0
U2 4
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD FEB
PY 2017
VL 40
IS 2
BP 138
EP 145
DI 10.1016/j.jfo.2017.01.002
PG 8
WC Ophthalmology
SC Ophthalmology
GA EO0VP
UT WOS:000396416800018
PM 28189347
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Lasave, AF
   Wu, L
   Maia, M
   Diaz-Llopis, M
   Alezzandrini, AA
   Brito, M
AF Arevalo, J. Fernando
   Lasave, Andres F.
   Wu, Lihteh
   Maia, Mauricio
   Diaz-Llopis, Manuel
   Alezzandrini, Arturo A.
   Brito, Miguel
CA Pan-Amer Collaborative Retina Stu
TI INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY Results
   From the Pan-American Collaborative Retina Study Group (PACORES) at 24
   Months of Follow-up
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; diabetic retinopathy; intravitreal injections;
   proliferative; retinal neovascularizatiuon
ID ENDOTHELIAL GROWTH-FACTOR; PANRETINAL PHOTOCOAGULATION; LASER
   PHOTOCOAGULATION; RAPID RESOLUTION; MACULAR EDEMA; AVASTIN; VESSELS;
   NEOVASCULARIZATION; PERSISTENT; INJECTION
AB Purpose: To evaluate the effects of intravitreal bevacizumab (IVB) on retinal neo-vascularization in patients with proliferative diabetic retinopathy (PDR).
   Methods: Retrospective multicenter interventional case series. A chart review was performed of 81 consecutive patients (97 eyes) with retinal neovascularization due to PDR, who received at least 1 IVB injection.
   Results: The mean age of the patients was 55.6 +/- 11.6 years. The mean number of IVB injections was 4 +/- 2.5 injections (range, 1-8 injections) per eye. The mean interval between IVB applications was 3 +/- 7 months. The mean duration of follow-up was 29.6 +/- 2 months (range, 24-30 months). Best-corrected visual acuity and optical coherence tomography improved statistically significantly (P < 0.0001, both comparisons). Three eyes without previous panretinal photocoagulation ("naive" eyes) and with vitreous hemorrhage did not require vitreoretinal surgery. Five (5.2%) eyes with PDR progressed to tractional retinal detachment requiring vitrectomy. No systemic adverse events were noted.
   Conclusion: Intravitreal bevacizumab resulted in marked regression of retinal neovascularization in patients with PDR and previous panretinal photocoagulation. Intravitreal bevacizumab in naive eyes resulted in control or regression of 42.1% of eyes without adjunctive laser or vitrectomy during 24 months of follow-up. There were no safety concerns during the 2 years of follow-up of IVB for PDR.
C1 [Arevalo, J. Fernando] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Retina Div, Baltimore, MD 21218 USA.
   [Lasave, Andres F.] Clin Privada Ojos, Retina & Vitreous Serv, Mar Del Plata, Buenos Aires, Argentina.
   [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Maia, Mauricio] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Diaz-Llopis, Manuel] Gen Univ Valencia, Consorcio Hosp, Valencia, Spain.
   [Alezzandrini, Arturo A.] Univ Buenos Aires, OFTALMOS, Fac Med, Buenos Aires, DF, Argentina.
   [Brito, Miguel] IDEO, Maracaibo, Venezuela.
RP Arevalo, JF (corresponding author), Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, 600 N Wolfe St,Maumenee 708, Baltimore, MD 21287 USA.
EM arevalojf@jhmi.edu
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Lasave, Andres/0000-0002-9602-9769
FU Edmund F. and Virginia B. Ball Professorship; Arevalo-Coutinho
   Foundation for Research in Ophthalmology; John and Diana Lenahan Fund,
   Baltimore, MD
FX Supported in part by the Edmund F. and Virginia B. Ball Professorship,
   the Arevalo-Coutinho Foundation for Research in Ophthalmology; and the
   John and Diana Lenahan Fund, Baltimore, MD (Dr. Arevalo).
CR Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Arevalo JF, 2009, EYE, V23, P117, DOI 10.1038/sj.eye.6702980
   Arevalo JF, 2007, OPHTHALMOLOGY, V114, P743, DOI 10.1016/j.ophtha.2006.12.028
   Arevalo JF, 2011, OPHTHALMOLOGY, V118
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   AYLWARD GW, 1989, BRIT J OPHTHALMOL, V73, P197, DOI 10.1136/bjo.73.3.197
   Bin Cho W, 2009, RETINA-J RET VIT DIS, V29, P516, DOI 10.1097/IAE.0b013e31819a5fc2
   Chhablani J, 2015, AM J OPHTHALMOL, V159, P884, DOI 10.1016/j.ajo.2015.02.006
   Chung EJ, 2011, YONSEI MED J, V52, P151, DOI 10.3349/ymj.2011.52.1.151
   DOFT BH, 1982, OPHTHALMOLOGY, V89, P772
   FERRIS FL, 1987, OPHTHALMOLOGY, V94, P754
   FLYNN HW, 1992, OPHTHALMOLOGY, V99, P1351
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Friedlander SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1363
   Gross JG, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI 10.1001/jama.2015.15217
   Isaacs TW, 2006, CLIN EXP OPHTHALMOL, V34, P802, DOI 10.1111/j.1442-9071.2006.01378.x
   Jorge R, 2006, RETINA-J RET VIT DIS, V26, P1006, DOI 10.1097/01.iae.0000246884.76018.63
   KASSOFF A, 1993, OPHTHALMOLOGY, V100, P1655
   KAUFMAN SC, 1989, INVEST OPHTH VIS SCI, V30, P23
   MCDONALD HR, 1985, OPHTHALMOLOGY, V92, P388
   Mendrinos E, 2009, ACTA OPHTHALMOL, V87, P683, DOI 10.1111/j.1755-3768.2008.01391.x
   Minnella AM, 2008, ACTA OPHTHALMOL, V86, P683, DOI 10.1111/j.1600-0420.2007.01042.x
   Mirshahi A, 2008, EUR J OPHTHALMOL, V18, P263
   Moradian S, 2008, GRAEF ARCH CLIN EXP, V246, P1699, DOI 10.1007/s00417-008-0914-4
   Nonaka A, 2002, INVEST OPHTH VIS SCI, V43, P1204
   PEER J, 1995, LAB INVEST, V72, P638
   Rizzo S, 2008, GRAEF ARCH CLIN EXP, V246, P837, DOI 10.1007/s00417-008-0774-y
   Schmidinger G, 2011, ACTA OPHTHALMOL, V89, P76, DOI 10.1111/j.1755-3768.2009.01622.x
   Shimura M, 2003, OPHTHALMOLOGY, V110, P2386, DOI 10.1016/j.ophtha.2003.05.008
   Shin Yong Woon, 2009, Korean J Ophthalmol, V23, P266, DOI 10.3341/kjo.2009.23.4.266
   Sinawat S, 2013, EYE, V27, P1391, DOI 10.1038/eye.2013.200
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Thew M, 2009, CLIN EXP OPTOM, V92, P34, DOI 10.1111/j.1444-0938.2008.00295.x
   Tonello M, 2008, ACTA OPHTHALMOL, V86, P385, DOI 10.1111/j.1600-0420.2007.01056.x
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P1575
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
NR 41
TC 22
Z9 22
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2017
VL 37
IS 2
BP 334
EP 343
PG 10
WC Ophthalmology
SC Ophthalmology
GA EK1FO
UT WOS:000393671400023
PM 27429384
DA 2020-12-15
ER

PT J
AU Maia, M
   Soares, AW
   Falcao, L
   Visconti, V
   Pereira, L
   Araujo, JL
AF Maia, M.
   Soares, A. Watts
   Falcao, L.
   Visconti, V.
   Pereira, L.
   Araujo, J. Lomelino
TI The VERAcity of an ischemic stroke diagnosis
SO CEREBROVASCULAR DISEASES
LA English
DT Meeting Abstract
C1 [Maia, M.; Soares, A. Watts; Falcao, L.; Visconti, V.; Pereira, L.; Araujo, J. Lomelino] Hosp Beatriz Angelo, Internal Med, Loures, Portugal.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-9770
EI 1421-9786
J9 CEREBROVASC DIS
JI Cerebrovasc. Dis.
PY 2017
VL 43
SU 1
MA P039
PG 2
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA FR3DC
UT WOS:000418945200059
DA 2020-12-15
ER

PT J
AU Caiado, RR
   Peris, CS
   Lima, AAS
   Urushima, JGP
   Novais, E
   Badaro, E
   Maia, A
   Sinigaglia-Coimbra, R
   Watanabe, SES
   Rodrigues, EB
   Farah, ME
   Maia, M
AF Caiado, Rafael R.
   Peris, Cristiane S.
   Souza Lima-Filho, Acacio Alves
   Palma Urushima, Joao Guilherme
   Novais, Eduardo
   Badaro, Emmerson
   Maia, Andre
   Sinigaglia-Coimbra, Rita
   Watanabe, Sung Eun S.
   Rodrigues, Eduardo B.
   Farah, Michel Eid
   Maia, Mauricio
TI Retinal Toxicity of Acai Fruit (Euterpe Oleracea) Dye Concentrations in
   Rabbits: Basic Principles of a New Dye for Chromovitrectomy in Humans
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Acai fruit; anthocyanins; chromovitrectomy; Euterpe oleracea
ID INTERNAL LIMITING MEMBRANE; MACULAR HOLE SURGERY; INDOCYANINE GREEN
   INJECTION; VITREORETINAL SURGERY; VITAL DYES; ANTIOXIDANT ACTIVITY;
   EPIRETINAL MEMBRANE; TRYPAN BLUE; ANTHOCYANINS; DETACHMENT
AB Purpose: Evaluate toxicity of acai fruit (Euterpe oleracea) dye concentrations in a rabbit model.Methods: Rabbits were injected intravitreously with 10%, 25%, and 35% acai dye concentrations. Control eyes received balanced salt solution (BSS). Electroretinogram (ERG), fundus imaging, fluorescein angiography (FA), optical coherence tomography (OCT), and light and transmission electron microscopy (LM/TEM) were performed.Results: Fundus imaging showed increased vitreous opacity with increased dye concentrations. FA and OCT showed normality with all concentrations. Comparisons between BSS and dye concentrations were analyzed using Kruskal-Wallis and Mood's median test (p < 0.05). At 24 h, ERGs showed reduced amplitudes from baseline in all eyes. Median b-wave amplitudes nonsignificantly decreased and latency increased with 10% and 25%; findings were significant (p < 0.05) for 35%. LM and TEM showed no abnormalities for 10% and 25%. With 35%, TEM showed ganglion cell edema at 24 h that resolved after 7 days. Vacuolization, multilamellar bodies, and nerve bundle damage occurred at 24 h/7 days in the inner nuclear layer. Mitochondrial cristae disruption occurred in the inner photoreceptor segment at 24 h that decreased by 7 days.Conclusion: Ten and twenty-five percent concentrations were safe and may improve identification of the posterior hyaloid and internal limiting membrane during chromovitrectomy in humans.
C1 [Caiado, Rafael R.; Peris, Cristiane S.; Souza Lima-Filho, Acacio Alves; Palma Urushima, Joao Guilherme; Novais, Eduardo; Badaro, Emmerson; Maia, Andre; Sinigaglia-Coimbra, Rita; Rodrigues, Eduardo B.; Farah, Michel Eid; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Sinigaglia-Coimbra, Rita] Univ Fed Sao Paulo, Electron Microscopy Ctr CEME, Sao Paulo, Brazil.
   [Watanabe, Sung Eun S.; Maia, Mauricio] Brazilian Inst Fighting Blindness INBRACE, Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, 822 Botucatu St, BR-06023062 Sao Paulo, SP, Brazil.
EM retina@femanet.com.br
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015;
   Sinigaglia-Coimbra, Rita/C-9155-2012; de Souza Lima Filho, Acacio
   Alves/C-7189-2012
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Sinigaglia-Coimbra,
   Rita/0000-0001-8747-6316; Alves de Souza Lima Filho,
   Acacio/0000-0003-1802-9592; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; Sao Paulo,
   Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq;
   Brasilia, Brazil)National Council for Scientific and Technological
   Development (CNPq); Pan-American Association of
   Ophthalmology/Pan-American Ophthalmological Foundation, Paul Kayser
   Global Award (PAAO/PAOF; Arlington, Texas).
FX Publication of this article was supported by Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP; Sao Paulo, Brazil), Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; Brasilia,
   Brazil), and Pan-American Association of Ophthalmology/Pan-American
   Ophthalmological Foundation, Paul Kayser Global Award (PAAO/PAOF;
   Arlington, Texas).
CR Ansari MA, 2009, J NUTR BIOCHEM, V20, P269, DOI 10.1016/j.jnutbio.2008.03.002
   Badaro Emmerson, 2015, Int J Retina Vitreous, V1, P1
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Caiado RR, 2015, RETINA-J RET VIT DIS, V35, P326, DOI 10.1097/IAE.0000000000000307
   Cardoso EB, 2013, GRAEF ARCH CLIN EXP, V251, P1115, DOI 10.1007/s00417-013-2258-y
   Chen J, 2013, RETINA-J RET VIT DIS, V33, P89, DOI 10.1097/IAE.0b013e3182618a6d
   Dias JRD, 2014, OSLI RETINA, V45, P577, DOI 10.3928/23258160-20141118-15
   De Rosso VV, 2008, FREE RADICAL RES, V42, P885, DOI 10.1080/10715760802506349
   Del Pozo-Insfran D, 2004, J AGR FOOD CHEM, V52, P1539, DOI 10.1021/jf035189n
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Feron EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P141
   Gandorfer A, 2001, AM J OPHTHALMOL, V132, P431, DOI 10.1016/S0002-9394(01)01087-X
   Havener WH, 1994, OCULAR PHARM, P630
   Hiebl W, 2005, KLIN MONATSBL AUGENH, V222, P309, DOI 10.1055/s-2005-858030
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Kadonosono K, 2000, ARCH OPHTHALMOL-CHIC, V118, P1116, DOI 10.1001/archopht.118.8.1116
   Kadonosono K, 2001, AM J OPHTHALMOL, V131, P203, DOI 10.1016/S0002-9394(00)00728-5
   Kahkonen MP, 2003, J AGR FOOD CHEM, V51, P628, DOI 10.1021/jf025551i
   Kumar Atul, 2004, Indian J Ophthalmol, V52, P339
   Kurihara K, 1999, GRAEF ARCH CLIN EXP, V237, P648, DOI 10.1007/s004170050292
   Kusaka S, 2001, AM J OPHTHALMOL, V131, P388, DOI 10.1016/S0002-9394(00)00848-5
   Lam DSC, 1999, RETINA-J RET VIT DIS, V19, P478, DOI 10.1097/00006982-199919050-00030
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Maia M, 2009, BRIT J OPHTHALMOL, V93, P1687, DOI 10.1136/bjo.2008.151597
   Mennel S, 2006, OPHTHALMOLOGICA, V220, P190, DOI 10.1159/000091764
   Mester V, 2000, AM J OPHTHALMOL, V129, P769, DOI 10.1016/S0002-9394(00)00358-5
   Peris CS, 2013, J OCUL PHARMACOL TH, V29, P746, DOI 10.1089/jop.2013.0003
   Perrier M, 2003, AM J OPHTHALMOL, V135, P909, DOI 10.1016/S0002-9394(02)02256-0
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Qin CG, 2009, NAT PROD RES, V23, P1589, DOI 10.1080/14786410802496903
   Rahman MM, 2006, FREE RADICAL RES, V40, P993, DOI 10.1080/10715760600815322
   Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   Schauss AG, 2006, J AGR FOOD CHEM, V54, P8604, DOI 10.1021/jf0609779
   Shiner M, 2007, BIOL CHEM, V388, P1353, DOI 10.1515/BC.2007.145
   Yuen D, 2009, AM J OPHTHALMOL, V147, P251, DOI 10.1016/j.ajo.2008.08.031
NR 41
TC 5
Z9 5
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2017
VL 42
IS 8
BP 1185
EP 1193
DI 10.1080/02713683.2017.1297995
PG 9
WC Ophthalmology
SC Ophthalmology
GA FC8GW
UT WOS:000407080800017
PM 28494212
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Lasave, AF
   Wu, L
   Acon, D
   Farah, ME
   Gallego-Pinazo, R
   Alezzandrini, AA
   Fortuna, V
   Quiroz-Mercado, H
   Salcedo-Villanueva, G
   Maia, M
   Serrano, M
   Rojas, S
AF Arevalo, J. Fernando
   Lasave, Andres F.
   Wu, Lihteh
   Acon, Dhariana
   Farah, Michel E.
   Gallego-Pinazo, Roberto
   Alezzandrini, Arturo A.
   Fortuna, Veronica
   Quiroz-Mercado, Hugo
   Salcedo-Villanueva, Guillermo
   Maia, Mauricio
   Serrano, Martin
   Rojas, Sergio
CA Pan-Amer Collaborative Retina
TI Intravitreal bevacizumab for diabetic macular oedema: 5-year results of
   the Pan-American Collaborative Retina Study group
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; DEGENERATION; RANIBIZUMAB; LASER;
   PHOTOCOAGULATION; TACHYPHYLAXIS; THERAPY; TRIAL
AB Background/aims To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB).
   Methods Retrospective case series. Patients diagnosed with centre-involved DME that were treated with at least one injection of 1.25 mg IVB and had a minimum follow-up of 60 months. Patients underwent measurement of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography and fluorescein angiography at baseline, 6-month, 12-month, 24-month, 36-month, 48-month and 60-month visits. The paired samples t test was used to compare the central macular thickness (CMT) and BCVA with baseline values. Statistical significance was indicated by p<0.05.
   Results Two hundred and one consecutive patients (296 eyes) were included. The mean number of IVB injections per eye was 8.4 +/- 7.1 (range: 1-47 injections). At 5 years, the BCVA remained stable at 20/100 (logarithm of the minimum angle of resolution=0.7 +/- 0.4). Eighty-six (29%) eyes improved >= 2 lines of BCVA, 129 (43.6%) eyes remained stable and 81 (27.4%) eyes lost >= 2 lines of BCVA at 60 months. Mean CMT decreased from 403.5 +/- 142.2 mu m at baseline to 313.7 +/- 117.7 mu m over 5 years follow-up (p=0.0001).
   Conclusions The early visual gains due to IVB were not maintained 5 years after treatment.
C1 [Arevalo, J. Fernando] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21287 USA.
   [Lasave, Andres F.] Clin Privada Ojos, Retina & Vitreous Serv, Mar Del Plata, Buenos Aires, Argentina.
   [Wu, Lihteh; Acon, Dhariana] Inst Cirugia Ocular, Retina Serv, San Jose, Costa Rica.
   [Farah, Michel E.; Maia, Mauricio] Fed Univ Sao Paulo UNIFESP, Dept Ophthalmol & Visual Sci, Retina Div, Sao Paulo, Brazil.
   [Gallego-Pinazo, Roberto] Gen Univ Valencia, Consorcio Hosp, Dept Ophthalmol, Valencia, Spain.
   [Alezzandrini, Arturo A.; Fortuna, Veronica] Univ Buenos Aires, OFTALMOS, Fac Med, Buenos Aires, DF, Argentina.
   [Quiroz-Mercado, Hugo; Salcedo-Villanueva, Guillermo] Univ Colorado, Sch Med, Dept Ophthalmol, Denver, CO USA.
   [Serrano, Martin] Ctr Caracas, Retina Serv, Clin Oftalmol, Caracas, Venezuela.
   [Serrano, Martin] Arevalo Coutinho Fdn Res Ophthalmol, Caracas, Venezuela.
   [Rojas, Sergio] Fdn Hosp Nuestra Senora de la Luz, Retina Serv, Mexico City, DF, Mexico.
RP Arevalo, JF (corresponding author), Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St,Maumenee 708, Baltimore, MD 21287 USA.
EM arevalojf@jhmi.edu
RI Maia, Mauricio/I-5892-2015; Salcedo-Villanueva, Guillermo/AAE-9695-2019;
   Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Salcedo-Villanueva,
   Guillermo/0000-0003-2526-6342; Farah, Michel Eid E/0000-0001-5951-0193;
   Lasave, Andres/0000-0002-9602-9769
CR Anothaisintawee T, 2012, CLINICOECONOMIC OUTC, V4, P361, DOI 10.2147/CEOR.S37458
   Arevalo JF, 2013, WORLD J DIABETES, V4, P231, DOI [10.4239/wjd.v4.i2.19, 10.4239/wjd.v4.i6.231]
   Arevalo JF, 2013, RETINA-J RET VIT DIS, V33, P403, DOI 10.1097/IAE.0b013e3182695b83
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Campochiaro PA, 2012, OPHTHALMOLOGY, V119, P2125, DOI 10.1016/j.ophtha.2012.04.030
   Elman MJ, 2012, OPHTHALMOLOGY, V119, P2312, DOI 10.1016/j.ophtha.2012.08.022
   Arevalo JF, 2009, OPHTHALMOLOGY, V116, P1488, DOI 10.1016/j.ophtha.2009.03.016
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Funk M, 2010, RETINA-J RET VIT DIS, V30, P1412, DOI 10.1097/IAE.0b013e3181e095c0
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Goyal S, 2011, GRAEF ARCH CLIN EXP, V249, P15, DOI 10.1007/s00417-010-1452-4
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P7
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Marques IR, 2013, OPHTHALMOLOGICA, V229, P158, DOI 10.1159/000343709
   Mehta S, 2010, OPHTHAL SURG LAS IM, V41, P323, DOI 10.3928/15428877-20100430-05
   Moss SE, 1998, OPHTHALMOLOGY, V105, P998, DOI 10.1016/S0161-6420(98)96025-0
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Rajendram R, 2012, ARCH OPHTHALMOL-CHIC, V130, P972, DOI 10.1001/archophthalmol.2012.393
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P1045, DOI 10.1016/j.ophtha.2013.11.041
   Soheilian M, 2012, RETINA-J RET VIT DIS, V32, P314, DOI 10.1097/IAE.0b013e31822f55de
   Solaiman KAM, 2013, RETINA-J RET VIT DIS, V33, P1623, DOI 10.1097/IAE.0b013e318285c99d
   Stewart MW, 2012, CURR DIABETES REP, V12, P364, DOI 10.1007/s11892-012-0281-8
NR 25
TC 12
Z9 12
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2016
VL 100
IS 12
BP 1605
EP 1610
DI 10.1136/bjophthalmol-2015-307950
PG 6
WC Ophthalmology
SC Ophthalmology
GA EC7XD
UT WOS:000388353500004
PM 26912377
DA 2020-12-15
ER

PT J
AU Ventura, CV
   Ventura, LO
   Bravo, V
   Martins, TT
   Berrocal, AM
   Gois, AL
   Dias, JRD
   Araujo, L
   Escariao, P
   van der Linden, V
   Belfort, R
   Maia, M
AF Ventura, Camila V.
   Ventura, Liana O.
   Bravo-Filho, Vasco
   Martins, Thayze T.
   Berrocal, Audina M.
   Gois, Adriana L.
   de Oliveira Dias, Joao Rafael
   Araujo, Leandro
   Escariao, Paulo
   van der Linden, Vanessa
   Belfort, Rubens, Jr.
   Maia, Mauricio
TI Optical Coherence Tomography of Retinal Lesions in Infants With
   Congenital Zika Syndrome
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID VIRUS; OUTBREAK
AB IMPORTANCE Zika virus (ZIKV) can cause severe changes in the retina and choroid that may result in marked visual impairment in infants with congenital Zika syndrome (CZS), the term created for a variety of anomalies associated with intrauterine ZIKV infection.
   OBJECTIVE To evaluate the affected retinal layers in infants with CZS and associated retinal abnormalities using optical coherence tomography (OCT).
   DESIGN, SETTING, AND PARTICIPANTS This cross-sectional, consecutive case series included 8 infants (age range, 3.0-5.1 months) with CZS. Optical coherence tomographic images were obtained in the affected eyes of 7 infants with CZS who had undergone previous ophthalmologic examinations on March 17, 2016, and in 1 infant on January 1, 2016. An IgM antibody-capture enzyme-linked immunosorbent assay for ZIKV was performed on the cerebrospinal fluid samples of 7 of the 8 infants (88%), and other congenital infections were ruled out.
   MAIN OUTCOMES AND MEASURES Observation of retinal and choroidal findings in the OCT images.
   RESULTS Among the 8 infants included in the study (3 male; 5 female; mean [SD] age at examination, 4.1 [0.7] months), 7 who underwent cerebrospinal fluid analysis for ZIKV had positive findings for IgM antibodies. Eleven of the 16 eyes (69%) of the 8 infants had retinal alterations and OCT imaging was performed in 9 (82%) of them. Optical coherence tomography was also performed in 1 unaffected eye. The main OCT findings in the affected eyes included discontinuation of the ellipsoid zone and hyperreflectivity underlying the retinal pigment epithelium in 9 eyes (100%), retinal thinning in 8 eyes (89%), choroidal thinning in 7 eyes (78%), and colobomatouslike excavation involving the neurosensory retina, retinal pigment epithelium, and choroid in 4 eyes (44%).
   CONCLUSIONS AND RELEVANCE Zika virus can cause severe damage to the retina, including the internal and external layers, and the choroid. The colobomatouslike finding seen in the OCT images relate to the excavated chorioretinal scar observed clinically.
C1 [Ventura, Camila V.; Ventura, Liana O.; Bravo-Filho, Vasco; Martins, Thayze T.; Gois, Adriana L.; Araujo, Leandro; Escariao, Paulo] Altino Ventura Fdn, Dept Ophthalmol, Recife, PE, Brazil.
   [Ventura, Camila V.; Ventura, Liana O.; Bravo-Filho, Vasco; Martins, Thayze T.; Gois, Adriana L.; Araujo, Leandro; Escariao, Paulo] Pernambuco Eye Hosp, Dept Ophthalmol, Recife, PE, Brazil.
   [Ventura, Camila V.; de Oliveira Dias, Joao Rafael; Belfort, Rubens, Jr.; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Paulista Sch Med, Rua Botucatu 831, BR-04023062 Sao Paulo, SP, Brazil.
   [Ventura, Camila V.; Berrocal, Audina M.; de Oliveira Dias, Joao Rafael] Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [van der Linden, Vanessa] Barao de Lucena Hosp, Dept Pediat Neurol, Recife, PE, Brazil.
RP Belfort, R (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Paulista Sch Med, Rua Botucatu 831, BR-04023062 Sao Paulo, SP, Brazil.
EM clinbelf@uol.com.br
RI Filho, Vasco/N-6993-2018; Maia, Mauricio/I-5892-2015; Ventura, Liana
   Vieira O/N-6151-2018; Ventura, Camila V/N-2654-2018; Escariao,
   Paulo/N-3349-2018
OI Filho, Vasco/0000-0003-4460-3236; Maia, Mauricio/0000-0002-7034-8091;
   Ventura, Liana Vieira O/0000-0001-6529-6883; Ventura, Camila
   V/0000-0002-2927-4684; Escariao, Paulo/0000-0003-3710-9475; Gois,
   Adriana/0000-0001-5542-1097; Martins, Thayze/0000-0002-8082-2623
CR Brasil Ministerio da Saude, INF EP NO 32 MON CAS
   de Miranda HA, 2016, OPHTHALMOLOGY, V123, P1788, DOI 10.1016/j.ophtha.2016.05.001
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Freitas BD, 2016, JAMA OPHTHALMOL, V134, P529, DOI 10.1001/jamaophthalmol.2016.0267
   Garg S, 2009, RETINA-J RET VIT DIS, V29, P631, DOI 10.1097/IAE.0b013e318198d8de
   Goldenberg D, 2013, GRAEF ARCH CLIN EXP, V251, P2037, DOI 10.1007/s00417-013-2334-3
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Oh Joo Youn, 2007, Korean J Ophthalmol, V21, P175, DOI 10.3341/kjo.2007.21.3.175
   Optovue, RTVUE 100 OPT COH TO
   Optovue, AV OPT COH TOM BROCH
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Sun Lisa L, 2012, Digit J Ophthalmol, V18, P1, DOI 10.5693/djo.02.2012.04.001
   Tognarelli J, 2016, ARCH VIROL, V161, P665, DOI 10.1007/s00705-015-2695-5
   Trevino R, 2014, OPTOMETRY VISION SCI, V91, pS71, DOI 10.1097/OPX.0000000000000181
   Ventura CV, 2016, JAMA OPHTHALMOL, V134, P912, DOI 10.1001/jamaophthalmol.2016.1784
   Ventura CV, 2016, LANCET, V387, P2502, DOI 10.1016/S0140-6736(16)30776-0
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   Villegas VM, 2014, OSLI RETINA, V45, P222, DOI 10.3928/23258160-20140410-01
   World Health Organization, 2015, EP AL NEUR SYNDR CON
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14, DOI 10.1001/jama.2013.281053
   Yakob L, 2016, LANCET GLOB HEALTH, V4, pE148, DOI 10.1016/S2214-109X(16)00048-6
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 25
TC 27
Z9 27
U1 0
U2 36
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD DEC 1
PY 2016
VL 134
IS 12
BP 1420
EP 1427
DI 10.1001/jamaophthalmol.2016.4283
PG 9
WC Ophthalmology
SC Ophthalmology
GA EF8SR
UT WOS:000390600300020
PM 27832267
DA 2020-12-15
ER

PT J
AU Wu, L
   Zas, M
   Berrocal, MH
   Arevalo, JF
   Figueroa, M
   Rodriguez, F
   Serrano, M
   Graue, F
   Alezzandrini, A
   Gallego-Pinazo, R
   Roca, JA
   Iglicki, M
   Dalma-Weishauz, J
   Kozak, I
   Collado, A
   Badal, J
   Maia, M
   Salcedo-Villanueva, G
   Quiroz-Mercado, H
   Fromow-Guerra, J
   Lozano-Rechy, D
   Avila, M
   Chhablani, J
AF Wu, Lihteh
   Zas, Marcelo
   Berrocal, Maria H.
   Arevalo, J. Fernando
   Figueroa, Marta
   Rodriguez, Francisco
   Serrano, Martin
   Graue, Federico
   Alezzandrini, Arturo
   Gallego-Pinazo, Roberto
   Roca, Jose A.
   Iglicki, Matias
   Dalma-Weishauz, Jose
   Kozak, Igor
   Collado, Alberto
   Badal, Josep
   Maia, Mauricio
   Salcedo-Villanueva, Guillermo
   Quiroz-Mercado, Hugo
   Fromow-Guerra, Jans
   Lozano-Rechy, David
   Avila, Marcos
   Chhablani, Jay
TI ANATOMICAL AND FUNCTIONAL OUTCOMES OF SYMPTOMATIC IDIOPATHIC
   VITREOMACULAR TRACTION: A Natural History Study From the Pan American
   Collaborative Retina Study Group
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE vitreomacular traction; macular hole; vitrectomy; ocriplasmin
ID OPTICAL COHERENCE TOMOGRAPHY; POSTERIOR VITREOUS DETACHMENT;
   CLINICAL-COURSE; MACULAR HOLES; OCRIPLASMIN; VITRECTOMY; ADHESION;
   COMPLICATIONS; SEPARATION; INJECTION
AB Purpose:To describe the natural history of eyes with symptomatic idiopathic vitreomacular traction (VMT).Methods:Retrospective multicenter study of 168 eyes with spectral-domain optical coherence tomography (SD-OCT) findings consistent with idiopathic VMT. All eyes were graded according to SD-OCT findings. Grade 1 was defined as incomplete cortical vitreous separation with foveal attachment. Grade 2 was defined as Grade 1 plus intraretinal cysts or clefts. Grade 3 was defined as Grade 2 plus a foveal detachment. All patients were followed for at least 6 months.Results:There were 168 patients (51 men) with a mean age of 68.8 10.7 years. Patients were followed for a mean of 22.7 +/- 20.1 months. The mean duration of symptoms before the initial presentation was 3.65 +/- 5.42 months. At baseline, 72 eyes had Grade 1, 74 eyes had Grade 2, and 22 eyes had Grade 3 SD-OCT findings. Over the follow-up period, 36 eyes (21.4%) had spontaneous resolution of the VMT with normalization of the foveal anatomy. The mean time to resolution was 12.3 +/- 12.6 months. An unfavorable anatomical outcome occurred in 7.7% (13 of 168) of the eyes, with 6 eyes developing a lamellar macular hole and 7 eyes developing a full-thickness macular hole. This occurred at a mean of 10.3 +/- 10.7 months after the presentation. Subgroup analysis based on baseline SD-OCT grade showed that 4.1% (3 of 73) of Grade 1 eyes compared with 6.8% (5 of 74) of Grade 2 eyes, and 23.8% (5 of 21) of Grade 3 eyes developed a full-thickness macular hole or lamellar macular hole (P = 0.0109, chi-square test). In the remaining 119 eyes, at the last follow-up, 65 eyes had Grade 1, 42 eyes had Grade 2, and 12 eyes had Grade 3 VMT. On average, the best-corrected visual acuity improved from 0.40 +/- 0.35 logarithm of the minimum angle of resolution (Snellen, 20/50) at baseline to 0.35 +/- 0.36 logarithm of the minimum angle of resolution (Snellen, 20/45; P = 0.0372), and the mean central macular thickness improved from 350 +/- 132 m to 323 +/- 121 m.Conclusion:Spontaneous resolution of VMT occurred in 21.4% (36 of 168) of eyes after a mean follow-up of 11.4 +/- 12.6 months. An unfavorable anatomical outcome occurred in 7.7% (13 of 168) of eyes. The baseline SD-OCT grade may predict the progression to full-thickness macular hole.
C1 [Wu, Lihteh] Macula Vitreous & Retina Associates Costa Rica, San Jose, Costa Rica.
   [Zas, Marcelo; Iglicki, Matias] Univ Buenos Aires, Buenos Aires, DF, Argentina.
   [Berrocal, Maria H.] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Arevalo, J. Fernando; Kozak, Igor] King Khalid Eye Specialist Hosp, Riyadh, Saudi Arabia.
   [Arevalo, J. Fernando] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Figueroa, Marta] Ramon & Cajal Univ Hosp, Retina Dept, Madrid, Spain.
   [Figueroa, Marta] VISSUM Madrid, Madrid, Spain.
   [Rodriguez, Francisco] Rosario Univ, Natl Ophthalmol Fdn, Bogota, Colombia.
   [Serrano, Martin] Ctr Caracas Ophthalmol Clin, Caracas, Venezuela.
   [Graue, Federico; Collado, Alberto; Lozano-Rechy, David] Conde Valenciana Fdn, Mexico City, DF, Mexico.
   [Alezzandrini, Arturo] OFTALMOS Univ Buenos Aires, Buenos Aires, DF, Argentina.
   [Gallego-Pinazo, Roberto] Univ Valencia, La Fe Hosp, Valencia, Spain.
   [Roca, Jose A.] Ricardo Palma Clin, Lima, Peru.
   [Dalma-Weishauz, Jose; Fromow-Guerra, Jans] Assoc Blindness Prevent Mexico, Mexico City, DF, Mexico.
   [Badal, Josep] Moises Broggi Hosp, Dept Ophthalmol, Retina & Vitreous Unit, Barcelona, Spain.
   [Maia, Mauricio] Univ Fed Sao Paulo, Vision Inst, Dept Ophthalmol, Sao Paulo, Brazil.
   [Salcedo-Villanueva, Guillermo; Quiroz-Mercado, Hugo] Univ Colorado, Sch Med, Denver, CO 80309 USA.
   [Avila, Marcos] Univ Fed Goias, Dept Ophthalmol, Goiania, Go, Brazil.
   [Chhablani, Jay] LV Prasad Eye Inst, Hyderabad, Andhra Pradesh, India.
RP Wu, L (corresponding author), Vitreo & Retina Costa Rica, Asociados Macula, Apdo 144-1225 Plaza Mayor, San Jose, Costa Rica.
EM LW65@cornell.edu
RI Zas, Marcelo/AAF-2679-2020; Fromow-Guerra, J. Jans/A-3346-2015;
   Salcedo-Villanueva, Guillermo/AAE-9695-2019; Kozak, Igor/AAC-4645-2019;
   Maia, Mauricio/I-5892-2015
OI Fromow-Guerra, J. Jans/0000-0001-5335-1275; Salcedo-Villanueva,
   Guillermo/0000-0003-2526-6342; Maia, Mauricio/0000-0002-7034-8091
CR Bottos J, 2015, OSLI RETINA, V46, P235, DOI 10.3928/23258160-20150213-14
   Bottos JM, 2012, CURR OPIN OPHTHALMOL, V23, P195, DOI 10.1097/ICU.0b013e328352404c
   CHAN CK, 1995, OPHTHALMOLOGY, V102, P757, DOI 10.1016/S0161-6420(95)30958-X
   Codenotti M, 2014, GRAEF ARCH CLIN EXP, V252, P1729, DOI 10.1007/s00417-014-2645-z
   Davis RP, 2010, OPHTHAL SURG LAS IM, V41, P150, DOI 10.3928/15428877-20100303-01
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Fahim AT, 2014, JAMA OPHTHALMOL, V132, P484, DOI 10.1001/jamaophthalmol.2013.8142
   HIKICHI T, 1995, AM J OPHTHALMOL, V119, P55, DOI 10.1016/S0002-9394(14)73813-9
   Huang HW, 2013, TAIWAN J OPHTHALMOL, V3, P26
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P2012, DOI 10.1097/IAE.0b013e3182a6b3e2
   John VJ, 2014, RETINA-J RET VIT DIS, V34, P442, DOI 10.1097/IAE.0b013e3182a15f8b
   Johnson Mark W, 2005, Trans Am Ophthalmol Soc, V103, P537
   Johnson MW, 2015, RETINA-J RET VIT DIS, V35, P1055, DOI 10.1097/IAE.0000000000000667
   Johnson MW, 2013, AM J OPHTHALMOL, V155, P203, DOI 10.1016/j.ajo.2012.10.016
   Johnson MW, 2010, AM J OPHTHALMOL, V149, P371, DOI 10.1016/j.ajo.2009.11.022
   Kim JE, 2014, JAMA OPHTHALMOL, V132, P379, DOI 10.1001/jamaophthalmol.2014.278
   Larsson J, 2004, ACTA OPHTHALMOL SCAN, V82, P691, DOI 10.1111/j.1600-0420.2004.00344.x
   MCDONALD HR, 1994, OPHTHALMOLOGY, V101, P1397
   Mirza RG, 2007, SURV OPHTHALMOL, V52, P397, DOI 10.1016/j.survophthal.2007.04.007
   Odrobina D, 2011, RETINA-J RET VIT DIS, V31, P324, DOI 10.1097/IAE.0b013e3181eef08c
   Rodrigues IA, 2013, AM J OPHTHALMOL, V155, P270, DOI 10.1016/j.ajo.2012.08.018
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   SMIDDY WE, 1988, ARCH OPHTHALMOL-CHIC, V106, P624
   Sonmez K, 2008, RETINA-J RET VIT DIS, V28, P1207, DOI 10.1097/IAE.0b013e31817b6b0f
   Stalmans P, 2012, NEW ENGL J MED, V367, P606, DOI 10.1056/NEJMoa1110823
   Theodossiadis GP, 2015, GRAEF ARCH CLIN EXP, V253, P1425, DOI 10.1007/s00417-014-2826-9
   Theodossiadis GP, 2014, AM J OPHTHALMOL, V157, P842, DOI 10.1016/j.ajo.2014.01.011
   Toklu Y, 2012, SEMIN OPHTHALMOL, V27, P73, DOI 10.3109/08820538.2012.680640
   Tzu JH, 2015, OSLI RETINA, V46, P571, DOI 10.3928/23258160-20150521-09
   Yamada N, 2005, AM J OPHTHALMOL, V139, P112, DOI 10.1016/j.ajo.2004.08.055
   Zhang ZQ, 2015, CAN J OPHTHALMOL, V50, P172, DOI 10.1016/j.jcjo.2014.12.003
NR 31
TC 13
Z9 12
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2016
VL 36
IS 10
BP 1913
EP 1918
DI 10.1097/IAE.0000000000001015
PG 6
WC Ophthalmology
SC Ophthalmology
GA DZ6US
UT WOS:000385998600026
PM 26966868
DA 2020-12-15
ER

PT J
AU Belangero, V
   Schvartsman, B
   Nussenzveig, P
   Abreu, AL
   Andrade, OVB
   Facincani, I
   Maia, M
   Nogueira, PK
AF Belangero, V.
   Schvartsman, B.
   Nussenzveig, P.
   Abreu, A. L.
   Andrade, O. V. B.
   Facincani, I.
   Maia, M.
   Koch Nogueira, P.
TI Factors Involved in Pediatric Chronic Kidney Disease Progression
SO PEDIATRIC NEPHROLOGY
LA English
DT Meeting Abstract
C1 [Belangero, V.] Univ Estadual Campinas, Campinas, SP, Brazil.
   [Schvartsman, B.] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Nussenzveig, P.; Maia, M.] Hosp Infantil Darcy Vargas, Sao Paulo, Brazil.
   [Abreu, A. L.] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
   [Andrade, O. V. B.] Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, Brazil.
   [Facincani, I.] Univ Sao Paulo, Fac Med, Ribeirao Preto, Brazil.
   [Koch Nogueira, P.] Hosp Samaritano Sao Paulo, Sao Paulo, Brazil.
   [Koch Nogueira, P.] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
RI Nogueira, Paulo Cesar Koch/E-8376-2010; belangero, vera/A-7934-2013;
   Maia, Mauricio/I-5892-2015
OI Nogueira, Paulo Cesar Koch/0000-0002-9536-9665; belangero,
   vera/0000-0002-6828-5431; Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0931-041X
EI 1432-198X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD OCT
PY 2016
VL 31
IS 10
MA PO-459
BP 1912
EP 1913
PG 2
WC Pediatrics; Urology & Nephrology
SC Pediatrics; Urology & Nephrology
GA DU3AI
UT WOS:000382082600582
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Lasave, A
   Wu, L
   Maia, M
   Diaz-Llopis, M
   Alezzandrini, A
   Brito, M
AF Arevalo, J. Fernando
   Lasave, Andres
   Wu, Lihteh
   Maia, Mauricio
   Diaz-Llopis, Manuel
   Alezzandrini, Arturo
   Brito, Miguel
TI Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy: Results
   from the Pan-American Collaborative Retina Study Group (PACORES) at 24
   Months of Follow-up
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
CY MAY 01-05, 2016
CL Seattle, WA
SP Assoc Res Vis & Ophthalmol
C1 [Arevalo, J. Fernando] Johns Hopkins Univ, Wilmer Eye Inst, Retina Div, Baltimore, MD 21218 USA.
   [Lasave, Andres] Clin Privada Ojos, Retina & Vitreous Serv, Mar Del Plata, Argentina.
   [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Maia, Mauricio] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Diaz-Llopis, Manuel] Univ Hosp, Valencia, Spain.
   [Alezzandrini, Arturo] Univ Buenos Aires, OFTALMOS, Buenos Aires, DF, Argentina.
   [Brito, Miguel] Inst Docente Especialidades Oftalmol IDEO, Maracaibo, Venezuela.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2016
VL 57
IS 12
PG 2
WC Ophthalmology
SC Ophthalmology
GA EK8YM
UT WOS:000394210604141
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Belucio-Neto, J
   Xavier, CD
   Dias, JRD
   Passos, RM
   Maia, M
   Maia, A
AF Belucio-Neto, Jose
   Xavier, Camilla de Oliveira
   de Oliveira Dias, Joao Rafael
   Passos, Renato Magalhaes
   Maia, Mauricio
   Maia, Andre
TI Functional and anatomical outcomes in patients submitted to panretinal
   photocoagulation using 577nm multispot vs 532nm single-spot laser: a
   clinical trial
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
CY MAY 01-05, 2016
CL Seattle, WA
SP Assoc Res Vis & Ophthalmol
C1 [Belucio-Neto, Jose; Xavier, Camilla de Oliveira; de Oliveira Dias, Joao Rafael; Passos, Renato Magalhaes; Maia, Mauricio; Maia, Andre] Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Sao Paulo, Brazil.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2016
VL 57
IS 12
MA 5856
PG 3
WC Ophthalmology
SC Ophthalmology
GA EK8YM
UT WOS:000394210602087
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Kato, RT
   Novais, EA
   Maia, M
   de Mello, PA
   Dias, JRD
   Avila, M
   Maia, A
   Arevalo, IF
   Wu, L
   Berrocal, MH
   Farah, M
AF Kato, Renata Tiemi
   Novais, Eduardo Amorim
   Maia, Mauricio
   de Mello Filho, Paulo Augusto
   de Oliveira Dias, Joao Rafael
   Avila, Marcos
   Maia, Andre
   Arevalo, I. Fernando
   Wu, Lihteh
   Berrocal, Maria H.
   Farah, Michel
TI TWELVE-MONTH FOLLOW-UP OF DEXAMETHASONE IMPLANTS FOR MACULAR EDEMA FROM
   VARIOUS DISEASES IN VITRECTOMIZED AND NON-VITRECTOMIZED EYES: RESULTS
   FROM THE PAN AMERICAN COLLABORATIVE RETINA STUDY GROUP
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
CY MAY 01-05, 2016
CL Seattle, WA
SP Assoc Res Vis & Ophthalmol
C1 [Kato, Renata Tiemi; Novais, Eduardo Amorim; Maia, Mauricio; de Mello Filho, Paulo Augusto; de Oliveira Dias, Joao Rafael; Maia, Andre; Farah, Michel] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Avila, Marcos] Univ Fed Goias, Sao Paulo, Brazil.
   [Arevalo, I. Fernando] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Wu, Lihteh] Asociados Macula Vitreo & Retina Costa Rica, San Jose, Costa Rica.
   [Berrocal, Maria H.] Univ Puerto Rico, San Juan, PR 00936 USA.
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2016
VL 57
IS 12
MA 4151
PG 3
WC Ophthalmology
SC Ophthalmology
GA EK8YI
UT WOS:000394210204004
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Ventura, CV
   Maia, M
   Travassos, SB
   Martins, TT
   Patriota, F
   Nunes, ME
   Agra, C
   Torres, VL
   van der Linden, V
   Ramos, RC
   Rocha, MAW
   Silva, PS
   Ventura, LO
   Belfort, R
AF Ventura, Camila V.
   Maia, Mauricio
   Travassos, Simone B.
   Martins, Thayze T.
   Patriota, Felipe
   Nunes, Marcos Eugenio
   Agra, Cristiana
   Torres, Virginia L.
   van der Linden, Vanessa
   Ramos, Regina C.
   Rocha, Maria Angela W.
   Silva, Paula S.
   Ventura, Liana O.
   Belfort, Rubens, Jr.
TI Risk Factors Associated With the Ophthalmoscopic Findings Identified in
   Infants With Presumed Zika Virus Congenital Infection
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID TRANSMISSION; CHILD
AB IMPORTANCE The Zika virus (ZIKV) might cause microcephaly and ophthalmoscopic findings in infants of mothers infected during pregnancy.
   OBJECTIVE To assess and identify possible risk factors for ophthalmoscopic findings in infants born with microcephaly and a presumed clinical diagnosis of ZIKV intrauterine infection.
   DESIGN, SETTING, AND PARTICIPANTS We conducted a cross-sectional study at the Altino Ventura Foundation in Recife, Brazil, that included 40 infants with microcephaly born in Pernambuco state, Brazil, between May and December 2015. Toxoplasmosis, rubella, cytomegalovirus, syphilis, and human immunodeficiency virus were ruled out in all of them. Testing of cerebrospinal fluid for ZIKV using IgM antibody-capture enzyme-linked immunosorbent assay was performed in 24 of 40 infants (60.0%). The infants and mothers underwent ocular examinations. The infants were divided into 2 groups, those with and without ophthalmoscopic alterations, for comparison.
   MAIN OUTCOMES AND MEASURES Identification of risk factors for ophthalmoscopic findings in infants born with microcephaly and ZIKV intrauterine infection.
   RESULTS Among the 40 infants, the mean (SD) age was 2.2 (1.2) months (range, 0.1-7.3 months). Of the 24 infants tested, 100% had positive results for ZIKV infection: 14 of 22 infants (63.6%) from the group with ophthalmoscopic findings and 10 of 18 infants (55.6%) from the group without ophthalmoscopic findings. The major symptoms reported in both groups were rash by 26 mothers (65.0%), fever by 9 mothers (22.5%), headache by 9 mothers (22.5%), and arthralgia by 8 mothers (20.0%). No mothers reported conjunctivitis or other ocular symptoms during pregnancy or presented signs of uveitis at the time of examination. Thirty-seven eyes (46.3%) of 22 infants (55.0%) had ophthalmoscopic alterations. Ten mothers (71.4%) of infants with ocular findings reported symptoms during the first trimester (frequency, 0.48; 95% CI, 0.02-0.67; P = .04). A difference was also observed between the groups of infants with and without ocular findings regarding the cephalic perimeter: mean (SD) of 28.8 (1.7) and 30.3 (1.5), respectively (frequency, -1.50; 95% CI, -2.56 to -0.51; P = .004).
   CONCLUSIONS AND RELEVANCE Ocular involvement in infants with presumed ZIKV congenital infection were more often seen in infants with smaller cephalic diameter at birth and in infants whose mothers reported symptoms during the first trimester.
C1 [Ventura, Camila V.; Travassos, Simone B.; Martins, Thayze T.; Patriota, Felipe; Nunes, Marcos Eugenio; Torres, Virginia L.; Ventura, Liana O.] Altino Ventura Fdn, Recife, PE, Brazil.
   [Ventura, Camila V.; Travassos, Simone B.; Martins, Thayze T.; Patriota, Felipe; Nunes, Marcos Eugenio; Agra, Cristiana; Torres, Virginia L.; Ventura, Liana O.] Pernambucos Eye Hosp HOPE, Recife, PE, Brazil.
   [Ventura, Camila V.; Maia, Mauricio; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Paulista Sch Med, Sao Paulo, Brazil.
   [Ventura, Camila V.; Maia, Mauricio; Belfort, Rubens, Jr.] Vis Inst, Sao Paulo, Brazil.
   [van der Linden, Vanessa] Barao de Lucena Hosp, Recife, PE, Brazil.
   [Ramos, Regina C.; Rocha, Maria Angela W.; Silva, Paula S.] Oswaldo Cruz Univ Hosp, Recife, PE, Brazil.
RP Belfort, R (corresponding author), Escola Paulista Med, Dept Oftalmol, Rua Botucatu 831, BR-04023062 Sao Paulo, Brazil.
EM clinbelf@uol.com.br
RI Ventura, Camila V/N-2654-2018; Ventura, Liana Vieira O/N-6151-2018;
   Torres, Virginia/N-6951-2018; Maia, Mauricio/I-5892-2015
OI Ventura, Camila V/0000-0002-2927-4684; Ventura, Liana Vieira
   O/0000-0001-6529-6883; Torres, Virginia/0000-0002-3744-0961; Maia,
   Mauricio/0000-0002-7034-8091; Martins, Thayze/0000-0002-8082-2623; AGRA,
   CRISTIANA/0000-0002-4400-7744
CR Alpert SG, 2003, AM J OPHTHALMOL, V136, P733, DOI 10.1016/S0002-9394(03)00452-5
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Brasil Ministerio da Saude, PROT VIG RESP OC MIC
   Brasil - Ministerio da Saude, SAUD CONF 1 113 CAS
   Centers for Disease Control and Prevention, TRAV HLTH NOT
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dunn D, 1999, LANCET, V353, P1829, DOI 10.1016/S0140-6736(98)08220-8
   European Centre for Disease Prevention and Control, MICR BRAZ POT LINK Z
   Freitas BP, 2016, JAMA OPHTHALMOL
   Kaur Savleen, 2013, Oman J Ophthalmol, V6, P77, DOI 10.4103/0974-620X.116622
   MACNAMARA FN, 1954, T ROY SOC TROP MED H, V48, P139, DOI 10.1016/0035-9203(54)90006-1
   Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Mets MB, 2008, SURV OPHTHALMOL, V53, P95, DOI 10.1016/j.survophthal.2007.12.003
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Rasmussen SA, 2016, N ENGL J MED
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   Ventura CV, 2014, ARQ BRAS OFTALMOL, V77, P300, DOI 10.5935/0004-2749.20140076
   World Health Organization, WHO DIR GEN SUMM OUT
   World Health Organization (WHO), EP AL NEUR SYNDR CON
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14, DOI 10.1001/jama.2013.281053
NR 26
TC 87
Z9 87
U1 0
U2 81
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD AUG
PY 2016
VL 134
IS 8
BP 912
EP 918
DI 10.1001/jamaophthalmol.2016.1784
PG 7
WC Ophthalmology
SC Ophthalmology
GA DT1AD
UT WOS:000381213200015
PM 27228275
OA Bronze
DA 2020-12-15
ER

PT J
AU Ventura, CV
   Maia, M
   Ventura, BV
   Linden, VVD
   Araojo, EB
   Ramos, RC
   Rocha, MAW
   Carvalho, DCG
   Belfort, R
   Ventura, LO
AF Ventura, Camila V.
   Maia, Mauricio
   Ventura, Bruna V.
   Linden, Vanessa V. D.
   Araojo, Eveline B.
   Ramos, Regina C.
   Rocha, Maria Angela W.
   Carvalho, Durce C. G.
   Belfort, Rubens, Jr.
   Ventura, Liana O.
TI Response letter: Serological evidence confirms the presumed diagnosis of
   Zika virus congenital infection in infants with microcephaly and ocular
   findings
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Letter
C1 [Ventura, Camila V.; Ventura, Bruna V.; Araojo, Eveline B.; Ventura, Liana O.] FAV, Recife, PE, Brazil.
   [Ventura, Camila V.; Ventura, Bruna V.; Araojo, Eveline B.; Ventura, Liana O.] Hosp Olhos HOPE, Recife, PE, Brazil.
   [Ventura, Camila V.; Maia, Mauricio; Ventura, Bruna V.; Belfort, Rubens, Jr.] Univ Fed Sao Paulo UNIFESP, EPM, Dept Ophthalmol & Visual Sci, Sao Paulo, SP, Brazil.
   [Maia, Mauricio; Belfort, Rubens, Jr.] Inst Visiao, Sao Paulo, SP, Brazil.
   [Linden, Vanessa V. D.] Hosp Barao de Lucena, Recife, PE, Brazil.
   [Ramos, Regina C.; Rocha, Maria Angela W.; Carvalho, Durce C. G.] HUOC, Recife, PE, Brazil.
RP Belfort, R (corresponding author), Escola Paulista Med, Dept Oftalmol, Rua Botucatu 831, BR-04023062 Sao Paulo, SP, Brazil.
EM clinbelf@uol.com.br
RI Maia, Mauricio/I-5892-2015; Ventura, Bruna/N-2724-2018; Ventura, Liana
   Vieira/N-6151-2018
OI Maia, Mauricio/0000-0002-7034-8091; Ventura, Bruna/0000-0003-4333-3932;
   Ventura, Liana Vieira/0000-0001-6529-6883
CR Cugola F. R., 2016, NATURE
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   Ventura CV, 2016, JAMA IN PRESS
   Yakob L., 2016, LANCET GLOB HLTH
NR 5
TC 0
Z9 0
U1 0
U2 2
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD JUL-AUG
PY 2016
VL 79
IS 4
BP 280
EP 280
PG 1
WC Ophthalmology
SC Ophthalmology
GA DX4EN
UT WOS:000384334100025
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Ventura, CV
   Maia, M
   Dias, N
   Ventura, LO
   Belfort, R
AF Ventura, Camila V.
   Maia, Mauricio
   Dias, Natalia
   Ventura, Liana O.
   Belfort, Rubens, Jr.
TI Zika: neurological and ocular findings in infant without microcephaly
SO LANCET
LA English
DT Letter
ID VIRUS
C1 [Ventura, Camila V.; Dias, Natalia; Ventura, Liana O.] Altino Ventura Fdn, Recife, PE, Brazil.
   [Maia, Mauricio; Belfort, Rubens, Jr.] HOPE Eye Hosp, Recife, PE, Brazil.
   [Ventura, Camila V.; Ventura, Liana O.] Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Paulista Sch Med, Sao Paulo, Brazil.
   [Ventura, Camila V.; Ventura, Liana O.] Vis Inst, Sao Paulo, Brazil.
RP Belfort, R (corresponding author), HOPE Eye Hosp, Recife, PE, Brazil.
EM clinbelf@uol.com.br
RI Ventura, Camila V/N-2654-2018; Ventura, Liana Vieira O/N-6151-2018;
   Maia, Mauricio/I-5892-2015
OI Ventura, Camila V/0000-0002-2927-4684; Ventura, Liana Vieira
   O/0000-0001-6529-6883; Maia, Mauricio/0000-0002-7034-8091
CR Freitas BD, 2016, JAMA OPHTHALMOL, V134, P529, DOI 10.1001/jamaophthalmol.2016.0267
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   World Health Organisation, 2016, WHO DIR GEN SUMM OUT
   World Health Organization, 2015, EP AL NEUR SYNDR CON
NR 5
TC 75
Z9 75
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUN 18
PY 2016
VL 387
IS 10037
BP 2502
EP 2502
DI 10.1016/S0140-6736(16)30776-0
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA DO7FG
UT WOS:000377947200018
PM 27287830
OA Bronze
DA 2020-12-15
ER

PT J
AU Freitas, BD
   Dias, JRD
   Prazeres, J
   Sacramento, GA
   Ko, AI
   Maia, M
   Belfort, R
AF Freitas, Bruno de Paula
   de Oliveira Dias, Joao Rafael
   Prazeres, Juliana
   Sacramento, Gielson Almeida
   Ko, Albert Icksang
   Maia, Mauricio
   Belfort, Rubens, Jr.
TI Ocular Findings in Infants With Microcephaly Associated With Presumed
   Zika Virus Congenital Infection in Salvador, Brazil
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID FRENCH-POLYNESIA; PERINATAL TRANSMISSION; VERTICAL TRANSMISSION;
   DECEMBER 2013; DENGUE; PREGNANCY; OUTBREAK; OUTCOMES; FEVER
AB IMPORTANCE The Zika virus (ZIKV) has rapidly reached epidemic proportions, especially in northeastern Brazil, and has rapidly spread to other parts of the Americas. A recent increase in the prevalence of microcephaly in newborn infants and vision-threatening findings in these infants is likely associated with the rapid spread of ZIKV.
   OBJECTIVE To evaluate the ocular findings in infants with microcephaly associated with presumed intrauterine ZIKV infection in Salvador, Bahia, Brazil.
   DESIGN, SETTING, AND PARTICIPANTS Case series at a tertiary hospital. Twenty-nine infants with microcephaly (defined by a cephalic circumference of <= 32 cm) with a presumed diagnosis of congenital ZIKV were recruited through an active search and referrals from other hospitals and health unities. The study was conducted between December 1 and December 21, 2015.
   INTERVENTIONS All infants and mothers underwent systemic and ophthalmic examinations from December 1 through December 21, 2015, in the Roberto Santos General Hospital, Salvador, Brazil. Anterior segment and retinal, choroidal, and optic nerve abnormalities were documented using a wide-field digital imaging system. The differential diagnosis included toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus, syphilis, and human immunodeficiency virus, which were ruled out through serologic and clinical examinations.
   MAIN OUTCOMES AND MEASURES Ocular abnormalities associated with ZIKV.
   RESULTS Twenty-three of 29 mothers (79.3%) reported suspected ZIKV infection signs and symptoms during pregnancy, 18 in the first trimester, 4 in the second trimester, and 1 in the third trimester. Of the 29 infants (58 eyes) examined (18 [62.1%] female), ocular abnormalities were present in 17 eyes (29.3%) of 10 children (34.5%). Bilateral findings were found in 7 of 10 patients presenting with ocular lesions, the most common of which were focal pigment mottling of the retina and chorioretinal atrophy in 11 of the 17 eyes with abnormalities (64.7%), followed by optic nerve abnormalities in 8 eyes (47.1%), bilateral iris coloboma in 1 patient (2 eyes [11.8%]), and lens subluxation in 1 eye (5.9%).
   CONCLUSIONS AND RELEVANCE Congenital infection due to presumed ZIKV exposure is associated with vision-threatening findings, which include bilateral macular and perimacular lesions as well as optic nerve abnormalities in most cases.
C1 [Freitas, Bruno de Paula] Hosp Geral Roberto Santos, Dept Ophthalmol, Salvador, BA, Brazil.
   [de Oliveira Dias, Joao Rafael; Prazeres, Juliana; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Vis Inst, Dept Ophthalmol, Paulista Med Sch, Rua Botucatu 822, BR-04023062 Sao Paulo, Brazil.
   [Sacramento, Gielson Almeida; Ko, Albert Icksang] Fundacao Oswaldo Cruz, Goncalo Moniz Res Ctr, Salvador, BA, Brazil.
   [Ko, Albert Icksang] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
RP Belfort, R (corresponding author), Univ Fed Sao Paulo, Vis Inst, Dept Ophthalmol, Paulista Med Sch, Rua Botucatu 822, BR-04023062 Sao Paulo, Brazil.
EM clinbelf@uol.com.br
RI Maia, Mauricio/I-5892-2015; de Oliveira Dias, Joao/J-6735-2016; Ko,
   Albert Icksang/P-2343-2015
OI Maia, Mauricio/0000-0002-7034-8091; Ko, Albert
   Icksang/0000-0001-9023-2339
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Federal University of Sao Paulo (Paulista Medical School);
   Vision Institute (IPEPO); FOGARTY INTERNATIONAL CENTERUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Fogarty International Center (FIC) [R01TW009504, R01TW009504,
   R01TW009504, R01TW009504, R01TW009504] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI121207, R01AI121207, R01AI121207, R01AI121207] Funding Source: NIH
   RePORTER
FX Hospital Geral Roberto Santos provided the site and materials for
   ophthalmologic examination. Federal University of Sao Paulo (Paulista
   Medical School), Vision Institute (IPEPO), and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) provided funds for
   travel expenses as well as the materials necessary for the ocular
   examinations.
CR Adam I, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-153
   Alpert SG, 2003, AM J OPHTHALMOL, V136, P733, DOI 10.1016/S0002-9394(03)00452-5
   Barthel A, 2013, CLIN INFECT DIS, V57, P415, DOI 10.1093/cid/cit227
   Bentlin MR, 2011, EMERG INFECT DIS, V17, P1779, DOI 10.3201/eid1709.110242
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P877
   Centro de Operacoes de Emergencias em Saude Publica sobre Microcefalias, MON CAS MICR BRAS
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dupont-Rouzeyrol M, 2015, EMERG INFECT DIS, V21, P381, DOI 10.3201/eid2102.141553
   European Center for Disease Prevention and Control, 2015, ZIK VIR EP AM POT AS
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Fritel X, 2010, EMERG INFECT DIS, V16, P418, DOI 10.3201/eid1603.091403
   Gerardin P, 2008, PLOS MED, V5, P413, DOI 10.1371/journal.pmed.0050060
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   Kelly JC, 2016, MEDSCAPE
   Kuno G, 2007, ARCH VIROL, V152, P687, DOI 10.1007/s00705-006-0903-z
   Kutsuna S, 2014, EUROSURVEILLANCE, V19, P8, DOI 10.2807/1560-7917.ES2014.19.4.20683
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Ministerio da Saude, MICR 3174 CAS SAO IN
   Ministerio da Saude, NOT MED PER CEF DIAG
   Ministerio da Saude, MIN SAUD CONF REL EN
   Ministerio da Saude Secretaria de Vigilancia em Saude, PROT VIG RESP OC MIC
   Ministerio de Saude (MS), 2015, B EPIDEMIOL, V46, P1
   Musso D, 2015, EMERG INFECT DIS, V21, P1887, DOI 10.3201/eid2110.151125
   Pouliot SH, 2010, OBSTET GYNECOL SURV, V65, P107, DOI 10.1097/OGX.0b013e3181cb8fbc
   Stewart RD, 2013, CASE REP INFECT DIS, DOI 10.1155/2013/351872
   Tan PC, 2008, OBSTET GYNECOL, V111, P1111, DOI 10.1097/AOG.0b013e31816a49fc
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   World Health Organization (WHO), EP AL NEUR SYNDR CON
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14, DOI 10.1001/jama.2013.281053
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 35
TC 137
Z9 141
U1 0
U2 97
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2016
VL 134
IS 5
BP 529
EP 535
DI 10.1001/jamaophthalmol.2016.0267
PG 7
WC Ophthalmology
SC Ophthalmology
GA DL7CB
UT WOS:000375796100014
PM 26865554
OA Bronze, Green Published, Green Accepted
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Lasave, AF
   Wu, L
   Acon, D
   Berrocal, MH
   Diaz-Llopis, M
   Gallego-Pinazo, R
   Serrano, MA
   Alezzandrini, AA
   Rojas, S
   Maia, M
   Lujan, S
AF Arevalo, J. Fernando
   Lasave, Andres F.
   Wu, Lihteh
   Acon, Dhariana
   Berrocal, Maria H.
   Diaz-Llopis, Manuel
   Gallego-Pinazo, Roberto
   Serrano, Martin A.
   Alezzandrini, Arturo A.
   Rojas, Sergio
   Maia, Mauricio
   Lujan, Silvio
CA Pan-Amer Collaborative Retina
TI INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED
   MACULAR DEGENERATION 5-Year Results of The Pan-American Collaborative
   Retina Study Group
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; bevacizumab; choroidal neovascularization; ranibizumab;
   vascular endothelial growth factor
ID CLINICAL-PRACTICE; RANIBIZUMAB; TACHYPHYLAXIS; TRIAL; VERTEPORFIN;
   INJECTION
AB Purpose: To report the long-term anatomical and functional outcomes of patients with choroidal neovascularization secondary to age-related macular degeneration treated with intravitreal bevacizumab (IVB).
   Methods: Retrospective case series. Patients diagnosed with subfoveal choroidal neovascularization secondary to age-related macular degeneration that were treated with at least 1 intravitreal injection of 1.25 mg of IVB and had a minimum follow-up of 60 months. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits.
   Results: Two hundred and forty-seven consecutive patients (292 eyes) were included. The mean number of IVB injections per eye was 10.9 +/- 6.4. At 5 years, the BCVA decreased from 20/150 (logMAR 0.9 +/- 0.6) at baseline to 20/250 (logMAR 1.1 +/- 0.7) (P = <0.0001). The mean CMT decreased from 343.1+ 122.3 mm at baseline to 314.7 +/- 128.8 mm at 60 months of follow-up (P = 0.009). Geographic atrophy (GA) was observed at baseline in 47 (16%) of 292 eyes. By 5 years, GA developed or progressed in 124 (42.5%) of 292 eyes (P < 0.0001).
   Conclusion: The early visual gains obtained from IVB were not maintained at 5 years of follow-up. In addition, IVB may play a role in the development or progression of GA.
C1 [Arevalo, J. Fernando] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21287 USA.
   [Arevalo, J. Fernando] King Khalid Eye Specialist Hosp, Vitreoretinal & Uveitis Div, Riyadh, Saudi Arabia.
   [Lasave, Andres F.] Clin Privada Ojos, Retina & Vitreous Serv, Mar Del Plata, Buenos Aires, Argentina.
   [Wu, Lihteh; Acon, Dhariana] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Berrocal, Maria H.] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Diaz-Llopis, Manuel; Gallego-Pinazo, Roberto] Univ Valencia, Hosp La Fe, E-46003 Valencia, Spain.
   [Serrano, Martin A.] Ctr Caracas, Clin Oftalmol, Caracas, Venezuela.
   [Serrano, Martin A.] Arevalo Coutinho Fdn Res Ophthalmol, Caracas, Venezuela.
   [Alezzandrini, Arturo A.] Univ Buenos Aires, Fac Med, OFTALMOS, Buenos Aires, DF, Argentina.
   [Rojas, Sergio] Fundac Hosp Nuestra Senora Luz, Mexico City, DF, Mexico.
   [Maia, Mauricio] Fed Univ Sao Paulo UNIFESP, Dept Ophthalmol & Visual Sci, Retina Div, Sao Paulo, Brazil.
   [Lujan, Silvio] MACULA D&T Diagnst, Tratamiento & Rehabil Visual, Lima, Peru.
RP Arevalo, JF (corresponding author), Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St,Maumenee 708, Baltimore, MD 21287 USA.
EM arevalojf@jhmi.edu
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Lasave, Andres/0000-0002-9602-9769
FU SECOND SIGHT LLC; Springer SBM LLC; ALCON LABORATORIESNovartis;
   EyEngineering Inc; DORC International B.V.; Bayer AGBayer AG
FX SECOND SIGHT LLC (C)(L); Springer SBM LLC (P); ALCON LABORATORIES
   (C)(L); EyEngineering Inc (C); DORC International B.V. (C)(L); Bayer AG
   (C). None of the remaining authors have any financial/conflicting
   interests to disclose.
CR Anothaisintawee T, 2012, CLINICOECONOMIC OUTC, V4, P361, DOI 10.2147/CEOR.S37458
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Marques IR, 2013, OPHTHALMOLOGICA, V229, P158, DOI 10.1159/000343709
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Muniraju R, 2013, OPHTHALMOLOGICA, V230, P27, DOI 10.1159/000350238
   Rasmussen A, 2014, CURR OPIN OPHTHALMOL, V25, P158, DOI 10.1097/ICU.0000000000000050
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 29
TC 20
Z9 20
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2016
VL 36
IS 5
BP 859
EP 867
DI 10.1097/IAE.0000000000000827
PG 9
WC Ophthalmology
SC Ophthalmology
GA DL2RG
UT WOS:000375482100009
PM 26529555
DA 2020-12-15
ER

PT J
AU Fernandes, RAB
   Koss, MJ
   Falabella, P
   Stefanini, FR
   Maia, M
   Diniz, B
   Ribeiro, R
   Hu, YT
   Hinton, D
   Clegg, DO
   Chader, G
   Humayun, MS
AF Fernandes, Rodrigo A. Brant
   Koss, Michael Janusz
   Falabella, Paulo
   Stefanini, Francisco Rosa
   Maia, Mauricio
   Diniz, Bruno
   Ribeiro, Ramiro
   Hu, Yuntao
   Hinton, David
   Clegg, Dennis O.
   Chader, Gerald
   Humayun, Mark S.
TI An Innovative Surgical Technique for Subretinal Transplantation of Human
   Embryonic Stem Cell-Derived Retinal Pigmented Epithelium in Yucatan Mini
   Pigs: Preliminary Results
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID MACULAR DEGENERATION; TRANSLOCATION; DIFFERENTIATION; ACCUMULATION;
   IMPLANTATION; MONOLAYER; DISEASE; SURGERY; EYES
AB BACKGROUND AND OBJECTIVE: To develop a safe and efficient surgical procedure for subretinal implantation into porcine eyes of a human embryonic stem cell-derived retinal pigmented epithelium (hESC-RPE) monolayer seeded onto a Parylene-C scaffold. This implant is referred to as CPCB-RPE1.
   MATERIALS AND METHODS: Ultrathin Parylene-C scaffolds were seeded with hESC-RPE and surgically implanted into the subretinal space of Yucat-an mini pigs (n = 8). The surgery consisted of pars plana vitrectomy, induction of a limited retinal detachment, and peripheral retinotomy for insertion of the monolayer using a novel tissue injector, followed by silicone oil tamponade injection, laser photocoagulation around the retinotomy site, and inferior iridectomy. Oral cyclosporine was administered from day 1 and during the entire follow-up period. Three months later, the animals were euthanized and the eyes and major organs were submitted for histological analysis. Adjacent sections underwent immunohistochemical analysis to detect human cells using anti-TRA-1-85 (human blood group antigen) antibody and DAPI antibodies.
   RESULTS: The cell monolayer was immunopositive for TRA-1-85 3 months after implantation and migration from the Parylene-C scaffold was not detected. One eye had a mild inflammatory reaction around the implant that was negative for human biomarkers. No intraocular or systemic tumors were detected.
   CONCLUSION: The hESC-RPE cells survived for 3 months in this animal model. The surgical procedure for subretinal implantation of CPCB-RPE1 is feasible and safe, without cell migration off the scaffold or development of ocular or systemic tumors.
C1 [Fernandes, Rodrigo A. Brant; Koss, Michael Janusz; Falabella, Paulo; Stefanini, Francisco Rosa; Diniz, Bruno; Ribeiro, Ramiro; Hu, Yuntao; Hinton, David; Chader, Gerald; Humayun, Mark S.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Fernandes, Rodrigo A. Brant; Falabella, Paulo; Stefanini, Francisco Rosa; Maia, Mauricio; Diniz, Bruno; Ribeiro, Ramiro] Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Rua Botucatu 822, BR-04023062 Sao Paulo, Brazil.
   [Koss, Michael Janusz] Univ Heidelberg Hosp, Dept Ophthalmol, Heidelberg, Germany.
   [Hu, Yuntao] Tsinghua Univ, Dept Ophthalmol, Beijing Tsinghua Changgung Hosp, Beijing 100084, Peoples R China.
   [Hinton, David] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Clegg, Dennis O.] Univ Calif Santa Barbara, Ctr Stem Cell Biol & Engn, Santa Barbara, CA 93106 USA.
RP Fernandes, RAB (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Rua Botucatu 822, BR-04023062 Sao Paulo, Brazil.
EM ro-drigo.brant@ophthal.com.br
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Falabella, Paulo/0000-0001-8773-7168
FU California Institute of Regenerative Medicine (CIRM)California Institute
   for Regenerative Medicine [CIRM DRI-01444, CIRM CL1-00521]; National Eye
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Eye Institute (NEI)
   [EY03040]; Research to Prevent Blindness, New YorkResearch to Prevent
   Blindness (RPB) [NY 10022]; NEI grant [EY03040]; CAPES Foundation,
   Brasilia, BrazilCAPES [BEX 2326-11-6, BEX 4601-14-9]; CNPq (The National
   Council of Research, Brasilia, Brazil); German Research Foundation DFG
   (Berlin, Germany) [Ko4294/1-1]; UCSB Institute for Collaborative
   Biotechnologies from the U.S. Army Research Office [W911NF-09-0001];
   NATIONAL EYE INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Eye
   Institute (NEI) [P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040] Funding Source: NIH RePORTER
FX Supported by the California Institute of Regenerative Medicine (CIRM),
   grant CIRM DRI-01444, CIRM CL1-00521; National Eye Institute grant
   EY03040; an unrestricted departmental grant from Research to Prevent
   Blindness, New York, NY 10022; NEI grant EY03040; the CAPES Foundation,
   Brasilia, Brazil, [BEX 2326-11-6 (Brant); BEX 4601-14-9 (Falabella)],
   CNPq (The National Council of Research, Brasilia, Brazil); the German
   Research Foundation DFG Ko4294/1-1 (Berlin, Germany); the UCSB Institute
   for Collaborative Biotechnologies through grant W911NF-09-0001 from the
   U.S. Army Research Office. The content of the information does not
   necessarily reflect the position or the policy of the U.S. Government,
   and no official endorsement should be inferred.
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Croze RH, 2014, DEV OPHTHALMOL, V53, P81, DOI 10.1159/000357361
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Evans JR, 2006, COCHRANE DB SYST REV, V2
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Haruta Masathoshi, 2005, Semin Ophthalmol, V20, P17, DOI 10.1080/08820530590921846
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Montezuma SR, 2006, INVEST OPHTH VIS SCI, V47, P3514, DOI 10.1167/iovs.06-0106
   Morris RG, 2002, THER DRUG MONIT, V24, P479, DOI 10.1097/00007691-200208000-00003
   Mruthyunjaya P, 2005, RETINA-J RET VIT DIS, V25, P597, DOI 10.1097/00006982-200507000-00010
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Rowland TJ, 2013, J TISSUE ENG REGEN M, V7, P642, DOI 10.1002/term.1458
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Stanga Paulo E., 2001, International Ophthalmology, V23, P297, DOI 10.1023/A:1014482025960
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   U.S. FDA (CDER/CVM), 1994, GUID IND SUBM DOC ST
NR 30
TC 9
Z9 9
U1 0
U2 13
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD APR
PY 2016
VL 47
IS 4
BP 342
EP 351
DI 10.3928/23258160-20160324-07
PG 10
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA DP9VJ
UT WOS:000378845400007
PM 27065374
OA Green Published
DA 2020-12-15
ER

PT J
AU Wang, Y
   Maia, M
   Burgess, T
   Liao, X
   Tavel, J
   Deng, R
AF Wang, Y.
   Maia, M.
   Burgess, T.
   Liao, X.
   Tavel, J.
   Deng, R.
TI PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS OF RG7667, A COMBINATION
   MONOCLONAL ANTIBODY THERAPY, IN KIDNEY TRANSPLANT RECIPIENTS AT HIGH
   RISK OF CMV INFECTION.
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT)
CY MAR 08-12, 2016
CL San Diego, CA
SP Amer Soc Clin Pharmacol & Therapeut
C1 [Wang, Y.; Maia, M.; Burgess, T.; Liao, X.; Tavel, J.; Deng, R.] Genentech Inc, San Francisco, CA 94080 USA.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD FEB
PY 2016
VL 99
SU 1
MA PII-064
BP S92
EP S92
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DB7JZ
UT WOS:000368692600329
DA 2020-12-15
ER

PT J
AU Ventura, CV
   Maia, M
   Bravo-Filho, V
   Gois, AL
   Belfort, R
AF Ventura, Camila V.
   Maia, Mauricio
   Bravo-Filho, Vasco
   Gois, Adriana L.
   Belfort, Rubens, Jr.
TI Zika virus in Brazil and macular atrophy in a child with microcephaly
SO LANCET
LA English
DT Letter
C1 [Ventura, Camila V.; Bravo-Filho, Vasco; Gois, Adriana L.] Altino Ventura Fdn, Recife, PE, Brazil.
   [Ventura, Camila V.; Maia, Mauricio; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Bravo-Filho, Vasco; Gois, Adriana L.] HOPE Eye Hosp, Recife, PE, Brazil.
RP Belfort, R (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
EM clinbelf@uol.com.br
RI Ventura, Camila V/N-2654-2018; Filho, Vasco/N-6993-2018; Maia,
   Mauricio/I-5892-2015
OI Ventura, Camila V/0000-0002-2927-4684; Filho, Vasco/0000-0003-4460-3236;
   Maia, Mauricio/0000-0002-7034-8091; Gois, Adriana/0000-0001-5542-1097
CR [Anonymous], 2015, Wkly Epidemiol Rec, V90, P609
   Brazil Ministry of Health, MICR MIN HLTH REL EP
   Brazil Ministry of Health, MIN SAUD CONF REL EN
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   World Health Organization (WHO), EP AL NEUR SYNDR CON
NR 5
TC 325
Z9 338
U1 0
U2 187
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JAN 16
PY 2016
VL 387
IS 10015
BP 228
EP 228
DI 10.1016/S0140-6736(16)00006-4
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA DA9LQ
UT WOS:000368130700028
PM 26775125
OA Bronze
DA 2020-12-15
ER

PT J
AU Ventura, C
   Maia, M
   Martins, T
   Patriota, F
   Agra, C
   Ventura, L
   Belfort, R
AF Ventura, Camila
   Maia, Mauricio
   Martins, Thayze
   Patriota, Felipe
   Agra, Cristiana
   Ventura, Liana
   Belfort, Rubens, Jr.
TI Variables Related to the Ophthalmoscopic Findings Identified in Infants
   with Presumed Zika Virus Congenital Infection
SO OPHTHALMOLOGICA
LA English
DT Meeting Abstract
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2016
VL 236
SU 1
MA 69
BP 33
EP 33
PG 1
WC Ophthalmology
SC Ophthalmology
GA DX3HO
UT WOS:000384264400070
DA 2020-12-15
ER

PT J
AU Koss, MJ
   Choi, CY
   Krueger, RR
   Maia, M
   Fam, HB
AF Koss, M. J.
   Choi, C. Y.
   Krueger, R. R.
   Maia, M.
   Fam, H. B.
TI Visual Rehabilitation in Combined Surgical Procedures: Bridging Two Eye
   Poles for Better Vision
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Editorial Material
C1 [Koss, M. J.] Augenzentrum Nymphenburger Hofe, Munich, Germany.
   [Koss, M. J.] Augenklin Herzog Carl Theodor, Munich, Germany.
   [Koss, M. J.] Heidelberg Univ, Dept Ophthalmol, Heidelberg, Germany.
   [Choi, C. Y.] Sungkyunkwan Univ, Dept Ophthalmol, Sch Med, Kangbuk Samsung Hosp, Seoul, South Korea.
   [Krueger, R. R.] Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Maia, M.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, SP, Brazil.
   [Fam, H. B.] Tan Tock Seng Hosp, Dept Ophthalmol, Singapore, Singapore.
RP Koss, MJ (corresponding author), Augenzentrum Nymphenburger Hofe, Munich, Germany.; Koss, MJ (corresponding author), Augenklin Herzog Carl Theodor, Munich, Germany.; Koss, MJ (corresponding author), Heidelberg Univ, Dept Ophthalmol, Heidelberg, Germany.
EM michael.koss@me.com
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 1
Z9 1
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2016
VL 2016
AR 1265342
DI 10.1155/2016/1265342
PG 2
WC Medicine, Research & Experimental; Ophthalmology
SC Research & Experimental Medicine; Ophthalmology
GA DU3DF
UT WOS:000382090300001
PM 27635255
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Ventura, CV
   Maia, M
   Ventura, BV
   Van Der Linden, V
   Araujo, EB
   Ramos, RC
   Rocha, MAW
   Carvalho, MDCG
   Belfort, R
   Ventura, LO
AF Ventura, Camila V.
   Maia, Mauricio
   Ventura, Bruna V.
   Van Der Linden, Vanessa
   Araujo, Eveline B.
   Ramos, Regina C.
   Rocha, Maria Angela W.
   Carvalho, Maria Durce C. G.
   Belfort, Rubens, Jr.
   Ventura, Liana O.
TI Ophthalmological findings in infants with microcephaly and presumable
   intra-uterus Zika virus infection
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Microcephaly; Zika virus; Ocular findings; Vertical transmission; Retina
AB Purpose: In 2015, a twenty-fold increase in the prevalence of microcephaly in Brazil was reported, and the Ministry of Health associated this abnormal prevalence with the maternal-fetal Zika virus (ZIKV) transmission.
   Methods: We assessed the ophthalmological findings of ten mothers and their infants that had been clinically diagnosed with ZIKV-related microcephaly and presented ocular abnormalities, born from May to December 2015.
   Results: Seven mothers (70.0%) referred symptoms during pregnancy (malaise, rash and arthralgia), of which six (85.7%) were in the first trimester. At the time of exam, no ophthalmological abnormalities were identified in the mothers and they did not report ocular symptoms during pregnancy. Serology was negative in all infants for Toxoplasmosis, Rubella, Cytomegalovirus, Syphilis and Human Immunodeficiency Viruses. Ocular findings included macular alterations (gross pigment mottling and/or chorioretinal atrophy) in fifteen eyes (75.0%), and optic nerve abnormalities (hypoplasia with double-ring sign, pallor, and/or increased cup-to-disk ratio) in nine eyes (45.0%).
   Conclusions: Patients presented normal anterior segment and important macular and optic nerve abnormalities. Further studies will assess the visual significance of these alterations.
C1 [Ventura, Camila V.; Ventura, Bruna V.; Araujo, Eveline B.; Ventura, Liana O.] FAV, Recife, PE, Brazil.
   [Ventura, Camila V.; Ventura, Bruna V.; Araujo, Eveline B.; Ventura, Liana O.] Hosp Olhos Pernambuco HOPE, Recife, PE, Brazil.
   [Ventura, Camila V.; Maia, Mauricio; Ventura, Bruna V.; Belfort, Rubens, Jr.] Univ Fed Sao Paulo UNIFESP, EPM, Dept Ophthalmol & Visual Sci, Sao Paulo, SP, Brazil.
   [Van Der Linden, Vanessa] Hosp Barao de Lucena, Recife, PE, Brazil.
   [Ramos, Regina C.; Rocha, Maria Angela W.; Carvalho, Maria Durce C. G.] HUOC, Recife, PE, Brazil.
RP Belfort, R (corresponding author), Escola Paulista Med, Dept Oftalmol, Rua Botucatu 831, BR-04023062 Sao Paulo, SP, Brazil.
EM clinbelf@uol.com.br
RI Ventura, Bruna/N-2724-2018; Ventura, Liana Vieira O/N-6151-2018; Maia,
   Mauricio/I-5892-2015; Ventura, Camila V/N-2654-2018
OI Ventura, Bruna/0000-0003-4333-3932; Ventura, Liana Vieira
   O/0000-0001-6529-6883; Maia, Mauricio/0000-0002-7034-8091; Ventura,
   Camila V/0000-0002-2927-4684
CR Alpert SG, 2003, AM J OPHTHALMOL, V136, P733, DOI 10.1016/S0002-9394(03)00452-5
   Balm MND, 2012, J MED VIROL, V84, P1501, DOI 10.1002/jmv.23241
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   BRASIL. Ministerio do Planejamento Orcamento e Gestao. Instituto Brasileiro de Geografia e Estatistica (IBGE), 2015, PROT VIG RESP OC MIC, P1
   Centro de Operacoes de Emergencias em Saude Publica sobre Microcefalias (COES), 2015, INF EP SEM EP, V47
   GORDON RA, 1985, ARCH OPHTHALMOL-CHIC, V103, P785
   Kaur Savleen, 2013, Oman J Ophthalmol, V6, P77, DOI 10.4103/0974-620X.116622
   Mets MB, 2008, SURV OPHTHALMOL, V53, P95, DOI 10.1016/j.survophthal.2007.12.003
   Ventura CV, 2015, LANCET
NR 9
TC 167
Z9 175
U1 2
U2 171
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD JAN-FEB
PY 2016
VL 79
IS 1
BP 1
EP 3
DI 10.5935/0004-2749.20160002
PG 3
WC Ophthalmology
SC Ophthalmology
GA DD1BS
UT WOS:000369656700002
PM 26840156
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Novais, EA
   Maia, M
   Mello, PAD
   Dias, JRD
   Garcia, JMBB
   de Andrade, GC
   Louzada, RN
   Avila, M
   Maia, A
   Arevalo, JF
   Wu, L
   Berrocal, M
   Badaro, E
   Farah, M
AF Novais, Eduardo A.
   Maia, Mauricio
   de Arruda Mello Filho, Paulo Augusto
   de Oliveira Dias, Joao Rafael
   Garcia, Jose Mauricio B. B.
   de Andrade, Gabriel C.
   Louzada, Ricardo N.
   Avila, Marcos
   Maia, Andre
   Arevalo, J. Fernando
   Wu, Lihteh
   Berrocal, Maria
   Badaro, Emmerson
   Farah, Michel
TI Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from
   Various Diseases in Vitrectomized and Nonvitrectomized Eyes
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL IMPLANT; PHARMACOKINETICS; BEVACIZUMAB; RANIBIZUMAB
AB Purpose. To evaluate the best-corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of dexamethasone implants needed to treat cystoid macular edema (CME) from various etiologies over 12 months in vitrectomized and nonvitrectomized eyes. Methods. This multicenter retrospective cohort study included 112 patients with CME secondary to retinal diseases treated pro re nata (PRN) with a 0.7 mg intravitreal dexamethasone implant for 12 months. The BCVA, CRT, adverse events, safety data, and number of implants were recorded. Results. Vitrectomized and nonvitrectomized eyes received means of three implants and one implant, respectively, over 12 months (p < 0.001). The mean BCVA of all patients improved from 0.13 at baseline to 0.33 (p < 0.001) 12 months after one (p = 0.001), two (p = 0.041), and three (p < 0.001) implants but not four implants (p = 0.068). The mean baseline CRT decreased significantly (p < 0.001) from 463 to 254 microns after 12 months with one (p < 0.001), two (p = 0.002), and three (p = 0.001) implants but not with four implants (p = 0.114). The anatomic and functional outcomes were not significantly different between vitrectomized and nonvitrectomized eyes. Increased IOP was the most common adverse event (23.2%). Conclusions. Dexamethasone implant administered PRN improved VA and decreased CRT in CME, with possible long-term clinically relevant benefits for treating CME from various etiologies. Vitrectomized eyes needed more implants compared with nonvitrectomized eyes.
C1 [Novais, Eduardo A.; Maia, Mauricio; de Arruda Mello Filho, Paulo Augusto; de Oliveira Dias, Joao Rafael; de Andrade, Gabriel C.; Maia, Andre; Badaro, Emmerson; Farah, Michel] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, SP, Brazil.
   [Maia, Mauricio] Brazilian Inst Fighting Blindness INBRACE, Assis Presidente Prudent, SP, Brazil.
   [Garcia, Jose Mauricio B. B.; Louzada, Ricardo N.; Avila, Marcos] Univ Fed Goias, Goiania, GO, Brazil.
   [Arevalo, J. Fernando] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Wu, Lihteh] Asociados Macula Vitreo & Retina Costa Rica, San Jose, Costa Rica.
   [Berrocal, Maria] Univ Puerto Rico, San Juan, PR 00936 USA.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, SP, Brazil.; Maia, M (corresponding author), Brazilian Inst Fighting Blindness INBRACE, Assis Presidente Prudent, SP, Brazil.
EM maiamauricio@terra.com.br
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Arevalo, J. Fernando/0000-0001-6104-5737;
   Novais, Eduardo/0000-0001-6790-4627
FU CAPES Foundation Ministry of Education of BrazilCAPES; CNPq (Brazilian
   National Council of Research), Brasilia, DF, BrazilNational Council for
   Scientific and Technological Development (CNPq)
FX Eduardo A. Novais, Emmerson Badaro, and Ricardo N. Louzada are
   researchers supported by CAPES Foundation Ministry of Education of
   Brazil and CNPq (Brazilian National Council of Research), Brasilia, DF,
   Brazil.
CR Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   Bezatis A, 2013, ACTA OPHTHALMOL, V91, pE340, DOI 10.1111/aos.12020
   Bhatnagar P, 2008, CURR OPIN OPHTHALMOL, V19, P243, DOI 10.1097/ICU.0b013e3282fc25f3
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Boyer DS, 2011, RETINA-J RET VIT DIS, V31, P915, DOI 10.1097/IAE.0b013e318206d18c
   Capone A, 2014, RETINA-J RET VIT DIS, V34, P342, DOI 10.1097/IAE.0b013e318297f842
   Chang-Lin JE, 2011, INVEST OPHTH VIS SCI, V52, P80, DOI 10.1167/iovs.10-5285
   Chin HS, 2005, RETINA-J RET VIT DIS, V25, P556, DOI 10.1097/00006982-200507000-00002
   Christoforidis JB, 2013, RETINA-J RET VIT DIS, V33, P946, DOI 10.1097/IAE.0b013e3182753b12
   Medeiros MD, 2014, J OCUL PHARMACOL TH, V30, P709, DOI 10.1089/jop.2014.0010
   Medeiros MD, 2014, OPHTHALMOLOGICA, V231, P141, DOI 10.1159/000356413
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Lam WC, 2015, CLIN OPHTHALMOL, V9, P1255, DOI 10.2147/OPTH.S80500
   Lowder C, 2011, ARCH OPHTHALMOL-CHIC, V129, P545, DOI 10.1001/archophthalmol.2010.339
   Pelegrin L, 2015, EYE, V29, P943, DOI 10.1038/eye.2015.73
   Petrash JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12940
   Sarao V, 2014, SCI WORLD J, DOI 10.1155/2014/989501
   Tomkins-Netzer O, 2015, PROG RETIN EYE RES, V48, P119, DOI 10.1016/j.preteyeres.2015.05.002
   Tomkins-Netzer O, 2014, OPHTHALMOLOGY, V121, P1649, DOI 10.1016/j.ophtha.2014.02.003
   Wolfensberger TJ, 2010, DEV OPHTHALMOL, V47, P49, DOI 10.1159/000320073
   Yanyali A, 2007, AM J OPHTHALMOL, V144, P124, DOI 10.1016/j.ajo.2007.02.048
   Zalewski D, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/364143
   Zucchiatti I, 2012, OPHTHALMOLOGICA, V228, P117, DOI 10.1159/000336225
NR 26
TC 1
Z9 1
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2016
VL 2016
AR 7984576
DI 10.1155/2016/7984576
PG 6
WC Medicine, Research & Experimental; Ophthalmology
SC Research & Experimental Medicine; Ophthalmology
GA DY4SD
UT WOS:000385088500001
PM 27721989
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Dickmann, LJ
   Yip, V
   Li, CW
   Abundes, J
   Maia, M
   Young, C
   Stainton, S
   Hass, PE
   Joseph, SB
   Prabhu, S
   Boswell, CA
AF Dickmann, Leslie J.
   Yip, Victor
   Li, Cuiwen
   Abundes, Juan, Jr.
   Maia, Mauricio
   Young, Cynthia
   Stainton, Shannon
   Hass, Philip E.
   Joseph, Sean B.
   Prabhu, Saileta
   Boswell, C. Andrew
TI Evaluation of Fluorophotometry to Assess the Vitreal Pharmacokinetics of
   Protein Therapeutics
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE fluorophotometry; vitreous pharmacokinetics; protein therapeutics;
   ranibizumab; 3Rs (replacement, reduction, refinement)
ID INTRAOCULAR DRUG-DELIVERY; OCULAR FLUOROPHOTOMETRY; RANIBIZUMAB;
   RABBITS; EYES
AB PURPOSE. In this work, we assessed the ability of fluorophotometry to measure the vitreal pharmacokinetics (PK) of fluorescently-labeled ranibizumab in the rabbit after intravitreal injection. We compared these values to those obtained using enzyme-linked immunosorbent assays (ELISA). Data obtained in this study were also compared to historical ranibizumab ocular PK data, either measured in-house or previously published.
   METHODS. Three individual in vivo studies were performed in New Zealand White rabbits to assess the feasibility of using fluorophotometry to measure rabbit ocular PK of ranibizumab; explore the dynamic range of dosing fluorescently-labeled ranibizumab; and directly compare ranibizumab concentrations and calculated PK parameters measured by vitreal fluorophotometry to those measured using ELISA.
   RESULTS. In direct comparisons between fluorophotometry and ELISA, the calculated clearance (CL) values were 0.26 and 0.21 mL/day, the volumes of distribution at steady state (V-ss) were 0.80 and 0.94 mL, the half-lives (t(1/2)) were 3.1 and 2.9 days and the dose normalized areas under the curve (AUC/D) were 4.7 and 3.9 mu g.day/mL/mu g, respectively. These values fell within the ranges of 0.13 to 0.44 mL/day for CL, 0.5 to 1.8 mL for V-ss, 2.8 to 3.5 days for t(1/2), and 2.3 to 7.9 mu g.day/mL/mu g for AUC/D that have been either measured previously in-house or published elsewhere.
   CONCLUSIONS. Although not suitable for measuring retinal concentrations, fluorophotometry is a valuable, noninvasive method to measure vitreous concentrations of protein therapeutics after intravitreal injection.
C1 [Dickmann, Leslie J.; Yip, Victor; Li, Cuiwen; Joseph, Sean B.; Prabhu, Saileta; Boswell, C. Andrew] Genentech Inc, Dept Preclin & Translat Pharmacokinet, San Francisco, CA 94080 USA.
   [Abundes, Juan, Jr.; Maia, Mauricio] Genentech Inc, Dept Bioanalyt Sci, San Francisco, CA 94080 USA.
   [Young, Cynthia; Stainton, Shannon] Genentech Inc, Dept In Vivo Studies, San Francisco, CA 94080 USA.
   [Hass, Philip E.] Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA.
RP Dickmann, LJ (corresponding author), Genentech Inc, Preclin & Translat Pharmacokinet, 1 DNA Way, San Francisco, CA 94080 USA.
EM dickmanl@gene.com
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Boswell,
   Charles/0000-0002-0426-9846; Joseph, Sean/0000-0002-2602-8517
CR Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Berezovsky DE, 2011, INVEST OPHTH VIS SCI, V52, P7038, DOI 10.1167/iovs.11-7207
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Ghate D, 2007, INVEST OPHTH VIS SCI, V48, P2230, DOI 10.1167/iovs.06-0954
   Kim H, 2004, INVEST OPHTH VIS SCI, V45, P2722, DOI 10.1167/iovs.04-0091
   Kizhakkethara Indrajith, 1995, International Ophthalmology, V19, P363
   Knudsen LL, 2002, ACTA OPHTHALMOL SCAN, V80, P6
   Lee SJ, 2008, INVEST OPHTH VIS SCI, V49, P4506, DOI 10.1167/iovs.08-1989
   Li SK, 2008, NMR BIOMED, V21, P941, DOI 10.1002/nbm.1230
   McCarey BE, 2011, AAPS ADV PHARM SCI, V2, P47, DOI 10.1007/978-1-4419-9920-7_3
   Muraoka Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036135
   SPALTON DJ, 1990, BRIT J OPHTHALMOL, V74, P431, DOI 10.1136/bjo.74.7.431
   ZEIMER RC, 1985, GRAEF ARCH CLIN EXP, V222, P222, DOI 10.1007/BF02133682
NR 14
TC 10
Z9 10
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2015
VL 56
IS 11
BP 6991
EP 6999
DI 10.1167/iovs.15-17457
PG 9
WC Ophthalmology
SC Ophthalmology
GA DB0YQ
UT WOS:000368235100104
PM 26513505
DA 2020-12-15
ER

PT J
AU Casaroli-Marano, RP
   Sousa-Martins, D
   Martinez-Conesa, EM
   Badaro, E
   Nunes, RP
   Lima, AA
   Rodrigues, EB
   Belfort, R
   Maia, M
AF Casaroli-Marano, Ricardo P.
   Sousa-Martins, Diogo
   Martinez-Conesa, Eva M.
   Badaro, Emmerson
   Nunes, Renata Portella
   Lima-Filho, Acacio A. S.
   Rodrigues, Eduardo B.
   Belfort, Rubens, Jr.
   Maia, Mauricio
TI Dye Solutions Based on Lutein and Zeaxanthin: In Vitro and In Vivo
   Analysis of Ocular Toxicity Profiles
SO CURRENT EYE RESEARCH
LA English
DT Article
DE ARPE-19; chromovitrectomy; in vitro validation assays; lutein; retinal
   pigment epithelium; zeaxanthin
ID INTERNAL LIMITING MEMBRANE; BRILLIANT BLUE-G; MACULAR PIGMENT;
   INDOCYANINE GREEN; VITAL DYES; CHROMOVITRECTOMY; CAROTENOIDS;
   SUPPLEMENTATION; DEGENERATION; MONOLAYER
AB Purpose: To study the safety profile of Lutein/Zeaxanthin(L/Z)-based natural dye solutions in in vitro and in vivo models.
   Material and methods: In vitro cytotoxicity and cellular growth experiments were carried out on ARPE-19 and human corneal epithelial (HCE) cell lines using different L/Z-based dye solutions, either alone or in association with brilliant blue (BB) or trypan blue (TB). Light and transmission electron microscopy studies were performed seven days after intravitreal injection of dye solutions in rabbits. Electroretinogram (ERG) recordings were taken at baseline and before histopathology.
   Results: In vitro cytotoxicity assays demonstrated that the different L/Z-based solutions (from 0.3 to 2%), either alone or in association with BB (0.025%) or TB (0.04%), did not significantly alter mitochondrial activity (<= 15%) in the cell lines tested. In addition, in vitro cell growth was inhibited by up to 60% depending on the dye solution, and in direct proportion to the concentration assayed. There was no evidence of structural alterations in the neurosensory retina, retinal pigment epithelium (RPE), or choriocapillaris-choroidal complex. b-Wave ERG records showed no significant differences (+/- 15.2%) in comparison with baseline.
   Conclusions: L/Z-based dye solutions demonstrated a safe profile in in vitro and in vivo models, and may be a useful tool for staining intraocular structures.
C1 [Casaroli-Marano, Ricardo P.; Sousa-Martins, Diogo; Badaro, Emmerson; Nunes, Renata Portella; Lima-Filho, Acacio A. S.; Rodrigues, Eduardo B.; Belfort, Rubens, Jr.; Maia, Mauricio] Univ Fed Sao Paulo, Inst Visao IPEPO, Dept Ophthalmol & Visual Sci, Sao Paulo, Brazil.
   [Casaroli-Marano, Ricardo P.] Univ Barcelona, Sch Med, Dept Surg, Barcelona, Spain.
   [Casaroli-Marano, Ricardo P.] Univ Barcelona, Cell Tec UB, Barcelona, Spain.
   [Martinez-Conesa, Eva M.] Hosp Clin Barcelona, Transplant Serv Fdn, E-08028 Barcelona, Spain.
RP Casaroli-Marano, RP (corresponding author), Hosp Clin Barcelona, Inst Clin Oftalmol, Calle Sabino de Arana 1, E-08028 Barcelona, Spain.
EM rcasaroli@ub.edu
RI Sousa-Martins, Diogo/B-1554-2019; Maia, Mauricio/I-5892-2015; de Souza
   Lima Filho, Acacio Alves/C-7189-2012; Casaroli-Marano, Ricardo
   Pedro/D-4535-2014
OI Sousa-Martins, Diogo/0000-0002-2285-3990; Maia,
   Mauricio/0000-0002-7034-8091; Casaroli-Marano, Ricardo
   Pedro/0000-0003-1812-9323; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921; Alves de Souza Lima Filho,
   Acacio/0000-0003-1802-9592
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo,
   Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CNPq (Conselho Nacional de Pesquisa, Brazil)National Council for
   Scientific and Technological Development (CNPq); FIS (Fondo de
   Investigacion Sanitaria del Instituto de Salud Carlos III, Spain)
   [PI09/0992]
FX This study was supported by grants from the FAPESP (Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo, Brazil), CNPq (Conselho Nacional de
   Pesquisa, Brazil) and FIS (PI09/0992; Fondo de Investigacion Sanitaria
   del Instituto de Salud Carlos III, Spain). The authors declare no
   competing interests.
CR Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Baszkin A, 2006, ADV COLLOID INTERFAC, V128, P111, DOI 10.1016/j.cis.2006.11.008
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Caseli L, 2013, COLLOID SURFACE B, V107, P124, DOI 10.1016/j.colsurfb.2013.01.076
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Da Mata AP, 2004, OPHTHALMOLOGY, V111, P2246, DOI 10.1016/j.ophtha.2004.05.037
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Enaida Hiroshi, 2008, Dev Ophthalmol, V42, P115, DOI 10.1159/000138989
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Farah ME, 2010, RETINAL PHARMACOTHER, P331
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Lo HM, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-18
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2007, CURR EYE RES, V32, P309, DOI 10.1080/02713680701199377
   Maia M, 2014, RETINA-J RET VIT DIS, V34, P262, DOI 10.1097/IAE.0b013e3182a0b7f4
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   Pavinatto FJ, 2010, BIOMACROMOLECULES, V11, P1897, DOI 10.1021/bm1004838
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Rodrigues EB, 2010, AM J OPHTHALMOL, V149, P265, DOI 10.1016/j.ajo.2009.08.020
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Rodrigues Eduardo B, 2008, Dev Ophthalmol, V42, P29, DOI 10.1159/000138911
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   Seddon JM, 1994, EYE DIS CASE CONTROL, V272, P1413, DOI DOI 10.1001/JAMA.272.18.1413)
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sousa-Martins D, 2012, RETINA-J RET VIT DIS, V32, P1328, DOI 10.1097/IAE.0b013e318239e2b6
   Steel DHW, 2011, OPHTHALMOLOGICA, V226, P27, DOI 10.1159/000328207
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Toropainen E, 2001, INVEST OPHTH VIS SCI, V42, P2942
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   Yuen D, 2009, AM J OPHTHALMOL, V147, P251, DOI 10.1016/j.ajo.2008.08.031
NR 39
TC 7
Z9 8
U1 0
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUL
PY 2015
VL 40
IS 7
BP 707
EP 718
DI 10.3109/02713683.2014.952831
PG 12
WC Ophthalmology
SC Ophthalmology
GA CP4NC
UT WOS:000359858000007
PM 25153042
DA 2020-12-15
ER

PT J
AU Bachmann, BO
   Sousa, SH
   Matthaei, M
   Cursiefen, C
   Siebelmann, SE
   Cunha, CSE
   Sousa-Martins, D
   Lima, A
   Belfort, R
   Maia, M
AF Bachmann, Bjoern O.
   Sousa, Sara Homem
   Matthaei, Mario
   Cursiefen, Claus
   Siebelmann, Sebastian E.
   Sa e Cunha, Claudia
   Sousa-Martins, Diogo
   Lima, Acacio
   Belfort, Rubens
   Maia, Mauricio
TI Trypan Blue free DMEK: Use of Brilliant Blue combined with Lutein /
   Zeaxanthin for staining of Descemet's membrane during DMEK surgery
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
CY MAY 03-07, 2015
CL Denver, CO
SP Assoc Res Vis & Ophthalmol
C1 [Bachmann, Bjoern O.; Matthaei, Mario; Cursiefen, Claus; Siebelmann, Sebastian E.] Universityhosp Cologne, Ophthalmol, Cologne, Germany.
   [Sousa, Sara Homem; Sa e Cunha, Claudia; Sousa-Martins, Diogo] Kemin Pharma, Barcarena, Portugal.
   [Sousa-Martins, Diogo; Lima, Acacio; Belfort, Rubens; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
RI Cursiefen, Claus/ABE-5284-2020; Maia, Mauricio/I-5892-2015; de Souza
   Lima Filho, Acacio Alves/C-7189-2012
OI Maia, Mauricio/0000-0002-7034-8091; Alves de Souza Lima Filho,
   Acacio/0000-0003-1802-9592
NR 0
TC 2
Z9 2
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2015
VL 56
IS 7
MA 1589
PG 3
WC Ophthalmology
SC Ophthalmology
GA CT5WQ
UT WOS:000362882204050
DA 2020-12-15
ER

PT J
AU Ishioka, P
   Rodrigues, SB
   Hirata, SH
   Maia, M
   Marta, AC
AF Ishioka, Priscila
   Rodrigues, Sarita Bartholomei
   Hirata, Sergio Henrique
   Maia, Marcus
   Marta, Alessandra Cristina
TI Evaluation of the therapeutic results of actinic keratosis treated with
   topical 5% fluorouracil by reflectance confocal laser microscopy:
   preliminary study
SO ANAIS BRASILEIROS DE DERMATOLOGIA
LA English
DT Article
DE Fluorouracil; Keratosis, actinic; Microscopy, confocal
ID IN-VIVO; 5-FLUOROURACIL; IMIQUIMOD
AB Topical treatment for actinic keratosis with 5% fluorouracil has a recurrence rate of 54% in 12 months of follow-up. This study analyzed thirteen actinic keratoses on the upper limbs through confocal microscopy, at the time of clinical diagnosis and after 4 weeks of treatment with fluorouracil. After the treatment was established and evidence of clinical cure was achieved, in two of the nine actinic keratoses, confocal microscopy enabled visualization of focal areas of atypical honeycomb pattern in the epidermis indicating therapeutic failure. Preliminary data suggest the use of confocal microscopy as a tool for diagnosis and therapeutic control of actinic keratosis.
C1 [Ishioka, Priscila; Hirata, Sergio Henrique] Univ Fed Sao Paulo, Sao Paulo, SP, Brazil.
   [Ishioka, Priscila; Rodrigues, Sarita Bartholomei; Maia, Marcus; Marta, Alessandra Cristina] Santa Casa Misericordia Sao Paulo, Sao Paulo, SP, Brazil.
RP Ishioka, P (corresponding author), Av Jabaquara 3060 Cj 400-401, BR-04046500 Sao Paulo, SP, Brazil.
EM pishioka@uol.com.br
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
CR Aghassi D, 2000, J AM ACAD DERMATOL, V43, P42, DOI 10.1067/mjd.2000.105565
   Callen JP, 1997, J AM ACAD DERMATOL, V36, P650, DOI 10.1016/S0190-9622(97)70265-2
   Glogau RG, 2000, J AM ACAD DERMATOL, V42, pS23, DOI 10.1067/mjd.2000.103339
   Gupta AK, 2005, J CUTAN MED SURG, V9, P209, DOI 10.1007/s10227-005-0148-6
   Krawtchenko N, 2007, BRIT J DERMATOL, V157, P34, DOI 10.1111/j.1365-2133.2007.08271.x
   Rajadhyaksha M, 1999, J INVEST DERMATOL, V113, P293, DOI 10.1046/j.1523-1747.1999.00690.x
   Rishpon A, 2009, ARCH DERMATOL, V145, P766, DOI 10.1001/archdermatol.2009.134
   Sterry W, 2011, GUIDELINES MANAGEMEN
   Ulrich M, 2010, DERMATOLOGY, V220, P15, DOI 10.1159/000254893
   Ulrich M, 2008, DERMATOL SURG, V34, P610, DOI 10.1111/j.1524-4725.2007.34117.x
NR 10
TC 7
Z9 7
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0365-0596
EI 1806-4841
J9 AN BRAS DERMATOL
JI An. Brasil. Dermatol.
PD MAY-JUN
PY 2015
VL 90
IS 3
BP 426
EP 429
DI 10.1590/abd1806-4841.20153437
PG 4
WC Dermatology
SC Dermatology
GA CM0SX
UT WOS:000357389900024
PM 26131881
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Machado, LM
   Furlani, BA
   Navarro, RM
   Farah, ME
   Maia, A
   Magalhaes, O
   Rodrigues, EB
   Moraes, N
   Maia, M
AF Machado, Leonardo M.
   Furlani, Bruno A.
   Navarro, Rodrigo M.
   Farah, Michel E.
   Maia, Andre
   Magalhaes, Octaviano, Jr.
   Rodrigues, Eduardo B.
   Moraes, Nilva
   Maia, Mauricio
TI Preoperative and Intraoperative Prognostic Factors of Epiretinal
   Membranes Using Chromovitrectomy and Internal Limiting Membrane Peeling
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID POSTERIOR VITREOUS DETACHMENT; OPTICAL COHERENCE TOMOGRAPHY; PIGMENT
   EPITHELIAL-CELLS; MACULAR PUCKER; TRYPAN BLUE; SURGERY; ASSOCIATIONS;
   PREVALENCE; REMOVAL; VITRECTOMY
AB BACKGROUND AND OBJECTIVE: To evaluate the pre-operative and intraoperative findings as prognostic indicators of functional and anatomic results of idiopathic epiretinal membrane (ERM) surgery.
   PATIENTS AND METHODS: Vitrectomies included ERM and internal limiting membrane (ILM) removal with vital dyes. Best corrected visual acuity (BCVA), optical coherence tomography (OCT), fluorescein angiography, and autofluorescence were performed at baseline and postoperatively. Intraoperative ILM status after ERM removal was also evaluated.
   RESULTS: Thirty-one eyes were monitored for a mean of 16.78 months. BCVA and central foveal thickness (CFT) improved significantly (P < .001) from baseline at 3 and 12 months. Preoperative hyperautofluorescence was associated with greater CFT reduction (P < .005). ILM status after ERM peeling did not influence visual recovery but was associated with anatomical results as measured by OCT.
   CONCLUSION: Preoperative poor initial BCVA and RPE defects by FAF may not be bad prognostic factors. Preoperative hyperautofluorescence was associated with greater CFT reduction. Intraoperative classification of ILM status after ERM and ILM staining/peeling was reported and may be useful for future studies, though it was not associated neither with preoperative nor postoperative BCVA.
C1 [Machado, Leonardo M.; Furlani, Bruno A.; Farah, Michel E.; Maia, Andre; Magalhaes, Octaviano, Jr.; Rodrigues, Eduardo B.; Moraes, Nilva; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, BR-06023062 Sao Paulo, Brazil.
   [Navarro, Rodrigo M.; Maia, Mauricio] Brazilian Inst Fight Blindness, Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Vitreoretinal Surg Unit, Dept Ophthalmol, Rua Botucatu 822, BR-06023062 Sao Paulo, Brazil.
EM maiamauricio@terra.com.br
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
CR Asaria R, 2008, OPHTHALMOLOGY, V115, P1930, DOI 10.1016/j.ophtha.2008.05.020
   Awad D, 2013, GRAEF ARCH CLIN EXP, V251, P1735, DOI 10.1007/s00417-013-2342-3
   Banach MJ, 2001, OPHTHALMOLOGY, V108, P23, DOI 10.1016/S0161-6420(00)00473-5
   Chang S, 2012, RETINA SUPPL 2, V32, pS3
   Chang Stanley, 2012, Retina, V32 Suppl 2, pS200, DOI 10.1097/IAE.0b013e31825bc02b
   DEBUSTROS S, 1988, BRIT J OPHTHALMOL, V72, P692, DOI 10.1136/bjo.72.9.692
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Gibran SK, 2008, BRIT J OPHTHALMOL, V92, P373, DOI 10.1136/bjo.2007.129965
   Gomes NL, 2009, AM J OPHTHALMOL, V147, P865, DOI 10.1016/j.ajo.2008.12.021
   Konstantinidis L, 2009, RETINA-J RET VIT DIS, V29, P380, DOI 10.1097/IAE.0b013e31818eccdb
   Kwok AKH, 2004, BRIT J OPHTHALMOL, V88, P1590, DOI 10.1136/bjo.2004.044537
   Kwok AKH, 2004, AM J OPHTHALMOL, V138, P194, DOI 10.1016/j.ajo.2004.03.013
   Carrero JL, 2012, AM J OPHTHALMOL, V153, P497, DOI 10.1016/j.ajo.2011.08.036
   McCarty DJ, 2005, AM J OPHTHALMOL, V140, P288, DOI 10.1016/j.ajo.2005.03.032
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P1033, DOI 10.1016/S0161-6420(97)30190-0
   Ophir A, 2011, INVEST OPHTH VIS SCI, V52, P6414, DOI 10.1167/iovs.10-6781
   Park DW, 2003, OPHTHALMOLOGY, V110, P62, DOI 10.1016/S0161-6420(02)01440-9
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   SIDD RJ, 1982, AM J OPHTHALMOL, V94, P44, DOI 10.1016/0002-9394(82)90189-1
   Sorcinelli R, 2003, OPHTHALMOLOGICA, V217, P107, DOI 10.1159/000068556
   Suh MH, 2009, AM J OPHTHALMOL, V147, P473, DOI 10.1016/j.ajo.2008.09.020
NR 23
TC 5
Z9 6
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD APR
PY 2015
VL 46
IS 4
BP 457
EP 462
DI 10.3928/23258160-20150422-09
PG 6
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA CO6UP
UT WOS:000359292300009
PM 25932723
DA 2020-12-15
ER

PT J
AU Pradella, CO
   Belmonte, GM
   Maia, MN
   Delgado, CS
   Luise, APT
   Nascimento, OA
   Gazzotti, MR
   Jardim, JR
AF Pradella, Cristiane O.
   Belmonte, Graziela M.
   Maia, Marcilene N.
   Delgado, Cioneia S.
   Luise, Ana Paula T.
   Nascimento, Oliver A.
   Gazzotti, Mariana R.
   Jardim, Jose R.
TI Home-Based Pulmonary Rehabilitation for Subjects With COPD: A Randomized
   Study
SO RESPIRATORY CARE
LA English
DT Article
DE chronic obstructive pulmonary disease; home pulmonary rehabilitation;
   pulmonary rehabilitation; exercise capacity; 6MWT; COPD
ID MINIMAL IMPORTANT DIFFERENCE; QUALITY-OF-LIFE; EXERCISE TOLERANCE;
   DISEASE; TESTS; GUIDELINES; STATEMENT; ADHERENCE; PROGRAM; TRIAL
AB BACKGROUND: The aim of this study was to develop an efficient, low-cost, home-based pulmonary rehabilitation program and to evaluate the impact of the program on exercise as measured by the 6-min walk test (6MWT) and treadmill endurance test. METHODS: Twenty-nine subjects with COPD (FEV1 = 62.4 +/- 10.7% of predicted, 62.4 +/- 10.7 y old) were included in a randomized and prospective pulmonary rehabilitation program, and they performed 24 sessions, 5 d/week. The control group included 15 subjects (FEV1 = 54 +/- 26.2% of predicted, 65.3 +/- 8 y old). They were evaluated pre-intervention and post-intervention by the 6MWT, St George Respiratory Questionnaire (SGRQ), treadmill endurance test, and spirometry. The home-based pulmonary rehabilitation program consisted of walking for 40 min along a corridor or a street, climbing stairs for 15 min, and exercising the arms with an oil can (1 kg) using diagonal movements for 15 min. Subjects were called once each week for encouragement and verification of adherence. Both groups received the usual pharmacologic treatment; in addition, the control group received a telephone call without guidance on exercise. RESULTS: The 2 groups were similar regarding age, FEV1, and FVC. The home-based pulmonary rehabilitation group increased by 65 m in the 6MWT (P <.05) and 316.6 +/- 81.8 m in the endurance test (P <.05) and decreased by > 4 units in all SGRQ domains. The control group showed no difference in any variable. CONCLUSIONS: This study demonstrates that a simple, low-cost, home-based pulmonary rehabilitation program adapted to real-life situations leads to improvement in exercise capacity and quality of life.
C1 [Pradella, Cristiane O.; Belmonte, Graziela M.; Maia, Marcilene N.; Delgado, Cioneia S.; Luise, Ana Paula T.; Nascimento, Oliver A.; Gazzotti, Mariana R.; Jardim, Jose R.] Univ Fed Sao Paulo, Pulm Rehabil Ctr, Sao Paulo, Brazil.
   [Nascimento, Oliver A.; Jardim, Jose R.] Univ Fed Sao Paulo, Escola Paulista Med, Div Resp, Sao Paulo, Brazil.
RP Jardim, JR (corresponding author), Escola Paulista Med, Div Resp, Rua Botucatu 740,3 Anda, BR-04023062 Sao Paulo, SP, Brazil.
EM jardimpneumo@gmail.com
RI Nascimento, Oliver A./B-3039-2011; Maia, Mauricio/I-5892-2015; Jardim,
   Jose R/E-3205-2016; Maia, Mauricio/Z-1042-2019
OI Nascimento, Oliver A./0000-0003-3138-2219; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
CR Behnke M, 2000, RESP MED, V94, P1184, DOI 10.1053/rmed.2000.0949
   Boxall Anne-Marie, 2005, J Cardiopulm Rehabil, V25, P378, DOI 10.1097/00008483-200511000-00012
   Cambach W, 1997, EUR RESPIR J, V10, P104, DOI 10.1183/09031936.97.10010104
   Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111
   Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149
   Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108
   Holland AE, 2010, ARCH PHYS MED REHAB, V91, P221, DOI 10.1016/j.apmr.2009.10.017
   Jones PW, 2001, THORAX, V56, P880, DOI 10.1136/thorax.56.11.880
   Maltais F, 2008, ANN INTERN MED, V149, P869, DOI 10.7326/0003-4819-149-12-200812160-00006
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Fernandez AM, 2009, J CARDIOPULM REHABIL, V29, P325, DOI 10.1097/HCR.0b013e3181ac7b9d
   Murphy N, 2005, RESP MED, V99, P1297, DOI 10.1016/j.rmed.2005.02.033
   Nici L, 2006, AM J RESP CRIT CARE, V173, P1390, DOI 10.1164/rccm.200508-1211ST
   O'Donnell DE, 1998, AM J RESP CRIT CARE, V158, P1557, DOI 10.1164/ajrccm.158.5.9804004
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   Porto EF, 2009, RESP MED, V103, P251, DOI 10.1016/j.rmed.2008.08.018
   Puhan MA, 2011, EUR RESPIR J, V37, P784, DOI 10.1183/09031936.00063810
   Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO
   Ries AL, 2007, CHEST, V131, p4S, DOI 10.1378/chest.06-2418
   Schneider C, 2010, CHEST, V137, P341, DOI 10.1378/chest.09-0614
   Singh Virendra, 2003, Indian J Chest Dis Allied Sci, V45, P13
   Sousa TC, 2000, J PNEUMOL, V26, P119, DOI DOI 10.1590/S0102-35862000000300004
   Vermeire E, 2001, J CLIN PHARM THER, V26, P331, DOI 10.1046/j.1365-2710.2001.00363.x
   WIJKSTRA PJ, 1995, THORAX, V50, P824, DOI 10.1136/thx.50.8.824
NR 24
TC 23
Z9 24
U1 0
U2 22
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD APR
PY 2015
VL 60
IS 4
BP 526
EP 532
DI 10.4187/respcare.02994
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA CH7BQ
UT WOS:000354191000017
PM 25269680
OA Bronze
DA 2020-12-15
ER

PT J
AU Sousa-Martins, D
   Caseli, L
   Figueiredo, MC
   Cunha, CSE
   Mota-Filipe, H
   Souza-Lima, A
   Belfort, R
   Rodrigues, E
   Maia, M
AF Sousa-Martins, Diogo
   Caseli, Luciano
   Figueiredo, Mafalda C.
   Sa e Cunha, Claudia
   Mota-Filipe, Helder
   Souza-Lima, Acacio
   Belfort, Rubens, Jr.
   Rodrigues, Eduardo
   Maia, Mauricio
TI Comparing the Mode of Action of Intraocular Lutein-Based Dyes With
   Synthetic Dyes
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE lutein-based dyes; synthetic dyes; intraocular membranes; Langmuir films
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; PIGMENT EPITHELIAL-CELLS;
   BRILLIANT BLUE; CATARACT-SURGERY; MACULAR PIGMENT; TRYPAN BLUE; VITAL
   DYES; ACUTE ENDOPHTHALMITIS; OPTICAL-DENSITY; ZEAXANTHIN
AB PURPOSE. To investigate and compare the mechanism by which lutein-based and synthetic intraocular dyes interact with their target membranes during ophthalmic surgeries.
   METHODS. Surrogate membrane models were used in order to simulate the different intraocular membranes: internal limiting membrane (ILM), vitreous, anterior capsule (AC), and epiretinal membrane (ERM). Different lutein-based dyes, such as Phacodyne, Retidyne, Retidyne Plus, and Vitreodyne were tested, as well as Trypan Blue (TB), Indocyanine Green (ICG), Brilliant Blue (BB), and Triamcinolone Acetonide (TA). The interactions between the film components occurring at the air-water interface were investigated with surface pressure-area isotherms and polarization modulation infrared reflection-absorption spectroscopy (PM-IRRAS).
   RESULTS. With the exception of TA and ICG, none of the tested dyes revealed toxicity to the analyzed membranes. The interaction of TA with the vitreous model affected deeply the biointerface structure of the model. A significant condensation of the monolayer is noted when ICG contacted with ILM by the isotherms or even a solubilization of part of the monolayer toward the aqueous subphase. Retidyne Plus may provide the fluidization of the membrane, but maintains intact the structure of proteins present in the model.
   CONCLUSIONS. The present study demonstrates for the first time that lutein-based dyes interact through a physical mechanism of action with membrane models of structures present in human eye. On the other hand, the chemical interaction of synthetic dyes TA and ICG resulted in an alteration of the membrane models.
C1 [Sousa-Martins, Diogo; Figueiredo, Mafalda C.; Sa e Cunha, Claudia; Mota-Filipe, Helder] Univ Lisbon, Coll Pharm, Dept Social Pharm, P-1649003 Lisbon, Portugal.
   [Sousa-Martins, Diogo; Souza-Lima, Acacio; Belfort, Rubens, Jr.; Rodrigues, Eduardo; Maia, Mauricio] Fed Univ Sao Paulo Unifesp, Escola Paulista Med, Dept Ophthalmol, Sao Paulo, Brazil.
   [Caseli, Luciano] Fed Univ Sao Paulo Unifesp, Dept Earth & Exacts Sci, Sao Paulo, Brazil.
RP Sousa-Martins, D (corresponding author), Univ Lisbon, Coll Pharm, Dept Social Pharm, Ave Prof Gama Pinto, P-1649003 Lisbon, Portugal.
EM dsousamartins@gmail.com
RI de Souza Lima Filho, Acacio Alves/C-7189-2012; Mota-Filipe,
   Helder/M-6298-2013; Sousa-Martins, Diogo/B-1554-2019; Caseli,
   Luciano/D-9533-2012; Maia, Mauricio/Z-1042-2019; Mota-Filipe,
   Helder/M-6199-2019; Maia, Mauricio/I-5892-2015
OI Mota-Filipe, Helder/0000-0003-3045-2553; Sousa-Martins,
   Diogo/0000-0002-2285-3990; Maia, Mauricio/0000-0002-7034-8091;
   Mota-Filipe, Helder/0000-0003-3045-2553; Maia,
   Mauricio/0000-0002-7034-8091; Caseli, Luciano/0000-0002-1177-8454; Alves
   de Souza Lima Filho, Acacio/0000-0003-1802-9592
CR Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   Ando F, 2004, GRAEF ARCH CLIN EXP, V242, P995, DOI 10.1007/s00417-004-0864-4
   Badaro E, 2014, GRAEF ARCH CLIN EXP, V252, P1071, DOI 10.1007/s00417-013-2539-5
   Baszkin A, 2006, ADV COLLOID INTERFAC, V128, P111, DOI 10.1016/j.cis.2006.11.008
   Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Brockman H, 1999, CURR OPIN STRUC BIOL, V9, P438, DOI 10.1016/S0959-440X(99)80061-X
   Casaroli-Marano RP, 2014, CURR EYE RES, P1
   Caseli L, 2013, COLLOID SURFACE B, V107, P124, DOI 10.1016/j.colsurfb.2013.01.076
   Cekic O, 2005, AM J OPHTHALMOL, V139, P993, DOI 10.1016/j.ajo.2005.01.022
   Dynarowicz-Latka P, 2001, ADV COLLOID INTERFAC, V91, P221, DOI 10.1016/S0001-8686(99)00034-2
   Farah Michel E, 2008, Dev Ophthalmol, V42, P91, DOI 10.1159/000138980
   FULLER D, 1978, AM J OPHTHALMOL, V85, P519, DOI 10.1016/S0002-9394(14)75250-X
   Furlani BA, 2014, J OCUL PHARMACOL TH, V30, P559, DOI 10.1089/jop.2013.0171
   Jacobs DS, 2006, OPHTHALMOLOGY, V113, P707, DOI 10.1016/j.ophtha.2006.01.024
   Jin Y, 2005, EXP EYE RES, V81, P395, DOI 10.1016/j.exer.2005.02.010
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P462
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kadonosono K, 2003, GRAEF ARCH CLIN EXP, V241, P284, DOI 10.1007/s00417-003-0636-6
   Krishnan V, 2011, CURR OPIN COLLOID IN, V16, P459, DOI 10.1016/j.cocis.2011.08.005
   Luke C, 2005, BRIT J OPHTHALMOL, V89, P1188, DOI 10.1136/bjo.2004.062794
   Maia M, 2009, BRIT J OPHTHALMOL, V93, P1687, DOI 10.1136/bjo.2008.151597
   Maia M, 2014, RETINA-J RET VIT DIS, V34, P262, DOI 10.1097/IAE.0b013e3182a0b7f4
   Marticorena J, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/928123
   Vianna LMM, 2014, ARQ BRAS OFTALMOL, V77, P173, DOI 10.5935/0004-2749.20140044
   Morales MC, 2010, INVEST OPHTH VIS SCI, V51, P6018, DOI 10.1167/iovs.09-4916
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   Narayanan R, 2005, CURR EYE RES, V30, P471, DOI 10.1080/02713680590959312
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Pavinatto FJ, 2010, BIOMACROMOLECULES, V11, P1897, DOI 10.1021/bm1004838
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Rodrigues EB, 2007, RETINA-J RET VIT DIS, V27, P958, DOI 10.1097/01.iae.0000253051.01194.ab
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Sakamoto T, 2004, AM J OPHTHALMOL, V138, P137, DOI 10.1016/j.ajo.2004.02.072
   Sasaki M, 2009, INVEST OPHTH VIS SCI, V50, P1433, DOI 10.1167/iovs.08-2493
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Sousa-Martins D, 2012, RETINA-J RET VIT DIS, V32, P1328, DOI 10.1097/IAE.0b013e318239e2b6
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   Veckeneer M, 2001, GRAEF ARCH CLIN EXP, V239, P698, DOI 10.1007/s004170100341
   Woo TTY, 2013, GRAEF ARCH CLIN EXP, V251, P41, DOI 10.1007/s00417-012-2128-z
   Yuen D, 2009, AM J OPHTHALMOL, V147, P251, DOI 10.1016/j.ajo.2008.08.031
NR 48
TC 2
Z9 2
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2015
VL 56
IS 3
BP 1993
EP 2000
DI 10.1167/iovs.14-16187
PG 8
WC Ophthalmology
SC Ophthalmology
GA CE9BF
UT WOS:000352137600074
PM 25698703
DA 2020-12-15
ER

PT J
AU Bottos, J
   Elizalde, J
   Rodrigues, EB
   Farah, M
   Maia, M
AF Bottos, Juliana
   Elizalde, Javier
   Rodrigues, Eduardo B.
   Farah, Michael
   Maia, Mauricio
TI Vitreomacular Traction Syndrome: Postoperative Functional and Anatomic
   Outcomes
SO Ophthalmic Surgery Lasers & Imaging Retina
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL OUTCOMES; MACULAR HOLE; DETACHMENT;
   VITRECTOMY; DIAGNOSIS; ADHESION; SURGERY
AB BACKGROUND AND OBJECTIVE: To analyze a variety of vitreomacular traction (VMT) morphologies to establish a major classification that better reflects the preoperative predictive factors of postoperative visual and anatomic outcomes.
   PATIENTS AND METHODS: Thirty-six eyes submitted to vitrectomy surgery were categorized with a VMT pattern (V- or J-shaped) and diameter (focal < 1,500 mu m or broad > 1,500 mu m) based on optical coherence tomography.
   RESULTS: The researchers compared different classifications of VMT. Despite similar postoperative best corrected visual acuity (BCVA) values (P = .393), cases with focal VMT had greater visual improvement (P = .027) because the preoperative BCVA was significantly lower in the focal group (P = .007). However, the BCVA improvements did not differ between the groups regarding the classic VMT morphologic patterns (P = .235).
   CONCLUSION: Postoperative outcomes and macular disorders are closely related to VMT size. The adhesion diameter (focal or broad VMT) and not the classic VMT morphologic pattern (V- or J-shaped) may better predict the postoperative anatomic and functional outcomes.
C1 [Bottos, Juliana; Rodrigues, Eduardo B.; Farah, Michael; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Elizalde, Javier] Univ Autonoma Barcelona, IUB, Inst Univ Barraquer, E-08193 Barcelona, Spain.
RP Maia, M (corresponding author), 822 Botucatu St,Second Floor, BR-06023062 Sao Paulo, SP, Brazil.
EM maiamauricio@terra.com.br
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Buchele Rodrigues, Eduardo/0000-0002-4224-0921
CR Asami T, 2001, AM J OPHTHALMOL, V131, P134, DOI 10.1016/S0002-9394(00)00856-4
   Bottos J, 2013, VITREOMACULAR UNPUB
   Bottos JM, 2012, CURR OPIN OPHTHALMOL, V23, P195, DOI 10.1097/ICU.0b013e328352404c
   Chang LK, 2008, AM J OPHTHALMOL, V146, P121, DOI 10.1016/j.ajo.2008.03.001
   Gallemore RP, 2000, RETINA-J RET VIT DIS, V20, P115, DOI 10.1097/00006982-200002000-00002
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1503, DOI 10.1097/IAE.0b013e31829232fd
   Johnson MW, 2010, AM J OPHTHALMOL, V149, P371, DOI 10.1016/j.ajo.2009.11.022
   Johnson MW, 2005, AM J OPHTHALMOL, V140, P184, DOI 10.1016/j.ajo.2005.01.033
   Koizumi H, 2008, AM J OPHTHALMOL, V145, P509, DOI 10.1016/j.ajo.2007.10.014
   MCDONALD HR, 1994, OPHTHALMOLOGY, V101, P1397
   MELBERG NS, 1995, RETINA-J RET VIT DIS, V15, P192, DOI 10.1097/00006982-199515030-00002
   Mirza RG, 2007, SURV OPHTHALMOL, V52, P397, DOI 10.1016/j.survophthal.2007.04.007
   Odrobina D, 2011, RETINA-J RET VIT DIS, V31, P324, DOI 10.1097/IAE.0b013e3181eef08c
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Shechtman DL, 2009, OPTOMETRY, V80, P681, DOI 10.1016/j.optm.2009.07.014
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P356, DOI 10.1136/bjophthalmol-2013-304219
   SMIDDY WE, 1990, RETINA-J RET VIT DIS, V10, P288, DOI 10.1097/00006982-199010000-00012
   SMIDDY WE, 1988, ARCH OPHTHALMOL-CHIC, V106, P624
   Sonmez K, 2008, RETINA-J RET VIT DIS, V28, P1207, DOI 10.1097/IAE.0b013e31817b6b0f
   Spaide RF, 2002, AM J OPHTHALMOL, V133, P226, DOI 10.1016/S0002-9394(01)01377-0
   Steel DHW, 2013, EYE, V27, pS1, DOI 10.1038/eye.2013.212
   Yamada N, 2005, AM J OPHTHALMOL, V139, P112, DOI 10.1016/j.ajo.2004.08.055
NR 23
TC 3
Z9 4
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD FEB
PY 2015
VL 46
IS 2
BP 235
EP 242
DI 10.3928/23258160-20150213-14
PG 8
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA CG5TZ
UT WOS:000353360100012
PM 25707050
DA 2020-12-15
ER

PT J
AU Caiado, RR
   Magalhaes, O
   Badaro, E
   Maia, A
   Novais, EA
   Stefanini, FR
   Navarro, RM
   Arevalo, F
   Wu, L
   Moraes, N
   Farah, ME
   Maia, M
AF Caiado, Rafael R.
   Magalhaes, Octaviano, Jr.
   Badaro, Emmerson
   Maia, Andre
   Novais, Eduardo A.
   Stefanini, Francisco Rosa
   Navarro, Rodrigo Milan
   Arevalo, Fernando
   Wu, Lihteh
   Moraes, Nilva
   Farah, Michel Eid
   Maia, Mauricio
TI EFFECT OF LENS STATUS IN THE SURGICAL SUCCESS OF 23-GAUGE PRIMARY
   VITRECTOMY FOR THE MANAGEMENT OF RHEGMATOGENOUS RETINAL DETACHMENT The
   Pan American Collaborative Retina Study (PACORES) Group Results
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE pars plana vitrectomy; rhegmatogenous retina detachment; retinal
   surgery; chromovitrectomy
ID PARS-PLANA VITRECTOMY; SCLERAL BUCKLE; PROLIFERATIVE VITREORETINOPATHY;
   CHANDELIER ILLUMINATION; CATARACT-SURGERY; FOLLOW-UP; REPAIR; OUTCOMES;
   CUTTER; SYSTEM
AB Purpose: To determine the effects of lens status on the success rate of primary pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment using either perfluoropropane gas (C3F8) or silicone oil (SO) tamponade.
   Methods: A retrospective chart analysis was made of 97 eyes from 92 patients with rhegmatogenous retinal detachment with no proliferative vitreoretinopathy that were treated with primary 23-gauge PPV. Eyes included in this were phakic (n = 28), pseudophakic (n = 41), or phakic eyes subject to simultaneous phacoemulsification, intraocular lens implantation, and PPV during primary rhegmatogenous retinal detachment repair (n = 28). Tamponade at the end of PPV was with either C3F8 (n = 65) or SO (n = 32). Success was defined as retinal reattachment at 1 year follow-up after a single procedure in eyes submitted to C3F8 injection; in eyes treated with SO injection, the success rate was defined as retina reattached 1 year after oil removal. Statistical comparisons were made between groups using chi-square, Fisher's exact test, Kruskal-Wallis, Mann-Whitney, and multivariate analysis. All eyes were operated by 2 experienced retina surgeons and had a minimum follow-up of 12 months.
   Results: The vitreoretinal redetachment rate in eyes subjected to C3F8 tamponade was significantly higher (28.6%) for phakic eyes (P = 0.011) compared with pseudophakic or phakic eyes that underwent to phacoemulsification and intraocular lens implantation (4.5%). Eyes in which SO was used at the end of the surgical procedure demonstrated a similar trend of higher reoperation rates in phakic eyes (28.6%) compared with pseudophakic or phakic eyes (8%) subjected to phacoemulsification and intraocular lens implantation; however, no statistically significant difference was observed (P = 0.201). No statistically significant differences were found between groups in relation to the number of tears (P = 0.863) and their location (inferior: P = 0.189, superior: P = 0.708, nasal: P = 0.756, and temporal: P = 0.08).
   Conclusion: The success rates of primary 23-gauge PPV with either C3F8 or SO tamponade in pseudophakic eyes with rhegmatogenous retinal detachment was higher than the same procedure performed in phakic eyes. Still, the retrospective and limited data presented is too preliminary to suggest or recommend that practitioners perform simultaneous combined cataract surgery with retinal detachment and requires further studies in a larger and prospective design to confirm these present findings.
C1 [Caiado, Rafael R.; Magalhaes, Octaviano, Jr.; Badaro, Emmerson; Maia, Andre; Novais, Eduardo A.; Stefanini, Francisco Rosa; Moraes, Nilva; Farah, Michel Eid; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Navarro, Rodrigo Milan; Maia, Mauricio] Brazilian Inst Fight Blindness INBRACE, Assis Presidente Prudent, Brazil.
   [Arevalo, Fernando; Maia, Mauricio] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
   [Arevalo, Fernando; Maia, Mauricio] King Khalid Eye Specialist Hosp, Vitreoretinal & Uveitis Div, Riyadh, Saudi Arabia.
   [Wu, Lihteh] Inst Cirugia Ocular, Retina & Vitreous Serv, San Jose, Costa Rica.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, 822 Botucatu St, BR-06023062 Vila Clementino, Brazil.
EM retina@femanet.com.br
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/Z-1042-2019;
   Fromow-Guerra, J. Jans/A-3346-2015; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Fromow-Guerra, J.
   Jans/0000-0001-5335-1275; Maia, Mauricio/0000-0002-7034-8091
CR Ahmadieh H, 2005, OPHTHALMOLOGY, V112, P1421, DOI 10.1016/j.ophtha.2005.02.018
   Bernheim D, 2013, RETINA-J RET VIT DIS, V33, P2039, DOI 10.1097/IAE.0b013e31828992ac
   Brazitikos PD, 2005, RETINA-J RET VIT DIS, V25, P957, DOI 10.1097/00006982-200512000-00001
   Brazitikos PD, 2003, RETINA-J RET VIT DIS, V23, P615, DOI 10.1097/00006982-200310000-00002
   Campo RV, 1999, OPHTHALMOLOGY, V106, P1811, DOI 10.1016/S0161-6420(99)90353-6
   Chaudhry NA, 2000, RETINA-J RET VIT DIS, V20, P257, DOI 10.1097/00006982-200005000-00005
   Diniz B, 2013, RETINA-J RET VIT DIS, V33, P933, DOI 10.1097/IAE.0b013e3182733f38
   Diniz B, 2013, OPHTHALMOLOGICA, V229, P15, DOI 10.1159/000343073
   Eckardt C, 2003, RETINA-J RET VIT DIS, V23, P893, DOI 10.1097/00006982-200312000-00039
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   GARTRY DS, 1993, BRIT J OPHTHALMOL, V77, P199, DOI 10.1136/bjo.77.4.199
   Ghazi NG, 2002, RETINA-J RET VIT DIS, V22, P509, DOI 10.1097/00006982-200208000-00023
   Ghazi NG, 2002, EYE, V16, P411, DOI 10.1038/sj.eye.6700197
   Han DP, 1998, AM J OPHTHALMOL, V126, P658, DOI 10.1016/S0002-9394(98)00181-0
   Heimann H, 2007, OPHTHALMOLOGY, V114, P2142, DOI 10.1016/j.ophtha.2007.09.013
   HUTTON WL, 1994, ARCH OPHTHALMOL-CHIC, V112, P778, DOI 10.1001/archopht.1994.01090180076038
   Kinori M, 2011, AM J OPHTHALMOL, V152, P291, DOI 10.1016/j.ajo.2011.01.049
   Lewis Shawn A, 2011, Ophthalmic Surg Lasers Imaging, V42, P107, DOI 10.3928/15428877-20101223-02
   MACHEMER R, 1991, AM J OPHTHALMOL, V112, P159, DOI 10.1016/S0002-9394(14)76695-4
   Magalhaes O, 2011, AM J OPHTHALMOL, V151, P401, DOI 10.1016/j.ajo.2010.11.009
   Maia M, 2014, RETINA-J RET VIT DIS, V34, P262, DOI 10.1097/IAE.0b013e3182a0b7f4
   Mendrinos E, 2008, AM J OPHTHALMOL, V145, P1063, DOI 10.1016/j.ajo.2008.01.018
   Mester U, 1991, Klin Oczna, V93, P211
   Mura M, 2009, RETINA-J RET VIT DIS, V29, P1299, DOI 10.1097/IAE.0b013e3181aa0f5f
   Oshima Y, 2007, AM J OPHTHALMOL, V143, P166, DOI 10.1016/j.ajo.2006.07.051
   Sakaguchi H, 2011, RETINA-J RET VIT DIS, V31, P1231, DOI 10.1097/IAE.0b013e31822091ca
   Schaal S, 2011, RETINA-J RET VIT DIS, V31, P1500, DOI 10.1097/IAE.0b013e31820d3f55
   Schmidt JC, 2003, OPHTHALMOLOGICA, V217, P387, DOI 10.1159/000073067
   Schneider EW, 2012, RETINA-J RET VIT DIS, V32, P213, DOI 10.1097/IAE.0b013e3182278b29
   Schwartz SG, 2002, ARCH OPHTHALMOL-CHIC, V120, P325
   Soni C, 2013, OPHTHALMOLOGY, V120, P1440, DOI 10.1016/j.ophtha.2012.12.033
   Speicher MA, 2000, RETINA-J RET VIT DIS, V20, P459, DOI 10.1097/00006982-200009000-00005
   Tornambe P E, 1997, Trans Am Ophthalmol Soc, V95, P551
   Weichel ED, 2006, OPHTHALMOLOGY, V113, P2033, DOI 10.1016/j.ophtha.2006.05.038
   Wickham L, 2004, BRIT J OPHTHALMOL, V88, P1376, DOI 10.1136/bjo.2004.043687
   Wilkinson CP, 2006, RETINA-J RET VIT DIS, V26, pS26, DOI 10.1097/00006982-200607001-00007
NR 36
TC 16
Z9 16
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2015
VL 35
IS 2
BP 326
EP 333
DI 10.1097/IAE.0000000000000307
PG 8
WC Ophthalmology
SC Ophthalmology
GA CA2UU
UT WOS:000348764200023
PM 25158939
DA 2020-12-15
ER

PT J
AU Navarro, RM
   Machado, LM
   Maia, O
   Wu, LT
   Farah, ME
   Magalhaes, O
   Arevalo, JF
   Maia, M
AF Navarro, Rodrigo M.
   Machado, Leonardo M.
   Maia, Ossires, Jr.
   Wu, Lihteh
   Farah, Michel E.
   Magalhaes, Octaviano, Jr.
   Arevalo, J. Fernando
   Maia, Mauricio
TI Small-Gauge Pars Plana Vitrectomy for the Management of Symptomatic
   Posterior Vitreous Detachment after Phacoemulsification and Multifocal
   Intraocular Lens Implantation: A Pilot Study from the Pan-American
   Collaborative Retina Study Group
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL PERFORMANCE; FLOATERS; OUTCOMES; COMPLICATIONS; SAFETY
AB Purpose. To determine the efficacy of 23-gauge pars plana vitrectomy (PPV) for symptomatic posterior vitreous detachment (PVD) on visual acuity (VA) and quality after multifocal intraocular lenses (IOLs). Methods. In this prospective case series, patients who developed symptomatic PVD and were not satisfied with visual quality due to floaters and halos after multifocal IOL implantation underwent PPV. Examinations included LogMAR uncorrected visual acuity (UCVA), intraocular pressure, biomicroscopy, and indirect ophthalmoscopy at baseline and 1, 7, 30, and 180 days postoperatively. Ultrasonography and aberrometry were performed. The Visual Functioning Questionnaire 25 (VFQ-25) was administered preoperatively and at 30 days postoperatively. Both the postoperative UCVA and questionnaire results were compared to preoperative findings using the Wilcoxon test. Results. Sixteen eyes of 8 patients were included. VA significantly improved from 0.17 to 0.09 postoperatively (P = 0.017). All patients reported improvement of halos, glare, and floaters. VFQ-25 scores significantly improved in general vision (P = 0.023), near activities (P = 0.043), distance activities (P = 0.041), mental health (P = 0.011), role difficulties (P = 0.042), and driving (P = 0.016). Conclusion. PPV may increase UCVA and quality of vision in patients with bilateral multifocal IOLs and symptomatic PVD. Larger studies are advised.
C1 [Navarro, Rodrigo M.; Maia, Ossires, Jr.; Maia, Mauricio] Brazilian Inst Fight Blindness, BR-19815040 Assis, SP, Brazil.
   [Machado, Leonardo M.; Farah, Michel E.; Magalhaes, Octaviano, Jr.; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Vitreoretinal Surg Unit, BR-04023062 Sao Paulo, SP, Brazil.
   [Wu, Lihteh] Inst Cirugia Ocular, Retina & Vitreous Serv, San Jose, Costa Rica.
   [Arevalo, J. Fernando] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21287 USA.
RP Maia, M (corresponding author), Brazilian Inst Fight Blindness, 901 Otto Ribeiro, BR-19815040 Assis, SP, Brazil.
EM maiamauricio@terra.com.br
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091
FU Conselho Nacional de Pesquisa (CNPq)National Council for Scientific and
   Technological Development (CNPq); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES
FX The current research was conducted with funding resources provided by
   the following institutions in Brazil: Conselho Nacional de Pesquisa
   (CNPq) and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES). A complete listing of participating members of PACORES is as
   follows. The following investigators belong to the Pan-American
   Collaborative Retina Study Group (PACORES): L. Wu (principal
   investigator, PI), Instituto de Cirugia Ocular, San Jose, Costa Rica;
   J.F. Arevalo (PI), King Khalid Eye Specialist Hospital, Riyadh, Saudi
   Arabia, and the Wilmer Eye Institute, Johns Hopkins University,
   Baltimore, MD, USA; M. A. Serrano (PI) and A. F. Lasave, Clinica
   Oftalmologica Centro Caracas and the Arevalo-Coutinho Foundation for
   Research in Ophthalmology, Caracas, Venezuela; M. Farah (PI), M. Maia,
   F. M. Penha, and E. B. Rodrigues, Departamento de Oftalmologia,
   Instituto da Visao, Universidade Federal de Sao Paulo, Sao Paulo,
   Brazil; V. Morales-Canton (PI), J. Fromow-Guerra, J. L.
   Guerrero-Naranjo, and J. Dalma-Weiszhausz, Asociacion para Evitar la
   Ceguera en Mexico, Mexico City, Mexico; H. Quiroz-Mercado (PI) and R.
   Velez-Montoya, University of Colorado, School of Medicine, Denver,
   Colorado; F. J. Rodriguez (PI), F. E. Gomez, and A. C. Brieke, Fundacion
   Oftalmologica Nacional, Universidad del Rosario, Bogota, Colombia; M. H.
   Berrocal (PI) and V. Cruz-Villegas, University of Puerto Rico, San Juan,
   Puerto Rico; F. Graue-Wiechers (PI), D. Lozano-Rechy, and E.
   Ariza-Camacho, Fundacion Conde Valenciana, Mexico City, Mexico; J. A.
   Roca (PI) and R. G. Chico, Clinica Ricardo Palma, Lima, Peru; M. J.
   Saravia (PI), A. Schlaen, A. Lupinacci, and M. N. Gabin, Hospital
   Universitario Austral, Buenos Aires, Argentina; M. Avila (PI) and L.
   Carla, Departamento de Oftalmologia, Universidade Federal de Goias,
   Goiania, Brazil; J. Cardillo (PI), Hospital de Olhos Araraquara and
   Universidade de Sao Paulo, Sao Paulo, Brazil; J. Verdaguer (PI), C.
   Carpentier, J. I. Verdaguer, and G. Sepulveda, Fundacion Oftalmologica
   Los Andes, Santiago de Chile, Chile; A. Alezzandrini (PI), B. Garcia,
   and G. Bregliano, OFTALMOS, Catedra de Oftalmologia, Universidad de
   Buenos Aires, Buenos Aires, Argentina; G. Alvira (PI), P. Flor, and F.
   Jaramillo, Hospital Metropolitano, Quito, Ecuador; M. Diaz-Llopis (PI),
   R. Gallego-Pinazo, P. Udaondo, and D. Salom, Hospital La Fe, Universidad
   de Valencia, Spain; M. Figueroa (PI), I. Contreras, and D. Ruiz-Casas,
   Departamento de Retina, Hospital Universitario Ramon y Cajal and VISSUM
   Madrid Mirasierra de Oftalmologia Integral, Madrid, Spain.
CR Castilla-Marti M, 2015, RETINA-J RET VIT DIS, V35, P1240, DOI 10.1097/IAE.0000000000000456
   Prieto JC, 2010, J CATARACT REFR SURG, V36, P1508, DOI 10.1016/j.jcrs.2010.03.048
   Chang JSM, 2012, J REFRACT SURG, V28, P468, DOI 10.3928/1081597X-20120612-01
   Coffee RE, 2007, AM J OPHTHALMOL, V144, P409, DOI 10.1016/j.ajo.2007.05.002
   de Nie KF, 2013, GRAEF ARCH CLIN EXP, V251, P1373, DOI 10.1007/s00417-012-2205-3
   Delaney YM, 2002, EYE, V16, P21, DOI 10.1038/sj.eye.6700026
   FOOS R Y, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P480
   FOOS RY, 1982, OPHTHALMOLOGY, V89, P1502
   Ji J, 2013, EXP THER MED, V5, P277, DOI 10.3892/etm.2012.740
   KANSKI JJ, 1975, AM J OPHTHALMOL, V80, P44, DOI 10.1016/0002-9394(75)90866-1
   Khanduja Sumeet, 2013, Oman J Ophthalmol, V6, P3, DOI 10.4103/0974-620X.111893
   Langeslag MJM, 2014, J CATARACT REFR SURG, V40, P2120, DOI 10.1016/j.jcrs.2014.10.017
   Martínez-Sanz F., 2009, Arch Soc Esp Oftalmol, V84, P259
   Mirshahi A, 2009, J CATARACT REFR SURG, V35, P987, DOI 10.1016/j.jcrs.2009.02.016
   Bautista CP, 2009, EUR J OPHTHALMOL, V19, P762
   Pinero DP, 2010, OPTOMETRY VISION SCI, V87, pE682, DOI 10.1097/OPX.0b013e3181e87da6
   Santhiago MR, 2010, INDIAN J OPHTHALMOL, V58, P109, DOI 10.4103/0301-4738.60075
   Schulz-Key S, 2011, ACTA OPHTHALMOL, V89, P159, DOI 10.1111/j.1755-3768.2009.01682.x
   Sebag J, 2011, AM J OPHTHALMOL, V152, P3, DOI 10.1016/j.ajo.2011.02.015
   Shah VC, 2010, J REFRACT SURG, V26, P565, DOI 10.3928/1081597X-20100303-01
   Simao LM, 2008, ARQ BRAS OFTALMOL, V71, P540, DOI 10.1590/S0004-27492008000400014
   Sood P, 2011, CLIN OPHTHALMOL, V5, P403, DOI 10.2147/OPTH.S11126
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Tan HS, 2011, AM J OPHTHALMOL, V151, P995, DOI 10.1016/j.ajo.2011.01.005
   Vega F, 2011, INVEST OPHTH VIS SCI, V52, P5695, DOI 10.1167/iovs.10-7123
   Wilkinson CP, 2011, AM J OPHTHALMOL, V151, P919, DOI 10.1016/j.ajo.2011.01.037
   Yoshino M, 2010, CLIN OPHTHALMOL, V4, P467
NR 27
TC 4
Z9 4
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 156910
DI 10.1155/2015/156910
PG 7
WC Medicine, Research & Experimental; Ophthalmology
SC Research & Experimental Medicine; Ophthalmology
GA CT9SX
UT WOS:000363158000001
PM 26504590
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Fernandes, RAB
   Diniz, B
   Falabella, P
   Ribeiro, R
   Teixeira, AG
   Magalhaes, O
   Moraes, N
   Maia, A
   Farah, ME
   Maia, M
   Humayun, MS
AF Brant Fernandes, Rodrigo A.
   Diniz, Bruno
   Falabella, Paulo
   Ribeiro, Ramiro
   Teixeira, Anderson G.
   Magalhaes, Octaviano, Jr.
   Moraes, Nilva
   Maia, Andre
   Farah, Michel E.
   Maia, Mauricio
   Humayun, Mark S.
TI Fluidics Comparison Between Dual Pneumatic and Spring Return High-Speed
   Vitrectomy Systems
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID PERFORMANCE ANALYSIS; 25-GAUGE; CUTTER; 23-GAUGE; 20-GAUGE; DYNAMICS;
   OUTCOMES
AB BACKGROUND AND OBJECTIVE: To compare the water and vitreous flow rates and duty cycle (DC) between two ultrahigh-speed vitrectomy systems: pneumatic with spring return (SR) and dual pneumatic (DP) probes.
   MATERIALS AND METHODS: The flow rate was calculated using a high-sampling precision balance that measured the mass of water and vitreous removed from a vial by a vitreous cutter. Frame-by-frame analysis of a high-speed video of the cutter was used to determine the DC. Three cutters of each gauge (20, 23, and 25 G) were tested with an SR and a DP system using the standard DC setting (biased open) at 0 (water only), 1,000, 2,000, 3,000, 4,000, and 5,000 cuts per minute (CPM) with aspiration levels of 100, 200, 300, 400, 500, and 600 mm Hg.
   RESULTS: The DC was slightly higher with the SR system using most parameters and gauges although without statistical significance. The water flow rate was somewhat higher with the SR system, except for 25 G with 4,000 and 5,000 CPM. The vitreous flow rate was similar using most parameters, with the SR system showing higher flows at lower cut rates (1,000-3,000 CPM).
   CONCLUSIONS: SR and DP systems produced similar water and vitreous flow rates. Additional studies in human eyes are necessary to confirm these findings.
C1 [Brant Fernandes, Rodrigo A.; Diniz, Bruno; Falabella, Paulo; Ribeiro, Ramiro; Teixeira, Anderson G.; Magalhaes, Octaviano, Jr.; Moraes, Nilva; Maia, Andre; Farah, Michel E.; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Sao Paulo, Brazil.
   [Ribeiro, Ramiro] Hosp Evangel Curitiba, Dept Ophthalmol, Curitiba, Parana, Brazil.
   [Falabella, Paulo; Ribeiro, Ramiro; Humayun, Mark S.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
RP Humayun, MS (corresponding author), 1355 San Pablo St,DVRC 119, Los Angeles, CA 90033 USA.
EM humayun@med.usc.edu
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019; Farah, Michel
   Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Farah, Michel Eid E/0000-0001-5951-0193; Teixeira,
   Anderson/0000-0001-7585-712X; Falabella, Paulo/0000-0001-8773-7168
CR DeBoer C, 2008, RETINA-J RET VIT DIS, V28, P1061, DOI 10.1097/IAE.0b013e3181840b64
   Diniz B, 2013, RETINA-J RET VIT DIS, V33, P933, DOI 10.1097/IAE.0b013e3182733f38
   Diniz B, 2013, OPHTHALMOLOGICA, V229, P15, DOI 10.1159/000343073
   Fang SY, 2008, GRAEF ARCH CLIN EXP, V246, P61, DOI 10.1007/s00417-007-0672-8
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1814, DOI 10.1016/S0161-6420(02)01119-3
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1807, DOI 10.1016/S0161-6420(02)01179-X
   Hubschman JP, 2009, RETINA-J RET VIT DIS, V29, P1289, DOI 10.1097/IAE.0b013e3181acd3a9
   Ibarra MS, 2005, AM J OPHTHALMOL, V139, P831, DOI 10.1016/j.ajo.2004.12.002
   Kellner L, 2007, BRIT J OPHTHALMOL, V91, P945, DOI 10.1136/bjo.2006.106799
   Lakhanpal RR, 2005, OPHTHALMOLOGY, V112, P817, DOI 10.1016/j.ophtha.2004.11.053
   Magalhaes O, 2008, ACTA OPHTHALMOL, V86, P156, DOI 10.1111/j.1600-0420.2007.00988.x
   Magalhaes O, 2008, RETINA-J RET VIT DIS, V28, P236, DOI 10.1097/IAE.0b013e318158e9e0
   Matsuoka N, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20101223-03
   Ribeiro RM, 2013, RETINA-J RET VIT DIS, V33, P928, DOI 10.1097/IAE.0b013e31826f069e
   Rizzo S, 2011, RETINA-J RET VIT DIS, V31, P2007, DOI 10.1097/IAE.0b013e318213623a
   Steel DHW, 2011, OPHTHALMOLOGICA, V226, P27, DOI 10.1159/000328207
   Thompson JT, 2011, SURV OPHTHALMOL, V56, P162, DOI 10.1016/j.survophthal.2010.08.003
NR 17
TC 2
Z9 2
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JAN
PY 2015
VL 46
IS 1
BP 68
EP 72
DI 10.3928/23258160-20150101-11
PG 5
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA CG5TO
UT WOS:000353358500010
PM 25559512
DA 2020-12-15
ER

PT J
AU Avery, RL
   Castellarin, AA
   Steinle, NC
   Dhoot, DS
   Pieramici, DJ
   See, R
   Couvillion, S
   Nasir, MA
   Rabena, MD
   Le, K
   Maia, M
   Visich, JE
AF Avery, Robert L.
   Castellarin, Alessandro A.
   Steinle, Nathan C.
   Dhoot, Dilsher S.
   Pieramici, Dante Joseph
   See, Robert
   Couvillion, Stephen
   Nasir, Ma'an A.
   Rabena, Melvin D.
   Le, Kha
   Maia, Mauricio
   Visich, Jennifer E.
TI Systemic pharmacokinetics following intravitreal injections of
   ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; PLASMA-LEVELS;
   VEGF-TRAP; INTRAOCULAR PHARMACOKINETICS; DEGENERATION; BINDING; HUMANS;
   TRIAL
AB Background Data comparing systemic exposure and systemic vascular endothelial growth factor (VEGF) suppression of ranibizumab, bevacizumab and aflibercept following intravitreal injection are lacking.
   Methods Fifty-six patients with wet age-related macular degeneration received intravitreal ranibizumab (0.5 mg), bevacizumab (1.25 mg), or aflibercept (2.0 mg). Serum pharmacokinetics and plasma free VEGF were evaluated after the first and third injections.
   Results Following the first dose, systemic exposure to aflibercept was 5-, 37-, and 9-fold higher than ranibizumab, whereas, bevacizumab was 9-, 310-, and 35-fold higher than ranibizumab, based on geometric mean ratio of peak and trough concentrations and area under the curve, respectively. The third dose showed accumulation of bevacizumab and aflibercept but not ranibizumab. Aflibercept substantially suppressed plasma free VEGF, with mean levels below lower limit of quantitation (10 pg/mL) as early as 3 h postdose until >= 7 days postdose. Mean free (unbound) VEGF levels with ranibizumab were largely unchanged, with mean trough level of 14.4 pg/mL compared with baseline of 17 pg/mL.
   Conclusions There are notable differences in systemic pharmacokinetics and pharmacodynamics among anti-VEGF treatments after intravitreal administration. All three agents rapidly moved into the bloodstream, but ranibizumab very quickly cleared, whereas bevacizumab and aflibercept demonstrated greater systemic exposure and produced a marked reduction in plasma free VEGF.
C1 [Avery, Robert L.; Castellarin, Alessandro A.; Steinle, Nathan C.; Dhoot, Dilsher S.; Pieramici, Dante Joseph; See, Robert; Couvillion, Stephen; Nasir, Ma'an A.; Rabena, Melvin D.] Calif Retina Consultants, Santa Barbara, CA 93103 USA.
   [Le, Kha; Maia, Mauricio; Visich, Jennifer E.] Genentech Inc, San Francisco, CA 94080 USA.
RP Avery, RL (corresponding author), Calif Retina Consultants, 515 E Micheltorena St,Suite C, Santa Barbara, CA 93103 USA.
EM bobave@gmail.com
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Le, Kha/0000-0002-5446-819X
FU Genentech, IncRoche HoldingGenentech [ML28032]
FX This investigator-sponsored trial was partially funded through a grant
   from Genentech, Inc (ML28032). Presented in part at the American Society
   of Retina Specialists, Toronto, Canada; American Academy of
   Ophthalmology, New Orleans; Angiogenesis, Exudation, and Degeneration,
   Miami Florida; and Macula Society, Key Largo, Florida.
CR Aguilar-Mahecha A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038290
   Avery RL, 2013, INVEST OPHTHALMOL VI, V54
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Bakbak B, 2013, J OCUL PHARMACOL TH, V29, P728, DOI 10.1089/jop.2013.0049
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   European Medicines Agency, EPAR EYL AFL PROC EM
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gu XY, 2014, CURR EYE RES, V39, P518, DOI 10.3109/02713683.2013.848899
   Harding SP, 2013, INVEST OPHTHALMOL VI, P54
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kim H, 2009, MOL VIS, V15
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rothen Michelle, 2005, Ophthalmol Clin North Am, V18, P561
   Stewart Michael W., 2011, Inflammation & Allergy Drug Targets, V10, P497
   Ternant D, 2005, EXPERT OPIN BIOL TH, V5, pS37, DOI 10.1517/14712598.5.1.S37
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 30
TC 170
Z9 175
U1 0
U2 33
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2014
VL 98
IS 12
BP 1636
EP 1641
DI 10.1136/bjophthalmol-2014-305252
PG 6
WC Ophthalmology
SC Ophthalmology
GA AU0AB
UT WOS:000345284300007
PM 25001321
OA Green Published, Other Gold
DA 2020-12-15
ER

PT J
AU Gallego-Pinazo, R
   Dolz-Marco, R
   Berrocal, M
   Wu, L
   Maia, M
   Serrano, M
   Alezzandrini, A
   Arevalo, JF
   Diaz-Llopis, M
AF Gallego-Pinazo, Roberto
   Dolz-Marco, Rosa
   Berrocal, Maria
   Wu, Lihteh
   Maia, Mauricio
   Serrano, Martin
   Alezzandrini, Arturo
   Arevalo, J. Fernando
   Diaz-Llopis, Manuel
CA Pan-Amer Collaborative Retina Stud
TI Outcomes of cataract surgery in diabetic patients: results of the Pan
   American Collaborative Retina Study Group
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Diabetic retinopathy; Macular edema; Cataract extraction; Intraoperative
   care; Phacoemulsification; Lens implantation; intraocular; Antibodies;
   monoclonal; Multicenter study
ID DEXAMETHASONE INTRAVITREAL IMPLANT; CYSTOID MACULAR EDEMA; TRIAMCINOLONE
   ACETONIDE; BEVACIZUMAB INJECTION; RANIBIZUMAB; PHACOEMULSIFICATION;
   RETINOPATHY; PREVENTION; LASER
AB Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies.
   Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuvant medication (Group 1), 59 patients received intraoperative bevacizumab (Group 2) and 37 patients received intraoperative triamcinolone (4 mg/0.1 ml) (Group 3).
   Results: The mean logMAR [+/- standard deviation (SD)] BCVA improved from 0.82 (+/- 0.43) at baseline, to 0.14 (+/- 0.23) at 6-month follow-up (p<0.001) in Group 1; from 0.80 (+/- 0.48) to 0.54 (+/- 0.45) (p<0.001) in Group 2; and from 1.0 (+/- 0.40) to 0.46 (+/- 0.34) (p<0.001) in Group 3. The mean central subfield thickness increased from 263.57 mu m (+/- 35.7) at baseline to 274.57 mu m (+/- 48.7) at 6-month follow-up (p=0.088) in Group 1; from 316.02 mu m (+/- 100.4) to 339.56 mu m (+/- 145.3) (p=0.184) in Group 2; and from 259.18 mu m (+/-97.9) to 282.21 mu m (+/-87.24) (p=0.044) in Group 3.
   Conclusions: Diabetic patients may significantly benefit from cataract surgery. This study provides evidence to support the use of intravitreal triamcinolone or bevacizumab at the time of cataract surgery in cases with pre-existent diabetic macular edema or moderate-severe non-proliferative diabetic retinopathy.
C1 [Gallego-Pinazo, Roberto; Dolz-Marco, Rosa; Diaz-Llopis, Manuel] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Valencia 46026, Spain.
   [Berrocal, Maria] Univ Puerto Rico, Dept Ophthalmol, San Juan, PR 00936 USA.
   [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Maia, Mauricio] Univ Fed Sao Paulo UNIFESP, Escola Paulista Med EPM, Dept Ophthalmol & Visual Sci, Sao Paulo, Brazil.
   [Serrano, Martin] Clin Oftalmol Ctr Caracas, Caracas, Venezuela.
   [Serrano, Martin] Arevalo Coutinho Fdn Res Ophthalmol, Caracas, Venezuela.
   [Alezzandrini, Arturo] Univ Buenos Aires, Catedra Oftalmol, Buenos Aires, DF, Argentina.
   [Arevalo, J. Fernando] King Khalid Eye Specialist Hosp, Vitreoretinal Div, Riyadh, Saudi Arabia.
   [Arevalo, J. Fernando] Johns Hopkins Univ, Wilmer Eye Inst, Retina Div, Baltimore, MD 21218 USA.
   [Diaz-Llopis, Manuel] Univ Valencia, Fac Med, Valencia, Spain.
RP Dolz-Marco, R (corresponding author), Univ & Polytech Hosp La Fe, Dept Ophthalmol, Bulevar Sur S-N, Valencia 46026, Spain.
EM rosadolzmarco@gmail.com
RI Maia, Mauricio/I-5892-2015; Fromow-Guerra, J. Jans/A-3346-2015; Maia,
   Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Fromow-Guerra, J.
   Jans/0000-0001-5335-1275; Maia, Mauricio/0000-0002-7034-8091;
   Dalma-Weiszhausz, Jose/0000-0001-7186-4568; Cardillo, Jose
   Augusto/0000-0002-5791-3201; Dolz-Marco, Rosa/0000-0002-2963-2541
CR Agarwal A, 2013, OPHTHALMOLOGY, V120, P211, DOI 10.1016/j.ophtha.2012.08.002
   Akinci A, 2011, RETINA-J RET VIT DIS, V31, P755, DOI 10.1097/IAE.0b013e3182006da1
   Akinci A, 2009, RETINA-J RET VIT DIS, V29, P1432, DOI 10.1097/IAE.0b013e3181b77422
   Boyer DS, 2011, RETINA-J RET VIT DIS, V31, P915, DOI 10.1097/IAE.0b013e318206d18c
   Dowler JGF, 1999, OPHTHALMOLOGY, V106, P663, DOI 10.1016/S0161-6420(99)90148-3
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Eriksson U, 2011, GRAEF ARCH CLIN EXP, V249, P349, DOI 10.1007/s00417-010-1484-9
   Fard MA, 2011, EUR J OPHTHALMOL, V21, P276, DOI 10.5301/EJO.2010.1405
   Ip MS, 2012, ARCH OPHTHALMOL-CHIC, V130, P1145, DOI 10.1001/archophthalmol.2012.1043
   Kim SJ, 2007, OPHTHALMOLOGY, V114, P881, DOI 10.1016/j.ophtha.2006.08.053
   Klein R, 2009, OPHTHALMOLOGY, V116, P497, DOI 10.1016/j.ophtha.2008.10.016
   Kwon Soon Il, 2011, Korean J Ophthalmol, V25, P238, DOI 10.3341/kjo.2011.25.4.238
   Lanzagorta-Aresti A, 2009, RETINA-J RET VIT DIS, V29, P530, DOI 10.1097/IAE.0b013e31819c6302
   Mentes J, 2003, OPHTHALMOLOGICA, V217, P408, DOI 10.1159/000073070
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   POLLACK A, 1992, BRIT J OPHTHALMOL, V76, P221, DOI 10.1136/bjo.76.4.221
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Querques G, 2009, RETINA-J RET VIT DIS, V29, P1274, DOI 10.1097/IAE.0b013e3181aa8e50
   Rauen PI, 2012, RETINA-J RET VIT DIS, V32, P1799, DOI 10.1097/IAE.0b013e31824bebb8
   Singh R, 2012, CLIN OPHTHALMOL, V6, P1259, DOI 10.2147/OPTH.S31902
   Takamura Y, 2009, OPHTHALMOLOGY, V116, P1151, DOI 10.1016/j.ophtha.2009.01.014
   Takata C, 2010, RETINA-J RET VIT DIS, V30, P562, DOI 10.1097/IAE.0b013e3181c969b4
NR 23
TC 9
Z9 9
U1 0
U2 1
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD NOV-DEC
PY 2014
VL 77
IS 6
BP 355
EP 359
DI 10.5935/0004-2749.20140089
PG 5
WC Ophthalmology
SC Ophthalmology
GA CA0EU
UT WOS:000348589700004
PM 25627180
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Zhang, Y
   Yao, ZL
   Kaila, N
   Kuebler, P
   Visich, J
   Maia, M
   Tuomi, L
   Ehrlich, JS
   Rubio, RG
   Campochiaro, PA
AF Zhang, Yi
   Yao, Zhenling
   Kaila, Nitin
   Kuebler, Peter
   Visich, Jennifer
   Maia, Mauricio
   Tuomi, Lisa
   Ehrlich, Jason S.
   Rubio, Roman G.
   Campochiaro, Peter A.
TI Pharmacokinetics of Ranibizumab after Intravitreal Administration in
   Patients with Retinal Vein Occlusion or Diabetic Macular Edema
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; SUSTAINED BENEFITS; 12-MONTH OUTCOMES;
   PHASE-III; IN-VITRO; VEGF; DEGENERATION; NEOVASCULARIZATION;
   BEVACIZUMAB; INHIBITION
AB Objective: To describe the systemic pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion (RVO) or diabetic macular edema (DME).
   Design: A population approach of nonlinear mixed-effect pharmacokinetics modeling based on serum concentrations of ranibizumab measured at various times after intravitreal administration.
   Participants: Patients with RVO (n = 441) and DME (n = 435) from 4 large, randomized, phase 3 clinical trials of monthly ranibizumab intravitreal administration.
   Methods: A 1-compartment pharmacokinetics model with first-order absorption and elimination rate constants previously developed in patients with age-related macular degeneration (AMD) was fitted separately to RVO and DME data. Population pharmacokinetic parameters and interindividual variability were estimated for each model. Baseline covariates were evaluated for potential effects on systemic pharmacokinetics. Model performance was validated using general diagnostic plots and a visual predictive check.
   Main Outcome Measures: Ranibizumab disposition was determined in RVO and DME patients and compared with that previously seen in AMD patients.
   Results: The AMD pharmacokinetics model correctly predicted the measured serum ranibizumab concentration data for RVO and DME patients. Most observed data points were within the simulated 90% confidence interval, indicating that systemic ranibizumab concentrations were comparable among AMD, RVO, and DME patients. No disease-related covariates were identified by the population pharmacokinetics analysis.
   Conclusions: The systemic pharmacokinetics of ranibizumab were similar among patients with AMD, RVO, or DME. Disease-related differences and patient demographics, measured in this study, did not lead to variability in ocular elimination or in systemic exposure of ranibizumab after intravitreal administration. In all disease processes tested, ranibizumab exits the eye slowly and then is eliminated rapidly from the circulation, thus minimizing systemic exposure. (C) 2014 by the American Academy of Ophthalmology.
C1 [Zhang, Yi; Yao, Zhenling; Kuebler, Peter; Visich, Jennifer; Maia, Mauricio; Tuomi, Lisa; Ehrlich, Jason S.; Rubio, Roman G.] Genentech Inc, South San Francisco, CA USA.
   [Kaila, Nitin] Quantitat Solut, Menlo Pk, CA USA.
   [Campochiaro, Peter A.] Johns Hopkins Univ Hosp, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
RP Campochiaro, PA (corresponding author), Johns Hopkins Univ Hosp, Sch Med, Wilmer Eye Inst, 719 Maumenee,600 North Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
RI Maia, Mauricio/I-5892-2015; Yao, Zhenling/AAJ-5968-2020
OI Maia, Mauricio/0000-0002-7034-8091; 
FU GenentechRoche HoldingGenentech; GlaxoSmithKlineGlaxoSmithKline;
   GenzymeGenzyme Corporation; Oxford BioMedica; Genentech, Inc., South San
   Francisco, CaliforniaRoche HoldingGenentech
FX Peter A. Campochiaro: Consultant - Genentech, Inc. (South San Francisco,
   California), GlaxoSmithKline, Regeneron, Aerpio Therapeutics (employer,
   Johns Hopkins University, receives compensation), and Elan, Gene Signal,
   Norvorx (receives personal compensation); Data and Safety Monitoring
   Committee - Advanced Cell Technology, Regeneron; Financial support -
   Genentech, GlaxoSmithKline, Genzyme, Oxford BioMedica; Equity owner -
   Graybug, Inc.; Genentech, Inc., South San Francisco, California,
   provided support for the study; participated in study design and conduct
   of the study; provided data collection, management, and interpretation;
   as well as reviewed and approved the manuscript.
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Beal SL, 2001, J PHARMACOKINET PHAR, V28, P481, DOI 10.1023/A:1012299115260
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022
   Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P2041, DOI 10.1016/j.ophtha.2011.02.038
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Center for Drug Evaluation and Research, 1998, GUID IND GUID IND PH
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ip MS, 2012, ARCH OPHTHALMOL-CHIC, V130, P1145, DOI 10.1001/archophthalmol.2012.1043
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Lowe J, 2010, J PHARMACEUT BIOMED, V52, P680, DOI 10.1016/j.jpba.2010.01.048
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 28
TC 20
Z9 21
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2014
VL 121
IS 11
BP 2237
EP 2246
DI 10.1016/j.ophtha.2014.05.012
PG 10
WC Ophthalmology
SC Ophthalmology
GA AS8DM
UT WOS:000344480400030
PM 25001159
DA 2020-12-15
ER

PT J
AU Wu, L
   Berrocal, MH
   Rodriguez, FJ
   Maia, M
   Morales-Canton, V
   Figueroa, M
   Serrano, M
   Roca, JA
   Arevalo, JF
   Navarro, R
   Hernandez, H
   Salinas, S
   Romero, R
   Alpizar-Alvarez, N
   Chico, G
AF Wu, Lihteh
   Berrocal, Maria H.
   Rodriguez, Francisco J.
   Maia, Mauricio
   Morales-Canton, Virgilio
   Figueroa, Marta
   Serrano, Martin
   Roca, Jose A.
   Arevalo, J. Fernando
   Navarro, Rodrigo
   Hernandez, Hector
   Salinas, Samantha
   Romero, Rafael
   Alpizar-Alvarez, Natalia
   Chico, Giovanna
TI INTRAOCULAR PRESSURE ELEVATION AFTER UNCOMPLICATED PARS PLANA VITRECTOMY
   Results of the Pan American Collaborative Retina Study Group
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE vitrectomy; open-angle glaucoma; epiretinal membrane; intraocular
   pressure; oxygen; oxidative stress; ocular hypertension
ID OPEN-ANGLE GLAUCOMA; OCULAR HYPERTENSION; RISK-FACTORS; NUCLEAR
   CATARACT; OXYGEN-TENSION; VITREOUS-HUMOR; FOLLOW-UP; LENS; INCREASE; EYE
AB Purpose:To compare the incident rates of sustained elevation of intraocular pressure (IOP) after uncomplicated pars plana vitrectomy for idiopathic epiretinal membrane and the unoperated fellow eye.Methods:Retrospective multicenter study of 198 patients who underwent pars plana vitrectomy for an idiopathic epiretinal membrane that was followed for at least 12 months. The diagnosis of sustained IOP elevation was defined as an elevation of IOP 24 mmHg or an increase of 5 mmHg in the IOP from baseline on 2 separate visits that warranted the initiation of ocular hypotensive therapy. The main outcome measured was the development of sustained IOP elevation as defined above.Results:Patients were followed for an average of 47.3 24 months (range, 12-106 months). In the vitrectomized eyes, 38 of the 198 (19.2%) patients developed elevated IOP compared with 9 of the 198 (4.5%) unoperated fellow eyes (P < 0.0001, Fisher exact test; odds ratio, 4.988). Possible risk factors include a family history of open-angle glaucoma (P = 0.0004 Fisher exact test; odds ratio, 7.206) and cataract surgery (P = 0.0270 Fisher exact test; odds ratio, 2.506).Conclusion:Uncomplicated PPV seems to increase the IOP, particularly in those who are pseudophakic and have a family history of open-angle glaucoma. This increase in IOP may lead to glaucomatous damage if not managed appropriately. Patients with a previous PPV need to be followed by an ophthalmologist to monitor the IOP in the vitrectomized eye.
C1 [Wu, Lihteh; Alpizar-Alvarez, Natalia] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Berrocal, Maria H.] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Rodriguez, Francisco J.; Hernandez, Hector] Univ Rosario, Fdn Oftalmol Nacl, Bogota, Colombia.
   [Maia, Mauricio; Navarro, Rodrigo] Brazilian Inst Fighting Blindness, Vitreoretinal Surg Unit, Assis Presidente Prudente, Sao Paulo, Brazil.
   [Maia, Mauricio; Salinas, Samantha; Romero, Rafael] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Morales-Canton, Virgilio] Hosp Luis Sanchez Bulnes, Asociac Evitar La Ceguera, Mexico City, DF, Mexico.
   [Figueroa, Marta] Hosp Univ Ramon & Cajal, Dept Retina, Madrid, Spain.
   [Figueroa, Marta] Hosp Univ Ramon & Cajal, VISSUM Madrid Mirasierra Oftalmol Integral, Madrid, Spain.
   [Serrano, Martin] Clin Oftalmol Ctr Caracas, Caracas, Venezuela.
   [Roca, Jose A.; Chico, Giovanna] Clin Ricardo Palma, Lima, Peru.
   [Arevalo, J. Fernando] King Khalid Eye Specialist Hosp, Riyadh, Saudi Arabia.
   [Arevalo, J. Fernando] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
RP Wu, L (corresponding author), Inst Cirugia Ocular, Apdo 144-1225 Plaza Mayor, San Jose, Costa Rica.
EM LW65@cornell.edu
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019; Fromow-Guerra,
   J. Jans/A-3346-2015
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Fromow-Guerra, J. Jans/0000-0001-5335-1275
CR Barbazetto IA, 2004, EXP EYE RES, V78, P917, DOI 10.1016/j.exer.2004.01.003
   Chang S, 2006, AM J OPHTHALMOL, V141, P1033, DOI 10.1016/j.ajo.2006.02.014
   Chang S, 2012, GRAEF ARCH CLIN EXP, V250, P461, DOI 10.1007/s00417-011-1634-8
   Doshi V, 2008, OPHTHALMOLOGY, V115, P639, DOI 10.1016/j.ophtha.2007.05.032
   Ekstrom C, 2012, ACTA OPHTHALMOL, V90, P316, DOI 10.1111/j.1755-3768.2010.01943.x
   Ganea E, 2006, CURR EYE RES, V31, P1, DOI 10.1080/02713680500477347
   Gisladottir S, 2009, GRAEF ARCH CLIN EXP, V247, P1677, DOI 10.1007/s00417-009-1141-3
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P302, DOI 10.1016/j.ajo.2004.09.046
   Lalezary M, 2011, RETINA-J RET VIT DIS, V31, P679, DOI 10.1097/IAE.0b013e3181ff0d5a
   Luk FOJ, 2009, RETINA-J RET VIT DIS, V29, P218, DOI 10.1097/IAE.0b013e31818ba9ca
   McNulty R, 2004, J PHYSIOL-LONDON, V559, P883, DOI 10.1113/jphysiol.2004.068619
   REDDY DVN, 1960, ARCH OPHTHALMOL-CHIC, V63, P715
   Sacca SC, 2007, EXP EYE RES, V84, P389, DOI 10.1016/j.exer.2006.10.008
   SAKAUE H, 1989, INVEST OPHTH VIS SCI, V30, P1933
   Siegfried CJ, 2010, INVEST OPHTH VIS SCI, V51, P5731, DOI 10.1167/iovs.10-5666
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Sun J, 2012, EYE, V26, P283, DOI 10.1038/eye.2011.243
   Thompson JT, 2011, RETINA-J RET VIT DIS, V31, P1007, DOI 10.1097/IAE.0b013e31820d4019
   Truscott RJW, 2005, EXP EYE RES, V80, P709, DOI 10.1016/j.exer.2004.12.007
   Yu AL, 2010, GRAEF ARCH CLIN EXP, V248, P1407, DOI 10.1007/s00417-010-1409-7
NR 20
TC 26
Z9 28
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2014
VL 34
IS 10
BP 1985
EP 1989
DI 10.1097/IAE.0000000000000189
PG 5
WC Ophthalmology
SC Ophthalmology
GA AQ8BX
UT WOS:000343048200017
PM 24736465
DA 2020-12-15
ER

PT J
AU Bottos, J
   Elizalde, J
   Rodrigues, EB
   Farah, M
   Maia, M
AF Bottos, J.
   Elizalde, J.
   Rodrigues, E. B.
   Farah, M.
   Maia, M.
TI Classifications of vitreomacular traction syndrome: diameter vs
   morphology
SO EYE
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; POSTERIOR VITREOUS DETACHMENT; IDIOPATHIC
   MACULAR HOLE; OUTCOMES
AB Purpose The aim of this study is to analyze the agreement between the classifications based on morphology and diameter of vitreomacular traction (VMT) syndrome, as well as to correlate the morphological findings of VMT with specific maculopathies.
   Methods Fifty-three eyes with VMT syndrome were categorized into two classifications based on optical coherence tomography images: the VMT morphology (V- or J-shaped) and the diameter of adhesion (focal <= 1500 mu m or broad >1500 mu m).
   Results High correlation was seen between V-shaped and focal-VMT and between J-shaped and broad-VMT (kappa = 0.850; P < 0.001), except in four cases with broad adhesion despite the presence of a V-shaped pattern. These four cases had common characteristics to those with broad vitreal attachment regarding associated maculopathies and visual function. V-shaped VMT (n = 29) and focal-VMT (n = 25) led to tractional cystoid macular edema (CME; 79.31% and 84%, respectively) and macular hole (MH; 37.93% and 44%); J-shaped VMT (n = 24) and broad-VMT (n = 28) were associated with epiretinal membranes (ERMs; 91.66% and 92.85%, respectively) and diffuse retinal thickening (62.50% and 64.28%). The best-corrected visual acuity (BCVA) was not significantly different between the groups (BCVA logarithm of the minimum angle of resolution: V-shaped, 0.45; J-shaped, 0.46; P = 0.816; and focal, 0.50; broad, 0.42; P = 0.198).
   Conclusions Although highly concordant, the classification based on the diameter of the adhesion and not on the classical adhesion morphology seemed to better reflect the specific macular changes. V-shaped and focal VMT led to tractional CME and MH, while J-shaped and broad VMT were associated with ERM and diffuse retinal thickening.
C1 [Bottos, J.; Rodrigues, E. B.; Farah, M.; Maia, M.] Univ Fed Sao Paulo, Dept Ophthalmol, BR-04023062 Sao Paulo, Brazil.
   [Elizalde, J.] Univ Autonoma Barcelona, IUB, E-08193 Barcelona, Spain.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, 2nd Floor,Botucatu St,Vila Clementino, BR-04023062 Sao Paulo, Brazil.
EM maiamauricio@terra.com.br
RI Rodrigues, Eduardo Buchele/C-6852-2015; Maia, Mauricio/I-5892-2015;
   Maia, Mauricio/Z-1042-2019; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Farah, Michel Eid E/0000-0001-5951-0193; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
FU Instituto Barraquer de Oftalmologia, Barcelona, Spain
FX We are grateful to our colleagues in the Vitreoretinal Service Unit of
   Federal University of Sao Paulo and Instituto Universitario Barraquer;
   Fundacion Carolina, Spain; Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo and CNPq (Conselho Nacional de Pesquisa). This study was the
   winner of Joaquin Rutllan 2010 Award, from the Instituto Barraquer de
   Oftalmologia, Barcelona, Spain.
CR Chang LK, 2008, AM J OPHTHALMOL, V146, P121, DOI 10.1016/j.ajo.2008.03.001
   Gaudric A, 1999, ARCH OPHTHALMOL-CHIC, V117, P744
   Haouchine B, 2001, OPHTHALMOLOGY, V108, P15, DOI 10.1016/S0161-6420(00)00519-4
   HIKICHI T, 1993, AM J OPHTHALMOL, V116, P273, DOI 10.1016/S0002-9394(14)71343-1
   Ito Y, 2003, AM J OPHTHALMOL, V135, P351, DOI 10.1016/S0002-9394(02)01944-X
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1503, DOI 10.1097/IAE.0b013e31829232fd
   Johnson MW, 2010, AM J OPHTHALMOL, V149, P371, DOI 10.1016/j.ajo.2009.11.022
   Johnson MW, 2005, AM J OPHTHALMOL, V140, P184, DOI 10.1016/j.ajo.2005.01.033
   Koizumi H, 2008, AM J OPHTHALMOL, V145, P509, DOI 10.1016/j.ajo.2007.10.014
   MCDONALD HR, 1994, OPHTHALMOLOGY, V101, P1397
   Mirza RG, 2007, SURV OPHTHALMOL, V52, P397, DOI 10.1016/j.survophthal.2007.04.007
   Odrobina D, 2011, RETINA-J RET VIT DIS, V31, P324, DOI 10.1097/IAE.0b013e3181eef08c
   Shechtman DL, 2009, OPTOMETRY, V80, P681, DOI 10.1016/j.optm.2009.07.014
   SMIDDY WE, 1990, RETINA-J RET VIT DIS, V10, P288, DOI 10.1097/00006982-199010000-00012
   Smiddy WE, 2004, AM J OPHTHALMOL, V137, P525, DOI 10.1016/j.ajo.2003.12.011
   Sonmez K, 2008, RETINA-J RET VIT DIS, V28, P1207, DOI 10.1097/IAE.0b013e31817b6b0f
   Spaide RF, 2002, AM J OPHTHALMOL, V133, P226, DOI 10.1016/S0002-9394(01)01377-0
   Yamada N, 2005, AM J OPHTHALMOL, V139, P112, DOI 10.1016/j.ajo.2004.08.055
NR 18
TC 11
Z9 11
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2014
VL 28
IS 9
BP 1107
EP 1112
DI 10.1038/eye.2014.128
PG 6
WC Ophthalmology
SC Ophthalmology
GA AP4QX
UT WOS:000342064400009
PM 24993318
OA Green Published, Bronze
DA 2020-12-15
ER

PT J
AU Furlani, BA
   Barroso, L
   Sousa-Martins, D
   Maia, M
   Moraes, MN
   Badaro, E
   Portella, R
   Lima, AA
   Rodrigues, EB
   Belfort, R
AF Furlani, Bruno Albuquerque
   Barroso, Leticia
   Sousa-Martins, Diogo
   Maia, Mauricio
   Moraes-Filho, Milton Nunes
   Badaro, Emerson
   Portella, Renata
   Lima-Filho, Acacio Alves
   Rodrigues, Eduardo Buchelle
   Belfort, Rubens, Jr.
TI Lutein and Zeaxanthin Toxicity With and Without Brilliant Blue in
   Rabbits
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID INTERNAL LIMITING MEMBRANE; INTRAVITREAL INDOCYANINE GREEN;
   RETINAL-PIGMENT EPITHELIUM; MACULAR HOLE SURGERY; SELECTIVELY STAINS;
   TRYPAN BLUE; RAT RETINA; VITAL DYES; IN-VITRO; CAROTENOIDS
AB Purpose: To evaluate the safety profile of solutions containing lutein and zeaxanthin alone or associated with brilliant blue (BB).
   Methods: Twenty-eight New Zealand rabbits were used to evaluate 4 concentrations of the various dye solutions: 0.5% lutein/zeaxanthin; 0.5% lutein/zeaxanthin associated with 0.0125% BB; 0.3% lutein/zeaxanthin associated with 0.025% BB; and 0.25% lutein/zeaxanthin associated with 0.05% BB. The pHs of the dye solutions ranged from 6.5 to 7.2 and the osmolarities from 280 to 320 mOsm/mL. Each rabbit had 0.1mL of one of the dyeing solutions injected into the vitreous cavity of the right eye, while balanced salt solution (BSS) was injected into the left eye as the control. Scotopic electroretinography responses were recorded in all eyes at different time points. The animals were sacrificed at 1 and 7 days after injection; the eyes were analyzed by light and transmission electron microscopy.
   Results: No significant (P > 0.05) differences were seen in the a- and b-wave amplitudes among groups at any given point in time. Light and electron microscopy findings showed no significant abnormalities either, and were similar to the histological findings after intravitreal BSS injection.
   Conclusions: Lutein and zeaxanthin alone or in association with BB showed a good safety profile in this experimental model.
C1 [Furlani, Bruno Albuquerque; Barroso, Leticia; Sousa-Martins, Diogo; Maia, Mauricio; Moraes-Filho, Milton Nunes; Badaro, Emerson; Portella, Renata; Lima-Filho, Acacio Alves; Rodrigues, Eduardo Buchelle; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Dept Ophthalmol, BR-06023062 Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Vitreoretinal Surg Unit, 822 Botucatu St, BR-06023062 Sao Paulo, Brazil.
EM retina@femanet.com.br
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; Rodrigues,
   Eduardo Buchele/C-6852-2015; de Souza Lima Filho, Acacio
   Alves/C-7189-2012; Sousa-Martins, Diogo/B-1554-2019
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Sousa-Martins, Diogo/0000-0002-2285-3990; Alves de Souza Lima Filho,
   Acacio/0000-0003-1802-9592; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
CR Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Creuzot-Garcher C, 2010, RETINA-J RET VIT DIS, V30, P1294, DOI 10.1097/IAE.0b013e3181d205aa
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P623, DOI 10.1097/00006982-200607000-00006
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Enaida Hiroshi, 2008, Dev Ophthalmol, V42, P115, DOI 10.1159/000138989
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Gandorfer A, 2001, AM J OPHTHALMOL, V131, P387, DOI 10.1016/S0002-9394(00)00924-7
   Haritoglou C, 2003, GRAEF ARCH CLIN EXP, V241, P958, DOI 10.1007/s00417-003-0737-2
   Haritoglou C, 2002, AM J OPHTHALMOL, V134, P836, DOI 10.1016/S0002-9394(02)01816-0
   Ho JD, 2003, ARCH OPHTHALMOL-CHIC, V121, P1423, DOI 10.1001/archopht.121.10.1423
   Iriyama A, 2004, INVEST OPHTH VIS SCI, V45, P943, DOI 10.1167/iovs.03-1026
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Narayanan R, 2005, CURR EYE RES, V30, P471, DOI 10.1080/02713680590959312
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   Penha FM, 2008, J OCUL PHARMACOL TH, V24, P52, DOI 10.1089/jop.2007.0047
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Remy M, 2008, BRIT J OPHTHALMOL, V92, P1142, DOI 10.1136/bjo.2008.138164
   Rezai KA, 2004, AM J OPHTHALMOL, V137, P931, DOI 10.1016/j.ajo.2003.11.016
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Rodrigues Eduardo B, 2008, Dev Ophthalmol, V42, P29, DOI 10.1159/000138911
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sousa-Martins D, 2012, RETINA-J RET VIT DIS, V32, P1328, DOI 10.1097/IAE.0b013e318239e2b6
   Tokuda K, 2009, RETINA-J RET VIT DIS, V29, P371, DOI 10.1097/IAE.0b013e318195cb00
   Wu WC, 2005, PHOTOCHEM PHOTOBIOL, V81, P537, DOI 10.1562/2004-09-03-RA-302.1
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   Yuen D, 2009, AM J OPHTHALMOL, V147, P251, DOI 10.1016/j.ajo.2008.08.031
NR 34
TC 7
Z9 7
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD SEP
PY 2014
VL 30
IS 7
BP 559
EP 566
DI 10.1089/jop.2013.0171
PG 8
WC Ophthalmology; Pharmacology & Pharmacy
SC Ophthalmology; Pharmacology & Pharmacy
GA AP0FR
UT WOS:000341737200007
PM 24901374
DA 2020-12-15
ER

PT J
AU Badaro, E
   Furlani, B
   Prazeres, J
   Maia, M
   Lima, AAS
   Souza-Martins, D
   Muccioli, C
   Lucatto, LFA
   Belfort, R
AF Badaro, Emmerson
   Furlani, Bruno
   Prazeres, Juliana
   Maia, Mauricio
   Souza Lima, Acacio Alves
   Souza-Martins, Diogo
   Muccioli, Cristina
   Adami Lucatto, Luiz Filipe
   Belfort, Rubens, Jr.
TI Soluble lutein in combination with brilliant blue as a new dye for
   chromovitrectomy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Chromovitrectomy; Internal limiting membrane; Lutein; Macular hole;
   Vitreoretinal surgery; Zeaxanthin
ID INTERNAL LIMITING MEMBRANE; INDOCYANINE GREEN INJECTION; MACULAR
   PIGMENT; TRYPAN BLUE; ZEAXANTHIN; CAROTENOIDS; SURGERY; RABBITS; RETINA;
   LIGHT
AB A new dye for vitreoretinal surgery comprised of soluble lutein/zeaxanthin 1 % and brilliant blue 0.025 % is advantageous compared with other dyes currently used for chromovitrectomy, and showed no signs of toxicity at 1 month of follow-up.
   To evaluate the feasibility and safety of a dye [soluble lutein/zeaxanthin (LZ) 1 % and brilliant blue (BB) 0.025 %] for improving removal of vitreous, epiretinal membranes (ERM), and internal limiting membranes (ILM) in humans.
   We prospectively evaluated 18 eyes treated surgically for a macular hole or ERM. Eighteen surgeons performed chromovitrectomy using the dye, and completed a questionnaire to evaluate the efficacy and safety of the dye. . Examinations included best-corrected visual acuity and intraocular pressure measurements and optical coherence tomography, fluorescein angiography, and autofluorescence performed at baseline and days 1, 7, and 30 postoperatively.
   The green dye was deposited on the posterior pole; vigorous dye flushing into the vitreous cavity was unnecessary. All surgeons reported that the ILM stained greenish-blue; 94.4 % reported ILM peeling adequate; the ERM stained poorly. No evidence of toxicity was observed.
   The new dye deposited on the posterior pole due to its higher density. The ability to stain the ILM was similar to BB. The new dye has ability to stain the vitreous, hyaloid, and especially the ILM satisfactorily. The new dye may be useful during chromovitrectomy.
C1 [Badaro, Emmerson; Furlani, Bruno; Prazeres, Juliana; Maia, Mauricio; Souza Lima, Acacio Alves; Souza-Martins, Diogo; Muccioli, Cristina; Adami Lucatto, Luiz Filipe; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Dept Ophthalmol, BR-06023062 Sao Paulo, Brazil.
   [Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Vitreoretinal Surg Unit, BR-06023062 Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Vitreoretinal Surg Unit, Rua Botucatu 822, BR-06023062 Sao Paulo, Brazil.
EM maiamauricio@terra.com.br
RI Sousa-Martins, Diogo/B-1554-2019; de Souza Lima Filho, Acacio
   Alves/C-7189-2012; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015; Belfort Jr, Rubens/E-2252-2012
OI Sousa-Martins, Diogo/0000-0002-2285-3990; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091; Alves
   de Souza Lima Filho, Acacio/0000-0003-1802-9592; Belfort Jr,
   Rubens/0000-0002-8422-3898
FU Kemin Inc., Des Moines, IA, USA
FX The use of the combination of lutein/zeaxanthin and brilliant blue in
   human eyes is protected by international patent law (international
   patent number 61/468,838). The study was sponsored by Kemin Inc., Des
   Moines, IA, USA.
CR Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Feron EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P141
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kumar Atul, 2004, Indian J Ophthalmol, V52, P339
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Maia M, 2013, LUTEIN NEW DYE CHROM
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   Perrier M, 2003, AM J OPHTHALMOL, V135, P909, DOI 10.1016/S0002-9394(02)02256-0
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sousa-Martins D, 2012, RETINA-J RET VIT DIS, V32, P1328, DOI 10.1097/IAE.0b013e318239e2b6
   Teba FA, 2003, OPHTHALMOLOGY, V110, P2409, DOI 10.1016/S0161-6420(03)00716-4
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
NR 25
TC 6
Z9 7
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2014
VL 252
IS 7
BP 1071
EP 1078
DI 10.1007/s00417-013-2539-5
PG 8
WC Ophthalmology
SC Ophthalmology
GA AK5US
UT WOS:000338492500007
PM 24441951
DA 2020-12-15
ER

PT J
AU Badaro, E
   Novais, EA
   Penha, FM
   Maia, M
   Farah, ME
   Rodrigues, EB
AF Badaro, Emmerson
   Novais, Eduardo Amorim
   Penha, Fernando Marcondes
   Maia, Mauricio
   Farah, Michel Eid
   Rodrigues, Eduardo Buchele
TI Vital Dyes in Ophthalmology: a Chemical Perspective
SO CURRENT EYE RESEARCH
LA English
DT Review
DE Chromovitrectomy; indocyanine green; staining; trypan blue; vital dye
ID MACULAR HOLE SURGERY; INTERNAL LIMITING MEMBRANE; BRILLIANT BLUE-G;
   RETINAL-PIGMENT EPITHELIUM; VISUAL-FIELD DEFECTS; SUBRETINAL INDOCYANINE
   GREEN; PERFUSED VERTEBRATE RETINA; IN-VIVO EVALUATION; INFRACYANINE
   GREEN; TRYPAN BLUE
AB Vital dyes have advanced diagnosis and surgical technique in various specialties, including oncology, gastroenterology and ophthalmology. Intra-operative and diagnostic dyes are finding uses in all areas of ophthalmology, including cornea, cataract, retina, glaucoma, orbit and conjunctiva. We provide a summary of current knowledge of the chemical concepts of vital dyes in ophthalmology. We review the properties of dyes, techniques of application, indications and complications in ocular surgery. Vital dyes represent an expanding area of research, and novel dyes deserve further investigation.
C1 [Badaro, Emmerson; Novais, Eduardo Amorim; Penha, Fernando Marcondes; Maia, Mauricio; Farah, Michel Eid; Rodrigues, Eduardo Buchele] Univ Fed Sao Paulo, Vis Inst, Paulista Sch Med, Dept Ophthalmol, Sao Paulo, Brazil.
RP Badaro, E (corresponding author), Univ Fed Sao Paulo, Vis Inst, Paulista Sch Med, Dept Ophthalmol, Sao Paulo, Brazil.
EM badarojf@yahoo.com.br
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012; Rodrigues,
   Eduardo Buchele/C-6852-2015; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Buchele
   Rodrigues, Eduardo/0000-0002-4224-0921
CR ABRAMS GW, 1978, ARCH OPHTHALMOL-CHIC, V96, P521
   Arevalo JF, 2007, GRAEF ARCH CLIN EXP, V245, P751, DOI 10.1007/s00417-006-0430-3
   Beija M, 2009, CHEM SOC REV, V38, P2410, DOI 10.1039/b901612k
   Bishop RM, 2005, J CATARACT REFR SURG, V31, P1272, DOI 10.1016/j.jcrs.2005.06.030
   Brouzas D, 2006, CORNEA, V25, P470, DOI 10.1097/01.ico.0000183488.78012.33
   Cacciatori M, 2007, AM J OPHTHALMOL, V143, P726, DOI 10.1016/j.ajo.2007.01.020
   Chang YS, 2005, J CATARACT REFR SURG, V31, P792, DOI 10.1016/j.jcrs.2004.07.020
   Dada VK, 2004, J CATARACT REFR SURG, V30, P326, DOI 10.1016/S0886-3350(03)00573-X
   Delaey E, 2000, J PHOTOCH PHOTOBIO B, V55, P27, DOI 10.1016/S1011-1344(00)00021-X
   Dib E, 2009, ARQ BRAS OFTALMOL, V72, P845, DOI 10.1590/S0004-27492009000600022
   Ejstrup R, 2012, GRAEF ARCH CLIN EXP, V250, P669, DOI 10.1007/s00417-011-1886-3
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Enaida Hiroshi, 2008, Dev Ophthalmol, V42, P115, DOI 10.1159/000138989
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Glickman RD, 2002, INT J TOXICOL, V21, P473, DOI 10.1080/10915810290169909
   Guo SQ, 2006, J PEDIAT OPHTH STRAB, V43, P281, DOI 10.3928/01913913-20060901-02
   Haritoglou C, 2008, BRIT J OPHTHALMOL, V92, P1265, DOI 10.1136/bjo.2008.141911
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P3315, DOI 10.1167/iovs.04-1142
   Haritoglou C, 2004, AM J OPHTHALMOL, V137, P345, DOI 10.1016/S0002-9394(03)00845-6
   Haritoglou C, 2002, AM J OPHTHALMOL, V134, P661, DOI 10.1016/S0002-9394(02)01751-8
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P673, DOI 10.1097/00006982-200607000-00014
   Hiebl W, 2005, KLIN MONATSBL AUGENH, V222, P309, DOI 10.1055/s-2005-858030
   Ho JD, 2004, BRIT J OPHTHALMOL, V88, P556, DOI 10.1136/bjo.2003.018523
   Ho JD, 2003, AM J OPHTHALMOL, V135, P258, DOI 10.1016/S0002-9394(02)01976-1
   Hoing A, 2011, KLIN MONATSBL AUGENH, V228, P724, DOI 10.1055/s-0031-1273351
   HOFFER KJ, 1993, J CATARACT REFR SURG, V19, P566, DOI 10.1016/S0886-3350(13)80636-0
   Horiguchi M, 1998, ARCH OPHTHALMOL-CHIC, V116, P535, DOI 10.1001/archopht.116.4.535
   Iriyama A, 2004, INVEST OPHTH VIS SCI, V45, P943, DOI 10.1167/iovs.03-1026
   Jackson TL, 2007, OPHTHALMOLOGY, V114, P587, DOI 10.1016/j.ophtha.2006.05.079
   Jackson TL, 2005, EXP EYE RES, V81, P446, DOI 10.1016/j.exer.2005.03.004
   Jacobs DS, 2006, OPHTHALMOLOGY, V113, P707, DOI 10.1016/j.ophtha.2006.01.024
   Januschowski K, 2012, GRAEF ARCH CLIN EXP, V250, P1013, DOI 10.1007/s00417-012-1989-5
   Januschowski K, 2011, GRAEF ARCH CLIN EXP, V249, P483, DOI 10.1007/s00417-010-1508-5
   John T, 2003, J CATARACT REFR SURG, V29, P437, DOI 10.1016/S0886-3350(02)01699-1
   Jutte A, 1968, Buch Augenarzt, V49, P1
   Kaji Y, 2006, ACTA OPHTHALMOL SCAN, V84, P825, DOI 10.1111/j.1600-0420.2006.00739.x
   Kalariya NM, 2011, BIOFACTORS, V37, P104, DOI 10.1002/biof.152
   Kalariya NM, 2011, EXP EYE RES
   Kanda S, 2004, ARCH OPHTHALMOL-CHIC, V122, P1447, DOI 10.1001/archopht.122.10.1447
   KHURANA AK, 1991, ACTA OPHTHALMOL, V69, P79
   Kiernan JA, 2001, BIOTECH HISTOCHEM, V76, P261, DOI 10.1080/714028154
   Kim J, 2000, Curr Opin Ophthalmol, V11, P241, DOI 10.1097/00055735-200008000-00005
   Kodjikian L, 2005, GRAEF ARCH CLIN EXP, V243, P917, DOI 10.1007/s00417-004-1121-6
   Koenig SB, 2007, J CATARACT REFR SURG, V33, P189, DOI 10.1016/j.jcrs.2006.09.035
   Kumagai K, 2006, RETINA-J RET VIT DIS, V26, P613, DOI 10.1097/00006982-200607000-00004
   Luke C, 2006, GRAEF ARCH CLIN EXP, V244, P1188, DOI 10.1007/s00417-005-0239-5
   Luke M, 2008, GRAEF ARCH CLIN EXP, V246, P817, DOI 10.1007/s00417-007-0761-8
   Luke C, 2005, BRIT J OPHTHALMOL, V89, P1188, DOI 10.1136/bjo.2004.062794
   Maia M, 2007, CURR EYE RES, V32, P309, DOI 10.1080/02713680701199377
   Matsui Hirofumi, 2007, Nippon Ganka Gakkai Zasshi, V111, P587
   Mencucci R, 2013, CLIN OPHTHALMOL, V7, P965, DOI 10.2147/OPTH.S43934
   Mennel S, 2006, OPHTHALMOLOGICA, V220, P190, DOI 10.1159/000091764
   Murata M, 2005, RETINA-J RET VIT DIS, V25, P75, DOI 10.1097/00006982-200501000-00011
   NORN MS, 1970, ACTA OPHTHALMOL, V48, P546
   NORN MS, 1973, ACTA OPHTHALMOL, V51, P483
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Rebolleda G, 2004, OPHTHALMOLOGY, V111, P1622, DOI 10.1016/j.ophtha.2004.05.008
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Rodrigues EB, 2007, RETINA-J RET VIT DIS, V27, P958, DOI 10.1097/01.iae.0000253051.01194.ab
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Rodrigues EB, 2010, AM J OPHTHALMOL, V149, P265, DOI 10.1016/j.ajo.2009.08.020
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Romero IL, 2012, CORNEA
   Schmid-Kubista KE, 2010, GRAEF ARCH CLIN EXP, V248, P381, DOI 10.1007/s00417-009-1213-4
   Stanescu-Segall D, 2009, EYE, V23, P504, DOI 10.1038/eye.2008.249
   Thaler S, 2012, GRAEFES ARCH CLIN EX
   Tsuiki E, 2007, AM J OPHTHALMOL, V143, P704, DOI 10.1016/j.ajo.2006.10.051
   Uemoto R, 2005, AM J OPHTHALMOL, V140, P752, DOI 10.1016/j.ajo.2005.04.035
   Ueno A, 2007, RETINA-J RET VIT DIS, V27, P499, DOI 10.1097/IAE.0b013e318030a129
   Ullern M, 2002, J FR OPHTALMOL, V25, P915
   Unlu K, 2000, J CATARACT REFR SURG, V26, P1228, DOI 10.1016/S0886-3350(00)00360-6
   VENNERSTROM JL, 1995, ANTIMICROB AGENTS CH, V39, P2671, DOI 10.1128/AAC.39.12.2671
   Wilhelm F., 1995, Ophthalmologe, V92, P496
   Wilhelm F., 1993, Ophthalmologe, V90, P171
   Yonemura N, 2001, OPHTHALMOLOGY, V108, P1638, DOI 10.1016/S0161-6420(01)00677-7
NR 77
TC 5
Z9 5
U1 0
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUL
PY 2014
VL 39
IS 7
BP 649
EP 658
DI 10.3109/02713683.2013.865759
PG 10
WC Ophthalmology
SC Ophthalmology
GA AI6OS
UT WOS:000336995500001
PM 24400745
DA 2020-12-15
ER

PT J
AU Fortes, JB
   Maia, M
   Tartarella, MB
   Meyer, FS
   Fortes, BGB
   Kliemann, LM
AF Fortes Filho, Joao Borges
   Maia, Mauricio
   Tartarella, Marcia Beatriz
   Meyer, Fabiola Schons
   Borges Fortes, Barbara Gastal
   Kliemann, Lucia Maria
TI Experimental histopathological study on retinal and renal cellular
   response to intravitreous antiangiogenic drugs
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE antiangiogenic drugs; ranibizumab; bevacizumab; therapy; oxygen induced
   retinopathy; retinopathy of prematurity
ID ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB AVASTIN; TOXICITY; RETINOPATHY;
   CHEMOTHERAPY; PREMATURITY; ABSENCE
AB AIM: To evaluate histopathological retinal and renal response after one single dose of intravitreous injection of antiangiogenic drugs ranibizumab and bevacizumab in rats.
   METHODS: Experimental study in 60d of life adults Wistar rats. Ten animals were included. Group 1 included 5 animals that were injected with 1 mu L ranibizumab 1.25 mg in the right eye and with 1 mu L of balanced salt solution (BSS) in the left eye, as control; Group 2 included 5 animals that were injected with 1 mu L of bevacizumab in the right eye and with 1 mu L of BSS in the fellow eye. All injections were performed with Hamilton syringes. After 15d of the interventions, all animals were sacrificed in CO2 chamber. Both eyes were enucleated and one kidney was removed, fixed and embedded in paraffin for histopathological analysis by optic microscopy. For statistical purposes the initial expected abnormal histopathological responses were defined as 0%.
   RESULTS: Atypical histopathological retinal response was detected in 2 eyes injected with ranibizumab (40%) as well as in 2 control eyes in group 1. Same was detected in 1 eye injected with bevacizumab (20%) as well as in 1 control eye, in group 2. The noted atypical findings were lymphocytes and eosinophils in the vitreous posterior cavity and mild retinal inflammatory reaction with ganglion cell layer edema but without clinical significance. No atypical histopathological renal response was detected.
   CONCLUSION: Unexpected atypical histopathological retinal response without clinical significance was observed in 3 eyes injected with antiangiogenic drugs (2 in group 1 and 1 in group 2) as well as in 3 control eyes (2 in group 1 and 1 in group 2). No atypical renal response was detected suggesting no extra ocular involvement of the intravitreous injected antiangiogenic drugs.
C1 [Fortes Filho, Joao Borges; Borges Fortes, Barbara Gastal] Univ Fed Rio Grande do Sul, Sch Med, Dept Ophthalmol, BR-90035903 Porto Alegre, RS, Brazil.
   [Fortes Filho, Joao Borges; Borges Fortes, Barbara Gastal; Kliemann, Lucia Maria] Hosp Clin Porto Alegre, BR-90035903 Porto Alegre, RS, Brazil.
   [Fortes Filho, Joao Borges] Univ Fed Sao Paulo, Sch Med, Dept Ophthalmol, BR-04002306 Sao Paulo, Brazil.
   [Tartarella, Marcia Beatriz; Meyer, Fabiola Schons] Hosp Clin Porto Alegre, Anim Expt Unit, BR-90035903 Porto Alegre, RS, Brazil.
   [Kliemann, Lucia Maria] Univ Fed Rio Grande do Sul, Sch Med, Dept Pathol, BR-90035903 Porto Alegre, RS, Brazil.
RP Fortes, JB (corresponding author), Dept Ophthalmol, Ramiro Barcelos 2350, BR-90035903 Porto Alegre, RS, Brazil.
EM jbfortes@prorop.com.br
RI FILHO, JOAO B FORTES/K-8446-2017; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015
OI FILHO, JOAO B FORTES/0000-0001-5682-0962; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
CR Ababneh OH, 2013, RETINA-J RET VIT DIS, V33, P748, DOI 10.1097/IAE.0b013e3182721153
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Akkoyun I, 2012, ACTA OPHTHALMOL, V90, P564, DOI 10.1111/j.1755-3768.2010.01963.x
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Borzomati D, 2013, UPDATES SURG-ITALY, V65, P121, DOI 10.1007/s13304-013-0207-2
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Hoerster R, 2013, ACTA OPHTHALMOL, V91, pe74, DOI 10.1111/j.1755-3768.2012.02469.x
   Hurwitz H, 2005, ONCOLOGY-BASEL, V69, P17, DOI 10.1159/000088480
   Hurwitz H, 2006, SEMIN ONCOL, V33, pS26, DOI 10.1053/j.seminoncol.2006.08.001
   Kim JH, 2008, NEUROTOXICOLOGY, V29, P1131, DOI 10.1016/j.neuro.2008.06.006
   Kong L, 2008, ARCH OPHTHALMOL-CHIC, V126, P1161, DOI 10.1001/archophthalmol.2008.1
   Lubezky N, 2013, J GASTROINTEST SURG, V17, P527, DOI 10.1007/s11605-012-2108-y
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   MIGLIORATI G, 1994, IMMUNOLOGY, V81, P21
   Mota A, 2012, CASE REP OPHTHALM, V3, P136, DOI 10.1159/000338623
   Pelle G, 2011, AM J KIDNEY DIS, V57, P756, DOI 10.1053/j.ajkd.2010.11.030
   Penha FM, 2011, EXPERT OPIN DRUG MET, V7, P1021, DOI 10.1517/17425255.2011.585970
   Penha FM, 2010, OPHTHALMIC RES, V44, P205, DOI 10.1159/000316695
   Orozco-Gomez LP, 2011, CIR CIR, V79, P207
   Sato T, 2012, AM J OPHTHALMOL, V153, P327, DOI 10.1016/j.ajo.2011.07.005
   Thaler S, 2010, ACTA OPHTHALMOL, V88, pE170, DOI 10.1111/j.1755-3768.2010.01927.x
NR 21
TC 2
Z9 2
U1 0
U2 3
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JUN 18
PY 2014
VL 7
IS 3
BP 437
EP 440
DI 10.3980/j.issn.2222-3959.2014.03.09
PG 4
WC Ophthalmology
SC Ophthalmology
GA AJ4PN
UT WOS:000337658400009
PM 24967187
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Rodrigues, EB
   Shiroma, H
   Penha, FM
   Maia, M
   Moraes, MN
   Ferreira, M
   Portella, R
   Novais, E
   Hagedorn, N
   Farah, ME
AF Rodrigues, Eduardo B.
   Shiroma, Helio
   Penha, Fernando M.
   Maia, Mauricio
   Moraes-Filho, Milton N.
   Ferreira, Magno
   Portella, Renata
   Novais, Eduardo
   Hagedorn, Nadine
   Farah, Michel E.
TI DEVELOPMENT AND INITIAL EXPERIENCE WITH A COLORED PERFLUOROCARBON LIQUID
   FOR INTRAOCULAR TAMPONADE IN VITREORETINAL SURGERY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE chromovitrectomy; perfluorocarbon liquid; vital dye; retinal detachment;
   proliferative vitreoretinopathy; anthraquinone
ID N-OCTANE; PROLIFERATIVE VITREORETINOPATHY; RETINAL DETACHMENTS; HEAVY
   TAMPONADES; VITAL DYES; TOLERANCE; MANAGEMENT; PERFLUORODECALIN;
   SILICONE; RABBIT
AB Purpose: To present the development and initial experience of a novel colored perfluorocarbon liquid (PFCL) in vitreoretinal surgery.
   Methods: This was an experimental laboratory study and prospective human interventional study. F6H8 (Fluoron GmbH) was colored by adding 0.3 g/L blue anthraquinone dye. Subsequently, 20% colored F6H8 was prepared by mixing with perfluorooctane or perfluorodecalin (Fluoron GmbH). The novel product is not yet FDA approved for human application. In the laboratory, the colored PFCL was covered with 1) uncolored PFCL, 2) BSS, and 3) silicone oil. Cell toxicity was evaluated in L929 mouse fibroblasts using a growth inhibition assay. Porcine ex vivo eyes were evaluated after vitrectomy followed by intravitreal and subretinal colored PFCL infusion. A pilot, prospective, noncomparative interventional study was conducted in patients with retinal detachment with proliferative vitreoretinopathy (PVR).
   Results: The density of the colored PFLC mixture was 1.664 g/cm(3) for perfluorooctane and 1.802 g/cm(3) for perfluorodecalin. There was no relevant cell growth inhibition with any concentration of colored PFCL tested. Experiments in pigs revealed that infusion of the colored PFCL caused neither staining of the internal limiting membrane nor intravitreal residual droplets. In the prospective study, 9 eyes (75%) underwent surgery for rhegmatogenous retinal detachment with at least grade C PVR. The colored PFCL enabled retinal break examination and detection of residual intravitreal droplets in all surgeries. There was no case of separation or leakage of the dye from the PFCL solution that could have caused unwanted staining of the vitreous or epiretinal surface.
   Conclusion: The colored PFCL enabled intraoperative maneuvers such as endolaser use. In addition, removal of the colored PFCL was easily achieved at the end of surgery.
C1 [Rodrigues, Eduardo B.; Shiroma, Helio; Penha, Fernando M.; Maia, Mauricio; Moraes-Filho, Milton N.; Ferreira, Magno; Portella, Renata; Novais, Eduardo; Hagedorn, Nadine; Farah, Michel E.] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, Sao Paulo, Brazil.
RP Rodrigues, EB (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, Rua Almirante Barroso 45,Jade 204, BR-88030460 Florianopolis, SC, Brazil.
EM rodriguesretina@gmail.com
RI Rodrigues, Eduardo Buchele/C-6852-2015; Maia, Mauricio/I-5892-2015;
   Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Buchele
   Rodrigues, Eduardo/0000-0002-4224-0921
CR Bourke RD, 1996, ARCH OPHTHALMOL-CHIC, V114, P537, DOI 10.1001/archopht.1996.01100130529005
   CHANG S, 1989, ARCH OPHTHALMOL-CHIC, V107, P761, DOI 10.1001/archopht.1989.01070010779046
   CHANG S, 1989, OPHTHALMOLOGY, V96, P785
   CHANG S, 1988, AM J OPHTHALMOL, V106, P668, DOI 10.1016/0002-9394(88)90698-8
   CHANG S, 1991, RETINA-J RET VIT DIS, V11, P367
   COLL GE, 1995, OPHTHALMOLOGY, V102, P630, DOI 10.1016/S0161-6420(95)30975-X
   COMARATTA MR, 1991, CURR OPIN OPHTHALMOL, V2, P291
   CRAFOORD S, 1995, ACTA OPHTHALMOL SCAN, V73, P442
   DEQUEIROZ JM, 1992, RETINA-J RET VIT DIS, V12, pS33, DOI 10.1097/00006982-199212031-00008
   DEVIN F, 1995, OPHTHALMOLOGICA, V209, P306, DOI 10.1159/000310648
   Dib E, 2009, ARQ BRAS OFTALMOL, V72, P845, DOI 10.1590/S0004-27492009000600022
   Haidt SJ, 1982, INVEST OPHTH VIS SCI, V22, pS233
   HAN DP, 1994, AM J OPHTHALMOL, V118, P24, DOI 10.1016/S0002-9394(14)72838-7
   HAN DP, 1994, RETINA-J RET VIT DIS, V14, P219, DOI 10.1097/00006982-199414030-00006
   Heimann H, 2008, EYE, V22, P1342, DOI 10.1038/eye.2008.61
   Inoue M, 2009, RETINA-J RET VIT DIS, V29, P677, DOI 10.1097/IAE.0b013e318196fca1
   Joussen AM, 2009, KLIN MONATSBL AUGENH, V226, P693, DOI 10.1055/s-0028-1109696
   Joussen AM, 2008, GRAEF ARCH CLIN EXP, V246, P1217, DOI 10.1007/s00417-008-0861-0
   Kobuch K, 2001, GRAEF ARCH CLIN EXP, V239, P635, DOI 10.1007/s004170100330
   Liang CP, 1999, RETINA-J RET VIT DIS, V19, P230, DOI 10.1097/00006982-199905000-00009
   Mackiewicz J, 2007, GRAEF ARCH CLIN EXP, V245, P665, DOI 10.1007/s00417-006-0414-3
   Orzalesi N, 1998, CURR EYE RES, V17, P828, DOI 10.1076/ceyr.17.8.828.5157
   PEYMAN GA, 1995, SURV OPHTHALMOL, V39, P375
   Rizzo S, 2012, GRAEF ARCH CLIN EXP, V250, P653, DOI 10.1007/s00417-011-1874-7
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   SPARROW JR, 1993, RETINA-J RET VIT DIS, V13, P56, DOI 10.1097/00006982-199313010-00013
   Versura P, 2001, OPHTHALMOLOGICA, V215, P276, DOI 10.1159/000050874
   Wong D, 2000, Semin Ophthalmol, V15, P25
   Zimmerman NJ, 1984, INVEST OPHTH VIS SCI, V25, pS258
NR 29
TC 1
Z9 1
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2014
VL 34
IS 6
BP 1103
EP 1111
DI 10.1097/IAE.0000000000000078
PG 9
WC Ophthalmology
SC Ophthalmology
GA AI8GP
UT WOS:000337149000010
PM 24480841
DA 2020-12-15
ER

PT J
AU Avery, RL
   Van Everen, SA
   Rabena, MD
   Maia, M
   Le, K
   Visich, JE
AF Avery, Robert L.
   Van Everen, Sherri A.
   Rabena, Melvin D.
   Maia, Mauricio
   Le, Kha
   Visich, Jennifer E.
TI Systemic Safety Profile of Intravitreal VEGF Inhibitors for Diabetic
   Macular Edema (DME): Differences in Systemic Pharmacokinetics and
   Systemic VEGF Levels
SO DIABETES
LA English
DT Meeting Abstract
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD JUN
PY 2014
VL 63
SU 1
MA 2433-PO
BP A617
EP A617
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CO9GG
UT WOS:000359481603299
DA 2020-12-15
ER

PT J
AU Vianna, LMM
   Cohen, MJ
   Muccioli, C
   Lima, A
   Sousa-Martins, D
   Maia, M
   Belfort, R
AF Monteiro Vianna, Lucas Monferrari
   Cohen, Marcos J.
   Muccioli, Cristina
   Lima, Acacio
   Sousa-Martins, Diogo
   Maia, Mauricio
   Belfort, Rubens, Jr.
TI Efficacy of a lutein-based dye (Phacodyne (TM)) for visualizing anterior
   capsulorhexis during cataract surgery by phacoemulsification
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Cataract extraction; Lutein; Phacoemulsification; Capsulorhexis; Lenses,
   intraocular
ID TRYPAN BLUE; WHITE CATARACT; RABBIT MODEL; CAPSULE; ADJUNCT; EYES
AB Purpose: To evaluate the efficacy and safety of a novel lutein-based dye for the anterior capsulorhexis during phacoemulsification in cataract surgery in humans.
   Methods: Twenty-five eyes from 25 patients were operated by 25 different surgeons who performed continuous circular capsulorhexis (CCC) guided by a lutein-based dye (Phacodyne (TM)) during cataract surgery by phacoemulsification. A questionnaire assessed the surgeon's opinion regarding the efficacy of the dye. Follow-up examinations were performed at 1, 7, and 30 days post-surgery. Eyes were evaluated by full ophthalmic examination, corneal topography/ pachymetry, and corneal endothelial cell count.
   Results: As revealed by the answers to the questionnaire, the dye facilitated the CCC procedure in all eyes. Baseline nuclear cataract classification (according to the Lens Opacities Classification System III; LOCS III) was 3.24 (+/- 1.12). Preoperative BCVA (logMAR) was 0.89 +/- 0.59 and improved to 0.23 +/- 0.22 on day 30 after surgery. The intraocular pressure (IOP) remained stable and the inflammatory reaction subsided in all cases within the first 7 days after surgery. The pre-operative values of corneal pachymetry and IOP were similar to those found on follow-up day 30. Loss in endothelial cell number was similar to earlier reports.
   Conclusion: Phacodyne T was efficient when used for anterior capsulorhexis during cataract surgery by phacoemulsification and showed no signs of toxicity or side effects during the 30-day follow-up period.
C1 [Monteiro Vianna, Lucas Monferrari; Cohen, Marcos J.; Muccioli, Cristina; Lima, Acacio; Sousa-Martins, Diogo; Maia, Mauricio; Belfort, Rubens, Jr.] Univ Fed Sao Paulo UNIFESP, Dept Oftalmol, Sao Paulo, Brazil.
RP Vianna, LMM (corresponding author), Rua Botucatu 821, BR-04023900 Sao Paulo, Brazil.
EM lucasmmvianna@yahoo.com.br
RI Maia, Mauricio/I-5892-2015; Belfort, Rubens/E-2252-2012; de Souza Lima
   Filho, Acacio Alves/C-7189-2012; Sousa-Martins, Diogo/B-1554-2019; Maia,
   Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Belfort, Rubens/0000-0002-8422-3898;
   Sousa-Martins, Diogo/0000-0002-2285-3990; Maia,
   Mauricio/0000-0002-7034-8091; Alves de Souza Lima Filho,
   Acacio/0000-0003-1802-9592
FU Kemin Industries Inc.
FX This study has been conducted under grants from Kemin Industries Inc.
CR ASSIA EI, 1991, ARCH OPHTHALMOL-CHIC, V109, P642, DOI 10.1001/archopht.1991.01080050056028
   Brown SM, 2004, J CATARACT REFR SURG, V30, P2033, DOI 10.1016/j.jcrs.2004.06.073
   Chang YS, 2005, J CATARACT REFR SURG, V31, P799, DOI 10.1016/j.jcrs.2004.09.029
   Chang YS, 2005, J CATARACT REFR SURG, V31, P792, DOI 10.1016/j.jcrs.2004.07.020
   Chung CF, 2005, J CATARACT REFR SURG, V31, P938, DOI 10.1016/j.jcrs.2004.12.046
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Furlani BA, J OCUL PHARM THER, V30, P559
   GIMBEL HV, 1990, J CATARACT REFR SURG, V16, P31, DOI 10.1016/S0886-3350(13)80870-X
   Hengerer FH, J CATARACT REFRACT S
   HOFFER KJ, 1993, J CATARACT REFR SURG, V19, P566, DOI 10.1016/S0886-3350(13)80636-0
   Horiguchi M, 2003, ARCH OPHTHALMOL-CHIC, V121, P327, DOI 10.1001/archopht.121.3.327
   Horiguchi M, 1998, ARCH OPHTHALMOL-CHIC, V116, P535, DOI 10.1001/archopht.116.4.535
   Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057
   Jacob S, 2002, J CATARACT REFR SURG, V28, P1819, DOI 10.1016/S0886-3350(01)01316-5
   Jacobs DS, 2006, OPHTHALMOLOGY, V113, P707, DOI 10.1016/j.ophtha.2006.01.024
   Ma L, 2010, J SCI FOOD AGR, V90, P2, DOI 10.1002/jsfa.3785
   Marback EF, 2001, ARQ BRAS OFTALMOL, V64, P333
   Rosado-Adames N, 2012, CURR OPIN OPHTHALMOL, V23, P3, DOI 10.1097/ICU.0b013e32834e4b5f
   Sato Y, 2011, BIOPHARM DRUG DISPOS, V32, P151, DOI 10.1002/bdd.746
   Shrivastava A, 2010, CURR OPIN OPHTHALMOL, V21, P118, DOI 10.1097/ICU.0b013e3283360ac3
   Sousa-Martins D, 2012, RETINA-J RET VIT DIS, V32, P1328, DOI 10.1097/IAE.0b013e318239e2b6
   Stock G, 2011, ACTA OPHTHALMOL, V89, P369, DOI 10.1111/j.1755-3768.2009.01704.x
   Yetik H, 2002, J CATARACT REFR SURG, V28, P988, DOI 10.1016/S0886-3350(02)01217-8
NR 23
TC 3
Z9 3
U1 0
U2 2
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAY-JUN
PY 2014
VL 77
IS 3
BP 173
EP 177
DI 10.5935/0004-2749.20140044
PG 5
WC Ophthalmology
SC Ophthalmology
GA AR5PR
UT WOS:000343636700010
PM 25295905
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Bardal, RC
   Badaro, E
   Arana, J
   Alves, F
   De Souza, EC
   Bonomo, PP
   Portella, E
   Maia, M
AF Bardal, Ricardo Canto
   Badaro, Emmerson
   Arana, Jayme
   Alves, Fabio
   De Souza, Eduardo Cunha
   Bonomo, Pedro Paulo
   Portella, Ezequiel
   Maia, Mauricio
TI Susac syndrome: diverse clinical findings and treatment
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Susac syndrome; Retinal artery occlusion; Hearing loss; Corpus callosum;
   Fluorescein angiography; Humans; Female; Adult; Case reports
AB We report a case of a 19-year-old woman presenting bilateral neurosensorial hearing loss, mental abnormalities, and loss of visual field in the left eye. Visual acuity was 20/20 in OD and 20/25 in OS. Patient was examined systemically. Audiometry showed sensorineural hearing loss in both ears. The magnetic resonance imaging (MRI) of brain revealed multiple small lesions in the white matter in both cerebral hemispheres and at the corpus callosum. Fundoscopy showed bilateral normal optic disc and sheathing of the arterioles in the middle periphery of OD. Retinal edema and cotton-wool spots were observed. Fluorescein angiography showed bilateral peripheral occlusive arterial vasculopathy. The patient was diagnosed with Susac syndrome and treated with quetiapine fumarate, flunitrazepam, and prednisone, which resulted in stabile outcome. This case shows that a high index of suspicion leading to early recognition and treatment is important to avoid irreversible damage.
C1 Hosp Evangel, Dept Ophthalmol, Curitiba, Parana, Brazil.
   Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
RP Maia, M (corresponding author), Rua Otto Ribeiro 901, BR-19840050 Assis, SP, Brazil.
EM maiamauricio@terra.com.br
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
CR COPPETO JR, 1984, AM J OPHTHALMOL, V98, P189, DOI 10.1016/0002-9394(87)90354-0
   Dorr J, 2011, NERVENARZT, V82, P1250, DOI 10.1007/s00115-011-3280-0
   Egan RA, 2003, AM J OPHTHALMOL, V135, P483, DOI 10.1016/S0002-9394(02)02085-8
   Milbratz GH, 2009, ARQ BRAS OFTALMOL, V72, P397, DOI 10.1590/S0004-27492009000300024
   Naacke H, 2003, J FR OPHTALMOL, V26, P284
   Rennebohm R, 2010, J NEUROL SCI, V299, P86, DOI 10.1016/j.jns.2010.08.032
   Rennebohm RM, 2007, J NEUROL SCI, V257, P215, DOI 10.1016/j.jns.2007.01.031
   Susac JO, 2007, J NEUROL SCI, V257, P270, DOI 10.1016/j.jns.2007.01.036
NR 8
TC 2
Z9 2
U1 0
U2 2
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAY-JUN
PY 2014
VL 77
IS 3
BP 188
EP 190
DI 10.5935/0004-2749.20140048
PG 3
WC Ophthalmology
SC Ophthalmology
GA AR5PR
UT WOS:000343636700014
PM 25295909
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Pisaniello, AD
   Dundon, BK
   Maia, M
   Teo, KSL
   Worthley, SG
   Bannister, KM
   Faull, RJ
   Coates, PT
   Russ, GR
   Worthley, MI
AF Pisaniello, A. D.
   Dundon, B. K.
   Maia, M.
   Teo, K. S. L.
   Worthley, S. G.
   Bannister, K. M.
   Faull, R. J.
   Coates, P. T.
   Russ, G. R.
   Worthley, M., I
TI DOBUTAMINE STRESS CARDIAC MRI RELIABLY PREDICTS SIGNIFICANT CORONARY
   DISEASE IN RENAL TRANSPLANT CANDIDATES
SO INTERNAL MEDICINE JOURNAL
LA English
DT Meeting Abstract
C1 [Pisaniello, A. D.; Maia, M.; Teo, K. S. L.; Worthley, S. G.; Worthley, M., I] Royal Adelaide Hosp, Cardiol Unit, Adelaide, SA 5000, Australia.
   [Pisaniello, A. D.; Teo, K. S. L.; Worthley, S. G.; Bannister, K. M.; Faull, R. J.; Coates, P. T.; Russ, G. R.; Worthley, M., I] Univ Adelaide, Discipline Med, Adelaide, SA 5005, Australia.
   [Dundon, B. K.] Monash Med Ctr, Cardiol Unit, Melbourne, Vic, Australia.
   [Bannister, K. M.; Faull, R. J.; Coates, P. T.; Russ, G. R.] Royal Adelaide Hosp, Cent Northern Adelaide Renal & Transplantat Serv, Adelaide, SA 5000, Australia.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1444-0903
EI 1445-5994
J9 INTERN MED J
JI Intern. Med. J.
PD MAY
PY 2014
VL 44
SU 3
SI SI
BP 21
EP 21
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA AH1MJ
UT WOS:000335884600076
DA 2020-12-15
ER

PT J
AU Nunes, RP
   Rodrigues, E
   Hirai, FE
   Barroso, LF
   Novais, E
   Badaro, E
   Magalhaes, O
   Maia, M
   Farah, M
AF Nunes, Renata Portella
   Rodrigues, Eduardo
   Hirai, Flavio E.
   Barroso, Leticia Fernandes
   Novais, Eduardo
   Badaro, Emmerson
   Magalhaes, Octaviano
   Maia, Mauricio
   Farah, Michel
TI Efficacy and cost-effectiveness of anti-VEGF treatments for age-related
   macular degeneration (AMD)
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
DE 412 age-related macular degeneration; 453 choroid: neovascularization;
   688 retina
C1 [Nunes, Renata Portella; Rodrigues, Eduardo; Hirai, Flavio E.; Barroso, Leticia Fernandes; Novais, Eduardo; Badaro, Emmerson; Magalhaes, Octaviano; Maia, Mauricio; Farah, Michel] Univ Sao Paulo, Paulista Sch Med, Ophthalmol & Visual Sci Dept, Sao Paulo, Brazil.
RI Hirai, Flavio E/G-3583-2012; Farah, Michel Eid E/F-3285-2012; Maia,
   Mauricio/I-5892-2015
OI Hirai, Flavio E/0000-0002-5757-4254; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2014
VL 55
IS 13
MA 4939
PG 3
WC Ophthalmology
SC Ophthalmology
GA VC2FU
UT WOS:000433205502104
DA 2020-12-15
ER

PT J
AU Maia, M
   Furlani, BA
   Souza-Lima, AA
   Martins, DS
   Navarro, RM
   Belfort, R
AF Maia, Mauricio
   Furlani, Bruno A.
   Souza-Lima, Acacio A.
   Martins, Diogo S.
   Navarro, Rodrigo M.
   Belfort, Rubens, Jr.
TI LUTEIN A New Dye for Chromovitrectomy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE chromovitrectomy; internal limiting membrane; lutein; zeaxanthin;
   macular hole; vitreoretinal surgery
ID INTERNAL LIMITING MEMBRANE; MACULAR HOLE SURGERY; INDOCYANINE GREEN
   INJECTION; TRYPAN BLUE; PIGMENT; ZEAXANTHIN; CAROTENOIDS;
   SUPPLEMENTATION; DEGENERATION; RABBITS
AB Purpose: To evaluate the feasibility, advantages, and safety of a novel lutein-based dye for improving identification and removal of the vitreous, internal limiting membrane, and epiretinal membrane during chromovitrectomy in humans.
   Methods: We prospectively evaluated 12 eyes that underwent pars plana vitrectomy using the dye in patients with macular hole, epiretinal membrane, or proliferative diabetic retinopathy/tractional diabetic macular edema. One surgeon performed standard chromovitrectomy and completed a postoperative questionnaire to compare the staining with that of the available dyes. The peeled membranes were evaluated histologically. Follow-up examinations were performed on postoperative Days 1, 7, 30, 90 and 180; best-corrected visual acuity, optical coherence tomography, fluorescein angiography, autofluorescence, and visual fields were performed.
   Results: The green dye was deposited on the posterior pole because of its higher density than balanced saline solution; vigorous dye flushing into the vitreous cavity was unnecessary. The dye stained the posterior hyaloid/vitreous base by deposition onto the vitreous; brilliant blue stained the internal limiting membrane. The epiretinal membrane was poorly stained. The best-corrected visual acuity improved in all eyes without clinical toxicity or toxicity on images/visual fields. Histology showed effective removal of the internal limiting membrane and epiretinal membrane in all eyes.
   Conclusion: The new dye improved intraoperative identification of the internal limiting membrane and the posterior hyaloid/ vitreous base during chromovitrectomy.
C1 [Maia, Mauricio; Furlani, Bruno A.; Souza-Lima, Acacio A.; Martins, Diogo S.; Navarro, Rodrigo M.; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Dept Ophthalmol, BR-06023062 Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Vitreoretinal Surg Unit, Rua Botucatu 822, BR-06023062 Sao Paulo, Brazil.
EM retina@femanet.com.br
RI de Souza Lima Filho, Acacio Alves/C-7189-2012; Maia,
   Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; Sousa-Martins,
   Diogo/B-1554-2019; Belfort Jr, Rubens/E-2252-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Sousa-Martins, Diogo/0000-0002-2285-3990; Belfort Jr,
   Rubens/0000-0002-8422-3898; Alves de Souza Lima Filho,
   Acacio/0000-0003-1802-9592
CR Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Feron EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P141
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kumar Atul, 2004, Indian J Ophthalmol, V52, P339
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Lim JW, 2010, CLIN OPHTHALMOL, V4, P689
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   Oberstein SYL, 2010, EYE, V24, P1177, DOI 10.1038/eye.2010.3
   Perrier M, 2003, AM J OPHTHALMOL, V135, P909, DOI 10.1016/S0002-9394(02)02256-0
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sousa-Martins D, 2012, RETINA-J RET VIT DIS, V32, P1328, DOI 10.1097/IAE.0b013e318239e2b6
   Stahl W, 2005, DEV OPHTHALMOL, V38, P70, DOI 10.1159/000082768
   Teba FA, 2003, OPHTHALMOLOGY, V110, P2409, DOI 10.1016/S0161-6420(03)00716-4
   Trevithick-Sutton CC, 2006, MOL VIS, V12, P1127
   Yamashita T, 2008, RETINA-J RET VIT DIS, V28, P1228, DOI 10.1097/IAE.0b013e31817b6b2e
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
NR 33
TC 10
Z9 11
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2014
VL 34
IS 2
BP 262
EP 272
DI 10.1097/IAE.0b013e3182a0b7f4
PG 11
WC Ophthalmology
SC Ophthalmology
GA AI6DF
UT WOS:000336959400009
PM 23917540
DA 2020-12-15
ER

PT J
AU Tanaka, LMS
   Azevedo, LCP
   Park, M
   Schettino, G
   Nassar, AP
   Rea-Neto, A
   Tannous, L
   de Souza-Dantas, VC
   Torelly, A
   Lisboa, T
   Piras, C
   Carvalho, FB
   Maia, MD
   Giannini, FP
   Machado, FR
   Dal-Pizzol, F
   de Carvalho, AGR
   dos Santos, RB
   Tierno, PFGMM
   Soares, M
   Salluh, JIF
AF Sobreira Tanaka, Lilian Maria
   Pontes Azevedo, Luciano Cesar
   Park, Marcelo
   Schettino, Guilherme
   Nassar, Antonio Paulo, Jr.
   Rea-Neto, Alvaro
   Tannous, Luana
   de Souza-Dantas, Vicente Ces
   Torelly, Andre
   Lisboa, Thiago
   Piras, Claudio
   Carvalho, Frederico Bruzzi
   Maia, Marcelo de Oliveira
   Giannini, Fabio Poianas
   Machado, Flavia Ribeiro
   Dal-Pizzol, Felipe
   Ribeiro de Carvalho, Alexandre Guilherme
   dos Santos, Ronaldo Batista
   Morando Marzocchi Tierno, Paulo Fernando Guimaraes
   Soares, Marcio
   Figueira Salluh, Jorge Ibrain
CA ERICC Study Investigators
TI Early sedation and clinical outcomes of mechanically ventilated
   patients: a prospective multicenter cohort study
SO CRITICAL CARE
LA English
DT Article
ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; LONG-TERM MORTALITY; ACUTE
   LUNG INJURY; DELIRIUM; DEXMEDETOMIDINE; ICU; ANALGESIA; AGITATION;
   MIDAZOLAM
AB Introduction: Sedation overuse is frequent and possibly associated with poor outcomes in the intensive care unit (ICU) patients. However, the association of early oversedation with clinical outcomes has not been thoroughly evaluated. The aim of this study was to assess the association of early sedation strategies with outcomes of critically ill adult patients under mechanical ventilation (MV).
   Methods: A secondary analysis of a multicenter prospective cohort conducted in 45 Brazilian ICUs, including adult patients requiring ventilatory support and sedation in the first 48 hours of ICU admissions, was performed. Sedation depth was evaluated after 48 hours of MV. Multivariate analysis was used to identify variables associated with hospital mortality.
   Results: A total of 322 patients were evaluated. Overall, ICU and hospital mortality rates were 30.4% and 38.8%, respectively. Deep sedation was observed in 113 patients (35.1%). Longer duration of ventilatory support was observed (7 (4 to 10) versus 5 (3 to 9) days, P = 0.041) and more tracheostomies were performed in the deep sedation group (38.9% versus 22%, P=0.001) despite similar PaO2/FiO(2) ratios and acute respiratory distress syndrome (ARDS) severity. In a multivariate analysis, age (Odds Ratio (OR) 1.02; 95% confidence interval (CI) 1.00 to 1.03), Charlson Comorbidity Index >2 (OR 2.06; 95% Cl, 1.44 to 2.94), Simplified Acute Physiology Score 3 (SAPS 3) score (OR 1.02; Cl 95%, 1.00 to 1.04), severe ARDS (OR 1.44; Cl 95%, 1.09 to 1.91) and deep sedation (OR 2.36; Cl 9596, 1.31 to 4.25) were independently associated with increased hospital mortality.
   Conclusions: Early deep sedation is associated with adverse outcomes and constitutes an independent predictor of hospital mortality in mechanically ventilated patients.
C1 [Sobreira Tanaka, Lilian Maria] Hosp Copa DOr, BR-22031010 Rio De Janeiro, Brazil.
   [Pontes Azevedo, Luciano Cesar; Park, Marcelo; Schettino, Guilherme] Hosp Sirio Libanes, Res & Educ Inst, BR-01308060 Sao Paulo, Brazil.
   [Pontes Azevedo, Luciano Cesar; Park, Marcelo] Univ Sao Paulo, Fac Med, Hosp Clin, ICU,Emergency Med Dept, BR-05403000 Sao Paulo, Brazil.
   [Nassar, Antonio Paulo, Jr.] Hosp Sao Camilo Pompeia, ICU, BR-05022000 Sao Paulo, Brazil.
   [Rea-Neto, Alvaro; Tannous, Luana] CEPETI, BR-82530200 Curitiba, Parana, Brazil.
   [de Souza-Dantas, Vicente Ces] Hosp Canc I, Inst Nacl Canc, ICU, BR-20230130 Rio De Janeiro, Brazil.
   [de Souza-Dantas, Vicente Ces] Pasteur Hosp, ICU, BR-20735040 Rio De Janeiro, Brazil.
   [Torelly, Andre; Lisboa, Thiago] Irmandade Santa Casa Misericordia Porto Alegre, RIPIMI, BR-90020090 Porto Alegre, RS, Brazil.
   [Piras, Claudio] Vitoria Apart Hosp, ICU, BR-29161900 Serra, ES, Brazil.
   [Carvalho, Frederico Bruzzi] Hosp Mater Dei, ICU, BR-30140093 Belo Horizonte, MG, Brazil.
   [Maia, Marcelo de Oliveira] Hosp Santa Luzia, ICU, BR-70390902 Brasilia, DF, Brazil.
   [Giannini, Fabio Poianas] Hosp Sao Luiz, ICU, BR-04544000 Sao Paulo, Brazil.
   [Machado, Flavia Ribeiro] Univ Fed Sao Paulo, Anesthesiol Pain & Intens Care Dept, ICU, BR-04024900 Sao Paulo, Brazil.
   [Dal-Pizzol, Felipe] Hosp Sao Jose Criciuma, ICU, BR-88801250 Criciuma, Brazil.
   [Ribeiro de Carvalho, Alexandre Guilherme] UDI Hosp, ICU, BR-65076820 Sao Luis, Brazil.
   [dos Santos, Ronaldo Batista] Univ Sao Paulo, Univ Hosp, ICU, BR-05508000 Sao Paulo, Brazil.
   [Morando Marzocchi Tierno, Paulo Fernando Guimaraes] Univ Sao Paulo, Fac Med, Hosp Clin, ICU,Surg Emergency Dept, BR-05403000 Sao Paulo, Brazil.
   [Soares, Marcio; Figueira Salluh, Jorge Ibrain] IDOR DOr Inst Res & Educ, BR-22281100 Rio De Janeiro, Brazil.
   [Soares, Marcio; Figueira Salluh, Jorge Ibrain] Inst Nacl Canc, Postgrad Program, BR-20230130 Rio De Janeiro, Brazil.
RP Salluh, JIF (corresponding author), IDOR DOr Inst Res & Educ, Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, Brazil.
EM jorgesalluh@gmail.com
RI Santos, Ronaldo/U-4747-2019; Carvalho, Frederico B/J-4879-2012; Lisboa,
   Thiago/W-2973-2019; Rea-Neto, Alvaro/AAR-7909-2020; Soares,
   Marcio/B-3083-2013; Tanaka, Lilian/U-8569-2019; dantas, vicente c
   souza/L-2648-2013; Maia, Mauricio/I-5892-2015; Nassar, Antonio
   P/I-5508-2015; Maia, Mauricio/Z-1042-2019; Azevedo, Luciano
   CP/H-2652-2012; Dal-Pizzol, Felipe/F-2756-2015
OI Carvalho, Frederico B/0000-0002-9752-5625; Lisboa,
   Thiago/0000-0003-4306-2212; Rea-Neto, Alvaro/0000-0001-5524-0907;
   Soares, Marcio/0000-0003-2503-6088; Tanaka, Lilian/0000-0002-4678-5558;
   Maia, Mauricio/0000-0002-7034-8091; Nassar, Antonio
   P/0000-0002-0522-7445; Maia, Mauricio/0000-0002-7034-8091; Azevedo,
   Luciano CP/0000-0001-6759-3910; Dal-Pizzol, Felipe/0000-0003-3003-8977
FU Research and Education Institute from Hospital Sirio-Libanes, Sao Paulo;
   D'Or Institute for Research and Education, Rio de Janeiro, Brazil;
   Brazilian Research in Intensive Care Network
FX This study was funded by the Research and Education Institute from
   Hospital Sirio-Libanes, Sao Paulo and the D'Or Institute for Research
   and Education, Rio de Janeiro, Brazil. The funding institutions had no
   active role in the design, analysis and interpretation of the results or
   in the publication process. The study was supported by the Brazilian
   Research in Intensive Care Network.
CR Benitez-Rosario MA, 2013, J PAIN SYMPTOM MANAG, V45, P1112, DOI 10.1016/j.jpainsymman.2012.05.015
   Arabi Yaseen, 2007, Middle East Journal of Anesthesiology, V19, P429
   Arroliga AC, 2008, CRIT CARE MED, V36, P1083, DOI 10.1097/CCM.0B013E3181653895
   Awissi DK, 2012, ANN PHARMACOTHER, V46, P21, DOI 10.1345/aph.1Q284
   Azevedo LCP, 2013, CRIT CARE, V17, DOI 10.1186/cc12594
   Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72
   Bellomo R, 2007, CURR OPIN ANESTHESIO, V20, P100, DOI 10.1097/ACO.0b013e32802c7cd5
   Bucknall TK, 2008, CRIT CARE MED, V36, P1444, DOI 10.1097/CCM.0b013e318168f82d
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Dasta JF, 2010, CRIT CARE MED, V38, P497, DOI 10.1097/CCM.0b013e3181bc81c9
   Devlin JW, 2009, CRIT CARE CLIN, V25, P431, DOI 10.1016/j.ccc.2009.03.003
   Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983
   Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753
   Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625
   Granja C, 2008, CRIT CARE MED, V36, P2801, DOI 10.1097/CCM.0b013e318186a3e7
   Ho BCH, 2006, CRIT CARE, V10, DOI 10.1186/cc4918
   Hughes CG, 2012, CLIN PHARMACOL-ADV A, V4, P53, DOI 10.2147/CPAA.S26582
   Jackson DL, 2010, CRIT CARE, V14, DOI 10.1186/cc8956
   Jackson JC, 2010, AM J RESP CRIT CARE, V182, P183, DOI 10.1164/rccm.200903-0442OC
   Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304
   Judson JA, 2006, CRIT CARE CLIN, V22, P407, DOI 10.1016/j.ccc.2006.03.012
   Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
   Mansouri P, 2013, J CRIT CARE, V28, P918, DOI 10.1016/j.jcrc.2013.06.019
   Mascia MF, 2000, CRIT CARE MED, V28, P2300, DOI 10.1097/00003246-200007000-00019
   Mehta S, 2012, JAMA-J AM MED ASSOC, V308, P1985, DOI 10.1001/jama.2012.13872
   Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5
   MOULTON C, 1991, BRIT MED J, V303, P1240, DOI 10.1136/bmj.303.6812.1240
   Nelson BJ, 2000, CRIT CARE MED, V28, P3626, DOI 10.1097/00003246-200011000-00013
   Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644
   Patel RP, 2009, CRIT CARE MED, V37, P825, DOI 10.1097/CCM.0b013e31819b8608
   Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da
   Pun BT, 2013, SEMIN RESP CRIT CARE, V34, P223, DOI 10.1055/s-0033-1342985
   Puntillo KA, 2014, AM J RESP CRIT CARE, V189, P39, DOI 10.1164/rccm.201306-1174OC
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56
   Rosolem MM, 2012, J CRIT CARE, V27, P301, DOI 10.1016/j.jcrc.2011.06.014
   Salluh JI, 2010, CRIT CARE, V14, DOI 10.1186/cc9333
   Salluh JIF, 2009, J CRIT CARE, V24, P556, DOI 10.1016/j.jcrc.2009.04.004
   Sessler CN, 2012, AM J RESP CRIT CARE, V166, P1338
   Shehabi Y, 2013, INTENS CARE MED, V39, P910, DOI 10.1007/s00134-013-2830-2
   Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC
   Shehabi Y, 2010, CRIT CARE MED, V38, P2311, DOI 10.1097/CCM.0b013e3181f85759
   Shinotsuka Cassia Righy, 2013, Rev. bras. ter. intensiva, V25, P155, DOI 10.5935/0103-507X.20130027
   TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156
NR 45
TC 58
Z9 70
U1 2
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PY 2014
VL 18
IS 4
AR R156
DI 10.1186/cc13995
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA CA4MJ
UT WOS:000348878200040
PM 25047960
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Diniz, B
   Ribeiro, R
   Heussen, FM
   Maia, M
   Sadda, S
AF Diniz, Bruno
   Ribeiro, Ramiro
   Heussen, Florian M.
   Maia, Mauricio
   Sadda, Srinivas
TI DRUSEN MEASUREMENTS COMPARISON BY FUNDUS PHOTOGRAPH MANUAL DELINEATION
   VERSUS OPTICAL COHERENCE TOMOGRAPHY RETINAL PIGMENT EPITHELIAL
   SEGMENTATION AUTOMATED ANALYSIS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE drusen; optical coherence tomography; retinal pigment epithelial;
   algorithm
ID AGE-RELATED MACULOPATHY; SCANNING LASER OPHTHALMOSCOPY; SIMPLIFIED
   SEVERITY SCALE; MACULAR DEGENERATION; EYE DISEASE; GEOGRAPHIC ATROPHY;
   VISUAL IMPAIRMENT; SD-OCT; AREDS; PERFORMANCE
AB Purpose: To compare drusen measurements obtained from color fundus and infrared retromode photographs with those derived from spectral-domain optical coherence tomography.
   Methods: Drusen lesions identified on the planar (color and infrared) imaging modalities were manually segmented by two independent graders using previously described reading center software to produce quantitative measurements of drusen area and number. The corresponding volume Cirrus OCT datasets were analyzed using commercial retinal pigment epithelium analysis algorithms to segment the retinal pigment epithelium band and estimated the drusen area. Drusen numbers were extracted from retinal pigment epithelium elevation maps. Intraclass correlation coefficients assessed agreement between graders; graders' average measurements were compared with optical coherence tomography (OCT) using paired T-tests.
   Results: Excellent agreement between graders was observed (r = 0.951-0.974). No statistical difference was found in the area values obtained by color (0.85 +/- 0.26 mm(2), P = 0.43) or retromode (1.15 +/- 0.32 mm(2), P = 0.35) compared with those obtained by OCT (0.98 +/- 0.28 mm(2)). The number of drusen identified by OCT (13.15 +/- 3.19) was significantly lower than that determined by manual segmentation of color (53.7 +/- 13.18) and retromode (100.13 +/- 16.18) images.
   Conclusion: Although the number of drusen individualized by commercial OCT algorithms is significantly lower than by planar fundus imaging modalities, the OCT-measured drusen area is not affected, suggesting that the algorithm counts confluent drusen as a single drusen.
C1 [Diniz, Bruno; Ribeiro, Ramiro; Heussen, Florian M.; Sadda, Srinivas] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Diniz, Bruno; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Ribeiro, Ramiro] Evangel Hosp Curitiba, Dept Ophthalmol, Curitiba, Parana, Brazil.
   [Sadda, Srinivas] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
RP Sadda, S (corresponding author), Doheny Eye Inst, 1450 San Pablo St,DEI 3623, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
FU National Eye InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Eye
   Institute (NEI) [EY03040]; Beckman Institute for Macular Research;
   Research to Prevent BlindnessResearch to Prevent Blindness (RPB);
   Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG
   He6094/1-1]; CAPES Foundation (Brasilia, Brazil)CAPES; Optos; Optovue;
   Carl Zeiss Meditec
FX Supported in part by National Eye Institute grant for basic research
   EY03040, the Beckman Institute for Macular Research, Research to Prevent
   Blindness, a Research to Prevent Blindness Physician Scientist Award,
   the Deutsche Forschungsgemeinschaft (DFG He6094/1-1), and CAPES
   Foundation (Brasilia, Brazil).; Dr. S. Sadda previously shared in
   royalties from intellectual property licensed by the Doheny Eye
   Institute to Topcon Medical Systems. He also previously served on the
   Scientific Advisory Board for Heidelberg Engineering. He receives
   research support from Optos, Optovue, and Carl Zeiss Meditec. The
   remaining authors have no conflicting interests to disclose.
CR Acton JH, 2011, ACTA OPHTHALMOL, V89, pE404, DOI 10.1111/j.1755-3768.2011.02123.x
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Diniz B, 2013, BRIT J OPHTHALMOL, V97, P285, DOI 10.1136/bjophthalmol-2012-302575
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Ishiko S, 2002, OPHTHALMOLOGY, V109, P2165, DOI 10.1016/S0161-6420(02)01227-7
   Iwama D, 2012, INVEST OPHTH VIS SCI, V53, P1576, DOI 10.1167/iovs.11-8103
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Mitchell P, 2005, ARCH OPHTHALMOL-CHIC, V123, P1598, DOI 10.1001/archopht.123.11.1598
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schlanitz FG, 2010, INVEST OPHTH VIS SCI, V51, P6715, DOI 10.1167/iovs.10-5288
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Yehoshua Zohar, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS6, DOI 10.3928/15428877-20101031-19
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
NR 27
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2014
VL 34
IS 1
BP 55
EP 62
DI 10.1097/IAE.0b013e31829d0015
PG 8
WC Ophthalmology
SC Ophthalmology
GA AI6CZ
UT WOS:000336958700010
PM 24096882
DA 2020-12-15
ER

PT J
AU Prazeres, J
   Magalhaes, O
   Lucatto, LFA
   Navarro, RM
   Moraes, NS
   Farah, ME
   Maia, A
   Maia, M
AF Prazeres, Juliana
   Magalhaes, Octaviano, Jr.
   Lucatto, Luiz F. A.
   Navarro, Rodrigo Milan
   Moraes, Nilva S.
   Farah, Michel E.
   Maia, Andre
   Maia, Mauricio
TI Heavy Silicone Oil as a Long-Term Endotamponade Agent for Complicated
   Retinal Detachments
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID INTRAOCULAR TAMPONADE; INTERNAL TAMPONADE; OXANE HD; DENSIRON-68;
   OIL-RMN3
AB We retrospectively evaluated a heavy silicone oil (HSO) as a long-term intraocular endotamponade agent to treat complicated RD by inferior PVR in 25 eyes of 25 patients. Patients underwent PPV and injection of Oxane HD as an internal tamponade agent. A comparison of preoperative and postoperative BCVA at month 1, month 6, and last visit was made in the group in which HSO was removed and in the group in which HSO was not removed. Statistical calculations were performed using the Wilcoxon test. The HSO was removed from 11 patients after a mean of 26.55 +/- 21.38 months. The HSO remained inside the vitreous cavity in 14 eyes due to a high chance of PVR recurrence (mean follow-up period, 11.07 +/- 7.44 months). Anatomic success was achieved in 92%. The BCVA in the group, in which HSO was not removed, improved significantly during the first 6 months. Among the patients who had the oil removed, there was improvement in BCVA after 1 month. Oil emulsification was the most common adverse effect in 52% of eyes. HSO is an effective tamponade in complex rhegmatogenous and tractional RD complicated by PVR. HSO can remain in the eye for long periods with relative tolerability and safety.
C1 [Prazeres, Juliana; Magalhaes, Octaviano, Jr.; Lucatto, Luiz F. A.; Navarro, Rodrigo Milan; Moraes, Nilva S.; Farah, Michel E.; Maia, Andre; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Vitreoretinal Dis Unit, BR-04023062 Sao Paulo, Brazil.
   [Navarro, Rodrigo Milan; Maia, Mauricio] Brazilian Inst Fight Blindness, BR-19814050 Assis, SP, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Vitreoretinal Dis Unit, Botucatu St 862, BR-04023062 Sao Paulo, Brazil.
EM maiamauricio@terra.com.br
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015; Maia,
   Mauricio/Z-1042-2019
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
CR Boscia F, 2008, GRAEF ARCH CLIN EXP, V246, P943, DOI 10.1007/s00417-008-0806-7
   Duan AL, 2011, RETINA-J RET VIT DIS, V31, P547, DOI 10.1097/IAE.0b013e3181eef2fd
   FISK MJ, 1995, AUST NZ J OPHTHALMOL, V23, P25, DOI 10.1111/j.1442-9071.1995.tb01641.x
   Han L, 1998, AUST NZ J OPHTHALMOL, V26, P299, DOI 10.1111/j.1442-9071.1998.tb01333.x
   Herbrig E, 2007, OPHTHALMIC RES, V39, P198, DOI 10.1159/000104681
   Hussain RN, 2011, CLIN OPHTHALMOL, V5, P603, DOI 10.2147/OPTH.S17753
   Joussen AM, 2007, ACTA OPHTHALMOL SCAN, V85, P623, DOI 10.1111/j.1600-0420.2007.00898.x
   Kocak I, 2013, INT J OPHTHALMOL-CHI, V6, P81, DOI 10.3980/j.issn.2222-3959.2013.01.17
   Levasseur SD, 2013, RETINA-J RET VIT DIS, V33, P627, DOI 10.1097/IAE.0b013e3182725d49
   MACHEMER R, 1991, AM J OPHTHALMOL, V112, P159, DOI 10.1016/S0002-9394(14)76695-4
   Meng QL, 2010, GRAEF ARCH CLIN EXP, V248, P1091, DOI 10.1007/s00417-010-1351-8
   Ozdek S, 2011, CAN J OPHTHALMOL, V46, P51, DOI 10.3129/i10-107
   PETERSEN J, 1987, GRAEF ARCH CLIN EXP, V225, P452, DOI 10.1007/BF02334175
   Rizzo S, 2005, GRAEF ARCH CLIN EXP, V243, P1153, DOI 10.1007/s00417-005-0015-6
   Romano MR, 2008, GRAEF ARCH CLIN EXP, V246, P1541, DOI 10.1007/s00417-008-0894-4
   Romano MR, 2012, CURR EYE RES, V37, P563, DOI 10.3109/02713683.2012.669511
   Sandner D, 2006, GRAEF ARCH CLIN EXP, V244, P609, DOI 10.1007/s00417-005-0110-8
   Sandner D, 2007, GRAEF ARCH CLIN EXP, V245, P1097, DOI 10.1007/s00417-006-0496-y
   Scheer S, 2006, J FR OPHTALMOL, V29, P129, DOI 10.1016/S0181-5512(06)73760-3
   Scholda C, 1997, ACTA OPHTHALMOL SCAN, V75, P695
   Scholda C, 2000, ACTA OPHTHALMOL SCAN, V78, P182, DOI 10.1034/j.1600-0420.2000.078002182.x
   Theelen T, 2004, GRAEF ARCH CLIN EXP, V242, P617, DOI 10.1007/s00417-004-0898-7
   VANMEURS JC, 1993, RETINA-J RET VIT DIS, V13, P285, DOI 10.1097/00006982-199313040-00003
   Wolf S, 2003, RETINA-J RET VIT DIS, V23, P335, DOI 10.1097/00006982-200306000-00008
   Wong D, 2009, EYE, V23, P190, DOI 10.1038/sj.eye.6703055
NR 25
TC 8
Z9 8
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 136031
DI 10.1155/2014/136031
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AF9IN
UT WOS:000335028700001
PM 24822176
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Stefanini, FR
   Badaro, E
   Falabella, P
   Koss, M
   Farah, ME
   Maia, M
AF Stefanini, Francisco Rosa
   Badaro, Emmerson
   Falabella, Paulo
   Koss, Michael
   Farah, Michel Eid
   Maia, Mauricio
TI Anti-VEGF for the Management of Diabetic Macular Edema
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; RANDOMIZED-TRIAL;
   TRAP-EYE; VISUAL IMPAIRMENT; DEFERRED LASER; DA VINCI; RANIBIZUMAB;
   TRIAMCINOLONE; PHOTOCOAGULATION
AB Diabetic retinopathy (DR) is an important cause of vision loss around the world, being the leading cause in the population between 20 and 60 years old. Among patients with DR, diabetic macular edema (DME) is the most frequent cause of vision impairment and represents a significant public health issue. Macular photocoagulation has been the standard treatment for this condition reducing the risk of moderate visual loss by approximately 50%. The role of vascular endothelial growth factor (VEGF) in DR and DME pathogenesis has been demonstrated in recent studies. This review addresses and summarizes data from the clinical trials that investigated anti-VEGF for the management of DME and evaluates their impact on clinical practice. The literature searches were conducted between August and October 2013 in PubMed and Cochrane Library with no date restrictions and went through the most relevant studies on pegaptanib, ranibizumab, bevacizumab, and aflibercept for the management of DME. The efficacy and safety of intravitreal anti-VEGF as therapy for DME have recently been proved by various clinical trials providing significantly positive visual and anatomical results. Regarding clinical practice, those outcomes have placed intravitreal injection of anti-VEGF as an option that must be considered for the treatment of DME.
C1 [Stefanini, Francisco Rosa; Badaro, Emmerson; Falabella, Paulo; Farah, Michel Eid; Maia, Mauricio] Fed Univ Sao Paulo UNIFESP, Dept Ophthalmol & Visual Sci, Retina Div, BR-04023062 Sao Paulo, Brazil.
   [Stefanini, Francisco Rosa; Falabella, Paulo; Koss, Michael] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Doheny Eye Inst, Los Angeles, CA USA.
   [Koss, Michael; Maia, Mauricio] Goethe Univ Frankfurt, Dept Ophthalmol, D-60590 Frankfurt, Germany.
RP Stefanini, FR (corresponding author), Fed Univ Sao Paulo UNIFESP, Dept Ophthalmol & Visual Sci, Retina Div, 821 Botucatu St,2nd Floor, BR-04023062 Sao Paulo, Brazil.
EM fstefanini@doheny.org
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Falabella, Paulo/0000-0001-8773-7168
CR Administration USFaD, 2012, FDA APPR LUC TREAT D
   Administration USFaD, 2004, FDA APPR NEW DRUG TR
   Administration USFaD, 2011, FDA APPR EYL EYE DIS
   Arevalo J. F., 2009, OPHTHALMOLOGY, V116
   Arevalo JF, 2007, OPHTHALMOLOGY, V114, P743, DOI 10.1016/j.ophtha.2006.12.028
   Arevalo JF, 2013, WORLD J DIABETES, V4, P231, DOI [10.4239/wjd.v4.i2.19, 10.4239/wjd.v4.i6.231]
   Arevalo JF, 2009, GRAEF ARCH CLIN EXP, V247, P735, DOI 10.1007/s00417-008-1034-x
   Beck RW, 2009, ARCH OPHTHALMOL-CHIC, V127, P245, DOI 10.1001/archophthalmol.2008.610
   Bressler SB, 2013, JAMA OPHTHALMOL, V131, P1033, DOI 10.1001/jamaophthalmol.2013.4154
   Brown D. M., 2013, P 46 RET SOC ANN SCI
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   de Faria JML, 1999, ACTA OPHTHALMOL SCAN, V77, P170
   Do DV, 2009, BRIT J OPHTHALMOL, V93, P144, DOI 10.1136/bjo.2008.138271
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Do DV, 2011, OPHTHALMOLOGY, V118, P1819, DOI 10.1016/j.ophtha.2011.02.018
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Elman MJ, 2012, OPHTHALMOLOGY, V119, P2312, DOI 10.1016/j.ophtha.2012.08.022
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1447, DOI 10.1016/j.ophtha.2008.06.015
   Klein BEK, 2007, OPHTHAL EPIDEMIOL, V14, P179, DOI 10.1080/09286580701396720
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464
   Lam DSC, 2009, RETINA-J RET VIT DIS, V29, P292, DOI 10.1097/IAE.0b013e31819a2d61
   Lang GE, 2011, KLIN MONATSBL AUGENH, V228, pR1, DOI 10.1055/s-0030-1250754
   Lang GE, 2012, OPHTHALMOLOGICA, V227, P21, DOI 10.1159/000337156
   Malik VS, 2013, NAT REV ENDOCRINOL, V9, P13, DOI 10.1038/nrendo.2012.199
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Michaelides M, 2010, OPHTHALMOLOGY, V117
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Nguyen Q. D., 2006, AM J OPHTHALMOL, V142
   Nguyen QD, 2009, OPHTHALMOLOGY, V116
   Nicholson BP, 2010, GRAEF ARCH CLIN EXP, V248, P915, DOI 10.1007/s00417-010-1315-z
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Pontiroli AE, 1998, ACTA DIABETOL, V35, P130, DOI 10.1007/s005920050117
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rajendram R, 2012, ARCH OPHTHALMOL-CHIC, V130, P972, DOI 10.1001/archophthalmol.2012.393
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Soheilian M, 2012, RETINA-J RET VIT DIS, V32, P314, DOI 10.1097/IAE.0b013e31822f55de
   Soheilian M, 2009, OPHTHALMOLOGY, V116, P1142, DOI 10.1016/j.ophtha.2009.01.011
   Sultan MB, 2011, OPHTHALMOLOGY, V118, P1107, DOI 10.1016/j.ophtha.2011.02.045
   Tranos PG, 2004, SURV OPHTHALMOL, V49, P470, DOI 10.1016/j.survophthal.2004.06.002
   Yilmaz T, 2011, ACTA OPHTHALMOL, V89, P709, DOI 10.1111/j.1755-3768.2010.01918.x
NR 48
TC 28
Z9 28
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PY 2014
VL 2014
AR 632307
DI 10.1155/2014/632307
PG 8
WC Immunology
SC Immunology
GA AC5EO
UT WOS:000332544000001
PM 24741610
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Buchaim, G
   Rezende, MP
   Maia, M
AF Buchaim, Guilherme
   Rezende, Marcussi Palata
   Maia, Mauricio
TI Intravitreal implantation of Ozurdex (R) chronic delivery system for
   management of macular edema related to retinitis pigmentosa: case report
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA Portuguese
DT Article
DE Retinitis pigmentosa/complications Macular edema/etiology; Macular
   edema/drug therapy; Injections; Drug implants;
   Dexamethasone/administration & dosage; Visual acuity; Humans; Female;
   Adult; Case report
ID RETINAL-VEIN-OCCLUSION; TRIAMCINOLONE ACETONIDE
AB Retinitis pigmentosa denotes a heterogeneous group of rare genetic diseases in which both rods and cones eye are damaged. It is a disease of poor prognosis. We describe the case of a 22 years old woman successfully treated with intravitreal implant of dexamentasone (OZURDEX (R), Allergan, USA) for the treatment of macular edema due to retinitis pigmentosa.
C1 Hosp Olhos Oeste Paulista, Assis, SP, Brazil.
RP Maia, M (corresponding author), Ave Otto Ribeiro 901, BR-19840050 Assis, SP, Brazil.
EM retina@femanet.com.br
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR Audren F, 2004, INVEST OPHTH VIS SCI, V45, P3435, DOI 10.1167/iovs.03-1110
   Chieh JJ, 2005, RETINA-J RET VIT DIS, V25, P828, DOI 10.1097/00006982-200510000-00002
   Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014
   Ip MS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1101, DOI 10.1001/archophthalmol.2009.234
   Loukianou E, 2011, CASE REP OPHTHALM, V2, P45, DOI 10.1159/000324037
   Lowder C, 2011, ARCH OPHTHALMOL-CHIC, V129, P545, DOI 10.1001/archophthalmol.2010.339
   Sahel J, 2010, DEV OPHTHALMOL, V47, P160, DOI 10.1159/000320079
   Saraiva VS, 2003, OPHTHALMIC SUR LA IM, V34, P398
NR 8
TC 5
Z9 5
U1 0
U2 2
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD NOV-DEC
PY 2013
VL 76
IS 6
BP 377
EP 379
DI 10.1590/S0004-27492013000600013
PG 3
WC Ophthalmology
SC Ophthalmology
GA AB2XP
UT WOS:000331655800013
PM 24510088
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Carpentier, C
   Zanolli, M
   Wu, L
   Sepulveda, G
   Berrocal, MH
   Saravia, M
   Diaz-Llopis, M
   Gallego-Pinazo, R
   Filsecker, L
   Verdaguer-Diaz, JI
   Milan-Navarro, R
   Arevalo, JF
   Maia, M
AF Carpentier, Cristian
   Zanolli, Mario
   Wu, Lihteh
   Sepulveda, Gonzalo
   Berrocal, Maria H.
   Saravia, Mario
   Diaz-Llopis, Manuel
   Gallego-Pinazo, Roberto
   Filsecker, Luis
   Verdaguer-Diaz, Juan I.
   Milan-Navarro, Rodrigo
   Arevalo, J. Fernando
   Maia, Mauricio
TI RESIDUAL INTERNAL LIMITING MEMBRANE AFTER EPIRETINAL MEMBRANE PEELING
   Results of the Pan-American Collaborative Retina Study Group
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE epiretinal membrane; internal limiting membrane; brilliant blue G;
   chromovitrectomy; macular pucker; ILM
ID NERVE-FIBER LAYER; BRILLIANT BLUE G; INDOCYANINE GREEN; MACULAR PUCKER;
   REMOVAL; APPEARANCE; SURGERY; VITRECTOMY; ILM
AB Purpose: To determine the degree of residual internal limiting membrane (ILM) after idiopathic epiretinal membrane (ERM) peeling and the usefulness of staining with brilliant blue G.
   Methods: A prospective, multicenter, observational study of 98 eyes undergoing pars plana vitrectomy and membrane peeling for idiopathic ERM. All eyes underwent core vitrectomy (20, 23, or 25 gauge) followed by intravitreal triamcinolone to verify that the posterior hyaloid had been removed. Brilliant blue G (0.2 mL of 0.25 mg/mL) was injected into the vitreous cavity and washed out immediately. The ERM was peeled and then the surgeon observed and recorded the characteristics of the underlying ILM. The posterior pole was restained with brilliant blue G (0.2 mL of 0.25 mg/mL), and the same observations on the characteristics of the ILM were recorded. Peeling of the remaining ILM was performed. The main outcome measured was the status of the ILM after ERM peel. Secondary outcomes included best-corrected visual acuity and central macular thickness at 6 months postoperatively.
   Results: After ERM peel, all of the eyes had residual ILM. In 74 eyes, the ILM was present and damaged, whereas in 24 eyes, the ILM was present and undamaged. In 37 eyes, the operating surgeon was unable to determine the status of the ILM before brilliant blue G staining. At 6 months, the logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.75 +/- 0.39 at baseline to 0.31 +/- 0.26 (P < 0.0001). The central macular thickness also improved from 460 +/- 91 mu m at baseline to 297 +/- 102 mu m (P < 0.003).
   Conclusion: Internal limiting membrane is frequently still present after ERM peeling. Staining with brilliant blue G facilitates its identification.
C1 [Carpentier, Cristian; Zanolli, Mario; Sepulveda, Gonzalo; Filsecker, Luis; Verdaguer-Diaz, Juan I.] Fdn Oftalmol Los Andes, Santiago, Chile.
   [Wu, Lihteh] Inst Cirugia Ocular, San Jose 50622562134, Costa Rica.
   [Berrocal, Maria H.] Univ Puerto Rico, Dept Ophthalmol, San Juan, PR 00936 USA.
   [Saravia, Mario] Univ Austral, Dept Ophthalmol, Buenos Aires, DF, Argentina.
   [Diaz-Llopis, Manuel; Gallego-Pinazo, Roberto] Inst Oftalmol Valencia, Valencia, Spain.
   [Milan-Navarro, Rodrigo; Maia, Mauricio] Brazilian Inst Fighting Blindness, Vitreoretinal Surg Unit, Sao Paulo, Brazil.
   [Arevalo, J. Fernando] King Khalid Eye Specialist Hosp, Riyadh, Saudi Arabia.
   [Arevalo, J. Fernando] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Maia, Mauricio] Univ Fed Sao Paulo, Sao Paulo, Brazil.
RP Wu, L (corresponding author), Inst Cirugia Ocular, Apdo 144-1225 Plaza Mayor, San Jose 50622562134, Costa Rica.
EM LW65@cornell.edu
RI Fromow-Guerra, J. Jans/A-3346-2015; Maia, Mauricio/I-5892-2015; Maia,
   Mauricio/Z-1042-2019
OI Fromow-Guerra, J. Jans/0000-0001-5335-1275; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); CNPq (Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico)National Council
   for Scientific and Technological Development (CNPq)
FX Supported by FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo) and CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico).
CR Bovey EH, 2004, RETINA-J RET VIT DIS, V24, P728, DOI 10.1097/00006982-200410000-00007
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Chang Stanley, 2012, Retina, V32 Suppl 2, pS200, DOI 10.1097/IAE.0b013e31825bc02b
   Clark A, 2012, RETINA-J RET VIT DIS, V32, P1608, DOI 10.1097/IAE.0b013e3182437e86
   DEBUSTROS S, 1988, BRIT J OPHTHALMOL, V72, P692, DOI 10.1136/bjo.72.9.692
   Eckardt C, 1997, OPHTHALMOLOGE, V94, P545, DOI 10.1007/s003470050156
   Ejstrup R, 2012, GRAEF ARCH CLIN EXP, V250, P669, DOI 10.1007/s00417-011-1886-3
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Gandorfer A, 2012, RETINA-J RET VIT DIS, V32, P477, DOI 10.1097/IAE.0b013e3182246e2a
   Grewing R, 1996, BRIT J OPHTHALMOL, V80, P323, DOI 10.1136/bjo.80.4.323
   Haritoglou C, 2006, OPHTHALMOLOGY, V113, P1690, DOI 10.1016/j.ophtha.2006.01.020
   Hisatomi T, 2005, AM J OPHTHALMOL, V139, P1121, DOI 10.1016/j.ajo.2004.11.051
   Kifuku K, 2009, BRIT J OPHTHALMOL, V93, P1016, DOI 10.1136/bjo.2008.150623
   Maia M, 2009, BRIT J OPHTHALMOL, V93, P1687, DOI 10.1136/bjo.2008.151597
   MARGHERIO RR, 1985, OPHTHALMOLOGY, V92, P1075
   Mitamura Y, 2005, OPHTHALMOLOGY, V112, P1766, DOI 10.1016/j.ophtha.2005.04.026
   Mitamura Y, 2004, AM J OPHTHALMOL, V137, P1155, DOI 10.1016/j.ajo.2004.01.052
   Nakamura T, 2003, CURR EYE RES, V27, P395, DOI 10.1076/ceyr.27.6.395.18189
   Notomi S, 2011, AM J PATHOL, V179, P2798, DOI 10.1016/j.ajpath.2011.08.035
   Park DW, 2003, OPHTHALMOLOGY, V110, P62, DOI 10.1016/S0161-6420(02)01440-9
   POLINER LS, 1988, ARCH OPHTHALMOL-CHIC, V106, P761
   Pournaras CJ, 2011, SEMIN OPHTHALMOL, V26, P42, DOI 10.3109/08820538.2010.544237
   Rodrigues EB, 2008, OPHTHALMOLOGICA, V222, P123, DOI 10.1159/000112630
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   Shimada H, 2009, OPHTHALMOLOGY, V116, P1370, DOI 10.1016/j.ophtha.2009.01.024
   SIVALINGAM A, 1990, OPHTHALMOLOGY, V97, P1549
   SMIDDY WE, 1989, OPHTHALMOLOGY, V96, P811
   Tadayoni R, 2001, OPHTHALMOLOGY, V108, P2279, DOI 10.1016/S0161-6420(01)00856-9
   Terasaki H, 2001, INVEST OPHTH VIS SCI, V42, P229
   TRESE M, 1983, GRAEF ARCH CLIN EXP, V221, P16, DOI 10.1007/BF02171726
   Uemura A, 2003, AM J OPHTHALMOL, V136, P252, DOI 10.1016/S0002-9394(03)00157-0
   WILKINSON CP, 1979, AM J OPHTHALMOL, V88, P1029, DOI 10.1016/0002-9394(79)90411-2
   Wollensak Gregor, 2008, Dev Ophthalmol, V42, P82, DOI 10.1159/000138975
NR 33
TC 18
Z9 19
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2013
VL 33
IS 10
BP 2026
EP 2031
DI 10.1097/IAE.0b013e31828e69c2
PG 6
WC Ophthalmology
SC Ophthalmology
GA 297EI
UT WOS:000330237900005
PM 23612051
DA 2020-12-15
ER

PT J
AU Peris, CS
   Badaro, E
   Ferreira, MA
   Lima, AAS
   Ferreira, EL
   Maia, A
   Rodrigues, EB
   Farah, ME
   Maia, M
AF Peris, Cristiane Siqueira
   Badaro, Emmerson
   Ferreira, Magno Antonio
   Souza Lima-Filho, Acacio Alves
   Ferreira, Eber Lopes
   Maia, Andre
   Rodrigues, Eduardo Buchele
   Farah, Michel Eid
   Maia, Mauricio
TI Color Variation Assay of the Anthocyanins from Acai Fruit (Euterpe
   oleracea): A Potential New Dye for Vitreoretinal Surgery
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID INTERNAL LIMITING MEMBRANE; BRILLIANT BLUE-G; VITAL DYES; INDOCYANINE
   GREEN; TRIAMCINOLONE ACETONIDE; TRYPAN BLUE; INTRAOCULAR SURGERY;
   TOXICITY; STAINS; CHROMOVITRECTOMY
AB Aim: The goals of this study were to determine the potential for use of the natural anthocyanins from the acai fruit (Euterpe oleracea) during vitreoretinal surgery and the ideal physicochemical properties of the dye. Methods: We evaluated the color variations of the dye at different pHs and osmolarities with or without the use of mordants as a potential new tool for internal limiting membrane peeling. The extracts of anthocyanin from the acai fruit were analyzed by spectrophotometry to determine the degree of color variations associated with various pHs and osmolarities. The experiments were conducted in test tubes filled with tryptophan soya media and Petri dishes prepared with agar media. Results: We observed various shades of green, red, and purple in the extracts of the anthocyanin dye at different pHs and osmolarities. The assay to adjust the anthocyanin solution similar to the physiologic retinal environment (osmolarity, 300 mOsm; pH, 7.00) resulted in a shade of purple that may be useful to stain the intraocular microstructures during vitreoretinal surgery. The physicochemical property of the purple anthocyanin solutions from the acai fruit was observed at physiologic pH and osmolarity. Conclusion: Anthocyanins from the acai fruit may be useful to enhance visualization of the intraocular microstructures during vitreoretinal surgery.
C1 [Peris, Cristiane Siqueira; Badaro, Emmerson; Ferreira, Magno Antonio; Souza Lima-Filho, Acacio Alves; Maia, Andre; Rodrigues, Eduardo Buchele; Farah, Michel Eid; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, BR-04023062 Sao Paulo, Brazil.
   [Souza Lima-Filho, Acacio Alves] Ophthalmos Ind, Sao Paulo, Brazil.
   [Ferreira, Eber Lopes] Etno Bot Res & Technol Innovat, Sao Paulo, Brazil.
   [Maia, Mauricio] Brazilian Inst Fighting Blindness, Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Vitreoretinal Surg Unit, Vis Inst IPEPO, 822 Botucatu St, BR-04023062 Sao Paulo, Brazil.
EM retina@femanet.com.br
RI Farah, Michel Eid E/F-3285-2012; de Souza Lima Filho, Acacio
   Alves/C-7189-2012; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015; Rodrigues, Eduardo Buchele/C-6852-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091; Alves
   de Souza Lima Filho, Acacio/0000-0003-1802-9592; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921; ferreira, magno/0000-0002-8596-4997
CR Albini TA, 2007, INVEST OPHTH VIS SCI, V48, P390, DOI 10.1167/iovs.06-0145
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Chen J., 2012, RETINA, V33, P89
   Dapson RW, 2005, BIOTECH HISTOCHEM, V80, P49, DOI 10.1080/10520290500219982
   Elmorsi TM, 2010, J HAZARD MATER, V174, P352, DOI 10.1016/j.jhazmat.2009.09.057
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P623, DOI 10.1097/00006982-200607000-00006
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Feron EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P141
   Costa EDF, 2009, INVEST OPHTH VIS SCI, V50, P385, DOI 10.1167/iovs.08-2285
   Gandorfer A, 2003, INVEST OPHTH VIS SCI, V44, P316, DOI 10.1167/iovs.02-0545
   GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P3315, DOI 10.1167/iovs.04-1142
   Jackson TL, 2005, EXP EYE RES, V81, P446, DOI 10.1016/j.exer.2005.03.004
   Kumar Atul, 2004, Indian J Ophthalmol, V52, P339
   LILLIE RD, 1976, STAIN TECHNOL, V51, P25, DOI 10.3109/10520297609116665
   Llewellyn BD, 2009, BIOTECH HISTOCHEM, V84, P159, DOI 10.1080/10520290903052899
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2009, BRIT J OPHTHALMOL, V93, P1687, DOI 10.1136/bjo.2008.151597
   Mennel S, 2006, OPHTHALMOLOGICA, V220, P190, DOI 10.1159/000091764
   Mennel S, 2006, KLIN MONATSBL AUGENH, V223, P568, DOI 10.1055/s-2006-926479
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   Perrier M, 2003, AM J OPHTHALMOL, V135, P909, DOI 10.1016/S0002-9394(02)02256-0
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Qin Y, 2009, AM J CLIN NUTR, V90, P485, DOI 10.3945/ajcn.2009.27814
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   Schuettauf F, 2006, INVEST OPHTH VIS SCI, V47, P3573, DOI 10.1167/iovs.06-0211
   Teba FA, 2003, OPHTHALMOLOGY, V110, P2409, DOI 10.1016/S0161-6420(03)00716-4
   Wilkinson A., 1997, COMPENDIUM CHEM TERM
   Yanagi Y, 2006, BRIT J OPHTHALMOL, V90, P229, DOI 10.1136/bjo.2005.076711
NR 32
TC 4
Z9 4
U1 0
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD OCT 1
PY 2013
VL 29
IS 8
BP 746
EP 753
DI 10.1089/jop.2013.0003
PG 8
WC Ophthalmology; Pharmacology & Pharmacy
SC Ophthalmology; Pharmacology & Pharmacy
GA 224UR
UT WOS:000324915900009
PM 23883110
DA 2020-12-15
ER

PT J
AU Ribeiro, RM
   Oregon, A
   Diniz, B
   Fernandes, RB
   Koss, MJ
   Charafeddin, W
   Hu, YT
   Thomas, P
   Thomas, BB
   Maia, M
   Chader, GJ
   Hinton, DR
   Humayun, MS
AF Ribeiro, Ramiro M.
   Oregon, Aldo
   Diniz, Bruno
   Fernandes, Rodrigo B.
   Koss, Michael J.
   Charafeddin, Wissam
   Hu, Yuntao
   Thomas, Padmaja
   Thomas, Biju B.
   Maia, Mauricio
   Chader, Gerald J.
   Hinton, David R.
   Humayun, Mark S.
TI In Vivo Detection of hESC-RPE Cells via Confocal Near-Infrared Fundus
   Reflectance
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL DEGENERATION; RAT;
   TRANSPLANTATION; MODELS
AB BACKGROUND AND OBJECTIVE: To investigate whether the confocal near-infrared reflectance (NIR) imaging modality could detect the in vivo presence of retinal pigment epithelium cells derived from embryonic human stem cells (hESC-RPE) implanted into the subretinal space of the Royal College of Surgeons (RCS) rat.
   MATERIALS AND METHODS: Monthly NIR images were obtained from RCS rats implanted with either hESC-RPE seeded on a parylene membrane (n = 14) or parylene membrane without cells (n = 14). Two independent, masked investigators graded the images. Histology and immunohistochemistry were performed at different time points (150, 210, and 270 postnatal days of age).
   RESULTS: NIR images revealed that an average of 20.53% of the parylene membrane area was covered by hESC-RPE. RPE-65 and TRA-1-85 confirmed the presence of human-specific RPE cells in those animals. No areas corresponding to cells were found in the group implanted with membrane only. Intergrader agreement was high (r = 0.89-0.92).
   CONCLUSION: The NIR mode was suitable to detect the presence of hESC-RPE seeded on a membrane and implanted into the subretinal space of the RCS rat.
C1 [Thomas, Biju B.; Hinton, David R.; Humayun, Mark S.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Ribeiro, Ramiro M.; Oregon, Aldo; Diniz, Bruno; Fernandes, Rodrigo B.; Koss, Michael J.; Charafeddin, Wissam; Hu, Yuntao; Thomas, Padmaja; Thomas, Biju B.; Chader, Gerald J.; Hinton, David R.; Humayun, Mark S.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Ribeiro, Ramiro M.; Diniz, Bruno; Fernandes, Rodrigo B.; Maia, Mauricio] Univ Fed Sao Paulo UNIFESP EPM, Sao Paulo, Brazil.
RP Ribeiro, RM (corresponding author), Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
EM rribeiro@doheny.org
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
FU California Institute of Regenerative MedicineCalifornia Institute for
   Regenerative Medicine [DR1-01444]
FX Supported by the California Institute of Regenerative Medicine
   (DR1-01444). The authors have no financial or proprietary interest in
   the materials presented herein.
CR Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Engelhardt M, 2012, VISUAL NEUROSCI, V29, P83, DOI 10.1017/S0952523812000041
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Hariri S, 2012, INVEST OPHTH VIS SCI, V53, P1982, DOI 10.1167/iovs.11-8395
   Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   MANIVANNAN A, 1994, BRIT J OPHTHALMOL, V78, P84, DOI 10.1136/bjo.78.2.84
   Paques M, 2006, VISION RES, V46, P1336, DOI 10.1016/j.visres.2005.09.037
   Sarunic MV, 2010, OPT EXPRESS, V18, P23435, DOI 10.1364/OE.18.023435
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Scoles D, 2009, BMC OPHTHALMOL, V9, DOI 10.1186/1471-2415-9-9
   Seeliger MW, 2005, VISION RES, V45, P3512, DOI 10.1016/j.visres.2005.08.014
   Seiler MJ, 2010, J NEUROSCI METH, V188, P250, DOI 10.1016/j.jneumeth.2010.02.018
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Strauss O, 1998, ACTA ANAT, V162, P101
   Theelen T, 2009, GRAEF ARCH CLIN EXP, V247, P1625, DOI 10.1007/s00417-009-1148-9
   Thomas BB, 2006, J NEUROSCI METH, V151, P186, DOI 10.1016/j.jneumeth.2005.07.004
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P416, DOI 10.1167/iovs.07-0992
   Zambarakji HJ, 2006, EXP EYE RES, V82, P164, DOI 10.1016/j.exer.2005.06.006
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
NR 26
TC 8
Z9 8
U1 0
U2 7
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JUL-AUG
PY 2013
VL 44
IS 4
BP 380
EP 384
DI 10.3928/23258160-20130715-09
PG 5
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA 219UB
UT WOS:000324534900011
PM 23883533
DA 2020-12-15
ER

PT J
AU Diniz, B
   Thomas, P
   Thomas, B
   Ribeiro, R
   Hu, YT
   Brant, R
   Ahuja, A
   Zhu, DH
   Liu, L
   Koss, M
   Maia, M
   Chader, G
   Hinton, DR
   Humayun, MS
AF Diniz, Bruno
   Thomas, Padmaja
   Thomas, Biju
   Ribeiro, Ramiro
   Hu, Yuntao
   Brant, Rodrigo
   Ahuja, Ashish
   Zhu, Danhong
   Liu, Laura
   Koss, Michael
   Maia, Mauricio
   Chader, Gerald
   Hinton, David R.
   Humayun, Mark S.
TI Subretinal Implantation of Retinal Pigment Epithelial Cells Derived From
   Human Embryonic Stem Cells: Improved Survival When Implanted as a
   Monolayer
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium; human
   embryonic stem cells
ID HUMAN BRUCHS MEMBRANE; MACULAR DEGENERATION; RCS RATS; IMMUNE-RESPONSES;
   VISUAL FUNCTION; INTACT SHEETS; ATHYMIC RAT; NUDE RATS; TRANSPLANTATION;
   MODEL
AB PURPOSE. To evaluate cell survival and tumorigenicity of human embryonic stem cell-derived retinal pigment epithelium (hESC-RPE) transplantation in immunocompromised nude rats. Cells were transplanted as a cell suspension (CS) or as a polarized monolayer plated on a parylene membrane (PM).
   METHODS. Sixty-nine rats (38 male, 31 female) were surgically implanted with CS (n = 33) or PM (n = 36). Cohort subsets were killed at 1, 6, and 12 months after surgery. Both ocular tissues and systemic organs (brain, liver, kidneys, spleen, heart, and lungs) were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned. Every fifth section was stained with hematoxylin and eosin and analyzed histologically. Adjacent sections were processed for immunohistochemical analysis (as needed) using the following antibodies: anti-RPE65 (RPE-specific marker), anti-TRA-1-85 (human cell marker), anti-Ki67 (proliferation marker), anti-CD68 (macrophage), and anti-cytokeratin (epithelial marker).
   RESULTS. The implanted cells were immunopositive for the RPE65 and TRA-1-85. Cell survival (P = 0.006) and the presence of a monolayer (P < 0.001) of hESC-RPE were significantly higher in eyes that received the PM. Gross morphological and histological analysis of the eye and the systemic organs after the surgery revealed no evidence of tumor or ectopic tissue formation in either group.
   CONCLUSIONS. hESC-RPE can survive for at least 12 months in an immunocompromised animal model. Polarized monolayers of hESC-RPE show improved survival compared to cell suspensions. The lack of teratoma or any ectopic tissue formation in the implanted rats bodes well for similar results with respect to safety in human subjects.
C1 [Diniz, Bruno; Thomas, Padmaja; Thomas, Biju; Ribeiro, Ramiro; Hu, Yuntao; Brant, Rodrigo; Ahuja, Ashish; Zhu, Danhong; Liu, Laura; Koss, Michael; Chader, Gerald; Hinton, David R.; Humayun, Mark S.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Diniz, Bruno; Ribeiro, Ramiro; Brant, Rodrigo; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Thomas, Biju; Hinton, David R.; Humayun, Mark S.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Ribeiro, Ramiro] Hosp Univ Curitiba, Dept Ophthalmol, Curitiba, Parana, Brazil.
   [Hu, Yuntao] Peking Univ, Hosp 3, Ctr Eye, Beijing 100871, Peoples R China.
   [Liu, Laura] Chang Gung Mem Hosp, Dept Ophthalmol, Linkou, Taiwan.
   [Koss, Michael] Goethe Univ Frankfurt, Dept Ophthalmol, D-60054 Frankfurt, Germany.
   [Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
RP Diniz, B (corresponding author), Inst Olhos Goiania, Retina Sect, Rua 9-B,48 Setor Oeste, BR-74110120 Goiania, Go, Brazil.
EM dinizb@me.com
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
FU California Institute of Regenerative MedicineCalifornia Institute for
   Regenerative Medicine [DR1-01444]; Research to Prevent BlindnessResearch
   to Prevent Blindness (RPB); National Eye InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Eye Institute (NEI) [EY03040]; CAPES FoundationCAPES
   [BEX 2326-11-6]; NATIONAL EYE INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Eye Institute (NEI) [P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040] Funding Source: NIH RePORTER
FX Supported by the California Institute of Regenerative Medicine
   (DR1-01444), Research to Prevent Blindness, National Eye Institute Core
   Grant EY03040, and CAPES Foundation (BEX 2326-11-6 [BD]).
CR Anisimov SV, 2010, STEM CELL REV REP, V6, P411, DOI 10.1007/s12015-010-9134-5
   Aramant RB, 1999, INVEST OPHTH VIS SCI, V40, P1557
   ARAMANT RB, 1994, CELL TRANSPLANT, V3, P461, DOI 10.1177/096368979400300603
   Aramant RB, 2002, EXP EYE RES, V75, P115, DOI 10.1006/exer.2002.2001
   Blum B, 2009, CELL CYCLE, V8, P3822, DOI 10.4161/cc.8.23.10067
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   DAWSON PJ, 1982, CANCER, V50, P1151, DOI 10.1002/1097-0142(19820915)50:6<1151::AID-CNCR2820500619>3.0.CO;2-H
   Dressel R, 2011, SEMIN IMMUNOPATHOL, V33, P573, DOI 10.1007/s00281-011-0266-8
   Elkabetz Y, 2008, GENE DEV, V22, P152, DOI 10.1101/gad.1616208
   Engelhardt M, 2012, VISUAL NEUROSCI, V29, P83, DOI 10.1017/S0952523812000041
   Fong CY, 2010, J CELL BIOCHEM, V111, P769, DOI 10.1002/jcb.22775
   Grisanti S, 2002, JPN J OPHTHALMOL, V46, P36, DOI 10.1016/S0021-5155(01)00464-6
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   KJONNIKSEN I, 1989, CANCER RES, V49, P5148
   KJONNIKSEN I, 1990, J NATL CANCER I, V82, P408, DOI 10.1093/jnci/82.5.408
   Kolossov E, 2006, J EXP MED, V203, P2315, DOI 10.1084/jem.20061469
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Montezuma SR, 2006, INVEST OPHTH VIS SCI, V47, P3514, DOI 10.1167/iovs.06-0106
   Mruthyunjaya P, 2005, RETINA-J RET VIT DIS, V25, P597, DOI 10.1097/00006982-200507000-00010
   Nussbaum J, 2007, FASEB J, V21, P1345, DOI 10.1096/fj.06-6769com
   Preynat-Seauve O, 2009, J CELL MOL MED, V13, P3556, DOI 10.1111/j.1582-4934.2009.00746.x
   Rolstad B, 2001, IMMUNOL REV, V184, P136, DOI 10.1034/j.1600-065x.2001.1840113.x
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seiler MJ, 1998, INVEST OPHTH VIS SCI, V39, P2121
   STRAGAND JJ, 1982, CANCER RES, V42, P3111
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Taylor AW, 2009, EYE, V23, P1885, DOI 10.1038/eye.2008.382
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Timmers A, 2001, MOL VIS, V7, P131
   Utermohlen O, 2009, BIOL CHEM, V390, P977, DOI 10.1515/BC.2009.114
   Yu Weihong, 2009, J Ocul Biol Dis Infor, V2, P33, DOI 10.1007/s12177-009-9018-6
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
NR 38
TC 124
Z9 127
U1 0
U2 35
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2013
VL 54
IS 7
BP 5087
EP 5096
DI 10.1167/iovs.12-11239
PG 10
WC Ophthalmology
SC Ophthalmology
GA 194MI
UT WOS:000322637000085
PM 23833067
OA Green Published
DA 2020-12-15
ER

PT J
AU Caseli, L
   Sousa-Martins, D
   Maia, M
   Lima, AAS
   Rodrigues, EB
   Belfort, R
AF Caseli, L.
   Sousa-Martins, D.
   Maia, M.
   Lima-Filho, A. A. S.
   Rodrigues, E. B.
   Belfort, R., Jr.
TI An intraocular dye solution based on lutein and zeaxanthin in a
   surrogate internal limiting membrane model: A Langmuir monolayer study
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Lutein; Zeaxanthin; Internal limiting membrane; Chromovitrectomy;
   Retina; Langmuir films
ID BRILLIANT BLUE-G; MACULAR PIGMENT; VITAL DYES; CAROTENOIDS;
   SUPPLEMENTATION; RETINA
AB Investigating the role of biomolecules and bioactive molecules associated With membranes is fundamental to comprehend at the molecular point-of-view biochemical and clinical processes that occur at biointerfaces. In this paper we exploit the interaction of an intraocular dye solution based on lutein and zeaxanthin in surrogate internal limiting membrane (ILM) models, consisting of dipalmitoyphosphatidylcholine (DPPC) Langmuir monolayers, pure or mixed with collagen, proteoglycan and laminin. The interactions between the film components occurring at the air-water interface were investigated with surface pressure-area isotherms and polarization modulation infrared reflection-absorption spectroscopy (PM-IRRAS). A natural dye solution based on lutein and zeaxanthin, employed to label ILM in ophthalmic surgery, was incorporated in the ILM model, and the data suggested non-rupture of the structure of the membrane, with predominance of interactions based on intermolecular forces. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Caseli, L.] Univ Fed Sao Paulo, Dept Earth & Exacts Sci, Diadema, Brazil.
   [Sousa-Martins, D.; Maia, M.; Lima-Filho, A. A. S.; Rodrigues, E. B.; Belfort, R., Jr.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
RP Caseli, L (corresponding author), Rua Arthur Riedel 245, Sao Paulo, Brazil.
EM lcaseli@unifesp.br
RI Caseli, Luciano/D-9533-2012; de Souza Lima Filho, Acacio
   Alves/C-7189-2012; Maia, Mauricio/I-5892-2015; Maia,
   Mauricio/Z-1042-2019; Sousa-Martins, Diogo/B-1554-2019; Belfort Jr,
   Rubens/E-2252-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Sousa-Martins, Diogo/0000-0002-2285-3990; Caseli,
   Luciano/0000-0002-1177-8454; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921; Belfort Jr, Rubens/0000-0002-8422-3898;
   Alves de Souza Lima Filho, Acacio/0000-0003-1802-9592
CR Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Barth A, 2002, Q REV BIOPHYS, V35, P369, DOI 10.1017/S0033583502003815
   Baszkin A, 2006, ADV COLLOID INTERFAC, V128, P111, DOI 10.1016/j.cis.2006.11.008
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   BLAUDEZ D, 1992, THIN SOLID FILMS, V210, P648, DOI 10.1016/0040-6090(92)90364-H
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Brockman H, 1999, CURR OPIN STRUC BIOL, V9, P438, DOI 10.1016/S0959-440X(99)80061-X
   Caseli L, 2002, COLLOID SURFACE B, V25, P119, DOI 10.1016/S0927-7765(01)00302-2
   CHIFU E, 1983, J COLLOID INTERF SCI, V95, P346, DOI 10.1016/0021-9797(83)90194-7
   Da Mata AP, 2004, OPHTHALMOLOGY, V111, P2246, DOI 10.1016/j.ophtha.2004.05.037
   Dynarowicz-Latka P, 2001, ADV COLLOID INTERFAC, V91, P221, DOI 10.1016/S0001-8686(99)00034-2
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Enaida Hiroshi, 2008, Dev Ophthalmol, V42, P115, DOI 10.1159/000138989
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Farah M. E., 2009, USE VITAL DYES VITRE
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   GLASS CA, 1993, EMBO J, V12, P4413, DOI 10.1002/j.1460-2075.1993.tb06126.x
   Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502
   Krishnan V, 2011, CURR OPIN COLLOID IN, V16, P459, DOI 10.1016/j.cocis.2011.08.005
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Lee JJ, 2009, J MATER SCI-MATER M, V20, P1927, DOI 10.1007/s10856-009-3743-z
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3
   NAKANISHI H, 1995, PROG SURF SCI, V49, P197, DOI 10.1016/0079-6816(95)00037-Y
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   Pavinatto FJ, 2010, BIOMACROMOLECULES, V11, P1897, DOI 10.1021/bm1004838
   Prieto I, 1998, LANGMUIR, V14, P1853, DOI 10.1021/la9711241
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Rodrigues EB, 2010, AM J OPHTHALMOL, V149, P265, DOI 10.1016/j.ajo.2009.08.020
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Rodrigues Eduardo B, 2008, Dev Ophthalmol, V42, P29, DOI 10.1159/000138911
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   Santos TCF, 2010, LANGMUIR, V26, P5869, DOI 10.1021/la9038107
   Schalke M., 1995, PROG SURF SCI, V49, P197
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sousa-Martins D, 2012, RETINA-J RET VIT DIS, V32, P1328, DOI 10.1097/IAE.0b013e318239e2b6
   Ulrich WP, 1999, BIOPHYS J, V76, P1639, DOI 10.1016/S0006-3495(99)77323-6
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   Yuen D, 2009, AM J OPHTHALMOL, V147, P251, DOI 10.1016/j.ajo.2008.08.031
NR 44
TC 8
Z9 8
U1 0
U2 58
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD JUL 1
PY 2013
VL 107
BP 124
EP 129
DI 10.1016/j.colsurfb.2013.01.076
PG 6
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 133MG
UT WOS:000318141900016
PM 23475059
DA 2020-12-15
ER

PT J
AU Penha, FM
   Pons, M
   Costa, EF
   Barros, NMT
   Rodrigues, EB
   Cardoso, EB
   Dib, E
   Maia, M
   Marin-Castano, ME
   Farah, ME
AF Penha, Fernando M.
   Pons, Marianne
   Costa, Elaine Fiod
   Tenorio Barros, Nilana Meza
   Rodrigues, Eduardo B.
   Cardoso, Emmerson Badaro
   Dib, Eduardo
   Maia, Mauricio
   Marin-Castano, Maria E.
   Farah, Michel Eid
TI Retinal Pigmented Epithelial Cells Cytotoxicity and Apoptosis through
   Activation of the Mitochondrial Intrinsic Pathway: Role Of Indocyanine
   Green, Brilliant Blue and Implications for Chromovitrectomy
SO PLOS ONE
LA English
DT Article
ID INTERNAL LIMITING MEMBRANE; IDIOPATHIC MACULAR HOLE; TRYPAN BLUE;
   CYTOCHROME-C; EPIRETINAL MEMBRANE; VITAL DYES; SUBRETINAL INJECTION;
   INTRAOCULAR SURGERY; CLINICAL-TRIAL; METHYL BLUE
AB Purpose: To investigate the in vitro effect of four vital dyes on toxicity and apoptosis in a human retinal pigment epithelial (RPE) cell line.
   Methods: ARPE-19 cells were exposed to brilliant blue (BriB), methyl blue (MetB), acid violet (AcV) and indocyanine green (ICG). Balanced salt solution was used as control. Five different concentrations of each dye (1, 0.5, 0.25, 0.05 and 0.005 mg/mL) and two exposure times (3 and 30 min) were tested. Cell viability was determined by cell count and MTS assay and cell toxicity by LDH assay. Real-time PCR and Western blotting were used to access the apoptosis process.
   Results: ICG significantly reduced cell viability after 3 minutes of exposure at all concentrations (p < 0.01). BriB was safe at concentrations up to 0.25 mg/mL and MetB at concentrations up to 0.5 mg/mL, while AcV was safe up to 0.05 mg/ml, after 3 minutes of exposure. Toxicity was higher, when the cells were treated for 30 minutes. Expression of Bax, cytochrome c and caspase-9 was upregulated at the mRNA and protein level after ICG exposure, while Bcl-2 was downregulated. AcV and MetB were similar to control. However, BriB resulted in upregulation of Bcl-2, an antiapoptotic protein.
   Conclusions: The safest dye used on RPE cells was MetB followed by BriB and AcV. ICG was toxic at all concentrations and exposure times tested. Moreover, ICG was the only dye that induced apoptosis in ARPE-19 cells. BriB significantly increased Bcl-2 protein levels, which might protect against the apoptosis process.
C1 [Penha, Fernando M.; Costa, Elaine Fiod; Tenorio Barros, Nilana Meza; Cardoso, Emmerson Badaro; Dib, Eduardo; Maia, Mauricio; Farah, Michel Eid] Univ Fed Sao Paulo, Inst Visao IPEPO, Dept Oftalmol, Sao Paulo, Brazil.
   [Pons, Marianne; Marin-Castano, Maria E.] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA.
RP Penha, FM (corresponding author), Univ Fed Sao Paulo, Inst Visao IPEPO, Dept Oftalmol, Sao Paulo, Brazil.
EM penhaepm@yahoo.com.br; mcastano@med.miami.edu
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; Barros,
   Nilana/E-2589-2012; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Farah, Michel Eid E/0000-0001-5951-0193; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); National Institutes of
   Health CenterUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P30EY014801]; Research to Prevent
   BlindnessResearch to Prevent Blindness (RPB); Department of Defense
   (DOD)United States Department of Defense [W81XWH-09-1-0675]; NATIONAL
   EYE INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Eye Institute (NEI)
   [P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801] Funding Source: NIH RePORTER
FX Supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) and Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq), National Institutes of Health Center Core Grant
   P30EY014801, Research to Prevent Blindness Unrestricted Grant, and
   Department of Defense (DOD-grant#W81XWH-09-1-0675). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Balaiya S, 2011, RETINA-J RET VIT DIS, V31, P1128, DOI 10.1097/IAE.0b013e3181fe543a
   Beutel J, 2007, ARCH OPHTHALMOL-CHIC, V125, P326, DOI 10.1001/archopht.125.3.326
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Christensen UC, 2009, BRIT J OPHTHALMOL, V93, P1005, DOI 10.1136/bjo.2008.151266
   Costa EF, 2013, AM J OPHTHALMOL, V155, P705, DOI 10.1016/j.ajo.2012.10.004
   Enaida Hiroshi, 2008, Dev Ophthalmol, V42, P115, DOI 10.1159/000138989
   Feron EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P141
   Haritoglou C, 2004, RETINA-J RET VIT DIS, V24, P582, DOI 10.1097/00006982-200408000-00012
   Haritoglou C, 2009, RETINA-J RET VIT DIS, V29, P1266, DOI 10.1097/IAE.0b013e3181b8626f
   Hillenkamp J, 2007, GRAEF ARCH CLIN EXP, V245, P973, DOI 10.1007/s00417-006-0485-1
   Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P2778, DOI 10.1167/iovs.04-0320
   Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997
   Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229
   Li K, 2003, BRIT J OPHTHALMOL, V87, P216, DOI 10.1136/bjo.87.2.216
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9
   Luke M, 2008, GRAEF ARCH CLIN EXP, V246, P817, DOI 10.1007/s00417-007-0761-8
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Maia M, 2009, BRIT J OPHTHALMOL, V93, P1687, DOI 10.1136/bjo.2008.151597
   Maia M, 2007, CURR EYE RES, V32, P309, DOI 10.1080/02713680701199377
   Meyer CH, 2004, AM J OPHTHALMOL, V137, P207, DOI 10.1016/j.ajo.2003.09.014
   NACHLAS MM, 1960, ANAL BIOCHEM, V1, P317, DOI 10.1016/0003-2697(60)90029-4
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O
   Parone PA, 2002, BIOCHIMIE, V84, P105, DOI 10.1016/S0300-9084(02)01380-9
   Penha FM, 2008, J OCUL PHARMACOL TH, V24, P52, DOI 10.1089/jop.2007.0047
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153
   Rodrigues EB, 2010, AM J OPHTHALMOL, V149, P265, DOI 10.1016/j.ajo.2009.08.020
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   Rosse T, 1998, NATURE, V391, P496
   Sayanagi K, 2007, AM J OPHTHALMOL
   Sayanagi K, 2007, BRIT J OPHTHALMOL, V91, P939, DOI 10.1136/bjo.2006.108746
   Smiddy W E, 1996, Bull Soc Belge Ophtalmol, V262, P31
   Stanescu-Segall D, 2009, EYE, V23, P504, DOI 10.1038/eye.2008.249
   Thaler S, 2009, RETINA-J RET VIT DIS, V29, P1257, DOI 10.1097/IAE.0b013e3181b8615b
   Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3
   Vote BJ, 2004, RETINA-J RET VIT DIS, V24, P736, DOI 10.1097/00006982-200410000-00008
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129
   Yoon HS, 1996, AM J OPHTHALMOL, V122, P67, DOI 10.1016/S0002-9394(14)71965-8
   Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2
NR 46
TC 11
Z9 13
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 10
PY 2013
VL 8
IS 5
AR e64094
DI 10.1371/journal.pone.0064094
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 143FO
UT WOS:000318852400060
PM 23675521
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Diniz, B
   Fernandes, RB
   Ribeiro, RM
   Lue, JC
   Teixeira, AG
   Magalhaes, O
   Maia, M
   Humayun, MS
AF Diniz, Bruno
   Fernandes, Rodrigo B.
   Ribeiro, Ramiro M.
   Lue, Jaw-Chyng
   Teixeira, Anderson G.
   Magalhaes, Octaviano
   Maia, Mauricio
   Humayun, Mark S.
TI ANALYSIS OF A 23-GAUGE ULTRA HIGH-SPEED CUTTER WITH DUTY CYCLE CONTROL
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE vitrectomy; duty cycle; cut rate; aspiration
ID 25-GAUGE VITREOUS CUTTERS; VITRECTOMY; PERFORMANCE; 20-GAUGE; DYNAMICS;
   SURGERY
AB Purpose: The purpose of the study was to determine the performance of dual pneumatic ultra high-speed 23-gauge cutters operated with variable duty cycle (DC) settings.
   Methods: Frame-by-frame analysis of high-speed video was used to determine the DC in core, 50-50, and shave modes. Using three cutters at various cycles per minute and aspiration levels, mass of water or vitreous removed from a vial was measured within a specified time period. Average flow rates were calculated for each aspiration level and cut rate with the different DC options.
   Results: The DC increased with increasing cut rate in the shave mode was relatively stable in the 50-50 mode and decreased for the core mode. The DC converged at 5,000 cycles per minute for the 3 different modes. Water flow curves followed the DC variation. Vitreous flow rates for all the DC modes increased with increasing cut rates and peaked at 5,000 cycles per minute (P < 0.05). The results of the 50-50 mode, which had isolated the DC influence, showed that increasing aspiration and/or cut rate independently increased the vitreous flow rate.
   Conclusion: Progressive values of aspiration and/or cut rate increase the vitreous flow rate, independently of the DC. The DC control also has an important effect on the vitreous flow, but this effect was reduced at high cut rates because of convergence of the DC modes. RETINA 33: 933-938, 2013
C1 [Diniz, Bruno; Fernandes, Rodrigo B.; Ribeiro, Ramiro M.; Lue, Jaw-Chyng; Humayun, Mark S.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Diniz, Bruno; Fernandes, Rodrigo B.; Teixeira, Anderson G.; Magalhaes, Octaviano; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, BR-04023900 Sao Paulo, Brazil.
   [Ribeiro, Ramiro M.] Hosp Evangel Curitiba FEMPAR, Dept Ophthalmol, Curitiba, Parana, Brazil.
   [Humayun, Mark S.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Rua Botucatu 821, BR-04023900 Sao Paulo, Brazil.
EM maiamauricio@terra.com.br
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; Teixeira,
   Anderson/K-2320-2013
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Teixeira, Anderson/0000-0001-7585-712X
FU National Eye InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Eye
   Institute (NEI) [EY03040]; Research to Prevent BlindnessResearch to
   Prevent Blindness (RPB); Eye Concepts Laboratory at the Doheny Eye
   Institute; CAPES Foundation, BrazilCAPES [BEX 2326-11-6]; CNPq (National
   Council of Research, Brazil)National Council for Scientific and
   Technological Development (CNPq); NATIONAL EYE INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Eye Institute (NEI) [P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040] Funding Source: NIH RePORTER
FX Supported in part by the National Eye Institute core grant (EY03040), an
   unrestricted grant to the Department of Ophthalmology from the Research
   to Prevent Blindness, Eye Concepts Laboratory at the Doheny Eye
   Institute, CAPES Foundation, Brazil (BEX 2326-11-6 [B. D.]), and CNPq
   (National Council of Research, Brazil).
CR Charles S, 2004, RETINA-J RET VIT DIS, V24, P435, DOI 10.1097/00006982-200406000-00015
   DeBoer C, 2008, RETINA-J RET VIT DIS, V28, P1061, DOI 10.1097/IAE.0b013e3181840b64
   Fang SY, 2008, GRAEF ARCH CLIN EXP, V246, P61, DOI 10.1007/s00417-007-0672-8
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1807, DOI 10.1016/S0161-6420(02)01179-X
   Hubschman JP, 2008, RETINA-J RET VIT DIS, V28, P249, DOI 10.1097/IAE.0b013e31815ec2b3
   Hubschman JP, 2009, RETINA-J RET VIT DIS, V29, P1289, DOI 10.1097/IAE.0b013e3181acd3a9
   Juan TT, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4002796
   Magalhaes O, 2008, RETINA-J RET VIT DIS, V28, P236, DOI 10.1097/IAE.0b013e318158e9e0
   Magalhaes O, 2011, AM J OPHTHALMOL, V151, P401, DOI 10.1016/j.ajo.2010.11.009
   Matsuoka N, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20101223-03
   Sato T, 2008, RETINA-J RET VIT DIS, V28, P749, DOI 10.1097/IAE.0b013e3181631907
   Sharif-Kashani P, 2012, RETINA IN PRESS
   Steel DHW, 2011, OPHTHALMOLOGICA, V226, P27, DOI 10.1159/000328207
   Teixeira A, 2010, OPHTHALMOLOGY, V117, P1387, DOI 10.1016/j.ophtha.2009.11.004
NR 14
TC 13
Z9 13
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2013
VL 33
IS 5
BP 933
EP 938
DI 10.1097/IAE.0b013e3182733f38
PG 6
WC Ophthalmology
SC Ophthalmology
GA 131QY
UT WOS:000318011100006
PM 23416512
OA Green Accepted
DA 2020-12-15
ER

PT J
AU Costa, EF
   Barros, NMT
   Coppini, LP
   Neves, RL
   Carmona, AK
   Penha, FM
   Rodrigues, EB
   Dib, E
   Magalhaes, O
   Moraes, MN
   Lima, AAS
   Maia, M
   Farah, ME
AF Costa, Elaine F.
   Barros, Nilana M. T.
   Coppini, Larissa P.
   Neves, Raquel L.
   Carmona, Adriana K.
   Penha, Fernando M.
   Rodrigues, Eduardo B.
   Dib, Eduardo
   Magalhaes, Octaviano, Jr.
   Moraes-Filho, Milton N.
   Lima Filho, Acacio A. S.
   Maia, Mauricio
   Farah, Michel E.
TI Effects of Light Exposure, pH, Osmolarity, and Solvent on the Retinal
   Pigment Epithelial Toxicity of Vital Dyes
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTERNAL LIMITING MEMBRANE; MACULAR HOLE SURGERY; HEAVY TRYPAN BLUE;
   INDOCYANINE-GREEN; VITREORETINAL INTERFACE; IONOTROPIC GLUTAMATE;
   VITRECTOMY SURGERY; GLUCOSE; EXPRESSION; ELECTRORETINOGRAM
AB PURPOSE: To investigate the in vitro effect of pH, osmolarity, solvent, and light interaction on currently used an l novel dyes to minimize dye-related retinal toxicity.
   DESIGN: Laboratory investigation.
   METHODS: Retinal pigment epithelium (RPE) human cells (ARPE-19) were exposed for 10 minutes to different pH solutions (4, 5, 6, 7, 7.5, 8, and 9) and glucose solutions (2.5%, 5.0%, 10%, 20%, 40%, and 50%) with osmolarity from 142 to 2530 mOsm, with and without 0.5 mg/mL trypan blue. R28 cells were also incubated with glucose (150, 310, and 1000 mOsm) and mannitol used as an osmotic control agent in both experiments. Dye-light interaction was assessed by incubating ARPE-19 for 10 minutes with trypan blue, brilliant blue, bromophenol blue, fast green, light green, or indigo carmine (0.05 mg/mL diluted in balanced saline solution) in the presence of high-brightness xenon and mercury vapor light sources.
   RESULTS: Solutions with nonphysiologic pH, below 7 and above 7.5, proved to be remarkably toxic to RPE cells with or without trypan blue. Also, all glucose solutions were deleterious to RPE (P < .001) even in iso-osmolar range. No harmful effect was found with mannitol solutions. Among the dyes tested, only light green and fast green were toxic to ARPE-19 (P < .001). Light exposure did not increase RPE toxicity either with xenon light or mercury vapor lamp.
   CONCLUSIONS: Solutions containing glucose as a dye solvent or nonphysiologic pH should be used with care in surgical situations where the RPE is exposed. Light exposure under present assay conditions did not increase the RPE toxicity. (Am J Ophthalmol 2013;155:705-712. (C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Costa, Elaine F.; Penha, Fernando M.; Rodrigues, Eduardo B.; Dib, Eduardo; Magalhaes, Octaviano, Jr.; Moraes-Filho, Milton N.; Lima Filho, Acacio A. S.; Maia, Mauricio; Farah, Michel E.] Univ Fed Sao Paulo, Inst Visao IPEPO, Dept Oftalmol, Sao Paulo, Brazil.
   [Barros, Nilana M. T.; Coppini, Larissa P.; Neves, Raquel L.; Carmona, Adriana K.] Univ Fed Sao Paulo, Dept Biofis, Sao Paulo, Brazil.
   [Barros, Nilana M. T.] Univ Fed Sao Paulo, Dept Ciencias Exatas & Terra, Diadema, Brazil.
RP Barros, NMT (corresponding author), Rua Pedro de Toledo 669, BR-04039032 Sao Paulo, Brazil.
EM nilana.barros@unifesp.br
RI Maia, Mauricio/Z-1042-2019; Carmona, Adriana K/D-2240-2012; Maia,
   Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012; de Souza Lima
   Filho, Acacio Alves/C-7189-2012
OI Maia, Mauricio/0000-0002-7034-8091; Carmona, Adriana
   K/0000-0003-3311-5456; Maia, Mauricio/0000-0002-7034-8091; Farah, Michel
   Eid E/0000-0001-5951-0193; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921; Alves de Souza Lima Filho,
   Acacio/0000-0003-1802-9592
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; Sao Paulo,
   Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq;
   Brasilia, Brazil)National Council for Scientific and Technological
   Development (CNPq); Pan-American Association of
   Ophthalmology/Pan-American Ophthalmological Foundation (PAAO/PAOF;
   Arlington, Texas)
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and none were reported. Publication
   of this article was supported by Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP; Sao Paulo, Brazil), Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq; Brasilia, Brazil), and
   Pan-American Association of Ophthalmology/Pan-American Ophthalmological
   Foundation (PAAO/PAOF; Arlington, Texas). Contributions of authors:
   design of the study (E.F.C., N.M.T.B.); conduct of the study (E.F.C.,
   N.M.T.B., L.P.C., R.L.N.); collection and management (E.D., O.M.J.,
   M.N.M.F., F.M.P.); analysis and interpretation of the data (A.K.C.,
   E.D., O.M.J., E.B.R., A.A.S.L.F.); and preparation, review, or approval
   of the manuscript (E.F.C., N.M.T.B., A.K.C., M.M., M.E.F.).
CR Badr GA, 2000, DIABETES, V49, P1016, DOI 10.2337/diabetes.49.6.1016
   Beutel J, 2007, ARCH OPHTHALMOL-CHIC, V125, P326, DOI 10.1001/archopht.125.3.326
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Bursell SE, 1997, INVEST OPHTH VIS SCI, V38, P2711
   Ciardella AP, 2003, AM J OPHTHALMOL, V136, P174, DOI 10.1016/S0002-9394(03)00090-4
   Da Mata AP, 2004, OPHTHALMOLOGY, V111, P2246, DOI 10.1016/j.ophtha.2004.05.037
   Da Mata AP, 2001, OPHTHALMOLOGY, V108, P1187, DOI 10.1016/S0161-6420(01)00593-0
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Costa EDF, 2009, INVEST OPHTH VIS SCI, V50, P385, DOI 10.1167/iovs.08-2285
   Gandorfer A, 2003, BRIT J OPHTHALMOL, V87, P1530, DOI 10.1136/bjo.87.12.1530
   Gandorfer A, 2003, INVEST OPHTH VIS SCI, V44, P316, DOI 10.1167/iovs.02-0545
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P1468, DOI 10.1167/iovs.04-0838
   Haritoglou C, 2004, AM J OPHTHALMOL, V138, P1, DOI 10.1016/j.ajo.2004.03.005
   Haritoglou C, 2004, AM J OPHTHALMOL, V137, P345, DOI 10.1016/S0002-9394(03)00845-6
   Haritoglou C, 2003, INVEST OPHTH VIS SCI, V44, P2722, DOI 10.1167/iovs.02-1283
   Haritoglou C, 2008, RETINA-J RET VIT DIS, V28, P333, DOI 10.1097/IAE.0b013e31814fb0ff
   HIROI K, 1994, INVEST OPHTH VIS SCI, V35, P3957
   Januschowski K, 2011, GRAEF ARCH CLIN EXP, V249, P483, DOI 10.1007/s00417-010-1508-5
   Kim DI, 2007, LIFE SCI, V80, P626, DOI 10.1016/J.LFS.2006.10.026
   KUMAGAI AK, 1994, INVEST OPHTH VIS SCI, V35, P2887
   LUNDQUIST O, 1994, GRAEF ARCH CLIN EXP, V232, P71, DOI 10.1007/BF00171666
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   MARMOR MF, 1979, INVEST OPHTH VIS SCI, V18, P1237
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P1016
   Nakamura M, 2001, J BIOL CHEM, V276, P43748, DOI 10.1074/jbc.M108594200
   NIEMEYER G, 1986, DOC OPHTHALMOL, V63, P113, DOI 10.1007/BF00157120
   Oberstein SYL, 2010, EYE, V24, P1177, DOI 10.1038/eye.2010.3
   Oberstein SYL, 2007, BRIT J OPHTHALMOL, V91, P955, DOI 10.1136/bjo.2006.112425
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Santiago AR, 2006, INVEST OPHTH VIS SCI, V47, P4130, DOI 10.1167/iovs.06-0085
   Seigel GM, 1996, IN VITRO CELL DEV-AN, V32, P66
   Seigel GM, 2004, CURR EYE RES, V28, P257, DOI 10.1076/ceyr.28.4.257.27831
   Selton J, 2012, J FR OPHTALMOL, V35, P397, DOI 10.1016/j.jfo.2011.08.015
   Sheu ML, 2005, ARTERIOSCL THROM VAS, V25, P539, DOI 10.1161/01.ATV.0000155462.24263.e4
   SHIRAO Y, 1987, INVEST OPHTH VIS SCI, V28, P2015
   Sippy BD, 2001, AM J OPHTHALMOL, V132, P433, DOI 10.1016/S0002-9394(01)01061-3
   Stalmans P, 2002, AM J OPHTHALMOL, V134, P282, DOI 10.1016/S0002-9394(02)01468-X
   Sun W, 2002, NEUROREPORT, V13, P2421, DOI 10.1097/00001756-200212200-00009
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
NR 40
TC 12
Z9 12
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2013
VL 155
IS 4
BP 705
EP 712
DI 10.1016/j.ajo.2012.10.004
PG 8
WC Ophthalmology
SC Ophthalmology
GA 118JS
UT WOS:000317022400013
PM 23253911
DA 2020-12-15
ER

PT J
AU Cardoso, EB
   Moraes-Filho, M
   Rodrigues, EB
   Maia, M
   Penha, FM
   Novais, EA
   Souza-Lima, RA
   Meyer, CH
   Farah, ME
AF Cardoso, Emmerson Badaro
   Moraes-Filho, Milton
   Rodrigues, Eduardo B.
   Maia, Mauricio
   Penha, Fernando M.
   Novais, Eduardo Amorim
   Souza-Lima, Rodrigo A.
   Meyer, Carsten H.
   Farah, Michel Eid
TI Investigation of the retinal biocompatibility of acid violet for
   chromovitrectomy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Chromovitrectomy; Acid violet; Vitreoretinal dyes; Retinal toxicity;
   Electroretinogram; Intraocular toxicity
ID BRILLIANT BLUE-G; INDOCYANINE GREEN; TRYPAN BLUE; VITAL DYES;
   TRIAMCINOLONE ACETONIDE; VITREORETINAL SURGERY; INTRAOCULAR SURGERY;
   EPIRETINAL MEMBRANES; RABBIT EYES; EVANS BLUE
AB The primary objective was to investigate the retinal biocompatibility of acid violet (AV) as a vital dye for chromovitrectomy. The secondary objective was to evaluate the capacity of AV to stain the anterior capsule of the lens.
   An amount of 0.05 ml of 0.25 g/l and 0.5 g/l AV was injected intravitreally in the OD, while balanced salt solution (BSS) was applied in the OS for control. Clinical examination and histology with light microscopy (LM) were performed after 7 days. Retinal cell layers were evaluated for morphologic alterations and number of cells. The electroretinographic (ERG) changes were assessed at baseline and 7 days. In another part of the study, 0.1 ml of 0.25 g/l AV was injected into the anterior chamber of ex-vivo porcine eyes, and its capacity to stain the anterior capsule was determined. Cadaveric eyes were used to test the capacity of AV to stain the internal limitant membrane (ILM) during vitrectomy.
   The gross histopathologic appearance of the retina, choroids, sclera, and optic nerve was within normal limits, without any signs of severe retinal necrosis or cystic degeneration. AV caused no substantial retinal alterations in retinal layers by LM at either the lower or higher dose when compared with the control eye. The injection of AV did not induce considerable ERG alterations. The violet dye stained the anterior capsule after anterior chamber injection and the ILM, allowing a safer capsulorrhexis and vitrectomy.
   Acid violet may be safe for the retina at concentrations of 0.25 and 0.50 g/l after intravitreous injection, and may be used as a vital dye for staining the anterior capsule and the ILM.
C1 [Cardoso, Emmerson Badaro; Moraes-Filho, Milton; Rodrigues, Eduardo B.; Maia, Mauricio; Penha, Fernando M.; Novais, Eduardo Amorim; Souza-Lima, Rodrigo A.; Farah, Michel Eid] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, Sao Paulo, Brazil.
   [Rodrigues, Eduardo B.] Univ Fed Sao Paulo, Electron Microscopy Ctr CEME, Sao Paulo, Brazil.
   [Meyer, Carsten H.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
RP Cardoso, EB (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, Sao Paulo, Brazil.
EM ebadaro@me.com
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015; Meyer, Carsten H./A-3981-2017
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091; Meyer,
   Carsten H./0000-0002-0530-5298; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
FU German Academic Exchange Service (DAAD)Deutscher Akademischer Austausch
   Dienst (DAAD); Pan-American Association of Ophthalmology-Pan-American
   Ophthalmological Foundation (PAAO/PAOF); Vision Institute - UNIFESP;
   FAPESP - Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX From the German Academic Exchange Service (DAAD); from the Pan-American
   Association of Ophthalmology-Pan-American Ophthalmological Foundation
   (PAAO/PAOF); from the Vision Institute - UNIFESP; and to the FAPESP -
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo.
CR Albini TA, 2007, INVEST OPHTH VIS SCI, V48, P390, DOI 10.1167/iovs.06-0145
   Baba Y, 2000, ACTA RADIOL, V41, P329, DOI 10.1034/j.1600-0455.2000.041004329.x
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P623, DOI 10.1097/00006982-200607000-00006
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Feron EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P141
   Costa EDF, 2009, INVEST OPHTH VIS SCI, V50, P385, DOI 10.1167/iovs.08-2285
   Foster RE, 2002, RETINA-J RET VIT DIS, V22, P106, DOI 10.1097/00006982-200202000-00019
   Gandorfer A, 2003, INVEST OPHTH VIS SCI, V44, P316, DOI 10.1167/iovs.02-0545
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P3315, DOI 10.1167/iovs.04-1142
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P673, DOI 10.1097/00006982-200607000-00014
   Jackson TL, 2005, EXP EYE RES, V81, P446, DOI 10.1016/j.exer.2005.03.004
   Kiernan JA, 2001, BIOTECH HISTOCHEM, V76, P261, DOI 10.1080/714028154
   Kumar Atul, 2004, Indian J Ophthalmol, V52, P339
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Mennel S, 2006, OPHTHALMOLOGICA, V220, P190, DOI 10.1159/000091764
   Mennel S, 2006, KLIN MONATSBL AUGENH, V223, P568, DOI 10.1055/s-2006-926479
   Mennel Stefan, 2008, Dev Ophthalmol, V42, P101, DOI 10.1159/000138988
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   NYBERG MA, 1977, A GRAEF ARCH KLIN EX, V204, P153, DOI 10.1007/BF00414843
   OHTA Y, 1991, NEUROSCI LETT, V130, P137, DOI 10.1016/0304-3940(91)90246-P
   Ozawa T, 2005, NEUROSURGERY, V57, P1041, DOI 10.1227/01.NEU.0000180036.42193.f6
   Pandey SK, 2000, J CATARACT REFR SURG, V26, P1052, DOI 10.1016/S0886-3350(00)00296-0
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Perrier M, 2003, AM J OPHTHALMOL, V135, P909, DOI 10.1016/S0002-9394(02)02256-0
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Schuettauf F, 2006, INVEST OPHTH VIS SCI, V47, P3573, DOI 10.1167/iovs.06-0211
   Shoemaker K, 1996, J THORAC CARDIOV SUR, V112, P542, DOI 10.1016/S0022-5223(96)70286-6
   Sorsby A, 1939, T OPHTHAL SOC UK, V59, P727
   Teba FA, 2003, OPHTHALMOLOGY, V110, P2409, DOI 10.1016/S0161-6420(03)00716-4
   Ueno A, 2007, RETINA-J RET VIT DIS, V27, P499, DOI 10.1097/IAE.0b013e318030a129
NR 34
TC 12
Z9 13
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2013
VL 251
IS 4
BP 1115
EP 1121
DI 10.1007/s00417-013-2258-y
PG 7
WC Ophthalmology
SC Ophthalmology
GA 114RD
UT WOS:000316759000010
PM 23329403
DA 2020-12-15
ER

PT J
AU Diniz, B
   Ribeiro, RM
   Rodger, DC
   Maia, M
   Sadda, S
AF Diniz, Bruno
   Ribeiro, Ramiro M.
   Rodger, Damien C.
   Maia, Mauricio
   Sadda, SriniVas
TI Drusen detection by confocal aperture-modulated infrared scanning laser
   ophthalmoscopy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; VISUAL IMPAIRMENT; EYE
   DISEASE; LESIONS
AB Aim To evaluate the efficiency of drusen detection by scanning laser ophthalmoscopy (SLO) using various infrared confocal apertures and differential contrast (DC) strategies.
   Methods 11 eyes with non-neovascular age-related macular degeneration (AMD) underwent infrared imaging with a Nidek F-10 confocal SLO using multiple confocal apertures: central, ring, aperture on the right side (AR) and left side (AL), with and without use of the DC. A conventional colour fundus photograph was also obtained. Images were exported into a certified grading tool and all visible drusen were manually outlined by two graders. For each image type, the number of drusen and total drusen area were calculated, and the measurements obtained by the two graders were averaged. Intergrader reliability was evaluated, and paired t tests compared measurements between the various aperture/DC modes and the colour image.
   Results Agreement between graders was high (r=0.93-0.98). Drusen number values obtained with the AR (121.0, p=0.01) mode were higher than for the colour photographs (69.1). Area measurements were also significantly higher in the AR (1.93 mm(2); p=0.04) and AL modes (1.41 mm(2); p=0.03) when compared with the colour photographs (1.24 mm(2)). The addition of the DC did not seem to improve drusen detection compared with the unmodified infrared images.
   Conclusions In this pilot study, drusen number and area grades were significantly higher using the AR and AL in which the laterally scattered light is captured (retromode). Use of the lateral confocal aperture may highlight subclinical drusen and aid in monitoring disease progression and response to emerging non-neovascular AMD therapies.
C1 [Diniz, Bruno; Ribeiro, Ramiro M.; Rodger, Damien C.; Sadda, SriniVas] Doheny Eye Inst, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Diniz, Bruno; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Ribeiro, Ramiro M.] Hosp Evangel Curitiba, Curitiba, Parana, Brazil.
   [Sadda, SriniVas] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
RP Diniz, B (corresponding author), Doheny Eye Inst, Dept Ophthalmol, 1355 San Pablo St,DVRC 121, Los Angeles, CA 90033 USA.
EM dinizb@me.com
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Rodger, Damien/0000-0002-1583-5946
FU NEIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Eye Institute (NEI);
   Beckman Institute for Macular Research; CAPES Foundation (Brasilia,
   Brazil)CAPES; NATIONAL EYE INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National Eye
   Institute (NEI) [P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040] Funding Source: NIH RePORTER
FX Supported in part by the NEI grant for basic research EY03040, the
   Beckman Institute for Macular Research, Research to Prevent Blindness, a
   Research to Prevent Blindness Physician Scientist Award, and the CAPES
   Foundation (Brasilia, Brazil). The authors thank Laurie Dustin for
   statistical analysis and Susan Clarke for text review.
CR Acton JH, 2011, ACTA OPHTHALMOL, V89, pE404, DOI 10.1111/j.1755-3768.2011.02123.x
   Barthes A, 2001, MED PHYS, V28, P2410, DOI 10.1118/1.1420735
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Ishiko S, 2002, OPHTHALMOLOGY, V109, P2165, DOI 10.1016/S0161-6420(02)01227-7
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   KIRKPATRICK JNP, 1995, EYE, V9, P48, DOI 10.1038/eye.1995.7
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   MANIVANNAN A, 1994, BRIT J OPHTHALMOL, V78, P84, DOI 10.1136/bjo.78.2.84
   Ohkoshi I, 2012, AM J OPHTHALMOL, V150, P856
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Quellec G, 2011, IEEE T MED IMAGING, V30, P523, DOI 10.1109/TMI.2010.2089383
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schlanitz FG, 2010, INVEST OPHTH VIS SCI, V51, P6715, DOI 10.1167/iovs.10-5288
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Tanaka Y, 2010, AM J OPHTHALMOL, V149, P635, DOI 10.1016/j.ajo.2009.10.024
   Yehoshua Zohar, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS6, DOI 10.3928/15428877-20101031-19
   Yoshida A, 1998, GRAEF ARCH CLIN EXP, V236, P445, DOI 10.1007/s004170050104
NR 25
TC 7
Z9 7
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2013
VL 97
IS 3
BP 285
EP 290
DI 10.1136/bjophthalmol-2012-302575
PG 6
WC Ophthalmology
SC Ophthalmology
GA 092ZW
UT WOS:000315162500010
PM 23264545
DA 2020-12-15
ER

PT J
AU Kac, G
   Maia, M
   da Sila, A
   Perez-Escamilla, R
AF Kac, G.
   Maia, M.
   da Sila, A.
   Perez-Escamilla, R.
TI HOUSEHOLD FOOF INSECURITY AND EXCESSIVE WEIGHT AMONG BRAZILIAN SUBJECTS:
   A LIFE-COURSE APPROACH
SO ANNALS OF NUTRITION AND METABOLISM
LA English
DT Meeting Abstract
DE Adolescents; children; food insecurity; women
C1 [Kac, G.; Maia, M.] Rio de Janeiro Fed Univ, Rio De Janeiro, Brazil.
   [da Sila, A.] Univ Fed Maranhao, Dept Saude Publ, Sao Luis, Brazil.
   [Perez-Escamilla, R.] Yale Univ, Sch Publ Hlth, Off Community Hlth, New Haven, CT 06520 USA.
RI Kac, Gilberto/H-6862-2012; Maia, Mauricio/I-5892-2015
OI Kac, Gilberto/0000-0001-8603-9077; Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-6807
EI 1421-9697
J9 ANN NUTR METAB
JI Ann. Nutr. Metab.
PY 2013
VL 63
SU 1
BP 54
EP 54
PG 1
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 219YR
UT WOS:000324548201116
DA 2020-12-15
ER

PT J
AU Penha, FM
   Pons, M
   Costa, EDF
   Rodrigues, EB
   Maia, M
   Marin-Castano, ME
   Farah, ME
AF Penha, Fernando M.
   Pons, Marianne
   Fiod Costa, Elaine de Paula
   Rodrigues, Eduardo B.
   Maia, Mauricio
   Marin-Castano, Maria E.
   Farah, Michel Eid
CA Int Chromovitrectomy Collaboration
TI Effect of Vital Dyes on Retinal Pigmented Epithelial Cell Viability and
   Apoptosis: Implications for Chromovitrectomy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Apoptosis; Cell viability; Retinal pigment epithelium; Vital dyes
ID INTERNAL LIMITING MEMBRANE; MACULAR HOLE SURGERY; INDOCYANINE GREEN
   INJECTION; TRYPAN BLUE; EPIRETINAL MEMBRANE; INFRACYANINE GREEN;
   SUBRETINAL INJECTION; FLUORESCENCE PATTERN; INTRAOCULAR SURGERY;
   CLINICAL-TRIAL
AB Purpose: To investigate the in vitro effect of vital dyes on toxicity and apoptosis in a human retinal pigment epithelial cell line. Methods: ARPE-19 cells were exposed to brilliant blue (BBG), Evans Blue (EB), bromophenol blue (BroB), indocyanine green (ICG), infracyanine green (IfCG), light green (LG), fast green (FG), indigo carmine (IC) and Congo red (CR). Balanced salt solution was used as the control. Five different concentrations and 2 exposure times were tested. Cell viability was determined by the MTS (1-solution methyl thiazolyl tetrazolium) assay and apoptosis by Bax expression on Western blot. Results: All dyes significantly reduced cell viability after 3 min of exposure at all concentrations (p < 0.01), except for BBG that was safe at concentrations up to 0.25 mg/ml and CR up to 0.05 mg/ml, while LG was safe at all concentrations. Toxicity was higher after 30 min of exposure. Expression of Bax was upregulated after all dye exposures, except BBG; ICG had the highest Bax expression (p < 0.01). Conclusions: Overall the safest dye was BBG followed by LG, IfCG, FG, CR, IC, BroB, EB and ICG. ICG was toxic at all concentrations and exposure times tested. Moreover, BBG was the only dye that did not induce apoptosis in ARPE-19 cells. (C) 2013 S. Karger AG, Basel
C1 [Penha, Fernando M.; Fiod Costa, Elaine de Paula; Rodrigues, Eduardo B.; Maia, Mauricio; Farah, Michel Eid] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao IPEPO, Sao Paulo, Brazil.
   [Pons, Marianne; Marin-Castano, Maria E.] Univ Miami, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
RP Marin-Castano, ME (corresponding author), Univ Miami, Bascom Palmer Eye Inst, Ctr Mol Ophthalmol, 1638 NW 10th Ave, Miami, FL 33136 USA.
EM mcastano@med.miami.edu
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019; Farah, Michel
   Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Farah, Michel Eid E/0000-0001-5951-0193; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e TecnologicoNational Council for Scientific
   and Technological Development (CNPq); NIH centerUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [P30EY014801]; Research to Prevent Blindness Unrestricted grantResearch
   to Prevent Blindness (RPB); Department of Defense (DOD)United States
   Department of Defense [W81X-WH-09-1-0675]; NATIONAL EYE INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Eye Institute (NEI) [P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801, P30EY014801, P30EY014801, P30EY014801,
   P30EY014801, P30EY014801] Funding Source: NIH RePORTER
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo and Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico, an NIH center core grant P30EY014801, a Research to Prevent
   Blindness Unrestricted grant, and the Department of Defense (DOD grant
   No. W81X-WH-09-1-0675).
CR Balaiya S, 2011, RETINA-J RET VIT DIS, V31, P1128, DOI 10.1097/IAE.0b013e3181fe543a
   Beutel J, 2007, ARCH OPHTHALMOL-CHIC, V125, P326, DOI 10.1001/archopht.125.3.326
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Christensen UC, 2009, BRIT J OPHTHALMOL, V93, P1005, DOI 10.1136/bjo.2008.151266
   Enaida Hiroshi, 2008, Dev Ophthalmol, V42, P115, DOI 10.1159/000138989
   Feron EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P141
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P3315, DOI 10.1167/iovs.04-1142
   Haritoglou C, 2004, RETINA-J RET VIT DIS, V24, P582, DOI 10.1097/00006982-200408000-00012
   Haritoglou C, 2007, BRIT J OPHTHALMOL, V91, P1125, DOI 10.1136/bjo.2007.115113
   Haritoglou Christos, 2005, Retina, V25, P545, DOI 10.1097/00006982-200506000-00033
   Hillenkamp J, 2007, GRAEF ARCH CLIN EXP, V245, P973, DOI 10.1007/s00417-006-0485-1
   Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668
   Iwamaru Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037896
   Jackson TL, 2005, EXP EYE RES, V81, P446, DOI 10.1016/j.exer.2005.03.004
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P2778, DOI 10.1167/iovs.04-0320
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P3697, DOI 10.1167/iovs.04-0387
   Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997
   Kadonosono K, 2000, ARCH OPHTHALMOL-CHIC, V118, P1116, DOI 10.1001/archopht.118.8.1116
   Kernt M, 2012, ACTA OPHTHALMOL, V90, P571, DOI 10.1111/j.1755-3768.2010.01961.x
   Kodjikian L, 2005, GRAEF ARCH CLIN EXP, V243, P917, DOI 10.1007/s00417-004-1121-6
   LANDSMAN MLJ, 1976, J APPL PHYSIOL, V40, P575
   Li K, 2003, BRIT J OPHTHALMOL, V87, P216, DOI 10.1136/bjo.87.2.216
   Luke M, 2008, GRAEF ARCH CLIN EXP, V246, P817, DOI 10.1007/s00417-007-0761-8
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Maia M, 2009, BRIT J OPHTHALMOL, V93, P1687, DOI 10.1136/bjo.2008.151597
   Maia M, 2007, CURR EYE RES, V32, P309, DOI 10.1080/02713680701199377
   Meyer CH, 2004, AM J OPHTHALMOL, V137, P207, DOI 10.1016/j.ajo.2003.09.014
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   NYBERG MA, 1977, A GRAEF ARCH KLIN EX, V204, P153, DOI 10.1007/BF00414843
   OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O
   Parone PA, 2002, BIOCHIMIE, V84, P105, DOI 10.1016/S0300-9084(02)01380-9
   Penha FM, 2008, J OCUL PHARMACOL TH, V24, P52, DOI 10.1089/jop.2007.0047
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Rodrigues EB, 2010, AM J OPHTHALMOL, V149, P265, DOI 10.1016/j.ajo.2009.08.020
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   Rosse T, 1998, NATURE, V391, P496
   Sayanagi K, 2007, AM J OPHTHALMOL, V144, P600, DOI 10.1016/j.ajo.2007.05.039
   Sayanagi K, 2007, BRIT J OPHTHALMOL, V91, P939, DOI 10.1136/bjo.2006.108746
   Schuettauf F, 2006, INVEST OPHTH VIS SCI, V47, P3573, DOI 10.1167/iovs.06-0211
   Smiddy W E, 1996, Bull Soc Belge Ophtalmol, V262, P31
   Sorsby A, 1939, Br J Ophthalmol, V23, P20, DOI 10.1136/bjo.23.1.20
   Stanescu-Segall D, 2009, EYE, V23, P504, DOI 10.1038/eye.2008.249
   Thaler S, 2012, GRAEF ARCH CLIN EXP, V250, P1597, DOI 10.1007/s00417-012-2000-1
   Ullern M, 2007, J FR OPHTALMOL, V30, P53, DOI 10.1016/S0181-5512(07)89551-9
   Vote BJ, 2004, RETINA-J RET VIT DIS, V24, P736, DOI 10.1097/00006982-200410000-00008
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   WOLLENSAK J, 1977, KLIN MONATSBL AUGENH, V171, P278
   Yoon HS, 1996, AM J OPHTHALMOL, V122, P67, DOI 10.1016/S0002-9394(14)71965-8
NR 51
TC 15
Z9 16
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 230
SU 2
BP 41
EP 50
DI 10.1159/000354251
PG 10
WC Ophthalmology
SC Ophthalmology
GA 218PM
UT WOS:000324444600007
PM 24022718
OA Green Accepted, Bronze
DA 2020-12-15
ER

PT J
AU Penha, FM
   Rodrigues, EB
   Maia, M
   Meyer, CH
   Cost, EPF
   Dib, E
   Bechara, E
   Lourenco, A
   Lima, AAS
   Freymuller, EH
   Farah, ME
AF Penha, Fernando M.
   Rodrigues, Eduardo B.
   Maia, Mauricio
   Meyer, Carsten H.
   Fiod Cost, Elaine de Paula
   Dib, Eduardo
   Bechara, Etelvino
   Lourenco, Andreia
   Lima Filho, Acacio A. S.
   Freymueller, Edna H.
   Farah, Michel Eid
CA Int Chromovitrectomy Collaboration
TI Biochemical Analysis and Decomposition Products of Indocyanine Green in
   Relation to Solvents, Dye Concentrations and Laser Exposure
SO OPHTHALMOLOGICA
LA English
DT Article
DE Indocyanine green; lnfracyanine green; Biochemical analysis; Osmolarity;
   Precipitation; Decomposition products; Quenchers; Chromovitrectomy;
   Vitrectonny; Internal limiting membrane; Retina
ID INTERNAL LIMITING MEMBRANE; RETINAL-PIGMENT EPITHELIUM; MACULAR HOLE
   SURGERY; INFRACYANINE GREEN; VITAL DYES; TOXICITY; LIGHT; RABBITS;
   CHROMOVITRECTOMY; INJECTION
AB Purpose: To investigate pH, ions, osmolarity and precipitation of indocyanine green (ICG), as well as the profile of ICG decomposition products (DPs) after laser exposure and the interaction with quenchers. Methods: ICG was diluted in water, 5% glucose (GL) or balanced salt solution (BSS) to achieve concentrations of 2.5, 1, 0.25 and 0.1 mg/ml. Osmolarity, pH and precipitation were analyzed immediately and after 24 h. Precipitation analyses were done with a scanning electron microscope. Anion and iodate analyses of ICG and infracyanine green (IfCG) were performed by capillary zone electrophoresis. With regard to DPs, 0.5 mg/ml of ICG was assessed with high-performance liquid chromatography (HPLC) after 810-nm laser irradiation. DP profiles were evaluated with ICG dilution in quenchers (Trolox, histidine and DABCO) in 3 concentrations (0.1, 1 and 10 m). Results: BSS promoted iso-osmotic ICG solutions of 208 mOsm (147-266) compared to GL with 177 mOsm. BSS solutions had a higher physiological pH of 7.2 compared with the GL one of 6.55. ICG precipitated more when diluted with BSS (5.95 mg); in contrast, GL showed less precipitate (3.6 mg). IfCG has no iodine derivates and other ICGs have an average 4.6% of iodate derivates. From HPLC analysis, 5 DPs were observed. The rate of DPs was higher when BSS was used (p < 0.05). Five DPs have been generated with ICG, and they may be altered with the quenchers DABCO, histidine and Trolox. Conclusions: BSS dilution induces more precipitation and DPs. ICG dilution in any solvent induces DPs. Quencher use reduces the amount of toxic DPs. (C) 2013 S. Karger AG, Basel
C1 [Penha, Fernando M.; Rodrigues, Eduardo B.; Maia, Mauricio; Fiod Cost, Elaine de Paula; Dib, Eduardo; Lourenco, Andreia; Lima Filho, Acacio A. S.; Farah, Michel Eid] Univ Fed Sao Paulo, Vis Inst IPEPO, Dept Ophthalmol, Sao Paulo, Brazil.
   [Freymueller, Edna H.] Univ Fed Sao Paulo, Electron Microscopy Ctr, Sao Paulo, Brazil.
   [Bechara, Etelvino] Univ Sao Paulo, Inst Chem, Sao Paulo, Brazil.
   [Meyer, Carsten H.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
RP Rodrigues, EB (corresponding author), Rua Botucatu,821,2 Andar, BR-04023062 Sao Paulo, Brazil.
EM rodriguesretina@gmail.com
RI de Souza Lima Filho, Acacio Alves/C-7189-2012; Meyer, Carsten
   H./A-3981-2017; Farah, Michel Eid E/F-3285-2012; Maia,
   Mauricio/Z-1042-2019; Bechara, Etelvino JH/M-6251-2013; Maia,
   Mauricio/I-5892-2015
OI Meyer, Carsten H./0000-0002-0530-5298; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Bechara,
   Etelvino JH/0000-0001-9526-2529; Maia, Mauricio/0000-0002-7034-8091;
   Alves de Souza Lima Filho, Acacio/0000-0003-1802-9592; Buchele
   Rodrigues, Eduardo/0000-0002-4224-0921
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Pan-American Association of Ophthalmology (PAAO)
FX This work was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP), and the Pan-American Association of Ophthalmology
   (PAAO).
CR Engel E, 2008, INVEST OPHTH VIS SCI, V49, P1777, DOI 10.1167/iovs.07-0911
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Gandorfer A, 2001, AM J OPHTHALMOL, V132, P431, DOI 10.1016/S0002-9394(01)01087-X
   Gratz H, 1999, J PHOTOCH PHOTOBIO A, V128, P101, DOI 10.1016/S1010-6030(99)00174-4
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P1468, DOI 10.1167/iovs.04-0838
   Haritoglou C, 2003, INVEST OPHTH VIS SCI, V44, P2722, DOI 10.1167/iovs.02-1283
   Ho JD, 2004, ARCH OPHTHALMOL-CHIC, V122, P871, DOI 10.1001/archopht.122.6.871
   Ho JD, 2004, BRIT J OPHTHALMOL, V88, P556, DOI 10.1136/bjo.2003.018523
   Holzer W, 1998, J PHOTOCH PHOTOBIO B, V47, P155, DOI 10.1016/S1011-1344(98)00216-4
   Ikagawa H, 2005, INVEST OPHTH VIS SCI, V46, P2531, DOI 10.1167/iovs.04-1521
   Jackson TL, 2005, EXP EYE RES, V81, P446, DOI 10.1016/j.exer.2005.03.004
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P3697, DOI 10.1167/iovs.04-0387
   Lanzetta P, 2006, AM J OPHTHALMOL, V142, P771, DOI 10.1016/j.ajo.2006.06.032
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Narayanan R, 2005, CURR EYE RES, V30, P471, DOI 10.1080/02713680590959312
   NIEMEYER G, 1986, DOC OPHTHALMOL, V63, P113, DOI 10.1007/BF00157120
   Nishimura A, 2003, JPN J OPHTHALMOL, V47, P18, DOI 10.1016/S0021-5155(02)00648-2
   OLSEN KJ, 1979, ACTA PHARMACOL TOX, V44, P241
   Penha FM, 2008, J OCUL PHARMACOL TH, V24, P52, DOI 10.1089/jop.2007.0047
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Penha FM, 2010, OPHTHAL RES, V44, P82, DOI 10.1159/000312817
   Pereira EA, 2004, ANAL BIOANAL CHEM, V380, P178, DOI 10.1007/s00216-004-2725-8
   Rivett K, 2004, GRAEF ARCH CLIN EXP, V242, P393, DOI 10.1007/s00417-003-0857-8
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Rodrigues EB, 2004, ARCH OPHTHALMOL-CHIC, V122, P663, DOI 10.1001/archopht.122.4.663
   Rodrigues EB, 2007, RETINA-J RET VIT DIS, V27, P958, DOI 10.1097/01.iae.0000253051.01194.ab
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   Saxena V, 2003, J PHARM SCI, V92, P2090, DOI 10.1002/jps.10470
   Stalmans P, 2002, AM J OPHTHALMOL, V134, P282, DOI 10.1016/S0002-9394(02)01468-X
   Stanescu-Segall D, 2009, EYE, V23, P504, DOI 10.1038/eye.2008.249
   Ullern M, 2002, J FR OPHTALMOL, V25, P915
NR 33
TC 8
Z9 10
U1 2
U2 13
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 230
SU 2
BP 59
EP 67
DI 10.1159/000353871
PG 9
WC Ophthalmology
SC Ophthalmology
GA 218PM
UT WOS:000324444600009
PM 24022720
DA 2020-12-15
ER

PT J
AU Rodrigues, EB
   Maia, M
   Penha, FM
   Dib, E
   Melo, GB
   Maia, A
   Farah, ME
AF Rodrigues, Eduardo B.
   Maia, Mauricio
   Penha, Fernando M.
   Dib, Eduardo
   Melo, Gustavo B.
   Maia, Andre
   Farah, Michel E.
CA Int Chromovitrectomy Collaboration
TI Staining Properties of Brilliant Blue Depending on Different Incubation
   Times and Solvents in Humans
SO OPHTHALMOLOGICA
LA English
DT Article
DE Brilliant blue; Retina; Internal limiting membrane; Macular hole;
   Vitrectomy
ID INDOCYANINE GREEN; VITAL DYES; TRYPAN BLUE; EPIRETINAL MEMBRANE
AB Purpose: Intravitreous injection of vital dyes, e.g. brilliant blue (BBG), promotes better visualization of the internal limiting membrane (ILM). This paper investigates the staining properties of BBG depending on different incubation times and 2 types of solvents - 5% glucose (GL) or saline solution - in a prospective study in patients. Methods: This paper investigates various aspects of BBG in various methods. An interventional prospective study was conducted in patients to examine the binding properties of the blue dye diluted in either saline or 5% GL to epiretinal membranes (ERMs) and ILMs. Forty-nine consecutive patients older than 18 years scheduled for macular ERM, vitreomacular traction and macular hole surgeries were prospectively recruited. The primary outcomes of this study were the degree of ILM and ERM staining. The secondary outcomes of the study were the need of reinjection of BBG or any other dye, the ability of BBG to stain the vitreous, and frequency of complications. The staining of the ILM and ERM were graded as no staining, little, moderate or strong staining. Results:There was no correlation between age (p = 0.32) or gender (p = 0.33) in the staining affinity of BBG to either the ILM or ERM. BBG may be an appropriate staining agent for the ILM in the majority (82%) of surgeries; however, in approximately half of the cases (45%) surgeons considered BBG not enough for ERM coloring and visualization. There is a tendency of BBG to stain the ILM better when saline solution is used compared to GL 5%; however, this was not statistically significant (p = 0.64). There was no difference in the staining efficacy of BBG to the ERMs by either solution (p = 0.70), despite the low staining affinity. Conclusion: BBG became the state-of-the-art dye for ILM identification. Differences in staining properties may imply that BBG should not be considered as first-line stain for ERM surgery. BBG is effective in ILM staining in over 80% of macular hole surgeries. (C) 2013 S. Karger AG, Basel
C1 [Rodrigues, Eduardo B.; Maia, Mauricio; Penha, Fernando M.; Dib, Eduardo; Melo, Gustavo B.; Maia, Andre; Farah, Michel E.; Int Chromovitrectomy Collaboration] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, BR-88030460 Florianopolis, SC, Brazil.
RP Rodrigues, EB (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, Almirante Barroso 45,Jade 204 Joao Paulo, BR-88030460 Florianopolis, SC, Brazil.
EM rodriguesretina@gmail.com
RI Melo, Gustavo/AAD-3844-2019; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012
OI Melo, Gustavo/0000-0001-5765-2008; Maia, Mauricio/0000-0002-7034-8091;
   Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Buchele Rodrigues, Eduardo/0000-0002-4224-0921
FU Conselho Nacional de D esenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Pan-American Association of Ophthalmology (PAAO)
FX This work was supported by the Conselho Nacional de D esenvolvimento
   Cientifico e Tecnologico (CNPq), Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP), and the Pan-American Association of Ophthalmology
   (PAAO).
CR Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Dib E, 2009, ARQ BRAS OFTALMOL, V72, P845, DOI 10.1590/S0004-27492009000600022
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P623, DOI 10.1097/00006982-200607000-00006
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Feron EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P141
   Hoing A, 2011, KLIN MONATSBL AUGENH, V228, P724, DOI 10.1055/s-0031-1273351
   Kiernan JA, 2001, BIOTECH HISTOCHEM, V76, P261, DOI 10.1080/714028154
   Kumagai K, 2010, AM J OPHTHALMOL, V149, P127, DOI 10.1016/j.ajo.2009.08.002
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2009, BRIT J OPHTHALMOL, V93, P1687, DOI 10.1136/bjo.2008.151597
   Mennel S, 2006, OPHTHALMOLOGICA, V220, P190, DOI 10.1159/000091764
   Morales MC, 2010, INVEST OPHTH VIS SCI, V51, P6018, DOI 10.1167/iovs.09-4916
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Perrier M, 2003, AM J OPHTHALMOL, V135, P909, DOI 10.1016/S0002-9394(02)02256-0
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Rodrigues EB, 2003, BRIT J OPHTHALMOL, V87, P1431, DOI 10.1136/bjo.87.11.1431-a
   Rodrigues EB, 2007, RETINA-J RET VIT DIS, V27, P958, DOI 10.1097/01.iae.0000253051.01194.ab
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Rodrigues EB, 2010, AM J OPHTHALMOL, V149, P265, DOI 10.1016/j.ajo.2009.08.020
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Ueno A, 2007, RETINA-J RET VIT DIS, V27, P499, DOI 10.1097/IAE.0b013e318030a129
NR 22
TC 1
Z9 1
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 230
SU 2
BP 68
EP 72
DI 10.1159/000353872
PG 5
WC Ophthalmology
SC Ophthalmology
GA 218PM
UT WOS:000324444600010
PM 24022721
DA 2020-12-15
ER

PT J
AU Chen, J
   Ferreira, MA
   Farah, ME
   de Carvalho, AM
   Ferreira, REA
   de Moraes, MN
   Lima, AA
   Lago, JHG
   Sartorelli, P
   Rodrigues, EB
   Ferreira, E
   Peris, C
   Maia, M
AF Chen, Jane
   Ferreira, Magno Antonio
   Farah, Michel Eid
   de Carvalho, Andre Maia
   Alves Ferreira, Raquel Eustaquio
   de Moraes Filho, Milton Nunes
   Souza Lima-Filho, Acacio Alves
   Lago, Joao Henrique G.
   Sartorelli, Patricia
   Rodrigues, Eduardo Buchele
   Ferreira, Eber
   Peris, Cristiane
   Maia, Mauricio
TI POSTERIOR HYALOID DETACHMENT AND INTERNAL LIMITING MEMBRANE PEELING
   ASSISTED BY ANTHOCYANINS FROM ACAI FRUIT (EUTERPE OLERACEA) AND 10 OTHER
   NATURAL VITAL DYES Experimental Study in Cadaveric Eyes
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE chromovitrectomy; natural dyes; posterior vitreous detachment; internal
   limiting membrane peeling
ID INDOCYANINE GREEN; BLUE; INJECTION; SURGERY
AB Purpose: The purpose of this study was to determine whether natural dyes facilitate posterior hyaloid detachment (posterior vitreous detachment [PVD]) and retinal internal limiting membrane (ILM) peeling in human eyes.
   Methods: Open-sky vitrectomy with posterior hyaloid and ILM removal was performed in 86 human cadaveric eyes. After core vitrectomy, 11 different dyes were injected into the vitreous cavity to aid hyaloid detachment and ILM removal. The dyes were allowed to settle on the macula for 5 minutes after PVD and were removed by mechanical aspiration. Intraocular forceps were used for ILM peeling, which was confirmed by light microscopy of the peeled tissue. Acai fruit (Euterpe oleracea) extract and 10 additional dyes from plants or animal sources were tested: pomegranate (Punica granatum), logwood (Haematoxylum campechianum), chlorophyll extract from alfalfa (Medicago sativa), cochineal (Dactylopius coccus), hibiscus (Hibiscus rosa-sinensis), indigo (Indigofera tinctoria), paprika (Capiscum annuum), turmeric (Curcuma longa), old fustic (Maclura tinctoria), and grape (Vitis vinifera).
   Results: The dyes facilitated PVD and ILM peeling. Acai fruit (E. oleracea) extract, logwood (H. campechianum), cochineal (D. coccus), and old fustic (M. tinctoria) facilitated PVD in all cases; dye-assisted PVD was compared with triamcinolone-assisted PVD performed previously in a comparative model. Acai fruit (E. oleracea) extract, cochineal (D. coccus), and chlorophyll extract from alfalfa (M. sativa) showed the best capability for ILM staining; dye-assisted ILM removal was compared with the ILM peeling guided by indocyanine green staining performed previously in a comparative model. Light microscopy confirmed the ILM removal in all cases.
   Conclusion: Anthocyanin dye of the acai fruit (E. oleracea) and the dyes from cochineal (D. coccus) and chlorophyll extract from alfalfa (M. sativa) resulted in the best capability for posterior hyaloid and ILM staining in human cadaveric eyes and may be a useful tool for vitreoretinal surgery. RETINA 33:89-96, 2013
C1 [Chen, Jane; Ferreira, Magno Antonio; Farah, Michel Eid; de Carvalho, Andre Maia; de Moraes Filho, Milton Nunes; Rodrigues, Eduardo Buchele; Peris, Cristiane; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, Paulista Sch Med, Sao Paulo, Brazil.
   [Ferreira, Magno Antonio] Univ Fed Uberlandia, Dept Ophthalmol, Vitreoretinal Surg Unit, BR-38400328 Uberlandia, MG, Brazil.
   [Souza Lima-Filho, Acacio Alves] Ophthalmos, Sao Paulo, Brazil.
   [Lago, Joao Henrique G.; Sartorelli, Patricia] Univ Fed Sao Paulo, Inst Environm Sci Chem & Pharm, Sao Paulo, Brazil.
   [Ferreira, Eber] Ethno, Sao Paulo, Brazil.
RP Ferreira, MA (corresponding author), Univ Fed Uberlandia, Dept Ophthalmol, Vitreoretinal Surg Unit, 855 Av Marcos de Freitas Costa, BR-38400328 Uberlandia, MG, Brazil.
EM drmagno@holhosudi.com.br
RI de Souza Lima Filho, Acacio Alves/C-7189-2012; Lago, Joao/W-5238-2019;
   Rodrigues, Eduardo Buchele/C-6852-2015; Sartorelli,
   Patricia/E-2556-2016; Maia, Mauricio/I-5892-2015; Maia,
   Mauricio/Z-1042-2019; Sartorelli, Patricia/AAN-2911-2020; Farah, Michel
   Eid E/F-3285-2012
OI Lago, Joao/0000-0002-1193-8374; Maia, Mauricio/0000-0002-7034-8091;
   Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Buchele Rodrigues, Eduardo/0000-0002-4224-0921;
   Alves de Souza Lima Filho, Acacio/0000-0003-1802-9592; ferreira,
   magno/0000-0002-8596-4997
CR Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Clarke M, 2007, ICON NEWS, V9, P33
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P623, DOI 10.1097/00006982-200607000-00006
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Feron EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P141
   Gandorfer A, 2003, INVEST OPHTH VIS SCI, V44, P316, DOI 10.1167/iovs.02-0545
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P3315, DOI 10.1167/iovs.04-1142
   Jackson TL, 2005, EXP EYE RES, V81, P446, DOI 10.1016/j.exer.2005.03.004
   Kumar Atul, 2004, Indian J Ophthalmol, V52, P339
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Maia M, 2009, BRIT J OPHTHALMOL, V93, P1687, DOI 10.1136/bjo.2008.151597
   Mennel S, 2006, OPHTHALMOLOGICA, V220, P190, DOI 10.1159/000091764
   Penha FM, 2008, J OCUL PHARMACOL TH, V24, P52, DOI 10.1089/jop.2007.0047
   Perrier M, 2003, AM J OPHTHALMOL, V135, P909, DOI 10.1016/S0002-9394(02)02256-0
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Phipps E, 2008, J AM INST CONSERV, V47, P150
   Qin Y, 2009, AM J CLIN NUTR, V90, P485, DOI 10.3945/ajcn.2009.27814
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Rodrigues EB, 2010, AM J OPHTHALMOL, V149, P265, DOI 10.1016/j.ajo.2009.08.020
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Rodrigues Eduardo B, 2008, Dev Ophthalmol, V42, P29, DOI 10.1159/000138911
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   Sanchez TA, 2009, J COMPUT ASSIST TOMO, V33, P666, DOI 10.1097/RCT.0b013e31819012a0
   Schauss AG, 2006, J AGR FOOD CHEM, V54, P8598, DOI 10.1021/jf060976g
   Schuettauf F, 2006, INVEST OPHTH VIS SCI, V47, P3573, DOI 10.1167/iovs.06-0211
   Teba FA, 2003, OPHTHALMOLOGY, V110, P2409, DOI 10.1016/S0161-6420(03)00716-4
   Vera de Rosso V, 2007, J AGR FOOD CHEM, V55, P9135, DOI 10.1021/jf071316u
NR 29
TC 10
Z9 11
U1 0
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2013
VL 33
IS 1
BP 89
EP 96
DI 10.1097/IAE.0b013e3182618a6d
PG 8
WC Ophthalmology
SC Ophthalmology
GA 069GE
UT WOS:000313422500011
PM 22990318
DA 2020-12-15
ER

PT J
AU Diniz, B
   Ribeiro, RM
   Fernandes, RB
   Lue, JC
   Teixeira, AG
   Maia, M
   Humayun, MS
AF Diniz, Bruno
   Ribeiro, Ramiro M.
   Fernandes, Rodrigo B.
   Lue, Jaw-Chyng
   Teixeira, Anderson G.
   Maia, Mauricio
   Humayun, Mark S.
TI Fluidics in a Dual Pneumatic Ultra High-Speed Vitreous Cutter System
SO OPHTHALMOLOGICA
LA English
DT Article
DE Vitreoretinal surgery; Pars plana vitrectomy; Vitrectomy
ID PLANA VITRECTOMY; 20-GAUGE; SURGERY; PERFORMANCE; 23-GAUGE; DYNAMICS
AB Background: Dual pneumatic systems use two separate air line tubes to open and close the cutter and can achieve high cut rates. The purpose of this study is to evaluate the influence of gauge size, cut rate and aspiration on the flow rate performance of ultra high-speed cutters operated with a commercially available dual pneumatic vitrectomy system. Methods: Analysis of a high-speed video was used to determine duty cycle. Flow rates from 20-, 23- and 25-gauge cutters were calculated in predetermined conditions of aspiration levels and cut rates; water and fresh porcine vitreous samples were studied. Results: For all three gauges of cutters, the duty cycle and water flow showed an inverse correlation with increasing cut rates and a direct correlation with increasing aspiration levels (p < 0.05). Vitreous flow rates from all gauges increased with increasing aspiration and cut rates (p < 0.05). Conclusion: Larger gauges of the cutters as well as higher aspiration and cut rate levels resulted in improvement of the vitreous flow rates. A good understanding of the different flow rate settings is essential for the surgeon and optimizes the safety of surgical procedures. Copyright (C) 2012 S. Karger AG, Basel
C1 [Diniz, Bruno; Ribeiro, Ramiro M.; Fernandes, Rodrigo B.; Lue, Jaw-Chyng; Humayun, Mark S.] Univ So Calif, Doheny Eye Inst, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Humayun, Mark S.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Diniz, Bruno; Fernandes, Rodrigo B.; Teixeira, Anderson G.; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Ribeiro, Ramiro M.] Hosp Univ Curitiba FEMPAR, Dept Ophthalmol, Curitiba, Parana, Brazil.
RP Diniz, B (corresponding author), Univ So Calif, Doheny Eye Inst, Keck Sch Med, 1355 San Pablo St,DVRC 121, Los Angeles, CA 90033 USA.
EM drbrunodiniz@gmail.com
RI Maia, Mauricio/I-5892-2015; Teixeira, Anderson/K-2320-2013; Maia,
   Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Teixeira, Anderson/0000-0001-7585-712X
FU Eye Concepts Laboratory at the Doheny Eye Institute; National Eye
   Institute basic research grant [EY03040]; CAPES Foundation - BrazilCAPES
   [BEX 2326-11-6]; CNPq (the National Council of Research - Brazil);
   Research to Prevent BlindnessResearch to Prevent Blindness (RPB);
   NATIONAL EYE INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Eye
   Institute (NEI) [P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040] Funding Source: NIH RePORTER
FX This study was supported in part by the Eye Concepts Laboratory at the
   Doheny Eye Institute, National Eye Institute basic research grant
   (EY03040), the CAPES Foundation - Brazil [BEX 2326-11-6 (BD)], CNPq (the
   National Council of Research - Brazil) and an unrestricted grant from
   Research to Prevent Blindness. We thank Laurie Dustin for the
   statistical analysis and Susan Clarke for the text review.
CR Charles S, 2004, RETINA-J RET VIT DIS, V24, P435, DOI 10.1097/00006982-200406000-00015
   Fang SY, 2008, GRAEF ARCH CLIN EXP, V246, P61, DOI 10.1007/s00417-007-0672-8
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1807, DOI 10.1016/S0161-6420(02)01179-X
   Hubschman JP, 2008, RETINA-J RET VIT DIS, V28, P249, DOI 10.1097/IAE.0b013e31815ec2b3
   Hubschman JP, 2009, RETINA-J RET VIT DIS, V29, P1289, DOI 10.1097/IAE.0b013e3181acd3a9
   Magalhaes O, 2008, RETINA-J RET VIT DIS, V28, P236, DOI 10.1097/IAE.0b013e318158e9e0
   Magalhaes Octaviano Jr, 2009, Retin Cases Brief Rep, V3, P64, DOI 10.1097/ICB.0b013e31815657a7
   Magalhaes O, 2011, AM J OPHTHALMOL, V151, P401, DOI 10.1016/j.ajo.2010.11.009
   Matsuoka N, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20101223-03
   Rizzo S, 2011, RETINA-J RET VIT DIS, V31, P2007, DOI 10.1097/IAE.0b013e318213623a
   Sato T, 2008, RETINA-J RET VIT DIS, V28, P749, DOI 10.1097/IAE.0b013e3181631907
   Steel DHW, 2011, OPHTHALMOLOGICA, V226, P27, DOI 10.1159/000328207
   Teixeira A, 2010, OPHTHALMOLOGY, V117, P1387, DOI 10.1016/j.ophtha.2009.11.004
   Thompson JT, 2011, SURV OPHTHALMOL, V56, P162, DOI 10.1016/j.survophthal.2010.08.003
   Williams GA, 2008, EYE, V22, P1263, DOI 10.1038/eye.2008.20
   Yanyali A, 2006, EUR J OPHTHALMOL, V16, P141
NR 16
TC 15
Z9 15
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 229
IS 1
BP 15
EP 20
DI 10.1159/000343073
PG 6
WC Ophthalmology
SC Ophthalmology
GA 057TH
UT WOS:000312586400002
PM 23108417
OA Green Accepted, Bronze
DA 2020-12-15
ER

PT J
AU Bottos, JM
   Torres, VLL
   Kanecadan, LAA
   Martinez, AAG
   Moraes, NSB
   Maia, M
   Allemann, N
AF Bottos, Juliana Mantovani
   Lucas Torres, Virginia Laura
   Almeida Kanecadan, Liliane Andrade
   Gonzalez Martinez, Andrea Alejandra
   Bueno Moraes, Nilva Simeren
   Maia, Mauricio
   Allemann, Norma
TI Macular hole: 10 and 20-MHz ultrasound and spectral-domain optical
   coherence tomography
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Retinal perforations/ultrasonography; Tomography, optical
   coherence/instrumentation; Transducers; Vitreous detachment/diagnosis
ID POSTERIOR VITREOUS DETACHMENT; B-SCAN ULTRASONOGRAPHY
AB Purpose: Optical coherence tomography (OCT) is valuable for macula evaluation. However, as this technique relies on light energy it cannot be performed in the presence of opaque media. In such cases, the ultrasound (US) may predict some macular features. The aim of this study was to characterize images obtained by ultrasound with 10 and 20-MHz transducers comparing to OCT, as well as to analyze the relationship between the vitreous and retina in eyes with macular hole (MH).
   Methods: 29 eyes of 22 patients with biomicroscopic evidence of MH at different stages were included. All patients were evaluated using ultrasonography with 10 and 20-MHz transducers and OCT.
   Results: OCT identified signs of MH in 25 of 29 eyes. The remaining 4 cases not identified by US were pseudoholes caused by epiretinal membranes. In MH stages I (2 eyes) and II (1 eye), both transducers were not useful to analyze the macular thickening, but suggestive findings as macular irregularity, operculum or partial posterior vitreous detachment (PVD) were highlighted. In stages III (14 eyes) and IV (5 eyes), both transducers identified the double hump irregularity and thickening. US could measure the macular thickness and other suggestive findings for MH: operculum, vitreomacular traction and partial or complete PVD. In cases of pseudoholes, US identified irregularities macular contour and a discrete depression.
   Conclusion: 10-MHz US was useful for an overall assessment of the vitreous body as well as its relationship to the retina. The 20-MHz transducer allowed valuable information on the vitreomacular interface and macular contour. OCT provides superior quality for fine morphological study of macular area, except in cases of opaque media. In these cases, and even if OCT is not available, the combined US study is able to provide a valid evaluation of the macular area improving therapeutic approach.
C1 [Bottos, Juliana Mantovani; Almeida Kanecadan, Liliane Andrade; Gonzalez Martinez, Andrea Alejandra; Bueno Moraes, Nilva Simeren; Maia, Mauricio; Allemann, Norma] Univ Fed Sao Paulo UNIFESP, Dept Ophthalmol, Sao Paulo, Brazil.
   [Lucas Torres, Virginia Laura] Univ Fed Paraiba UFPB, Dept Ophthalmol, Joao Pessoa, PB, Brazil.
RP Allemann, N (corresponding author), Ave Indianopolis 1-797, BR-04063003 Sao Paulo, Brazil.
EM norma.allemann@pobox.com
RI Allemann, Norma/K-5451-2013; Maia, Mauricio/Z-1042-2019; Torres,
   Virginia/N-6951-2018; Ambrogini, Nilva SBM/K-6136-2016; Maia,
   Mauricio/I-5892-2015
OI Allemann, Norma/0000-0001-5432-4287; Maia, Mauricio/0000-0002-7034-8091;
   Torres, Virginia/0000-0002-3744-0961; Maia, Mauricio/0000-0002-7034-8091
CR Coleman DJ, 2006, EXPERT REV OPHTHALMO, V1, P63, DOI 10.1586/17469899.1.1.63
   Coleman DJ, 2004, OPHTHALMOLOGY, V111, P1344, DOI 10.1016/j.ophtha.2003.10.029
   Gallemore RP, 2000, RETINA-J RET VIT DIS, V20, P115, DOI 10.1097/00006982-200002000-00002
   GASS JDM, 1988, ARCH OPHTHALMOL-CHIC, V106, P629, DOI 10.1001/archopht.1988.01060130683026
   GASS JDM, 1995, AM J OPHTHALMOL, V119, P752, DOI 10.1016/S0002-9394(14)72781-3
   Gaudric A, 1999, ARCH OPHTHALMOL-CHIC, V117, P744
   Glacet-Bernard A, 2005, AM J OPHTHALMOL, V139, P814, DOI 10.1016/j.ajo.2004.12.030
   Gonçalves Allan Christian Pieroni, 2005, Arq. Bras. Oftalmol., V68, P445, DOI 10.1590/S0004-27492005000400006
   Haouchine B, 2001, OPHTHALMOLOGY, V108, P15, DOI 10.1016/S0161-6420(00)00519-4
   Hewick SA, 2004, BRIT J OPHTHALMOL, V88, P551, DOI 10.1136/bjo.2003.028126
   HIKICHI T, 1993, AM J OPHTHALMOL, V116, P273, DOI 10.1016/S0002-9394(14)71343-1
   Ito Y, 2003, AM J OPHTHALMOL, V135, P351, DOI 10.1016/S0002-9394(02)01944-X
   Johnson MW, 2001, ARCH OPHTHALMOL-CHIC, V119, P215
   Kicova N, 2012, ACTA OPHTHALMOL, V90, pE264, DOI 10.1111/j.1755-3768.2011.02330.x
   Carrero JL, 2012, AM J OPHTHALMOL, V153, P497, DOI 10.1016/j.ajo.2011.08.036
   MCDONALD HR, 1994, OPHTHALMOLOGY, V101, P1397
   McDonald HR, 1994, OPHTHALMOLOGY, V101, P1403
   Mirza RG, 2007, SURV OPHTHALMOL, V52, P397, DOI 10.1016/j.survophthal.2007.04.007
   Primiano Júnior Hélio Paulo, 2007, Arq. Bras. Oftalmol., V70, P143, DOI 10.1590/S0004-27492007000100027
   Siahmed K, 2005, J FR OPHTALMOL, V28, P733, DOI 10.1016/S0181-5512(05)80985-4
   Spaide RF, 2002, AM J OPHTHALMOL, V133, P226, DOI 10.1016/S0002-9394(01)01377-0
   Stalmans P, 2010, RETINA-J RET VIT DIS, V30, P1122, DOI 10.1097/IAE.0b013e3181e0970a
   Van Newkirk M R, 2000, Trans Am Ophthalmol Soc, V98, P163
   Van Newkirk M. R., 2000, T AM OPHTHAL SOC, V98
   YONEMOTO J, 1994, GRAEF ARCH CLIN EXP, V232, P67, DOI 10.1007/BF00171665
NR 25
TC 4
Z9 4
U1 0
U2 4
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD NOV-DEC
PY 2012
VL 75
IS 6
BP 415
EP 419
DI 10.1590/S0004-27492012000600009
PG 5
WC Ophthalmology
SC Ophthalmology
GA 158PL
UT WOS:000319984500009
PM 23715145
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Arana, LA
   Pinto, AT
   Chader, GJ
   Barbosa, JD
   Morales, S
   Moreira, AT
   Maia, M
   Humayun, MS
AF Arana, Luis A.
   Pinto, Anderson T.
   Chader, Gerald J.
   Barbosa, Jose D.
   Morales, Sabina
   Moreira, Ana T.
   Maia, Mauricio
   Humayun, Mark S.
TI Fluorescein angiography, optical coherence tomography, and
   histopathologic findings in a VEGF(165) animal model of retinal
   angiogenesis
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE VEGF; Retinal neovascularization; OCT; Fluorescein angiography; Animal
   model
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL SUSTAINED-RELEASE;
   DIABETIC-RETINOPATHY; SUBRETINAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; VEIN OCCLUSION; UNITED-STATES; RABBITS; VEGF;
   MICROANGIOPATHY
AB To establish an animal model of retinal neovascularization using vascular endothelial growth factor (VEGF165) and analyze the model using optical coherence tomography (OCT), fluorescein angiography (FA), and histopathologic evaluation.
   Twelve rabbits were divided into groups as follows: group 1 (n = 3), sham intravitreous injections of 0.1 ml of balanced saline; group 2 (n = 6), one 10-mu g intravitreal injection of VEGF165 on day 0; and group 3 (n = 3), two 10-mu g intravitreal injections of VEGF165, one on day 0 and one on day 7. Follow-up evaluations (days 0, 3, 7, 14, 21, 28) included obtaining fundus color photographs and FA, OCT, and histopathologic examinations. Eyes were enucleated and stained with hematoxylin and eosin (H&E).
   One injection of VEGF (group 2) was associated with dilatation and tortuosity of the retinal blood vessels that developed within 72 h. Retinal neovascularization was present by day 7 and regressed by day 14. However, even on day 28, the capillaries were still tortuous. Two VEGF injections (group 3) caused increased leakage and neovascularization up to day 14; severe capillary nonperfusion was seen during week 4. At the end of the follow-up period, OCT and histopathologic examination of group 3 showed peripapillary tractional retinal detachments. By day 7, the differences between the retinal thickness seen on OCT in groups 2 and 3 and the group 1 control group were significant (p < 0.001). The histologic findings showed increased vessel size in groups 2 and 3 by days 14 and 28 compared with the controls.
   FA, OCT, and histopathologic findings showed that this retinal neovascularization model is efficient, sustainable, and reliable. One injection of VEGF165 created neovascularization that peaked after 1 week; two injections created more intense neovascularization that evolved to retinal detachments after 4 weeks.
C1 [Arana, Luis A.; Moreira, Ana T.] Univ Fed Parana, Dept Ophthalmol, Curitiba, PR, Brazil.
   [Arana, Luis A.; Pinto, Anderson T.; Chader, Gerald J.; Barbosa, Jose D.; Morales, Sabina; Humayun, Mark S.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Arana, Luis A.; Pinto, Anderson T.; Chader, Gerald J.; Barbosa, Jose D.; Morales, Sabina; Humayun, Mark S.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Pinto, Anderson T.; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
RP Arana, LA (corresponding author), Univ Fed Parana, Dept Ophthalmol, Rua Padre Anchieta 1251, Curitiba, PR, Brazil.
EM aranaoftalmologia@gmail.com
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019; Teixeira,
   Anderson/K-2320-2013
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Arana, Luis Augusto/0000-0002-2154-4707
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Alikacem N, 2000, INVEST OPHTH VIS SCI, V41, P1561
   Ameri H, 2007, INVEST OPHTH VIS SCI, V48, P5708, DOI 10.1167/iovs.07-0731
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   DEEM CW, 1974, INVEST OPHTH VISUAL, V13, P580
   FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18
   FINKELSTEIN D, 1977, AM J OPHTHALMOL, V83, P660, DOI 10.1016/0002-9394(77)90132-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219
   HAMILTON AM, 1975, EXP EYE RES, V20, P493, DOI 10.1016/0014-4835(75)90216-X
   Hofman P, 2001, ARCH OPHTHALMOL-CHIC, V119, P861
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   PARK JE, 1993, MOL BIOL CELL, V4, P1317
   PENN JS, 1993, INVEST OPHTH VIS SCI, V34, P576
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   POURNARAS CJ, 1990, OPHTHALMOLOGY, V97, P1321
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2010.01.060, 10.1016/j.ophtha.2009.07.017]
   Saati S, 2010, GRAEF ARCH CLIN EXP, V248, P457, DOI 10.1007/s00417-009-1153-z
   Sampaio RB, 2010, CURR EYE RES, V35, P56, DOI 10.3109/02713680903374216
   Sato T, 2009, OPHTHALMOLOGY, V116, P2165, DOI 10.1016/j.ophtha.2009.04.026
   Suto C, 1992, Nippon Ganka Gakkai Zasshi, V96, P959
   Tamura M, 2001, JPN J OPHTHALMOL, V45, P144, DOI 10.1016/S0021-5155(00)00353-1
   TANO Y, 1981, AM J OPHTHALMOL, V92, P103, DOI 10.1016/S0002-9394(14)75913-6
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Wong CG, 2001, CURR EYE RES, V22, P140, DOI 10.1076/ceyr.22.2.140.5528
NR 34
TC 3
Z9 3
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2012
VL 250
IS 10
BP 1421
EP 1428
DI 10.1007/s00417-012-1978-8
PG 8
WC Ophthalmology
SC Ophthalmology
GA 013ZR
UT WOS:000309345300003
PM 22427240
DA 2020-12-15
ER

PT J
AU Cavalcanti, AB
   Berwanger, O
   Suzumura, EA
   Amato, MBP
   Tallo, FS
   Rezende, EAC
   Telles, JMM
   Romano, E
   Guimaraes, HP
   Regenga, MM
   Takahashi, LN
   Teixeira, C
   Oliveira, RP
   Carvalho, VO
   Diaz-Quijano, FA
   Carvalho, CRR
   Cavalcanti, AB
   Suzumura, EA
   Berwanger, O
   Kodama, AA
   Ribeiro, GFM
   Abreu, MO
   Oliveira, IM
   Guyatt, G
   Ferguson, N
   Walter, S
   Vasconcelos, MOM
   Segundo, VJ
   Ferraz, IL
   Silva, RS
   de Oliveira, W
   Silva, NB
   Heirel, DCB
   Takatani, RR
   Neto, JAS
   Neto, JCB
   Almeida, SD
   Chamy, G
   de Oliveira, W
   Neto, GJLG
   Almeida, SD
   Dias, AP
   Silva, RR
   Tavares, RC
   Souza, MLVD
   Decio, JC
   Lima, CMLS
   Neto, FF
   Oliveira, KR
   Dias, PPLC
   Brandao, ALSB
   Ramos, JE
   Vasconcelos, PT
   Flores, DG
   Pinheiro, GR
   Andrade, IG
   Martinez, A
   Franca, GGP
   Monteiro, LL
   Correia, EIS
   Ribeiro, W
   Pereira, AJ
   Andrade, W
   Leite, PA
   Pinheiro, GR
   Flores, DG
   Feto, JEF
   Holanda, MA
   Amorim, FF
   Margalho, SB
   Domingues, SM
   Ferreira, CS
   Ferreira, CM
   Rabelo, LA
   Duarte, JN
   Lima, FB
   Kawaguchi, IAL
   Neto, JAA
   Maia, MO
   Correa, FG
   Ribeiro, RAB
   Caser, E
   Moreira, CLCB
   Marcilino, A
   Falcao, JG
   Jesus, KR
   Tcherniakovisk, L
   Dutra, VG
   Thompson, MM
   Piras, C
   Giuberti, J
   Silva, AS
   Santos, JRP
   Potratz, JL
   Paula, LN
   Bozi, GG
   Gomes, BC
   Vassallo, PF
   Rocha, EP
   Lima, MHBS
   Ferreira, DM
   Goncalves, FAF
   Pereira, SA
   Nobrega, MS
   Caixeta, CR
   Moraes, APP
   Carvalho, AGR
   Alves, JD
   Carvalho, FB
   Moreira, FBR
   Starling, CM
   Couto, WAD
   Bitencourt, WS
   Bitencourt, WS
   Carvalho, FB
   Peixoto, DC
   Carvalho, ILV
   Silva, SGA
   Felizardo, LRSM
   Nascimento, FJM
   Santos, PJCD
   Zanta, CC
   Martins, MF
   Naves, SA
   Silva, FD
   Laube, G
   Galvao, EL
   Sousa, MF
   Souza, MMF
   Carvalho, FLG
   Bergo, RR
   Rezende, CM
   Tamazato, EY
   Sarat, SC
   Almeida, PS
   Gorski, AG
   Matsui, M
   Neto, EE
   Nomoto, SH
   Lima, ZB
   Inagaki, AS
   Gil, FSU
   Araujo, MFA
   Oliveira, AE
   Correa, TA
   Mendonca, A
   Reis, H
   Carneiro, SR
   Castanelo, C
   Coelho, E
   Amaral, KAEH
   Rego, LRM
   Cunha, AFC
   Barra, WF
   Carneiro, M
   Batista, RA
   Zoghbi, KK
   Machado, NJN
   Ferreira, R
   Apoena, P
   Leao, RM
   Martins, ER
   Oliveira, ME
   Odir, I
   Kleber, W
   Tavares, D
   Martins, ER
   Araujo, MEU
   Brilhante, YN
   Tavares, DCC
   Kleber, W
   Carvalho, WLN
   Winveler, GFP
   Chagas, A
   Cavalcanti, RA
   Grion, CMC
   Reis, ATJB
   Festti, J
   Gimenez, FMP
   Grion, CMC
   Larangeira, AS
   Cardoso, LTQ
   Mezzaroba, AL
   Giancursi, TS
   Kauss, IAM
   Duarte, PAD
   Tozo, TC
   Peliser, P
   Germano, A
   Gurgel, SJT
   Silva, SRB
   Kuroda, CM
   Herek, A
   Yamada, SS
   Schiavetto, PM
   Wysocki, N
   Matsubara, RR
   Sales, JAL
   Laprovita, MP
   Pena, FM
   Sa, A
   Vianna, A
   Verdeal, JC
   Martins, GA
   Salgado, DR
   Coelho, AM
   Coelho, MPPM
   Morong, AS
   Poquiriqui, RMB
   Ferreira, AP
   Lucena, DNL
   Marino, NF
   Moreira, MA
   Uratani, CCS
   Severino, MA
   Silva, PN
   Medeiros, LG
   Chaves, FG
   Guimaraes, DMQS
   Rezende, VMC
   Carbonell, RCC
   Trindade, RS
   Pellegrini, JAS
   Boniatti, MM
   Santos, MC
   Boldo, R
   Oliveira, VM
   Correa, VM
   Nedel, W
   Teixeira, C
   Oliveira, RP
   Schaich, F
   Tagliari, L
   Savi, A
   Schulz, LF
   Maccari, JG
   Oliveira, RP
   Teixeira, C
   Seeger, GM
   Foernges, RB
   Rieder, MM
   Becker, DA
   Broilo, FP
   Schwarz, P
   Alencastro, A
   Berto, P
   Backes, F
   Pellegrini, JAS
   Dias, FS
   Blattner, C
   Martins, ETJ
   Scaglia, NC
   Vieira, SRR
   Prado, KF
   Fialkow, L
   Franke, C
   Vieira, DFVB
   Moraes, RB
   Schwarz, P
   Marques, LS
   Hopf, JLS
   Wawrzeniak, IC
   Rech, TH
   Albuquerque, RB
   Guerreiro, MO
   Teixeira, LO
   Macedo, PL
   Bainy, MP
   Ferreira, EV
   Martins, MA
   Andrade, LAS
   Machado, FO
   Burigo, AC
   Pincelli, M
   Kretzer, L
   Maia, IS
   Cordeiro, RB
   Westphal, G
   Caldeira, M
   Cramer, AS
   Dadam, MM
   Barbosa, PO
   Caldeira, M
   Westphal, G
   Brilenger, CO
   Horner, MBW
   Oliveira, GL
   Germiniani, BC
   Teixeira, C
   Duarte, R
   Assef, MGPL
   Rosso, D
   Bigolin, R
   Vanzuita, R
   Martins, MA
   Prado, LFA
   Oliveira, ALV
   Reis, DL
   Morais, MO
   Bastos, RS
   Santana, HSR
   Silva, AO
   Cacau, LAP
   Almeida, MS
   Canavessi, HS
   Nogueira, EEF
   Pavia, CLP
   Reis, DL
   Araujo, JF
   Lira, JA
   Nienstedt, EC
   Smith, TC
   Romano, E
   Romano, M
   Regenga, MM
   Barros, D
   Costa, AF
   Takahashi, L
   Werneck, V
   Farran, J
   Henriques, LA
   Miura, C
   Lopes, RD
   Vendrame, LS
   Guimaraes, HP
   Sandri, P
   Galassi, MS
   Carvalho, CRR
   Amato, MBP
   Toufen, C
   Santiago, RRS
   Hirota, AS
   Park, M
   Azevedo, LCP
   Malbouison, LM
   Costa, MC
   Taniguchi, L
   Pompilio, CE
   Baruzzi, C
   Andrade, AHV
   Taira, EE
   Taino, B
   Oliveira, CS
   Silva, AC
   Isola, A
   Rezende, E
   Rodrigues, RG
   Rangel, VPL
   Luzzi, S
   Giacomassi, IWS
   Nassar, AP
   Souza, AR
   Rahal, L
   Nunes, AL
   Giannini, F
   Menescal, B
   Morais, JEP
   Toledo, D
   Morsch, RD
   Merluzzi, T
   Amorim, DS
   Bastos, ACAG
   Santos, PL
   Silva, SF
   Gallego, RCN
   Santos, GD
   Tucci, M
   Costa, RT
   Santos, LS
   Demarzo, SE
   Schettino, GPP
   Azevedo, LCP
   Suzuki, VC
   Patrocinio, ACL
   Martins, ML
   Passos, DBVG
   Cappi, SB
   Goncalves, I
   Borges, MC
   Lovato, W
   Tavares, MV
   Morales, D
   Machado, LAMW
   Torres, FCC
   Gomes, TM
   Cerantola, RB
   Gois, A
   Marraccini, T
   Margarida, K
   Cavalcante, E
   Machado, FR
   Mazza, BF
   Santana, HBR
   Mendez, VMF
   Xavier, PA
   Rabelo, MV
   Schievano, FR
   Pinto, WAM
   Francisco, RS
   Ferreira, EM
   Silva, DCB
   Arduini, RG
   Aldrighi, JR
   Amaro, AF
   Conde, KAP
   Pereira, CA
   Tarkieltaub, E
   Oliver, WR
   Guadalupe, EGL
   Acerbi, PSC
   Tomizuka, CI
   Oliveira, TA
   Geha, NN
   Mecatti, GC
   Piovesan, MZR
   Salomao, MC
   Moreno, MS
   Orsatti, VN
   Miranda, W
   Ray, A
   Guerra, A
   Baptista, MLA
   Ferreira, FH
   Viera, E
   Canzi, RA
   Giuberti, AFT
   Garcez, MCM
   Pedro, A
   Sala, AD
   Suguitani, EO
   Kazue, P
   Oliveira, LRC
   Infantini, RM
   Carvalho, FRT
   Andrade, LC
   Guimaraes, HP
   Santos, TM
   Carmona, CV
   Figueiredo, LC
   Falcao, A
   Dragosavak, D
   Nogueira, W
   Lunardi, MC
   Lago, R
   Gatti, C
   Chiasso, TM
   Santos, GO
   Silva, ACF
   Araujo, AC
   Ornellas, IB
   Vieira, VM
   Hajjar, LA
   Figueiredo, AC
   Vieira, VM
   Damasceno, B
   Pizarro, C
   Hinestrosa, A
   Diaz-Quijano, FA
   Garcia, SMC
   Gonzalez, O
   Diaz, E
   Raineri, SM
   Cortegiani, A
AF Cavalcanti, Alexandre B.
   Berwanger, Otavio
   Suzumura, Erica A.
   Amato, Marcelo B. P.
   Tallo, Fernando S.
   Rezende, Ederlon A. C.
   Telles, Jose M. M.
   Romano, Edson
   Guimaraes, Helio P.
   Regenga, Marisa M.
   Takahashi, Luzia N.
   Teixeira, Cassiano
   Oliveira, Roselaine P.
   Carvalho, Vitor O.
   Diaz-Quijano, Fredi A.
   Carvalho, Carlos R. R.
   Cavalcanti, Alexandre B.
   Suzumura, Erica A.
   Berwanger, Otavio
   Kodama, Alessandra A.
   Ribeiro, Gisele F. M.
   Abreu, Matheus O.
   Oliveira, Ivonaldo M.
   Guyatt, Gordon
   Ferguson, Niall
   Walter, Stephen
   Vasconcelos, Marcia O. M.
   Segundo, Valerio J.
   Ferraz, Iris L.
   Silva, Rosicley S.
   de Oliveira Filho, Wilson
   Silva, Nelson B.
   Heirel, Debora C. B.
   Takatani, Rodrigo R.
   Sousa Neto, Jefferson A.
   Neto, Jeronimo C. B.
   Almeida, Samara D.
   Chamy, Gauco
   de Oliveira Filho, Wilson
   Goncalves Neto, Graciliano J. L.
   Almeida, Samara D.
   Dias, Alysson P.
   Silva, Rozangela R.
   Tavares, Roberta C.
   Souza, Marcia L. V. D.
   Decio, Janaina C.
   Lima, Cyntia M. L. S.
   Ferreira Neto, Fleury
   Oliveira, Katia R.
   Dias, Polyana P. L. C.
   Brandao, Andre L. S. B.
   Ramos, Joroastro E., Jr.
   Vasconcelos, Paula T.
   Flores, Dimitri G.
   Pinheiro Filho, Gilvan R.
   Andrade, Isaac G.
   Martinez, Amadeu
   Franca, Gustavo G. P.
   Monteiro, Livia L.
   Correia, Emmanuel I. S.
   Ribeiro, Wagner
   Pereira, Antonio J.
   Andrade, Wandalvo
   Leite, Petronio A.
   Pinheiro Filho, Gilvan R.
   Flores, Dimitri G.
   Filgueira Feto, Jose E.
   Holanda, Marcelo A.
   Amorim, Fabio F.
   Margalho, Silviano B.
   Domingues, Sergio M., Jr.
   Ferreira, Claiton S.
   Ferreira, Cassia M.
   Rabelo, Livia A.
   Duarte, Juliana N.
   Lima, Fernando B.
   Kawaguchi, Ines A. L.
   Araujo Neto, Jose A.
   Maia, Marcelo O.
   Correa, Fabiano G.
   Ribeiro, Rubens A. B.
   Caser, Eliana
   Moreira, Cora L. C. B.
   Marcilino, Antonielen
   Falcao, Jansen G.
   Jesus, Karinne R.
   Tcherniakovisk, Leo
   Dutra, Victor G.
   Thompson, Marlus M.
   Piras, Claudio
   Giuberti, Jonas, Jr.
   Silva, Albano S.
   Santos, Jose R. P.
   Potratz, Jorge L.
   Paula, Ludmila N.
   Bozi, Giovana G.
   Gomes, Bruno C.
   Vassallo, Paula F.
   Rocha, Edson P.
   Lima, Maria H. B. S.
   Ferreira, Denise M.
   Goncalves, Fernanda A. F.
   Pereira, Sheila A.
   Nobrega, Marciano S.
   Caixeta, Carlos R.
   Moraes, Ana P. P.
   Carvalho, Alexandre G. R.
   Alves, Janine D.
   Carvalho, Frederico B.
   Moreira, Fabiana B. R.
   Starling, Claudia M.
   Couto, Wivian A. D.
   Bitencourt, Wesley S.
   Bitencourt, Wesley S.
   Carvalho, Frederico B.
   Peixoto, Daniela C.
   Carvalho, Ivana L. V.
   Silva, Silvangela G. A.
   Felizardo, Livia R. S. M.
   Magalhaes Nascimento, Francine J.
   Santos, Priscila J. C. D.
   Zanta, Camila C.
   Martins, Marcele F.
   Naves, Sergio A.
   Silva, Fabiano D.
   Laube, Gilberto, Jr.
   Galvao, Endi L.
   Sousa, Marcelo F.
   Souza, Marcia M. F.
   Carvalho, Fernanda L. G.
   Bergo, Ricardo R.
   Rezende, Claudnei M.
   Tamazato, Edys Y.
   Sarat, Saturnino Campo, Jr.
   Almeida, Patricia S.
   Gorski, Anthony G.
   Matsui, Mirna
   Eberhart Neto, Ervin
   Nomoto, Silmara H.
   Lima, Zildamara B.
   Inagaki, Alexandre S.
   Gil, Fernando S. U.
   Araujo, Mario F. A.
   Oliveira, Aline E.
   Correa, Tiago A.
   Mendonca, Angela
   Reis, Helder
   Carneiro, Saul R.
   Castanelo, Carlos
   Coelho, Edward, Jr.
   Amaral, Karine A. E. H.
   Rego, Leila R. M.
   Cunha, Adenard F. C.
   Barra, Williams F.
   Carneiro, Mauricio
   Batista, Roseane A.
   Zoghbi, Karina K.
   Machado, Nelma J. N.
   Ferreira, Reinaldo
   Apoena, Pablo
   Leao, Rosangela M.
   Martins, Eliauria R.
   Oliveira, Marcelo E.
   Odir, Isaura
   Kleber, Wladimy
   Tavares, Daniele
   Martins, Eliauria R.
   Araujo, Marcelo E. U.
   Brilhante, Yuzeth Nobrega
   Tavares, Daniele C. C.
   Kleber, Wladmy
   Carvalho, Waneska L. N.
   Winveler, Georgia F. P.
   Chagas Filho, Aldir
   Cavalcanti, Raphael Ali
   Grion, Cintia M. C.
   Reis, Andrezza T. J. B.
   Festti, Josiane
   Gimenez, Francielli M. P.
   Grion, Cintia M. C.
   Larangeira, Alexandre S.
   Cardoso, Lucienne T. Q.
   Mezzaroba, Ana L.
   Giancursi, Thiago S.
   Kauss, Ivanil A. M.
   Duarte, Pericles A. D.
   Tozo, Tatiane C.
   Peliser, Priscila
   Germano, Almir
   Gurgel, Sanderland J. T.
   Silva, Sandra R. B.
   Kuroda, Cristina M.
   Herek, Andrea
   Yamada, Sergio S.
   Schiavetto, Paulo M.
   Wysocki, Natacha
   Matsubara, Rosely R.
   Sales, Joao A. L., Jr.
   Laprovita, Maria P.
   Pena, Felipe M.
   Sa, Alexandre
   Vianna, Arthur
   Verdeal, Juan C.
   Martins, Gloria A.
   Salgado, Diamantino R.
   Coelho, Adalberto M.
   Coelho, Milena P. P. M.
   Morong, Aline S.
   Poquiriqui, Rodolfo M. B.
   Ferreira, Ana P.
   Lucena, Debora N. L.
   Marino, Nathalia F.
   Moreira, Monique A.
   Uratani, Cristiana C. S.
   Severino, Marta A.
   Silva, Patricia N.
   Medeiros, Luciana G.
   Chaves Filho, Francisco G.
   Guimaraes, Daniela M. Q. S.
   Rezende, Valeria M. C.
   Carbonell, Roberto C. C.
   Trindade, Renata S.
   Pellegrini, Jose A. S.
   Boniatti, Marcio M.
   Santos, Moreno C.
   Boldo, Rodrigo
   Oliveira, Vanessa M.
   Correa, Viviane M.
   Nedel, Wagner
   Teixeira, Cassiano
   Oliveira, Roselaine P.
   Schaich, Felipe
   Tagliari, Luciana
   Savi, Augusto
   Schulz, Luis F.
   Maccari, Juara G.
   Oliveira, Roselaine P.
   Teixeira, Cassiano
   Seeger, Gabriela M.
   Foernges, Rafael B.
   Rieder, Marcelo M.
   Becker, Daniel A.
   Broilo, Fabiano P.
   Schwarz, Patricia
   Alencastro, Andre
   Berto, Paula
   Backes, Fabiane
   Pellegrini, Jose A. S.
   Dias, Fernando S.
   Blattner, Clarissa
   Martins, Edna T. J.
   Scaglia, Nris C.
   Vieira, Silvia R. R.
   Prado, Karen F.
   Fialkow, Lea
   Franke, Cristiano
   Vieira, Debora F. V. B.
   Moraes, Rafael B.
   Schwarz, Patricia
   Marques, Leonardo S.
   Hopf, Joao L. S.
   Wawrzeniak, Iuri C.
   Rech, Tatiana H.
   Albuquerque, Regis B.
   Guerreiro, Marcio O.
   Teixeira, Luciano O.
   Macedo, Pedro L.
   Bainy, Marina P.
   Ferreira, Edgard V.
   Martins, Marcio A.
   Andrade, Luciana A. S.
   Machado, Fernando O.
   Burigo, Ana C.
   Pincelli, Mariangela
   Kretzer, Lara
   Maia, Israel S.
   Cordeiro, Rodrigo B.
   Westphal, Glauco
   Caldeira, Milton
   Cramer, Amanda S.
   Dadam, Michelli M.
   Barbosa, Pierry O.
   Caldeira, Milton
   Westphal, Glauco
   Brilenger, Caroline O.
   Horner, Marina B. W.
   Oliveira, Glauce L.
   Germiniani, Bruno C.
   Teixeira, Cristina
   Duarte, Robson
   Assef, Maria G. P. L.
   Rosso, Deorgelis
   Bigolin, Rodrigo
   Vanzuita, Raquel
   Martins, Marcio A.
   Prado, Luiz F. A.
   Oliveira, Andre L. V.
   Reis, Diego L.
   Morais, Mirene O.
   Bastos, Rafael S.
   Santana, Hericalizandra S. R.
   Silva, Alline O.
   Cacau, Lucas A. P.
   Almeida, Marilia S.
   Canavessi, Hugo Schlebinger
   Nogueira, Eduardo E. F.
   Pavia, Caio L. P.
   Reis, Diego L.
   Araujo, Jose F.
   Lira, Jose A.
   Nienstedt, Esteban C.
   Smith, Thiago C.
   Romano, Edson
   Romano, Marcelo
   Regenga, Marisa M.
   Barros, Dalton
   Costa, Andre F.
   Takahashi, Luzia
   Werneck, Vinicius
   Farran, Jorge
   Henriques, Lilian A.
   Miura, Claudia
   Lopes, Renato D.
   Vendrame, Leticia S.
   Guimaraes, Helio P.
   Sandri, Priscila
   Galassi, Marcela S.
   Carvalho, Carlos R. R.
   Amato, Marcelo B. P.
   Toufen, Carlos, Jr.
   Santiago, Roberta R. S.
   Hirota, Adriana S.
   Park, Marcelo
   Azevedo, Luciano C. P.
   Malbouison, Luiz M.
   Costa, Maristela C.
   Taniguchi, Leandro
   Pompilio, Carlos E.
   Baruzzi, Claudio
   Andrade, Ana H. V.
   Taira, Elisabete E.
   Taino, Bruno
   Oliveira, Clezio S.
   Silva, Anselmo C.
   Isola, Alexandre
   Rezende, Ederlon
   Rodrigues, Ricardo G.
   Rangel, Vivian P. L.
   Luzzi, Sergio
   Giacomassi, Ivens W. S.
   Nassar, Antonio P., Jr.
   Souza, Ana R.
   Rahal, Luciana
   Nunes, Andre L.
   Giannini, Fabio
   Menescal, Brena
   Morais, Jussara E. P.
   Toledo, Diogo
   Morsch, Rafaela D.
   Merluzzi, Thalita
   Amorim, Denise S.
   Bastos, Ana C. A. G.
   Santos, Patricia L.
   Silva, Sabrina F.
   Gallego, Raquel C. N.
   Santos, Gheisa D.
   Tucci, Mauro
   Costa, Ramon T.
   Santos, Lucio S.
   Demarzo, Sergio E.
   Schettino, Guilherme P. P.
   Azevedo, Luciano C. P.
   Suzuki, Vivian C.
   Patrocinio, Ana C. L.
   Martins, Mariana L.
   Passos, Denise B. V. G.
   Cappi, Sylas B.
   Goncalves, Iran, Jr.
   Borges, Marcos C.
   Lovato, Wilson
   Tavares, Marcel V.
   Morales, Daniela
   Machado, Luis A. M. W.
   Torres, Franciele C. C.
   Gomes, Tania M.
   Cerantola, Rodrigo B.
   Gois, Aecio
   Marraccini, Thiago
   Margarida, Kathia
   Cavalcante, Eulalia
   Machado, Flavia R.
   Mazza, Bruno F.
   Rossetti Santana, Heloisa B.
   Mendez, Vanessa M. F.
   Xavier, Patricia A.
   Rabelo, Melina V.
   Schievano, Fabiana R.
   Pinto, Walkyria A. M.
   Francisco, Renata S.
   Ferreira, Elaine M.
   Silva, Dafne C. B.
   Arduini, Rodrigo G.
   Aldrighi, Jose R.
   Amaro, Andreson F.
   Conde, Katia A. P.
   Pereira, Cesar A.
   Tarkieltaub, Elcio
   Oliver, Wilson R.
   Guadalupe, Erika G. L.
   Acerbi, Paulo S. C.
   Tomizuka, Carlos I.
   Oliveira, Tatiana A.
   Geha, Nadia N.
   Mecatti, Giovana C.
   Piovesan, Maysa Z. R.
   Salomao, Maria C.
   Moreno, Marcelo S.
   Orsatti, Vinicius N.
   Miranda, Whiniton
   Ray, Alexandre
   Guerra, Andre
   Baptista Filho, Mario L. A.
   Ferreira, Firmino H., Jr.
   Viera Filho, Edesio
   Canzi, Regina A.
   Giuberti, Adriana F. T.
   Garcez, Melissa C. M.
   Pedro, A.
   Sala, Andrea D.
   Suguitani, Edmundo O.
   Kazue, Priscila
   Oliveira, Luiz R. C.
   Infantini, Rodrigo M.
   Carvalho, Fabricio R. T.
   Andrade, Lucia C.
   Guimaraes, Helio P.
   Santos, Thiago M.
   Carmona, Cesar V.
   Figueiredo, Luciana C.
   Falcao, Antonio
   Dragosavak, Desanka
   Nogueira Filho, Wilson
   Lunardi, Maria C.
   Lago, Roberto
   Gatti, Ciro
   Chiasso, Tatiana M.
   Santos, Grazielle O.
   Silva, Aline C. F.
   Araujo, Arthur C.
   Ornellas, Izadora B.
   Vieira, Vitor M.
   Hajjar, Ludhmila A.
   Figueiredo, Adelaide C.
   Vieira, Vitor M.
   Damasceno, Bruna
   Pizarro, Camilo
   Hinestrosa, Alfredo
   Diaz-Quijano, Fredi A.
   Garcia L., Sandra M. C.
   Gonzalez C., Octavio
   Diaz S., Edgard
   Raineri, Santi M.
   Cortegiani, Andrea
CA ART Investigators
   Writing Steering Comm
   Trial Management Team
   Data Monitoring Comm
   Trial Ctr
TI Rationale, study design, and analysis plan of the Alveolar Recruitment
   for ARDS Trial (ART): Study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE Acute respiratory distress syndrome; Alveolar recruitment; PEEP;
   Mechanical ventilation; Clinical trials; Randomized
ID RESPIRATORY-DISTRESS-SYNDROME; END-EXPIRATORY PRESSURE; LOW AIRWAY
   PRESSURES; ACUTE LUNG INJURY; MECHANICAL VENTILATION; OUTCOMES;
   CYTOKINES; STRATEGY; BENEFIT; MODEL
AB Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART).
   Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH(2)O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure <= 30 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle.
   Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration method.
C1 [Vasconcelos, Marcia O. M.; Segundo, Valerio J.; Ferraz, Iris L.; Silva, Rosicley S.] Hosp Urgencias & Emergencias Rio Branco HUERB, Rio Branco, AC, Brazil.
   [de Oliveira Filho, Wilson; Silva, Nelson B.; Heirel, Debora C. B.; Takatani, Rodrigo R.; Sousa Neto, Jefferson A.; Neto, Jeronimo C. B.; Almeida, Samara D.; Chamy, Gauco] Hosp & Pronto Socorro 28 Agosto, Manaus, Amazonas, Brazil.
   [de Oliveira Filho, Wilson; Goncalves Neto, Graciliano J. L.; Almeida, Samara D.; Dias, Alysson P.; Silva, Rozangela R.] UNIMED Manaus, Manaus, Amazonas, Brazil.
   [Tavares, Roberta C.; Souza, Marcia L. V. D.; Decio, Janaina C.] Fundacao Hosp Adriano Jorge, Manaus, Amazonas, Brazil.
   [Lima, Cyntia M. L. S.; Ferreira Neto, Fleury] Hosp Santa Izabel Santa Casa Misericordia Bahia, Salvador, BA, Brazil.
   [Oliveira, Katia R.; Dias, Polyana P. L. C.; Brandao, Andre L. S. B.; Ramos, Joroastro E., Jr.; Vasconcelos, Paula T.] Hosp Reg Juazeiro Gestao IMIP, Juazeiro, BA, Brazil.
   [Flores, Dimitri G.; Pinheiro Filho, Gilvan R.; Andrade, Isaac G.] Hosp Univ Prof Edgar Santos, Salvador, BA, Brazil.
   [Martinez, Amadeu; Franca, Gustavo G. P.; Monteiro, Livia L.; Correia, Emmanuel I. S.; Ribeiro, Wagner; Pereira, Antonio J.; Andrade, Wandalvo; Leite, Petronio A.; Pinheiro Filho, Gilvan R.] Hosp Espanhol, Salvador, BA, Brazil.
   [Flores, Dimitri G.] Hosp Geral Roberto Santos, Salvador, BA, Brazil.
   [Filgueira Feto, Jose E.; Holanda, Marcelo A.] Hosp Messejana, Fortaleza, Ceara, Brazil.
   [Amorim, Fabio F.; Margalho, Silviano B.] Hosp Reg Samambaia, Brasilia, DF, Brazil.
   [Domingues, Sergio M., Jr.; Ferreira, Claiton S.; Ferreira, Cassia M.; Rabelo, Livia A.; Duarte, Juliana N.; Lima, Fernando B.; Kawaguchi, Ines A. L.] Hosp Reg Asa Norte HRAN, Brasilia, DF, Brazil.
   [Araujo Neto, Jose A.; Maia, Marcelo O.] Hosp Santa Luzia, Brasilia, DF, Brazil.
   [Correa, Fabiano G.] Hosp Santa Lucia, Brasilia, DF, Brazil.
   [Ribeiro, Rubens A. B.] Hosp Anchieta, Brasilia, DF, Brazil.
   [Caser, Eliana; Moreira, Cora L. C. B.; Marcilino, Antonielen; Falcao, Jansen G.; Jesus, Karinne R.; Tcherniakovisk, Leo; Dutra, Victor G.] Ctr Integrado Atencao Saude CIAS, Vitoria, ES, Brazil.
   [Thompson, Marlus M.] Hosp Evangel Cachoeiro Itapemirin, Cachoeiro De Itapemirim, ES, Brazil.
   [Piras, Claudio; Giuberti, Jonas, Jr.; Silva, Albano S.] Vitoria Apart Hosp, Vitoria, ES, Brazil.
   [Santos, Jose R. P.; Potratz, Jorge L.; Paula, Ludmila N.; Bozi, Giovana G.; Gomes, Bruno C.] Vila Velha Hosp, Vila Velha, ES, Brazil.
   [Vassallo, Paula F.; Rocha, Edson P.; Lima, Maria H. B. S.] Hosp Clin UFES, Vitoria, ES, Brazil.
   [Ferreira, Denise M.; Goncalves, Fernanda A. F.; Pereira, Sheila A.; Nobrega, Marciano S.; Caixeta, Carlos R.] Hosp Clin UFG, Goiania, Go, Brazil.
   [Moraes, Ana P. P.] Hosp Geral Tarquinio Lopes Filho, Sao Luis, MA, Brazil.
   [Carvalho, Alexandre G. R.] UDI Hosp, Sao Luis, MA, Brazil.
   [Alves, Janine D.] Santa Casa Misericordia Ouro Preto, Ouro Preto, MG, Brazil.
   [Carvalho, Frederico B.; Moreira, Fabiana B. R.; Starling, Claudia M.; Couto, Wivian A. D.] Hosp Eduardo de Menezes, Belo Horizonte, MG, Brazil.
   [Bitencourt, Wesley S.] Fundacao Hosp Sao Sebastiao, Tres Coracoes, MG, Brazil.
   [Bitencourt, Wesley S.] Hosp Conego Monte Raso, Baependi, MG, Brazil.
   [Carvalho, Frederico B.; Peixoto, Daniela C.; Carvalho, Ivana L. V.; Silva, Silvangela G. A.; Felizardo, Livia R. S. M.; Magalhaes Nascimento, Francine J.; Santos, Priscila J. C. D.; Zanta, Camila C.; Martins, Marcele F.] Hosp Municipal Odilon Behrens, Belo Horizonte, MG, Brazil.
   [Naves, Sergio A.; Silva, Fabiano D.; Laube, Gilberto, Jr.] Hosp Sao Lucas Governador Valadares, Governador Valadares, MG, Brazil.
   [Galvao, Endi L.; Sousa, Marcelo F.; Souza, Marcia M. F.; Carvalho, Fernanda L. G.] Santa Casa Caridade Diamantina, Diamantina, MG, Brazil.
   [Bergo, Ricardo R.] Hosp Coracao Pocos de Caldas, Hosp Santa Lucia, Pocos De Caldas, MG, Brazil.
   [Rezende, Claudnei M.; Tamazato, Edys Y.; Sarat, Saturnino Campo, Jr.; Almeida, Patricia S.; Gorski, Anthony G.] Hosp Reg Mato Grosso Sul Rosa Pedrossian, Campo Grande, MS, Brazil.
   [Matsui, Mirna; Eberhart Neto, Ervin; Nomoto, Silmara H.; Lima, Zildamara B.; Inagaki, Alexandre S.; Gil, Fernando S. U.; Araujo, Mario F. A.; Oliveira, Aline E.; Correa, Tiago A.; Mendonca, Angela] Fundacao Univ Fed Grande Dourados, Hosp Univ, Dourados, MS, Brazil.
   [Reis, Helder; Carneiro, Saul R.; Castanelo, Carlos; Coelho, Edward, Jr.; Amaral, Karine A. E. H.] Hosp Clin Gaspar Vianna, Belem, Para, Brazil.
   [Rego, Leila R. M.; Cunha, Adenard F. C.; Barra, Williams F.; Carneiro, Mauricio; Batista, Roseane A.; Zoghbi, Karina K.] Hosp Saude Mulher, Belem, Para, Brazil.
   [Machado, Nelma J. N.; Ferreira, Reinaldo; Apoena, Pablo; Leao, Rosangela M.] Fundacao Santa Casa Misericordia Para, Belem, Para, Brazil.
   [Martins, Eliauria R.; Oliveira, Marcelo E.; Odir, Isaura; Kleber, Wladimy; Tavares, Daniele] Hosp Emergencia Trauma Senador Humberto Lucena, Joao Pessoa, Paraiba, Brazil.
   [Martins, Eliauria R.; Araujo, Marcelo E. U.; Brilhante, Yuzeth Nobrega; Tavares, Daniele C. C.; Kleber, Wladmy; Carvalho, Waneska L. N.; Winveler, Georgia F. P.] Hosp UNIMED Joao Pessoa, Joao Pessoa, Paraiba, Brazil.
   [Chagas Filho, Aldir; Cavalcanti, Raphael Ali] Hosp Alfa, Recife, PE, Brazil.
   [Grion, Cintia M. C.; Reis, Andrezza T. J. B.; Festti, Josiane; Gimenez, Francielli M. P.] Hosp Evangel Londrina, Londrina, PR, Brazil.
   [Grion, Cintia M. C.; Larangeira, Alexandre S.; Cardoso, Lucienne T. Q.; Mezzaroba, Ana L.; Giancursi, Thiago S.; Kauss, Ivanil A. M.] Hosp Univ Reg Norte Parana, Londrina, PR, Brazil.
   [Duarte, Pericles A. D.; Tozo, Tatiane C.; Peliser, Priscila] Hosp Sao Lucas FAG, Cascavel, PR, Brazil.
   [Germano, Almir; Gurgel, Sanderland J. T.; Silva, Sandra R. B.; Kuroda, Cristina M.; Herek, Andrea; Yamada, Sergio S.] Hosp Univ Reg Maringa, Maringa, Parana, Brazil.
   [Schiavetto, Paulo M.] Hosp Santa Casa Campo Mourao, Campo Mourao, PR, Brazil.
   [Wysocki, Natacha; Matsubara, Rosely R.] Hosp Santa Tereza Guarapuava, Guarapuava, PR, Brazil.
   [Sales, Joao A. L., Jr.; Laprovita, Maria P.] Hosp Clin Padre Miguel, Rio De Janeiro, RJ, Brazil.
   [Pena, Felipe M.; Sa, Alexandre] Hosp Prontocardio, Campos Dos Goytacazes, RJ, Brazil.
   [Vianna, Arthur] Clin Sao Vicente, Rio De Janeiro, RJ, Brazil.
   [Verdeal, Juan C.; Martins, Gloria A.; Salgado, Diamantino R.] Hosp Barra DOr, Rio De Janeiro, RJ, Brazil.
   [Coelho, Adalberto M.; Coelho, Milena P. P. M.; Morong, Aline S.; Poquiriqui, Rodolfo M. B.; Ferreira, Ana P.; Lucena, Debora N. L.; Marino, Nathalia F.; Moreira, Monique A.; Uratani, Cristiana C. S.] Hosp Monte Sinai, Ariquemes, RO, Brazil.
   [Severino, Marta A.; Silva, Patricia N.; Medeiros, Luciana G.; Chaves Filho, Francisco G.; Guimaraes, Daniela M. Q. S.] Hosp Estadual & Pronto Socorro Joao Paulo II, Porto Velho, RO, Brazil.
   [Rezende, Valeria M. C.; Carbonell, Roberto C. C.; Trindade, Renata S.] Hosp Geral Roraima, Boa Vista, RR, Brazil.
   [Pellegrini, Jose A. S.; Boniatti, Marcio M.; Santos, Moreno C.; Boldo, Rodrigo; Oliveira, Vanessa M.; Correa, Viviane M.; Nedel, Wagner] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Teixeira, Cassiano; Oliveira, Roselaine P.; Schaich, Felipe; Tagliari, Luciana; Savi, Augusto; Schulz, Luis F.; Maccari, Juara G.] Hosp Moinhos Vento, Porto Alegre, RS, Brazil.
   [Oliveira, Roselaine P.; Teixeira, Cassiano; Seeger, Gabriela M.; Foernges, Rafael B.; Rieder, Marcelo M.; Becker, Daniel A.; Broilo, Fabiano P.] UTI Cent Irmandade Santa Casa Misericordia Porto, Porto Alegre, RS, Brazil.
   [Schwarz, Patricia; Alencastro, Andre; Berto, Paula; Backes, Fabiane; Pellegrini, Jose A. S.] UTI Pavilhao Pereira Filho Santa Casa Misericord, Porto Alegre, RS, Brazil.
   [Dias, Fernando S.; Blattner, Clarissa; Martins, Edna T. J.; Scaglia, Nris C.] Hosp Sao Lucas PUCRS, Porto Alegre, RS, Brazil.
   [Vieira, Silvia R. R.; Prado, Karen F.; Fialkow, Lea; Franke, Cristiano; Vieira, Debora F. V. B.; Moraes, Rafael B.; Schwarz, Patricia; Marques, Leonardo S.; Hopf, Joao L. S.; Wawrzeniak, Iuri C.; Rech, Tatiana H.; Albuquerque, Regis B.] Hosp Clin Porto Alegre HCPA, Porto Alegre, RS, Brazil.
   [Guerreiro, Marcio O.; Teixeira, Luciano O.; Macedo, Pedro L.; Bainy, Marina P.; Ferreira, Edgard V.] Hosp Univ Sao Francisco Paula, Pelotas, RS, Brazil.
   [Martins, Marcio A.; Andrade, Luciana A. S.] Hosp Coracao, Balneario De Camboriu, SC, Brazil.
   [Machado, Fernando O.] Hosp Univ UFSC, Florianopolis, SC, Brazil.
   [Burigo, Ana C.; Pincelli, Mariangela; Kretzer, Lara; Maia, Israel S.] Hosp Nereu Ramos, Florianopolis, SC, Brazil.
   [Cordeiro, Rodrigo B.; Westphal, Glauco; Caldeira, Milton; Cramer, Amanda S.; Dadam, Michelli M.; Barbosa, Pierry O.] Hosp UNIMED Joinville, Joinville, SC, Brazil.
   [Caldeira, Milton; Westphal, Glauco; Brilenger, Caroline O.; Horner, Marina B. W.; Oliveira, Glauce L.; Germiniani, Bruno C.; Teixeira, Cristina; Duarte, Robson] Hosp Sao Jose, Joinville, SC, Brazil.
   [Assef, Maria G. P. L.; Rosso, Deorgelis; Bigolin, Rodrigo; Vanzuita, Raquel] Hosp Reg Hans Dieter Schmidt, Joinville, SC, Brazil.
   [Martins, Marcio A.] Assoc Hosp & Maternidade Consul Carlos Renaux, Brusque, SC, Brazil.
   [Prado, Luiz F. A.; Oliveira, Andre L. V.; Reis, Diego L.; Morais, Mirene O.; Bastos, Rafael S.; Santana, Hericalizandra S. R.; Silva, Alline O.; Cacau, Lucas A. P.; Almeida, Marilia S.] Hosp Primavera, Aracaju, SE, Brazil.
   [Canavessi, Hugo Schlebinger; Nogueira, Eduardo E. F.; Pavia, Caio L. P.; Reis, Diego L.; Araujo, Jose F.; Lira, Jose A.; Nienstedt, Esteban C.; Smith, Thiago C.] Hosp Urgencia Sergipe HUSE, Aracaju, SE, Brazil.
   [Romano, Edson; Romano, Marcelo; Regenga, Marisa M.; Barros, Dalton; Costa, Andre F.; Takahashi, Luzia; Werneck, Vinicius; Farran, Jorge; Henriques, Lilian A.; Miura, Claudia] Hosp Coracao HCor, Sao Paulo, Brazil.
   [Lopes, Renato D.; Vendrame, Leticia S.; Guimaraes, Helio P.; Sandri, Priscila; Galassi, Marcela S.] Univ Fed Sao Paulo, Hosp Sao Paulo, UTI Clin Med, Sao Paulo, Brazil.
   [Carvalho, Carlos R. R.; Amato, Marcelo B. P.; Toufen, Carlos, Jr.; Santiago, Roberta R. S.; Hirota, Adriana S.] FMUSP, Hosp Clin, UTI Resp, Sao Paulo, Brazil.
   [Park, Marcelo; Azevedo, Luciano C. P.] FMUSP, Hosp Clin, UTI Clin, Sao Paulo, Brazil.
   [Malbouison, Luiz M.] FMUSP, Hosp Clin, UAC 1, Sao Paulo, Brazil.
   [Malbouison, Luiz M.] FMUSP, Hosp Clin, UAC 2, Sao Paulo, Brazil.
   [Costa, Maristela C.] FMUSP, Hosp Clin, UTI Nefrol, Sao Paulo, Brazil.
   [Taniguchi, Leandro] FMUSP, Hosp Clin, UTI Clin Pronto Socorro, Sao Paulo, Brazil.
   [Pompilio, Carlos E.] FMUSP, Hosp Clin, UTI Cirurg, Sao Paulo, Brazil.
   [Baruzzi, Claudio; Andrade, Ana H. V.; Taira, Elisabete E.; Taino, Bruno; Oliveira, Clezio S.; Silva, Anselmo C.] Hosp Moyses Deutsch MBoi Mirim, Sao Paulo, Brazil.
   [Isola, Alexandre; Rezende, Ederlon; Rodrigues, Ricardo G.; Rangel, Vivian P. L.; Luzzi, Sergio; Giacomassi, Ivens W. S.] Hosp Servidor Publ Estadual, Sao Paulo, Brazil.
   [Nassar, Antonio P., Jr.; Souza, Ana R.] Hosp & Maternidade Sao Camilo, Unidade Pompeia, Sao Paulo, Brazil.
   [Rahal, Luciana; Nunes, Andre L.; Giannini, Fabio; Menescal, Brena; Morais, Jussara E. P.; Toledo, Diogo] Hosp Sao Luiz, Unidade Itaim, Sao Paulo, Brazil.
   [Morsch, Rafaela D.; Merluzzi, Thalita; Amorim, Denise S.; Bastos, Ana C. A. G.; Santos, Patricia L.; Silva, Sabrina F.; Gallego, Raquel C. N.; Santos, Gheisa D.] Hosp Sao Luiz, Unidade Analia Franco, Sao Paulo, Brazil.
   [Tucci, Mauro; Costa, Ramon T.; Santos, Lucio S.; Demarzo, Sergio E.] AC Camargo, Sao Paulo, Brazil.
   [Schettino, Guilherme P. P.; Azevedo, Luciano C. P.; Suzuki, Vivian C.; Patrocinio, Ana C. L.; Martins, Mariana L.; Passos, Denise B. V. G.] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Cappi, Sylas B.] Hosp Luz, Sao Paulo, Brazil.
   [Goncalves, Iran, Jr.] Hosp SaoLuiz, Unidade Morumbi, Sao Paulo, Brazil.
   [Borges, Marcos C.; Lovato, Wilson; Tavares, Marcel V.; Morales, Daniela; Machado, Luis A. M. W.; Torres, Franciele C. C.; Gomes, Tania M.; Cerantola, Rodrigo B.] Univ Sao Paulo, FMRP, HCRP, Ribeirao Preto, SP, Brazil.
   [Gois, Aecio; Marraccini, Thiago; Margarida, Kathia; Cavalcante, Eulalia] Univ Fed Sao Paulo, Hosp Sao Paulo, UTI Pronto Socorro, Sao Paulo, Brazil.
   [Machado, Flavia R.; Mazza, Bruno F.; Rossetti Santana, Heloisa B.; Mendez, Vanessa M. F.; Xavier, Patricia A.; Rabelo, Melina V.; Schievano, Fabiana R.; Pinto, Walkyria A. M.; Francisco, Renata S.; Ferreira, Elaine M.] Univ Fed Sao Paulo, Hosp Sao Paulo, UTI Anestesiol, Sao Paulo, Brazil.
   [Silva, Dafne C. B.; Arduini, Rodrigo G.] Univ Fed Sao Paulo, Inst Oncol Pediat GRAACC, Sao Paulo, Brazil.
   [Aldrighi, Jose R.; Amaro, Andreson F.] Hosp & Maternidade Sao Cristovao, Sao Paulo, Brazil.
   [Conde, Katia A. P.] Hosp Jose Soares Hungria, Sao Paulo, Brazil.
   [Pereira, Cesar A.; Tarkieltaub, Elcio; Oliver, Wilson R.; Guadalupe, Erika G. L.; Acerbi, Paulo S. C.; Tomizuka, Carlos I.; Oliveira, Tatiana A.; Geha, Nadia N.] Hosp Municipal Prof Doutor Alipio Correa Neto, Sao Paulo, Brazil.
   [Mecatti, Giovana C.; Piovesan, Maysa Z. R.; Salomao, Maria C.] Hosp Univ Sao Francisco, Braganca Paulista, SP, Brazil.
   [Moreno, Marcelo S.; Orsatti, Vinicius N.; Miranda, Whiniton] Hosp UNIMED, Aracatuba, SP, Brazil.
   [Ray, Alexandre; Guerra, Andre; Baptista Filho, Mario L. A.] Hosp Bandeirantes, Sao Paulo, Brazil.
   [Ferreira, Firmino H., Jr.; Viera Filho, Edesio; Canzi, Regina A.; Giuberti, Adriana F. T.; Garcez, Melissa C. M.] Hosp Geral Sao Mateus Dr Manoel Bifulco, Sao Paulo, Brazil.
   [Carvalho, Fabricio R. T.; Andrade, Lucia C.; Guimaraes, Helio P.] Inst Infectol Emilio Ribas, Sao Paulo, Brazil.
   [Santos, Thiago M.; Carmona, Cesar V.; Figueiredo, Luciana C.; Falcao, Antonio; Dragosavak, Desanka] Univ Estadual Campinas, Hosp Clin, Campinas, SP, Brazil.
   [Nogueira Filho, Wilson; Lunardi, Maria C.; Lago, Roberto; Gatti, Ciro; Chiasso, Tatiana M.; Santos, Grazielle O.; Silva, Aline C. F.; Araujo, Arthur C.] Hosp Clin Luzia de Pinho & Melo SPDM, Mogi Das Cruzes, SP, Brazil.
   [Ornellas, Izadora B.; Vieira, Vitor M.] Irmandade Santa Casa Misericordia Mogi Guacu, Mogi Guacu, SP, Brazil.
   [Hajjar, Ludhmila A.; Figueiredo, Adelaide C.] Inst Canc Estado Sao Paulo ICESP, Sao Paulo, Brazil.
   [Vieira, Vitor M.; Damasceno, Bruna] Hosp Maternidade UNIMED Leste Paulista, Sao Joao Da Boa Vista, SP, Brazil.
   [Pizarro, Camilo] Fdn Cardiovasc Colombia, Bucaramanga, Colombia.
   [Hinestrosa, Alfredo] Los Comuneros Hosp Univ Bucaramanga, Bucaramanga, Colombia.
   [Diaz-Quijano, Fredi A.] Org Latinoamer Fomento Invest Salud OLFSI, Bucaramanga, Colombia.
   [Garcia L., Sandra M. C.; Gonzalez C., Octavio; Diaz S., Edgard] Medica Sur, Mexico City, DF, Mexico.
   [Raineri, Santi M.; Cortegiani, Andrea] Azienda Osped Univ P Giaccone, Palermo, Italy.
   Hosp Coracao IEP HCor, Res Inst, BR-04005000 Sao Paulo, Brazil.
RP Cavalcanti, AB (corresponding author), Hosp Urgencias & Emergencias Rio Branco HUERB, Rio Branco, AC, Brazil.
RI Ferguson, Niall/D-7619-2019; Marques, Leandro S/J-4053-2014; amato,
   Marcelo Britto Passo/L-5001-2016; Romano, Marcelo Luz
   Pereira/AAN-6490-2020; Mallor, Fermin/K-2355-2015; Maia,
   Mauricio/Z-1042-2019; Taniguchi, Leandro U/J-2099-2015; Grion, Cintia M.
   C./C-2039-2014; Cortegiani, Andrea/H-4902-2016; Hajjar, Ludhmila
   A/K-3512-2017; Pompilio, Carlos E/C-6051-2014; Suzumura, Erica
   A/C-4197-2013; Guimaraes, Helio Penna/AAD-8681-2019; Taniguchi, Leandro
   Utino/L-6471-2015; Carvalho, Vitor Oliveira/C-7170-2012; Teixeira,
   Cassiano/V-8764-2019; Arduini, Rodrigo Genaro/A-1067-2013; de Carvalho,
   Carlos Roberto Ribeiro/N-9827-2018; Rech, Tatiana/V-2711-2019; Boniatti,
   Marcio/AAA-4195-2020; Borges, Marcos Carvalho/A-3585-2014; Amorim, Fabio
   F/J-4251-2012; Diaz-Quijano, Fredi Alexander/I-3740-2012; Maia,
   Mauricio/I-5892-2015; De Santis Santiago, Roberta Ribeiro/AAV-7359-2020;
   Machado, Flavia R/G-4651-2012; Lima, Fabio Bessa/H-2677-2014; Barbosa,
   Tiago M./ABE-6789-2020; Azevedo, Luciano CP/H-2652-2012
OI Ferguson, Niall/0000-0002-6213-5264; Marques, Leandro
   S/0000-0002-7089-8739; amato, Marcelo Britto Passo/0000-0003-3525-8282;
   Romano, Marcelo Luz Pereira/0000-0001-6773-1666; Mallor,
   Fermin/0000-0001-9800-1498; Maia, Mauricio/0000-0002-7034-8091;
   Taniguchi, Leandro U/0000-0003-4384-0408; Grion, Cintia M.
   C./0000-0001-9669-2010; Cortegiani, Andrea/0000-0003-1416-9993;
   Pompilio, Carlos E/0000-0003-2559-8689; Suzumura, Erica
   A/0000-0003-1752-6095; Taniguchi, Leandro Utino/0000-0003-4384-0408;
   Arduini, Rodrigo Genaro/0000-0003-2108-6176; de Carvalho, Carlos Roberto
   Ribeiro/0000-0002-1618-8509; Borges, Marcos
   Carvalho/0000-0001-6280-0714; Amorim, Fabio F/0000-0003-0929-5733;
   Diaz-Quijano, Fredi Alexander/0000-0002-1134-1930; Maia,
   Mauricio/0000-0002-7034-8091; De Santis Santiago, Roberta
   Ribeiro/0000-0002-5818-0361; Machado, Flavia R/0000-0002-2356-4867;
   Lima, Fabio Bessa/0000-0003-0573-9544; Barbosa, Tiago
   M./0000-0001-7071-2116; Azevedo, Luciano CP/0000-0001-6759-3910
FU Hospital do Coracao (HCor) as part of the Program 'Hospitais de
   Excelencia a Servico do SUS (PROADI-SUS)'; Brazilian Ministry of Health
FX This study is funded by the Hospital do Coracao (HCor) as part of the
   Program 'Hospitais de Excelencia a Servico do SUS (PROADI-SUS)' in
   partnership with the Brazilian Ministry of Health.
CR [Anonymous], 1999, Am J Respir Crit Care Med, V160, P2118
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Borges JB, 2006, AM J RESP CRIT CARE, V174, P268, DOI 10.1164/rccm.200506-976OC
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046
   de Matos GFJ, 2012, CRIT CARE, V16, DOI 10.1186/cc10602
   Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345
   Fan E, 2008, AM J RESP CRIT CARE, V178, P1156, DOI 10.1164/rccm.200802-335OC
   Gattinoni L, 2010, CRIT CARE MED, V38, pS539, DOI 10.1097/CCM.0b013e3181f1fcf7
   Grasso S, 2007, AM J RESP CRIT CARE, V176, P761, DOI 10.1164/rccm.200702-193OC
   Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802
   Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450
   Hodgson CL, 2011, CRIT CARE, V15, DOI 10.1186/cc10249
   Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203
   Mueller PS, 2007, ANN INTERN MED, V146, P878, DOI 10.7326/0003-4819-146-12-200706190-00009
   MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774
   Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259
   Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01
NR 20
TC 17
Z9 17
U1 1
U2 32
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD AUG 28
PY 2012
VL 13
AR 153
DI 10.1186/1745-6215-13-153
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 078LJ
UT WOS:000314100100001
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Sousa-Martins, D
   Maia, M
   Moraes, M
   Lima, AAS
   Rodrigues, EB
   Chen, J
   Farah, ME
   Santos, LB
   Belfort, R
AF Sousa-Martins, Diogo
   Maia, Mauricio
   Moraes, Milton
   Lima-Filho, Acacio A. S.
   Rodrigues, Eduardo B.
   Chen, Jane
   Farah, Michel E.
   Santos, Leticia B.
   Belfort, Rubens, Jr.
TI USE OF LUTEIN AND ZEAXANTHIN ALONE OR COMBINED WITH BRILLIANT BLUE TO
   IDENTIFY INTRAOCULAR STRUCTURES INTRAOPERATIVELY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE blue; brilliant; capsule; chromovitrectomy; dye; internal limiting
   membrane; lutein; safety; vitreous; zeaxanthin
ID INDOCYANINE GREEN INJECTION; VITAL DYES; TRIAMCINOLONE ACETONIDE;
   MACULAR PIGMENT; TRYPAN BLUE; SUBRETINAL INJECTION; CAROTENOIDS;
   TOXICITY; SURGERY
AB Purpose: To determine whether a natural dye solution based on lutein and zeaxanthin alone or combined with Brilliant Blue stains and facilitates peeling of intraocular membranes in human eyes.
   Methods: In this study of 60 cadaveric eyes, open-sky vitrectomy including posterior hyaloid detachment was performed. Different lutein and zeaxanthin concentrations (0.01-20%) were tested alone or combined with different Brilliant Blue concentrations (0.0125-0.025%) in the corneal endothelium, corneal epithelium, anterior and posterior capsule, vitreous cavity through the macula including the posterior hyaloid, and internal limiting membrane. The various dye solutions were in contact with the intraocular membranes for <1 minute and then were removed by mechanical aspiration or membrane peeling initiated and completed with intraocular forceps. The specimens were examined by light and electron transmission microscopy.
   Results: Contact between lutein and zeaxanthin and the retinal, lens, and vitreous surface resulted in orange and greenish staining of the intraocular membranes, which facilitated surgical steps in all eyes. Lutein and zeaxanthin alone was useful for vitreous identification and lutein and zeaxanthin combined with Brilliant Blue had strong affinity for internal limiting membrane and anterior capsule. Light microscopy confirmed internal limiting membrane removal in all eyes tested. No dye solutions remained in the eyes after the membrane removal.
   Conclusion: A natural dye solution based on lutein and zeaxanthin alone or combined with Brilliant Blue efficiently stained the anterior capsule, vitreous, and internal limiting membrane in human cadaveric eyes and may be a useful tool for vitreoretinal or cataract surgery. RETINA 32:1328-1336, 2012
C1 [Maia, Mauricio] Univ Fed Sao Paulo, Vitreoretinal Surg Unit, Dept Ophthalmol, Inst Visao IPEPO, BR-06023062 Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Vitreoretinal Surg Unit, Dept Ophthalmol, Inst Visao IPEPO, 822 Botucatu St, BR-06023062 Sao Paulo, Brazil.
EM retina@femanet.com.br
RI Sousa-Martins, Diogo/B-1554-2019; Farah, Michel Eid E/F-3285-2012; de
   Souza Lima Filho, Acacio Alves/C-7189-2012; Maia, Mauricio/Z-1042-2019;
   Belfort, Rubens/E-2252-2012; Maia, Mauricio/I-5892-2015
OI Sousa-Martins, Diogo/0000-0002-2285-3990; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Belfort,
   Rubens/0000-0002-8422-3898; Maia, Mauricio/0000-0002-7034-8091; Alves de
   Souza Lima Filho, Acacio/0000-0003-1802-9592; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); Kemin Industries, Inc;
   Ophthalmos Industria e Comercio de Produtos Farmaceuticos S.A.
FX Supported by the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo,
   Kemin Industries, Inc, and Ophthalmos Industria e Comercio de Produtos
   Farmaceuticos S.A.
CR Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   Albini TA, 2007, INVEST OPHTH VIS SCI, V48, P390, DOI 10.1167/iovs.06-0145
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Costa EPF, 2008, INVEST OPHTH VIS SCI, V49, P6
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P623, DOI 10.1097/00006982-200607000-00006
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Feron EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P141
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Gandorfer A, 2003, INVEST OPHTH VIS SCI, V44, P316, DOI 10.1167/iovs.02-0545
   Gonzalez S, 2003, J INVEST DERMATOL, V121, P399, DOI 10.1046/j.1523-1747.2003.12355.x
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P3315, DOI 10.1167/iovs.04-1142
   Jackson TL, 2005, EXP EYE RES, V81, P446, DOI 10.1016/j.exer.2005.03.004
   Kumar Atul, 2004, Indian J Ophthalmol, V52, P339
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Maia M, 2009, BR J OPHTHALMOL, V93, P330
   Maia M, 2008, GRAEF ARCH CLIN EXP, V246, P379, DOI 10.1007/s00417-007-0718-y
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Mennel S, 2006, OPHTHALMOLOGICA, V220, P190, DOI 10.1159/000091764
   Mennel S, 2006, KLIN MONATSBL AUGENH, V223, P568, DOI 10.1055/s-2006-926479
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   Penha FM, 2008, J OCUL PHARMACOL TH, V24, P52, DOI 10.1089/jop.2007.0047
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Perrier M, 2003, AM J OPHTHALMOL, V135, P909, DOI 10.1016/S0002-9394(02)02256-0
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Rodrigues EB, 2010, AM J OPHTHALMOL, V149, P265, DOI 10.1016/j.ajo.2009.08.020
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Rodrigues Eduardo B, 2008, Dev Ophthalmol, V42, P29, DOI 10.1159/000138911
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   Rodrigues EB, 2008, ARQ BRAS OFTALMOL, V71, P902, DOI 10.1590/S0004-27492008000600028
   Schuettauf F, 2006, INVEST OPHTH VIS SCI, V47, P3573, DOI 10.1167/iovs.06-0211
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Teba FA, 2003, OPHTHALMOLOGY, V110, P2409, DOI 10.1016/S0161-6420(03)00716-4
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
NR 47
TC 13
Z9 13
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2012
VL 32
IS 7
BP 1328
EP 1336
DI 10.1097/IAE.0b013e318239e2b6
PG 9
WC Ophthalmology
SC Ophthalmology
GA 965QK
UT WOS:000305782100015
PM 22450514
DA 2020-12-15
ER

PT J
AU Dib, E
   Maia, M
   Lima, AD
   Costa, EDF
   de Moraes, MN
   Rodrigues, EB
   Penha, FM
   Coppini, LP
   de Barros, NMT
   Coimbra, RDSG
   Magalhaes, O
   Guerra, T
   Furlani, BD
   Freymuller, E
   Farah, ME
AF Dib, Eduardo
   Maia, Mauricio
   Lima, Acacio de Souza
   Fiod Costa, Elaine de Paula
   de Moraes-Filho, Milton Nunes
   Rodrigues, Eduardo Buechele
   Penha, Fernando Marcondes
   Coppini, Larissa Pereira
   Tenorio de Barros, Nilana Meza
   Sinigaglia Galli Coimbra, Rita de Cassia
   Magalhaes Junior, Octaviano
   Guerra, Tarcisio
   Furlani, Bruno de Albuquerque
   Freymuller, Edna
   Farah, Michel Eid
TI In Vivo, In Vitro Toxicity and In Vitro Angiogenic Inhibition of
   Sunitinib Malate
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Angiogenesis; Choroidal neovascularization; Intravitreal injection; Drug
   toxicity; Tyrosine kinase inhibitor
ID INDOCYANINE GREEN INJECTION; RETINA STUDY-GROUP; MACULAR DEGENERATION;
   INTRAVITREAL BEVACIZUMAB; RABBIT RETINA; TRYPAN BLUE; RANIBIZUMAB;
   THERAPY; AVASTIN; SAFETY
AB Purpose: To evaluate the in vivo and in vitro toxicity of sunitinib malate, a multikinase inhibitor molecule.
   Design: Experimental, Prospective, Controlled.
   Methods: Human retinal pigment epithelial (ARPE-19) and human umbilical vein endothelialcells (HUVECS) were used in a culture toxicity test and exposed to different concentrations of sunitinib malate for 18 hours. The HUVECs also were cultured to evaluate the angiogenesis inhibitory effect of sunitinib malate. Fundus photography and angiographic, electrophysiologic, and histopathologic evaluations with light and electron microscopy were performed in two groups of five rabbits each that received different intravitreal concentrations of the drug. Each rabbit received 0.1 ml of sunitinib malate in the right eye (one group with 12.5 mg/ml, the other group with 25 mg/ml); all animals received 0.1 ml of physiologic saline solution in the left eye. After sacrifice, the eyes were enucleated and fixed with modified Karnovsky solution.
   Results: No toxicity related to sunitinib malate was observed using an in vitro model with the 12.5 and 25 mg/ml solutions in HUVEC and ARPE cell cultures. No toxicity was observed in the in vivo model with 12.5 mg/ml, but light microscopy showed that the 25 mg/ml solution damaged the photoreceptors layer. No functional changes in the electroretinogram were observed in any group.
   Conclusions: Sunitinib malate 12.5 mg/ml caused no toxicity in in vivo and in vitro models, but the 25 mg/ml concentration caused retinal changes suggesting toxicity in the in vivo model. Further research with the drug is needed in models of ocular neovascularization.
C1 [Dib, Eduardo; Maia, Mauricio; Fiod Costa, Elaine de Paula; de Moraes-Filho, Milton Nunes; Rodrigues, Eduardo Buechele; Penha, Fernando Marcondes; Magalhaes Junior, Octaviano; Guerra, Tarcisio; Furlani, Bruno de Albuquerque; Farah, Michel Eid] Sao Paulo Fed Univ UNIFESP, Dept Ophthalmol, Vitreoretinal Dis Sect, Sao Paulo, Brazil.
   [Lima, Acacio de Souza] Vis Inst IPEPO, Dept Ophthalmol, Ocular Pharmacol Sect, Sao Paulo, Brazil.
   [Coppini, Larissa Pereira; Tenorio de Barros, Nilana Meza] Univ Fed Sao Paulo, Dept Biophys, Sao Paulo, Brazil.
   [Sinigaglia Galli Coimbra, Rita de Cassia; Freymuller, Edna] Univ Fed Sao Paulo, Ctr Electron Microscopy, Sao Paulo, Brazil.
RP Maia, M (corresponding author), 901 Otto Ribeiro Ave, BR-19800320 Assis, SP, Brazil.
EM maiamauricio@terra.com.br
RI Xu, Qingguo/C-1962-2014; Farah, Michel Eid E/F-3285-2012; Rodrigues,
   Eduardo Buchele/C-6852-2015; de Souza Lima Filho, Acacio
   Alves/C-7189-2012; Sinigaglia-Coimbra, Rita/C-9155-2012; Maia,
   Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; Penha, Fernando
   M/G-1784-2012
OI Xu, Qingguo/0000-0003-3191-0771; Farah, Michel Eid
   E/0000-0001-5951-0193; Sinigaglia-Coimbra, Rita/0000-0001-8747-6316;
   Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Alves de Souza Lima Filho, Acacio/0000-0003-1802-9592; Buchele
   Rodrigues, Eduardo/0000-0002-4224-0921
CR [Anonymous], 2006, SUT LAB TEXT
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Arnold Jennifer, 2006, Clin Evid, P877
   ARVO, 1996, ARVO AN RES COMM, p[1, 20]
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Korpanty G, 2010, J ONCOL, V2010, DOI 10.1155/2010/652320
   Kwok AKH, 2005, BRIT J OPHTHALMOL, V89, P897, DOI 10.1136/bjo.2004.061093
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Marmor MF, 2009, DOC OPHTHALMOL, V118, P69, DOI 10.1007/s10633-008-9155-4
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moshfeghi A. A., 2002, OPHTHALMOLOGY, V113, pe1
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   Paschoalin T, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-44
   Penha FM, 2008, J OCUL PHARMACOL TH, V24, P52, DOI 10.1089/jop.2007.0047
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Price N, 2000, GASTROINTEST ENDOSC, V51, P438, DOI 10.1016/S0016-5107(00)70445-7
   Rodrigues EB, 2010, AM J OPHTHALMOL, V149, P265, DOI 10.1016/j.ajo.2009.08.020
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   Ropert S, 2011, INVEST NEW DRUG, V29, P1497, DOI 10.1007/s10637-010-9500-9
   Sablin MP, 2010, EXPERT OPIN DRUG MET, V6, P1005, DOI 10.1517/17425255.2010.506872
   Sugawara T, 2000, EXP EYE RES, V70, P693, DOI 10.1006/exer.2000.0842
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Veckeneer M, 2001, GRAEF ARCH CLIN EXP, V239, P698, DOI 10.1007/s004170100341
   Wu LT, 2008, RETINA-J RET VIT DIS, V28, P212, DOI 10.1097/IAE.0b013e3181619bee
   ZEMEL E, 1995, INVEST OPHTH VIS SCI, V36, P1875
NR 33
TC 12
Z9 12
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUL
PY 2012
VL 37
IS 7
BP 567
EP 574
DI 10.3109/02713683.2011.635916
PG 8
WC Ophthalmology
SC Ophthalmology
GA 955IG
UT WOS:000305010400003
PM 22587017
DA 2020-12-15
ER

PT J
AU Bottos, JM
   Elizalde, J
   Rodrigues, EB
   Maia, M
AF Bottos, Juliana M.
   Elizalde, Javier
   Rodrigues, Eduardo B.
   Maia, Mauricio
TI Current concepts in vitreomacular traction syndrome
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE optical coherence tomography; vitrectomy; vitreomacular traction
   syndrome; vitreoretinal interface; vitreous detachment
ID OPTICAL COHERENCE TOMOGRAPHY; POSTERIOR VITREOUS DETACHMENT; MACULAR
   HOLE FORMATION; VITRECTOMY; RESOLUTION; PATHOLOGY; OUTCOMES
AB Purpose of review
   As Reese first described the vitreomacular traction (VMT) syndrome in 1970, the knowledge base about the disease has been changing over time due to the advent of the high-definition optical coherence tomography (HD-OCT). The aim of this article was to present the current information on the pathophysiology, anatomic macular abnormality associations, treatments, and new concepts in VMT syndrome.
   Recent findings
   HD-OCT has provided unprecedented visualization of the vitreomacular interface, which has led to better comprehension of the VMT syndrome. The technologic advances also emphasized the need to review the basis of the VMT syndrome and define as yet unsettled and often confusing concepts.
   Summary
   The recognition of the role of VMT in a variety of macular conditions is imperative for proper diagnosis and appropriate management of these diseases.
C1 [Bottos, Juliana M.; Rodrigues, Eduardo B.; Maia, Mauricio] Univ Fed Sao Paulo, UNIFESP, Dept Ophthalmol, Sao Paulo, Brazil.
   [Elizalde, Javier] Univ Autonoma Barcelona, IUB, E-08193 Barcelona, Spain.
RP Bottos, JM (corresponding author), 21 Luiz Alves Gevaerd St, BR-88351230 Brusque, SC, Brazil.
EM jubottos@gmail.com
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Buchele Rodrigues, Eduardo/0000-0002-4224-0921
FU Instituto Barraquer de Oftalmologia, Barcelona, Spain
FX This study was the winner of the Joaquin Rutllan 2010 Award, from the
   Instituto Barraquer de Oftalmologia, Barcelona, Spain.
CR APPIAH AP, 1988, AM J OPHTHALMOL, V106, P533, DOI 10.1016/0002-9394(88)90581-8
   Chang LK, 2008, AM J OPHTHALMOL, V146, P121, DOI 10.1016/j.ajo.2008.03.001
   Chauhan DS, 2000, ARCH OPHTHALMOL-CHIC, V118, P32
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   de Smet MD, 2009, OPHTHALMOLOGY, V116, P1349, DOI 10.1016/j.ophtha.2009.03.051
   Díaz-Llopis M., 2009, Arch Soc Esp Oftalmol, V84, P91
   Farah ME, 2009, AM J OPHTHALMOL, V148, P332, DOI 10.1016/j.ajo.2009.04.003
   Gandorfer A, 2002, BRIT J OPHTHALMOL, V86, P902, DOI 10.1136/bjo.86.8.902
   GASS JDM, 1988, ARCH OPHTHALMOL-CHIC, V106, P629, DOI 10.1001/archopht.1988.01060130683026
   GASS JDM, 1995, AM J OPHTHALMOL, V119, P752, DOI 10.1016/S0002-9394(14)72781-3
   Gaudric A, 1999, ARCH OPHTHALMOL-CHIC, V117, P744
   HIKICHI T, 1993, AM J OPHTHALMOL, V116, P273, DOI 10.1016/S0002-9394(14)71343-1
   Ito Y, 2003, AM J OPHTHALMOL, V135, P351, DOI 10.1016/S0002-9394(02)01944-X
   Johnson MW, 2010, AM J OPHTHALMOL, V149, P371, DOI 10.1016/j.ajo.2009.11.022
   Johnson MW, 2005, AM J OPHTHALMOL, V140, P184, DOI 10.1016/j.ajo.2005.01.033
   Johnson MW, 2001, ARCH OPHTHALMOL-CHIC, V119, P215
   Koizumi H, 2008, AM J OPHTHALMOL, V145, P509, DOI 10.1016/j.ajo.2007.10.014
   Kusaka S, 2001, OPHTHALMOLOGICA, V215, P139, DOI 10.1159/000050847
   MCDONALD HR, 1994, OPHTHALMOLOGY, V101, P1397
   MELBERG NS, 1995, RETINA-J RET VIT DIS, V15, P192, DOI 10.1097/00006982-199515030-00002
   MILLER B, 1985, ARCH OPHTHALMOL-CHIC, V103, P1385
   Mirza RG, 2007, SURV OPHTHALMOL, V52, P397, DOI 10.1016/j.survophthal.2007.04.007
   MURPHY AI, 1983, RETINA-J RET VIT DIS, V3, P273, DOI 10.1097/00006982-198300340-00008
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   REESE AB, 1970, AM J OPHTHALMOL, V69, P975, DOI 10.1016/0002-9394(70)91041-X
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   SEBAG J, 1992, EYE, V6, P541, DOI 10.1038/eye.1992.119
   Shechtman DL, 2009, OPTOMETRY, V80, P681, DOI 10.1016/j.optm.2009.07.014
   SMIDDY WE, 1990, RETINA-J RET VIT DIS, V10, P288, DOI 10.1097/00006982-199010000-00012
   SMIDDY WE, 1989, OPHTHALMOLOGY, V96, P811
   SMIDDY WE, 1989, AM J OPHTHALMOL, V107, P177, DOI 10.1016/0002-9394(89)90219-5
   SMIDDY WE, 1988, ARCH OPHTHALMOL-CHIC, V106, P624
   Smiddy WE, 2004, AM J OPHTHALMOL, V137, P525, DOI 10.1016/j.ajo.2003.12.011
   Sonmez K, 2008, RETINA-J RET VIT DIS, V28, P1207, DOI 10.1097/IAE.0b013e31817b6b0f
   Spaide RF, 2002, AM J OPHTHALMOL, V133, P226, DOI 10.1016/S0002-9394(01)01377-0
   Sulkes DJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P286
   TAKAHASHI M, 1981, ARCH OPHTHALMOL-CHIC, V99, P1555
   Witkin AJ, 2010, OPHTHAL SURG LAS IM, V41, P425, DOI 10.3928/15428877-20100525-07
   Yamada N, 2005, AM J OPHTHALMOL, V139, P112, DOI 10.1016/j.ajo.2004.08.055
   YONEMOTO J, 1994, GRAEF ARCH CLIN EXP, V232, P67, DOI 10.1007/BF00171665
NR 41
TC 27
Z9 27
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2012
VL 23
IS 3
BP 195
EP 201
DI 10.1097/ICU.0b013e328352404c
PG 7
WC Ophthalmology
SC Ophthalmology
GA 933TQ
UT WOS:000303386000006
PM 22450220
DA 2020-12-15
ER

PT J
AU Eckert, GU
   Fortes, JB
   Maia, M
   Procianoy, RS
AF Eckert, G. U.
   Fortes Filho, J. B.
   Maia, M.
   Procianoy, R. S.
TI A predictive score for retinopathy of prematurity in very low birth
   weight preterm infants
SO EYE
LA English
DT Article
DE prematurity; retinopathy of prematurity; very low birth weight; risk
   factors; severity illness score
ID POSTNATAL WEIGHT; GESTATIONAL-AGE; RISK-FACTORS; GAIN; ERYTHROPOIETIN;
   POPULATION; SEVERITY; BABIES; ROP
AB Aims This study describes the development of a score based on cumulative risk factors for the prediction of severe retinopathy of prematurity (ROP) comparing the performance of the score against the birth weight (BW) and gestational age (GA) in order to predict the onset of ROP.
   Methods A prospective cohort of preterm infants with BWp1500 g and/or GAp32 weeks was studied. The score was developed based on BW, GA, proportional weight gain from birth to the 6th week of life, use of oxygen in mechanical ventilation, and need for blood transfusions from birth to the 6th week of life. The score was established after linear regression, considering the impact of each variable on the occurrences of any stage and severe ROP. Receiver operating characteristic (ROC) curves were used to determine the best sensitivity and specificity values for the score. All variables were entered into an Excel spreadsheet (Microsoft) for practical use by ophthalmologists during screening sessions.
   Results The sample included 474 patients. The area under the ROC curve for the score was 0.77 and 0.88 to predict any stage and severe ROP, respectively. These values were significantly higher for the score than for BW (0.71) and GA (0.69) when measured separately.
   Conclusions ROPScore is an excellent index of neonatal risk factors for ROP, which is easy to record and more accurate than BW and GA to predict any stage ROP or severe ROP in preterm infants. The scoring system is simple enough to be routinely used by ophthalmologists during screening examination for detection of ROP. Eye (2012) 26, 400-406; doi: 10.1038/eye. 2011.334; published online 23 December 2011
C1 [Fortes Filho, J. B.] Hosp Clin Porto Alegre, Dept Ophthalmol, BR-90035903 Porto Alegre, RS, Brazil.
   [Eckert, G. U.; Fortes Filho, J. B.] Univ Fed Rio Grande do Sul, Dept Ophthalmol, Sch Med, Porto Alegre, RS, Brazil.
   [Maia, M.] Univ Fed Sao Paulo, Dept Ophthalmol, Sch Med, Sao Paulo, Brazil.
   [Procianoy, R. S.] Univ Fed Rio Grande do Sul, Dept Paediat, Newborn Sect, Sch Med, Porto Alegre, RS, Brazil.
RP Fortes, JB (corresponding author), Hosp Clin Porto Alegre, Dept Ophthalmol, Rua Ramiro Barcelos, BR-90035903 Porto Alegre, RS, Brazil.
EM jbfortes@prorop.com.br
RI FILHO, JOAO B FORTES/K-8446-2017; Maia, Mauricio/I-5892-2015; Maia,
   Mauricio/Z-1042-2019; Eckert, G/K-6926-2017; Procianoy,
   Renato/I-5133-2014
OI FILHO, JOAO B FORTES/0000-0001-5682-0962; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Eckert, G/0000-0003-1592-4831; Procianoy, Renato/0000-0001-8297-4164
CR Aggarwal A, 1997, Indian Pediatr, V34, P1143
   Allegaert K, 2003, J AAPOS, V7, P34, DOI 10.1016/S1091-8531(02)42015-0
   Aydemir O, 2011, EYE, V25, P725, DOI 10.1038/eye.2011.29
   Binenbaum G, 2011, PEDIATRICS, V127, pE607, DOI 10.1542/peds.2010-2240
   Brooks SE, 1999, PEDIATRICS, V104, P514, DOI 10.1542/peds.104.3.514
   Brown MS, 2006, J AAPOS, V10, P143, DOI 10.1016/j.jaapos.2005.09.005
   Chen HL, 2009, PEDIATR NEONATOL, V50, P110, DOI 10.1016/S1875-9572(09)60045-0
   Chen J, 2008, J AAPOS, V12, P221, DOI 10.1016/j.jaapos.2008.02.001
   Eriksson M, 2002, ACTA PAEDIATR, V91, P1093, DOI 10.1080/080352502760311601
   Fluckiger S, 2011, KLIN MONATSBL AUGENH, V228, P306, DOI 10.1055/s-0031-1273217
   Fortes JB, 2009, EYE, V23, P25, DOI 10.1038/sj.eye.6702924
   Fortes JB, 2009, OPHTHALMOLOGICA, V223, P177, DOI 10.1159/000197114
   Fortes JB, 2011, ARQ BRAS OFTALMOL, V74, P217, DOI 10.1590/S0004-27492011000300016
   Fortes JB, 2010, GRAEF ARCH CLIN EXP, V248, P893, DOI 10.1007/s00417-009-1248-6
   Fortes JB, 2009, GRAEF ARCH CLIN EXP, V247, P831, DOI 10.1007/s00417-008-1012-3
   GARNER A, 1984, ARCH OPHTHALMOL-CHIC, V102, P1130
   Gilbert C, 2008, EARLY HUM DEV, V84, P77, DOI 10.1016/j.earlhumdev.2007.11.009
   Good WV, 2003, ARCH OPHTHALMOL-CHIC, V121, P1684
   Hagadorn J, 2007, J PERINATOL, V27, P502, DOI 10.1038/sj.jp.7211780
   Hard AL, 2010, ARCH OPHTHALMOL-CHIC, V128, P1432, DOI 10.1001/archophthalmol.2010.255
   Hellstrom A, 2001, P NATL ACAD SCI USA, V98, P5804, DOI 10.1073/pnas.101113998
   Hellstrom A, 2009, PEDIATRICS, V123, pE638, DOI 10.1542/peds.2008-2697
   Lofqvist C, 2006, ARCH OPHTHALMOL-CHIC, V124, P1711, DOI 10.1001/archopht.124.12.1711
   Loqvist C, 2009, ARCH OPHTHALMOL-CHIC, V127, P622, DOI 10.1001/archophthalmol.2009.69
   Manzoni P, 2005, NEW ENGL J MED, V353, P2190
   Martinez EZ, 2003, CADERNOS SAUDE COLET, V11, P7
   PATZ A, 1987, ARCH OPHTHALMOL-CHIC, V105, P905, DOI 10.1001/archopht.1987.01060070041024
   PATZ A, 1984, CURR EYE RES, V3, P159, DOI 10.3109/02713688408997197
   Quinn GE, 2007, J PEDIAT, V83, P191, DOI 10.1590/S0021-75572007000400001
   Shah VA, 2005, ANN ACAD MED SINGAP, V34, P169
   Smith Lois E H, 2003, Semin Neonatol, V8, P469, DOI 10.1016/S1084-2756(03)00119-2
   Wallace DK, 2000, J AAPOS, V4, P343, DOI 10.1067/mpa.2000.110342
NR 32
TC 41
Z9 43
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2012
VL 26
IS 3
BP 400
EP 406
DI 10.1038/eye.2011.334
PG 7
WC Ophthalmology
SC Ophthalmology
GA 907PD
UT WOS:000301428900007
PM 22193874
OA Green Published, Bronze
DA 2020-12-15
ER

PT J
AU Penha, FM
   Maia, M
   Cardillo, JA
   Arevalo, JF
   Wu, L
   Rodriguez, FJ
   Berrocal, MH
   Farah, ME
AF Penha, Fernando Marcondes
   Maia, Mauricio
   Cardillo, Jose Augusto
   Fernando Arevalo, J.
   Wu, Lihteh
   Rodriguez, Francisco J.
   Berrocal, Maria H.
   Farah, Michel Eid
CA Pan-Amer Collaborative Retina
TI Comparison of a single intravitreal injection of bevacizumab versus
   triamcinolone acetonide as primary treatment for diffuse diabetic
   macular oedema
SO ACTA OPHTHALMOLOGICA
LA English
DT Letter
C1 [Penha, Fernando Marcondes; Maia, Mauricio; Cardillo, Jose Augusto; Farah, Michel Eid] Univ Fed Sao Paulo, Vis Inst, Dept Ophthalmol, BR-04023062 Sao Paulo, Brazil.
   [Fernando Arevalo, J.] Clin Oftalmol Caracas Ctr, Caracas, Venezuela.
   [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Rodriguez, Francisco J.] Fdn Oftalmol Nacl, Bogota, Colombia.
   [Berrocal, Maria H.] Univ Puerto Rico, Santurce, PR USA.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Vis Inst, Dept Ophthalmol, Rua Botucatu 822, BR-04023062 Sao Paulo, Brazil.
EM maiamauricio@terra.com.br
RI Penha, Fernando M/G-1784-2012; Maia, Mauricio/Z-1042-2019; Farah, Michel
   Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Cardillo,
   Jose Augusto/0000-0002-5791-3201
CR Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Arevalo JF, 2009, OPHTHALMOLOGY, V116, P1488, DOI 10.1016/j.ophtha.2009.03.016
   Folgosa MS, 2010, ACTA OPHTHALMOL, V88, pe297, DOI 10.1111/j.1755-3768.2009.01721.x
   Kreutzer TC, 2010, OPHTHALMOLOGICA, V224, P258, DOI 10.1159/000284466
   Maia M, 2007, BRIT J OPHTHALMOL, V91, P1122, DOI 10.1136/bjo.2007.115386
NR 5
TC 5
Z9 5
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2012
VL 90
IS 2
BP e160
EP e161
DI 10.1111/j.1755-3768.2010.02098.x
PG 2
WC Ophthalmology
SC Ophthalmology
GA 899RW
UT WOS:000300834800028
PM 21470386
DA 2020-12-15
ER

PT J
AU Maia, M
   Figueiredo, FP
   Barbieri, MA
   Silva, AAM
   Loureiro, SR
   Bettiol, H
AF Maia, M.
   Figueiredo, F. P.
   Barbieri, M. A.
   Silva, A. A. M.
   Loureiro, S. R.
   Bettiol, H.
TI PROLONGED NON-NUTRITIVE SUCKLING HABITS ARE ASSOCIATED WITH EMOTIONAL
   AND BEHAVIORAL PROBLEMS IN SCHOOL-AGE CHILDREN
SO EUROPEAN PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Maia, M.; Figueiredo, F. P.; Barbieri, M. A.; Loureiro, S. R.; Bettiol, H.] Univ Sao Paulo, BR-14049 Ribeirao Preto, Brazil.
   [Silva, A. A. M.] Univ Fed Maranhao, Dept Publ Hlth, Sao Luis, Brazil.
RI Bettiol, Heloisa/B-4190-2013; Figueiredo, Felipe/D-2425-2013; Maia,
   Mauricio/I-5892-2015; Barbieri, Marco/J-2597-2014; Silva, Antonio A
   M/B-5410-2009
OI Bettiol, Heloisa/0000-0001-8744-4373; Figueiredo,
   Felipe/0000-0001-8616-0483; Maia, Mauricio/0000-0002-7034-8091; Silva,
   Antonio A M/0000-0003-4968-5138
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0924-9338
J9 EUR PSYCHIAT
JI Eur. Psychiat.
PY 2012
VL 27
SU 1
MA P-281
PG 1
WC Psychiatry
SC Psychiatry
GA 977WL
UT WOS:000306695400499
DA 2020-12-15
ER

PT J
AU Dias, JRD
   Rodrigues, EB
   Maia, M
   Magalhaes, O
   Penha, FM
   Farah, ME
AF de Oliveira Dias, Joao Rafael
   Rodrigues, Eduardo Buechele
   Maia, Mauricio
   Magalhaes, Octaviano, Jr.
   Penha, Fernando Marcondes
   Farah, Michel Eid
TI Cytokines in neovascular age-related macular degeneration: fundamentals
   of targeted combination therapy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR;
   TUMOR-NECROSIS-FACTOR; COMPLEMENT FACTOR-H; EXPERIMENTAL CHOROIDAL
   NEOVASCULARIZATION; PHOTORECEPTOR OUTER SEGMENTS; FACTOR FAMILY;
   FACTOR-RECEPTOR; OCULAR NEOVASCULARIZATION; FACTOR-B
AB The neovascular form of age-related macular degeneration (AMD), called wet-AMD or choroidal neovascularisation, begins with damage to the outer retinal cells and retinal pigment epithelium (RPE), which elicits a cascade of inflammatory and angiogenic responses leading to neovascularisation under the macula. Studies showed that oxidative damage, chronic inflammation of the RPE and complement misregulation work at different steps of this disease. After established neovascularisation, several pro-and antiangiogenic agents start to play an important role. Vascular endothelial growth factors (VEGFs) are the most specific and potent regulators of angiogenesis, which are inhibited by intravitreal injections of ranibizumab, bevacizumab, VEGF Trap, pegaptanib sodium and other agents under investigation. Pigment epithelium-derived factor, on the other hand, shows neuroprotective and antiangiogenic activities. Hepatocyte growth factor (HGF) has a mitogenic effect on a wide range of epithelial and endothelial cells, and it is inhibited by an anti-HGF monoclonal antibody. Platelet-derived growth factor is a potent chemoattractant and mitogen for both fibroblasts and retinal RPE cells, which has been inhibited experimentally by VEGF Trap and human anti-platelet-derived growth factor-D monoclonal antibody. Fibroblast growth factor-2 has pleiotropic effects in different cell and organ systems, and it is blocked by anti-FGF antibodies, with a greater benefit regarding antiangiogenesis when combined treatment with anti-VEGF is performed. Tumour necrosis factor alpha is expressed in the retina and the choroid, and its blockade in choroidal neovascularisation includes the use of monoclonals such as infliximab. This paper reviews the most important cytokines involved in the pathogenesis of wet-AMD, with emphasis on potential combined therapies for disease control.
C1 [de Oliveira Dias, Joao Rafael; Rodrigues, Eduardo Buechele; Maia, Mauricio; Magalhaes, Octaviano, Jr.; Penha, Fernando Marcondes; Farah, Michel Eid] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, Sao Paulo, Brazil.
RP Dias, JRD (corresponding author), Rua Napoleao de Barros 1098,Ap 74, BR-04024003 Sao Paulo, Brazil.
EM dias_joaor@yahoo.com.br
RI Penha, Fernando M/G-1784-2012; Farah, Michel Eid E/F-3285-2012; Maia,
   Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; de Oliveira Dias,
   Joao/J-6735-2016; Rodrigues, Eduardo Buchele/C-6852-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Buchele Rodrigues, Eduardo/0000-0002-4224-0921
CR Achen MG, 1998, INT J EXP PATHOL, V79, P255, DOI 10.1046/j.1365-2613.1998.700404.x
   Adamis AP, 2009, RETINA-J RET VIT DIS, V29, pS42, DOI 10.1097/IAE.0b013e3181ad2500
   Allavena P, 2008, IMMUNOL REV, V222, P155, DOI 10.1111/j.1600-065X.2008.00607.x
   Amaral J, 2010, INVEST OPHTH VIS SCI, V51, P1318, DOI 10.1167/iovs.09-4455
   Apte RS, 2004, INVEST OPHTH VIS SCI, V45, P4491, DOI 10.1167/iovs.04-0172
   Ashok D, 2005, RHEUMATOLOGY, V44, P950, DOI 10.1093/rheumatology/keh635
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X
   Baughman RR, 2005, INT J CLIN PHARM TH, V43, P7
   Benitez-del-Castillo JM, 2005, EYE, V19, P841, DOI 10.1038/sj.eye.6701689
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039
   BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CAMPOCHIARO PA, 1985, ARCH OPHTHALMOL-CHIC, V103, P576
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Cazabon S, 2005, EYE, V19, P222, DOI 10.1038/sj.eye.6701457
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Choudhury P, 1997, INVEST OPHTH VIS SCI, V38, P824
   CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Dadgostar H, 2008, EYE, V22, P761, DOI 10.1038/eye.2008.86
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Díaz-Valle D, 2004, Arch Soc Esp Oftalmol, V79, P405
   Do DV, 2009, BRIT J OPHTHALMOL, V93, P144, DOI 10.1136/bjo.2008.138271
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Do DV Investigators C-I, 2009, INVEST OPHTHALMOL VI, V50
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Duh EJ, 2004, AM J OPHTHALMOL, V137, P668, DOI 10.1016/j.ajo.2003.11.015
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Feucht N, 2008, CLIN OPHTHALMOL, V2, P253
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   GABRIELIAN K, 1994, INVEST OPHTH VIS SCI, V35, P4253
   Garcia M, 2003, HISTOL HISTOPATHOL, V18, P1205, DOI 10.14670/HH-18.1205
   Gerritsen ME, 2005, CIRC RES, V96, P272, DOI 10.1161/01.RES.0000157575.66295.e0
   Giganti M, 2010, SAFETY TOLERABILITY
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Gupta K, 2005, POSTGRAD MED J, V81, P236, DOI 10.1136/pgmj.2004.023309
   Hawthorne T, 2008, INT J CLIN PHARM TH, V46, P236
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hollborn M, 2004, GRAEF ARCH CLIN EXP, V242, P414, DOI 10.1007/s00417-004-0879-x
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   Hu WZ, 2009, EXP EYE RES, V88, P79, DOI 10.1016/j.exer.2008.10.014
   Hull J, 2001, AM J HUM GENET, V69, P413, DOI 10.1086/321291
   Im E, 2006, EMBO J, V25, P2075, DOI 10.1038/sj.emboj.7601100
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Karakousis PC, 2001, MOL VIS, V7, P154
   Kim K, 2007, BIOCHEM BIOPH RES CO, V354, P115, DOI 10.1016/j.bbrc.2006.12.164
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kobayashi S, 2005, BIOL PHARM BULL, V28, P242, DOI 10.1248/bpb.28.242
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P1218, DOI 10.1097/IAE.0b013e3181b32c45
   Li XR, 2000, NAT CELL BIOL, V2, P302
   Li X, 2008, ARTERIOSCL THROM VAS, V28, P1614, DOI 10.1161/ATVBAHA.107.158725
   Majka S, 2002, INVEST OPHTH VIS SCI, V43, P260
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Martin TA, 2001, CLIN CANCER RES, V7, P734
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1
   Nakamura Y, 1996, J HYPERTENS, V14, P1067, DOI 10.1097/00004872-199609000-00004
   Nishimura M, 1999, J CLIN ENDOCR METAB, V84, P659, DOI 10.1210/jc.84.2.659
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Otrock ZK, 2007, BLOOD CELL MOL DIS, V38, P258, DOI 10.1016/j.bcmd.2006.12.003
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regatieri CV, 2009, INVEST OPHTH VIS SCI, V50, P5487, DOI 10.1167/iovs.08-3171
   Reiff A, 2001, ARTHRITIS RHEUM, V44, P1411, DOI 10.1002/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O
   Rodrigues EB, 2009, PROG RETIN EYE RES, V28, P117, DOI 10.1016/j.preteyeres.2008.11.005
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenthal R, 2005, BIOCHEM BIOPH RES CO, V337, P241, DOI 10.1016/j.bbrc.2005.09.028
   RUSSELL WE, 1984, J CELL PHYSIOL, V119, P183, DOI 10.1002/jcp.1041190207
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schmid MC, 2008, METHOD ENZYMOL, V445, P343, DOI 10.1016/S0076-6879(08)03015-2
   Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Smith JR, 2001, ARTHRIT RHEUM-ARTHR, V45, P252, DOI 10.1002/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Stahl A, 2009, GRAEF ARCH CLIN EXP, V247, P767, DOI 10.1007/s00417-009-1058-x
   STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11
   Stock P, 2007, MOL CANCER THER, V6, P1932, DOI 10.1158/1535-7163.MCT-06-0720
   Suto K, 2005, J BIOL CHEM, V280, P2126, DOI 10.1074/jbc.M411395200
   Symons A, 2010, RETINAL PHARMACOTHER, P364
   Takahashi H, 2008, CURR EYE RES, V33, P1002, DOI 10.1080/02713680802492440
   Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5
   Taub D D, 1994, Ther Immunol, V1, P229
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tombran-Tink J, 2003, TRENDS MOL MED, V9, P244, DOI 10.1016/S1471-4914(03)00074-1
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Yamazaki Y, 2005, BIOCHEMISTRY-US, V44, P8858, DOI 10.1021/bi050197d
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou HH, 2005, J CLIN PHARMACOL, V45, P490, DOI 10.1177/0091270004273321
   Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231
NR 119
TC 65
Z9 66
U1 1
U2 13
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2011
VL 95
IS 12
BP 1631
EP 1637
DI 10.1136/bjo.2010.186361
PG 7
WC Ophthalmology
SC Ophthalmology
GA 851IM
UT WOS:000297261700004
PM 21546514
DA 2020-12-15
ER

PT J
AU Machado, LM
   Magalhaes, O
   Maia, M
   Rodrigues, EB
   Farah, ME
   Ismail, KAR
   Molon, L
   Oliveira, DA
AF Machado, Leonardo Martins
   Magalhaes, Octaviano, Jr.
   Maia, Mauricio
   Rodrigues, Eduardo B.
   Farah, Michel Eid
   Ismail, Kamal A. R.
   Molon, Leandro
   Oliveira, Danilo A.
TI COMPARISON OF 20-, 23-, AND 25-GAUGE AIR INFUSION FORCES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE vitrectomy; 23 gauge; 25 gauge; infusion; fluid-air exchange; macular
   hole
ID MACULAR HOLE SURGERY; VISUAL-FIELD DEFECTS; INTERNAL LIMITING MEMBRANE;
   PARS-PLANA VITRECTOMY; INDOCYANINE GREEN; RETINAL DAMAGE; VITREOUS
   SURGERY; EXCHANGE; PREVENTION; 23-GAUGE
AB Purpose: To determine and compare 20-, 23-, and 25-gauge retinal infusion air jet impact pressure (force per unit area) in an experimental setting.
   Methods: Experimental laboratory investigation. Infusion cannulas were connected to a compressed air system. A controlled valve mechanism was used to obtain increasing levels of infusion pressure. Each infusion tube was positioned in front of a manual transducer to measure force. Impact pressure was calculated using known formulas in fluid dynamics.
   Results: The 20-gauge infusion jet showed similar impact pressure values compared with the 23-gauge infusion jet. Both showed higher levels than the 25-gauge infusion jet. This was because of the smaller jet force for the 25-gauge system.
   Conclusion: In this experimental study, both the 23- and the 20-gauge air infusion jet showed higher impact pressure values compared with the 25-gauge air infusion jet. This could be of concern regarding air infusion during 23-gauge vitrectomy since retinal damage has been shown in standard-gauge surgeries. RETINA 31:2002-2006, 2011
C1 [Machado, Leonardo Martins; Magalhaes, Octaviano, Jr.; Maia, Mauricio; Rodrigues, Eduardo B.; Farah, Michel Eid] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Machado, Leonardo Martins] Univ Estadual Campinas, Fac Mech Engn, Dept Ophthalmol, Sao Paulo, Brazil.
   [Ismail, Kamal A. R.; Molon, Leandro; Oliveira, Danilo A.] Univ Estadual Campinas, Fac Mech Engn, Dept Therm & Fluid Engn, Sao Paulo, Brazil.
RP Machado, LM (corresponding author), Rua Timoteo Costa 297-1401, BR-22450130 Rio De Janeiro, Brazil.
EM leo_m@terra.com.br
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019; Farah, Michel
   Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Farah, Michel Eid E/0000-0001-5951-0193; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
CR Ando F, 2004, AM J OPHTHALMOL, V137, P609, DOI 10.1016/j.ajo.2003.08.038
   BERROD JP, 1994, INT OPHTHALMOL, V18, P237
   Boldt HC, 1996, AM J OPHTHALMOL, V122, P371, DOI 10.1016/S0002-9394(14)72064-1
   CHARLES S, 1981, ARCH OPHTHALMOL-CHIC, V99, P1398
   Cullinane AB, 2000, BRIT J OPHTHALMOL, V84, P372, DOI 10.1136/bjo.84.4.372
   Eckardt C, 2005, RETINA-J RET VIT DIS, V25, P208, DOI 10.1097/00006982-200502000-00015
   Ezra E, 1996, BRIT J OPHTHALMOL, V80, P519, DOI 10.1136/bjo.80.6.519
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1807, DOI 10.1016/S0161-6420(02)01179-X
   Gandorfer A, 2001, AM J OPHTHALMOL, V132, P431, DOI 10.1016/S0002-9394(01)01087-X
   Gass CA, 2001, BRIT J OPHTHALMOL, V85, P549, DOI 10.1136/bjo.85.5.549
   Goldstein RJ, 1996, FLUID MECH MEASUREME
   Haritoglou C, 2001, AM J OPHTHALMOL, V132, P363, DOI 10.1016/S0002-9394(01)01093-5
   Haritoglou C, 2001, BRIT J OPHTHALMOL, V85, P231, DOI 10.1136/bjo.85.2.231
   Hasumura T, 2000, INVEST OPHTH VIS SCI, V41, P4300
   Hinze J.O., 1975, TURBULENCE
   Hirata A, 2003, RETINA-J RET VIT DIS, V23, P682, DOI 10.1097/00006982-200310000-00013
   Hirata A, 2000, AM J OPHTHALMOL, V130, P611, DOI 10.1016/S0002-9394(00)00597-3
   Holman J.P., 1993, EXPT METHODS ENG
   Hubschman JP, 2007, OPHTHAL SURG LAS IM, V38, P345, DOI 10.3928/15428877-20070701-16
   Hutton WL, 1996, OPHTHALMOLOGY, V103, P2152, DOI 10.1016/S0161-6420(96)30376-X
   Hutton WL, 1996, OPHTHALMOLOGY, V103, P2158
   Kanda S, 2004, ARCH OPHTHALMOL-CHIC, V122, P1447, DOI 10.1001/archopht.122.10.1447
   Kerrison JB, 1996, ARCH OPHTHALMOL-CHIC, V114, P564, DOI 10.1001/archopht.1996.01100130556010
   Kokame GT, 2000, AM J OPHTHALMOL, V130, P653, DOI 10.1016/S0002-9394(00)00656-5
   Kongsap P, 2010, CLIN OPHTHALMOL, V4, P625
   Magalhaes O, 2008, ACTA OPHTHALMOL, V86, P156, DOI 10.1111/j.1600-0420.2007.00988.x
   Magalhaes O, 2008, RETINA-J RET VIT DIS, V28, P236, DOI 10.1097/IAE.0b013e318158e9e0
   Magalhaes Octaviano Jr, 2009, Retin Cases Brief Rep, V3, P64, DOI 10.1097/ICB.0b013e31815657a7
   Malinowski SM, 1997, AM J OPHTHALMOL, V123, P707, DOI 10.1016/S0002-9394(14)71093-1
   MCCUEN BW, 1983, AM J OPHTHALMOL, V95, P717, DOI 10.1016/0002-9394(83)90405-1
   MELBERG NS, 1995, AM J OPHTHALMOL, V120, P386, DOI 10.1016/S0002-9394(14)72169-5
   Munson B. R., 2003, FUNDAMENTALS FLUID M
   Ohashi H, 2004, GRAEF ARCH CLIN EXP, V242, P484, DOI 10.1007/s00417-004-0877-z
   Ohji M, 1999, AM J OPHTHALMOL, V127, P62, DOI 10.1016/S0002-9394(98)00287-6
   Oshitari K, 2001, AM J OPHTHALMOL, V131, P814, DOI 10.1016/S0002-9394(00)00927-2
   Pendergast SD, 1996, OPHTHALMOLOGY, V103, P1069, DOI 10.1016/S0161-6420(96)30565-4
   Schanze T, 2007, OPHTHALMOLOGICA, V221, P1, DOI 10.1159/000096514
   Tornambe Paul E, 2007, Retin Cases Brief Rep, V1, P229, DOI 10.1097/01.iae.0000223713.17726.db
   Tsuiki E, 2007, AM J OPHTHALMOL, V143, P704, DOI 10.1016/j.ajo.2006.10.051
   Welch JC, 1997, AM J OPHTHALMOL, V124, P698, DOI 10.1016/S0002-9394(14)70915-8
   Yamashita T, 2008, RETINA-J RET VIT DIS, V28, P1228, DOI 10.1097/IAE.0b013e31817b6b2e
   Yonemura N, 2003, GRAEF ARCH CLIN EXP, V241, P314, DOI 10.1007/s00417-003-0629-5
   Yonemura N, 2001, OPHTHALMOLOGY, V108, P1638, DOI 10.1016/S0161-6420(01)00677-7
NR 43
TC 2
Z9 2
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2011
VL 31
IS 10
BP 2002
EP 2006
DI 10.1097/IAE.0b013e318211164d
PG 5
WC Ophthalmology
SC Ophthalmology
GA 842AS
UT WOS:000296558500005
PM 21673614
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Sanchez, JG
   Saldarriaga, L
   Berrocal, MH
   Fromow-Guerra, J
   Morales-Canton, V
   Wu, L
   Maia, M
   Saravia, MJ
   Bareno, J
AF Arevalo, J. Fernando
   Sanchez, Juan G.
   Saldarriaga, Lucas
   Berrocal, Maria H.
   Fromow-Guerra, Jans
   Morales-Canton, Virgilio
   Wu, Lihteh
   Maia, Mauricio
   Saravia, Mario J.
   Bareno, Jose
CA Pan Amer Collaborative Retina
TI Retinal Detachment after Bevacizumab
SO OPHTHALMOLOGY
LA English
DT Letter
RI bareno, jose/ABE-2435-2020; Fromow-Guerra, J. Jans/A-3346-2015; Maia,
   Mauricio/I-5892-2015
OI Fromow-Guerra, J. Jans/0000-0001-5335-1275; Maia,
   Mauricio/0000-0002-7034-8091
CR Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
NR 1
TC 12
Z9 12
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2011
VL 118
IS 11
PG 5
WC Ophthalmology
SC Ophthalmology
GA 842EG
UT WOS:000296573500030
DA 2020-12-15
ER

PT J
AU De Stefano, VS
   Abechain, JJK
   de Almeida, LFS
   Verginassi, DM
   Rodrigues, EB
   Freymuller, E
   Maia, M
   Magalhaes, O
   Nguyen, QD
   Farah, ME
AF De Stefano, Vinicius S.
   Abechain, Jose J. K.
   de Almeida, Luiz F. S.
   Verginassi, Diego M.
   Rodrigues, Eduardo B.
   Freymuller, Edna
   Maia, Maurcio
   Magalhaes, Octaviano, Jr.
   Nguyen, Quan D.
   Farah, Michel E.
TI Experimental investigation of needles, syringes and techniques for
   intravitreal injections
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE intravitreal injection; needle; retinal pharmacotherapy; vitreal reflux;
   vitreoretinal surgery
ID TRIAMCINOLONE ACETONIDE; INTRAOCULAR-PRESSURE; VOLUME; MODEL
AB P>Background:
   To assess the techniques and materials used in intravitreal injections.
   Design:
   Descriptive study realized at the Vision Institute of the Federal University of Sao Paulo, Brazil.
   Samples:
   Different brands of needles and syringes, as well as enucleated porcine eyeballs.
   Methods:
   The ultra-structures of commonly used needles were analysed by scanning electron microscope, and they were compared using different criteria, such as irregularities and debris from the lubrication process. The scleral incision was also assessed using needles of different brands and sizes. Accuracies in drug administration were studied by comparing the residual and delivered volume of needles and also by the analysis of reflux after intravitreal injections.
   Main Outcome Measures:
   Efficiency and quality of materials used in intravitreal injections.
   Results:
   Ultra-structure analyses showed that all needles had different types of irregularities. Some photographs showed debris from the lubrication process, especially in BD needles. Scleral incision analysis showed a tendency of reducing the ocular damage with increasing gauge (P = 0.024). The investigation of delivery accuracy showed that almost all needles underdosed the amount injected (P < 0.05), and that the reflux could be minimized by tunnelled injections with thinner needles.
   Conclusion:
   Needles used in intravitreal injections possess many irregularities in their structures, which may cause different injection outcomes. Analyses of scleral incisions showed that the larger the needle gauge, the lesser the scleral damage and the risk of complications. Moreover, drug administration inaccuracies might be one of the causes for some unsuccessful attempts of treatment.
C1 [De Stefano, Vinicius S.; Abechain, Jose J. K.; de Almeida, Luiz F. S.; Verginassi, Diego M.; Rodrigues, Eduardo B.; Freymuller, Edna; Maia, Maurcio; Magalhaes, Octaviano, Jr.; Farah, Michel E.] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, Sao Paulo, Brazil.
   [Nguyen, Quan D.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
RP De Stefano, VS (corresponding author), 234 Orissanga St Apt 32, BR-04052030 Sao Paulo, Brazil.
EM vsstefano@uol.com.br
RI Maia, Mauricio/Z-1042-2019; Farah, Michel Eid E/F-3285-2012; Maia,
   Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Buchele
   Rodrigues, Eduardo/0000-0002-4224-0921
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Anijeet DR, 2007, EYE, V21, P480, DOI 10.1038/sj.eye.6702232
   Boon CJF, 2008, OPHTHALMOLOGY, V115, P1268, DOI 10.1016/j.ophtha.2008.02.021
   Bucher RS, 2005, RETINA-J RET VIT DIS, V25, P269, DOI 10.1097/00006982-200504000-00003
   Bucher RS, 2005, ARCH OPHTHALMOL-CHIC, V123, P649, DOI 10.1001/archopht.123.5.649
   Bylsma G, 2006, CLIN EXP OPHTHALMOL, V34, P388, DOI 10.1111/j.1442-9071.2006.01231.x
   Friedrich S, 1997, CURR EYE RES, V16, P663, DOI 10.1076/ceyr.16.7.663.5061
   Hubschman JP, 2010, RETINA-J RET VIT DIS, V30, P167, DOI 10.1097/IAE.0b013e3181b094cf
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   KELLY TSB, 1948, BRIT J OPHTHALMOL, V32, P153, DOI 10.1136/bjo.32.3.153
   Korobelnik JF, 2006, J FR OPHTALMOL, V29, P82, DOI 10.1016/S0181-5512(06)73754-8
   Kotliar K, 2007, ACTA OPHTHALMOL SCAN, V85, P777, DOI 10.1111/j.1600-0420.2007.00939.x
   Kozak I, 2006, RETINA-J RET VIT DIS, V26, P679, DOI 10.1097/00006982-200607000-00015
   MAURICE DM, 1979, S OC THER ST LOUIS M, P959
   PRICE DD, 1994, PAIN, V56, P217, DOI 10.1016/0304-3959(94)90097-3
   Pulido JS, 2007, EYE, V21, P1210, DOI 10.1038/sj.eye.6702577
   Pulido JS, 2007, EYE, V21, P829, DOI 10.1038/sj.eye.6702514
   Raju JR, 2002, AM J OPHTHALMOL, V133, P564, DOI 10.1016/S0002-9394(01)01408-8
   Rodrigues EB, 2007, AM J OPHTHALMOL, V143, P1035, DOI 10.1016/j.ajo.2007.01.035
   Rodrigues Eduardo Büchele, 2006, Arq. Bras. Oftalmol., V69, P756, DOI 10.1590/S0004-27492006000500027
   Sitzman BT, 1996, ANESTH ANALG, V82, P297, DOI 10.1097/00000539-199602000-00014
   Tojo K, 2001, ADV DRUG DELIVER REV, V52, P17, DOI 10.1016/S0169-409X(01)00187-9
   2004, RETINA, V24, P699
NR 24
TC 21
Z9 21
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD APR
PY 2011
VL 39
IS 3
BP 236
EP 242
DI 10.1111/j.1442-9071.2010.02447.x
PG 7
WC Ophthalmology
SC Ophthalmology
GA 749MX
UT WOS:000289473100009
PM 20973898
DA 2020-12-15
ER

PT J
AU Rodrigues, EB
   Grumann, A
   Penha, FM
   Shiroma, H
   Rossi, E
   Meyer, CH
   Stefano, V
   Maia, M
   Magalhaes, O
   Farah, ME
AF Rodrigues, Eduardo B.
   Grumann, Astor, Jr.
   Penha, Fernando M.
   Shiroma, Helio
   Rossi, Eglas
   Meyer, Carsten H.
   Stefano, Vinicius
   Maia, Mauricio
   Magalhaes, Octaviano, Jr.
   Farah, Michel E.
TI Effect of Needle Type and Injection Technique on Pain Level and Vitreal
   Reflux in Intravitreal Injection
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID INTRAOCULAR-PRESSURE CHANGES; BEVACIZUMAB; TRIAMCINOLONE; PENETRATION;
   PEGAPTANIB; DELIVERY; AVASTIN
AB Purpose: To evaluate the amount of reflux and degree of pain with intravitreal injection (IVT) using 6 different types of syringes/needles and 5 techniques of scleral incision, including 3 modifications of a beveled scleral incision.
   Methods: This was a study conducted in 205 eyes of 205 patients. IVT of bevacizumab for retinal pharmacotherapy with 6 types of needles and 5 techniques of scleral incision. The severity of subjectively evaluated pain (0-10) and the width of the subconjunctival bleb arising from the vitreal reflux. Secondary outcomes were increase in intraocular pressure and complication rate.
   Results: The straight technique caused greater vitreal reflux than the beveled approaches, when compared individually or as a group (P < 0.01). No difference in the severity of pain was found among all 5 types of incisions (P > 0.05). There was greater reflux with 26- and 27-gauge needles in comparison to 29- and 30-gauge needles (P < 0.001); however, the width of the needle significantly affected the degree of reflux only when using the nonbeveled incision (P < 0.001). The patients injected with the 26- or 27-gauge needle experienced more pain matched to the 29- and 30-gauge needles (P < 0.001). No difference was found between the incision technique or width of subconjunctival reflux and the increase in intraocular pressure (P > 0.05). Postinjection events included transient mild uveitis, disease-related vitreous hemorrhage, foreign body sensation, conjunctival hemorrhage, and mild punctuate keratitis.
   Conclusions: The beveled scleral incision showed benefit in performing IVTs. The 29- and 30-gauge needles caused less pain.
C1 [Rodrigues, Eduardo B.; Penha, Fernando M.; Meyer, Carsten H.; Stefano, Vinicius; Maia, Mauricio; Magalhaes, Octaviano, Jr.; Farah, Michel E.] Univ Fed Sao Paulo, Vision Inst IPEPO, Dept Ophthalmol, Sao Paulo, Brazil.
   [Grumann, Astor, Jr.; Shiroma, Helio; Rossi, Eglas] Hosp Reg Sao Jose, Serv Ophthalmol, Florianopolis, SC, Brazil.
RP Rodrigues, EB (corresponding author), R Almirante Barroso 45 Ed Jade 204 Joao Paulo, BR-88030460 Florianopolis, SC, Brazil.
EM edubrodriguess@yahoo.com.br
RI Farah, Michel Eid E/F-3285-2012; Penha, Fernando M/G-1784-2012; Maia,
   Mauricio/I-5892-2015; Meyer, Carsten H./A-3981-2017; Maia,
   Mauricio/Z-1042-2019
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Meyer, Carsten H./0000-0002-0530-5298;
   Maia, Mauricio/0000-0002-7034-8091; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
FU Deutsche Opthalmologische Gesellschaft
FX To FAPESP-Fundacao de Amparo a Pesquisa do Estado de Sao Paulo;
   CAPES-Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior; and
   PAAO/PAOF-Pan-American Association of Ophthalmology/Pan-American
   Ophthalmologic Foundation. The authors had full access to all the data
   in the study and take responsibility for the integrity of the data and
   the accuracy of the data analysis. Financial support: None. The visiting
   professorship in Brazil for Prof. Meyer was supported by the Deutsche
   Opthalmologische Gesellschaft.
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Anijeet DR, 2007, EYE, V21, P480, DOI 10.1038/sj.eye.6702232
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Benz MS, 2006, OPHTHALMOLOGY, V113, P1174, DOI 10.1016/j.ophtha.2005.10.061
   Boon CJF, 2008, OPHTHALMOLOGY, V115, P1268, DOI 10.1016/j.ophtha.2008.02.021
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kaufmann C, 2004, INVEST OPHTH VIS SCI, V45, P3118, DOI 10.1167/iovs.04-0018
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kozak I, 2006, RETINA-J RET VIT DIS, V26, P679, DOI 10.1097/00006982-200607000-00015
   LEHTINEN R, 1983, INT J ORAL MAXILLOF, V12, P444, DOI 10.1016/S0300-9785(83)80036-2
   Lopez-Guajardo L, 2008, EYE, V22, P430, DOI 10.1038/sj.eye.6703054
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   Meyer CH, 2007, OPHTHALMOLOGE, V104, P952, DOI 10.1007/s00347-007-1634-6
   MORLET N, 1993, BRIT J OPHTHALMOL, V77, P572, DOI 10.1136/bjo.77.9.572
   Pallikaris IG, 2005, INVEST OPHTH VIS SCI, V46, P409, DOI 10.1167/iovs.04-0162
   Pulido JS, 2007, EYE, V21, P1210, DOI 10.1038/sj.eye.6702577
   Pulido JS, 2007, EYE, V21, P829, DOI 10.1038/sj.eye.6702514
   Rodrigues EB, 2004, RETINA-J RET VIT DIS, V24, P810, DOI 10.1097/00006982-200410000-00025
   Rodrigues EB, 2007, AM J OPHTHALMOL, V143, P1035, DOI 10.1016/j.ajo.2007.01.035
   Rodrigues EB, 2009, PROG RETIN EYE RES, V28, P117, DOI 10.1016/j.preteyeres.2008.11.005
   Watson PG, 2004, EXP EYE RES, V78, P609, DOI 10.1016/S0014-4835(03)00212-4
   Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 25
TC 58
Z9 58
U1 1
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD APR
PY 2011
VL 27
IS 2
BP 197
EP 203
DI 10.1089/jop.2010.0082
PG 7
WC Ophthalmology; Pharmacology & Pharmacy
SC Ophthalmology; Pharmacology & Pharmacy
GA 751NF
UT WOS:000289624100013
PM 21314588
DA 2020-12-15
ER

PT J
AU Wu, L
   Berrocal, MH
   Arevalo, JF
   Carpentier, C
   Rodriguez, FJ
   Alezzandrini, A
   Farah, ME
   Roca, JA
   Maia, M
   Saravia, M
   Morales-Canton, V
   Graue-Wiechers, F
   Cardillo, JA
AF Wu, Lihteh
   Berrocal, Maria H.
   Fernando Arevalo, J.
   Carpentier, Cristian
   Rodriguez, Francisco J.
   Alezzandrini, Arturo
   Farah, Michel E.
   Roca, Jose A.
   Maia, Mauricio
   Saravia, Mario
   Morales-Canton, Virgilio
   Graue-Wiechers, Federico
   Cardillo, Jose A.
TI ENDOPHTHALMITIS AFTER PARS PLANA VITRECTOMY Results of the Pan American
   Collaborative Retina Study Group
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE pars plana vitrectomy; endophthalmitis; postoperative; transconjunctival
   vitrectomy
ID TRANSCONJUNCTIVAL SUTURELESS VITRECTOMY; OPTICAL COHERENCE TOMOGRAPHY;
   25-GAUGE VITRECTOMY; VITREORETINAL SURGERY; 20-GAUGE; 23-GAUGE; SYSTEM;
   OUTCOMES
AB Purpose: To determine the incidence of endophthalmitis after 20-, 23-, and 25-gauge pars plana vitrectomies (PPVs).
   Methods: Retrospective comparative case series of consecutive patients who underwent 20-, 23-, or 25-gauge PPV at 11 centers from Latin America between 2005 to 2009. Pars plana vitrectomy cases were identified through a search of the billing records of each institution. Cases of PPV performed in the management of trauma, endophthalmitis, and combined PPV phacoemulsification cases were excluded. Endophthalmitis was diagnosed by clinical criteria regardless of the microbiologic results. The incidence of post-PPV endophthalmitis was compared between 20-, 23-, and 25-gauge PPVs.
   Results: A total of 35,427 cases of PPV were identified during the study period (n = 19,865 for 20 gauge, n = 10,845 for 23 gauge, and n = 4,717 for 25 gauge). The 5-year post-PPV endophthalmitis incidence rates were 0.020% (4 of 19,865), 0.028% (3 of 10,845), and 0.021% (1 of 4,717) for 20 gauge, 23 gauge, and 25 gauge, respectively (P = 0.9685).
   Conclusion: Small-gauge transconjunctival PPV does not appear to increase the rates of post-PPV endophthalmitis.
   RETINA 31: 673-678, 2011
C1 [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Berrocal, Maria H.] Univ Puerto Rico, Dept Ophthalmol, San Juan, PR 00936 USA.
   [Fernando Arevalo, J.] Clin Oftalmol Ctr Caracas, Caracas, Venezuela.
   [Carpentier, Cristian] Fdn Oftalmol Los Andes, Santiago, Chile.
   [Rodriguez, Francisco J.] Univ Nacl Rosario, Fdn Oftalmol, Bogota, Colombia.
   [Alezzandrini, Arturo] Univ Buenos Aires, Dept Ophthalmol, Buenos Aires, DF, Argentina.
   [Farah, Michel E.; Maia, Mauricio] Univ Fed Sao Paulo, Vis Inst, Dept Ophthalmol, Sao Paulo, Brazil.
   [Roca, Jose A.] Clin Ricardo Palma, Lima, Peru.
   [Saravia, Mario] Hosp Univ Austral, Buenos Aires, DF, Argentina.
   [Morales-Canton, Virgilio] Asociac Evitar Ceguera Mexico, Mexico City, DF, Mexico.
   [Graue-Wiechers, Federico] Fdn Conde Valenciana, Mexico City, DF, Mexico.
   [Cardillo, Jose A.] Hosp Olhos, Araraquara, Brazil.
RP Wu, L (corresponding author), Apdo 144-1225 Plaza Mayor, San Jose, Costa Rica.
EM lw65@cornell.edu
RI Farah, Michel Eid E/F-3285-2012; Fromow-Guerra, J. Jans/A-3346-2015;
   Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Fromow-Guerra, J.
   Jans/0000-0001-5335-1275; Maia, Mauricio/0000-0002-7034-8091; Maia,
   Mauricio/0000-0002-7034-8091; Cardillo, Jose Augusto/0000-0002-5791-3201
FU Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas,
   Venezuela
FX Supported in part by the Arevalo-Coutinho Foundation for Research in
   Ophthalmology, Caracas, Venezuela.
CR BACON AS, 1993, EYE, V7, P529, DOI 10.1038/eye.1993.115
   Chen E, 2007, CURR OPIN OPHTHALMOL, V18, P188, DOI 10.1097/ICU.0b013e328133889a
   Chen JK, 2009, EYE, V23, P780, DOI 10.1038/eye.2008.160
   Eckardt C, 2005, RETINA-J RET VIT DIS, V25, P208, DOI 10.1097/00006982-200502000-00015
   Eifrig CWG, 2004, AM J OPHTHALMOL, V138, P799, DOI 10.1016/j.ajo.2004.06.035
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1814, DOI 10.1016/S0161-6420(02)01119-3
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1807, DOI 10.1016/S0161-6420(02)01179-X
   Garcia-Valenzuela E, 2005, ARCH OPHTHALMOL-CHIC, V123, P1721, DOI 10.1001/archopht.123.12.1721
   HO PC, 1984, ARCH OPHTHALMOL-CHIC, V102, P207
   Hu AYH, 2009, OPHTHALMOLOGY, V116, P1360, DOI 10.1016/j.ophtha.2009.01.045
   Kaiser RS, 2010, RETINA-J RET VIT DIS, V30, P692, DOI 10.1097/IAE.0b013e3181db8bf7
   Kellner L, 2007, BRIT J OPHTHALMOL, V91, P945, DOI 10.1136/bjo.2006.106799
   Kunimoto DY, 2007, OPHTHALMOLOGY, V114, P2133, DOI 10.1016/j.ophtha.2007.08.009
   Lakhanpal RR, 2005, OPHTHALMOLOGY, V112, P817, DOI 10.1016/j.ophtha.2004.11.053
   Martidis A, 2007, OPHTHALMOLOGY, V114, P2131, DOI 10.1016/j.ophtha.2007.09.003
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P1352, DOI 10.1097/IAE.0b013e318180d308
   Parolini B, 2009, GRAEF ARCH CLIN EXP, V247, P895, DOI 10.1007/s00417-009-1063-0
   Rizzo S, 2006, GRAEF ARCH CLIN EXP, V244, P472, DOI 10.1007/s00417-005-0173-6
   Sakamoto T, 2004, AM J OPHTHALMOL, V138, P137, DOI 10.1016/j.ajo.2004.02.072
   Scott IU, 2008, RETINA-J RET VIT DIS, V28, P138, DOI 10.1097/IAE.0b013e31815e9313
   Shimada H, 2008, OPHTHALMOLOGY, V115, P2215, DOI 10.1016/j.ophtha.2008.07.015
   Taban M, 2009, AM J OPHTHALMOL, V147, P101, DOI 10.1016/j.ajo.2008.07.046
   Taban M, 2008, OPHTHALMOLOGY, V115, P2221, DOI 10.1016/j.ophtha.2008.08.027
   Wykoff CC, 2010, AM J OPHTHALMOL, V150, P392, DOI 10.1016/j.ajo.2010.04.010
NR 24
TC 41
Z9 43
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2011
VL 31
IS 4
BP 673
EP 678
DI 10.1097/IAE.0b013e318203c183
PG 6
WC Ophthalmology
SC Ophthalmology
GA 740HR
UT WOS:000288783200007
PM 21394065
DA 2020-12-15
ER

PT J
AU Lobo, SM
   Rezende, E
   Knibel, MF
   Silva, NB
   Paramo, JA
   Nacul, FE
   Mendes, CL
   Assuncao, M
   Costa, RC
   Grion, CC
   Pinto, SF
   Mello, PM
   Maia, MO
   Duarte, PA
   Gutierrez, F
   Silva, JM
   Lopes, MR
   Cordeiro, JA
   Mellot, C
AF Lobo, Suzana M.
   Rezende, Ederlon
   Knibel, Marcos F.
   Silva, Nilton B.
   Paramo, Jose A.
   Nacul, Flavio E.
   Mendes, Ciro L.
   Assuncao, Murilo
   Costa, Rubens C.
   Grion, Cintia C.
   Pinto, Sergio F.
   Mello, Patricia M.
   Maia, Marcelo O.
   Duarte, Pericles A.
   Gutierrez, Fernando
   Silva, Joao M., Jr.
   Lopes, Marcell R.
   Cordeiro, Jose A.
   Mellot, Charles
TI Early Determinants of Death Due to Multiple Organ Failure After
   Noncardiac Surgery in High-Risk Patients
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; INCREASED MORTALITY; LACTATE CLEARANCE;
   ADVERSE EVENTS; HOSPITAL STAY; UNITED-STATES; SERUM LACTATE; MORBIDITY;
   SEPSIS; OPTIMIZATION
AB BACKGROUND: Prediction of perioperative cardiac complications is important in the medical management of patients undergoing noncardiac surgery. However, these patients frequently die as a consequence of primary or secondary multiple organ failure (MOF), often as a result of sepsis. We investigated the early perioperative risk factors for in-hospital death due to MOF in surgical patients.
   METHODS: This was a prospective, multicenter, observational cohort study performed in 21 Brazilian intensive care units (ICUs). Adult patients undergoing noncardiac surgery who were admitted to the ICU within 24 hours after operation were evaluated. MOF was characterized by the presence of at least 2 organ failures. To determine the relative risk (RR) of in-hospital death due to MOF, we performed a logistic regression multivariate analysis.
   RESULTS: A total of 587 patients were included (mean age, 62.4 +/- 17 years). ICU and hospital mortality rates were 15% and 20.6%, respectively. The main cause of death was MOF (53%). Peritonitis (RR 4.17, 95% confidence interval [CI] 1.38-12.6), diabetes (RR 3.63, 95% CI 1.17-11.2), unplanned surgery (RR 3.62, 95% CI 1.18-11.0), age (RR 1.04, 95% CI 1 0.01-1.08), and elevated serum lactate concentrations (RR 1.52, 95% CI 1.14-2.02), a high central venous pressure (RR 1.12, 95% CI 1.04-1.22), a fast heart rate (RR 3.63, 95% CI 1.17-11.2) and pH (RR 0.04, 95% CI 0.0005-0.38) on the day of admission were independent predictors of death due to MOF.
   CONCLUSIONS: MOF is the main cause of death after surgery in high-risk patients. Awareness of the risk factors for death due to MOF may be important in risk stratification and can suggest routes for therapy. (Anesth Analg 2011;112: 877-83)
C1 [Lobo, Suzana M.] Hosp Base, Intens Care Unit, Sao Paulo, Brazil.
   [Lobo, Suzana M.] Sao Jose do Rio Preto Med Sch, Sao Paulo, Brazil.
   [Rezende, Ederlon] Hosp Servidor Publ Estadual Francisco Morato Oliv, Intens Care Unit, Sao Paulo, Brazil.
   [Knibel, Marcos F.] Hosp Sao Lucas & Hosp Cardiotrauma Ipanema, Intens Care Unit, Rio De Janeiro, Brazil.
   [Silva, Nilton B.] Hosp Moinhos Vento, Intens Care Unit, Porto Alegre, RS, Brazil.
   [Paramo, Jose A.] Clin Sorocaba, Intens Care Unit, Rio De Janeiro, Brazil.
   [Nacul, Flavio E.] Clin Sao Vicente, Intens Care Unit, Rio De Janeiro, Brazil.
   [Mendes, Ciro L.] Univ Fed Paraiba, Univ Hosp, Adult Intens Care Unit, BR-58059900 Joao Pessoa, Paraiba, Brazil.
   [Assuncao, Murilo] Univ Fed Sao Paulo, Dept Anesthesiol Pain & Intens Care, Sao Paulo, Brazil.
   [Costa, Rubens C.] Hosp Pro Cardiaco, Intens Care Unit, Rio De Janeiro, Brazil.
   [Grion, Cintia C.] Univ Estadual Londrina, Dept Intens Care, Londrina, Brazil.
   [Pinto, Sergio F.] Univ Fed Mato Grosso do Sul, Univ Hosp, Intens Care Unit, Campo Grande, Brazil.
   [Mello, Patricia M.] Univ Estadual Piaui, Teresina, Brazil.
   [Maia, Marcelo O.] Hosp Santa Luzia, Intens Care Unit, Brasilia, DF, Brazil.
   [Duarte, Pericles A.] Univ Estadual Oeste Parana, Sch Med, Cascavel, Brazil.
   [Silva, Joao M., Jr.] Hosp Servidor Publ Estadual Francisco Morato Oliv, Sao Paulo, Brazil.
   [Lopes, Marcell R.] Santa Casa Misericordia, Intens Care Unit, Passos, Brazil.
   [Cordeiro, Jose A.] Med Sch Sao Jose do Rio Preto, Sao Jose Do Rio Preto, Brazil.
   [Mellot, Charles] Free Univ Brussels, Erasme Hosp, Dept Intens Care, B-1050 Brussels, Belgium.
RP Lobo, SM (corresponding author), Serv Terapia Intens Hosp Base & Lab Sepse, Fac Med Sao Jose do Rio Preto, Ave Brigadeiro Faria Lima 5544, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
EM suzanalobo@yahoo.com
RI Maia, Mauricio/I-5892-2015; Grion, Cintia M. C./C-2039-2014; Silva, Joao
   Manoel/AAU-6551-2020; Junior, Joao M Silva/K-8275-2012; Assuncao,
   Murillo S C/K-1040-2012; Nacul, Flavio/AAK-5554-2020; Maia,
   Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Grion, Cintia M.
   C./0000-0001-9669-2010; Silva, Joao Manoel/0000-0003-1494-0784; Junior,
   Joao M Silva/0000-0003-1494-0784; Assuncao, Murillo S
   C/0000-0002-0741-4869; Maia, Mauricio/0000-0002-7034-8091
FU Centro de Estudos e Pesquisa em Medicina Intensiva, Hospital de Base,
   Sao Jose do Rio Preto, Brazil
FX Supported by Centro de Estudos e Pesquisa em Medicina Intensiva,
   Hospital de Base, Sao Jose do Rio Preto, Brazil.
CR Ali NA, 2008, CRIT CARE MED, V36, P2316, DOI 10.1097/CCM.0b013e3181810378
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI 10.1097/00003246-200107001-00035
   Arnold RC, 2009, SHOCK, V32, P35, DOI 10.1097/SHK.0b013e3181971d47
   Bakker J, 1996, AM J SURG, V171, P221, DOI 10.1016/S0002-9610(97)89552-9
   Baue AE, 1998, SHOCK, V10, P79, DOI 10.1097/00024382-199808000-00001
   Bellomo R, 2002, MED J AUSTRALIA, V176, P216, DOI 10.5694/j.1326-5377.2002.tb04376.x
   Bennett-Guerrero E, 1999, ANESTH ANALG, V89, P514, DOI 10.1097/00000539-199908000-00050
   Bernardin G, 1996, INTENS CARE MED, V22, P17
   Bianchi Renata Cristiane Gennari, 2006, J. bras. pneumol., V32, P489, DOI 10.1590/S1806-37132006000600004
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Conway DH, 2002, ANAESTHESIA, V57, P845, DOI 10.1046/j.1365-2044.2002.02708.x
   Davenport DL, 2007, J AM COLL SURGEONS, V204, P1199, DOI 10.1016/j.jamcollsurg.2007.02.065
   Dulhunty JM, 2008, INTENS CARE MED, V34, P1654, DOI 10.1007/s00134-008-1160-2
   Eagle KA, 2002, ANESTH ANALG, V94, P1052, DOI 10.1097/00000539-200205000-00002
   Fenwick E, 2002, INTENS CARE MED, V28, P599, DOI 10.1007/s00134-002-1257-y
   Gan TJ, 2002, ANESTHESIOLOGY, V97, P820, DOI 10.1097/00000542-200210000-00012
   Hamel MB, 2005, J AM GERIATR SOC, V53, P424, DOI 10.1111/j.1532-5415.2005.53159.x
   Husain FA, 2003, AM J SURG, V185, P485, DOI 10.1016/S0002-9610(03)00044-8
   Jhanji S, 2008, ANAESTHESIA, V63, P695, DOI 10.1111/j.1365-2044.2008.05560.x
   Kern JW, 2002, CRIT CARE MED, V30, P1686, DOI 10.1097/00003246-200208000-00002
   Kirchhoff P, 2008, ANN SURG, V248, P259, DOI 10.1097/SLA.0b013e31817bbe3a
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043
   Lobo SMA, 2000, CRIT CARE MED, V28, P3396, DOI 10.1097/00003246-200010000-00003
   MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Mayr VD, 2006, CRIT CARE, V10, DOI 10.1186/cc5086
   McCulloch P, 2003, BMJ-BRIT MED J, V327, P1192, DOI 10.1136/bmj.327.7425.1192
   McKendry M, 2004, BMJ-BRIT MED J, V329, P258, DOI 10.1136/bmj.38156.767118.7C
   McNelis J, 2001, AM J SURG, V182, P481, DOI 10.1016/S0002-9610(01)00755-3
   Meregalli A, 2004, CRIT CARE, V8, pR60, DOI 10.1186/cc2423
   MYTHEN MG, 1995, ARCH SURG-CHICAGO, V130, P423
   OLDER P, 1993, CHEST, V104, P701, DOI 10.1378/chest.104.3.701
   Payen D, 2008, CRIT CARE, V12, DOI 10.1186/cc6916
   Pinho C, 2007, CLINICS, V62, P17, DOI 10.1590/S1807-59322007000100004
   Polonen P, 2000, ANESTH ANALG, V90, P1052
   Prytherch DR, 1998, BRIT J SURG, V85, P1217
   Sakr Y, 2008, J CRIT CARE, V23, P475, DOI 10.1016/j.jcrc.2007.09.006
   Sauaia A, 1996, WORLD J SURG, V20, P392, DOI 10.1007/s002689900062
   Shapiro NI, 2005, ANN EMERG MED, V45, P524, DOI 10.1016/j.annemergmed.2004.12.006
   SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176
   Smith I, 2001, INTENS CARE MED, V27, P74, DOI 10.1007/s001340051352
   Sperry JL, 2007, J TRAUMA, V63, P487, DOI 10.1097/TA.0b013e31812e51fc
   Torgersen C, 2009, ANESTH ANALG, V108, P1841, DOI 10.1213/ane.0b013e318195e11d
   TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002
   Venn R, 2002, BRIT J ANAESTH, V88, P65, DOI 10.1093/bja/88.1.65
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156
   WEIL MH, 1970, CIRCULATION, V41, P989, DOI 10.1161/01.CIR.41.6.989
   Yung M, 2008, PEDIATR CRIT CARE ME, V9, P147, DOI 10.1097/PCC.0b013e3181668c22
NR 49
TC 43
Z9 48
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD APR
PY 2011
VL 112
IS 4
BP 877
EP 883
DI 10.1213/ANE.0b013e3181e2bf8e
PG 7
WC Anesthesiology
SC Anesthesiology
GA 739ET
UT WOS:000288697000020
PM 20530615
DA 2020-12-15
ER

PT J
AU Magalhaes, O
   Maia, M
   Rodrigues, EB
   Machado, L
   Costa, EF
   Maia, A
   Moares, MN
   Dib, E
   Farah, ME
AF Magalhaes, Octaviano, Jr.
   Maia, Mauricio
   Rodrigues, Eduardo B.
   Machado, Leonardo
   Costa, Elaine F.
   Maia, Andre
   Moares-Filho, Milton N.
   Dib, Eduardo
   Farah, Michel Eid
TI Perspective on Fluid and Solid Dynamics in Different Pars Plana
   Vitrectomy Systems
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Editorial Material
ID VISUAL-FIELD DEFECTS; MACULAR HOLE SURGERY; VITREORETINAL SURGERY;
   VITREOUS CUTTERS
AB PURPOSE: To summarize current concepts and recent data from the literature about different vitrectomy machines and small-gauge systems based on physical laws.
   DESIGN: Interpretive essay.
   METHODS: Review and synthesis of selected recent literature with interpretation and perspective.
   RESULTS: Pars plana vitrectomy can be performed with a wide variety of treatment strategies, for multiple diseases, and with different materials (solids and fluids). We discuss a variety of machines and system settings (peristaltic pump, duty cycle, aspiration, and infusion controls) targeting safer and the most effective surgery with detailed explanations of the physical properties.
   CONCLUSIONS: Effective management of new surgical strategies is based on recognizing and addressing various physical characteristics in disease and ocular settings. Although the properties of machine are expanding, the long-term efficacy and safety of most new approaches have yet to be established in controlled clinical trials. (Am J Ophthalmol 2011;151:401-405. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Magalhaes, Octaviano, Jr.; Maia, Mauricio; Rodrigues, Eduardo B.; Machado, Leonardo; Costa, Elaine F.; Maia, Andre; Moares-Filho, Milton N.; Dib, Eduardo; Farah, Michel Eid] Univ Fed Sao Paulo, Paulista Sch Med, Vis Inst, Dept Ophthalmol, BR-04023062 Sao Paulo, Brazil.
RP Magalhaes, O (corresponding author), Univ Fed Sao Paulo, Paulista Sch Med, Vis Inst, Dept Ophthalmol, Rua Botucatu 822, BR-04023062 Sao Paulo, Brazil.
EM octavianomj@terra.com.br
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Buchele Rodrigues, Eduardo/0000-0002-4224-0921
CR Boldt HC, 1996, AM J OPHTHALMOL, V122, P371, DOI 10.1016/S0002-9394(14)72064-1
   BRONNER A, 1972, ARCH OPHTALMOL-PARIS, V32, P593
   Charles S, 2004, RETINA-J RET VIT DIS, V24, P435, DOI 10.1097/00006982-200406000-00015
   Fang SY, 2008, GRAEF ARCH CLIN EXP, V246, P61, DOI 10.1007/s00417-007-0672-8
   FOX RW, 2004, INTRO FLUID MECH, P1
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1807, DOI 10.1016/S0161-6420(02)01179-X
   Gass CA, 2001, BRIT J OPHTHALMOL, V85, P549, DOI 10.1136/bjo.85.5.549
   Hirata A, 2000, AM J OPHTHALMOL, V130, P611, DOI 10.1016/S0002-9394(00)00597-3
   HUBSCHMAN JP, 2008, RETINA, V29, P1290
   Hutton WL, 1996, OPHTHALMOLOGY, V103, P2152, DOI 10.1016/S0161-6420(96)30376-X
   Hutton WL, 1996, OPHTHALMOLOGY, V103, P2158
   Machemer R, 1972, Mod Probl Ophthalmol, V10, P172
   MAGALHAES JR, 2008, RETINA, V28, P236
   Magalhaes O, 2008, ACTA OPHTHALMOL, V86, P156, DOI 10.1111/j.1600-0420.2007.00988.x
   Magalhaes Octaviano Jr, 2009, Retin Cases Brief Rep, V3, P64, DOI 10.1097/ICB.0b013e31815657a7
   MUNSON BR, 2003, FUNDAMENTALS FLUID M, P1
   Oshitari K, 2001, AM J OPHTHALMOL, V131, P814, DOI 10.1016/S0002-9394(00)00927-2
   SABERSKY RH, 1999, FLUID FLOW 1 COURSE, P1
   Sato T, 2008, RETINA-J RET VIT DIS, V28, P749, DOI 10.1097/IAE.0b013e3181631907
   Yonemura N, 2003, GRAEF ARCH CLIN EXP, V241, P314, DOI 10.1007/s00417-003-0629-5
NR 20
TC 10
Z9 10
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2011
VL 151
IS 3
BP 401
EP 405
DI 10.1016/j.ajo.2010.11.009
PG 5
WC Ophthalmology
SC Ophthalmology
GA 725BO
UT WOS:000287620400005
PM 21251644
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Adan, A
   Berrocal, MH
   Espinoza, JV
   Maia, M
   Wu, L
   Roca, JA
   Quiroz-Mercado, H
   Ruiz-Moreno, JM
   Serrano, MA
AF Arevalo, J. Fernando
   Adan, Alfredo
   Berrocal, Maria H.
   Espinoza, Juan V.
   Maia, Mauricio
   Wu, Lihteh
   Roca, Jose A.
   Quiroz-Mercado, Hugo
   Ruiz-Moreno, Jose M.
   Serrano, Martin A.
CA Pan-Amer Collaborat Retina Study
TI INTRAVITREAL BEVACIZUMAB FOR INFLAMMATORY CHOROIDAL NEOVASCULARIZATION
   Results from the Pan-American Collaborative Retina Study Group at 24
   Months
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE Avastin; bevacizumab; choroidal neovascularization; CNV; inflammatory;
   intravitreal injections
ID PUNCTATE INNER CHOROIDOPATHY; MACULAR DEGENERATION; OCULAR
   HISTOPLASMOSIS; PHOTODYNAMIC THERAPY; IDIOPATHIC ORIGIN; SECONDARY;
   AVASTIN; INJECTION; DISEASES; UVEITIS
AB Background: To evaluate the anatomical and functional outcomes of intravitreal bevacizumab (1.25 or 2.5 mg) in the treatment of inflammatory choroidal neovascularization at 24 months.
   Methods: We reviewed the clinical records of 22 consecutive patients (23 eyes) with choroidal neovascularization secondary to chorioretinal inflammatory disease in this interventional retrospective multicenter case series. Sixteen eyes (63.6%) received a dose of 1.25 mg of intravitreal bevacizumab, and 7 eyes (36.4%) received a dose of 2.5 mg of intravitreal bevacizumab.
   Results: At baseline, the mean best-corrected visual acuity was 0.68 logarithm of minimum angle of resolution (Early Treatment Diabetic Retinopathy Study chart = 20/100). After intravitreal bevacizumab, best-corrected visual acuity improved significantly to 0.41 logarithm of minimum angle of resolution (20/51), 0.42 logarithm of minimum angle of resolution (20/53), and 0.40 logarithm of minimum angle of resolution (20/50) at 6, 12, and 24 months, respectively (P < 0.05). Fourteen eyes (60.8%) received 1 injection. Central macular thickness by optical coherence tomography decreased from 375.3 mu m (range: 240-634 mu m) at baseline to 241.6 mu m (range: 189-306 mu m) at 24 months of follow-up (P < 0.0001).
   Conclusion: Intravitreal bevacizumab at doses of 1.25 mg and 2.5 mg seems to provide stability or improvement in best- corrected visual acuity, optical coherence tomography, and fluorescein angiogram in inflammatory choroidal neovascularization at 24 months. All patients were treated after the underlying uveitic condition was controlled.
   RETINA 31: 353-363, 2011
C1 [Arevalo, J. Fernando; Espinoza, Juan V.; Serrano, Martin A.] Edif Ctr Caracas PH 1, Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Caracas 1010, Venezuela.
   [Adan, Alfredo] Hosp Clin Barcelona, Dept Ophthalmol, Barcelona, Spain.
   [Berrocal, Maria H.] Univ Puerto Rico, Dept Ophthalmol, San Juan, PR 00936 USA.
   [Maia, Mauricio] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Roca, Jose A.] Clin Ricardo Palma, Lima, Peru.
   [Quiroz-Mercado, Hugo] Hosp Dr Luis Sanchez Bulnes, Asociac Evitar Ceguera Mexico, Mexico City, DF, Mexico.
   [Ruiz-Moreno, Jose M.] Inst Oftalmol Alicante, Unidad Vitreo Retinal, Alicante, Spain.
   [Ruiz-Moreno, Jose M.] Miguel Hernandez Univ, Escuela Med, Alicante, Spain.
RP Arevalo, JF (corresponding author), Edif Ctr Caracas PH 1, Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Av Panteon, Caracas 1010, Venezuela.
EM arevalojf2020@gmail.com
RI Ruiz-Moreno, Jose M/E-4644-2016; Maia, Mauricio/Z-1042-2019;
   Fromow-Guerra, J. Jans/A-3346-2015; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Fromow-Guerra, J.
   Jans/0000-0001-5335-1275; Maia, Mauricio/0000-0002-7034-8091; Adan,
   Alfredo/0000-0002-0849-8814; Serrano, Martin/0000-0002-0693-2517
FU Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas,
   Venezuela
FX Supported in part by the Arevalo-Coutinho Foundation for Research in
   Ophthalmology, Caracas, Venezuela.
CR Adan A, 2007, RETINA-J RET VIT DIS, V27, P1180, DOI 10.1097/IAE.0b013e31815e9834
   Adan A, 2007, GRAEF ARCH CLIN EXP, V245, P1873, DOI 10.1007/s00417-007-0637-y
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Arevalo JF, 2007, OPHTHALMOLOGY, V114, P743, DOI 10.1016/j.ophtha.2006.12.028
   Ben Yahia Salim, 2008, International Ophthalmology, V28, P311, DOI 10.1007/s10792-008-9218-2
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P71, DOI 10.1097/IAE.0b013e31815e9339
   Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016/j.ajo.2007.02.039
   Chang LK, 2008, ARCH OPHTHALMOL-CHIC, V126, P941, DOI 10.1001/archopht.126.7.941
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Doctor PP, 2009, OCUL IMMUNOL INFLAMM, V17, P118, DOI 10.1080/09273940802650406
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Fine HF, 2009, RETINA-J RET VIT DIS, V29, P8, DOI 10.1097/IAE.0b013e318187aff9
   FINE SL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1358
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   HO AC, 1995, OPHTHALMOLOGY, V102, P1411
   Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057
   Kramer M, 2010, RETINA-J RET VIT DIS, V30, P938, DOI 10.1097/IAE.0b013e3181c96a00
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lit ES, 2001, RETINA-J RET VIT DIS, V21, P317, DOI 10.1097/00006982-200108000-00004
   Mansour AM, 2008, AM J OPHTHALMOL, V146, P410, DOI 10.1016/j.ajo.2008.05.024
   Mansour AM, 2009, AM J OPHTHALMOL, V148, P310, DOI 10.1016/j.ajo.2009.03.023
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Quillen DA, 2004, AM J OPHTHALMOL, V137, P538, DOI 10.1016/j.ajo.2004.01.053
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schadlu R, 2008, AM J OPHTHALMOL, V145, P875, DOI 10.1016/j.ajo.2007.12.030
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782, DOI 10.1001/archopht.126.6.782
   Tran T, 2008, GRAEF ARCH CLIN EXP, V246, P1685, DOI 10.1007/s00417-008-0906-4
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P899, DOI 10.1007/s00417-003-0734-5
   Wu L, 2009, JPN J OPHTHALMOL, V53, P57, DOI 10.1007/s10384-008-0600-4
NR 31
TC 27
Z9 27
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2011
VL 31
IS 2
BP 353
EP 363
DI 10.1097/IAE.0b013e3181ed8cec
PG 11
WC Ophthalmology
SC Ophthalmology
GA 711JG
UT WOS:000286586500021
PM 20890239
DA 2020-12-15
ER

PT J
AU Marchioro, JC
   Belmonte, G
   Pradela, C
   Maia, MN
   Nascimento, OA
   Jardim, JR
AF Marchioro, J. C.
   Belmonte, G.
   Pradela, C.
   Maia, M. N.
   Nascimento, O. A.
   Jardim, J. R.
TI Effects Of Home-Based Pulmonary Rehabilitation In COPD Patients -
   Adaptation To Patient's Real Life
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
RI Nascimento, Oliver A./B-3039-2011; Maia, Mauricio/I-5892-2015
OI Nascimento, Oliver A./0000-0003-3138-2219; Maia,
   Mauricio/0000-0002-7034-8091
NR 0
TC 1
Z9 1
U1 0
U2 4
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2011
VL 183
MA A6438
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29TI
UT WOS:000208770306560
DA 2020-12-15
ER

PT J
AU Malerbi, FK
   Maia, M
   Farah, ME
   Rodrigues, EB
AF Malerbi, F. K.
   Maia, M.
   Farah, M. E.
   Rodrigues, E. B.
TI Subretinal Brilliant Blue G migration during internal limiting membrane
   peeling (vol 93, pg 1687, 2009)
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Correction
RI Maia, Mauricio/I-5892-2015; Malerbi, Fernando/AAD-3827-2019
OI Maia, Mauricio/0000-0002-7034-8091; 
CR Maia M, 2009, BRIT J OPHTHALMOL, V93, P1687, DOI 10.1136/bjo.2008.151597
NR 1
TC 1
Z9 1
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2011
VL 95
IS 1
BP 154
EP 154
DI 10.1136/bjo.2008.151597corr1
PG 1
WC Ophthalmology
SC Ophthalmology
GA 695OB
UT WOS:000285380300042
OA Bronze
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Sanchez, JG
   Lasave, AF
   Wu, L
   Maia, M
   Bonafonte, S
   Brito, M
   Alezzandrini, AA
   Restrepo, N
   Berrocal, MH
   Saravia, M
   Farah, ME
   Fromow-Guerra, J
   Morales-Canton, V
AF Fernando Arevalo, J.
   Sanchez, Juan G.
   Lasave, Andres F.
   Wu, Lihteh
   Maia, Mauricio
   Bonafonte, Sergio
   Brito, Miguel
   Alezzandrini, Arturo A.
   Restrepo, Natalia
   Berrocal, Maria H.
   Saravia, Mario
   Farah, Michel Eid
   Fromow-Guerra, Jans
   Morales-Canton, Virgilio
TI Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010
   GLADAOF Lecture
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; SCATTER LASER PHOTOCOAGULATION; MACULAR
   EDEMA; PANRETINAL PHOTOCOAGULATION; TUMOR ANGIOGENESIS; VISUAL-LOSS;
   INJECTIONS; NEOVASCULARIZATION; PERMEABILITY; REGRESSION
AB This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter interventional comparative case series of intravitreal injections of 1.25 or 2.5 mg of bevacizumab for DME, PDR without tractional retinal detachment (TRD), and patients who experienced the development or progression of TRD after an intravitreal injection of 1.25 or 2.5 mg of bevacizumab before vitrectomy for the management of PDR. The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse DME. Therefore, in the future this new therapy could complement focal/grid laser photocoagulation in DME. In PDR, this new option could be an adjuvant agent to panretina photocoagulation so that more selective therapy may be applied. Finally, TRD in PDR may occur or progress after IVB used as an adjuvant to vitrectomy. Surgery should be performed 4 days after IVB. Most patients had poorly controlled diabetes mellitus associated with elevated HbA1c, insulin administration, PDR refractory to panretinal photocoagulation, and longer time between IVB and vitrectomy.
C1 [Fernando Arevalo, J.; Lasave, Andres F.] Caracas Clin Opthalmol Ctr, Retina & Vitreous Serv, Caracas 1010, Venezuela.
   [Sanchez, Juan G.; Restrepo, Natalia] INIO, Retina & Vitreous Serv, Medellin, Colombia.
   [Wu, Lihteh] Inst Cirugia Ocular, Retina & Vitreous Serv, San Jose, Costa Rica.
   [Maia, Mauricio; Farah, Michel Eid] Univ Fed Sao Paulo, Inst Visao, Dept Oftalmol, BR-04021001 Sao Paulo, Brazil.
   [Bonafonte, Sergio] Ctr Oftalmol Bonafonte, Retina & Vitreous Serv, Barcelona, Spain.
   [Brito, Miguel] IDEO, Retina & Vitreous Serv, Maracaibo, Venezuela.
   [Alezzandrini, Arturo A.] Univ Buenos Aires, Fac Med, OFTALMOS, Buenos Aires, DF, Argentina.
   [Berrocal, Maria H.] Univ Puerto Rico, Dept Ophthalmol, San Juan, PR 00936 USA.
   [Saravia, Mario] Hosp Univ Austral, Dept Ophthalmol, Buenos Aires, DF, Argentina.
   [Fromow-Guerra, Jans; Morales-Canton, Virgilio] Asociac Evitar Ceguera Mexico 04030, Hosp Dr Luis Sanchez Bulnes, Mexico City, DF, Mexico.
RP Arevalo, JF (corresponding author), Caracas Clin Opthalmol Ctr, Retina & Vitreous Serv, Caracas 1010, Venezuela.
EM arevalojf2020@gmail.com
RI Maia, Mauricio/I-5892-2015; Fromow-Guerra, J. Jans/A-3346-2015; Maia,
   Mauricio/Z-1042-2019; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Fromow-Guerra, J.
   Jans/0000-0001-5335-1275; Maia, Mauricio/0000-0002-7034-8091; Farah,
   Michel Eid E/0000-0001-5951-0193; Lasave, Andres/0000-0002-9602-9769
FU Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas,
   Venezuela
FX This paper was presented in part at the IV Congreso de la Sociedad
   Panamericana de Retina y Vitreo (XIII Forum de GLADAOF) Lima, Peru. July
   7-10, 2010. It was Supported in part by the Arevalo-Coutinho Foundation
   for Research in Ophthalmology, Caracas, Venezuela. The following
   investigators belong to the Pan-American Collaborative Retina Study
   Group (PACORES): -L. Wu (PI), Instituto de Cirugia Ocular, San Jose,
   Costa Rica; J. F. Arevalo (PI), J. G. Sanchez, J. V. Espinoza, A. F.
   Lasave, Clinica Oftalmologica Centro Caracas and the Arevalo-Coutinho
   Foundation for Research in Ophthalmology, Caracas, Venezuela; M. Farah
   (PI), M. Maia, F. B. Aggio, Universidade Federal de Sao Paulo,
   Departamento de Oftalmologia, Instituto da Visao, Sao Paulo, Brazil; V.
   Morales-Canton (PI), H. Quiroz-Mercado, J. Fromow-Guerra, J. L.
   Guerrero-Naranjo, Asociacion para Evitar la Ceguera en Mexico, Mexico
   City, Mexico; F. J. Rodriguez (PI), R. Infante, D. Medina, Fundacion
   Oftalmologica Nacional, Universidad del Rosario, Bogota, Colombia; M. H.
   Berrocal (PI), V. Cruz-Villegas, University of Puerto Rico, San Juan,
   Puerto Rico; F. Graue-Wiechers (PI), D. Lozano-Rechy, V. Robledo, J. L.
   Rodriguez-Loaiza, Fundacion Conde Valenciana, Mexico City, Mexico; J. A.
   Roca (PI), Clinica Ricardo Palma, Lima, Peru; M. J. Saravia (PI), M.
   Martinez-Cartier, Hospital Universitario Austral, Buenos Aires,
   Argentina; M. Avila (PI), Universidade Federal de Goias-Departamento de
   Oftalmologia, Goiania, Brazil; J. Cardillo (PI), RA Costa, Hospital de
   Olhos de Araraquara, and the Universidade de Sao Paulo, Sao Paulo,
   Brazil; J. Verdaguer T. (PI), C. Carpentier, J. I. Verdaguer D., L.
   Filsecker, G. Sepulveda, Fundacion Oftalmologica Los Andes, Santiago de
   Chile, Chile; A. Alezzandrini (PI), F. Sanchez, C. Marini, B. Garcia,
   OFTALMOS, Catedra de Oftalmologia, Universidad de Buenos Aires, Buenos
   Aires, Argentina. (PI: Principal Investigator).
CR Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Arevalo JF, 2009, EYE, V23, P117, DOI 10.1038/sj.eye.6702980
   Arevalo J. F., 2009, OPHTHALMOLOGY, V116
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   AYLWARD GW, 1989, BRIT J OPHTHALMOL, V73, P197, DOI 10.1136/bjo.73.3.197
   BRESNICK GH, 1983, OPHTHALMOLOGY, V90, P1301
   Campochiaro PA, 2004, INVEST OPHTH VIS SCI, V45, P922, DOI 10.1167/iovs.03-0955
   Chen E, 2006, RETINA-J RET VIT DIS, V26, P699, DOI 10.1097/01.iae.0000225351.87205.69
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   DOFT BH, 1982, OPHTHALMOLOGY, V89, P772
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRIS FL, 1984, SURV OPHTHALMOL, V28, P452, DOI 10.1016/0039-6257(84)90227-3
   FERRIS FL, 1987, OPHTHALMOLOGY, V94, P754
   Fong DS, 1999, AM J OPHTHALMOL, V127, P137, DOI 10.1016/S0002-9394(98)00309-2
   Friedlander SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1363
   Isaacs TW, 2006, CLIN EXP OPHTHALMOL, V34, P802, DOI 10.1111/j.1442-9071.2006.01378.x
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   KASSOFF A, 1993, OPHTHALMOLOGY, V100, P1655
   KAUFMAN SC, 1989, INVEST OPHTH VIS SCI, V30, P23
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mason JO, 2006, AM J OPHTHALMOL, V142, P685, DOI 10.1016/j.ajo.2006.04.058
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   MCDONALD HR, 1985, OPHTHALMOLOGY, V92, P388
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Nguyen QD, 2004, INVEST OPHTH VIS SCI, V45, P617, DOI 10.1167/iovs.03-0557
   Nonaka A, 2002, INVEST OPHTH VIS SCI, V43, P1204
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   PEER J, 1995, LAB INVEST, V72, P638
   Richter B, 2004, EVIDENCE BASED OPHTH, P331
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Shimura M, 2003, OPHTHALMOLOGY, V110, P2386, DOI 10.1016/j.ophtha.2003.05.008
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Strom C, 2005, INVEST OPHTH VIS SCI, V46, P3855, DOI 10.1167/iovs.05-0096
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Tsujikawa A, 1999, RETINA-J RET VIT DIS, V19, P59, DOI 10.1097/00006982-199901000-00010
   Watanabe D, 2005, AM J OPHTHALMOL, V139, P476, DOI 10.1016/j.ajo.2004.10.004
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
NR 55
TC 27
Z9 32
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2011
VL 2011
AR 584238
DI 10.1155/2011/584238
PG 13
WC Medicine, Research & Experimental; Ophthalmology
SC Research & Experimental Medicine; Ophthalmology
GA 979BO
UT WOS:000306790100022
PM 21584260
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Assuncao, M
   Akamine, N
   Cardoso, GS
   Mello, PVC
   Teles, JMM
   Nunes, ALB
   Maia, MO
   Rea-Neto, A
   Machado, FR
AF Assuncao, Murillo
   Akamine, Nelson
   Cardoso, Guttemberg S.
   Mello, Patricia V. C.
   Teles, Jose Mario M.
   Nunes, Andre Luis B.
   Maia, Marcelo Oliveira
   Rea-Neto, Alvaro
   Machado, Flavia Ribeiro
CA SEPSES Study Grp
TI Survey on physicians' knowledge of sepsis: Do they recognize it
   promptly?
SO JOURNAL OF CRITICAL CARE
LA English
DT Article
DE Sepsis; Severe sepsis; Septic shock; Professional practice; Education
   and diagnoses
ID SYSTEMIC INFLAMMATORY RESPONSE; ILL INFECTED PATIENTS; INTENSIVE-CARE
   UNITS; SEPTIC SHOCK; EPIDEMIOLOGY; GUIDELINES; MANAGEMENT; MULTICENTER;
   CAMPAIGN; THERAPY
AB Purpose In Brazil, sepsis has a high mortality, and early recognition is essential in outcome The aim of the study was to evaluate physicians knowledge about systemic Inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock concepts
   Methods This was a prospective, observational study performed in 21 hospitals in Brazil, which enrolled physicians working in the participant institutions A previously validated questionnaire was applied to physicians including 5 clinical cases
   Results Twenty-one Brazilian institutions enrolled 917 physicians The percentage of physicians correctly recognizing SIRS infection sepsis severe sepsis, and septic shock was 78 2% 92 6%, 27 3%, 56 7%, and 81 0%, respectively Intenswists performed better in all diagnoses There was a significantly higher rate of correct answers for SIRS (P < 001), sepsis (P = 001) and severe sepsis (P = 032) among physicians from university hospitals as compared with those from public hospitals A mean global score of 3 36 1 08 was found, with better performance for residents (P = 012) and intensivists (P < 001) but no difference was found for emergency physicians (P = 875)
   Conclusion The prompt recognition of sepsis and its severity is not satisfactory This difference is probably due to the difficulty in the recognition of organ dysfunction, which hampers early identification of septic patients Crown Copyright (C) 2010 Published by Elsevier Inc All rights reserved
C1 [Assuncao, Murillo; Cardoso, Guttemberg S.; Machado, Flavia Ribeiro] Univ Fed Sao Paulo, Disciplina Anestesiol Dor & Terapia Intens, BR-04024002 Sao Paulo, Brazil.
   [Mello, Patricia V. C.] Univ Estadual Piaui, Hosp Terapia Intens, Teresina, Piaui, Brazil.
   [Teles, Jose Mario M.] Hosp Portugues, Salvador, BA, Brazil.
   [Nunes, Andre Luis B.] Hosp Sao Camilo Sao Paulo, Sao Paulo, Brazil.
   [Maia, Marcelo Oliveira] Hosp Santa Luzia, Brasilia, DF, Brazil.
   [Rea-Neto, Alvaro] Univ Fed Parana, Hosp Clin, BR-80060000 Curitiba, Parana, Brazil.
RP Assuncao, M (corresponding author), Univ Fed Sao Paulo, Disciplina Anestesiol Dor & Terapia Intens, Rua Napolcao de Barros 715,6 Andar Vila Clementin, BR-04024002 Sao Paulo, Brazil.
RI Rea-Neto, Alvaro/AAR-7909-2020; Maia, Mauricio/I-5892-2015; de cleva,
   roberto/L-8456-2013; Machado, Flavia R/G-4651-2012; Assuncao, Murillo S
   C/K-1040-2012; Maia, Mauricio/Z-1042-2019; de cleva,
   roberto/AAG-6927-2019
OI Rea-Neto, Alvaro/0000-0001-5524-0907; Maia,
   Mauricio/0000-0002-7034-8091; de cleva, roberto/0000-0001-8673-9014;
   Machado, Flavia R/0000-0002-2356-4867; Assuncao, Murillo S
   C/0000-0002-0741-4869; Maia, Mauricio/0000-0002-7034-8091; de cleva,
   roberto/0000-0001-8673-9014
CR Alberti C, 2002, INTENS CARE MED, V28, P108, DOI 10.1007/s00134-001-1143-z
   Alberti C, 2005, AM J RESP CRIT CARE, V171, P461, DOI 10.1164/rccm.200403-324OC
   Alberti C, 2003, AM J RESP CRIT CARE, V168, P77, DOI 10.1164/rccm.200208-785OC
   Annane D, 2003, AM J RESP CRIT CARE, V168, P165, DOI 10.1164/rccm.2201087
   [Anonymous], 2000, N ENGL J MED, V342, P1301
   Beale R, 2004, CHEST, V126, p864S, DOI 10.1378/chest.126.4_MeetingAbstracts.864S-b
   BEALE R, 2009, INFECTION
   Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Dellinger RP, 2008, INTENS CARE MED, V34, P17, DOI 10.1007/s00134-007-0934-2
   Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4
   Dremsizov T, 2006, CHEST, V129, P968, DOI 10.1378/chest.129.4.968
   FERNANDEZ R, 2006, CRITICAL CARE, V10, pP126
   FRAUSTO MSR, 1995, JAMA-J AM MED ASSOC, V273, P117
   Freitas FGR, 2008, CLINICS, V63, P483, DOI 10.1590/S1807-59322008000400012
   Padkin A, 2003, CRIT CARE MED, V31, P2332, DOI 10.1097/01.CCM.0000085141.75513.2B
   PIZZOLATTI ML, 2004, REV BRASILEIRA TERAP, V16, P210
   Poeze M, 2004, CRIT CARE, V8, pR409, DOI 10.1186/cc2959
   Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307
   Robson Wayne, 2007, Nurs Crit Care, V12, P86, DOI 10.1111/j.1478-5153.2007.00210.x
   SALES J, 2006, CRITICAL CARE, V10, pP111
   Silva E, 2004, CRIT CARE, V8, pR251, DOI 10.1186/cc2892
   Sivayoham N, 2007, EMERG MED J, V24, P422, DOI 10.1136/emj.2007.046060
   SOGAYAR AMC, PHARMACOECO IN PRESS
   Sogayar AMC, 2008, PHARMACOECONOMICS, V26, P425, DOI 10.2165/00019053-200826050-00006
   Srinivasan A, 2004, ARCH INTERN MED, V164, P1451, DOI 10.1001/archinte.164.13.1451
   Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300
   Ziglam HM, 2006, J ANTIMICROB CHEMOTH, V57, P963, DOI 10.1093/jac/dkl042
   1990, JAMA, V263, P937
NR 29
TC 29
Z9 31
U1 0
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0883-9441
J9 J CRIT CARE
JI J. Crit. Care
PD DEC
PY 2010
VL 25
IS 4
BP 545
EP 552
DI 10.1016/j.jcrc.2010.03.012
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 692PC
UT WOS:000285163700002
PM 20646902
DA 2020-12-15
ER

PT J
AU Lima, VC
   Rosen, RB
   Maia, M
   Prata, TS
   Dorairaj, S
   Farah, ME
   Sallum, J
AF Lima, Veronica Castro
   Rosen, Richard B.
   Maia, Mauricio
   Prata, Tiago Santos
   Dorairaj, Syril
   Farah, Michel Eid
   Sallum, Juliana
TI Macular Pigment Optical Density Measured by Dual-Wavelength
   Autofluorescence Imaging in Diabetic and Nondiabetic Patients: A
   Comparative Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID HETEROCHROMATIC FLICKER PHOTOMETRY; OXIDATIVE STRESS; CRYSTALLINE LENS;
   HUMAN RETINA; RETINOPATHY; ZEAXANTHIN; MELLITUS; CAROTENOIDS; LUTEIN;
   DEGENERATION
AB PURPOSE. To compare macular pigment optical density (MPOD) in type 2 diabetic and nondiabetic patients by using dual-wavelength autofluorescence imaging and to investigate the correlation of MPOD with glycosylated hemoglobin (HbA1C) and serum lipid levels.
   METHODS. Forty-three patients were divided into groups 1 (controls, n = 14), 2 (diabetic without retinopathy, n = 17), and 3 (diabetic with mild nonproliferative retinopathy, n = 12). MPOD was measured with a modified confocal scanning laser ophthalmoscope and compared among groups (analysis of variance). The correlation of HbA1C and serum lipid (HDL, LDL, total cholesterol, and triglycerides) levels with MPOD was determined for each group (linear regression analysis).
   RESULTS. Mean +/- SD ages in groups 1 (56.2 +/- 11.7 years), 2 (58.6 +/- 11.5 years), and 3 (62.8 +/- 9.8 years) were similar (P = 0.324). Mean MPOD averaged in a 2 degrees-diameter circle around the fovea was significantly different between the three groups: 1, (0.29 +/- 0.07 density units [DU]), 2 (0.22 +/- 0.09 DU), and 3 (0.14 +/- 0.05 DU) (P < 0.001). There was a significant difference in mean MPOD levels at 0.5 degrees between groups 1 (0.51 +/- 0.12 DU) and 2 (0.24 +/- 0.11 DU; P < 0.001), but not between groups 2 and 3 (0.33 +/- 0.15 DU; P > 0.05). A significant inverse correlation was observed between HbA1C levels and mean MPOD, averaged at 2 around the fovea in all patients (r = -0.63, P < 0.001). No significant correlations were found between MPOD and serum lipid levels or age.
   CONCLUSIONS. Type 2 diabetic patients, with or without retinopathy, had reduced MPOD when compared with that in nondiabetic patients. In addition, a significant inverse correlation between MPOD and HbA1C levels was observed. (Invest Ophthalmol Vis Sci. 2010;51:5840-5845) DOI:10.1167/iovs.09-4695
C1 [Lima, Veronica Castro; Rosen, Richard B.; Dorairaj, Syril] New York Eye & Ear Infirm, Dept Ophthalmol, Retina Serv, New York, NY 10003 USA.
   [Prata, Tiago Santos] New York Eye & Ear Infirm, Einhorn Clin Res Ctr, New York, NY 10003 USA.
   [Lima, Veronica Castro; Maia, Mauricio; Prata, Tiago Santos; Farah, Michel Eid; Sallum, Juliana] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Rosen, Richard B.] New York Med Coll, Dept Ophthalmol, New York, NY USA.
RP Rosen, RB (corresponding author), New York Eye & Ear Infirm, Dept Ophthalmol, Retina Serv, 310 E 14th St, New York, NY 10003 USA.
EM rrosen@nyee.edu
RI Prata, Tiago/AAV-6676-2020; Maia, Mauricio/I-5892-2015; Maia,
   Mauricio/Z-1042-2019; Sallum, Juliana Maria Ferraz/AAL-4000-2020; Farah,
   Michel Eid E/F-3285-2012
OI Prata, Tiago/0000-0003-1830-3766; Maia, Mauricio/0000-0002-7034-8091;
   Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Sallum, Juliana/0000-0002-7206-4447
CR Applegate RA, 1997, INVEST OPHTH VIS SCI, V38, P783
   Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   BONE RA, 1992, METHOD ENZYMOL, V213, P360
   BRESNICK GH, 1977, ARCH OPHTHALMOL-CHIC, V95, P1215, DOI 10.1001/archopht.1977.04450070113010
   Burstedt MSI, 2009, OPHTHALMOLOGY, V116, P324, DOI 10.1016/j.ophtha.2008.09.007
   Canovas R, 2010, INVEST OPHTH VIS SCI, V51, P3152, DOI 10.1167/iovs.09-3608
   Davies NP, 2002, INVEST OPHTH VIS SCI, V43, P281
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Dene BA, 2005, J OCUL PHARMACOL TH, V21, P28, DOI 10.1089/jop.2005.21.28
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DITZEL J, 1976, DIABETES, V25, P832
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   Elsner AE, 1998, INVEST OPHTH VIS SCI, V39, P2394
   ENGERMAN RL, 1986, METABOLISM, V35, P20, DOI 10.1016/0026-0495(86)90182-4
   Ford ES, 1999, AM J EPIDEMIOL, V149, P168, DOI 10.1093/oxfordjournals.aje.a009783
   Granado F, 1998, CLIN SCI, V94, P189, DOI 10.1042/cs0940189
   Gurler B, 2000, EYE, V14, P730, DOI 10.1038/eye.2000.193
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, P2531
   Haskins K, 2003, ANN NY ACAD SCI, V1005, P43, DOI 10.1196/annals.1288.006
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KINCAID MC, 1983, RETINA-J RET VIT DIS, V3, P218, DOI 10.1097/00006982-198300330-00013
   Kowluru RA, 2004, DIABETES, V53, P3233, DOI 10.2337/diabetes.53.12.3233
   Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938
   Kowluru RA, 2008, INVEST OPHTH VIS SCI, V49, P1645, DOI 10.1167/iovs.07-0764
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   LESPERANCE FA, 1983, DIABETIC RETINOPATHY, P11
   Madsen-Bouterse SA, 2008, REV ENDOCR METAB DIS, V9, P315, DOI 10.1007/s11154-008-9090-4
   MERIMEE TJ, 1990, NEW ENGL J MED, V322, P978, DOI 10.1056/NEJM199004053221406
   MOSIER MA, 1986, ARCH OPHTHALMOL-CHIC, V104, P1340
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nolan JM, 2007, INVEST OPHTH VIS SCI, V48, P571, DOI 10.1167/iovs.06-0864
   Pan HZ, 2008, BRIT J OPHTHALMOL, V92, P548, DOI 10.1136/bjo.2007.130542
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   SPARROW JM, 1992, BRIT J OPHTHALMOL, V76, P25, DOI 10.1136/bjo.76.1.25
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   VANDENENDEN MK, 1995, INVEST OPHTH VIS SCI, V36, P1675
   WILL JC, 1990, NEW ENGL J MED, V323, P613
   WILLIAMS JM, 1988, AM J OPHTHALMOL, V105, P491, DOI 10.1016/0002-9394(88)90240-1
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   YANOFF M, 1969, AM J OPHTHALMOL, V67, P21, DOI 10.1016/0002-9394(69)90004-X
   Zagers NPA, 2005, VISION RES, V45, P1745, DOI 10.1016/j.visres.2004.12.011
   Zeimer M, 2009, OPHTHALMOLOGE, V106, P29, DOI 10.1007/s00347-008-1773-4
NR 53
TC 33
Z9 33
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2010
VL 51
IS 11
BP 5840
EP 5845
DI 10.1167/iovs.09-4695
PG 6
WC Ophthalmology
SC Ophthalmology
GA 672BQ
UT WOS:000283558400056
PM 20505210
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Sanchez, JG
   Wu, L
   Berrocal, MH
   Alezzandrini, AA
   Restrepo, N
   Maia, M
   Farah, ME
   Brito, M
   Diaz-Llopis, M
   Rodriguez, FJ
   Reategui, G
   Iturralde-Iraola, J
   Udaondo-Mirete, P
AF Fernando Arevalo, J.
   Sanchez, Juan G.
   Wu, Lihteh
   Berrocal, Maria H.
   Alezzandrini, Arturo A.
   Restrepo, Natalia
   Maia, Mauricio
   Farah, Michel E.
   Brito, Miguel
   Diaz-Llopis, Manuel
   Rodriguez, Francisco J.
   Reategui, Guillermo
   Iturralde-Iraola, Juan
   Udaondo-Mirete, Patricia
CA Pan-Amer Collaborative Retina Stud
TI Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in
   Age-Related Macular Degeneration at Twenty-four Months: The Pan-American
   Collaborative Retina Study
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; AVASTIN TREATMENT; INJECTION; SECONDARY;
   ANTIBODY; TEAR
AB Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (IVB) (Avastin; Genentech Inc., San Francisco, CA) (1.25 or 2.5 mg) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   Design: Retrospective, multicenter, interventional, comparative case series.
   Participants: We reviewed the clinical records of 180 consecutive patients (207 eyes) with subfoveal CNV secondary to AMD at 9 centers from 8 countries.
   Methods: Patients were treated with at least 1 injection of IVB 1.25 mg (124 eyes [59.9%]) or 2.5 mg (83 eyes [40.1%]). Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and 1-, 3-, 6-, 12-, and 24-month visits.
   Main Outcome Measures: Changes in BCVA and OCT.
   Results: The mean age of our patients was 74.3 +/- 7.5 years. The mean number of IVB injections per eye was 5.1 (range, 1- 24 injections). In the 1.25 mg group, baseline BCVA improved from 20/235 (logarithm of the minimum angle of resolution [logMAR] 1.07) to 20/172 (logMAR 0.92) at 24 months (P<0.0001). Similar BCVA changes were observed in the 2.5 mg group. At baseline, the mean central macular thickness (CMT) by OCT in the 1.25 mg group was 308.4 +/- 127.52 mu m, which was reduced to 269.35 +/- 97.92 mu m, 262.1 +/- 94.81 mu m, 264.03 +/- 97.06 mu m, 245.91 +/- 89.52 mu m, and 249.27 +/- 89.14 mu m at 1, 3, 6, 12, and 24 months, respectively (P<0.0001). Similar changes were observed in the 2.5 mg group. In the 2.5 mg group, systemic complications included 2 new cases (2.6%) of arterial hypertension, 1 case (1.3%) of stroke, and 1 case (1.3%) of death.
   Conclusions: Primary IVB at a dose of 1.25 or 2.5 mg seems to provide stability or improvement in BCVA, OCT, and FA in subfoveal CNV secondary to AMD at 24 months. Our results show no significant difference regarding BCVA with IVB at doses of 1.25 or 2.5 mg.
C1 [Fernando Arevalo, J.] Clin Oftalmolog, Ctr Caracas, Retina & Vitreous Serv, Caracas 1010, Venezuela.
   [Sanchez, Juan G.; Restrepo, Natalia] Inst Nacl Invest Oftalmol, Medellin, Colombia.
   [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Berrocal, Maria H.] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Alezzandrini, Arturo A.] Univ Buenos Aires, Fac Med, OFTALMOS, Buenos Aires, DF, Argentina.
   [Maia, Mauricio; Farah, Michel E.] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Brito, Miguel; Iturralde-Iraola, Juan] Inst Docente Especialidades Oftalmol, Maracaibo, Venezuela.
   [Diaz-Llopis, Manuel; Udaondo-Mirete, Patricia] Gen Univ Valencia, Consorcio Hosp, Valencia, Spain.
   [Rodriguez, Francisco J.] Univ Rosario, Fdn Oftalmol Nacl, Bogota, Colombia.
   [Reategui, Guillermo] Inst Nacl Oftalmol, Lima, Peru.
RP Arevalo, JF (corresponding author), Clin Oftalmolog, Ctr Caracas, Retina & Vitreous Serv, Edif Ctr Caracas PH 1,Av Panteon, Caracas 1010, Venezuela.
EM arevalojf2020@gmail.com
RI Maia, Mauricio/Z-1042-2019; Farah, Michel Eid E/F-3285-2012;
   Fromow-Guerra, J. Jans/A-3346-2015; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Fromow-Guerra, J. Jans/0000-0001-5335-1275; Maia,
   Mauricio/0000-0002-7034-8091; Udaondo, Patricia/0000-0002-5241-0066
FU Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas,
   Venezuela
FX Supported in part by the Arevalo-Coutinho Foundation for Research in
   Ophthalmology, Caracas, Venezuela.
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P779, DOI 10.1007/s00417-007-0754-7
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DAMICO DJ, 1994, NEW ENGL J MED, V331, P95, DOI 10.1056/NEJM199407143310207
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER JW, 1994, AM J PATHOL, V145, P574
   MODARRES M, 2009, RETINA, V3, P319
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 35
TC 30
Z9 33
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2010
VL 117
IS 10
BP 1974
EP U155
DI 10.1016/j.ophtha.2010.01.056
PG 9
WC Ophthalmology
SC Ophthalmology
GA 656VV
UT WOS:000282370100017
PM 20569989
DA 2020-12-15
ER

PT J
AU Rodrigues, EB
   Farah, ME
   Penha, FM
   Maia, M
   Meyer, CH
AF Rodrigues, Eduardo B.
   Farah, Michel Eid
   Penha, Fernando M.
   Maia, Mauricio
   Meyer, Carsten H.
TI Novel Dyes in Intraocular Surgery Reply
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Letter
RI Farah, Michel Eid E/F-3285-2012; Penha, Fernando M/G-1784-2012; Maia,
   Mauricio/I-5892-2015; Meyer, Carsten H./A-3981-2017
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Meyer, Carsten H./0000-0002-0530-5298
CR Lahm A, 2004, ARCH ORTHOP TRAUM SU, V124, P431, DOI 10.1007/s00402-004-0701-6
   Pandey SK, 2000, J CATARACT REFR SURG, V26, P1052, DOI 10.1016/S0886-3350(00)00296-0
   Rodrigues EB, 2010, AM J OPHTHALMOL, V149, P265, DOI 10.1016/j.ajo.2009.08.020
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2010
VL 150
IS 3
BP 443
EP 443
DI 10.1016/j.ajo.2010.05.008
PG 1
WC Ophthalmology
SC Ophthalmology
GA 649ON
UT WOS:000281781800025
DA 2020-12-15
ER

PT J
AU Rossi, EE
   Silveira, L
   Pinheiro, ALB
   Zamuner, SR
   Aimbire, F
   Maia, M
   Pacheco, MTT
AF Rossi, Eglas Emanuel
   Silveira, Landulfo, Jr.
   Barbosa Pinheiro, Antonio Luiz
   Zamuner, Stella Regina
   Aimbire, Flavio
   Maia, Mauricio
   Tavares Pacheco, Marcos Tadeu
TI Raman spectroscopy for differential diagnosis of endophthalmitis and
   uveitis in rabbit iris in vitro
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Raman spectroscopy; iris; endophthalmitis; uveitis; differential
   diagnosis; principal components analysis; Mahalanobis distance;
   discriminant analysis
ID CATARACT-SURGERY; IDENTIFICATION; BOVINE; LENS; CELLS
AB We developed a diagnostic tool to differentiate between endophthalmitis and uveitis using Raman spectroscopy. Twenty-two New Zealand rabbits with endophthalmitis induced by Staphylococcus aureus (10 animals), noninfectious uveitis induced by lipopolysaccharide from Escherichia colt (10 animals) and controls (two animals) were analyzed. Twenty-four hours after the eyes were inoculated, iris tissue was dissected and subjected to dispersive Raman spectroscopy using an excitation source at 830 nm and a spectrograph/CCD camera to detect a Raman signal with an integration time of 50 s. With the collected spectra of endophthalmitis and uveitis, we developed a routine to classify spectra in each specimen using principal components analysis, using a leave-one-out cross-validation procedure. The mean Raman spectra of tissues with uveitis and endophthalmitis showed several bands in the region of 800-1800 cm(-1), which have been attributed to nucleic acids, amino acids, proteins, and lipids. The bands at 1004, 1339, and 1555 cm(-1) differed significantly (t-test. p < 0.05) between diseases. The principal components PC3 and PC4 differed significantly (ANOVA, p < 0.05) for the two tissue types, indicating that these PCs can be used to discriminate between the two diseases using Mahalanobis distance as a discriminator. This technique is useful for differentiating the spectral bands of uveitis and endophthalmitis, and the diagnostic model showed sensitivity of 89%, specificity of 100%, and accuracy of 92% using the leave-one-out cross-validation procedure. These results may be clinically relevant for differentiating endophthalmitis from uveitis, and this approach may become a noninvasive method to optimize the diagnosis of inflammatory and infectious vitreoretinal diseases. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Rossi, Eglas Emanuel] Univ Comunitaria Reg Chapeco UNOCHAPECO, Hlth Sci Ctr CCS, BR-89809000 Chapeco, SC, Brazil.
   [Silveira, Landulfo, Jr.] Univ Camilo Castelo Branco UNICASTELO, Nucleo Parque Tecnol Sao Jose dos Campos, Ctr Biomed Engn, BR-12247004 Sao Jose Dos Campos, SP, Brazil.
   [Barbosa Pinheiro, Antonio Luiz] Univ Fed Bahia, Sch Dent, BR-40110150 Salvador, BA, Brazil.
   [Zamuner, Stella Regina] Nove Julho Univ UNINOVE, Rehabil Sci Masters Program, BR-05001100 Sao Paulo, Brazil.
   [Maia, Mauricio] Univ Fed Sao Paulo UNIFESP, Vitreoretinal Surg Unit, Dept Ophthalmol, BR-04023062 Sao Paulo, Brazil.
RP Silveira, L (corresponding author), Univ Camilo Castelo Branco UNICASTELO, Nucleo Parque Tecnol Sao Jose dos Campos, Ctr Biomed Engn, Km 138, BR-12247004 Sao Jose Dos Campos, SP, Brazil.
EM landulfo.silveira@unicastelo.br
RI Pacheco, Marcos TT/B-7991-2012; Zamuner, Stella R/C-3132-2012; Silveira,
   Landulfo/I-2474-2012; Pinheiro, Antonio Luiz B/A-1962-2008; Zamuner,
   Stella Regina/AAA-8106-2019; Maia, Mauricio/I-5892-2015; Aimbire,
   Flavio/E-6193-2012; Maia, Mauricio/Z-1042-2019
OI Pacheco, Marcos TT/0000-0002-1725-4803; Zamuner, Stella
   R/0000-0002-4694-7617; Silveira, Landulfo/0000-0002-6616-3334; Pinheiro,
   Antonio Luiz B/0000-0002-5805-0321; Maia, Mauricio/0000-0002-7034-8091;
   Aimbire, Flavio/0000-0002-4290-541X; Maia, Mauricio/0000-0002-7034-8091
FU CNPq (National Council for Scientific and Technological
   Development)National Council for Scientific and Technological
   Development (CNPq) [305610/2008-2, 302444/2005-0]
FX L Silveira Jr. and A. L B. Pinheiro thank CNPq (National Council for
   Scientific and Technological Development) for the Productivity
   Fellowships (305610/2008-2 and 302444/2005-0).
CR [Anonymous], 1995, Arch Ophthalmol, V113, P1479
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   CHIKISHEV AY, 1992, BIOPHYS J, V63, P976, DOI 10.1016/S0006-3495(92)81691-0
   Curnow SJ, 2006, CURR OPIN OPHTHALMOL, V17, P532, DOI 10.1097/ICU.0b013e32801094b5
   de Smet MD, 2001, PROG RETIN EYE RES, V20, P761, DOI 10.1016/S1350-9462(01)00011-8
   Duindam JJ, 1998, INVEST OPHTH VIS SCI, V39, P94
   Erckens RJ, 2001, LASER MED SCI, V16, P236, DOI 10.1007/PL00011360
   Glenn JV, 2007, FASEB J, V21, P3542, DOI 10.1096/fj.06-7896com
   Gosselin ME, 2007, EXP EYE RES, V84, P493, DOI 10.1016/j.exer.2006.11.002
   Hanlon EB, 2000, PHYS MED BIOL, V45, pR1, DOI 10.1088/0031-9155/45/2/201
   Harz M, 2005, ANALYST, V130, P1543, DOI 10.1039/b507715j
   Hosseini K, 2003, LASER SURG MED, V32, P265, DOI 10.1002/lsm.10168
   Howes E.L., 1988, INVEST OPHTH VIS SCI, V29, P4031
   HOWES EL, 1994, INVEST OPHTH VIS SCI, V35, P4031
   Jolliffe I., 2002, PRINCIPAL COMPONENT
   Kresloff MS, 1998, SURV OPHTHALMOL, V43, P193, DOI 10.1016/S0039-6257(98)00036-8
   Lazaro JC, 2009, SPECTROSC-INT J, V23, P71, DOI 10.1155/2009/764524
   Lin SY, 2007, MICROSC MICROANAL, V13, P128, DOI 10.1017/S143192760707002X
   Maia M, 2007, BRIT J OPHTHALMOL, V91, P1122, DOI 10.1136/bjo.2007.115386
   Mannie MD, 2005, J IMMUNOL METHODS, V297, P53, DOI 10.1016/j.jim.2004.11.020
   Mayer E, 2003, BRIT J OPHTHALMOL, V87, P867, DOI 10.1136/bjo.87.7.867
   Miller JJ, 2005, AM J OPHTHALMOL, V139, P983, DOI 10.1016/j.ajo.2005.01.025
   MIZUNO A, 1989, INVEST OPHTH VIS SCI, V30, P132
   MIZUNO A, 1990, EXP EYE RES, V50, P647, DOI 10.1016/0014-4835(90)90108-7
   Molckovsky A, 2003, GASTROINTEST ENDOSC, V57, P396, DOI 10.1067/mge.2003.105
   Moreira LM, 2008, SPECTROSC-INT J, V22, P1, DOI 10.3233/SPE-2008-0326
   Mulvaney SP, 2000, ANAL CHEM, V72, p145R, DOI 10.1021/a10000155
   NAFIE AL, 1997, ANNU REV PHYS CHEM, V86, P357
   Neelam K, 2005, INVEST OPHTH VIS SCI, V46, P1023, DOI 10.1167/iovs.04-1032
   Nogueira GV, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1908129
   OREFICE F, 2005, UVEITE CLIN CIRURGIC
   Pande J, 2002, EXP EYE RES, V75, P359, DOI 10.1006/exer.2002.2038
   PUPPELS GJ, 1991, BIOPHYS J, V60, P1046, DOI 10.1016/S0006-3495(91)82142-7
   Rosch P, 2005, APPL ENVIRON MICROB, V71, P1626, DOI 10.1128/AEM.71.3.1626-1637.2005
   Sato H, 1996, EXP EYE RES, V62, P47, DOI 10.1006/exer.1996.0006
   SCHACHAR RA, 1975, INVEST OPHTH VISUAL, V14, P380
   SEBAG J, 1994, INVEST OPHTH VIS SCI, V35, P2976
   Silveira L, 2002, LASER SURG MED, V30, P290, DOI 10.1002/lsm.10053
   Taban M, 2005, ARCH OPHTHALMOL-CHIC, V123, P613, DOI 10.1001/archopht.123.5.613
   WOLLMAN ST, 1993, APPL SPECTROSC, V47, P125, DOI 10.1366/0003702934048479
   YU NT, 1975, J BIOL CHEM, V250, P2196
   Zhao DY, 2003, ARCH OPHTHALMOL-CHIC, V121, P967, DOI 10.1001/archopht.121.7.967
NR 42
TC 8
Z9 8
U1 0
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2010
VL 91
IS 3
BP 362
EP 368
DI 10.1016/j.exer.2010.06.005
PG 7
WC Ophthalmology
SC Ophthalmology
GA 645XY
UT WOS:000281500700006
PM 20599971
DA 2020-12-15
ER

PT J
AU Torres, RJD
   Muccioli, C
   Maia, M
   Noronha, L
   Luchini, A
   Alessi, A
   Olandoski, M
   Farah, ME
   Precoma, DB
AF de Almeida Torres, Rogil Jose
   Muccioli, Cristina
   Maia, Mauricio
   Noronha, Lucia
   Luchini, Andrea
   Alessi, Alexandre
   Olandoski, Marcia
   Farah, Michel Eid
   Precoma, Dalton Bertolin
TI Sclerochorioretinal Abnormalities in Hypercholesterolemic Rabbits
   Treated With Rosiglitazone
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
AB BACKGROUND AND OBJECTIVE: To evaluate early retinal, choroidal, and scleral abnormalities induced by a hypercholesterolemic diet and the prevention of these abnormalities after oral administration of rosiglitazone in rabbits.
   MATERIALS AND METHODS: Fifty-four New Zealand rabbits were divided into four study groups: control group, normal diet; group 1, hypercholesterolemic diet; group 2, hypercholesterolemic diet associated with daily administration of 3 mg of rosiglitazone from day 14 after beginning the diet; and group 3, hypercholesterolemic diet associated with daily administration of 3 mg of rosiglitazone since the beginning of the experiment. Sclera and choroid underwent histologic and histomorphometric analyses. Retina underwent immunohistochemical analysis with anti-calretinin and anti-glial fibrillary acidic protein (GFAP) antibodies.
   RESULTS: No abnormalities were observed in the control group. Group 1 had significant increases in scleral and choroidal thicknesses compared with the control group (P < .01) and group 3 (P < .05). Group 1 presented significant increases in immunoreactivity (P < .001) to the anti-calretinin antibody compared with the other groups. Groups 2 and 3 had significant (P < .002) increases in calretinin immunoreactivity compared with the control group. GFAP was negative in all groups.
   CONCLUSION: The hypercholesterolemic diet induced early retinal, choroidal, and scleral abnormalities. Rosiglitazone preserved the structural anatomy.
C1 [de Almeida Torres, Rogil Jose] Univ Fed Sao Paulo, SP Hosp Angelina Caron, Dept Ophthalmol, Curitiba, PR, Brazil.
   [Muccioli, Cristina; Maia, Mauricio; Farah, Michel Eid] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Luchini, Andrea] Pontificia Univ Catolica Parana, Curitiba, PR, Brazil.
   [Luchini, Andrea] Ctr Oftalmol Curitiba, Curitiba, Parana, Brazil.
   [Alessi, Alexandre; Precoma, Dalton Bertolin] Pontificia Univ Catolica Parana, Dept Cardiol, Curitiba, PR, Brazil.
   [Olandoski, Marcia] Pontificia Univ Catolica Parana, Dept Stat, Curitiba, PR, Brazil.
RP Torres, RJD (corresponding author), Rua Emiliano Perneta,390-14 Andar, Curitiba, Parana, Brazil.
EM rjat@terra.com.br
RI Farah, Michel Eid E/F-3285-2012; Muccioli, Cristina/C-3419-2013;
   noronha, lucia/F-6339-2015; Maia, Mauricio/I-5892-2015; Maia,
   Mauricio/Z-1042-2019
OI Farah, Michel Eid E/0000-0001-5951-0193; noronha,
   lucia/0000-0003-0310-7164; Maia, Mauricio/0000-0002-7034-8091; Maia,
   Mauricio/0000-0002-7034-8091
CR Aljada A, 2001, J CLIN ENDOCR METAB, V86, P3250, DOI 10.1210/jc.86.7.3250
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Assmann G, 2003, ANNU REV MED, V54, P321, DOI 10.1146/annurev.med.54.101601.152409
   Billing-Marczak K, 1999, POL J PHARMACOL, V51, P173
   BROEKHUYSE RM, 1975, OPHTHALMOLOGICA, V171, P82, DOI 10.1159/000307448
   Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411
   Chinetti G, 2001, NAT MED, V7, P53
   Chiquette E, 2004, ARCH INTERN MED, V164, P2097, DOI 10.1001/archinte.164.19.2097
   COGAN DG, 1959, ARCH OPHTHALMOL-CHIC, V61, P219
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Torres RJD, 2009, ARQ BRAS OFTALMOL, V72, P68, DOI 10.1590/S0004-27492009000100014
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Han KH, 2000, J CLIN INVEST, V106, P793, DOI 10.1172/JCI10052
   Hu JR, 1996, BBA-MOL CELL RES, V1313, P239, DOI 10.1016/0167-4889(96)00095-X
   Jackson SM, 1999, ARTERIOSCL THROM VAS, V19, P2094, DOI 10.1161/01.ATV.19.9.2094
   Kurebayashi S, 2005, ATHEROSCLEROSIS, V182, P71, DOI 10.1016/j.atherosclerosis.2005.02.004
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Liu HR, 2004, CARDIOVASC RES, V62, P135, DOI 10.1016/j.cardiores.2003.12.027
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Pasceri V, 2000, CIRCULATION, V101, P235, DOI 10.1161/01.CIR.101.3.235
   Patel Chetan B, 2006, Diab Vasc Dis Res, V3, P65, DOI 10.3132/dvdr.2006.016
   Pershadsingh HA, 2004, EXPERT OPIN INV DRUG, V13, P215, DOI 10.1517/13543784.13.3.215
   Ramirez AI, 2006, EXP EYE RES, V83, P1423, DOI 10.1016/j.exer.2006.07.023
   Ramirez JM, 1996, VISION RES, V36, P2029, DOI 10.1016/0042-6989(95)00322-3
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Salazar JJ, 2007, EXP EYE RES, V84, P412, DOI 10.1016/j.exer.2006.10.012
   Seki N, 2005, ATHEROSCLEROSIS, V178, P1, DOI 10.1016/j.atherosclerosis.2004.08.015
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Sucher NJ, 1997, VISION RES, V37, P3483, DOI 10.1016/S0042-6989(97)00047-3
   Sun YP, 2000, P SOC EXP BIOL MED, V224, P166, DOI 10.1046/j.1525-1373.2000.22416.x
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tao L, 2003, CIRCULATION, V108, P2805, DOI 10.1161/01.CIR.0000097003.49585.5E
   Torres RJA, 2009, VISION PANAMERICA, V8, P152
   Trivino A, 2006, EXP EYE RES, V83, P357, DOI 10.1016/j.exer.2005.12.020
   Volgyi B, 1997, BRAIN RES, V763, P79, DOI 10.1016/S0006-8993(97)00405-8
   Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001
   Yucel I, 2005, VISION RES, V45, P1107, DOI 10.1016/j.visres.2004.11.018
NR 47
TC 6
Z9 6
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD SEP-OCT
PY 2010
VL 41
IS 5
BP 562
EP 571
DI 10.3928/15428877-20100726-05
PG 10
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA V24NK
UT WOS:000208416900012
PM 20795574
DA 2020-12-15
ER

PT J
AU Regatieri, CV
   Dreyfuss, JL
   Melo, GB
   Lavinsky, D
   Hossaka, SK
   Rodrigues, EB
   Farah, ME
   Maia, M
   Nader, HB
AF Regatieri, C. V.
   Dreyfuss, J. L.
   Melo, G. B.
   Lavinsky, D.
   Hossaka, S. K.
   Rodrigues, E. B.
   Farah, M. E.
   Maia, M.
   Nader, H. B.
TI Quantitative evaluation of experimental choroidal neovascularization by
   confocal scanning laser ophthalmoscopy. Fluorescein angiogram parallels
   heparan sulfate proteoglycan expression
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Choroidal neovascularization; Fluorescein angiogram; Proteoglycans;
   Angiogenesis; Confocal scanning laser ophthalmoscope
ID IN-VIVO; INFLAMMATION; PERLECAN; MODEL; AUTOFLUORESCENCE
AB The objective of the present study was to develop a quantitative method to evaluate laser-induced choroidal neovascularization (CNV) in a rat model using Heidelberg Retina Angiograph 2 (HRA2) imaging. The expression of two heparan sulfate proteoglycans (HSPG) related to inflammation and angiogenesis was also investigated. CNV lesions were induced with argon laser in 21 heterozygous Zucker rats and after three weeks a fluorescein angiogram and autofluorescence exams were performed using HRA2. The area and greatest linear dimension were measured by two observers not aware of the protocol. Bland-Altman plots showed agreement between the observers, suggesting that the technique was reproducible. After fluorescein angiogram, HSPG (perlecan and syndecan-4) were analyzed by real-time RT-PCR and immunohistochemistry. There was a significant increase in the expression of perlecan and syndecan-4 (P < 0.0001) in retinas bearing CNV lesions compared to control retinas. The expression of these two HSPG increased with increasing CNV area. Immunohistochemistry demonstrated that the rat retina damaged with laser shots presented increased expression of perlecan and syndecan-4. Moreover, we observed that the overexpression occurred in the outer layer of the retina, which is related to choroidal damage. It was possible to develop a standardized quantitative method to evaluate CNV in a rat model using HRA2. In addition, we presented data indicating that the expression of HSPG parallels the area of CNV lesion. The understanding of these events offers opportunities for studies of new therapeutic interventions targeting these HSPG.
C1 [Nader, H. B.] Univ Sao Paulo, Disciplina Biol Mol, Dept Bioquim, Rua Tres de Maio 100, BR-04044020 Sao Paulo, Brazil.
   [Regatieri, C. V.; Melo, G. B.; Lavinsky, D.; Hossaka, S. K.; Rodrigues, E. B.; Farah, M. E.; Maia, M.] Univ Sao Paulo, Dept Oftalmol, BR-04044020 Sao Paulo, Brazil.
RP Nader, HB (corresponding author), Univ Sao Paulo, Disciplina Biol Mol, Dept Bioquim, Rua Tres de Maio 100, BR-04044020 Sao Paulo, Brazil.
EM hbnader.bioq@epm.br
RI Nader, Helena B/D-9253-2012; Melo, Gustavo/AAD-3844-2019; Lavinsky,
   Daniel/E-9524-2013; Dreyfuss, Juliana L. L/H-8660-2012; Regatieri,
   Caio/G-8152-2014; Maia, Mauricio/I-5892-2015; Farah, Michel Eid
   E/F-3285-2012
OI Melo, Gustavo/0000-0001-5765-2008; Dreyfuss, Juliana L.
   L/0000-0002-9825-1072; Regatieri, Caio/0000-0003-1511-8696; Maia,
   Mauricio/0000-0002-7034-8091; Farah, Michel Eid E/0000-0001-5951-0193;
   NADER, HELENA/0000-0002-7569-2166; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES
FX Research supported by FAPESP, CNPq, and CAPES.
CR Alexopoulou AN, 2007, INT J BIOCHEM CELL B, V39, P505, DOI 10.1016/j.biocel.2006.10.014
   Altman D., 1990, PRACTICAL STAT MED R
   Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228
   Beauvais DeannaLee M, 2004, Reprod Biol Endocrinol, V2, P3, DOI 10.1186/1477-7827-2-3
   Bix G, 2008, MICROSC RES TECHNIQ, V71, P339, DOI 10.1002/jemt.20562
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bui TV, 2006, J BIOL CHEM, V281, P18112, DOI 10.1074/jbc.M601380200
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Celie JWAM, 2009, FRONT BIOSCI-LANDMRK, V14, P4932, DOI 10.2741/3578
   Cordeiro MF, 2004, P NATL ACAD SCI USA, V101, P13352, DOI 10.1073/pnas.0405479101
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dolar-Szczasny Joanna, 2005, Klin Oczna, V107, P544
   Dreyfuss JL, 2009, AN ACAD BRAS CIENC, V81, P409, DOI 10.1590/S0001-37652009000300007
   Falkenstein IA, 2008, CURR EYE RES, V33, P599, DOI 10.1080/02713680802226582
   Gallagher JT, 2006, BIOCHEM SOC T, V34, P438, DOI 10.1042/BST0340438
   Goldenberg-Cohen N, 2008, EXP EYE RES, V87, P327, DOI 10.1016/j.exer.2008.06.014
   Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI200113738
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Jiang XN, 2003, J HISTOCHEM CYTOCHEM, V51, P1393, DOI 10.1177/002215540305101101
   Julien S, 2008, MOL VIS, V14, P1358
   Knox SM, 2006, CELL MOL LIFE SCI, V63, P2435, DOI 10.1007/s00018-006-6162-z
   Kohri T, 2003, GRAEF ARCH CLIN EXP, V241, P943, DOI 10.1007/s00417-003-0761-2
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Murata H, 2008, INVEST OPHTH VIS SCI, V49, P5546, DOI 10.1167/iovs.07-1211
   Nader HB, 1999, BRAZ J MED BIOL RES, V32, P529, DOI 10.1590/S0100-879X1999000500005
   Ng YS, 2006, EXP CELL RES, V312, P527, DOI 10.1016/j.yexcr.2005.11.008
   Nunes SS, 2008, J CELL PHYSIOL, V214, P828, DOI 10.1002/jcp.21281
   Paques M, 2006, VISION RES, V46, P1336, DOI 10.1016/j.visres.2005.09.037
   Qiu G, 2006, EXP EYE RES, V83, P141, DOI 10.1016/j.exer.2005.11.014
   Regatieri CV, 2009, INVEST OPHTH VIS SCI, V50, P5487, DOI 10.1167/iovs.08-3171
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   RYAN SJ, 1980, A GRAEF ARCH KLIN EX, V215, P21, DOI 10.1007/BF00413393
   Sampaio L., 2006, INSIGHTS CARBOHYDRAT, P12
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   TEETERS VW, 1973, AM J OPHTHALMOL, V76, P1
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wang YS, 2005, CURR EYE RES, V30, P479, DOI 10.1080/02713680590959358
   Xu HP, 2008, EXP EYE RES, V87, P319, DOI 10.1016/j.exer.2008.06.012
NR 40
TC 3
Z9 3
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JUL
PY 2010
VL 43
IS 7
BP 627
EP 633
DI 10.1590/S0100-879X2010007500043
PG 7
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 624VW
UT WOS:000279851100004
PM 20464343
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Wu, L
   Arevalo, JF
   Berrocal, MH
   Maia, M
   Roca, JA
   Morales-Canton, V
   Alezzandrini, AA
   Diaz-Llopis, MJ
AF Wu, Lihteh
   Arevalo, J. Fernando
   Berrocal, Maria H.
   Maia, Mauricio
   Roca, Jose A.
   Morales-Canton, Virgilio
   Alezzandrini, Arturo A.
   Diaz-Llopis, Manuel J.
TI COMPARISON OF TWO DOSES OF INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT
   FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION Results of
   the Pan American Collaborative Retina Study Group at 24 Months
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; intravitreal injection; macular edema; retinal vein
   occlusion; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; COHERENCE TOMOGRAPHY FINDINGS; VISUAL-ACUITY;
   AVASTIN; RANIBIZUMAB; NEOVASCULARIZATION; INJECTION; VEGF; EXPRESSION;
   ISCHEMIA
AB Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity after injecting 1.25 mg or 2.5 mg bevacizumab as needed in patients with primary macular edema secondary to central retinal vein occlusion.
   Methods: This is an interventional, retrospective, comparative multicenter study of 86 eyes with macular edema secondary to central retinal vein occlusion that were treated primarily with intravitreal bevacizumab (44 eyes, 1.25 mg; 42 eyes, 2.5 mg). The main outcome measures were the CMT and the change of best-corrected visual acuity at 24 months.
   Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye were 7.2 for the 1.25-mg dose group and 8.1 for the 2.5-mg dose group (P = 0.4492). At 24 months, in the 1.25-mg dose group, the logarithm of the minimal angle of resolution best-corrected visual acuity improved from baseline 0.35 +/- 6 0.57 units (P < 0.0001) versus 0.27 +/- 0.68 units for the 2.5-mg dose group (P < 0.0001). These differences were not statistically significant between both dose groups. In the 1.25-mg dose group, 25 (56.8%) eyes gained >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 6 (13.6%) lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg dose group, 24 (57.1 %) eyes improved >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 7 (16.7%) lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg dose group improved from 635 +/- 324 mu m to 264 +/- 160 mu m (P < 0.0001) versus 528 +/- mu m to 293 +/- 137 mu m in the 2.5-mg dose group (P < 0.0001). There was no statistically significant difference between both dose groups with regard to the CMT reduction.
   Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving visual acuity and reducing CMT in macular edema secondary to central retinal vein occlusion. There were no statistically significant differences between the two dose groups with regard to the number of injections, CMT, and change in visual acuity. RETINA 30:1002-1011, 2010
C1 [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Arevalo, J. Fernando] Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Caracas, Venezuela.
   [Berrocal, Maria H.] Univ Puerto Rico, Dept Ophthalmol, San Juan, PR 00936 USA.
   [Maia, Mauricio] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Roca, Jose A.] Clin Ricardo Palma, Lima, Peru.
   [Morales-Canton, Virgilio] Hosp Luis Sanchez Bulnes, Asociac Para Evitar La Ceguera, Mexico City, DF, Mexico.
   [Alezzandrini, Arturo A.] Univ Buenos Aires, Inst Oftalm Alta Complejidad, Buenos Aires, DF, Argentina.
   [Diaz-Llopis, Manuel J.] Inst Oftalmol Valencia, Valencia, Spain.
RP Wu, L (corresponding author), Apdo 144-1225 Plaza Mayor, San Jose, Costa Rica.
EM LW65@cornell.edu
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; Fromow-Guerra,
   J. Jans/A-3346-2015
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Fromow-Guerra, J. Jans/0000-0001-5335-1275
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Beutel Julia, 2010, International Ophthalmology, V30, P15, DOI 10.1007/s10792-008-9282-7
   Boyd SR, 2002, ARCH OPHTHALMOL-CHIC, V120, P1644
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Byeon SH, 2007, J OCUL PHARMACOL TH, V23, P387, DOI 10.1089/jop.2007.0012
   Campochiaro PA, 2008, MOL THER, V16, P791, DOI 10.1038/mt.2008.10
   Christoffersen NLB, 1999, OPHTHALMOLOGY, V106, P2054, DOI 10.1016/S0161-6420(99)90483-9
   Clarkson JC, 1997, ARCH OPHTHALMOL-CHIC, V115, P486
   CLARKSON JG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1087
   Costa RA, 2007, RETINA-J RET VIT DIS, V27, P141, DOI 10.1097/IAE.0b013e31802eff83
   Ferrara DC, 2007, AM J OPHTHALMOL, V144, P864, DOI 10.1016/j.ajo.2007.07.038
   Funk M, 2009, INVEST OPHTH VIS SCI, V50, P1025, DOI 10.1167/iovs.08-2510
   Hayreh Sohan Singh, 1994, Indian Journal of Ophthalmology, V42, P109
   HAYREH SS, 1990, GRAEF ARCH CLIN EXP, V228, P201, DOI 10.1007/BF00920022
   Hayreh SS, 2005, PROG RETIN EYE RES, V24, P493, DOI 10.1016/j.preteyeres.2004.12.001
   Hoeh AE, 2009, GRAEF ARCH CLIN EXP, V247, P1635, DOI 10.1007/s00417-009-1151-1
   Hofman P, 2001, ARCH OPHTHALMOL-CHIC, V119, P861
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hsu J, 2007, RETINA-J RET VIT DIS, V27, P1013, DOI 10.1097/IAE.0b013e318050ca7c
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Jaissle GB, 2006, OPHTHALMOLOGE, V103, P471, DOI 10.1007/s00347-006-1355-2
   Julien S, 2008, BRIT J OPHTHALMOL, V92, P1424, DOI 10.1136/bjo.2008.141317
   Kriechbaum K, 2008, BRIT J OPHTHALMOL, V92, P518, DOI 10.1136/bjo.2007.127282
   Lin TH, 2005, SCAND CARDIOVASC J, V39, P353, DOI 10.1080/14017430500234258
   Matsumoto Y, 2007, RETINA-J RET VIT DIS, V27, P426, DOI 10.1097/IAE.0b013e31804a7af2
   Mohamed Q, 2007, OPHTHALMOLOGY, V114, P507, DOI 10.1016/j.ophtha.2006.11.011
   Moschos MM, 2008, DOC OPHTHALMOL, V116, P147, DOI 10.1007/s10633-007-9110-9
   Noma H, 2009, OPHTHALMOLOGY, V116, P87, DOI 10.1016/j.ophtha.2008.09.034
   Ota M, 2008, RETINA-J RET VIT DIS, V28, P1502, DOI 10.1097/IAE.0b013e3181840b3c
   Pai SA, 2007, AM J OPHTHALMOL, V143, P601, DOI 10.1016/j.ajo.2006.12.037
   Pe'er J, 1998, OPHTHALMOLOGY, V105, P412, DOI 10.1016/S0161-6420(98)93020-2
   PEER J, 1995, LAB INVEST, V72, P638
   Pieramici Dante J, 2008, Ophthalmology, V115, pe47, DOI 10.1016/j.ophtha.2008.06.021
   Prager F, 2009, BRIT J OPHTHALMOL, V93, P452, DOI 10.1136/bjo.2008.141085
   Priglinger SG, 2007, RETINA-J RET VIT DIS, V27, P1004, DOI 10.1097/IAE.0b013e3180ed458d
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rensch F, 2009, OPHTHALMOLOGICA, V223, P124, DOI 10.1159/000183844
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schaal KB, 2007, OPHTHALMOLOGE, V104, P285, DOI 10.1007/s00347-007-1509-x
   Schultz A, 1999, CIRCULATION, V100, P547, DOI 10.1161/01.CIR.100.5.547
   Shetty R, 2008, DOC OPHTHALMOL, V116, P129, DOI 10.1007/s10633-007-9090-9
   Shima DT, 1996, INVEST OPHTH VIS SCI, V37, P1334
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P298, DOI 10.1016/j.ajo.2008.08.016
   Spandau UHM, 2006, ACTA OPHTHALMOL SCAN, V84, P555, DOI 10.1111/j.1600-0420.2006.00740.x
   Stahl A, 2007, GRAEF ARCH CLIN EXP, V245, P1429, DOI 10.1007/s00417-007-0569-6
   Takahashi K, 1998, AM J OPHTHALMOL, V126, P91, DOI 10.1016/S0002-9394(98)00069-5
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Wroblewski JJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P374, DOI 10.1001/archophthalmol.2009.14
NR 55
TC 32
Z9 33
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2010
VL 30
IS 7
BP 1002
EP 1011
DI 10.1097/IAE.0b013e3181cea68d
PG 10
WC Ophthalmology
SC Ophthalmology
GA 622CE
UT WOS:000279635600002
PM 20616679
DA 2020-12-15
ER

PT J
AU Mello, PAD
   Maia, M
   Rodrigues, EB
   Farah, ME
AF de Arruda Mello Filho, Paulo Augusto
   Maia, Mauricio
   Rodrigues, Eduardo Buchelle
   Farah, Michel Eid
TI Ocular pharmacology in the treatment of vitreous, retina and choroid
   diseases
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA Portuguese
DT Article
DE Eye diseases/drug therapy; Retinal diseases/drug therapy; Choroidal
   diseases/drug therapy; Drug delivery systems; Vitrectomy; Coloring
   agents
ID TRANSSCLERAL DRUG-DELIVERY; CYTOMEGALOVIRUS RETINITIS; INTRAVITREOUS
   INJECTION; MACULAR DEGENERATION; INDOCYANINE GREEN; SEVERE UVEITIS;
   IMPLANT; DEXAMETHASONE; GANCICLOVIR; RABBITS
AB Retinal diseases are frequently causes of impaired visual acuity and blindness. Recent progress in ocular pharmacology leads to the development of new promising drugs and better functional outcomes. Drug delivery and local management of diseases affecting the choroid and retina should enable better a natomical and functional outcomes. An overview of ocular pharmacology, emerging drug technologies and drug delivery is provided. Some relevant clinical features are discussed.
C1 [Farah, Michel Eid] Univ Fed Sao Paulo, UNIFESP, Dept Oftalmol, Sao Paulo, Brazil.
RP Mello, PAD (corresponding author), Av Pompeia 2-348, BR-05022001 Sao Paulo, Brazil.
EM paulomelloretina@yahoo.com
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Buchele Rodrigues, Eduardo/0000-0002-4224-0921
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   AKULA SK, 1994, BRIT J OPHTHALMOL, V78, P677, DOI 10.1136/bjo.78.9.677
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   Ambati J, 2002, PROG RETIN EYE RES, V21, P145, DOI 10.1016/S1350-9462(01)00018-0
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2006, NEW ENGL J MED, V355, P1493
   Brown DM, 2006, NEW ENGL J MED, V355, P1409
   COCHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348
   Dib E, 2008, INVEST OPHTH VIS SCI, V49, P1097, DOI 10.1167/iovs.07-1225
   FORRESTER D, 2002, EYE BASIC SCI PRACTI, P143
   Geroski DH, 2001, ADV DRUG DELIVER REV, V52, P37, DOI 10.1016/S0169-409X(01)00193-4
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P421, DOI 10.1016/j.ajo.2004.10.005
   HOLEKAMP NM, 2005, AM J OPHTHALMOL, V139, P533
   Jaffe GJ, 2000, RETINA-J RET VIT DIS, V20, P402, DOI 10.1097/00006982-200004000-00015
   Jaffe GJ, 2000, OPHTHALMOLOGY, V107, P2024, DOI 10.1016/S0161-6420(00)00466-8
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kato A, 2004, INVEST OPHTH VIS SCI, V45, P238, DOI 10.1167/iovs.02-1258
   KELLER N, 1993, INVEST OPHTH VIS SCI, V34, P1490
   Kompella UB, 2003, INVEST OPHTH VIS SCI, V44, P1192, DOI 10.1167/iovs.02-0791
   Le Bourlais C, 1998, PROG RETIN EYE RES, V17, P33, DOI 10.1016/S1350-9462(97)00002-5
   LIMA AAS, 2008, SERIE BRASILEIRA OFT, P627
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Mello PAA, 2009, OPHTHAL SURG LAS IM, V40, P160, DOI 10.3928/15428877-20090301-17
   MORITERA T, 1991, INVEST OPHTH VIS SCI, V32, P1785
   Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203
   Okabe J, 2003, INVEST OPHTH VIS SCI, V44, P740, DOI 10.1167/iovs.02-0375
   Penha FM, 2008, J OCUL PHARMACOL TH, V24, P52, DOI 10.1089/jop.2007.0047
   PEYMAN GA, 1995, ADV DRUG DELIVER REV, V16, P107, DOI 10.1016/0169-409X(95)00018-3
   PEYMAN GA, 1988, INT OPHTHALMOL, V12, P175, DOI 10.1007/BF00130002
   PEYMAN GA, 1974, ARCH OPHTHALMOL-CHIC, V91, P416, DOI 10.1001/archopht.1974.03900060428017
   Rodrigues Eduardo B, 2008, Dev Ophthalmol, V42, P29, DOI 10.1159/000138911
   Rodrigues EB, 2009, PROG RETIN EYE RES, V28, P117, DOI 10.1016/j.preteyeres.2008.11.005
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   Rosenfeld PJ, 2007, NEW ENGL J MED, V356, P749
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROSENFELD PJ, 2005, OPHTHAL SURG LAS IM, V36, P270
   Rudnick DE, 1999, INVEST OPHTH VIS SCI, V40, P3054
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   Warren KA, 2008, RETINA-J RET VIT DIS, V28, P1427, DOI 10.1097/IAE.0b013e31817e7ead
   Weijtens O, 2000, OPHTHALMOLOGY, V107, P1932, DOI 10.1016/S0161-6420(00)00344-4
   Yalvac IS, 2003, J CATARACT REFR SURG, V29, P487, DOI 10.1016/S0886-3350(02)01538-9
NR 44
TC 1
Z9 3
U1 1
U2 6
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAY-JUN
PY 2010
VL 73
IS 3
BP 294
EP 299
DI 10.1590/S0004-27492010000300018
PG 6
WC Ophthalmology
SC Ophthalmology
GA 642DF
UT WOS:000281183100018
PM 20730292
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Sanchez, JG
   Wu, L
   Berrocal, MH
   Alezzandrini, AA
   Restrepo, N
   Maia, M
   Farah, ME
   Diaz-Llopis, M
AF Arevalo, J. F.
   Sanchez, J. G.
   Wu, L.
   Berrocal, M. H.
   Alezzandrini, A. A.
   Restrepo, N.
   Maia, M.
   Farah, M. E.
   Diaz-Llopis, M.
CA Pan-Amer Collaborative Retina
TI Comparison of 2 Doses of Primary Intravitreal Bevacizumab for Subfoveal
   CNV in AMD at 24 Months: Results From the Pan-American Collaborative
   Retina Study Group
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
DE age-related macular degeneration; clinical (human) or epidemiologic
   studies: outcomes/complications; neovascularization
C1 [Arevalo, J. F.; Pan-Amer Collaborative Retina] Clin Oftal Ctr Caracas, Retina & Vitreous, Caracas, Venezuela.
   [Sanchez, J. G.; Restrepo, N.] INIO, Retina & Vitreous, Medellin, Colombia.
   [Wu, L.] Inst Cirugia Ocular, Retina & Vitreous, San Jose, Costa Rica.
   [Berrocal, M. H.] Univ Puerto Rico, Ophthalmol, San Juan, PR 00936 USA.
   [Alezzandrini, A. A.] Univ Buenos Aires, Fac Med, OFTALMOS, Buenos Aires, DF, Argentina.
   [Maia, M.; Farah, M. E.] Univ Fed Sao Paulo, Inst Visao, Dept Oftalmol, Sao Paulo, Brazil.
   [Diaz-Llopis, M.] Gen Univ Valencia, Hosp La Fe, Ophthalmol, Valencia, Spain.
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193
FU Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas,
   Venezuela
FX The Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas,
   Venezuela.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 13
MA 1250
PG 3
WC Ophthalmology
SC Ophthalmology
GA VF2UF
UT WOS:000442387302272
DA 2020-12-15
ER

PT J
AU Dib, E
   Maia, M
   Costa, ED
   Filho, MNM
   Barros, N
   Haapalainen, EF
   Sinigaglia-Coimbra, R
   Penha, FM
   Furlani, BA
   Farah, ME
AF Dib, E.
   Maia, M.
   Costa, E. d. F.
   Filho, M. N. M.
   Barros, N.
   Haapalainen, E. F.
   Sinigaglia-Coimbra, R.
   Penha, F. M.
   Furlani, B. A.
   Farah, M. E.
TI In vitro and in vivo Toxicity of Sunitinib Maleate
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
DE retina; drug toxicity/drug effects; neovascularization
C1 [Dib, E.; Maia, M.; Costa, E. d. F.; Filho, M. N. M.; Penha, F. M.; Furlani, B. A.; Farah, M. E.] Univ Fed Sao Paulo, Ophthalmol, Sao Paulo, Brazil.
   [Filho, M. N. M.] Univ Fed Sao Paulo, Biophys, Sao Paulo, Brazil.
   [Haapalainen, E. F.; Sinigaglia-Coimbra, R.] Univ Fed Sao Paulo, Elect Microscopy Sect, Sao Paulo, Brazil.
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 13
MA 2817
PG 3
WC Ophthalmology
SC Ophthalmology
GA VF2UF
UT WOS:000442387306028
DA 2020-12-15
ER

PT J
AU Furlani, BA
   Costa, EF
   Maia, M
   Penha, FM
   Rodrigues, EB
   Farah, ME
AF Furlani, B. A.
   Costa, E. F.
   Maia, M.
   Penha, F. M.
   Rodrigues, E. B.
   Farah, M. E.
TI Influences of Osmolality and Ph in Solution-Related EPR Cell Toxicity:
   An in vitro Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
DE retinal pigment epithelium; pH; drug toxicity/drug effects
C1 [Furlani, B. A.; Costa, E. F.; Maia, M.; Penha, F. M.; Rodrigues, E. B.; Farah, M. E.] Univ Fed Sao Paulo, Ophthalmol, Sao Paulo, Brazil.
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091
FU FAPESP :: - Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX Support FAPESP :: - Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 13
MA 3314
PG 2
WC Ophthalmology
SC Ophthalmology
GA VF2UT
UT WOS:000442393600014
DA 2020-12-15
ER

PT J
AU Guerra, TB
   Dib, E
   Rodrigues, EB
   Penha, FM
   Lima, AS
   Magalhaes, O
   Maia, M
   Maugeri, IL
   Farah, ME
AF Guerra, T. B.
   Dib, E.
   Rodrigues, E. B.
   Penha, F. M.
   Lima, A. S.
   Magalhaes, O., Jr.
   Maia, M.
   Longo Maugeri, I.
   Farah, M. E.
TI Viability and Sterility of Bevacizumab in Different Vials and
   Temperature Alone and Associated With Triancinolone
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
DE pH; retina; age-related macular degeneration
C1 [Guerra, T. B.; Dib, E.; Lima, A. S.; Magalhaes, O., Jr.; Maia, M.; Longo Maugeri, I.; Farah, M. E.] Univ Fed Sao Paulo, Ophthalmol, Sao Paulo, Brazil.
   [Rodrigues, E. B.; Penha, F. M.] Vis Inst, Ophthalmol, Florianopolis, SC, Brazil.
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Alves de Souza Lima Filho,
   Acacio/0000-0003-1802-9592
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 13
MA 2815
PG 3
WC Ophthalmology
SC Ophthalmology
GA VF2UF
UT WOS:000442387306026
DA 2020-12-15
ER

PT J
AU Machado, LM
   Magalhaes, O
   Rodrigues, EB
   Maia, M
   Farah, ME
   Molon, L
   Oliveira, D
   Ismail, KAR
AF Machado, L. M.
   Magalhaes, O., Jr.
   Rodrigues, E. B.
   Maia, M.
   Farah, M. E.
   Molon, L.
   Oliveira, D.
   Ismail, K. A. R.
TI Comparison of 20-, 23-and 25-Gauge Cannulas Air Infusion Forces
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
DE vitreoretinal surgery; retinal detachment
C1 [Machado, L. M.; Magalhaes, O., Jr.; Rodrigues, E. B.; Maia, M.; Farah, M. E.] Fed Univ Sao Paulo UNIFESP EPM, Ophthalmol, Sao Paulo, Brazil.
   [Molon, L.; Oliveira, D.; Ismail, K. A. R.] State Univ Campinas UNICAMP, Mech Engn, Campinas, SP, Brazil.
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 13
MA 3601
PG 2
WC Ophthalmology
SC Ophthalmology
GA VF2UT
UT WOS:000442393600294
DA 2020-12-15
ER

PT J
AU Maia, M
   Penha, FM
   Wu, L
   Arevalo, JF
   Cardillo, JA
   Farah, ME
   Rodriguez, FJ
   Berrocal, MH
   Furtado, WC
AF Maia, M.
   Penha, F. M.
   Wu, L.
   Arevalo, J. F.
   Cardillo, J. A.
   Farah, M. E.
   Rodriguez, F. J.
   Berrocal, M. H.
   Furtado, W. C.
CA Pan-Amer Collaborative Retina
TI Comparison of a Single Intravitreal Injection of Bevacizumab versus
   Triamcinolone Acetonide as Primary Treatment for Diffuse Diabetic
   Macular Edema: The Pan-American Collaborative Retina Study Group
   (PACORES)
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
DE diabetic retinopathy; retina
C1 [Maia, M.; Penha, F. M.; Cardillo, J. A.; Farah, M. E.; Furtado, W. C.; Pan-Amer Collaborative Retina] Univ Fed Sao Paulo, Ophthalmol, Sao Paulo, Brazil.
   [Wu, L.] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Arevalo, J. F.] Clin Oftalmol Ctr Caracas, Caracas, Venezuela.
   [Rodriguez, F. J.] Fdn Oftalmol Nacl, Bogota, Colombia.
   [Berrocal, M. H.] Univ Puerto Rico, Ophthalmol, Santurce, PR USA.
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091
FU Pan-American Collaborative Retina Study Group (PACORES); Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP)
FX The Pan-American Collaborative Retina Study Group (PACORES) and Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 13
MA 4225
PG 3
WC Ophthalmology
SC Ophthalmology
GA VF2UT
UT WOS:000442393602151
DA 2020-12-15
ER

PT J
AU Penha, FM
   Rodrigues, EB
   Costa, EPF
   Dib, E
   Maia, M
   Lima, AA
   Farah, ME
AF Penha, F. M.
   Rodrigues, E. B.
   Costa, E. P. F.
   Dib, E.
   Maia, M.
   Lima Filho, A. A., Sr.
   Farah, M. E.
TI Biochemical Analysis of Indocyanine Green Ph, Anions, Osmolarity,
   Preciptation and Decomposition Products: In Relation to Solvents, Dye
   Concentration and Light Exposure
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
DE pH; retina; vitreoretinal surgery
C1 [Penha, F. M.; Costa, E. P. F.; Dib, E.; Maia, M.; Lima Filho, A. A., Sr.; Farah, M. E.] Univ Fed Sao Paulo, Ophthalmol, Florianopolis, SC, Brazil.
   [Rodrigues, E. B.] Vis Inst, Ophthalmol, Florianopolis, SC, Brazil.
RI de Souza Lima Filho, Acacio Alves/C-7189-2012; Farah, Michel Eid
   E/F-3285-2012; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX Support Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 13
MA 3598
PG 2
WC Ophthalmology
SC Ophthalmology
GA VF2UT
UT WOS:000442393600291
DA 2020-12-15
ER

PT J
AU Restrepo, N
   Wu, L
   Sanchez, JG
   Maia, M
   Saravia, MJ
   Arevalo, J
AF Restrepo, N.
   Wu, L.
   Sanchez, J. G.
   Maia, M.
   Saravia, M. J.
   Arevalo, J.
CA Pan-Amer Collaborative Retina
TI Comparison of 2 Doses of Intravitreal Bevacizumab (Avastin) for
   Proliferative Diabetic Retinopathy: Results From the Pan-American
   Collaborative Retina Study Group (PACORES) at 24-Month Follow-Up
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
DE diabetic retinopathy; retinal neovascularization; vascular endothelial
   growth factor
C1 [Restrepo, N.; Sanchez, J. G.; Pan-Amer Collaborative Retina] Inst Nacl Invest Oftalmol, Retina, Medellin, Colombia.
   [Wu, L.] Inst Cirugia Ocular, Vitreoretinal, San Jose, Costa Rica.
   [Maia, M.] Univ Fed Sao Paulo, Retina, Inst Visao, Sao Paulo, Brazil.
   [Saravia, M. J.] Hosp Austral, Ophthalmol Retina, Buenos Aires, DF, Argentina.
   [Arevalo, J.] Clin Oftal Ctr Caracas, Retina & Vitreous, Caracas, Venezuela.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
FU Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas,
   Venezuela
FX Support in part by the Arevalo-Coutinho Foundation for Research in
   Ophthalmology, Caracas, Venezuela
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 13
MA 4233
PG 3
WC Ophthalmology
SC Ophthalmology
GA VF2UT
UT WOS:000442393602159
DA 2020-12-15
ER

PT J
AU Rodrigues, EB
   Magalhaes, O
   Penha, FM
   Dib, E
   Maia, M
   Abechain, J
   Stefano, V
   Farah, ME
AF Rodrigues, E. B.
   Magalhaes, O., Jr.
   Penha, F. M.
   Dib, E.
   Maia, M.
   Abechain, J.
   Stefano, V.
   Farah, M. E.
TI Investigation on the Techniques, Syringes and Needles Used in
   Intravitreal Injections
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
DE age-related macular degeneration; vitreoretinal surgery; injection
C1 [Rodrigues, E. B.; Magalhaes, O., Jr.; Penha, F. M.; Dib, E.; Maia, M.; Abechain, J.; Stefano, V.; Farah, M. E.] Vis Inst, Ophthalmol, Florianopolis, SC, Brazil.
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 13
MA 5131
PG 2
WC Ophthalmology
SC Ophthalmology
GA VF2UT
UT WOS:000442393604172
DA 2020-12-15
ER

PT J
AU Saldarriaga, L
   Arevalo, J
   Sanchez, JG
   Berrocal, MH
   Fromow-Guerra, JJ
   Wu, L
   Maia, M
   Saravia, MJ
   Bareno, J
AF Saldarriaga, L.
   Arevalo, J.
   Sanchez, J. G.
   Berrocal, M. H.
   Fromow-Guerra, J. J.
   Wu, L.
   Maia, M.
   Saravia, M. J.
   Bareno, J.
CA Pan-Amer Collaborative Retina
TI Risk Factors for the Development or Progression of Tractional Retinal
   Detachment (TRD) After Intravitreal Bevacizumab (Avastin) Used as an
   Adjuvant to Vitrectomy for the Management of Severe Proliferative
   Diabetic Retinopathy (PDR)
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
DE diabetic retinopathy; retinal detachment; vascular endothelial growth
   factor
C1 [Saldarriaga, L.; Sanchez, J. G.] INIO, Retina & Vitreous Svc, Medellin, Colombia.
   [Arevalo, J.] Clin Oftal Ctr Caracas, Retina & Vitreous, Caracas, Venezuela.
   [Berrocal, M. H.] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Fromow-Guerra, J. J.] Assoc Evitar Ceguera, Retina, Mexico City, DF, Mexico.
   [Wu, L.] Inst Cirugia Ocular, Vitreoretinal, San Jose, Costa Rica.
   [Maia, M.] Univ Fed Sao Paulo, Retina & Vitreous Svc, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Saravia, M. J.] Hosp Austral, Ophthalmol Retina, Buenos Aires, DF, Argentina.
   [Bareno, J.] INTO, Epidemiol, Medellin, Colombia.
   [Pan-Amer Collaborative Retina] INTO, Medellin, Colombia.
RI Maia, Mauricio/I-5892-2015; Fromow-Guerra, J. Jans/A-3346-2015; bareno,
   jose/ABE-2435-2020
OI Maia, Mauricio/0000-0002-7034-8091; Fromow-Guerra, J.
   Jans/0000-0001-5335-1275; 
FU Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas,
   Venezuela
FX Support in part by the Arevalo-Coutinho Foundation for Research in
   Ophthalmology, Caracas, Venezuela.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 13
MA 4239
PG 3
WC Ophthalmology
SC Ophthalmology
GA VF2UT
UT WOS:000442393602165
DA 2020-12-15
ER

PT J
AU Torres, RJ
   Muccioli, C
   Maia, M
   Noronha, L
   Precoma, D
   Luchini, A
   Torres, LAA
   Torres, CLA
   Torres, RRA
   Torres, RAA
AF Torres, R. J.
   Muccioli, C.
   Maia, M.
   Noronha, L.
   Precoma, D.
   Luchini, A.
   Torres, L. A. A.
   Torres, C. L. A.
   Torres, R. R. A.
   Torres, R. A. A.
TI Decrease of the Immunohistochemical Expression of Calcium Binding
   Protein (Calretinin) in the Retina of Hypercholesterolemic Rabbits
   Treated With Roziglitazone
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
DE calcium; retina; drug toxicity/drug effects
C1 [Torres, R. J.; Muccioli, C.; Maia, M.] Univ Fed Sao Paulo, Retina Vitreous, Curitiba, Parana, Brazil.
   [Noronha, L.] Pontificia Univ Catolica Parana, Retina Vitreous, Pathol, Curitiba, Parana, Brazil.
   [Precoma, D.] Pontificia Univ Catolica Parana, Cardiol, Curitiba, Parana, Brazil.
   [Luchini, A.] Ctr Oftalmol Curitiba, Retina Vitreous, Pathol, Curitiba, Parana, Brazil.
   [Torres, L. A. A.; Torres, C. L. A.] Univ Positivo, Curitiba, Parana, Brazil.
   [Torres, R. R. A.] Pontificia Univ Catolica Parana, Curitiba, Parana, Brazil.
   [Torres, R. A. A.] Ctr Oftalmol Curitiba, Curitiba, Parana, Brazil.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 13
MA 6148
PG 3
WC Ophthalmology
SC Ophthalmology
GA VF2UT
UT WOS:000442393606268
DA 2020-12-15
ER

PT J
AU Magalhaes, O
   De Avila, MP
   Maia, M
   Nose, R
   Costa, EF
AF Magalhaes, Octaviano, Jr.
   De Avila, Mariana Pereira
   Maia, Mauricio
   Nose, Ricardo
   Costa, Elaine Fiod
TI Difference Between Bevel-Up and Bevel-Down 23-Gauge One-Step Incisions:
   Analysis of Anterior Chamber Optical Coherence Tomography and IOP
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE instrumentation; surgery; vitrectomy; vitreoretinal surgery; vitreous
   body
ID ULTRASOUND BIOMICROSCOPY; 25-GAUGE VITRECTOMY; WOUND CLOSURE;
   SCLEROTOMIES; SURGERY
C1 [Magalhaes, Octaviano, Jr.] Univ Fed Sao Paulo, Paulista Sch Med, Vis Inst, Dept Ophthalmol, BR-04023062 Sao Paulo, Brazil.
   [Magalhaes, Octaviano, Jr.; De Avila, Mariana Pereira; Nose, Ricardo] Eye Clin, Eye Clin Retina Dept, Sao Paulo, Brazil.
RP Magalhaes, O (corresponding author), Univ Fed Sao Paulo, Paulista Sch Med, Vis Inst, Dept Ophthalmol, Rua Botucatu 822, BR-04023062 Sao Paulo, Brazil.
EM octavianomj@terra.com.br
RI Maia, Mauricio/Z-1042-2019; Farah, Michel Eid E/F-3285-2012; Maia,
   Mauricio/I-5892-2015; Nose, Walton/I-1431-2017
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Nose,
   Walton/0000-0003-4510-1289; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
CR CHEE CKL, 1994, EYE, V8, P414, DOI 10.1038/eye.1994.98
   Eckardt C, 2005, RETINA-J RET VIT DIS, V25, P208, DOI 10.1097/00006982-200502000-00015
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P172, DOI 10.1016/S0002-9394(01)00973-4
   Lakhanpal RR, 2005, OPHTHALMOLOGY, V112, P817, DOI 10.1016/j.ophtha.2004.11.053
   Lopez-Guajardo L, 2007, AM J OPHTHALMOL, V143, P881, DOI 10.1016/j.ajo.2006.12.036
   Rizzo S, 2007, GRAEF ARCH CLIN EXP, V245, P1281, DOI 10.1007/s00417-006-0533-x
   Scott IU, 2008, RETINA-J RET VIT DIS, V28, P138, DOI 10.1097/IAE.0b013e31815e9313
   Singh RP, 2008, RETINA-J RET VIT DIS, V28, P242, DOI 10.1097/IAE.0b013e318156dea3
   Taban M, 2009, AM J OPHTHALMOL, V147, P101, DOI 10.1016/j.ajo.2008.07.046
NR 9
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2010
VL 30
IS 3
BP 521
EP 523
DI 10.1097/IAE.0b013e3181a2c091
PG 3
WC Ophthalmology
SC Ophthalmology
GA 608AD
UT WOS:000278548800022
PM 19373125
DA 2020-12-15
ER

PT J
AU Rodrigues, EB
   Penha, FM
   Costa, EDF
   Maia, M
   Dib, E
   Moraes, M
   Meyer, CH
   Magalhaes, O
   Melo, GB
   Stefano, V
   Dias, AB
   Farah, ME
AF Rodrigues, Eduardo B.
   Penha, Fernando M.
   Fiod Costa, Elaine De Paula
   Maia, Mauricio
   Dib, Eduardo
   Moraes, Milton, Jr.
   Meyer, Carsten H.
   Magalhaes, Octaviano, Jr.
   Melo, Gustavo Barreto
   Stefano, Vinicius
   Dias, Ana Beatriz
   Farah, Michel Eid
TI Ability of New Vital Dyes to Stain Intraocular Membranes and Tissues in
   Ocular Surgery
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BRILLIANT BLUE-G; INDOCYANINE GREEN; CATARACT-SURGERY; PART 1;
   CHROMOVITRECTOMY; BIOCOMPATIBILITY; TOXICITY
AB PURPOSE: To evaluate the ability of novel dyes to stain lens capsule (LC), internal limiting membrane (ILM), epiretinal membrane (ERM), and vitreous.
   DESIGN: Experimental study in animal and human donor eyes.
   METHODS: Thirteen dyes, methyl violet, crystal violet, eosin Y, sudan black B, methylene blue, toluidine blue, light green, indigo carmine, fast green, congo red, evans blue, brilliant blue, and bromophenol blue, were injected onto the LC and ILM of enucleated porcine eyes. The vitreous was stained with 2 mL of dyes for 1 minute. Six dyes (indigo carmine, evans blue, fast green, light green, bromophenol blue, and brilliant blue) were selected for experiments in human donor eyes and freshly removed ERM.
   RESULTS: In the porcine eyes, ILM staining with methylene blue, toluidine blue, indigo carmine, evans blue, bromophenol blue, and fast green was moderate, and methyl violet, crystal violet, brilliant blue, or sudan black resulted in strong staining. Methyl violet, crystal violet, sudan black, toluidine blue, and methylene blue caused histologic damage in porcine retinas. Vitreous examination revealed moderate staining with congo red, crystal violet, fast green, eosin Y, methylene blue, toluidine blue, brilliant blue, bromophenol blue, and methyl violet and strong staining with light green and evans blue. ERMs showed strong staining with 0.5% evans blue and moderate staining with 0.5% light green, fast green, brilliant blue, and bromophenol blue. Evaluation of donor eyes disclosed moderate staining with evans blue, light green, and bromophenol blue and strong staining with 0.5% brilliant blue. Moderate or strong staining of the vitreous occurred with most dyes. LC evaluation showed moderate staining with 0.5% evans blue, fast green, and brilliant blue, whereas 0.5% light green produced strong LC staining.
   CONCLUSIONS: Brilliant blue shows the best ILM staining, whereas bromophenol blue, evans blue, and light green also stain ILM. Most dyes bind well to LC, vitreous, and ERM. (Am J Ophthalmol 2010;149: 265-277. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Rodrigues, Eduardo B.; Penha, Fernando M.; Fiod Costa, Elaine De Paula; Maia, Mauricio; Dib, Eduardo; Moraes, Milton, Jr.; Magalhaes, Octaviano, Jr.; Melo, Gustavo Barreto; Stefano, Vinicius; Dias, Ana Beatriz; Farah, Michel Eid] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, Sao Paulo, Brazil.
   [Meyer, Carsten H.] Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
RP Farah, ME (corresponding author), R Botucatu 820, BR-04023062 Sao Paulo, Brazil.
EM mefarah@uol.com.br
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012; Penha,
   Fernando M/G-1784-2012; Melo, Gustavo/AAD-3844-2019; Meyer, Carsten
   H./A-3981-2017; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Melo, Gustavo/0000-0001-5765-2008; Meyer, Carsten
   H./0000-0002-0530-5298; Maia, Mauricio/0000-0002-7034-8091; Buchele
   Rodrigues, Eduardo/0000-0002-4224-0921
CR Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Chang YS, 2005, J CATARACT REFR SURG, V31, P792, DOI 10.1016/j.jcrs.2004.07.020
   Czajka MP, 2004, RETINA-J RET VIT DIS, V24, P275, DOI 10.1097/00006982-200404000-00014
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P623, DOI 10.1097/00006982-200607000-00006
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Costa EDF, 2009, INVEST OPHTH VIS SCI, V50, P385, DOI 10.1167/iovs.08-2285
   Gandorfer A, 2003, INVEST OPHTH VIS SCI, V44, P316, DOI 10.1167/iovs.02-0545
   Grisanti S, 2004, INVEST OPHTH VIS SCI, V45, P282, DOI 10.1167/iovs.03-0797
   Haigh PI, 2001, CANCER, V92, P535, DOI 10.1002/1097-0142(20010801)92:3<535::AID-CNCR1352>3.0.CO;2-3
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P3315, DOI 10.1167/iovs.04-1142
   Hisatomi T, 2006, ARCH OPHTHALMOL-CHIC, V124, P514, DOI 10.1001/archopht.124.4.514
   Jackson TL, 2005, EXP EYE RES, V81, P446, DOI 10.1016/j.exer.2005.03.004
   Janknecht P, 2001, GRAEF ARCH CLIN EXP, V239, P705, DOI 10.1007/s004170100343
   Kiernan JA, 2001, BIOTECH HISTOCHEM, V76, P261, DOI 10.1080/714028154
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Melles GRJ, 1999, J CATARACT REFR SURG, V25, P7, DOI 10.1016/S0886-3350(99)80004-2
   Mennel S, 2006, OPHTHALMOLOGICA, V220, P190, DOI 10.1159/000091764
   Mennel S, 2006, KLIN MONATSBL AUGENH, V223, P568, DOI 10.1055/s-2006-926479
   Pandey SK, 2000, J CATARACT REFR SURG, V26, P1052, DOI 10.1016/S0886-3350(00)00296-0
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Rodrigues EB, 2007, RETINA-J RET VIT DIS, V27, P958, DOI 10.1097/01.iae.0000253051.01194.ab
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   Schuettauf F, 2006, INVEST OPHTH VIS SCI, V47, P3573, DOI 10.1167/iovs.06-0211
   Sorsby A, 1939, Br J Ophthalmol, V23, P20, DOI 10.1136/bjo.23.1.20
NR 26
TC 43
Z9 46
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2010
VL 149
IS 2
BP 265
EP 277
DI 10.1016/j.ajo.2009.08.020
PG 13
WC Ophthalmology
SC Ophthalmology
GA 551OU
UT WOS:000274219700015
PM 19896637
DA 2020-12-15
ER

PT J
AU Penha, FM
   Rodrigues, EB
   Maia, M
   Dib, E
   Costa, EF
   Furlani, BA
   Moraes, MN
   Dreyfuss, JL
   Bottos, J
   Farah, ME
AF Penha, Fernando Marcondes
   Rodrigues, Eduardo B.
   Maia, Mauricio
   Dib, Eduardo
   Costa, Elaine Fiod
   Furlani, Bruno A.
   Moraes Filho, Milton Nunes
   Dreyfuss, Juliana L.
   Bottos, Juliana
   Farah, Michel E.
TI Retinal and Ocular Toxicity in Ocular Application of Drugs and Chemicals
   - Part I: Animal Models and Toxicity Assays
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Cat; Cell culture; Dog; Electroretinogram; Electron microscopy;
   Histology; Immunohistochemistry; Intravitreal morphometry; Mouse;
   Nonhuman primates; Pharmacotherapy; Pig; Rabbit
ID ENDOTHELIAL GROWTH-FACTOR; TISSUE-PLASMINOGEN ACTIVATOR; OPTICAL
   COHERENCE TOMOGRAPHY; GALACTOSE-FED DOGS; EXPERIMENTAL PROLIFERATIVE
   VITREORETINOPATHY; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; INTERNAL
   LIMITING MEMBRANE; MONKEY MACACA-FASCICULARIS; OXYGEN-INDUCED
   RETINOPATHY; INDOCYANINE GREEN-DYE
AB Aims: Experimental retinal research has gained great importance due to the ophthalmic pharmacotherapy era. An increasing number of drugs are constantly released into the market for the treatment of retinal diseases. In this review, animal species, animal models and toxicity assays in retinal research are discussed. Methods: An extensive search of the literature was performed to review various aspects of the methods of investigation of drug toxicity. The different types of animal species, as well as single animal models available for the evaluation of safety and efficacy of retinal pharmacotherapy, were identified. In addition, a large variety of reported laboratory techniques were critically examined. Results: In vitro studies are the first-line experiments for the development of a new drug for retinal diseases, using retinal pigment epithelial cells and other cell lines. The next step involves in vivo animal studies where nonhuman primates are considered the gold standard. However, cost and legal issues make their use difficult. Mice and rats provide genetically controlled models for investigations. Pigs, dogs and cats represent good large-size animal models, while rabbits are one of the most used species for retinal toxicity evaluations. Various laboratory methods were identified, including light microscopy, electron microscopy, electroretinography and new emerging methods, such as optical coherence tomography and scanning laser ophthalmoscopy for experimental purposes. Conclusions: A great number of animal species and models are available that simulate retinal diseases and provide experimental data for further human use. Work with animal models should include properly designed toxicity assays to obtain reliable results for safety and efficacy. Copyright (C) 2010 S. Karger AG, Basel
C1 [Penha, Fernando Marcondes; Rodrigues, Eduardo B.; Maia, Mauricio; Dib, Eduardo; Costa, Elaine Fiod; Furlani, Bruno A.; Moraes Filho, Milton Nunes; Bottos, Juliana; Farah, Michel E.] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, Sao Paulo, Brazil.
   [Dreyfuss, Juliana L.] Univ Fed Sao Paulo, Dept Mol Biol, Sao Paulo, Brazil.
RP Penha, FM (corresponding author), Emilio Fernandes Schoroeder 111, BR-88025080 Florianopolis, SC, Brazil.
EM penhaepm@yahoo.com.br
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012; Penha,
   Fernando M/G-1784-2012; Maia, Mauricio/Z-1042-2019; Dreyfuss, Juliana L.
   L/H-8660-2012
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Dreyfuss,
   Juliana L. L/0000-0002-9825-1072; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
CR Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   ACLAND GM, 1994, AM J MED GENET, V52, P27, DOI 10.1002/ajmg.1320520106
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Ai YJ, 2000, HUM MOL GENET, V9, P1821, DOI 10.1093/hmg/9.12.1821
   Albini TA, 2007, INVEST OPHTH VIS SCI, V48, P390, DOI 10.1167/iovs.06-0145
   ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   Ammons WS, 2007, NEOPLASIA, V9, P625, DOI 10.1593/neo.07343
   ANAND R, 1994, INVEST OPHTH VIS SCI, V35, P3533
   Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794
   Auricchio A, 2005, CURR GENE THER, V5, P339, DOI 10.2174/1566523054065020
   Aydin E, 2006, RETINA-J RET VIT DIS, V26, P187, DOI 10.1097/00006982-200602000-00011
   Banat M, 2008, ACTA OPHTHALMOL, V86, P676, DOI 10.1111/j.1600-0420.2007.01126.x
   Bargagna-Mohan P, 2006, INVEST OPHTH VIS SCI, V47, P4138, DOI 10.1167/iovs.05-1452
   Battey J, 1999, NAT GENET, V21, P73, DOI 10.1038/5012
   Baudouin C, 2007, INVEST OPHTH VIS SCI, V48, P4123, DOI 10.1167/iovs.07-0266
   BEAUCHEMIN ML, 1974, A GRAEF ARCH KLIN EX, V190, P27, DOI 10.1007/BF00414333
   Behn D, 2003, DOC OPHTHALMOL, V106, P153, DOI 10.1023/A:1022511918823
   BENNER JD, 1991, ARCH OPHTHALMOL-CHIC, V109, P1731, DOI 10.1001/archopht.1991.01080120115039
   Bessho K, 2009, GRAEF ARCH CLIN EXP, V247, P729, DOI 10.1007/s00417-008-1033-y
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   BILL A, 1980, ACTA PHYSIOL SCAND, V108, P419, DOI 10.1111/j.1748-1716.1980.tb06553.x
   BLANKS JC, 1983, J COMP NEUROL, V221, P31, DOI 10.1002/cne.902210103
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   BONO VH, 1976, CANCER TREAT REP, V60, P699
   Boulton M, 1997, AM J PHYSIOL-REG I, V272, pR1613
   Bragadottir R, 2003, VET OPHTHALMOL, V6, P135, DOI 10.1046/j.1463-5224.2003.00280.x
   Brasnu E, 2008, CURR EYE RES, V33, P303, DOI 10.1080/02713680801971857
   Brigell M, 2003, DOC OPHTHALMOL, V107, P185, DOI 10.1023/A:1026244901657
   Brown ET, 2005, VISUAL NEUROSCI, V22, P615, DOI 10.1017/S0952523805225105
   Chandler Matthew J., 1999, Veterinary Ophthalmology, V2, P179
   Chang YS, 2008, EXP EYE RES, V86, P942, DOI 10.1016/j.exer.2008.03.011
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   Choudhry S, 2007, CLIN EXP OPHTHALMOL, V35, P713, DOI 10.1111/j.1442-9071.2007.01578.x
   Clark AF, 2003, NAT REV DRUG DISCOV, V2, P448, DOI 10.1038/nrd1106
   CONLEE JW, 1995, ACTA OTO-LARYNGOL, V115, P367, DOI 10.3109/00016489509139331
   CONLEE JW, 1994, HEARING RES, V72, P108, DOI 10.1016/0378-5955(94)90211-9
   CONNOLLY SE, 1988, MICROVASC RES, V36, P275, DOI 10.1016/0026-2862(88)90028-3
   CREEL D, 1980, PHARMACOL BIOCHEM BE, V12, P969, DOI 10.1016/0091-3057(80)90461-X
   Torres RJD, 2009, ARQ BRAS OFTALMOL, V72, P68, DOI 10.1590/S0004-27492009000100014
   DEAK ST, 1984, MICROCIRC ENDOTH LYM, V1, P569
   Derwent JJK, 2006, INVEST OPHTH VIS SCI, V47, P3673, DOI 10.1167/iovs.05-1283
   DESCHAEPDRIJVER L, 1990, ANAT HISTOL EMBRYOL, V19, P222, DOI 10.1111/j.1439-0264.1990.tb00884.x
   Dierks D, 2005, ARCH OPHTHALMOL-CHIC, V123, P1563, DOI 10.1001/archopht.123.11.1563
   Dinculescu A, 2005, HUM GENE THER, V16, P649, DOI 10.1089/hum.2005.16.649
   EDWARDS BS, 2007, CURR PROTOC CYTOM, P24
   El Bradey M, 2004, J OCUL PHARMACOL TH, V20, P217, DOI 10.1089/1080768041223657
   ENGERMAN RL, 1965, ARCH OPHTHALMOL-CHIC, V73, P205
   Fercher AF, 2003, REP PROG PHYS, V66, P239, DOI 10.1088/0034-4885/66/2/204
   Forte R, 2009, EYE, V23, P2071, DOI 10.1038/eye.2008.363
   Gao H, 2006, INVEST OPHTH VIS SCI, V47, P1606, DOI 10.1167/iovs.05-0702
   Gekeler F, 2007, VET OPHTHALMOL, V10, P173, DOI 10.1111/j.1463-5224.2007.00532.x
   Genaidy M, 2002, RETINA-J RET VIT DIS, V22, P772, DOI 10.1097/00006982-200212000-00014
   Gjorloff K, 2004, DOC OPHTHALMOL, V109, P163, DOI 10.1007/s10633-004-3924-5
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1403, DOI 10.1007/s00417-008-0911-7
   Grisanti S, 2006, AM J OPHTHALMOL, V142, P158, DOI 10.1016/j.ajo.2006.02.045
   Grunwald JE, 1996, AM J OPHTHALMOL, V122, P502, DOI 10.1016/S0002-9394(14)72109-9
   GRUSSNER R, 1993, HORM METAB RES, V25, P199, DOI 10.1055/s-2007-1002076
   Hainsworth DP, 1996, J OCUL PHARMACOL TH, V12, P183, DOI 10.1089/jop.1996.12.183
   HANAWA I, 1970, EXPERIENTIA, V26, P1311, DOI 10.1007/BF02112997
   Hata Y, 2007, GRAEF ARCH CLIN EXP, V245, P1019, DOI 10.1007/s00417-006-0499-8
   Hawes N L, 1999, Mol Vis, V5, P22
   Hawes NL, 2000, INVEST OPHTH VIS SCI, V41, P3149
   HAYREH SS, 1980, BRIT J OPHTHALMOL, V64, P896, DOI 10.1136/bjo.64.12.896
   HAYREH SS, 1980, BRIT J OPHTHALMOL, V64, P818, DOI 10.1136/bjo.64.11.818
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Higgins RD, 2003, CURR EYE RES, V27, P123, DOI 10.1076/ceyr.27.2.123.15955
   Higuchi A, 2008, MOL VIS, V14, P249
   Hood DC, 1996, J OPT SOC AM A, V13, P623, DOI 10.1364/JOSAA.13.000623
   Hood DC, 2008, DOC OPHTHALMOL, V116, P1, DOI 10.1007/s10633-007-9089-2
   Horio N, 2004, ARCH OPHTHALMOL-CHIC, V122, P992, DOI 10.1001/archopht.122.7.992
   Hornof M, 2005, EUR J PHARM BIOPHARM, V60, P207, DOI 10.1016/j.ejpb.2005.01.009
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   HSU WH, 1981, ENDOCRINOLOGY, V109, P825, DOI 10.1210/endo-109-3-825
   HUANG J C, 1991, Eye (London), V5, P476
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Ikeda S, 2000, HUM MOL GENET, V9, P155, DOI 10.1093/hmg/9.2.155
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Inoue Y, 2007, EXP EYE RES, V85, P234, DOI 10.1016/j.exer.2007.04.007
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P3697, DOI 10.1167/iovs.04-0387
   Jacobson SG, 2006, MOL THER, V13, P1074, DOI 10.1016/j.ymthe.2006.03.005
   Jeong MB, 2007, VET OPHTHALMOL, V10, P376, DOI 10.1111/j.1463-5224.2007.00573.x
   JEONG MB, 2008, INVEST OPHTHALMOL VI, V49
   JEONG MB, 2006, INVEST OPHTHALMOL VI, V47
   Jin Y, 2005, EXP EYE RES, V81, P395, DOI 10.1016/j.exer.2005.02.010
   John SWM, 1999, J GLAUCOMA, V8, P400
   Johnson GA, 2002, RADIOLOGY, V222, P789, DOI 10.1148/radiol.2223010531
   Jumper JM, 2006, RETINA-J RET VIT DIS, V26, P362, DOI 10.1097/00006982-200603000-00021
   JUNOD A, 1969, J CLIN INVEST, V48, P2129, DOI 10.1172/JCI106180
   KADOR PF, 1995, ARCH OPHTHALMOL-CHIC, V113, P352, DOI 10.1001/archopht.1995.01100030108031
   Kaji Y, 2008, ACTA OPHTHALMOL, V86, P97, DOI 10.1111/j.1600-0420.2007.01058.x
   Katz ML, 2008, INVEST OPHTH VIS SCI, V49, P2686, DOI 10.1167/iovs.08-1712
   Kawahara S, 2007, INVEST OPHTH VIS SCI, V48, P4426, DOI 10.1167/iovs.07-0358
   Kedzierski W, 2001, P NATL ACAD SCI USA, V98, P7718, DOI 10.1073/pnas.141124198
   Kern TS, 2007, DIABETES, V56, P373, DOI 10.2337/db05-1621
   Kim SY, 2005, DIABETES, V54, P1534, DOI 10.2337/diabetes.54.5.1534
   Kivilcim Muhamet, 2006, J Coll Physicians Surg Pak, V16, P351
   Kivilcim M, 2007, J OCUL PHARMACOL TH, V23, P57, DOI 10.1089/jop.2006.0083
   Klassen H, 2007, VET OPHTHALMOL, V10, P245, DOI 10.1111/j.1463-5224.2007.00547.x
   Kong H, 2003, DOC OPHTHALMOL, V106, P239, DOI 10.1023/A:1022988332578
   Kozak I, 2007, INVEST OPHTH VIS SCI, V48, P4861, DOI 10.1167/iovs.07-0532
   Krishnamoorthy V, 2008, INVEST OPHTH VIS SCI, V49, P2643, DOI 10.1167/iovs.07-1471
   Kummar S, 2006, BRIT J CLIN PHARMACO, V62, P15, DOI 10.1111/j.1365-2125.2006.02713.x
   Lackner PA, 1997, EXP EYE RES, V64, P431, DOI 10.1006/exer.1996.0221
   Lai TYY, 2007, SURV OPHTHALMOL, V52, P61, DOI 10.1016/j.survophthal.2006.10.005
   Lassota N, 2008, ACTA OPHTHALMOL, V86, P495, DOI [10.1111/j.1600-0420.2007.01127.x, 10.1111/j.1755-3768.2008.01412.x]
   LeHoang P, 2008, OPHTHAL RES, V40, P181, DOI 10.1159/000119873
   LENZEN S, 1988, DIABETOLOGIA, V31, P337, DOI 10.1007/BF02341500
   Li Q, 2008, RETINA-J RET VIT DIS, V28, P504, DOI 10.1097/IAE.0b013e318158e9c0
   Lichtenberger T, 2000, VISION RES, V40, P129, DOI 10.1016/S0042-6989(99)00148-0
   Limb GA, 2002, INVEST OPHTH VIS SCI, V43, P864
   Lu F, 2009, GRAEF ARCH CLIN EXP, V247, P171, DOI 10.1007/s00417-008-0936-y
   Luke M, 2008, GRAEF ARCH CLIN EXP, V246, P817, DOI 10.1007/s00417-007-0761-8
   Luke M, 2007, BRIT J OPHTHALMOL, V91, P1077, DOI 10.1136/bjo.2006.111260
   Luke C, 2005, BRIT J OPHTHALMOL, V89, P1188, DOI 10.1136/bjo.2004.062794
   Luke M, 2005, BRAIN RES PROTOC, V16, P27, DOI 10.1016/j.brainresprot.2005.09.001
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   MACALUSO C, 1992, INVEST OPHTH VIS SCI, V33, P2798
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Maia M, 2008, GRAEF ARCH CLIN EXP, V246, P379, DOI 10.1007/s00417-007-0718-y
   Maia M, 2007, CURR EYE RES, V32, P309, DOI 10.1080/02713680701199377
   Malvitte L, 2008, CURR EYE RES, V33, P769, DOI 10.1080/02713680802337397
   Manzano RPA, 2008, GRAEF ARCH CLIN EXP, V246, P907, DOI 10.1007/s00417-008-0765-z
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Margalit E, 2006, INVEST OPHTH VIS SCI, V47, P2093, DOI 10.1167/iovs.05-0764
   Marmor MF, 2009, DOC OPHTHALMOL, V118, P69, DOI 10.1007/s10633-008-9155-4
   Marmor MF, 2004, DOC OPHTHALMOL, V109, P101, DOI 10.1007/s10633-004-3299-7
   MARMOR MF, 1995, ARCH OPHTHALMOL-CHIC, V113, P1375, DOI 10.1001/archopht.1995.01100110035021
   Marmor MF, 2003, DOC OPHTHALMOL, V106, P105, DOI 10.1023/A:1022591317907
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   McLeod DS, 1998, INVEST OPHTH VIS SCI, V39, P1918
   MCMENAMIN PG, 1991, J ANAT, V178, P65
   Mentzer AE, 2005, DOC OPHTHALMOL, V111, P95, DOI 10.1007/s10633-005-4517-7
   MICHON JJ, 1991, INVEST OPHTH VIS SCI, V32, P280
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Miyamoto H, 1997, CURR EYE RES, V16, P930, DOI 10.1076/ceyr.16.9.930.5042
   Morgan JIW, 2008, INVEST OPHTH VIS SCI, V49, P3715, DOI 10.1167/iovs.07-1430
   Morita Y, 1998, BIOL PHARM BULL, V21, P188
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Mowat FM, 2008, MOL VIS, V14, P2518
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   NARFSTROM K, 1983, J HERED, V74, P273, DOI 10.1093/oxfordjournals.jhered.a109782
   NARFSTROM K, 1989, BRIT J OPHTHALMOL, V73, P516, DOI 10.1136/bjo.73.7.516
   NARFSTROM K, 1986, INVEST OPHTH VIS SCI, V27, P1569
   NARFSTROM K, 1985, INVEST OPHTH VIS SCI, V26, P193
   NARFSTROM K, 2009, INVEST OPHTHALMOL VI, V50
   Narfstrom Kristina, 2002, Documenta Ophthalmologica, V105, P83, DOI 10.1023/A:1020524305726
   Nascimento FD, 2005, ARCH BIOCHEM BIOPHYS, V436, P323, DOI 10.1016/j.abb.2005.01.013
   Niles Andrew L., 2008, V414, P137
   Novack GD, 2008, ANNU REV PHARMACOL, V48, P61, DOI 10.1146/annurev.pharmtox.48.060607.174028
   OGDEN TE, 1973, VISION RES, V13, P797, DOI 10.1016/0042-6989(73)90044-8
   OGDEN TE, 1973, VISION RES, V13, P1059, DOI 10.1016/0042-6989(73)90144-2
   Okamoto H, 2003, J BIOL CHEM, V278, P28359, DOI 10.1074/jbc.R300009200
   Olsen TW, 2002, INVEST OPHTH VIS SCI, V43, P2529
   Padnick-Silver L, 2006, INVEST OPHTH VIS SCI, V47, P3683, DOI 10.1167/iovs.05-1284
   PAIGEN K, 1995, NAT MED, V1, P215, DOI 10.1038/nm0395-215
   Panduri V, 2003, AM J RESP CELL MOL, V28, P241, DOI 10.1165/rcmb.4903
   Pease ME, 2006, J GLAUCOMA, V15, P512, DOI 10.1097/01.ijg.0000212276.57853.19
   PEICHL L, 1987, PROC R SOC SER B-BIO, V231, P169, DOI 10.1098/rspb.1987.0040
   Penha FM, 2008, J OCUL PHARMACOL TH, V24, P52, DOI 10.1089/jop.2007.0047
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   PENN JS, 1994, PEDIATR RES, V36, P724, DOI 10.1203/00006450-199412000-00007
   RAHIMY MH, 1994, J OCUL PHARMACOL, V10, P561, DOI 10.1089/jop.1994.10.561
   RAPAPORT DH, 1984, NEUROSCIENCE, V11, P289, DOI 10.1016/0306-4522(84)90024-1
   Rees DA, 2005, DIABETIC MED, V22, P359, DOI 10.1111/j.1464-5491.2005.01499.x
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Reynolds CP, 2007, CURR DRUG TARGETS, V8, P765
   Robinson MR, 2006, EXP EYE RES, V82, P479, DOI 10.1016/j.exer.2005.08.007
   Rodrigues EB, 2007, RETINA-J RET VIT DIS, V27, P958, DOI 10.1097/01.iae.0000253051.01194.ab
   Romano C, 2007, PROG RETIN EYE RES, V26, P379, DOI 10.1016/j.preteyeres.2007.03.001
   Rosolen SG, 2008, EXP TOXICOL PATHOL, V60, P17, DOI 10.1016/j.etp.2007.11.012
   Rosolen SG, 2005, DOC OPHTHALMOL, V110, P57, DOI 10.1007/s10633-005-7344-y
   Rosolen SG, 2002, VET OPHTHALMOL, V5, P19, DOI 10.1046/j.1463-5224.2002.00203.x
   Ruggeri M, 2009, OPT EXPRESS, V17, P4074, DOI 10.1364/OE.17.004074
   Ruiz-Ederra J, 2005, EXP EYE RES, V81, P561, DOI 10.1016/j.exer.2005.03.014
   Ruiz-Ederra J, 2003, NEUROSCI LETT, V337, P127, DOI 10.1016/S0304-3940(02)01322-8
   Saikia P, 2006, INVEST OPHTH VIS SCI, V47, P4998, DOI 10.1167/iovs.05-1665
   Sandalon S, 2009, DOC OPHTHALMOL, V118, P101, DOI 10.1007/s10633-008-9141-x
   Sasaki S, 2000, IN VIVO, V14, P535
   Seigel G M, 1996, Mol Vis, V2, P2
   Seigel GM, 1997, IN VITRO CELL DEV-AN, V33, P499
   Sengupta S, 2008, ADV EXP MED BIOL, V614, P65, DOI 10.1007/978-0-387-74911-2_8
   Short BG, 2008, TOXICOL PATHOL, V36, P49, DOI 10.1177/0192623307310955
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Smith RS, 1997, PATHOBIOLOGY, V65, P146, DOI 10.1159/000164116
   Smith RS, 2002, MOL VIS, V8, P26
   Song SJ, 2008, OPHTHALMIC RES, V40, P35, DOI 10.1159/000111157
   Srinivasan K, 2007, INDIAN J MED RES, V125, P451
   STAFFORD TJ, 1984, OPHTHALMOLOGY, V91, P513
   Stalmans P, 2002, AM J OPHTHALMOL, V134, P282, DOI 10.1016/S0002-9394(02)01468-X
   Syed NA, 1998, INVEST OPHTH VIS SCI, V39, P2800
   Tadesse M, 2001, INVEST OPHTH VIS SCI, V42, P1867
   TAKAHASHI Y, 1992, ARCH OPHTHALMOL-CHIC, V110, P1295, DOI 10.1001/archopht.1992.01080210113037
   TASHIRO C, 1986, GRAEF ARCH CLIN EXP, V224, P473, DOI 10.1007/BF02173367
   TIAN N, 1995, VISION RES, V35, P1359, DOI 10.1016/0042-6989(95)98715-L
   Trivino A, 2006, EXP EYE RES, V83, P357, DOI 10.1016/j.exer.2005.12.020
   Turnbull DH, 1999, COMPUT MED IMAG GRAP, V23, P25, DOI 10.1016/S0895-6111(98)00060-3
   TURNBULL DH, 1995, P NATL ACAD SCI USA, V92, P2239, DOI 10.1073/pnas.92.6.2239
   Ueno A, 2007, RETINA-J RET VIT DIS, V27, P499, DOI 10.1097/IAE.0b013e318030a129
   Umeda S, 2005, INVEST OPHTH VIS SCI, V46, P683, DOI 10.1167/iovs.04-1031
   Umeda S, 2003, EXP ANIM TOKYO, V52, P129, DOI 10.1538/expanim.52.129
   VANDERZYPEN E, 1977, OPHTHALMOLOGICA, V174, P285, DOI 10.1159/000308617
   VANNORREN D, 1977, VISION RES, V17, P807, DOI 10.1016/0042-6989(77)90123-7
   VANNORREN D, 1977, INVEST OPHTH VIS SCI, V16, P80
   Vavvas Demetrios, 2006, Ophthalmol Clin North Am, V19, P353
   Velez G, 2001, ARCH OPHTHALMOL-CHIC, V119, P1518
   Veske A, 1999, GENOMICS, V57, P57, DOI 10.1006/geno.1999.5754
   VIRDI PS, 1982, ARCH OPHTHALMOL-CHIC, V100, P331, DOI 10.1001/archopht.1982.01030030333024
   Wang WJ, 2003, TRANSPLANTATION, V76, P290, DOI 10.1097/01.TP.0000073613.25658.4D
   Wang ZY, 1998, DIABETES, V47, P50, DOI 10.2337/diabetes.47.1.50
   Weinberger AWA, 2001, GRAEF ARCH CLIN EXP, V239, P388, DOI 10.1007/s004170100267
   Weinreb RN, 2005, J GLAUCOMA, V14, P302, DOI 10.1097/01.ijg.0000169395.47921.02
   Weymouth AE, 2008, PROG RETIN EYE RES, V27, P1, DOI 10.1016/j.preteyeres.2007.09.003
   WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0
   Woodward WR, 2007, DOC OPHTHALMOL, V115, P187, DOI 10.1007/s10633-007-9079-4
   Xi SM, 2004, INT J EXP PATHOL, V85, P223, DOI 10.1111/j.0959-9673.2004.00394.x
   Xu JF, 2007, J OCUL PHARMACOL TH, V23, P527, DOI 10.1089/jop.2007.0002
   Yamashita T, 2000, J ENDOCRINOL, V164, P239, DOI 10.1677/joe.0.1640239
   Yang CS, 1998, ARCH OPHTHALMOL-CHIC, V116, P69, DOI 10.1001/archopht.116.1.69
   Yin Weidong, 2002, Int J Exp Diabetes Res, V3, P179, DOI 10.1080/15604280214274
   Yu DY, 2001, CLIN EXP OPHTHALMOL, V29, P164
   Yu SY, 2006, RETINA-J RET VIT DIS, V26, P531, DOI 10.1097/00006982-200605000-00006
   ZEMEL E, 1995, INVEST OPHTH VIS SCI, V36, P1875
NR 227
TC 18
Z9 18
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
J9 OPHTHAL RES
JI Ophthalmic Res.
PY 2010
VL 44
IS 2
BP 82
EP 104
DI 10.1159/000312817
PG 23
WC Ophthalmology
SC Ophthalmology
GA 633QS
UT WOS:000280519600001
PM 20484950
DA 2020-12-15
ER

PT J
AU Penha, FM
   Rodrigues, EB
   Maia, M
   Furlani, BA
   Regatieri, C
   Melo, GB
   Magalhaes, O
   Manzano, R
   Farah, ME
AF Penha, Fernando Marcondes
   Rodrigues, Eduardo B.
   Maia, Mauricio
   Furlani, Bruno A.
   Regatieri, Caio
   Melo, Gustavo B.
   Magalhaes, Octaviano, Jr.
   Manzano, Roberta
   Farah, Michel E.
TI Retinal and Ocular Toxicity in Ocular Application of Drugs and Chemicals
   - Part II: Retinal Toxicity of Current and New Drugs
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Avastin; Lucentis; Retina; Bevacizumab; Ranibizumab; Monoclonal
   antibodies; Tumor necrosis factor; Vascular endothelial growth factor;
   Corticosteroids; Antimetabolites; Triamcinolone; Nonsteroidal
   anti-inflammatory drugs; Microplasmin
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; CYSTOID MACULAR EDEMA;
   TISSUE-PLASMINOGEN-ACTIVATOR; IMMUNE-DEFICIENCY-SYNDROME; NERVOUS-SYSTEM
   LYMPHOMA; GROWTH-FACTOR ANTIBODY; LONG-ACTING THERAPY; OIL-FILLED EYE;
   CYTOMEGALOVIRUS-RETINITIS; BEVACIZUMAB AVASTIN
AB Aims: Retinal pharmacotherapy has gained great importance for the treatment of various retinal diseases. An increasing number of drugs have been constantly released into the market, especially for wet age-related macular disease and diabetic macular edema. In this review, the issues concerning the toxicity of current and new classes of drugs are discussed. Methods: An extensive search of the literature was performed to review various aspects of drug toxicity in retinal pharmacotherapy. The different major classes of drugs, such as corticosteroids, antibiotics, antimetabolites, antineoplastic agents, monoclonal antibodies (mAbs), nonsteroidal anti-inflammatory drugs, enzymes, fibrinolytics, miscellaneous anti-inflammatory and antiangiogenic agents, as well as toxicity unrelated to the drug were identified and discussed. Results: Corticosteroids like fluocinolone, dexamethasone or triamcinolone at low dose cause little damage to the retina, but at high doses signs of toxicity have been well documented. Complications like cataract and glaucoma are quite common with corticosteroids. Aminoglycosides showed differences in the type and doses associated with toxic reactions, thereby the following order of toxicity can be described (from most toxic to least toxic): gentamicin > netilmicin = tobramycin > amikacin = kanamycin. Vancomycin at the usual dose of 1 mg is not toxic to the retina, while further studies are necessary in order to clarify the safety of new-generation quinolones. 5-Fluorouracil has been shown to be nontoxic to the retina after an injection of 2.5 mg in animals. mAbs like ranibizumab and bevacizumab were demonstrated to be safe to the retina in cell culture, animals and humans at high doses. The exact biocompatibility of nonsteroidal anti-inflammatory agents like diclofenac needs further evaluation. Preservatives like benzyl alcohol and changes in pH or osmolarity exert an influence on the toxic effects of intravitreally applied drugs. Conclusions: A great number of drugs are now used mainly intravitreally without relevant retinal toxicity. Copyright (C) 2010 S. Karger AG, Basel
C1 [Penha, Fernando Marcondes; Rodrigues, Eduardo B.; Maia, Mauricio; Furlani, Bruno A.; Regatieri, Caio; Melo, Gustavo B.; Magalhaes, Octaviano, Jr.; Manzano, Roberta; Farah, Michel E.] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, Sao Paulo, Brazil.
RP Penha, FM (corresponding author), Emilio Fernandes Schoroeder 111, BR-88025080 Florianopolis, SC, Brazil.
EM penhaepm@yahoo.com.br
RI Melo, Gustavo/AAD-3844-2019; Regatieri, Caio/G-8152-2014; Maia,
   Mauricio/Z-1042-2019; Penha, Fernando M/G-1784-2012; Farah, Michel Eid
   E/F-3285-2012; Maia, Mauricio/I-5892-2015
OI Melo, Gustavo/0000-0001-5765-2008; Regatieri, Caio/0000-0003-1511-8696;
   Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Buchele
   Rodrigues, Eduardo/0000-0002-4224-0921
CR Abramson DH, 2008, OPHTHALMOLOGY, V115, P1398, DOI 10.1016/j.ophtha.2007.12.014
   Almeida Luciana Negrao Frota de, 2005, Arq Bras Oftalmol, V68, P837
   Amin HI, 2000, ARCH OPHTHALMOL-CHIC, V118, P426
   Arevalo JF, 2005, EUR J OPHTHALMOL, V15, P610
   Ausayakhun Somsanguan, 2005, Journal of the Medical Association of Thailand, V88, P103
   Avci R, 2006, GRAEF ARCH CLIN EXP, V244, P28, DOI 10.1007/s00417-005-0069-5
   Aydin E, 2006, RETINA-J RET VIT DIS, V26, P187, DOI 10.1097/00006982-200602000-00011
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   BARRADA A, 1984, OPHTHALMIC SURG LAS, V15, P767
   BESEN G, 1995, ANTIMICROB AGENTS CH, V39, P1485, DOI 10.1128/AAC.39.7.1485
   BESEN G, 1995, ARCH OPHTHALMOL-CHIC, V113, P661, DOI 10.1001/archopht.1995.01100050129042
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   BLANKENSHIP GW, 1989, GRAEF ARCH CLIN EXP, V227, P565, DOI 10.1007/BF02169453
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   BLUMENKRANZ M, 1984, OPHTHALMOLOGY, V91, P122
   BORHANI H, 1993, INT OPHTHALMOL, V17, P85, DOI 10.1007/BF00942780
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Cai Jiping, 2001, International Ophthalmology, V24, P225, DOI 10.1023/A:1022509614815
   CAMPOCHIARO PA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1625, DOI 10.1001/archopht.1992.01080230125035
   Cardillo JA, 2004, BRIT J OPHTHALMOL, V88, P1201, DOI 10.1136/bjo.2003.039917
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674
   Cheng CK, 2004, J OCUL PHARMACOL TH, V20, P430, DOI 10.1089/jop.2004.20.430
   Clark AF, 2003, NAT REV DRUG DISCOV, V2, P448, DOI 10.1038/nrd1106
   Coiffier B, 2007, ONCOGENE, V26, P3603, DOI 10.1038/sj.onc.1210376
   DAMICO DJ, 1985, AM J OPHTHALMOL, V100, P264, DOI 10.1016/0002-9394(85)90792-5
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   DAVIDSON C, 1983, INVEST OPHTH VIS SCI, V24, P301
   de Smet MD, 2009, INVEST OPHTH VIS SCI, V50, P814, DOI 10.1167/iovs.08-2185
   de Smet MD, 1999, OCUL IMMUNOL INFLAMM, V7, P189, DOI 10.1076/ocii.7.3.189.4007
   Dick AD, 2004, PROG RETIN EYE RES, V23, P617, DOI 10.1016/j.preteyeres.2004.06.005
   DOLNAK DR, 1992, INVEST OPHTH VIS SCI, V33, P1557
   Dyer D, 2009, RETINA-J RET VIT DIS, V29, P38, DOI 10.1097/IAE.0b013e318188c6e2
   Fauser S, 2004, GRAEF ARCH CLIN EXP, V242, P582, DOI 10.1007/s00417-004-0895-x
   Fishburne BC, 1997, ARCH OPHTHALMOL-CHIC, V115, P1152, DOI 10.1001/archopht.1997.01100160322009
   FLORESAGUILAR M, 1994, J INFECT DIS, V169, P642
   FRAMBACH DA, 1982, INVEST OPHTH VIS SCI, V22, P292
   Frenkel S, 2008, BRIT J OPHTHALMOL, V92, P383, DOI 10.1136/bjo.2007.127928
   FRIEDMAN AH, 1983, BRIT J OPHTHALMOL, V67, P372, DOI 10.1136/bjo.67.6.372
   Gao Hua, 2003, Trans Am Ophthalmol Soc, V101, P183
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Giansanti F, 2008, INVEST OPHTH VIS SCI, V49, P1151, DOI 10.1167/iovs.07-0932
   Gibran SK, 2006, EYE, V20, P720, DOI 10.1038/sj.eye.6701992
   Hancock HA, 2005, INVEST OPHTH VIS SCI, V46, P4804, DOI 10.1167/iovs.05-0604
   Hardwig PW, 2008, RETINA-J RET VIT DIS, V28, P1082, DOI 10.1097/IAE.0b013e3181754231
   Hardwig PW, 2006, AM J OPHTHALMOL, V142, P883, DOI 10.1016/j.ajo.2006.06.002
   Hariprasad SM, 2008, BRIT J OPHTHALMOL, V92, P871, DOI 10.1136/bjo.2007.136515
   Hegazy HM, 1999, RETINA-J RET VIT DIS, V19, P553, DOI 10.1097/00006982-199911000-00013
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Ho JD, 2003, ARCH OPHTHALMOL-CHIC, V121, P1423, DOI 10.1001/archopht.121.10.1423
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P421, DOI 10.1016/j.ajo.2004.10.005
   Huna R, 1996, RETINA-J RET VIT DIS, V16, P259, DOI 10.1097/00006982-199616030-00015
   Ikagawa H, 2005, INVEST OPHTH VIS SCI, V46, P2531, DOI 10.1167/iovs.04-1521
   Imrie FR, 2007, CURR OPIN OPHTHALMOL, V18, P481, DOI 10.1097/ICU.0b013e3282f03d42
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Iriyama A, 2007, BRIT J OPHTHALMOL, V91, P1230, DOI 10.1136/bjo.2007.117309
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Ivert L, 2002, GRAEF ARCH CLIN EXP, V240, P232, DOI 10.1007/s00417-001-0392-4
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Jonas JB, 2004, GRAEF ARCH CLIN EXP, V242, P184, DOI 10.1007/s00417-003-0841-3
   Jonas JB, 2003, AM J OPHTHALMOL, V136, P384, DOI 10.1016/S0002-9394(03)00230-7
   Jonas JB, 2003, EUR J OPHTHALMOL, V13, P575
   Jonas JB, 2001, AM J OPHTHALMOL, V131, P468, DOI 10.1016/S0002-9394(00)00882-5
   JOONDEPH BC, 1988, OPHTHALMIC SURG LAS, V19, P252
   Kaempf S, 2008, INVEST OPHTH VIS SCI, V49, P3164, DOI 10.1167/iovs.07-1265
   Kaneko A, 2003, JPN J CLIN ONCOL, V33, P601, DOI 10.1093/jjco/hyg113
   Kawashima S, 1996, DOC OPHTHALMOL, V92, P229, DOI 10.1007/BF02583294
   Kernt M, 2008, J CATARACT REFR SURG, V34, P480, DOI 10.1016/j.jcrs.2007.10.046
   Khan FA, 2007, PHARMACOTHERAPY, V27, P1711, DOI 10.1592/phco.27.12.1711
   Kim H, 2006, EXP EYE RES, V82, P760, DOI 10.1016/j.exer.2005.09.018
   Kim SJ, 2008, RETINA-J RET VIT DIS, V28, P595, DOI 10.1097/IAE.0b013e31815e98a5
   KIRSCH LS, 1995, OPHTHALMOLOGY, V102, P533, DOI 10.1016/S0161-6420(95)30985-2
   KIRSH LS, 1995, AM J OPHTHALMOL, V119, P466, DOI 10.1016/S0002-9394(14)71233-4
   Kitzmann AS, 2007, EYE, V21, P1524, DOI 10.1038/sj.eye.6702804
   Kivilcim Muhamet, 2006, J Coll Physicians Surg Pak, V16, P351
   Kivilcim M, 2007, J OCUL PHARMACOL TH, V23, P57, DOI 10.1089/jop.2006.0083
   Komarowska I, 2009, RETINA-J RET VIT DIS, V29, P98, DOI 10.1097/IAE.0b013e31817d8c09
   Kummar S, 2006, BRIT J CLIN PHARMACO, V62, P15, DOI 10.1111/j.1365-2125.2006.02713.x
   Kuppermann BD, 1996, J INFECT DIS, V173, P18, DOI 10.1093/infdis/173.1.18
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Lang YR, 2007, RETINA-J RET VIT DIS, V27, P778, DOI 10.1097/IAE.0b013e318030c517
   Lang Y, 2007, OPHTHALMOLOGY, V114, P724, DOI 10.1016/j.ophtha.2006.08.044
   Lee H, 2005, RETINA-J RET VIT DIS, V25, P551, DOI 10.1097/00006982-200507000-00001
   LEON JA, 1990, INVEST OPHTH VIS SCI, V31, P1709
   Li Q, 2008, RETINA-J RET VIT DIS, V28, P504, DOI 10.1097/IAE.0b013e318158e9c0
   Lim L, 2006, CLIN EXP OPHTHALMOL, V34, P365, DOI 10.1111/j.1442-9071.2006.01225.x
   LOEWENSTEIN A, 1993, INVEST OPHTH VIS SCI, V34, P3466
   LOEWENSTEIN A, 1991, INVEST OPHTH VIS SCI, V32, P3053
   Lopez-Cortes LF, 2001, INVEST OPHTH VIS SCI, V42, P1024
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Luke M, 2007, BRIT J OPHTHALMOL, V91, P1077, DOI 10.1136/bjo.2006.111260
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Macky TA, 2002, J MED CHEM, V45, P1122, DOI 10.1021/jm010511b
   Macky TA, 2007, GRAEF ARCH CLIN EXP, V245, P817, DOI 10.1007/s00417-006-0459-3
   Maia M, 2007, BRIT J OPHTHALMOL, V91, P1122, DOI 10.1136/bjo.2007.115386
   Manzano RPA, 2008, GRAEF ARCH CLIN EXP, V246, P907, DOI 10.1007/s00417-008-0765-z
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mochizuki K, 1992, Lens Eye Toxic Res, V9, P537
   Morales AM, 2009, OPHTHAL SURG LAS IM, V40, P38, DOI 10.3928/15428877-20090101-14
   Moshfeghi AA, 2009, RETINA-J RET VIT DIS, V29, P689, DOI 10.1097/IAE.0b013e31819e390a
   NEGI A, 1984, ARCH OPHTHALMOL-CHIC, V102, P445
   NEGI A, 1984, INVEST OPHTH VIS SCI, V25, P616
   NEGI A, 1993, DOC OPHTHALMOL, V83, P331, DOI 10.1007/BF01204335
   Novack GD, 2008, ANNU REV PHARMACOL, V48, P61, DOI 10.1146/annurev.pharmtox.48.060607.174028
   Ohm J., 1911, AV GRAEFES ARCH OPHT, V79, P442
   OUM BS, 1992, GRAEF ARCH CLIN EXP, V230, P56, DOI 10.1007/BF00166763
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   PEYMAN GA, 1984, OPHTHALMIC SURG LAS, V15, P411
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rodrigues EB, 2007, ACTA OPHTHALMOL SCAN, V85, P915, DOI 10.1111/j.1600-0420.2007.00968.x
   Rodriguez-Coleman H, 2004, ARCH OPHTHALMOL-CHIC, V122, P1085, DOI 10.1001/archopht.122.7.1085
   Rosenfeld PJ, 2007, LANCET, V370, P1479, DOI 10.1016/S0140-6736(07)61624-9
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rowley SA, 2004, BRIT J OPHTHALMOL, V88, P573, DOI 10.1136/bjo.2003.027466
   SARAN BR, 1994, RETINA-J RET VIT DIS, V14, P248, DOI 10.1097/00006982-199414030-00010
   Sen P, 2006, RETINA-J RET VIT DIS, V26, P935, DOI 10.1097/01.iae.0000250011.68532.a2
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shimoda Y, 2008, GRAEF ARCH CLIN EXP, V246, P501, DOI 10.1007/s00417-007-0685-3
   Sippy BD, 2001, AM J OPHTHALMOL, V132, P433, DOI 10.1016/S0002-9394(01)01061-3
   Smith JR, 2002, OPHTHALMOLOGY, V109, P1709, DOI 10.1016/S0161-6420(02)01125-9
   Sou R, 2008, JPN J OPHTHALMOL, V52, P167, DOI 10.1007/s10384-008-0519-9
   Srinivasan K, 2007, INDIAN J MED RES, V125, P451
   Stone TW, 2000, AM J OPHTHALMOL, V130, P242, DOI 10.1016/S0002-9394(00)00495-5
   Suhler EB, 2005, ARCH OPHTHALMOL-CHIC, V123, P903, DOI 10.1001/archopht.123.7.903
   Tammewar AM, 2007, J OCUL PHARMACOL TH, V23, P433, DOI 10.1089/jop.2007.0018
   TEXTORIUS O, 1983, ACTA OPHTHALMOL, V61, P322
   Theodossiadis PG, 2007, RETINA-J RET VIT DIS, V27, P399, DOI 10.1097/MAJ.0b013e3180318fbc
   Thompson AM, 2007, CLIN EXP OPHTHALMOL, V35, P566, DOI 10.1111/j.1442-9071.2007.01552.x
   Trese MT, 2002, EYE, V16, P365, DOI 10.1038/sj.eye.6700193
   Ueda Mitsuyuki, 1995, Nippon Ganka Gakkai Zasshi, V99, P1230
   Uwaydat SH, 2002, ARCH OPHTHALMOL-CHIC, V120, P854
   VANDER JF, 1992, OPHTHALMIC SURG LAS, V23, P361
   Vavvas Demetrios, 2006, Ophthalmol Clin North Am, V19, P353
   Velez G, 2001, ARCH OPHTHALMOL-CHIC, V119, P1518
   VERNOT J, 1985, INT OPHTHALMOL, V8, P193, DOI 10.1007/BF00137646
   Wang K, 2006, GRAEF ARCH CLIN EXP, V244, P1152, DOI 10.1007/s00417-005-0251-9
   Wang ZL, 2009, RETINA-J RET VIT DIS, V29, P269, DOI 10.1097/IAE.0b013e3181923ff0
   Wiechens B, 1999, OPHTHALMOLOGICA, V213, P120, DOI 10.1159/000027404
   Williamson TH, 2005, AM J OPHTHALMOL, V139, P860, DOI 10.1016/j.ajo.2005.01.001
   Yamane Takashi, 2004, Int J Clin Oncol, V9, P69, DOI 10.1007/s10147-004-0392-6
   YOSHIZUMI MO, 1985, ANN OPHTHALMOL, V17, P58
   Yu H G, 1997, Korean J Ophthalmol, V11, P98
   Yu SY, 2006, RETINA-J RET VIT DIS, V26, P531, DOI 10.1097/00006982-200605000-00006
   Ziche M, 2004, CURR DRUG TARGETS, V5, P485, DOI 10.2174/1389450043345371
   Zimmer-Galler IE, 1997, RETINA-J RET VIT DIS, V17, P507
NR 145
TC 40
Z9 42
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2010
VL 44
IS 4
BP 205
EP 224
DI 10.1159/000316695
PG 20
WC Ophthalmology
SC Ophthalmology
GA 638XL
UT WOS:000280932000001
PM 20699625
OA Bronze
DA 2020-12-15
ER

PT J
AU Maia, M
   Farah, ME
   Rodrigues, EB
   Malerbi, FK
AF Maia, M.
   Farah, M. E.
   Rodrigues, E. B.
   Malerbi, F. K.
TI Subretinal Brilliant Blue G migration during internal limiting membrane
   peeling
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Letter
ID TRYPAN BLUE; MODEL
C1 [Maia, M.; Farah, M. E.; Rodrigues, E. B.; Malerbi, F. K.] Univ Fed Sao Paulo, Paulista Sch Med, Sao Paulo, Brazil.
RP Malerbi, FK (corresponding author), Rua Jacques Felix 314-51, BR-04509001 Sao Paulo, Brazil.
EM femalerbi@terra.com.br
RI Malerbi, Fernando/AAD-3827-2019; Farah, Michel Eid E/F-3285-2012; Maia,
   Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Buchele Rodrigues, Eduardo/0000-0002-4224-0921
CR Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Luke M, 2008, GRAEF ARCH CLIN EXP, V246, P817, DOI 10.1007/s00417-007-0761-8
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Schumann RG, 2008, BRIT J OPHTHALMOL, V92, P330, DOI 10.1136/bjo.2007.128421
   Ueno A, 2007, RETINA-J RET VIT DIS, V27, P499, DOI 10.1097/IAE.0b013e318030a129
   Uno F, 2006, RETINA-J RET VIT DIS, V26, P237, DOI 10.1097/00006982-200602000-00026
NR 6
TC 24
Z9 25
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2009
VL 93
IS 12
BP 1687
EP 1687
DI 10.1136/bjo.2008.151597
PG 1
WC Ophthalmology
SC Ophthalmology
GA 525BE
UT WOS:000272187300031
PM 19939799
DA 2020-12-15
ER

PT J
AU Andreghetti, E
   Silva, MRBD
   Jose, NK
   Maia, M
   Andreghetti, MD
   Antunes, VC
AF Andreghetti, Eduardo
   Bet de Moraes Silva, Maria Rosa
   Jose, Newton Kara
   Maia, Mauricio
   Andreghetti, Mariana de Rezende
   Antunes, Valcir Coronado
TI Social inclusion for visually impaired - experience and results from
   Assis
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA Portuguese
DT Article
DE Vision disorders; Blindness; Vision, low/rehabilitation; Employment;
   Community health centers; Socialization
ID CHILDHOOD BLINDNESS; SCHOOLCHILDREN; PREVALENCE; ETIOLOGY
AB Purposes: To establish the visually impaired resource class users profile in the city of Assis - SP, to estimate the visually impaired employment percentage and to compare employment rate with age, gender, deficiency type and causing disease between two periods: 1984 - 1996 and 1997 - 2009. Methods: Retrospective review of both medical and school records from visually impaired individuals attending visually impaired resource class in Assis - SP between 1984 and 2009. This time period was divided into two intervals: 1984 - 1996 (G1) and 1997 - 2009 (G2). Collected data included demographic features and diseases, type of visual impairment (blindness or low vision), education, optic aids, attendance to visually impaired resource class and employment rate. Employment rate was associated with age, gender, type of visual impaiment and causing disease between both study time intervals. Results: A total of 149 visually impaired individuals were identified - 61.07% male, 38.9% female, 82.5% white, and 17.4% non-white. Mean age was 18 years. Of the 149 visually impaired, 63.75% had low vision and 36.24% were blind. In decreasing order, the more frequent conditions leading to visual impairment were toxoplasmosis retinochoroiditis (17.40%), congenital optic atrophy (9.39%), high hyperopia (8.72%), pigmentary retinosis and high myopia (with 6.71% each) and congenital glaucoma and congenital cataract (with 6.04% each). Attendance to visually impaired resource class was good by over 50% of the patients. Of the individuals > 14 years-old, 44.7% and 12.3% were regularly employed during 1984 - 1996 and 1997 - 2009 periods, respectively. Employment rate only correlated with age (individuals with higher mean age were most frequently employed) and there was not correlation with demographic characteristics, deficiency type and causing diseases. Conclusions: The main characteristics of the individuals attending the visually impaired resource class are: male, white, with low vision and ocular toxoplasmosis. Nearly half of the individuals older than 14 years-old (44.7%) were regularly employed up to 1996, suggesting that the joint effort of ophthalmologists and teachers helps the social inclusion of these patients. Employment rate dropped over 1997 - 2009 period, and the rate of retirees increased.
C1 [Andreghetti, Eduardo; Bet de Moraes Silva, Maria Rosa; Jose, Newton Kara; Maia, Mauricio; Andreghetti, Mariana de Rezende; Antunes, Valcir Coronado] Univ Estadual Paulista, Dept Oftalmol, Sao Paulo, Brazil.
RP Silva, MRBD (corresponding author), UNESP, Fac Med Botucatu, Dept OFT ORL CCP, Dist Rubiao Jr S-N, BR-18618970 Botucatu, SP, Brazil.
EM rosabet@fmb.unesp.br
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR ALVES LS, 1985, ARQ BRAS OFTALMOL, V48, P65
   Apushkin MA, 2006, OPHTHALMOLOGY, V113, P481, DOI 10.1016/j.ophtha.2005.12.012
   BAGHDASSARIAN SA, 1975, AM J OPHTHALMOL, V79, P827, DOI 10.1016/0002-9394(75)90744-8
   BARBIERI LC, 1984, ARQ BRAS OFTALMOL, V47, P107
   Brito PR, 2000, ARQ BRAS OFTALMOL, V63, P49
   BUCHER PJM, 1988, BRIT J OPHTHALMOL, V72, P721, DOI 10.1136/bjo.72.10.721
   BUCHIGNANI BPC, 1991, ARQ BRAS OFTALMOL, V50, P305
   CARVALHO KMM, 2002, ARQ BRAS OFTALMOL, V65, P445
   DIXON K, 2003, WORK TRENDS AM ATTIT, P7
   ELDER MJ, 1993, EYE, V7, P580, DOI 10.1038/eye.1993.126
   ESTEVES JF, 1996, ARQ BRAS OFTALMOL, V59, P244
   GOGGIN M, 1991, BRIT J OPHTHALMOL, V75, P425, DOI 10.1136/bjo.75.7.425
   JAY B, 1987, BRIT MED J, V294, P1183, DOI 10.1136/bmj.294.6581.1183
   Kara Jos N., 1988, ARQ BRAS OFTALMOL, V51, P65
   KARA-JOSE N, 1984, Boletin de la Oficina Sanitaria Panamericana, V97, P405
   LEAL DB, 1995, ARQ BRAS OFTALMOL, V58, P439
   Monteiro Gelse Beatriz Martins, 2006, Arq. Bras. Oftalmol., V69, P503, DOI 10.1590/S0004-27492006000400009
   MOREIRA ATR, 1991, ARQ BRAS OFTALMOL, V54, P275
   OLURIN O, 1970, AM J OPHTHALMOL, V70, P533, DOI 10.1016/0002-9394(70)90886-X
   PHILLIPS CI, 1987, BRIT J OPHTHALMOL, V71, P578, DOI 10.1136/bjo.71.8.578
   PINTO ALT, 2000, VADE MECUM
   ROCHA H, 1987, ENSAIOS PROBLEMATICA, P354
   Tartarella MB, 1991, ARQ BRAS OFTALMOL, V54, P221
   Wolffe K, 2002, EMPLOYMENT RELATIONS, V29, P59
NR 24
TC 0
Z9 1
U1 0
U2 14
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD NOV-DEC
PY 2009
VL 72
IS 6
BP 776
EP 782
DI 10.1590/S0004-27492009000600007
PG 7
WC Ophthalmology
SC Ophthalmology
GA 556LD
UT WOS:000274591700007
PM 20098898
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Torres, RJD
   Maia, M
   Precoma, DB
   Noronha, L
   Luchini, A
   Precoma, LB
   de Souza, GK
   Muccioli, C
AF de Almeida Torres, Rogil Jose
   Maia, Mauricio
   Precoma, Dalton Bertolin
   Noronha, Lucia
   Luchini, Andrea
   Precoma, Leonardo Brandao
   de Souza, Greyce Kelly
   Muccioli, Cristina
TI Evaluation of early abnormalities of the sensory retina in a
   hypercholesterolemia experimental model: an immunohistochemical study
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Retina; Models, animal; Calcium-binding proteins; Cholesterol; Anoxia;
   Immunohistochemistry; Rabbits
ID CALCIUM-BINDING PROTEIN; GUINEA-PIG; CHOLESTEROL; CALRETININ;
   NORMALIZATION; EXPRESSION; RABBITS
AB Purpose: The aim of this study is to demonstrate the early changes of the sensory retina induced by hypercholesterolemia in an experimental model. Methods: New Zealand rabbits were divided into two groups: CG (Control Group) was fed a normal diet for 6 weeks. G1 was initially fed a 1% cholesterol diet for two weeks and from the 14(th) day on a 0.5% cholesterol diet until the 42(nd) day. The eyes underwent an immunohistochemical analysis with monoclonal antibodies anti-calretinin and antiglial fibrillary acidic protein (GFAP). Results: G1 cells and cell elements presented significant immunoreactivity to anti-calretinin. No immunoreactivity to anti-glial fibrillary acidic protein was observed in both groups. Conclusion: This study has shown that a hypercholesterolemic diet may induce early changes in the sensory retina in rabbits. The anti-calretinin monoclonal antibody was able to reveal calcium accumulation inside the nerve cells.
C1 Hosp Angelina Caron Campina Grande Sul, Curitiba, Parana, Brazil.
   Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   Pontificia Univ Catolica Parana, Curitiba, Parana, Brazil.
RP Torres, RJD (corresponding author), Rua Emiliano Perneta,390 Conj 1-411, BR-80420080 Curitiba, Parana, Brazil.
EM rjat@terra.com.br
RI noronha, lucia/F-6339-2015; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015; Muccioli, Cristina/C-3419-2013
OI noronha, lucia/0000-0003-0310-7164; Maia, Mauricio/0000-0002-7034-8091;
   Maia, Mauricio/0000-0002-7034-8091; 
CR Billing-Marczak K, 1999, POL J PHARMACOL, V51, P173
   COGAN DG, 1959, ARCH OPHTHALMOL-CHIC, V61, P219
   Torres RJD, 2009, ARQ BRAS OFTALMOL, V72, P68, DOI 10.1590/S0004-27492009000100014
   DECHESNE CJ, 1991, BRAIN RES, V560, P139, DOI 10.1016/0006-8993(91)91224-O
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   JANDE SS, 1981, NATURE, V294, P765, DOI 10.1038/294765a0
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   MOCKEL V, 1994, BRAIN RES, V648, P109, DOI 10.1016/0006-8993(94)91911-9
   Monton C, 2001, P C C I D, V3, P179
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Puskas LG, 2004, BIOCHIMIE, V86, P817, DOI 10.1016/j.biochi.2004.10.004
   Ramirez AI, 2006, EXP EYE RES, V83, P1423, DOI 10.1016/j.exer.2006.07.023
   Ramirez JM, 1996, VISION RES, V36, P2029, DOI 10.1016/0042-6989(95)00322-3
   Salazar JJ, 2007, EXP EYE RES, V84, P412, DOI 10.1016/j.exer.2006.10.012
   SCHNITZER J, 1988, GLIA, V1, P74, DOI 10.1002/glia.440010109
   Sucher NJ, 1997, VISION RES, V37, P3483, DOI 10.1016/S0042-6989(97)00047-3
   Sun YP, 2000, P SOC EXP BIOL MED, V224, P166, DOI 10.1046/j.1525-1373.2000.22416.x
   Trivino A, 2006, EXP EYE RES, V83, P357, DOI 10.1016/j.exer.2005.12.020
   Volgyi B, 1997, BRAIN RES, V763, P79, DOI 10.1016/S0006-8993(97)00405-8
   Vreugdenhil M, 1996, P NATL ACAD SCI USA, V93, P12559, DOI 10.1073/pnas.93.22.12559
   Weisenhorn DMV, 1996, EXP BRAIN RES, V108, P101
   Yucel I, 2005, VISION RES, V45, P1107, DOI 10.1016/j.visres.2004.11.018
NR 22
TC 5
Z9 5
U1 0
U2 0
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD NOV-DEC
PY 2009
VL 72
IS 6
BP 793
EP 798
PG 6
WC Ophthalmology
SC Ophthalmology
GA 556LD
UT WOS:000274591700010
PM 20098901
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Dib, E
   Rodrigues, EB
   Maia, M
   Meyer, CH
   Penha, FM
   Furlani, BD
   Costa, EDF
   Farah, ME
AF Dib, Eduardo
   Rodrigues, Eduardo Buechelle
   Maia, Mauricio
   Meyer, Carsten H.
   Penha, Fernando Marcondes
   Furlani, Bruno de Albuquerque
   Fiod Costa, Elaine de Paula
   Farah, Michel Eid
TI Vital dyes in chromovitrectomy
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA Portuguese
DT Article
DE Vitrectomy; Vitreous body; Indocyanine green; Macular hole; Retina;
   Trypan blue; Coloring agents; Epiretinal membrane
ID MACULAR HOLE SURGERY; INTERNAL LIMITING MEMBRANE; RETINAL-PIGMENT
   EPITHELIUM; INDOCYANINE GREEN INJECTION; GLIAL-CELL CULTURES; BRILLIANT
   BLUE-G; TRYPAN BLUE; VITREORETINAL SURGERY; TRIAMCINOLONE ACETONIDE;
   INTRAOCULAR SURGERY
AB The aim of this article is to present the current data with regard to the application of vital dyes during vitreoretinal surgery, "chromovitrectomy", as well as to overview the current literature regarding the properties of dyes, techniques of application, indications and complications in chromovitrectomy. A large body of published research has recently addressed the toxicity profile of indocyanine green for chromovitrectomy. Experimental data demonstrate dose-dependent toxicity of indocyanine green to various retinal cells. Newer generation vital dyes for chromovitrectomy include trypan blue, patent blue, triamcinolone acetonide, infracyanine green, sodium fluorescein, bromophenol blue, fluorometholone acetate and brilliant blue. Novel instruments may enable a selective painting of preretinal tissues during chromovitrectomy. This review suggests that the field of chromovitrectomy represents an expanding area of research. The first line agents for internal limiting membrane staining in chromovitrectomy are indocyanine green, infracyanine green, and brilliant blue. Patent blue, bromophenol blue and trypan blue arose as outstanding biostains for visualization of epiretinal membranes. Novel dyes available for chromovitrectomy deserve further investigation.
C1 [Dib, Eduardo; Rodrigues, Eduardo Buechelle; Maia, Mauricio; Meyer, Carsten H.; Penha, Fernando Marcondes; Furlani, Bruno de Albuquerque; Fiod Costa, Elaine de Paula; Farah, Michel Eid] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao IPEPO, Sao Paulo, Brazil.
RP Dib, E (corresponding author), Rua Doutor Diogo Faria 917-73, BR-04037003 Sao Paulo, Brazil.
EM dibedu@gmail.com
RI Penha, Fernando M/G-1784-2012; Maia, Mauricio/I-5892-2015; Meyer,
   Carsten H./A-3981-2017; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Meyer, Carsten
   H./0000-0002-0530-5298; Farah, Michel Eid E/0000-0001-5951-0193; Buchele
   Rodrigues, Eduardo/0000-0002-4224-0921
CR ABRAMS GW, 1978, ARCH OPHTHALMOL-CHIC, V96, P521
   Ando F, 2004, AM J OPHTHALMOL, V137, P609, DOI 10.1016/j.ajo.2003.08.038
   Burk SE, 2003, J CATARACT REFR SURG, V29, P645, DOI 10.1016/S0886-3350(03)00016-6
   Czajka MP, 2004, RETINA-J RET VIT DIS, V24, P275, DOI 10.1097/00006982-200404000-00014
   Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Guo SQ, 2006, J PEDIAT OPHTH STRAB, V43, P281, DOI 10.3928/01913913-20060901-02
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P3315, DOI 10.1167/iovs.04-1142
   Hata Y, 2007, GRAEF ARCH CLIN EXP, V245, P1019, DOI 10.1007/s00417-006-0499-8
   Hillenkamp J, 2007, GRAEF ARCH CLIN EXP, V245, P973, DOI 10.1007/s00417-006-0485-1
   Hisatomi T, 2006, ARCH OPHTHALMOL-CHIC, V124, P514, DOI 10.1001/archopht.124.4.514
   Iriyama A, 2004, INVEST OPHTH VIS SCI, V45, P943, DOI 10.1167/iovs.03-1026
   Jackson TL, 2007, OPHTHALMOLOGY, V114, P587, DOI 10.1016/j.ophtha.2006.05.079
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P2778, DOI 10.1167/iovs.04-0320
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P3697, DOI 10.1167/iovs.04-0387
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P178, DOI 10.1016/S0002-9394(01)00976-X
   Lochhead J, 2004, EYE, V18, P804, DOI 10.1038/sj.eye.6701328
   Luke C, 2005, BRIT J OPHTHALMOL, V89, P1188, DOI 10.1136/bjo.2004.062794
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Mennel S, 2006, OPHTHALMOLOGICA, V220, P190, DOI 10.1159/000091764
   Mennel S, 2006, KLIN MONATSBL AUGENH, V223, P568, DOI 10.1055/s-2006-926479
   Meyer CH, 2005, GRAEF ARCH CLIN EXP, V243, P487, DOI 10.1007/s00417-004-1054-0
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   Ozawa T, 2005, NEUROSURGERY, V57, P1041, DOI 10.1227/01.NEU.0000180036.42193.f6
   PENHA MF, 2005, ARQ BRAS OFTALMOL S4, V68, P54
   Rebolleda G, 2004, OPHTHALMOLOGY, V111, P1622, DOI 10.1016/j.ophtha.2004.05.008
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2004, OPHTHALMOLOGICA, V218, P73, DOI 10.1159/000074571
   Rodrigues EB, 2008, OPHTHALMOLOGICA, V222, P123, DOI 10.1159/000112630
   Ruiz-Moreno JM, 2007, EXP EYE RES, V84, P342, DOI 10.1016/j.exer.2006.10.006
   Schuettauf F, 2006, INVEST OPHTH VIS SCI, V47, P3573, DOI 10.1167/iovs.06-0211
   Sheidow TG, 2003, OPHTHALMOLOGY, V110, P1697, DOI 10.1016/S0161-6420(03)00562-1
   SOKOLOWSKI J, 1974, LYMPHOLOGY, V7, P28
   Stalmans P, 2002, AM J OPHTHALMOL, V134, P282, DOI 10.1016/S0002-9394(02)01468-X
   Teba FA, 2003, OPHTHALMOLOGY, V110, P2409, DOI 10.1016/S0161-6420(03)00716-4
   Ullern M, 2002, J FR OPHTALMOL, V25, P915
   Veckeneer M, 2001, GRAEF ARCH CLIN EXP, V239, P698, DOI 10.1007/s004170100341
   Westermeier R, 2006, PROTEOMICS, P61
NR 40
TC 7
Z9 7
U1 0
U2 2
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD NOV-DEC
PY 2009
VL 72
IS 6
BP 845
EP 850
DI 10.1590/S0004-27492009000600022
PG 6
WC Ophthalmology
SC Ophthalmology
GA 556LD
UT WOS:000274591700022
PM 20098913
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Wu, L
   Arevalo, JF
   Berrocal, MH
   Maia, M
   Roca, JA
   Morales-Canton, V
   Alezzandrini, AA
   Diaz-Llopis, MJ
AF Wu, Lihteh
   Fernando Arevalo, J.
   Berrocal, Maria H.
   Maia, Mauricio
   Roca, Jose A.
   Morales-Canton, Virgilio
   Alezzandrini, Arturo A.
   Diaz-Llopis, Manuel J.
TI COMPARISON OF TWO DOSES OF INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT
   FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSIONS Results of
   the Pan American Collaborative Retina Study Group at 24 Months
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; branch retinal vein occlusion; intravitreal injections;
   macular edema; retinal vein occlusions; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; COHERENCE TOMOGRAPHY FINDINGS; ARTERIOVENOUS
   CROSSINGS; RISK FACTOR; AVASTIN; DEGENERATION; RANIBIZUMAB; PEGAPTANIB;
   THERAPY; EXPRESSION
AB Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity (BCVA) after injecting 1.25 mg or 2.5 mg of bevacizumab as needed in patients with primary macular edema secondary to branch retinal vein occlusion.
   Methods: An interventional, retrospective, comparative multicenter study was conducted of 63 eyes with macular edema secondary to branch retinal vein occlusion that were treated primarily with intravitreal bevacizumab (38 eyes, 1.25 mg; 25 eyes, 2.5 mg). The main outcome measures were the CMT and the change of BCVA at 24 months.
   Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye was 3.6 in the 1.25-mg group and 4.3 in the 2.5-mg group (P = 0.4770). At 24 months, in the 1.25-mg group, the logarithm of the minimum angle of resolution BCVA improved from baseline 0.38 +/- 0.63 (P < 0.0001) units to 0.64 +/- 0.6 units for the 2.5-mg group (P < 0.0001). In the 1.25-mg group, 26 (68%) eyes gained >= 3 of Early Treatment of Diabetic Retinopathy Study visual acuity and 2 (5%) eyes lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg group, 18 (72%) eyes improved >= 3 of Early Treatment of Diabetic Retinopathy Study visual acuity, and none of the eyes lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg group improved from 453 +/- 140 mu m to 244 +/- 125 mu m (P < 0.0001) versus 444 +/- 175 mu m to 234 +/- 80 mu m in the 2.5-mg group (P < 0.0001). There were no cases of endophthalmitis. No systemic adverse events were reported.
   Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving BCVA and reducing CMT in macular edema secondary to branch retinal vein occlusion. No statistically significant differences were found between the two dose groups with regard to the number of injections, CMT, and change in BCVA. RETINA 29:1396-1403, 2009
C1 [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Fernando Arevalo, J.] Ctr Caracas, Clin Oftalmol, Retina & Vitreous Serv, Caracas, Venezuela.
   [Berrocal, Maria H.] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Maia, Mauricio] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Roca, Jose A.] Clin Ricardo Palma, Lima, Peru.
   [Morales-Canton, Virgilio] Hosp Luis Sanchez Bulnes, Asociac Para Evitar La Ceguera, Mexico City, DF, Mexico.
   [Alezzandrini, Arturo A.] Univ Buenos Aires, Inst Oftalm Alta Complejidad, Buenos Aires, DF, Argentina.
   [Diaz-Llopis, Manuel J.] Inst Oftalmol Valencia, Valencia, Spain.
RP Wu, L (corresponding author), Apdo 144-1225 Plaza Mayor, San Jose, Costa Rica.
EM LW65@cornell.edu
RI Navea, Amparo/D-4577-2009; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015; Fromow-Guerra, J. Jans/A-3346-2015
OI Navea, Amparo/0000-0002-9856-5370; Maia, Mauricio/0000-0002-7034-8091;
   Maia, Mauricio/0000-0002-7034-8091; Fromow-Guerra, J.
   Jans/0000-0001-5335-1275
CR Abegg M, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-18
   Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Badala F, 2008, CURR OPIN OPHTHALMOL, V19, P234, DOI 10.1097/ICU.0b013e3282fb7fb0
   Cahill MT, 2003, BRIT J OPHTHALMOL, V87, P1329, DOI 10.1136/bjo.87.11.1329
   Campochiaro PA, 2008, MOL THER, V16, P791, DOI 10.1038/mt.2008.10
   Christoffersen NLB, 1999, OPHTHALMOLOGY, V106, P2054, DOI 10.1016/S0161-6420(99)90483-9
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Fekrat S, 1998, ARCH OPHTHALMOL-CHIC, V116, P43, DOI 10.1001/archopht.116.1.43
   Figueroa MS, 2004, EUR J OPHTHALMOL, V14, P40
   Funk M, 2009, INVEST OPHTH VIS SCI, V50, P1025, DOI 10.1167/iovs.08-2510
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gunduz K, 2008, EYE, V22, P1168, DOI 10.1038/sj.eye.6703040
   Hayashi A, 1997, INVEST OPHTH VIS SCI, V38, P372
   Heier JS, 2006, OPHTHALMOLOGY, V113, P642
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Jaissle GB, 2009, GRAEF ARCH CLIN EXP, V247, P27, DOI 10.1007/s00417-008-0916-2
   Kaiser PK, 2005, AM J OPHTHALMOL, V139, P1095, DOI 10.1016/j.ajo.2005.03.035
   Kreutzer TC, 2008, BRIT J OPHTHALMOL, V92, P351, DOI 10.1136/bjo.2007.123513
   Kriechbaum K, 2008, BRIT J OPHTHALMOL, V92, P518, DOI 10.1136/bjo.2007.127282
   Matsumoto Y, 2007, RETINA-J RET VIT DIS, V27, P426, DOI 10.1097/IAE.0b013e31804a7af2
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Noma H, 2006, GRAEF ARCH CLIN EXP, V244, P309, DOI 10.1007/s00417-004-1087-4
   ORTH DH, 1978, SURV OPHTHALMOL, V22, P357, DOI 10.1016/0039-6257(78)90132-7
   PEER J, 1995, LAB INVEST, V72, P638
   Pieramici Dante J, 2008, Ophthalmology, V115, pe47, DOI 10.1016/j.ophtha.2008.06.021
   Prager F, 2009, BRIT J OPHTHALMOL, V93, P452, DOI 10.1136/bjo.2008.141085
   Rabena MD, 2007, RETINA-J RET VIT DIS, V27, P419, DOI 10.1097/IAE.0b013e318030e77e
   Rehak M, 2009, INVEST OPHTH VIS SCI, V50, P2359, DOI 10.1167/iovs.08-2332
   Rensch F, 2009, OPHTHALMOLOGICA, V223, P124, DOI 10.1159/000183844
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Russo V, 2009, RETINA-J RET VIT DIS, V29, P511, DOI 10.1097/IAE.0b013e318195ca65
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P298, DOI 10.1016/j.ajo.2008.08.016
   Stahl A, 2007, GRAEF ARCH CLIN EXP, V245, P1429, DOI 10.1007/s00417-007-0569-6
   STAURENGHI G, 1994, AM J OPHTHALMOL, V117, P211, DOI 10.1016/S0002-9394(14)73078-8
   WEINBERG D, 1994, AM J OPHTHALMOL, V118, P263, DOI 10.1016/S0002-9394(14)72917-4
   WEINBERG D, 1990, AM J OPHTHALMOL, V109, P298, DOI 10.1016/S0002-9394(14)74554-4
   WEINBERG DV, 1993, OPHTHALMOLOGY, V100, P31
   Wroblewski JJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P374, DOI 10.1001/archophthalmol.2009.14
   Wu LT, 2008, RETINA-J RET VIT DIS, V28, P212, DOI 10.1097/IAE.0b013e3181619bee
   ZHAO JL, 1993, OPHTHALMOLOGY, V100, P423
   1984, AM J OPHTHALMOL, V98, P271
NR 45
TC 47
Z9 47
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2009
VL 29
IS 10
BP 1396
EP 1403
DI 10.1097/IAE.0b013e3181bcef53
PG 8
WC Ophthalmology
SC Ophthalmology
GA 519SH
UT WOS:000271787600002
PM 19898177
DA 2020-12-15
ER

PT J
AU Farah, ME
   Maia, M
   Rodrigues, EB
AF Farah, Michel Eid
   Maia, Mauricio
   Rodrigues, Eduardo B.
TI Dyes in Ocular Surgery: Principles for Use in Chromovitrectomy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Editorial Material
ID INTERNAL LIMITING MEMBRANE; MACULAR HOLE SURGERY; RETINAL-PIGMENT
   EPITHELIUM; INDOCYANINE GREEN; TRIAMCINOLONE ACETONIDE; TRYPAN BLUE;
   SUBRETINAL INJECTION; VITAL DYES; PROLIFERATIVE VITREORETINOPATHY;
   REMOVAL
AB PURPOSE: To present the current state-of,the-art in. formation regarding the properties, indications, surgical techniques, and toxic effects of current and past applications of vital dyes in chromovitrectomy.
   DESIGN: Critical analysis and surgical perspective of the literature and recent studies.
   METHODS: Review, interpretation, and commentary regarding the most relevant experimental as well as clinical studies including the authors' clinical and laboratory research.
   RESULTS: There is a consensus that the application of vital dyes facilitates the delicate removal of intraocular membranes during vitreoretinal surgery. Controversy still remains around various issues, mainly potential toxicity and safety. There is room for further investigation of novel and specific vital dyes. Dyes such as Evans blue and light green may stain the internal limiting membrane very well, whereas fast green and indigo carmine may be very safe to the retina. However, comparing the staining and toxicity data has revealed that Bromophenol blue and Brilliant blue may be even better novel agents. The dyes currently used for different steps in chromovitrectomy are: triamcinolone acetonide for vitreous identification; indocyanine green, infracyanine green, and Brilliant blue for internal limiting membrane identification; and Trypan blue for epiretinal membrane identification.
   CONCLUSIONS: Clear-cut safety profiles for the different dyes in chromovitrectomy have not yet been established, and current state-of-the-art staining-assisted procedures should be performed using concentrations and volumes as low as possible. (Am J Ophthalmol 2009;148:332-340. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Farah, Michel Eid; Maia, Mauricio; Rodrigues, Eduardo B.] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, Sao Paulo, Brazil.
RP Farah, ME (corresponding author), 331-17 Andar Moema, BR-04524020 Sao Paulo, Brazil.
EM mefarah@uol.com.br
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012; Maia,
   Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Buchele
   Rodrigues, Eduardo/0000-0002-4224-0921
CR ABRAMS GW, 1978, ARCH OPHTHALMOL-CHIC, V96, P521
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Cheema RA, 2007, OPHTHAL SURG LAS IM, V38, P365, DOI 10.3928/15428877-20070901-02
   Eckardt C, 1997, OPHTHALMOLOGE, V94, P545, DOI 10.1007/s003470050156
   Enaida H, 2002, GRAEF ARCH CLIN EXP, V240, P209, DOI 10.1007/s00417-002-0433-7
   Engel E, 2008, INVEST OPHTH VIS SCI, V49, P1777, DOI 10.1167/iovs.07-0911
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Feron EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P141
   Costa EDF, 2009, INVEST OPHTH VIS SCI, V50, P385, DOI 10.1167/iovs.08-2285
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P3315, DOI 10.1167/iovs.04-1142
   Haritoglou C, 2002, AM J OPHTHALMOL, V134, P836, DOI 10.1016/S0002-9394(02)01816-0
   Hiebl W, 2005, KLIN MONATSBL AUGENH, V222, P309, DOI 10.1055/s-2005-858030
   Ho JD, 2004, ARCH OPHTHALMOL-CHIC, V122, P871, DOI 10.1001/archopht.122.6.871
   Jacobs DS, 2006, OPHTHALMOLOGY, V113, P707, DOI 10.1016/j.ophtha.2006.01.024
   Kadonosono K, 2003, GRAEF ARCH CLIN EXP, V241, P284, DOI 10.1007/s00417-003-0636-6
   Koto T, 2007, ACTA OPHTHALMOL SCAN, V85, P913, DOI 10.1111/j.1600-0420.2007.00965.x
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P178, DOI 10.1016/S0002-9394(01)00976-X
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Maia M, 2008, GRAEF ARCH CLIN EXP, V246, P379, DOI 10.1007/s00417-007-0718-y
   Maia M, 2007, BRIT J OPHTHALMOL, V91, P1122, DOI 10.1136/bjo.2007.115386
   Maia M, 2007, CURR EYE RES, V32, P309, DOI 10.1080/02713680701199377
   MALERBI F, 2009, BJO IN PRESS
   MARMOR MF, 1979, INVEST OPHTH VIS SCI, V18, P1237
   Mester V, 2000, AM J OPHTHALMOL, V129, P769, DOI 10.1016/S0002-9394(00)00358-5
   Penha FM, 2008, J OCUL PHARMACOL TH, V24, P52, DOI 10.1089/jop.2007.0047
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2008, OPHTHALMOLOGICA, V222, P123, DOI 10.1159/000112630
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Rodrigues EB, 2009, RETINA-J RET VIT DIS, V29, P497, DOI 10.1097/IAE.0b013e318196b1ad
   Stalmans P, 2002, AM J OPHTHALMOL, V134, P282, DOI 10.1016/S0002-9394(02)01468-X
   Tadayoni R, 2003, OPHTHALMOLOGY, V110, P604, DOI 10.1016/S0161-6420(02)01761-X
   Uno F, 2006, RETINA-J RET VIT DIS, V26, P237, DOI 10.1097/00006982-200602000-00026
   Wollensak G, 2004, OPHTHALMOLOGICA, V218, P278, DOI 10.1159/000078621
NR 36
TC 67
Z9 72
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2009
VL 148
IS 3
BP 332
EP 340
DI 10.1016/j.ajo.2009.04.003
PG 9
WC Ophthalmology
SC Ophthalmology
GA 493RK
UT WOS:000269755400003
PM 19477708
DA 2020-12-15
ER

PT J
AU Rodrigues, EB
   Costa, EF
   Penha, FM
   Melo, GB
   Bottos, J
   Dib, E
   Furlani, B
   Lima, VC
   Maia, M
   Meyer, CH
   Hofling-Lima, AL
   Farah, ME
AF Rodrigues, Eduardo B.
   Costa, Elaine F.
   Penha, Fernando M.
   Melo, Gustavo B.
   Bottos, Juliana
   Dib, Eduardo
   Furlani, Bruno
   Lima, Veronica C.
   Maia, Mauricio
   Meyer, Carsten H.
   Hoefling-Lima, Ana Luisa
   Farah, Michel E.
TI The Use of Vital Dyes in Ocular Surgery
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE vital dye; staining; retina; trypan blue; indocyanine green; vitrectomy;
   chromvitrectomy
ID INTERNAL-LIMITING MEMBRANE; MACULAR HOLE SURGERY; RETINAL-PIGMENT
   EPITHELIUM; INDOCYANINE GREEN-DYE; PARS-PLANA VITRECTOMY; ANTERIOR LENS
   CAPSULE; VISUAL-FIELD DEFECTS; BRILLIANT BLUE-G; INTRAVITREAL
   TRIAMCINOLONE ACETONIDE; IDIOPATHIC EPIRETINAL MEMBRANE
AB Vital dyes have advanced diagnosis and surgical technique in various specialties, including oncology, gastroenterology, and ophthalmology. In ocular Surgery vital dyes are widely used in cataract and vitreoretinal surgery. Worldwide, inta-operative use of trypan blue during cataract surgery has enhanced Visualization of the anterior capsule during capsulorrhexis, and patent blue has been recently licensed in Europe for cataract surgery. For chromovitrectomy, the vital dyes indocyanine green, infracyanine green, and brilliant blue stain the internal limiting membrane, and trypan blue and triamcinolone acetonide help visualize epiretinal membranes and Vitreous, respectively. Intraoperative vital dyes are finding uses in corneal, glaucoma, orbit, strabismus, and conjunctival surgery. We provide a summary of current knowledge of the use of Vital dyes in ocular Surgery. We review the properties of dyes, techniques of application, indications, and complications in ocular surgery. Vital dyes represent an expanding area of research, and novel dyes deserve further investigation. (Surv Ophthalmol 54:576-617, 2009. (C) 2009 Elsevier Inc. All rights reserved.)
C1 [Rodrigues, Eduardo B.; Costa, Elaine F.; Penha, Fernando M.; Melo, Gustavo B.; Bottos, Juliana; Dib, Eduardo; Furlani, Bruno; Lima, Veronica C.; Maia, Mauricio; Hoefling-Lima, Ana Luisa; Farah, Michel E.] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, Sao Paulo, Brazil.
   [Meyer, Carsten H.] Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
RP Rodrigues, EB (corresponding author), R Almirante Barroso 45 Ed Jade 204, BR-88030460 Florianopolis, SC, Brazil.
EM edubrodriguess@gmail.com
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/Z-1042-2019;
   Hofling-Lima, Ana/O-7438-2019; Melo, Gustavo/AAD-3844-2019; Penha,
   Fernando M/G-1784-2012; Hofling-Lima, Ana Luisa/C-8865-2012; Meyer,
   Carsten H./A-3981-2017; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Hofling-Lima, Ana/0000-0003-0338-3951;
   Melo, Gustavo/0000-0001-5765-2008; Meyer, Carsten
   H./0000-0002-0530-5298; Maia, Mauricio/0000-0002-7034-8091; Buchele
   Rodrigues, Eduardo/0000-0002-4224-0921
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Pan-American
   Association of Ophthalmology/Pan-American Ophthalmologic Foundation
FX The authors reported no proprietary or commercial interest in any
   product mentioned or concept discussed in this article. This work was
   supported by FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo) and the Pan-American Association of Ophthalmology/Pan-American
   Ophthalmologic Foundation.
CR ABRAMS GW, 1978, ARCH OPHTHALMOL-CHIC, V96, P521
   Agrawal S, 2005, J CATARACT REFR SURG, V31, P235, DOI 10.1016/j.jcrs.2004.11.002
   Al-Abdulla NA, 2004, OPHTHALMOLOGY, V111, P142, DOI 10.1016/j.ophtha.2003.05.005
   Allen RC, 2006, J CATARACT REFR SURG, V32, P357, DOI 10.1016/j.jcrs.2005.12.038
   Alsagoff Z, 2001, CLIN EXP OPHTHALMOL, V29, P22, DOI 10.1046/j.1442-9071.2001.00365.x
   Ananth C, 2001, J NEUROSCI RES, V66, P177, DOI 10.1002/jnr.1210
   Ando F, 2004, AM J OPHTHALMOL, V138, P886, DOI 10.1016/j.ajo.2004.06.029
   Ando F, 2004, AM J OPHTHALMOL, V137, P609, DOI 10.1016/j.ajo.2003.08.038
   Arevalo JF, 2007, GRAEF ARCH CLIN EXP, V245, P751, DOI 10.1007/s00417-006-0430-3
   ASHBURN FS, 1980, INVEST OPHTH VIS SCI, V19, P1427
   Ashikari M, 2006, JPN J OPHTHALMOL, V50, P349, DOI 10.1007/s10384-006-0325-1
   Bacsal KME, 2006, EYE, V20, P1310, DOI 10.1038/sj.eye.6702164
   Balayre S, 2005, J FR OPHTALMOL, V28, P159, DOI 10.1016/S0181-5512(05)81038-1
   Balayre S, 2005, J FR OPHTALMOL, V28, P169, DOI 10.1016/S0181-5512(05)81039-3
   Balayre S, 2005, J FR OPHTALMOL, V28, P290, DOI 10.1016/S0181-5512(05)81056-3
   Balestrazzi E, 2002, J CATARACT REFR SURG, V28, P929, DOI 10.1016/S0886-3350(02)01225-7
   Bardak Y, 2006, EYE, V20, P1357, DOI 10.1038/sj.eye.6702152
   BARKER DE, 1977, PLAST RECONSTR SURG, V59, P82, DOI 10.1097/00006534-197701000-00015
   Bembenek AE, 2007, ANN SURG, V245, P858, DOI 10.1097/01.sla.0000250428.46656.7e
   Ben Simon GJ, 2004, OPHTHAL SURG LAS IM, V35, P109
   Beutel J, 2007, ARCH OPHTHALMOL-CHIC, V125, P326, DOI 10.1001/archopht.125.3.326
   Bhartiya P, 2002, BRIT J OPHTHALMOL, V86, P857, DOI 10.1136/bjo.86.8.857
   Bishop RM, 2005, J CATARACT REFR SURG, V31, P1272, DOI 10.1016/j.jcrs.2005.06.030
   Bisol T, 2004, J CATARACT REFR SURG, V30, P1732, DOI 10.1016/j.jcrs.2003.12.036
   BLACK GW, 1947, T OPHTHAL SOC UK, V67, P313
   Bopp S, 1997, GRAEF ARCH CLIN EXP, V235, P362, DOI 10.1007/BF00937285
   Brasil Oswaldo Moura, 2006, Arq. Bras. Oftalmol., V69, P157, DOI 10.1590/S0004-27492006000200004
   Brazitikos PD, 2004, ACTA OPHTHALMOL SCAN, V82, P613, DOI 10.1111/j.1600-0420.2004.00324.x
   Brooks HL, 2000, OPHTHALMOLOGY, V107, P1939, DOI 10.1016/S0161-6420(00)00331-6
   Brouzas D, 2006, CORNEA, V25, P470, DOI 10.1097/01.ico.0000183488.78012.33
   Brown SM, 2004, J CATARACT REFR SURG, V30, P2033, DOI 10.1016/j.jcrs.2004.06.073
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Burk SE, 2003, J CATARACT REFR SURG, V29, P645, DOI 10.1016/S0886-3350(03)00016-6
   Cacciatori M, 2006, J CATARACT REFR SURG, V32, P389, DOI 10.1016/j.jcrs.2005.12.076
   Cacciatori M, 2004, RETINA-J RET VIT DIS, V24, P160, DOI 10.1097/00006982-200402000-00025
   Cervera E., 2007, Arch Soc Esp Oftalmol, V82, P71
   Chan CML, 2001, BRIT J OPHTHALMOL, V85, P350, DOI 10.1136/bjo.85.3.350
   Chang YS, 2007, INVEST OPHTH VIS SCI, V48, P2792, DOI 10.1167/iovs.06-1146
   Chang YS, 2006, J CATARACT REFR SURG, V32, P1549, DOI 10.1016/j.jcrs.2006.04.025
   Chang YS, 2005, J CATARACT REFR SURG, V31, P799, DOI 10.1016/j.jcrs.2004.09.029
   Chang YS, 2005, J CATARACT REFR SURG, V31, P792, DOI 10.1016/j.jcrs.2004.07.020
   Chao AN, 2004, J OCUL PHARMACOL TH, V20, P450, DOI 10.1089/1080768042360852
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   Chen TY, 2006, EYE, V20, P423, DOI 10.1038/sj.eye.6701892
   Cheung LM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1125, DOI 10.1001/archopht.123.8.1125
   Chijiwa Hideki, 2007, Nihon Jibiinkoka Gakkai Kaiho, V110, P103
   Chung CF, 2005, J CATARACT REFR SURG, V31, P938, DOI 10.1016/j.jcrs.2004.12.046
   Ciardella AP, 2003, AM J OPHTHALMOL, V136, P174, DOI 10.1016/S0002-9394(03)00090-4
   COMBES RD, 1982, MUTAT RES, V98, P101, DOI 10.1016/0165-1110(82)90015-X
   Conn HJ, 1923, SCIENCE, V58, P41, DOI 10.1126/science.58.1490.41
   Costa RA, 2001, CURR EYE RES, V23, P271, DOI 10.1076/ceyr.23.4.271.5449
   Cullinane AB, 2000, BRIT J OPHTHALMOL, V84, P372, DOI 10.1136/bjo.84.4.372
   Czajka MP, 2004, RETINA-J RET VIT DIS, V24, P275, DOI 10.1097/00006982-200404000-00014
   Da Mata AP, 2004, OPHTHALMOLOGY, V111, P2246, DOI 10.1016/j.ophtha.2004.05.037
   Da Mata AP, 2001, OPHTHALMOLOGY, V108, P1187, DOI 10.1016/S0161-6420(01)00593-0
   Dada T, 2005, J CATARACT REFR SURG, V31, P1842, DOI 10.1016/j.jcrs.2005.09.015
   Dada T, 2006, EYE, V20, P858, DOI 10.1038/sj.eye.6702031
   Dada T, 2002, J CATARACT REFR SURG, V28, P575, DOI 10.1016/S0886-3350(02)01316-0
   Dada VK, 2004, J CATARACT REFR SURG, V30, P326, DOI 10.1016/S0886-3350(03)00573-X
   Das T, 2004, CLIN EXP OPHTHALMOL, V32, P55, DOI 10.1046/j.1442-9071.2003.00758.x
   Delaey E, 2000, J PHOTOCH PHOTOBIO B, V55, P27, DOI 10.1016/S1011-1344(00)00021-X
   DEQUEIROZ JM, 1992, RETINA-J RET VIT DIS, V12, pS33, DOI 10.1097/00006982-199212031-00008
   Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5
   DIAZLLOPIS M, 1994, BRIT J OPHTHALMOL, V78, P120, DOI 10.1136/bjo.78.2.120
   Dierks D, 2005, ARCH OPHTHALMOL-CHIC, V123, P1563, DOI 10.1001/archopht.123.11.1563
   Doi N, 2005, RETINA-J RET VIT DIS, V25, P742, DOI 10.1097/00006982-200509000-00009
   Earhart A, 2005, J INFUS MURS, V28, pS13, DOI 10.1097/00129804-200505001-00003
   Eckardt C, 1997, OPHTHALMOLOGE, V94, P545, DOI 10.1007/s003470050156
   EISNER G, 1966, OPHTHALMOLOGICA, V152, P396, DOI 10.1159/000304997
   Eldin SAG, 1999, J CATARACT REFR SURG, V25, P1289, DOI 10.1016/S0886-3350(99)00153-4
   Enaida H, 2002, GRAEF ARCH CLIN EXP, V240, P209, DOI 10.1007/s00417-002-0433-7
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P623, DOI 10.1097/00006982-200607000-00006
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Facino M, 2004, EUR J OPHTHALMOL, V14, P269
   Ferencz M, 2006, AM J OPHTHALMOL, V142, P765, DOI 10.1016/j.ajo.2006.05.054
   Feron EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P141
   FISHER SK, 1982, J COMP NEUROL, V206, P131, DOI 10.1002/cne.902060204
   FLAGE T, 1983, ACTA OPHTHALMOL, V61, P20
   Fletcher EC, 2004, AM J OPHTHALMOL, V138, P689, DOI 10.1016/j.ajo.2004.06.039
   Foster RE, 2002, RETINA-J RET VIT DIS, V22, P106, DOI 10.1097/00006982-200202000-00019
   FRAMBACH DA, 1982, INVEST OPHTH VIS SCI, V22, P292
   Fritz WL, 1998, J CATARACT REFR SURG, V24, P19, DOI 10.1016/S0886-3350(98)80069-2
   Fritz WL, 2002, J CATARACT REFR SURG, V28, P1034, DOI 10.1016/S0886-3350(02)01238-5
   Fukukita M, 2007, RETINA-J RET VIT DIS, V27, P122, DOI 10.1097/01.iae.0000258270.98012.62
   Furino C, 2003, RETINA-J RET VIT DIS, V23, P771, DOI 10.1097/00006982-200312000-00004
   Gain P, 2002, BRIT J OPHTHALMOL, V86, P306, DOI 10.1136/bjo.86.3.306
   Gale JS, 2004, AM J OPHTHALMOL, V138, P64, DOI 10.1016/j.ajo.2004.02.061
   Gandorfer A, 2005, CURR EYE RES, V30, P977, DOI 10.1080/02713680500320745
   Gandorfer A, 2004, CURR EYE RES, V29, P319, DOI 10.1080/02713680490515964
   Gandorfer A, 2003, BRIT J OPHTHALMOL, V87, P1530, DOI 10.1136/bjo.87.12.1530
   Gandorfer A, 2003, INVEST OPHTH VIS SCI, V44, P316, DOI 10.1167/iovs.02-0545
   Gandorfer A, 2001, AM J OPHTHALMOL, V132, P431, DOI 10.1016/S0002-9394(01)01087-X
   Gandorfer A, 2001, AM J OPHTHALMOL, V131, P387, DOI 10.1016/S0002-9394(00)00924-7
   Garweg JG, 2008, BRIT J OPHTHALMOL, V92, P220, DOI 10.1136/bjo.2007.131862
   Gass CA, 2003, GRAEF ARCH CLIN EXP, V241, P716, DOI 10.1007/s00417-003-0710-0
   Gibran SK, 2008, BRIT J OPHTHALMOL, V92, P373, DOI 10.1136/bjo.2007.129965
   Glickman RD, 2002, INT J TOXICOL, V21, P473, DOI 10.1080/10915810290169909
   Goldman JM, 2007, CURR OPIN OPHTHALMOL, V18, P52, DOI 10.1097/ICU.0b013e3280121b24
   Goldstein M, 2006, INVEST OPHTH VIS SCI, V47, P2100, DOI 10.1167/iovs.05-0206
   Gotzaridis EV, 1999, J CATARACT REFR SURG, V25, P1423, DOI 10.1016/S0886-3350(99)00293-X
   GREENBERG S, 1995, TRENDS CELL BIOL, V5, P93, DOI 10.1016/S0962-8924(00)88957-6
   Grisanti S, 2004, BRIT J OPHTHALMOL, V88, P1206, DOI 10.1136/bjo.2004.042101
   Grisanti S, 2004, INVEST OPHTH VIS SCI, V45, P282, DOI 10.1167/iovs.03-0797
   Guo SQ, 2003, J PEDIAT OPHTH STRAB, V40, P268, DOI 10.3928/0191-3913-20030901-06
   Guo SQ, 2006, J PEDIAT OPHTH STRAB, V43, P281, DOI 10.3928/01913913-20060901-02
   HALVERSON PB, 1992, SCANNING MICROSCOPY, V6, P791
   Haritoglou C, 2006, OPHTHALMOLOGE, V103, P927, DOI 10.1007/s00347-006-1393-9
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P21, DOI 10.1097/00006982-200601000-00004
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P3315, DOI 10.1167/iovs.04-1142
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P1468, DOI 10.1167/iovs.04-0838
   Haritoglou C, 2004, RETINA-J RET VIT DIS, V24, P582, DOI 10.1097/00006982-200408000-00012
   Haritoglou C, 2004, AM J OPHTHALMOL, V138, P1, DOI 10.1016/j.ajo.2004.03.005
   Haritoglou C, 2004, AM J OPHTHALMOL, V137, P345, DOI 10.1016/S0002-9394(03)00845-6
   Haritoglou C, 2002, AM J OPHTHALMOL, V134, P836, DOI 10.1016/S0002-9394(02)01816-0
   Haritoglou C, 2002, OPHTHALMOLOGY, V109, P1039, DOI 10.1016/S0161-6420(02)00970-3
   Haritoglou C, 2002, AM J OPHTHALMOL, V134, P661, DOI 10.1016/S0002-9394(02)01751-8
   Haritoglou C, 2003, AM J OPHTHALMOL, V135, P328, DOI 10.1016/S0002-9394(02)01969-4
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P673, DOI 10.1097/00006982-200607000-00014
   Haritoglou C, 2006, GRAEF ARCH CLIN EXP, V244, P1196, DOI 10.1007/s00417-005-0216-z
   HARTMANN C, 1989, ARCH OPHTHALMOL-CHIC, V107, P1511, DOI 10.1001/archopht.1989.01070020585045
   Hata Y, 2007, GRAEF ARCH CLIN EXP, V245, P1019, DOI 10.1007/s00417-006-0499-8
   Healey PR, 2005, BRIT J OPHTHALMOL, V89, P1152, DOI 10.1136/bjo.2005.071753
   Hiebl W, 2005, KLIN MONATSBL AUGENH, V222, P309, DOI 10.1055/s-2005-858030
   Hillenkamp J, 2005, BRIT J OPHTHALMOL, V89, P437, DOI 10.1136/bjo.2004.051250
   Hillenkamp J, 2007, GRAEF ARCH CLIN EXP, V245, P973, DOI 10.1007/s00417-006-0485-1
   Hirasawa H, 2007, RETINA-J RET VIT DIS, V27, P375, DOI 10.1097/01.iae.0000225090.02078.a7
   Hirata A, 2003, AM J OPHTHALMOL, V136, P353, DOI 10.1016/S0002-9394(03)00121-1
   Hisatomi T, 2006, ARCH OPHTHALMOL-CHIC, V124, P514, DOI 10.1001/archopht.124.4.514
   Hisatomi T, 2001, AM J PATHOL, V158, P1271, DOI 10.1016/S0002-9440(10)64078-3
   Ho JD, 2004, BRIT J OPHTHALMOL, V88, P556, DOI 10.1136/bjo.2003.018523
   Ho JD, 2003, AM J OPHTHALMOL, V135, P258, DOI 10.1016/S0002-9394(02)01976-1
   HOFFER KJ, 1993, J CATARACT REFR SURG, V19, P566, DOI 10.1016/S0886-3350(13)80636-0
   Holley GP, 2002, J CATARACT REFR SURG, V28, P1027, DOI 10.1016/S0886-3350(01)01306-2
   Horiguchi M, 2003, ARCH OPHTHALMOL-CHIC, V121, P327, DOI 10.1001/archopht.121.3.327
   Horiguchi M, 1998, ARCH OPHTHALMOL-CHIC, V116, P535, DOI 10.1001/archopht.116.4.535
   Horio N, 2005, ARCH OPHTHALMOL-CHIC, V123, P96, DOI 10.1001/archopht.123.1.96
   Horio N, 2004, ARCH OPHTHALMOL-CHIC, V122, P992, DOI 10.1001/archopht.122.7.992
   HOSODA L, 1993, ACTA OPHTHALMOL, V71, P616
   HRUBY K, 1946, Wien Klin Wochenschr, V58, P461
   Husson-Danan A, 2006, GRAEF ARCH CLIN EXP, V244, P291, DOI 10.1007/s00417-005-0046-z
   Ignacio TS, 2005, AM J OPHTHALMOL, V139, P325, DOI 10.1016/j.ajo.2004.09.068
   Ikagawa H, 2005, INVEST OPHTH VIS SCI, V46, P2531, DOI 10.1167/iovs.04-1521
   Iriyama A, 2004, INVEST OPHTH VIS SCI, V45, P943, DOI 10.1167/iovs.03-1026
   Ito K, 2007, JPN J OPHTHALMOL, V51, P57, DOI 10.1007/s10384-006-0364-7
   Ito Y, 2005, OPHTHALMOLOGY, V112, P1415, DOI 10.1016/j.ophtha.2005.02.023
   Ivert L, 2002, GRAEF ARCH CLIN EXP, V240, P232, DOI 10.1007/s00417-001-0392-4
   Jackson TL, 2007, OPHTHALMOLOGY, V114, P587, DOI 10.1016/j.ophtha.2006.05.079
   Jackson TL, 2005, EXP EYE RES, V81, P446, DOI 10.1016/j.exer.2005.03.004
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P2778, DOI 10.1167/iovs.04-0320
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P3697, DOI 10.1167/iovs.04-0387
   Jacob S, 2002, J CATARACT REFR SURG, V28, P1819, DOI 10.1016/S0886-3350(01)01316-5
   Jacobs DS, 2006, OPHTHALMOLOGY, V113, P707, DOI 10.1016/j.ophtha.2006.01.024
   Jermak CM, 2007, SURV OPHTHALMOL, V52, P503, DOI 10.1016/j.survophthal.2007.06.004
   Jin Y, 2005, EXP EYE RES, V81, P395, DOI 10.1016/j.exer.2005.02.010
   John T, 2003, J CATARACT REFR SURG, V29, P437, DOI 10.1016/S0886-3350(02)01699-1
   Jutte A, 1968, Buch Augenarzt, V49, P1
   Kadonosono K, 2000, ARCH OPHTHALMOL-CHIC, V118, P1116, DOI 10.1001/archopht.118.8.1116
   Kaji Y, 2006, ACTA OPHTHALMOL SCAN, V84, P825, DOI 10.1111/j.1600-0420.2006.00739.x
   Kampik A, 2006, RETINA-J RET VIT DIS, V26, P599, DOI 10.1097/00006982-200607000-00002
   Kampougeris G, 2007, EYE, V21, P591, DOI 10.1038/sj.eye.6702265
   Kamura Y, 2005, JPN J OPHTHALMOL, V49, P297, DOI 10.1007/s10384-005-0199-7
   KANDA S, ARCH OPHTHALMOL, V122, P1447
   Karacorlu M, 2005, GRAEF ARCH CLIN EXP, V243, P754, DOI 10.1007/s00417-005-1133-x
   Karacorlu M, 2003, AM J OPHTHALMOL, V135, P178, DOI 10.1016/S0002-9394(02)01925-6
   Kawahara S, 2007, INVEST OPHTH VIS SCI, V48, P4426, DOI 10.1167/iovs.07-0358
   Kawaji T, 2004, GRAEF ARCH CLIN EXP, V242, P158, DOI 10.1007/s00417-003-0798-2
   Kawaki H, 2004, CHEM PHARM BULL, V52, P221, DOI 10.1248/cpb.52.221
   Kayikcioglu O, 2007, J CATARACT REFR SURG, V33, P351, DOI 10.1016/j.jcrs.2006.07.049
   Kayikicioglu O, 2001, J CATARACT REFR SURG, V27, P970, DOI 10.1016/S0886-3350(01)01011-2
   Kazem MA, 2007, OPHTHAL SURG LAS IM, V38, P160, DOI 10.3928/15428877-20070301-14
   KELLY NE, 1991, ARCH OPHTHALMOL-CHIC, V109, P654, DOI 10.1001/archopht.1991.01080050068031
   Kersey TL, 2005, CLIN EXP OPHTHALMOL, V33, P538, DOI 10.1111/j.1442-9071.2005.01078.x
   Khng C, 2005, J CATARACT REFR SURG, V31, P1454, DOI 10.1016/j.jcrs.2005.05.014
   Khokhar S, 2003, J CATARACT REFR SURG, V29, P435, DOI 10.1016/S0886-3350(02)01607-3
   Kiel AW, 2003, J PEDIAT OPHTH STRAB, V40, P96, DOI 10.3928/0191-3913-20030301-09
   Kiernan JA, 2001, BIOTECH HISTOCHEM, V76, P261, DOI 10.1080/714028154
   Kiesslich R, 2005, EUR J GASTROEN HEPAT, V17, P793, DOI 10.1097/00042737-200508000-00003
   Kim H, 2006, RETINA-J RET VIT DIS, V26, P523, DOI 10.1097/00006982-200605000-00005
   Kimura H, 2004, AM J OPHTHALMOL, V137, P172, DOI 10.1016/S0002-9394(03)00782-7
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   Kobayashi A, 2005, CORNEA, V24, P759, DOI 10.1097/01.ico.0000154238.87230.05
   Kobayashi A, 2002, AM J OPHTHALMOL, V133, P827, DOI 10.1016/S0002-9394(02)01416-2
   Kobayashi A, 2007, OPHTHAL SURG LAS IM, V38, P81, DOI 10.3928/15428877-20070101-15
   Kodjikian L, 2005, GRAEF ARCH CLIN EXP, V243, P917, DOI 10.1007/s00417-004-1121-6
   Koenig SB, 2007, J CATARACT REFR SURG, V33, P189, DOI 10.1016/j.jcrs.2006.09.035
   Koestinger A, 2005, EUR J OPHTHALMOL, V15, P795
   KOLACNY D, 2005, B SOC BELGE OPHTALMO, V296, P15
   Kothari Kulin, 2001, Indian Journal of Ophthalmology, V49, P177
   Koto T, 2007, ACTA OPHTHALMOL SCAN, V85, P913, DOI 10.1111/j.1600-0420.2007.00965.x
   Kozak I, 2006, RETINA-J RET VIT DIS, V26, P811, DOI 10.1097/01.iae.0000244255.22406.2f
   Kromer I, 2004, OPHTHALMOLOGE, V101, P604, DOI 10.1007/s00347-003-0983-z
   Kumagai K, 2006, RETINA-J RET VIT DIS, V26, P613, DOI 10.1097/00006982-200607000-00004
   Kumar Atul, 2002, Indian Journal of Ophthalmology, V50, P123
   Kunikata H, 2006, AM J OPHTHALMOL, V141, P754, DOI 10.1016/j.ajo.2005.10.054
   Kusaka S, 2001, AM J OPHTHALMOL, V131, P388, DOI 10.1016/S0002-9394(00)00848-5
   KUTSCHERA E, 1969, Albrecht Von Graefes Archiv fuer Klinische und Experimentelle Ophthalmologie, V178, P72
   Kwiatkowska K, 1999, BIOESSAYS, V21, P422, DOI 10.1002/(SICI)1521-1878(199905)21:5<422::AID-BIES9>3.0.CO;2-#
   Kwok AK, 2003, CLIN EXP OPHTHALMOL, V31, P470, DOI 10.1046/j.1442-9071.2003.00709.x
   Kwok AKH, 2005, CLIN EXP OPHTHALMOL, V33, P379, DOI 10.1111/j.1442-9071.2005.01015.x
   Kwok AKH, 2005, BRIT J OPHTHALMOL, V89, P897, DOI 10.1136/bjo.2004.061093
   Kwok AKH, 2004, BRIT J OPHTHALMOL, V88, P1590, DOI 10.1136/bjo.2004.044537
   Kwok AKH, 2004, EYE, V18, P882, DOI 10.1038/sj.eye.6701359
   Kwok AKH, 2003, BRIT J OPHTHALMOL, V87, P71, DOI 10.1136/bjo.87.1.71
   Kwok AKH, 2003, AM J OPHTHALMOL, V136, P223, DOI 10.1016/S0002-9394(02)02144-X
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P1449, DOI 10.1136/bjo.86.12.1449
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P178, DOI 10.1016/S0002-9394(01)00976-X
   La Heij EC, 2005, AM J OPHTHALMOL, V140, P1123, DOI 10.1016/j.ajo.2005.05.054
   Lai CC, 2005, OPHTHALMOLOGY, V112, P1409, DOI 10.1016/j.ophtha.2005.02.025
   Lai MM, 2007, RETINA-J RET VIT DIS, V27, P477, DOI 10.1097/01.iae.0000247166.11120.21
   LANDSMAN MLJ, 1976, J APPL PHYSIOL, V40, P575
   Lanzetta P, 2006, AM J OPHTHALMOL, V142, P771, DOI 10.1016/j.ajo.2006.06.032
   Lee GA, 1998, AUST NZ J OPHTHALMOL, V26, P57, DOI 10.1046/j.1440-1606.1998.00083.x
   Lee JE, 2003, RETINA-J RET VIT DIS, V23, P675, DOI 10.1097/00006982-200310000-00012
   Lee KL, 2005, BRIT J OPHTHALMOL, V89, P420, DOI 10.1136/bjo.2004.049684
   LEVINE WG, 1991, DRUG METAB REV, V23, P253, DOI 10.3109/03602539109029761
   Li FCH, 2005, EYE, V19, P1020, DOI 10.1038/sj.eye.6701714
   Li K, 2003, BRIT J OPHTHALMOL, V87, P216, DOI 10.1136/bjo.87.2.216
   Lobeck E., 1932, ARCH OPHTHALMOL-CHIC, V128, P513
   Lochhead J, 2004, EYE, V18, P804, DOI 10.1038/sj.eye.6701328
   Lopes LAF, 2007, INT J GYNECOL CANCER, V17, P1113, DOI 10.1111/j.1525-1438.2007.00909.x
   Luke C, 2006, GRAEF ARCH CLIN EXP, V244, P1188, DOI 10.1007/s00417-005-0239-5
   Luke M, 2008, GRAEF ARCH CLIN EXP, V246, P817, DOI 10.1007/s00417-007-0761-8
   Luke C, 2005, BRIT J OPHTHALMOL, V89, P1188, DOI 10.1136/bjo.2004.062794
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Maia M, 2008, GRAEF ARCH CLIN EXP, V246, P379, DOI 10.1007/s00417-007-0718-y
   Maia M, 2007, CURR EYE RES, V32, P309, DOI 10.1080/02713680701199377
   Margalit E, 2006, INVEST OPHTH VIS SCI, V47, P2093, DOI 10.1167/iovs.05-0764
   Margherio RR, 2000, ARCH OPHTHALMOL-CHIC, V118, P495
   MARMOR MF, 1979, INVEST OPHTH VIS SCI, V18, P1237
   Matsui Hirofumi, 2007, Nippon Ganka Gakkai Zasshi, V111, P587
   Matsuo H, 2005, AM J OPHTHALMOL, V140, P742, DOI 10.1016/j.ajo.2005.04.013
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Mavrofrides E, 2006, RETINA-J RET VIT DIS, V26, P637, DOI 10.1097/00006982-200607000-00008
   MCENERNEY JK, 1978, ARCH OPHTHALMOL-CHIC, V96, P1445, DOI 10.1001/archopht.1978.03910060193019
   MEANS TL, 1995, ARCH OPHTHALMOL-CHIC, V113, P805, DOI 10.1001/archopht.1995.01100060131047
   MELBERG NS, 1995, AM J OPHTHALMOL, V120, P386, DOI 10.1016/S0002-9394(14)72169-5
   Melendez RF, 2005, AM J OPHTHALMOL, V140, P132, DOI 10.1016/j.ajo.2004.12.086
   Melles GRJ, 1999, J CATARACT REFR SURG, V25, P7, DOI 10.1016/S0886-3350(99)80004-2
   Melles GRJ, 1999, KLIN MONATSBL AUGENH, V215, P342, DOI 10.1055/s-2008-1034729
   Mennel S, 2006, OPHTHALMOLOGICA, V220, P190, DOI 10.1159/000091764
   Mennel S, 2006, KLIN MONATSBL AUGENH, V223, P568, DOI 10.1055/s-2006-926479
   Mester V, 2000, AM J OPHTHALMOL, V129, P769, DOI 10.1016/S0002-9394(00)00358-5
   Meyer CH, 2005, GRAEF ARCH CLIN EXP, V243, P487, DOI 10.1007/s00417-004-1054-0
   Meyer DR, 1999, OPHTHALMOLOGY, V106, P342, DOI 10.1016/S0161-6420(99)90074-X
   MICHELS M, 1995, INT OPHTHALMOL CLIN, V35, P157, DOI 10.1097/00004397-199503540-00013
   Morrison VL, 2006, RETINA-J RET VIT DIS, V26, P339, DOI 10.1097/00006982-200603000-00014
   Murata M, 2005, RETINA-J RET VIT DIS, V25, P75, DOI 10.1097/00006982-200501000-00011
   Nagai N, 2007, ACTA OPHTHALMOL SCAN, V85, P883, DOI 10.1111/j.1600-0420.2007.00973.x
   Nakamura H, 2005, OPHTHAL SURG LAS IM, V36, P37
   Nakamura T, 2003, CURR EYE RES, V27, P395, DOI 10.1076/ceyr.27.6.395.18189
   Nanavaty MA, 2006, J CATARACT REFR SURG, V32, P1483, DOI 10.1016/j.jcrs.2006.04.017
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   Narayanan R, 2005, CURR EYE RES, V30, P471, DOI 10.1080/02713680590959312
   Nawrocki J, 2005, KLIN MONATSBL AUGENH, V222, P572, DOI 10.1055/s-2005-858426
   NEAL CR, 1981, ARCH INTERN MED, V141, P171, DOI 10.1001/archinte.141.2.171
   NEGI A, 1984, INVEST OPHTH VIS SCI, V25, P616
   NEGI A, 1983, INVEST OPHTH VIS SCI, V24, P1475
   Newsom TH, 2000, J CATARACT REFR SURG, V26, P1691, DOI 10.1016/S0886-3350(00)00432-6
   NIEDERMEIER S, 1964, Albrecht Von Graefes Arch Ophthalmol, V167, P201, DOI 10.1007/BF00689773
   Nishimura A, 2003, JPN J OPHTHALMOL, V47, P18, DOI 10.1016/S0021-5155(02)00648-2
   Nodarian M, 2001, J FR OPHTALMOL, V24, P274
   NORN MS, 1980, ACTA OPHTHALMOL, V58, P550
   Oberstein SYL, 2007, BRIT J OPHTHALMOL, V91, P955, DOI 10.1136/bjo.2006.112425
   OFFRET G, 1950, B SOC OPHTHALMOL FR, V2, P66
   Oficjalska-Mlynczak Jolanta, 2005, Klin Oczna, V107, P650
   Oh J, 2007, ACTA OPHTHALMOL SCAN, V85, P786, DOI 10.1111/j.1600-0420.2007.00942.x
   Ohji M, 1999, AM J OPHTHALMOL, V127, P62, DOI 10.1016/S0002-9394(98)00287-6
   Oie Y, 2007, OPHTHALMOLOGY, V114, P303, DOI 10.1016/j.ophtha.2006.07.052
   Okazaki T, 2007, J GLAUCOMA, V16, P257, DOI 10.1097/IJG.0b013e31802d6982
   OLSEN KJ, 1979, ACTA PHARMACOL TOX, V44, P241
   Olsen TW, 1998, RETINA-J RET VIT DIS, V18, P322
   Olson JL, 2005, CLIN EXP OPHTHALMOL, V33, P576, DOI 10.1111/j.1442-9071.2005.01097.x
   Ozawa T, 2005, NEUROSURGERY, V57, P1041, DOI 10.1227/01.NEU.0000180036.42193.f6
   Ozkiris A, 2003, EUR J OPHTHALMOL, V13, P764
   Pandey SK, 2000, J CATARACT REFR SURG, V26, P1066, DOI 10.1016/S0886-3350(00)00297-2
   Pandey SK, 2000, J CATARACT REFR SURG, V26, P1052, DOI 10.1016/S0886-3350(00)00296-0
   Pandey SK, 2001, J CATARACT REFR SURG, V27, P647, DOI 10.1016/S0886-3350(01)00883-5
   Park DW, 1999, OPHTHALMOLOGY, V106, P1392, DOI 10.1016/S0161-6420(99)00730-7
   Park DW, 2003, OPHTHALMOLOGY, V110, P62, DOI 10.1016/S0161-6420(02)01440-9
   Pendergast SD, 1996, OPHTHALMOLOGY, V103, P1069, DOI 10.1016/S0161-6420(96)30565-4
   Penha FM, 2008, J OCUL PHARMACOL TH, V24, P52, DOI 10.1089/jop.2007.0047
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Perrier M, 2003, AM J OPHTHALMOL, V135, P903, DOI 10.1016/S0002-9394(02)02239-0
   Perrier M, 2003, AM J OPHTHALMOL, V135, P909, DOI 10.1016/S0002-9394(02)02256-0
   Persichetti P, 2004, PLAST RECONSTR SURG, V113, P373, DOI 10.1097/01.PRS.0000097290.64125.C3
   Peters S, 2007, EXP EYE RES, V85, P880, DOI 10.1016/j.exer.2007.08.024
   PEYMAN GA, 1995, SURV OPHTHALMOL, V39, P375
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   PEYMAN GA, 1989, JPN J OPHTHALMOL, V33, P392
   PHARMAKAKIS N, 1995, OPHTHALMIC RES, V27, P67, DOI 10.1159/000267598
   Portes ALF, 2007, J CATARACT REFR SURG, V33, P1135, DOI 10.1016/j.jcrs.2007.02.038
   Posselt D, 2005, EYE, V19, P279, DOI 10.1038/sj.eye.6701455
   Radetzky S, 2004, GRAEF ARCH CLIN EXP, V242, P273, DOI 10.1007/s00417-003-0731-8
   Raspotnig G, 1999, ANAL BIOCHEM, V275, P74, DOI 10.1006/abio.1999.4309
   Reeves G, 2007, J GLAUCOMA, V16, P479, DOI 10.1097/01.ijg.0000212263.89240.d6
   REICHEL E, 1994, OPHTHALMIC SURG LAS, V25, P195
   Rezai KA, 2004, AM J OPHTHALMOL, V138, P492, DOI 10.1016/j.ajo.2004.03.033
   Rivett K, 2004, GRAEF ARCH CLIN EXP, V242, P393, DOI 10.1007/s00417-003-0857-8
   Rizzo S, 2006, GRAEF ARCH CLIN EXP, V244, P1615, DOI 10.1007/s00417-006-0316-4
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Rodrigues EB, 2008, OPHTHALMOLOGICA, V222, P123, DOI 10.1159/000112630
   Rodrigues EB, 2007, RETINA-J RET VIT DIS, V27, P958, DOI 10.1097/01.iae.0000253051.01194.ab
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Roos JCP, 2005, J CATARACT REFR SURG, V31, P1867, DOI 10.1016/j.jcrs.2005.03.064
   Rossiter J, 2005, EYE, V19, P809, DOI 10.1038/sj.eye.6701646
   Rufer F, 2007, OPHTHALMOLOGE, V104, P54, DOI 10.1007/s00347-006-1379-7
   Ruiz-Moreno JM, 2007, EXP EYE RES, V84, P342, DOI 10.1016/j.exer.2006.10.006
   RYAN EH, 1994, ARCH OPHTHALMOL-CHIC, V112, P1545, DOI 10.1001/archopht.1994.01090240051025
   Saini JS, 2003, J CATARACT REFR SURG, V29, P1733, DOI 10.1016/S0886-3350(03)00229-3
   Saito M, 2006, OPHTHAL SURG LAS IM, V37, P511, DOI 10.3928/15428877-20061101-15
   Sakaguchi H, 2004, AM J OPHTHALMOL, V138, P1079, DOI 10.1016/j.ajo.2004.06.078
   Sakamoto H, 2003, GRAEF ARCH CLIN EXP, V241, P204, DOI 10.1007/s00417-002-0601-9
   Sakamoto T, 2002, GRAEF ARCH CLIN EXP, V240, P423, DOI 10.1007/s00417-002-0454-2
   Salicone A, 2006, OPHTHALMOLOGY, V113, P398, DOI 10.1016/j.ophtha.2005.10.002
   San Laureano J, 2004, J CATARACT REFR SURG, V30, P2046, DOI 10.1016/j.jcrs.2004.02.078
   Sato Y, 2006, OPHTHALMOLOGICA, V220, P153, DOI 10.1159/000091757
   Satofuka S, 2004, J CATARACT REFR SURG, V30, P1751, DOI 10.1016/j.jcrs.2003.12.040
   Saxena R, 2007, J PEDIAT OPHTH STRAB, V44, P45, DOI 10.3928/01913913-20070101-06
   Sayanagi K, 2007, AM J OPHTHALMOL, V144, P600, DOI 10.1016/j.ajo.2007.05.039
   Sayanagi K, 2007, BRIT J OPHTHALMOL, V91, P939, DOI 10.1136/bjo.2006.108746
   Schechter RJ, 2002, AM J OPHTHALMOL, V134, P150, DOI 10.1016/S0002-9394(02)01467-8
   Schinzel A, 2004, BBA-MOL CELL RES, V1644, P95, DOI 10.1016/j.bbamcr.2003.09.006
   Schmidt JC, 2004, OPHTHALMOLOGICA, V218, P176, DOI 10.1159/000076841
   Schuettauf F, 2006, INVEST OPHTH VIS SCI, V47, P3573, DOI 10.1167/iovs.06-0211
   SCHULTE EKW, 1991, HISTOCHEMISTRY, V95, P319, DOI 10.1007/BF00266958
   Scupola A, 2006, RETINA-J RET VIT DIS, V26, P236, DOI 10.1097/00006982-200602000-00025
   Sebag J, 2004, AM J OPHTHALMOL, V137, P744, DOI 10.1016/j.ajo.2003.11.058
   Sekiryu T, 2007, RETINA-J RET VIT DIS, V27, P190, DOI 10.1097/01.iae.0000237079.08886.87
   Shah GK, 2005, RETINA-J RET VIT DIS, V25, P972, DOI 10.1097/00006982-200512000-00003
   Shah GK, 2004, AM J OPHTHALMOL, V138, P656, DOI 10.1016/j.ajo.2004.04.025
   Sheidow TG, 2003, OPHTHALMOLOGY, V110, P1697, DOI 10.1016/S0161-6420(03)00562-1
   Shields CL, 2004, SURV OPHTHALMOL, V49, P3, DOI 10.1016/j.survophthal.2003.10.008
   SIMONELLI M, 1953, G ITAL OFTAL, V6, P322
   Singh AJ, 2003, EYE, V17, P567, DOI 10.1038/sj.eye.6700440
   Singh G, 1985, Cornea, V4, P80
   Sinha R, 2006, TROP DOCT, V36, P63, DOI 10.1258/004947506775598761
   Sinha R, 2003, BRIT J OPHTHALMOL, V87, P654, DOI 10.1136/bjo.87.5.654
   Sippy BD, 2001, AM J OPHTHALMOL, V132, P433, DOI 10.1016/S0002-9394(01)01061-3
   Slaughter K, 2004, EYE, V18, P376, DOI 10.1038/sj.eye.6700666
   SMIDDY WE, 1989, OPHTHALMOLOGY, V96, P811
   SMIT TJ, 1991, BRIT J OPHTHALMOL, V75, P342, DOI 10.1136/bjo.75.6.342
   SOKOLOWSKI J, 1974, LYMPHOLOGY, V7, P28
   Sonoda KH, 2004, OPHTHALMOLOGY, V111, P226, DOI 10.1016/j.ophtha.2003.05.034
   SORSBY A, 1939, T OPHTHAL SOC UK, V59, P727
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P637, DOI 10.1097/00006982-200210000-00016
   SPERLING S, 1986, GRAEF ARCH CLIN EXP, V224, P428, DOI 10.1007/BF02173358
   Stalmans P, 2003, AM J OPHTHALMOL, V135, P234, DOI 10.1016/S0002-9394(02)01891-3
   Stalmans P, 2003, BRIT J OPHTHALMOL, V87, P713, DOI 10.1136/bjo.87.6.713
   Stalmans P, 2001, Bull Soc Belge Ophtalmol, P21
   Stalmans P, 2002, AM J OPHTHALMOL, V134, P282, DOI 10.1016/S0002-9394(02)01468-X
   STOCKER FW, 1966, ARCH OPHTHALMOL-CHIC, V76, P833
   Szurman P, 2006, EXP EYE RES, V83, P584, DOI 10.1016/j.exer.2006.02.012
   Tadayoni R, 2003, OPHTHALMOLOGY, V110, P604, DOI 10.1016/S0161-6420(02)01761-X
   Takasu I, 2004, RETINA-J RET VIT DIS, V24, P620, DOI 10.1097/00006982-200408000-00021
   Tari SR, 2007, RETINA-J RET VIT DIS, V27, P567, DOI 10.1097/IAE.0b013e31802ea53d
   TAYLOR MJ, 1981, BRIT J OPHTHALMOL, V65, P815, DOI 10.1136/bjo.65.12.815
   Teba FA, 2003, OPHTHALMOLOGY, V110, P2409, DOI 10.1016/S0161-6420(03)00716-4
   Titiyal JS, 2006, EYE, V20, P386, DOI 10.1038/sj.eye.6701854
   Tognetto D, 2006, OPHTHALMOLOGY, V113, P1401, DOI 10.1016/j.ophtha.2006.02.061
   Toprak AB, 2003, OPHTHALMIC SUR LA IM, V34, P236, DOI 10.3928/1542-8877-20030501-17
   Tornambe P, 2002, OPHTHALMOLOGE, V99, P601, DOI 10.1007/s00347-002-0677-y
   Trost LW, 2007, J OCUL PHARMACOL TH, V23, P70, DOI 10.1089/jop.2006.0076
   Tsai CC, 2007, ACTA OPHTHALMOL SCAN, V85, P909, DOI 10.1111/j.1600-0420.2007.00946.x
   Tsuiki E, 2007, AM J OPHTHALMOL, V143, P704, DOI 10.1016/j.ajo.2006.10.051
   Uemoto R, 2005, AM J OPHTHALMOL, V140, P752, DOI 10.1016/j.ajo.2005.04.035
   Uemura A, 2003, AM J OPHTHALMOL, V136, P252, DOI 10.1016/S0002-9394(03)00157-0
   Ueno A, 2007, RETINA-J RET VIT DIS, V27, P499, DOI 10.1097/IAE.0b013e318030a129
   Ueno S, 2006, INVEST OPHTH VIS SCI, V47, P3545, DOI 10.1167/iovs.05-1481
   Ullern M, 2007, J FR OPHTALMOL, V30, P53, DOI 10.1016/S0181-5512(07)89551-9
   Ullern M, 2002, J FR OPHTALMOL, V25, P915
   Unlu K, 2000, J CATARACT REFR SURG, V26, P1228, DOI 10.1016/S0886-3350(00)00360-6
   Uno F, 2006, RETINA-J RET VIT DIS, V26, P237, DOI 10.1097/00006982-200602000-00026
   Van de Moere A, 2003, AM J OPHTHALMOL, V136, P879, DOI 10.1016/S0002-9394(03)00543-9
   van Dooren BTH, 2004, ARCH OPHTHALMOL-CHIC, V122, P736, DOI 10.1001/archopht.122.5.736
   van Dooren BTH, 2002, J CATARACT REFR SURG, V28, P574, DOI 10.1016/S0886-3350(02)01315-9
   Veckeneer M, 2001, GRAEF ARCH CLIN EXP, V239, P698, DOI 10.1007/s004170100341
   VENNERSTROM JL, 1995, ANTIMICROB AGENTS CH, V39, P2671, DOI 10.1128/AAC.39.12.2671
   Verdugo-Gazdik ME, 2006, ASSAY DRUG DEV TECHN, V4, P695, DOI 10.1089/adt.2006.4.695
   Verma Lalit, 2003, Indian J Ophthalmol, V51, P106
   Vote BJ, 2004, RETINA-J RET VIT DIS, V24, P736, DOI 10.1097/00006982-200410000-00008
   Wakabayashi T, 2002, J CATARACT REFR SURG, V28, P2042, DOI 10.1016/S0886-3350(02)01443-8
   Walmsley S, 1999, DRUG SAFETY, V21, P203, DOI 10.2165/00002018-199921030-00005
   Wang Hsin-Huang, 2005, Kaohsiung Journal of Medical Sciences, V21, P108
   Wang K, 2006, GRAEF ARCH CLIN EXP, V244, P1152, DOI 10.1007/s00417-005-0251-9
   Weinberger AWA, 2002, GRAEF ARCH CLIN EXP, V240, P913, DOI 10.1007/s00417-002-0544-1
   Weinberger AWA, 2001, GRAEF ARCH CLIN EXP, V239, P388, DOI 10.1007/s004170100267
   Welch JC, 1997, AM J OPHTHALMOL, V124, P698, DOI 10.1016/S0002-9394(14)70915-8
   Welch JC, 1999, AM J OPHTHALMOL, V128, P396
   WENDEL RT, 1993, OPHTHALMOLOGY, V100, P1671
   Werner L, 2002, J CATARACT REFR SURG, V28, P1279, DOI 10.1016/S0886-3350(02)01207-5
   Werner L, 2000, J CATARACT REFR SURG, V26, P1060, DOI 10.1016/S0886-3350(00)00363-1
   Westermeier R, 2006, PROTEOMICS, P61
   WHITACRE MM, 1990, CURR EYE RES, V9, P725, DOI 10.3109/02713689008999567
   Wilhelm F., 1995, Ophthalmologe, V92, P496
   Wilhelm F., 1993, Ophthalmologe, V90, P171
   Wollensak G, 2004, CURR EYE RES, V29, P413, DOI 10.1080/02713680490522498
   Wollensak G, 2004, J CATARACT REFR SURG, V30, P1526, DOI 10.1016/j.jcrs.2003.11.031
   Wollensak G, 2004, OPHTHALMOLOGICA, V218, P278, DOI 10.1159/000078621
   Wong VWY, 2006, EYE, V20, P820, DOI 10.1038/sj.eye.6702032
   Wrede J, 2006, OPHTHALMOLOGE, V103, P935, DOI 10.1007/s00347-006-1421-9
   Xiao Yang, 2004, International Ophthalmology, V25, P273, DOI 10.1007/s10792-005-2228-4
   Yam HF, 2003, INVEST OPHTH VIS SCI, V44, P370, DOI 10.1167/iovs.01-1113
   Yamakiri K, 2004, AM J OPHTHALMOL, V138, P650, DOI 10.1016/j.ajo.2004.05.033
   Yamakiri K, 2007, OPHTHALMOLOGY, V114, P289, DOI 10.1016/j.ophtha.2006.07.044
   Yamamoto N, 2004, OPHTHALMOLOGICA, V218, P297, DOI 10.1159/000079470
   Yamamoto N, 2004, OPHTHALMOLOGICA, V218, P248, DOI 10.1159/000078615
   Yamauchi Y, 2006, ACTA OPHTHALMOL SCAN, V84, P711, DOI 10.1111/j.1600-0420.2006.00702.x
   Yetik H, 2002, J CATARACT REFR SURG, V28, P988, DOI 10.1016/S0886-3350(02)01217-8
   Yeung CK, 2003, INVEST OPHTH VIS SCI, V44, P5293, DOI 10.1167/iovs.03-0490
   Yip HKF, 2006, BRIT J OPHTHALMOL, V90, P99, DOI 10.1136/bjo.2005.076042
   Yonemura N, 2001, OPHTHALMOLOGY, V108, P1638, DOI 10.1016/S0161-6420(01)00677-7
   YU DD, 1991, OPHTHALMIC SURG LAS, V22, P233
   Yu SY, 2006, RETINA-J RET VIT DIS, V26, P531, DOI 10.1097/00006982-200605000-00006
NR 418
TC 73
Z9 78
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD SEP-OCT
PY 2009
VL 54
IS 5
BP 576
EP 617
DI 10.1016/j.survophthal.2009.04.011
PG 42
WC Ophthalmology
SC Ophthalmology
GA 488KQ
UT WOS:000269348900004
PM 19682624
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Maia, M
   Garcia-Amaris, RA
   Roca, JA
   Sanchez, JG
   Berrocal, MH
   Wu, L
AF Fernando Arevalo, J.
   Maia, Mauricio
   Garcia-Amaris, Rafael A.
   Roca, Jose A.
   Sanchez, Juan G.
   Berrocal, Maria H.
   Wu, Lihteh
CA PACORES
TI Intravitreal Bevacizumab for Refractory Pseudophakic Cystoid Macular
   Edema The Pan-American Collaborative Retina Study Group Results
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; AVASTIN TREATMENT; RETINOPATHY; TOXICITY;
   THERAPY
AB Objective: To determine the feasibility, safety, and clinical effect of intravitreal (IVT) bevacizumab (Avastin; Genentech, Inc., San Francisco, CA) in patients with refractory cystoid macular edema (CME) after cataract surgery.
   Design: Interventional, retrospective, multicenter study.
   Participants: Thirty-six eyes of 31 patients with refractory CME after cataract surgery and with a mean age of 68.2 years (range, 67-87 years).
   Methods: Patients were treated with at least 1 IVT injection of 1.25 or 2.5 mg bevacizumab. Patients were followed up for 12 months.
   Main Outcome Measures: Best-corrected visual acuity (BCVA) and central macular thickness (CMT) by optical coherence tomography (OCT).
   Results: Twenty-six eyes (72.2%) demonstrated improvement of BCVA ( >= 2 Early Treatment Diabetic Retinopathy Study [ETDRS] lines), and no eye experienced worsening of visual acuity (>= 2 ETDRS lines). Mean baseline BCVA was 20/200 (0.96 logarithm of the minimum angle of resolution [logMAR] units), and the mean 12-month BCVA was 20/80 (0.62 logMAR units; P<0.0001). Optical coherence tomography demonstrated that mean CMT at baseline was 499.9 mu m (range, 298-784 mu m) and decreased to a mean of 286.1 mu m (range, 168-499 mu m) at 12 months (P<0.0001). Four (11%) eyes received 2 injections, 10 (27.8%) eyes received 3 injections, 10 (27.8%) eyes received 4 injections, 1 (2.8%) eye received 5 injections, and 1 (2.8%) eye received 6 injections. The mean number of injections was 2.7 (range, 1-6), and the mean interval between injections was 15.1 weeks (range, 4-45 weeks). No ocular or systemic adverse events were observed.
   Conclusions: Short-term results suggest that IVT bevacizumab is well tolerated in patients with refractory pseudophakic CME. Treated eyes had a significant improvement in BCVA and decrease in macular thickness by OCT at 12 months.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:1481-1487 0 2009 by the American Academy of Ophthalmology.
C1 [Fernando Arevalo, J.; Garcia-Amaris, Rafael A.; Sanchez, Juan G.] Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Caracas 1010, Venezuela.
   [Maia, Mauricio] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Roca, Jose A.] Clin Ricardo Palma, Lima, Peru.
   [Berrocal, Maria H.] Univ Puerto Rico, Dept Ophthalmol, San Juan, PR 00936 USA.
   [Wu, Lihteh] Inst Cirugia Ocular, Retina & Vitreous Serv, San Jose, Costa Rica.
RP Arevalo, JF (corresponding author), Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Edif Ctr Caracas PH 1,Av Panteon, Caracas 1010, Venezuela.
EM arevalojf2020@gmail.com
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019; Fromow-Guerra,
   J. Jans/A-3346-2015
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Fromow-Guerra, J. Jans/0000-0001-5335-1275
FU Arevalo-Coutinho Foundation for Research in Ophthalmology Caracas,
   Venezuela
FX Supported in Part by the Arevalo-Coutinho Foundation for Research in
   Ophthalmology Caracas, Venezuela.
CR Arevalo JF, 2007, J CATARACT REFR SURG, V33, P2098, DOI 10.1016/j.jcrs.2007.07.046
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Conway MD, 2003, J CATARACT REFR SURG, V29, P27, DOI 10.1016/S0886-3350(02)01441-4
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Flach A J, 1998, Trans Am Ophthalmol Soc, V96, P557
   HARBOUR JM, 1995, AM J OPHTHALMOL, V120, P302, DOI 10.1016/S0002-9394(14)72159-2
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Kent D, 2000, BRIT J OPHTHALMOL, V84, P542, DOI 10.1136/bjo.84.5.542
   Levin Darrin S, 2002, Ophthalmol Clin North Am, V15, P467, DOI 10.1016/S0896-1549(02)00041-X
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mason JO, 2006, RETINA-J RET VIT DIS, V26, P356, DOI 10.1097/00006982-200603000-00018
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Miyake K, 2002, SURV OPHTHALMOL, V47, pS203, DOI 10.1016/S0039-6257(02)00294-1
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Noma H, 2006, GRAEF ARCH CLIN EXP, V244, P309, DOI 10.1007/s00417-004-1087-4
   OGURA Y, 1987, AM J OPHTHALMOL, V104, P301, DOI 10.1016/0002-9394(87)90422-3
   Rho DS, 2003, J CATARACT REFR SURG, V29, P2378, DOI 10.1016/S0886-3350(03)00233-5
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Spitzer MS, 2008, J CATARACT REFR SURG, V34, P70, DOI 10.1016/j.jcrs.2007.08.021
   STARK WJ, 1984, SURV OPHTHALMOL, V28, P442, DOI 10.1016/0039-6257(84)90226-1
   STEINERT RF, 1989, J CATARACT REFR SURG, V15, P304, DOI 10.1016/S0886-3350(89)80089-6
   Thach AB, 1997, OPHTHALMOLOGY, V104, P2003, DOI 10.1016/S0161-6420(97)30065-7
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Tranos PG, 2004, SURV OPHTHALMOL, V49, P470, DOI 10.1016/j.survophthal.2004.06.002
NR 29
TC 66
Z9 70
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2009
VL 116
IS 8
BP 1481
EP 1487
DI 10.1016/j.ophtha.2009.04.006
PG 7
WC Ophthalmology
SC Ophthalmology
GA 480CT
UT WOS:000268710200011
PM 19545901
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Sanchez, JG
   Wu, L
   Maia, M
   Alezzandrini, AA
   Brito, M
   Bonafonte, S
   Lujan, S
   Diaz-Llopis, M
   Restrepo, N
   Rodriguez, FJ
   Udaondo-Mirete, P
AF Fernando Arevalo, J.
   Sanchez, Juan G.
   Wu, Lihteh
   Maia, Mauricio
   Alezzandrini, Arturo A.
   Brito, Miguel
   Bonafonte, Sergio
   Lujan, Silvio
   Diaz-Llopis, Manuel
   Restrepo, Natalia
   Rodriguez, Francisco J.
   Udaondo-Mirete, Patricia
CA PACORES
TI Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema The
   Pan-American Collaborative Retina Study Group at 24 Months
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1;
   TRIAMCINOLONE ACETONIDE; AVASTIN TREATMENT; VITREOUS LEVELS;
   RETINOPATHY; NEOVASCULARIZATION; INJECTION; REGRESSION; PHOTOCOAGULATION
AB Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin; Genentech, Inc., San Francisco, CA; 1.25 or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In addition, a comparison of the 2 different doses of intravitreal bevacizumab (IVB) used is presented.
   Design: Retrospective, multicenter, interventional, comparative case series.
   Participants: The clinical records of 115 consecutive patients (139 eyes) with DDME at 11 centers from 8 countries were reviewed.
   Methods: Patients were treated with at least 1 intravitreal injection of 1.25 or 2.5 mg of bevacizumab. All patients were followed up for 24 months. Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at the baseline, 1-, 3-, 6-, 12-, and 24-month visits.
   Main Outcome Measures: Changes in BCVA and OCT results.
   Results: The mean age of the patients was 59.4 +/- 11.1 years. The mean number of IVB injections per eye was 5.8 (range, 1-15 injections). In the 1.25-mg group at 1 month, BCVA improved from 20/150 (0.88 logarithm of the minimum angle of resolution [logMAR] units) to 20/107, 0.76 logMAR units (P<0.0001). The mean IBCVA at 24 months was 20/75 (0.57 logMAR units; P<0.0001). Similar BCVA changes were observed in the 2.5-mg group: at 1 month, BCVA improved from 20/168 (0.92 logMAR units) to 20/118 (0.78 logMAR units; P = 0.02). The mean BCVA at 24 months was 20/114 (0.76 logMAR units; P<0.0001). In the 1.25-mg group, the mean central macular thickness (CMT) decreased from 466.5 +/- 145.2 mu m at baseline to 332.2 +/- 129.6 mu m at 1 month and 286.6 +/- 81.5 mu m at 24 months (P<0.0001). Similar results were obtained in the 2.5-mg group.
   Conclusions: Primary IVB at doses of 1.25 to 2.5 mg seem to provide stability or improvement in BCVA, OCT, and FA in DDME at 24 months. The results show no evident difference between IVB at doses of 1.25 or 2.5 mg.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:1488-1497 (C) 2009 by the American Academy of Ophthalmology.
C1 [Fernando Arevalo, J.] Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Caracas 1010, Venezuela.
   [Sanchez, Juan G.; Restrepo, Natalia] INIO, Medellin, Colombia.
   [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Maia, Mauricio] Univ Fed Sao Paulo, Inst Visao, Dept Oftalmol, Sao Paulo, Brazil.
   [Alezzandrini, Arturo A.] Univ Buenos Aires, Fac Med, OFTALMOS, Buenos Aires, DF, Argentina.
   [Brito, Miguel] IDEO, Maracaibo, Venezuela.
   [Bonafonte, Sergio] Ctr Oftalmol Bonafonte Barcelona, Barcelona, Spain.
   [Lujan, Silvio] MACULA D&T Diagnost Tratamiento & Rehabil Visual, Lima, Peru.
   [Diaz-Llopis, Manuel; Udaondo-Mirete, Patricia] Gen Univ Valencia, Consorcio Hosp, Valencia, Spain.
   [Rodriguez, Francisco J.] Univ Nacl Rosario, Fdn Oftalmol Nacl, Bogota, Colombia.
RP Arevalo, JF (corresponding author), Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Edif Ctr Caracas PH 1,Av Panteon, Caracas 1010, Venezuela.
EM arevalojf2020@gmail.com
RI Maia, Mauricio/I-5892-2015; Navea, Amparo/D-4577-2009; Fromow-Guerra, J.
   Jans/A-3346-2015; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Navea, Amparo/0000-0002-9856-5370;
   Fromow-Guerra, J. Jans/0000-0001-5335-1275; Maia,
   Mauricio/0000-0002-7034-8091; Udaondo, Patricia/0000-0002-5241-0066
FU Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas,
   Venezuela
FX Supported in part by the Arevalo-Coutinho Foundation for Research in
   Ophthalmology, Caracas, Venezuela.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1995, Arch Ophthalmol, V113, P1144
   [Anonymous], 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI DOI 10.1001/ARCHOPHT.1985.01050120030015
   Antcliff R J, 1999, Semin Ophthalmol, V14, P223, DOI 10.3109/08820539909069541
   Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953
   Arevalo JF, 2007, OPHTHALMOLOGY, V114, P743, DOI 10.1016/j.ophtha.2006.12.028
   Audren F, 2006, ACTA OPHTHALMOL SCAN, V84, P624, DOI 10.1111/j.1600-0420.2006.00700.x
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bakri SJ, 2006, EYE, V20, P1474, DOI 10.1038/sj.eye.6702364
   BRESNICK GH, 1983, OPHTHALMOLOGY, V90, P1301
   Campochiaro PA, 2004, INVEST OPHTH VIS SCI, V45, P922, DOI 10.1167/iovs.03-0955
   Chieh JJ, 2005, RETINA-J RET VIT DIS, V25, P828, DOI 10.1097/00006982-200510000-00002
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRIS FL, 1987, OPHTHALMOLOGY, V94, P761
   FERRIS FL, 1984, SURV OPHTHALMOL, V28, P452, DOI 10.1016/0039-6257(84)90227-3
   Funatsu H, 2005, OPHTHALMOLOGY, V112, P806, DOI 10.1016/j.ophtha.2004.11.045
   Funatsu H, 2003, OPHTHALMOLOGY, V110, P1690, DOI 10.1016/S0161-6420(03)00568-2
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1447, DOI 10.1016/j.ophtha.2008.06.015
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Jonas JB, 2006, J OCUL PHARMACOL TH, V22, P200, DOI 10.1089/jop.2006.22.200
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464
   Kumar Atul, 2007, Indian Journal of Ophthalmology, V55, P451
   Ladewig MS, 2006, OPHTHALMOLOGE, V103, P463, DOI 10.1007/s00347-006-1352-5
   LEE CM, 1991, OPHTHALMOLOGY, V98, P1594
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mason JO, 2006, RETINA-J RET VIT DIS, V26, P839, DOI 10.1097/01.iae.0000230425.31296.3b
   Massin P, 2004, OPHTHALMOLOGY, V111, P218, DOI 10.1016/j.ophtha.2003.05.037
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836
   Miyamoto K, 1999, Semin Ophthalmol, V14, P233, DOI 10.3109/08820539909069542
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Oshima Y, 2006, AM J OPHTHALMOL, V142, P155, DOI 10.1016/j.ajo.2006.02.015
   Pendergast SD, 2000, AM J OPHTHALMOL, V130, P178, DOI 10.1016/S0002-9394(00)00472-4
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Richter B, 2004, EVIDENCE BASED OPHTH, P331
   Schachat AP, 2008, OPHTHALMOLOGY, V115, P1445, DOI 10.1016/j.ophtha.2008.06.030
   Schachat AP, 2003, OPHTHALMOLOGY, V110, P2073, DOI 10.1016/S0161-6420(03)01004-2
   SCHRODER S, 1991, AM J PATHOL, V139, P81
   Shah Parag K., 2007, Indian Journal of Ophthalmology, V55, P75
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Soheilian M, 2007, RETINA-J RET VIT DIS, V27, P1187, DOI 10.1097/IAE.0b013e31815ec261
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Spandau UHM, 2006, ACTA OPHTHALMOL SCAN, V84, P555, DOI 10.1111/j.1600-0420.2006.00740.x
   Starita Carla, 2007, Dev Ophthalmol, V39, P122, DOI 10.1159/000098504
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Strom C, 2005, INVEST OPHTH VIS SCI, V46, P3855, DOI 10.1167/iovs.05-0096
   Sutter FKP, 2004, OPHTHALMOLOGY, V111, P2044, DOI 10.1016/j.ophtha.2004.05.025
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   VERMES I, 1987, DIABETOLOGIA, V30, P434, DOI 10.1007/BF00292548
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
NR 63
TC 83
Z9 89
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2009
VL 116
IS 8
BP 1488
EP 1497
DI 10.1016/j.ophtha.2009.03.016
PG 10
WC Ophthalmology
SC Ophthalmology
GA 480CT
UT WOS:000268710200012
PM 19545900
DA 2020-12-15
ER

PT J
AU Fortes, JB
   Bonomo, PP
   Maia, M
   Procianoy, RS
AF Fortes Filho, Joao Borges
   Bonomo, Pedro P.
   Maia, Mauricio
   Procianoy, Renato S.
TI Weight gain measured at 6 weeks after birth as a predictor for severe
   retinopathy of prematurity: study with 317 very low birth weight preterm
   babies
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Retinopathy of prematurity; Risk factors; Weight gain; Prevalence; VLBW
   infants
ID POSTNATAL WEIGHT; RISK-FACTORS; GROWTH; INFANTS; ASSOCIATION; OXYGEN
AB Recent studies suggest that postnatal weight gain can play an important role in the development of retinopathy of prematurity (ROP).
   To analyze the low weight gain (WG) from birth to 6 weeks of life to predict the development of severe retinopathy of prematurity (ROP) among very low birth weight preterm babies (VLBW).
   A prospective cohort study included 317 newborns with birth weight (BW) a parts per thousand currency sign1,500 g and gestational age (GA) a parts per thousand currency sign32 weeks. The main outcome was the development of severe ROP (defined as threshold ROP and higher stages of ROP). In all patients, the proportion of the WG was defined as the preterm weight measured at 6 weeks of life minus the BW divided by the BW. Seventeen risk factors for ROP were studied by univariate analysis. Chi-square test and Student's t-test were used to compare no-ROP/mild ROP patients and severe ROP patients. Logistic regression and receiver operating characteristic (ROC) curve were used to determine if the WG proportion was independently related to severe ROP development and if it was capable of predicting severe ROP. Ophthalmological examinations started between the fourth and sixth week of life, and were repeated until the 45th week of postmenstrual age. Weight gain proportion was always calculated at completed 6 weeks of life.
   Mean GA and mean BW of the whole cohort were 29.6 weeks (+/- 1.9) and 1,124 grams (+/- 239.5) respectively. After logistic regression, the low WG proportion under 51.2% from the BW, measured at 6 weeks of life, showed OR 3.007 (95%CI: 1.195-7.566; P = 0.019), for severe ROP, when adjusted for BW and for any stage intraventricular hemorrhage. Area under the ROC curve was 0.63 (95%CI: 0.495-0.761; P = 0.037). For the discriminative cutoff of 51.2% of the WG proportion, sensitivity and specificity values were 66.3% and 62.6% respectively. Positive and negative predictive values were 10.2% and 94.7% respectively.
   Low WG by six weeks of life is an important and independent risk factor for severe ROP and is capable to predict the development of severe ROP in most patients that needed treatment.
C1 [Fortes Filho, Joao Borges] Univ Fed Rio Grande do Sul, Sch Med, Dept Ophthalmol, BR-90035003 Porto Alegre, RS, Brazil.
   [Fortes Filho, Joao Borges; Procianoy, Renato S.] Hosp Clin Porto Alegre, BR-90035003 Porto Alegre, RS, Brazil.
   [Procianoy, Renato S.] Univ Fed Rio Grande do Sul, Dept Pediat, Newborn Sect, BR-90035003 Porto Alegre, RS, Brazil.
   [Bonomo, Pedro P.; Maia, Mauricio] Univ Fed Sao Paulo, Sch Med, Dept Ophthalmol, Sao Paulo, Brazil.
RP Fortes, JB (corresponding author), Univ Fed Rio Grande do Sul, Sch Med, Dept Ophthalmol, Rua Ramiro Barcelos 2350, BR-90035003 Porto Alegre, RS, Brazil.
EM jbfortes@cursohbo.com.br
RI FILHO, JOAO B FORTES/K-8446-2017; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015; Procianoy, Renato/I-5133-2014
OI FILHO, JOAO B FORTES/0000-0001-5682-0962; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Procianoy, Renato/0000-0001-8297-4164
CR Allegaert K, 2003, J AAPOS, V7, P34, DOI 10.1016/S1091-8531(02)42015-0
   Brown MS, 2006, J AAPOS, V10, P143, DOI 10.1016/j.jaapos.2005.09.005
   Christiansen SP, 2002, J PEDIAT OPHTH STRAB, V39, P157, DOI 10.3928/0191-3913-20020501-07
   Ehrenkranz RA, 1999, PEDIATRICS, V104, P280, DOI 10.1542/peds.104.2.280
   Engstrom E, 2005, PEDIATR RES, V57, P605, DOI 10.1203/01.PDR.0000155950.67503.BC
   GARNER A, 1984, ARCH OPHTHALMOL-CHIC, V102, P1130
   Gilbert C, 2005, PEDIATRICS, V115, pE518, DOI 10.1542/peds.2004-1180
   Gilbert C, 1997, LANCET, V350, P12, DOI 10.1016/S0140-6736(97)01107-0
   Graziano R M, 1997, J Pediatr (Rio J), V73, P377
   HALL JG, 1995, AM J OPHTHALMOL, V119, P658, DOI 10.1016/S0002-9394(14)70233-8
   Hellstrom A, 2003, PEDIATRICS, V112, P1016, DOI 10.1542/peds.112.5.1016
   Holmes JM, 1996, CURR EYE RES, V15, P403, DOI 10.3109/02713689608995831
   Hussain N, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.3.e26
   Kim T, 2004, PAEDIATR PERINAT EP, V18, P130, DOI 10.1111/j.1365-3016.2003.00545.x
   KOERNER F, 1986, GRAEF ARCH CLIN EXP, V224, P40, DOI 10.1007/BF02144132
   Larsson E, 2002, BRIT J OPHTHALMOL, V86, P1122, DOI 10.1136/bjo.86.10.1122
   Lermann Viviane Levy, 2006, J. Pediatr. (Rio J.), V82, P27, DOI 10.1590/S0021-75572006000100007
   Lofqvist C, 2006, ARCH OPHTHALMOL-CHIC, V124, P1711, DOI 10.1001/archopht.124.12.1711
   LUCEY JF, 1984, PEDIATRICS, V73, P82
   PALMER EA, 1988, ARCH OPHTHALMOL-CHIC, V106, P471
   PATZ A, 1987, ARCH OPHTHALMOL-CHIC, V105, P905, DOI 10.1001/archopht.1987.01060070041024
   PATZ A, 1952, AM J OPHTHALMOL, V35, P1248, DOI 10.1016/0002-9394(52)91140-9
   PROCIANOY RS, 1981, ACTA PAEDIATR SCAND, V70, P473, DOI 10.1111/j.1651-2227.1981.tb05725.x
   SAITO Y, 1993, GRAEF ARCH CLIN EXP, V231, P151, DOI 10.1007/BF00920938
   Seiberth V, 2000, OPHTHALMOLOGICA, V214, P131, DOI 10.1159/000027482
   SHAFFER SG, 1987, PEDIATRICS, V79, P702
   Shah VA, 2005, ANN ACAD MED SINGAP, V34, P169
   Terry TL, 1942, AM J OPHTHALMOL, V25, P203, DOI DOI 10.1016/S0002-9394(42)92088-9
   Tin Win, 2002, Semin Neonatol, V7, P361, DOI 10.1053/siny.2002.0130
   Wallace DK, 2000, J AAPOS, V4, P343, DOI 10.1067/mpa.2000.110342
NR 30
TC 52
Z9 52
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2009
VL 247
IS 6
BP 831
EP 836
DI 10.1007/s00417-008-1012-3
PG 6
WC Ophthalmology
SC Ophthalmology
GA 440MP
UT WOS:000265704700016
PM 19052770
OA Green Published, Other Gold
DA 2020-12-15
ER

PT J
AU Torres, RJD
   Maia, M
   Muccioli, C
   Winter, G
   de Souza, GK
   Pasqualotto, LR
   Luchini, A
   Precoma, DB
AF de Almeida Torres, Rogil Jose
   Maia, Mauricio
   Muccioli, Cristina
   Winter, Guilherme
   de Souza, Greyce Kelly
   Pasqualotto, Luca Rodrigo
   Luchini, Andrea
   Precoma, Dalton Bertolim
TI Modifiable risk factors for age-related macular degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA Portuguese
DT Article
DE Smoking; Hypertension; Hypercholesterolemia; Atherosclerosis; Body mass
   index; Ultraviolet rays; Light; Antioxidants; Carotenoids; Lutein; Fatty
   acids, omega-3; Diet; Macular degeneration; Supplementary feeding; Free
   radicals; Randomized controlled trials as topic
ID CARDIOVASCULAR-DISEASE; CIGARETTE-SMOKING; OXIDATIVE STRESS; TERM
   INCIDENCE; DIETARY-FAT; BLUE-LIGHT; MACULOPATHY; ATHEROSCLEROSIS;
   PATHOGENESIS; ASSOCIATION
AB The authors present the main modifiable risk factors that may trigger and/or worsen age-related macular degeneration. Mechanisms of action related to these factors as well as preventive measures and intervention effectiveness are discussed.
C1 Univ Fed Sao Paulo, Hosp Angelina Caron, Dept Oftalmol, Campina Grande Do Sul, PR, Brazil.
   Pontificia Univ Catolica Parana, Curitiba, Parana, Brazil.
RP Torres, RJD (corresponding author), Praca Rui Barbosa 827,Conj 305, BR-80010030 Curitiba, Parana, Brazil.
EM rjat@terra.com.br
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; Muccioli,
   Cristina/C-3419-2013
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091; 
CR *AG REL DY DIS STU, 2008, ARCH OPHTHALMOL-CHIC, V125, P1225
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880
   CHIU CJ, 2006, AM J CLIN NUTR, V83, P733
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   DASHTI N, 2007, BR J OPHTHALMOL, V91, P403
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1997, ARCH OPHTHALMOL-CHIC, V115, P945, DOI 10.1001/archopht.1997.01100160115033
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2007, AM J OPHTHALMOL, V144, P483, DOI 10.1016/j.ajo.2007.05.032
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671
   Sastry BVR, 1998, J OCUL PHARMACOL TH, V14, P447, DOI 10.1089/jop.1998.14.447
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tomany SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P362
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Trumbo PR, 2006, AM J CLIN NUTR, V84, P971
   *US FDA, 2000, GUID IND SIGN SCI AG
   Van Gelder RN, 2004, BRIT J OPHTHALMOL, V88, P1353, DOI 10.1136/bjo.2004.042861/045120
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VANGELDER RN, 2003, BR J OPHTHALMOL, V87, P1523
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
NR 47
TC 5
Z9 7
U1 0
U2 5
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAY-JUN
PY 2009
VL 72
IS 3
BP 406
EP 412
PG 7
WC Ophthalmology
SC Ophthalmology
GA 558OO
UT WOS:000274754000027
PM 19668979
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Rodrigues, EB
   Penha, FM
   Farah, ME
   Costa, EDF
   Maia, M
   Dib, E
   Bottos, J
   Freymuller, E
   Furlani, B
   Meyer, CH
   Magalhaes, O
   Lima-Filho, AAS
   Safatle, A
AF Rodrigues, Eduardo B.
   Penha, Fernando Marcondes
   Farah, Michel Eid
   Fiod Costa, Elaine de Paula
   Maia, Mauricio
   Dib, Eduardo
   Bottos, Juliana
   Freymuller, Edna
   Furlani, Bruno
   Meyer, Carsten H.
   Magalhaes, Octaviano, Jr.
   Souza Lima-Filho, Acacio Alves
   Safatle, Angelica
TI PRECLINICAL INVESTIGATION OF THE RETINAL BIOCOMPATIBILITY OF SIX NOVEL
   VITAL DYES FOR CHROMOVITRECTOMY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE chromovitrectomy; indocyanine green; fast green; vital dye; trypan blue;
   retina; brilliant blue; bromophenol blue; toxicity
ID INTERNAL LIMITING MEMBRANE; BRILLIANT BLUE-G; INDOCYANINE GREEN; TRYPAN
   BLUE; TRIAMCINOLONE ACETONIDE; VITREORETINAL SURGERY; INTRAOCULAR
   SURGERY; EPIRETINAL MEMBRANES; RABBIT EYES; EVANS BLUE
AB Purpose: To investigate the retinal biocompatibility of six novel vital dyes for chromovitrectomy.
   Methods: An amount of 0.05 mL of 0.5% and 0.05% light green (LG), fast green (FG), Evans blue (EB), brilliant blue (BriB), bromophenol blue (BroB), or indigo carmine (IC) was injected intravitreally in the right eye, whereas in the left eye balanced salt solution was applied for control in rabbits' eyes. Clinical examination, fluorescein angiography, histology with light microscopy, and transmission electron microscopy were performed after 1 and 7 days. Retinal cell layers were evaluated for morphologic alterations and number of cells. The electroretinographic changes were assessed at baseline, 24 hours and 7 days.
   Results: Fluorescein angiography disclosed hypofluorescent spots only in the 0.5% EB group. Light microscopy and transmission electron microscopy disclosed slight focal morphologic changes in eyes exposed to 0.05% IC, FG, BriB, similar to the control at 1 and 7 days. In the lower dose groups, EB, LG, and BroB caused substantial retinal alterations by light microscopy. At the higher dose, BroB and EB produced diffuse cellular edema and vacuolization within the ganglion cells, bipolar cells, and photoreceptors. FG and IC at 0.5% caused slight retinal alterations similar to balanced salt solution injection. LG at 0.5% caused diffuse vacuolization of bipolar cells after 1 and 7 days. Injection of 0.5% EB caused a significant decrease in neuroretinal cell counts in comparison to control eyes in the 7-day examination (P < 0.05). Electroretinography revealed intermittent prolonged latency and decreased amplitude in eyes injected with 0.5% EB, LG, BriB, and BroB, while at the lower dose, only LG and EB induced few functional changes.
   Conclusion: The progressive order of retinal biocompatibility, from safest to most toxic, was IC, FG, BriB, BroB, LG, EB.
C1 [Rodrigues, Eduardo B.; Penha, Fernando Marcondes; Farah, Michel Eid; Fiod Costa, Elaine de Paula; Maia, Mauricio; Dib, Eduardo; Bottos, Juliana; Furlani, Bruno; Magalhaes, Octaviano, Jr.; Souza Lima-Filho, Acacio Alves] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, Sao Paulo, Brazil.
   [Freymuller, Edna] Univ Fed Sao Paulo, Elect Microscopy Ctr CEME, Sao Paulo, Brazil.
   [Meyer, Carsten H.] Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
   [Safatle, Angelica] Univ Sao Paulo, Sch Vet Med, Lab Invest Comparat Ophthalmol, Sao Paulo, Brazil.
RP Rodrigues, EB (corresponding author), Almirante Barroso 45,Jade 204, Ctr Florianopolis Sc, Brazil.
EM edubrodriguess@yahoo.com.br
RI Maia, Mauricio/Z-1042-2019; Meyer, Carsten H./A-3981-2017; Farah, Michel
   Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015; Penha, Fernando
   M/G-1784-2012; Safatle, Angelica M V/J-3367-2014; de Souza Lima Filho,
   Acacio Alves/C-7189-2012
OI Maia, Mauricio/0000-0002-7034-8091; Meyer, Carsten
   H./0000-0002-0530-5298; Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921; Alves de Souza Lima Filho,
   Acacio/0000-0003-1802-9592
FU German Academic Exchange Service (DAAD)Deutscher Akademischer Austausch
   Dienst (DAAD); Pan-American Association of Ophthalmology-Pan-American
   Ophthalmological Foundation (PAAO/PAOF); Vision Institute-UNIFESP;
   FAPESP-Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX Supported by the German Academic Exchange Service (DAAD); the
   Pan-American Association of Ophthalmology-Pan-American Ophthalmological
   Foundation (PAAO/PAOF); the Vision Institute-UNIFESP; and the
   FAPESP-Fundacao de Amparo a Pesquisa do Estado de Sao Paulo.
CR Albini TA, 2007, INVEST OPHTH VIS SCI, V48, P390, DOI 10.1167/iovs.06-0145
   Baba Y, 2000, ACTA RADIOL, V41, P329, DOI 10.1034/j.1600-0455.2000.041004329.x
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P623, DOI 10.1097/00006982-200607000-00006
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Feron EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P141
   Foster RE, 2002, RETINA-J RET VIT DIS, V22, P106, DOI 10.1097/00006982-200202000-00019
   Gandorfer A, 2003, INVEST OPHTH VIS SCI, V44, P316, DOI 10.1167/iovs.02-0545
   HARCH CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P3315, DOI 10.1167/iovs.04-1142
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P673, DOI 10.1097/00006982-200607000-00014
   Jackson TL, 2005, EXP EYE RES, V81, P446, DOI 10.1016/j.exer.2005.03.004
   Kiernan JA, 2001, BIOTECH HISTOCHEM, V76, P261, DOI 10.1080/714028154
   Kumar Atul, 2004, Indian J Ophthalmol, V52, P339
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Mennel S, 2006, OPHTHALMOLOGICA, V220, P190, DOI 10.1159/000091764
   Mennel S, 2006, KLIN MONATSBL AUGENH, V223, P568, DOI 10.1055/s-2006-926479
   Mennel Stefan, 2008, Dev Ophthalmol, V42, P101, DOI 10.1159/000138988
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   NYBERG MA, 1977, A GRAEF ARCH KLIN EX, V204, P153, DOI 10.1007/BF00414843
   OHTA Y, 1991, NEUROSCI LETT, V130, P137, DOI 10.1016/0304-3940(91)90246-P
   Ozawa T, 2005, NEUROSURGERY, V57, P1041, DOI 10.1227/01.NEU.0000180036.42193.f6
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Perrier M, 2003, AM J OPHTHALMOL, V135, P909, DOI 10.1016/S0002-9394(02)02256-0
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Schuettauf F, 2006, INVEST OPHTH VIS SCI, V47, P3573, DOI 10.1167/iovs.06-0211
   Shoemaker K, 1996, J THORAC CARDIOV SUR, V112, P542, DOI 10.1016/S0022-5223(96)70286-6
   Sorsby A, 1939, T OPHTHAL SOC UK, V59, P727
   Teba FA, 2003, OPHTHALMOLOGY, V110, P2409, DOI 10.1016/S0161-6420(03)00716-4
   Ueno A, 2007, RETINA-J RET VIT DIS, V27, P499, DOI 10.1097/IAE.0b013e318030a129
NR 34
TC 29
Z9 30
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2009
VL 29
IS 4
BP 497
EP 510
DI 10.1097/IAE.0b013e318196b1ad
PG 14
WC Ophthalmology
SC Ophthalmology
GA 433KX
UT WOS:000265203800012
PM 19174713
DA 2020-12-15
ER

PT J
AU Wu, L
   Arevalo, JF
   Maia, M
   Berrocal, M
   Sanchez, J
   Evans, T
AF Wu, Lihteh
   Fernando Arevalo, J.
   Maia, Mauricio
   Berrocal, Maria H.
   Sanchez, Juan
   Evans, Teodoro
CA Pan-Amer Collaborat Retina Study
TI Comparing outcomes in patients with subfoveal choroidal
   neovascularization secondary to age-related macular degeneration treated
   with two different doses of primary intravitreal bevacizumab: results of
   the pan-american collaborative retina study group (PACORES) at the
   12-month follow-up
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; AVASTIN TREATMENT; EYE DISEASE; SHORT-TERM;
   MEMBRANES; THERAPY; RANIBIZUMAB; VERTEPORFIN; ANTIBODY; CANCER
AB To compare the total number of injections and the anatomic and best-corrected visual acuity (VA) response after injecting 1.25 or 2.5 mg of bevacizumab as needed in patients with primary choroidal neovascularization secondary to age-related macular degeneration (AMD) at 12 months.
   This was a retrospective, interventional, comparative multicenter study of 60 eyes treated with intravitreal bevacizumab (35 eyes, 1.25 mg; 25 eyes, 2.5 mg).
   The mean number of injections per eye was 3.8 in the 1.25-mg group and 3.2 in the 2.5-mg group (P = 0.2752). At 12 months, in the 1.25-mg group, 16 (46%) eyes gained a parts per thousand yen3 lines of Early Treatment Diabetic Retinopathy Study (ETDRS) VA and seven (20%) lost a parts per thousand yen3 lines of ETDRS VA. In the 2.5-mg group, 11 (44%) eyes improved by a parts per thousand yen3 lines, and four (16%) lost a parts per thousand yen3 lines (P = 1.000). At 12 months, in the 1.25-mg group, the mean central macular thickness decreased from 419 +/- 201 mu m at baseline to 268 +/- 96 mu m, compared with a decrease from 388 +/- 162 to 296 +/- 114 mu m in the 2.5-mg group (P = 0.7896).
   There were no statistically significant differences between the two dose groups with regard to the number of injections, anatomic and VA outcomes.
C1 [Wu, Lihteh; Evans, Teodoro] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Fernando Arevalo, J.; Sanchez, Juan] Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Caracas, Venezuela.
   [Maia, Mauricio] Univ Fed Sao Paulo, Inst Visao, Dept Oftalmol, Sao Paulo, Brazil.
   [Berrocal, Maria H.] Univ Puerto Rico, San Juan, PR 00936 USA.
RP Wu, L (corresponding author), Apdo 144-1225 Plaza Mayor, San Jose 1225, Costa Rica.
EM LW65@CORNELL.EDU
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; Fromow-Guerra,
   J. Jans/A-3346-2015
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Fromow-Guerra, J. Jans/0000-0001-5335-1275
FU Arevalo-Coutinho Foundation, Caracas, Venezuela
FX This work was supported in part by the Arevalo-Coutinho Foundation for
   Research in Ophthalmology, Caracas, Venezuela.
CR Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schachat AP, 2003, OPHTHALMOLOGY, V110, P2073, DOI 10.1016/S0161-6420(03)01004-2
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 37
TC 8
Z9 8
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAR
PY 2009
VL 53
IS 2
BP 125
EP 130
DI 10.1007/s10384-008-0622-y
PG 6
WC Ophthalmology
SC Ophthalmology
GA 427YJ
UT WOS:000264814700007
PM 19333696
DA 2020-12-15
ER

PT J
AU Rodrigues, EB
   Farah, ME
   Maia, M
   Penha, FM
   Regatieri, C
   Melo, GB
   Pinheiro, MM
   Zanetti, CR
AF Rodrigues, Eduardo B.
   Farah, Michel E.
   Maia, Mauricio
   Penha, Fernando M.
   Regatieri, Caio
   Melo, Gustavo B.
   Pinheiro, Marcelo M.
   Zanetti, Carlos R.
TI Therapeutic monoclonal antibodies in ophthalmology
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Monoclonal antibodies; Avastin; Lucentis; Retina; Eye; Bevacizumab;
   Ranibizumab; Tumor necrosis factor; Vascular endothelial growth factor
ID ENDOTHELIAL-GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; INTRAVITREAL
   BEVACIZUMAB AVASTIN; EXPERIMENTAL CORNEAL NEOVASCULARIZATION; REFRACTORY
   POSTERIOR UVEITIS; RETINAL-PIGMENT EPITHELIUM; ENDOTOXIN-INDUCED
   UVEITIS; FACTOR-ALPHA BLOCKADE; TNF-ALPHA; CHOROIDAL NEOVASCULARIZATION
AB Monoclonal antibodies (mAbs) can be used therapeutically by binding to molecular targets with high specificity. Therefore, they have excellent therapeutic applications in ophthalmology. This manuscript presents four aspects of the therapeutic use of mAbs in ophthalmology: the scientific rationale, the unique characteristics of selected mAbs, the current state-of-the-art application, and relevant therapeutic mAbs for future applications in ophthalmology. We identified in the literature various single-agent therapies that inhibit the following targets: tumor necrosis factor (TNF), epithelial growth factor receptor, vascular endothelial growth factor (VEGF) receptor, basic fibroblast growth factor receptor, platelet-derived growth factor, and cluster of differentiation antigens. The roles of all biochemical targets in ocular diseases were evaluated. Current and future mAbs against various cytokines were assessed for the treatment of ocular diseases. The medical literature showed the clinical benefits of mAbs for treating angiogenic and inflammatory ocular diseases. Two anti-VEGF mAbs, bevacizumab and ranibizumab, and three anti-TNF agents, infliximab, etanercept, and adalimumab, control Ocular neovascularization and intraocular inflammation. Other mAbs such as rituximab, daclizumab, efalizumab, and alemtuzumab showed positive results in animal and early clinical studies and may represent useful adjuvant therapies for ocular lymphoma or ocular inflammation. Ranibizumab is the only FDA-approved therapy; for other mAbs the so-called off-label application remains the standard. Intravenous administration of mAbs has demonstrated acceptable toxicity profiles, while intraocular injection may decrease the chances of systemic complications and increase the amount of drug available to the retina and choroid. In conclusion, effective clinical use of mAbs in ophthalmology is more commonly seen in the field of angiogenic vitreoretinal and autoimmune inflammatory diseases. The challenge for the future is combining biologic therapies to improve the quality and duration of responses while diminishing side effects. The role of mAbs within ophthalmic treatments will be defined according to future clinical experience and the results of randomized clinical trials. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Rodrigues, Eduardo B.; Farah, Michel E.; Maia, Mauricio; Penha, Fernando M.; Regatieri, Caio; Melo, Gustavo B.] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, Sao Paulo, Brazil.
   [Pinheiro, Marcelo M.] Univ Fed Sao Paulo, Div Rheumatol, Sao Paulo, Brazil.
   [Zanetti, Carlos R.] Univ Fed Santa Catarina, Dept Immunol, Florianopolis, SC, Brazil.
RP Rodrigues, EB (corresponding author), Almirante Barroso 45 Jade 204, BR-88030460 Florianopolis, SC, Brazil.
EM edubrodriguess@yahoo.com.br
RI Maia, Mauricio/I-5892-2015; Melo, Gustavo/AAD-3844-2019; Regatieri,
   Caio/G-8152-2014; Farah, Michel Eid E/F-3285-2012; Penha, Fernando
   M/G-1784-2012; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Melo, Gustavo/0000-0001-5765-2008;
   Regatieri, Caio/0000-0003-1511-8696; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Buchele
   Rodrigues, Eduardo/0000-0002-4224-0921
CR Abu El-Asrar Ahmed M., 2005, International Ophthalmology, V26, P83, DOI 10.1007/s10792-006-9006-9
   Adan A, 2007, RETINA-J RET VIT DIS, V27, P1180, DOI 10.1097/IAE.0b013e31815e9834
   Ahmad T, 2003, ARTHRITIS RHEUM, V48, P807, DOI 10.1002/art.10815
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Andersen DC, 2004, CURR OPIN BIOTECH, V15, P456, DOI 10.1016/j.copbio.2004.08.002
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   AREVALO JF, EYE IN PRESS
   Ashok D, 2005, RHEUMATOLOGY, V44, P950, DOI 10.1093/rheumatology/keh635
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Avunduk MC, 2004, EXP EYE RES, V79, P357, DOI 10.1016/j.exer.2004.06.001
   Bahar I, 2008, CORNEA, V27, P142, DOI 10.1097/ICO.0b013e318159019f
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Baughman RR, 2005, INT J CLIN PHARM TH, V43, P7
   Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29
   Benitez-del-Castillo JM, 2005, EYE, V19, P841, DOI 10.1038/sj.eye.6701689
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Biester S, 2007, BRIT J OPHTHALMOL, V91, P319, DOI 10.1136/bjo.2006.103721
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bock F, 2007, INVEST OPHTH VIS SCI, V48, P2545, DOI 10.1167/iovs.06-0570
   Bodaghi B, 2005, ANN RHEUM DIS, V64, P962, DOI 10.1136/ard.2004.025882
   Boyd SR, 2002, BRIT J OPHTHALMOL, V86, P440, DOI 10.1136/bjo.86.4.440
   Braun J, 2005, ARTHRITIS RHEUM, V52, P2447, DOI 10.1002/art.21197
   Byeon SH, 2007, J OCUL PHARMACOL TH, V23, P387, DOI 10.1089/jop.2007.0012
   Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x
   Cahalan MD, 2006, NAT IMMUNOL, V7, P329, DOI 10.1038/ni0406-329
   Calabrese LH, 2003, CLIN EXP RHEUMATOL, V21, P241
   Caldwelll RB, 2003, DIABETES-METAB RES, V19, P442, DOI 10.1002/dmrr.415
   CAMPOCHIARO PA, 1985, ARCH OPHTHALMOL-CHIC, V103, P576
   Campochiaro PA, 2006, INVEST OPHTH VIS SCI, V47, P462, DOI 10.1167/iovs.05-1494
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Campochiaro PA, 2007, DRUG TODAY, V43, P529, DOI 10.1358/dot.2007.43.8.1120868
   Campochiaro PA, 2007, J CELL PHYSIOL, V213, P348, DOI 10.1002/jcp.21213
   Campochiaro PA, 2007, J CELL PHYSIOL, V210, P575, DOI 10.1002/jcp.20893
   Cazabon S, 2005, EYE, V19, P222, DOI 10.1038/sj.eye.6701457
   CHAMBERLAIN CG, 1987, CURR EYE RES, V6, P1165, DOI 10.3109/02713688709034890
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924
   Chung JH, 2006, J NEUROL SCI, V244, P133, DOI 10.1016/j.jns.2006.01.012
   Coiffier B, 2007, ONCOGENE, V26, P3603, DOI 10.1038/sj.onc.1210376
   Conti F, 2005, ARTHRITIS RHEUM-US, V52, P1224, DOI 10.1002/art.20979
   Cunningham ET, 1997, INVEST OPHTH VIS SCI, V38, P9
   DALESSANDRO AM, 1989, TRANSPLANTATION, V47, P297, DOI 10.1097/00007890-198902000-00021
   Deissler H, 2008, BRIT J OPHTHALMOL, V92, P839, DOI 10.1136/bjo.2007.135640
   Derevjanik NL, 2002, INVEST OPHTH VIS SCI, V43, P2462
   DEUTER CM, 2007, PROG RETIN EYE 1120
   DEVOS AF, 1994, INVEST OPHTH VIS SCI, V35, P3873
   Díaz-Valle D, 2004, Arch Soc Esp Oftalmol, V79, P405
   Dick AD, 2004, PROG RETIN EYE RES, V23, P617, DOI 10.1016/j.preteyeres.2004.06.005
   Dick AD, 2000, BRIT J OPHTHALMOL, V84, P107, DOI 10.1136/bjo.84.1.107
   Doganay S, 2002, EYE, V16, P163, DOI 10.1038/sj/eye/6700095
   Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899
   Durrani OM, 2005, ORBIT, V24, P117, DOI 10.1080/01676830590912562
   Edrees AF, 2005, CLIN EXP RHEUMATOL, V23, P469
   Ehlers JP, 2008, RETINA-J RET VIT DIS, V28, P696, DOI 10.1097/IAE.0b013e3181679c0b
   EISHABRAWI Y, 2002, OPHTHALMOLOGY, V109, P2342
   EISHABRAWI Y, 2005, EYE, V19, P1017
   Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X
   Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41
   Ettinger R, 1998, INT IMMUNOL, V10, P727, DOI 10.1093/intimm/10.6.727
   Evereklioglu C, 2005, SURV OPHTHALMOL, V50, P297, DOI 10.1016/j.survophthal.2005.04.009
   Falappone P C F, 2004, Reumatismo, V56, P185
   Fauser S, 2004, GRAEF ARCH CLIN EXP, V242, P582, DOI 10.1007/s00417-004-0895-x
   Ferrara DC, 2007, AM J OPHTHALMOL, V144, P864, DOI 10.1016/j.ajo.2007.07.038
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Foeldvari I, 2007, J RHEUMATOL, V34, P1146
   Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002
   Foote J, 2003, SCIENCE, V299, P1327, DOI 10.1126/science.1082717
   Foster CS, 2003, ARCH OPHTHALMOL-CHIC, V121, P437, DOI 10.1001/archopht.121.4.437
   Friedlander SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1363
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Furst DE, 2006, SEMIN ARTHRITIS RHEU, V36, P159, DOI 10.1016/j.semarthrit.2006.02.001
   Furst DE, 2003, J RHEUMATOL, V30, P2563
   Galor A, 2006, OPHTHALMOLOGY, V113, P2317, DOI 10.1016/j.ophtha.2006.04.038
   Gardiner TA, 2005, AM J PATHOL, V166, P637, DOI 10.1016/S0002-9440(10)62284-5
   GARDREAULT J, 2005, INVESTIG OPHTHALMOL, V46, P726
   Garrity JA, 2004, AM J OPHTHALMOL, V138, P925, DOI 10.1016/j.ajo.2004.06.077
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Giansanti F, 2004, EUR J OPHTHALMOL, V14, P445
   Giansanti F, 2008, INVEST OPHTH VIS SCI, V49, P1151, DOI 10.1167/iovs.07-0932
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   GOLDSTEIN G, 1986, TRANSPLANTATION, V42, P507, DOI 10.1097/00007890-198611000-00013
   Grant MB, 2004, EXPERT OPIN INV DRUG, V13, P1275, DOI 10.1517/13543784.13.10.1275
   Greiner K, 2004, INVEST OPHTH VIS SCI, V45, P170, DOI 10.1167/iovs.03-0659
   Gunduz Kaan, 2006, Neurosurg Focus, V21, pE9
   Hale S, 2006, CYTOKINE, V33, P231, DOI 10.1016/j.cyto.2005.12.012
   Hampton T, 2005, JAMA-J AM MED ASSOC, V293, P2985, DOI 10.1001/jama.293.24.2985
   Hangai M, 2006, J NEUROIMMUNOL, V171, P45, DOI 10.1016/j.jneuroim.2005.09.018
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x
   HEIDENKUMMER HP, 1991, GRAEF ARCH CLIN EXP, V229, P492, DOI 10.1007/BF00166316
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Hernandez-Rojas ML, 2007, RETINA-J RET VIT DIS, V27, P707
   Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142
   Homsi Jade, 2007, Cancer Control, V14, P285
   HONDA S, 2008, GRAEFES ARCH CL 0305
   Horn W, 2008, KLIN MONATSBL AUGENH, V225, P217, DOI 10.1055/s-2008-1027201
   Hurmeric V, 2008, CORNEA, V27, P357, DOI 10.1097/ICO.0b013e318160d019
   Hwang WYK, 2005, METHODS, V36, P3, DOI 10.1016/j.ymeth.2005.01.001
   Imanishi J, 2000, PROG RETIN EYE RES, V19, P113, DOI 10.1016/S1350-9462(99)00007-5
   Imrie FR, 2007, CURR OPIN OPHTHALMOL, V18, P481, DOI 10.1097/ICU.0b013e3282f03d42
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Iriyama A, 2007, BRIT J OPHTHALMOL, V91, P1230, DOI 10.1136/bjo.2007.117309
   Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242
   Johnston S, 2006, CLIN MED, V6, P337
   JONAS JB, 2007, ACTA OPHTHALMOL 1212
   JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0
   Joseph A, 2003, OPHTHALMOLOGY, V110, P1449, DOI 10.1016/S0161-6420(03)00406-8
   Joukov V, 1996, EMBO J, V15, P290
   KAHN R, 2006, OPHTHALMOLOGY, V113, P1
   KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kapadia Mitesh K., 2006, International Ophthalmology Clinics, V46, P165, DOI 10.1097/00004397-200604620-00014
   Kaushik VV, 2005, EXPERT OPIN BIOL TH, V5, P601, DOI 10.1517/14712598.5.4.601
   KAZI AA, 2006, INVESTIG OPHTHALMOL, V47
   Kim H, 2006, EXP EYE RES, V82, P760, DOI 10.1016/j.exer.2005.09.018
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kim TI, 2008, CORNEA, V27, P349, DOI 10.1097/ICO.0b013e31815cf67d
   Kipriyanov SM, 2004, MOL BIOTECHNOL, V26, P39, DOI 10.1385/MB:26:1:39
   Kitzmann AS, 2007, EYE, V21, P1524, DOI 10.1038/sj.eye.6702804
   Kivilcim M, 2007, J OCUL PHARMACOL TH, V23, P57, DOI 10.1089/jop.2006.0083
   Klenkler B, 2004, EXP EYE RES, V79, P677, DOI 10.1016/j.exer.2004.07.008
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   Kon CH, 1999, INVEST OPHTH VIS SCI, V40, P705
   Kriechbaum K, 2008, BRIT J OPHTHALMOL, V92, P518, DOI 10.1136/bjo.2007.127282
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kukk E, 1996, DEVELOPMENT, V122, P3829
   Lacomba MS, 2001, OPHTHALMIC RES, V33, P251
   LACOMBA MS, 2004, AM J OPHTHALMOL, V138, P1041
   Lanthier N, 2005, PRESSE MED, V34, P916, DOI 10.1016/S0755-4982(05)84079-5
   Leonardi A, 2003, EUR J OPHTHALMOL, V13, P606
   Li ZJ, 2006, AM J PATHOL, V169, P1590, DOI 10.2353/ajpath.2006.060415
   Lim L, 2006, CLIN EXP OPHTHALMOL, V34, P365, DOI 10.1111/j.1442-9071.2006.01225.x
   Limb GA, 1999, CLIN EXP IMMUNOL, V115, P409
   Limb GA, 2001, INVEST OPHTH VIS SCI, V42, P1586
   Lindstedt EW, 2005, BRIT J OPHTHALMOL, V89, P533, DOI 10.1136/bjo.2003.037192
   Loizos N, 2005, MOL CANCER THER, V4, P369
   Lonberg N, 2005, NAT BIOTECHNOL, V23, P1117, DOI 10.1038/nbt1135
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Luttun A, 2002, ANN NY ACAD SCI, V979, P80, DOI 10.1111/j.1749-6632.2002.tb04870.x
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6
   MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549
   Macias I, 2005, J RHEUMATOL, V32, P2102
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Mandal S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1487, DOI 10.1001/archopht.125.11.1487
   Manzano RPA, 2008, GRAEF ARCH CLIN EXP, V246, P907, DOI 10.1007/s00417-008-0765-z
   Manzano RPA, 2007, BRIT J OPHTHALMOL, V91, P804, DOI 10.1136/bjo.2006.107912
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Markomichelakis NN, 2004, AM J OPHTHALMOL, V138, P648, DOI 10.1016/j.ajo.2004.04.066
   Mathews MK, 1997, INVEST OPHTH VIS SCI, V38, P2729
   Matsumoto Y, 2007, RETINA-J RET VIT DIS, V27, P426, DOI 10.1097/IAE.0b013e31804a7af2
   McDermott MF, 2001, CELL MOL BIOL, V47, P619
   McKinnon SJ, 2003, FRONT BIOSCI-LANDMRK, V8, pS1140, DOI 10.2741/1172
   Mead AL, 2003, INVEST OPHTH VIS SCI, V44, P3394, DOI 10.1167/iovs.02-0978
   Melichar B, 2007, EUR J CANCER CARE, V16, P439, DOI 10.1111/j.1365-2354.2006.00763.x
   MEYER CH, ACTA OPHTHA IN PRESS
   Miller JW, 1997, AM J PATHOL, V151, P13
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Murphy CC, 2004, OPHTHALMOLOGY, V111, P352, DOI 10.1016/S0161-6420(03)00721-8
   Nakamura Satoshi, 2005, International Ophthalmology Clinics, V45, P179, DOI 10.1097/01.iio.0000155901.41938.3c
   Nakamura Y, 2001, EXP EYE RES, V72, P511, DOI 10.1006/exer.2000.0979
   Nakazawa T, 2006, MOL VIS, V12, P867
   Nanda S, 2004, EXPERT OPIN PHARMACO, V5, P1175, DOI 10.1517/eoph.5.5.1175.31081
   Nestorov I, 2005, J RHEUMATOL, V32, P13
   Neufeld G, 1999, FASEB J, V13, P9
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Niccoli L, 2007, RHEUMATOLOGY, V46, P1161, DOI 10.1093/rheumatology/kem101
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Ohno S, 2004, J RHEUMATOL, V31, P1362
   Okada AA, 2005, OCUL IMMUNOL INFLAMM, V13, P335, DOI 10.1080/09273940590951034
   Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Pessler F, 2006, CLIN RHEUMATOL, V25, P746, DOI 10.1007/s10067-005-0042-z
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Peterson NC, 2005, ILAR J, V46, P314, DOI 10.1093/ilar.46.3.314
   PFEFFER BA, 1994, EXP EYE RES, V59, P323, DOI 10.1006/exer.1994.1114
   Philipp W, 2000, INVEST OPHTH VIS SCI, V41, P2514
   Prager F, 2007, ACTA OPHTHALMOL SCAN, V85, P904, DOI 10.1111/j.1600-0420.2007.00927.x
   PRIGLINGER SG, 2001, RETINA, V27, P1004
   Quiroz-Mercado H, 2008, RETINA-J RET VIT DIS, V28, pS19, DOI 10.1097/IAE.0b013e318159ec6b
   Rajaraman RT, 2006, OPHTHALMOLOGY, V113, P308, DOI 10.1016/j.ophtha.2005.09.037
   Rau R, 2002, ANN RHEUM DIS, V61, P70
   Rayner SA, 2000, CLIN EXP IMMUNOL, V122, P109, DOI 10.1046/j.1365-2249.2000.01339.x
   Reichert JM, 2007, NAT REV DRUG DISCOV, V6, P349, DOI 10.1038/nrd2241
   Reichert JM, 2001, NAT BIOTECHNOL, V19, P819, DOI 10.1038/nbt0901-819
   Reiff A, 2001, ARTHRITIS RHEUM, V44, P1411, DOI 10.1002/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O
   Richards JC, 2005, CLIN EXP OPHTHALMOL, V33, P461, DOI 10.1111/j.1442-9071.2005.01062.x
   Rinaldi M, 2007, ARCH OPHTHALMOL-CHIC, V125, P1422, DOI 10.1001/archopht.125.10.1422
   RODRIGUES EB, 2007, ACTA OPHTHALMOL 0723
   Rosenbaum James T., 1993, Regional Immunology, V5, P299
   Rosenbaum JT, 2002, CLIN EXP RHEUMATOL, V20, pS143
   Rosenfeld PJ, 2007, BRIT J OPHTHALMOL, V91, P128, DOI 10.1136/bjo.2006.101337
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rubin PAD, 2004, AM J OPHTHALMOL, V138, P1041, DOI 10.1016/j.ajo.2004.09.032
   RUIZMORENO JM, 2007, ACTA OPHTHALMOL 0921
   Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887
   Salvi M, 2006, EUR J ENDOCRINOL, V154, P511, DOI 10.1530/eje.1.02119
   Saurenmann RK, 2006, RHEUMATOLOGY, V45, P982, DOI 10.1093/rheumatology/kel030
   Scallon B, 2002, J PHARMACOL EXP THER, V301, P418, DOI 10.1124/jpet.301.2.418
   Schmeling H, 2005, RHEUMATOLOGY, V44, P1008, DOI 10.1093/rheumatology/keh658
   Schulz MW, 1996, INVEST OPHTH VIS SCI, V37, P1509
   Scott DL, 2006, NEW ENGL J MED, V355, P704, DOI 10.1056/NEJMct055183
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Seo MS, 2000, AM J PATHOL, V157, P995, DOI 10.1016/S0002-9440(10)64612-3
   Sfikakis PP, 2005, DIABETES CARE, V28, P445, DOI 10.2337/diacare.28.2.445
   Sfikakis PP, 2001, LANCET, V358, P295, DOI 10.1016/S0140-6736(01)05497-6
   Sfikakis PP, 2004, ANN INTERN MED, V140, P404, DOI 10.7326/0003-4819-140-5-200403020-00025
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Shu SY, 1997, JAMA-J AM MED ASSOC, V278, P1972, DOI 10.1001/jama.278.22.1972
   Singh VK, 2001, IMMUNOL RES, V23, P59, DOI 10.1385/IR:23:1:59
   Sippy BD, 1996, EXP EYE RES, V63, P311, DOI 10.1006/exer.1996.0120
   Sivakumar V, 2008, J NEUROSCI RES, V86, P702, DOI 10.1002/jnr.21519
   Smith JR, 1998, IMMUNOL CELL BIOL, V76, P497, DOI 10.1046/j.1440-1711.1998.00783.x
   Smith JR, 2001, ARTHRIT RHEUM-ARTHR, V45, P252, DOI 10.1002/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5
   Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x
   SONG WK, OPHTHALMOLO IN PRESS
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   Stone EM, 2006, NEW ENGL J MED, V355, P1493, DOI 10.1056/NEJMe068191
   Suhler EB, 2005, ARCH OPHTHALMOL-CHIC, V123, P903, DOI 10.1001/archopht.123.7.903
   Tai TL, 2002, RHEUMATOLOGY, V41, P951, DOI 10.1093/rheumatology/41.8.951
   Takagi H, 1996, INVEST OPHTH VIS SCI, V37, P2165
   TEILLAUD JL, 2002, CLIN EXP RHEUMATOL, V20, pS143
   Tezel G, 2004, BRAIN RES, V996, P202, DOI 10.1016/j.brainres.2003.10.029
   Tezel G, 2001, INVEST OPHTH VIS SCI, V42, P1787
   Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002
   Theodossiadis PG, 2007, RETINA-J RET VIT DIS, V27, P399, DOI 10.1097/MAJ.0b013e3180318fbc
   Tracey D, 2008, PHARMACOL THERAPEUT, V117, P244, DOI 10.1016/j.pharmthera.2007.10.001
   Tsilimbaris Miltiadis K, 2007, Semin Ophthalmol, V22, P75, DOI 10.1080/08820530701418243
   Tugal-Tutkun I, 2005, ARTHRITIS RHEUM-US, V52, P2478, DOI 10.1002/art.21231
   Tuli SS, 2006, CURR EYE RES, V31, P709, DOI 10.1080/02713680600837390
   Valamanesh F, 2007, MOL VIS, V13, P1746
   Vazquez-Cobian LB, 2006, J PEDIATR-US, V149, P572, DOI 10.1016/j.jpeds.2006.04.058
   Verheul HMW, 2007, NAT REV CANCER, V7, P475, DOI 10.1038/nrc2152
   Vitetta ES, 2006, SCIENCE, V313, P308, DOI 10.1126/science.1130482
   Vogel R, 2007, OPHTHALMOLOGY, V114, P1822, DOI 10.1016/j.ophtha.2007.03.050
   Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7
   WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874
   WATANABE H, 1993, GRAEF ARCH CLIN EXP, V231, P228, DOI 10.1007/BF00918846
   Wechsler B, 2004, CLIN EXP RHEUMATOL, V22, pS14
   Weiner LM, 2006, J IMMUNOTHER, V29, P1, DOI 10.1097/01.cji.0000192105.24583.83
   Weisman MH, 2003, CLIN THER, V25, P1700, DOI 10.1016/S0149-2918(03)80164-9
   Wertheim MS, 2006, EYE, V20, P1453, DOI 10.1038/sj.eye.6702330
   WHITCUP SM, 1995, EXP EYE RES, V60, P597, DOI 10.1016/S0014-4835(05)80001-6
   Wilkinson-Berka JL, 2006, CURR MED CHEM, V13, P3307, DOI 10.2174/092986706778773086
   Wilson MW, 2004, OPHTHAL PLAST RECONS, V20, P381, DOI 10.1097/01.IOP.0000139521.38345.BA
   Wilson SE, 1999, PROG RETIN EYE RES, V18, P293, DOI 10.1016/S1350-9462(98)00017-2
   Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yazdani S, 2007, J GLAUCOMA, V16, P437, DOI 10.1097/IJG.0b013e3180457c47
   ZACK DJ, 1983, SCIENCE, V222, P721
   Zhao BJ, 2007, BRIT J OPHTHALMOL, V91, P538, DOI 10.1136/bjo.2006.101543
   Zheng M, 2001, J VIROL, V75, P9828, DOI 10.1128/JVI.75.20.9828-9835.2001
   Zhou HH, 2005, J CLIN PHARMACOL, V45, P490, DOI 10.1177/0091270004273321
NR 272
TC 93
Z9 97
U1 1
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAR
PY 2009
VL 28
IS 2
BP 117
EP 144
DI 10.1016/j.preteyeres.2008.11.005
PG 28
WC Ophthalmology
SC Ophthalmology
GA 418IS
UT WOS:000264142500002
PM 19114125
DA 2020-12-15
ER

PT J
AU Torres, RJD
   Maia, M
   Noronha, L
   Farah, ME
   Luchini, A
   Brik, D
   Muccioli, C
   Precoma, DB
AF de Almeida Torres, Rogil Jose
   Maia, Mauricio
   Noronha, Lucia
   Farah, Michel Eid
   Luchini, Andrea
   Brik, Decio
   Muccioli, Cristina
   Precoma, Dalton Bertolin
TI Evaluation of choroid and sclera early alterations in
   hypercholesterolemic rabbits. histologic and histomorphometric study
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA Portuguese
DT Article
DE Cholesterol/blood; Choroid/blood supply; Diet; Hypercholesterolemia;
   Macular degeneration; Atherosclerosis; Sclera; Models, animal; Rabbits;
   Comparative study
ID BRUCHS MEMBRANE; MACULAR DEGENERATION; BLOOD-FLOW; AGE; CHOLESTEROL;
   PATHOGENESIS; NORMALIZATION
AB Purpose: To demonstrate experimentally, by means of histological and histomorphometric examinations, the sclera and choroid degenerative alterations, which take place at an early stage due to a hypercholesterolemic diet. Methods: New Zealand rabbits were divided into two groups: CG (control group) of 6 rabbits (6 eyes) received a regular diet for 6 weeks; G1, of 12 rabbits (12 eyes), was first fed a 1% cholesterol diet (Sigma-Aldrich) for 2 weeks and then from the 14(th) day on a 0.5% cholesterol diet (Sigma-Aldrich). The eyes underwent a histological analysis, stained with hematoxiline-eosine, and a morphometric examination. The histomorphometric analysis was performed in the posterior region, adjacent to the optic disk, and in the peripheral region. Results: The CG presented a mean sclera and choroid thickness of 228.61 +/- 31.71 micrometers in the peripheral region, while the thickness in the posterior region was approximately 246.07 +/- 25.66 micrometers. In G1, these values were 303.56 +/- 44.21 micrometers in the peripheral region and 295.59 +/- 62.59 in the posterior region. There was a statistically significant difference in the sclera and choroid thickness between the groups in the peripheral region (p<0.001); however, this difference did not occur in the posterior region (p=0.250). The large number of histiocytes and collagen fibers accounted for the increase of G1 wall thickness in relation to CG. Conclusion: This study demonstrated that the hypercholesterolemic diet in rabbits induces a fast increase in the choroid and sclera thickness, mainly due to the increase in the number of histiocytes and collagen fibers.
C1 Hosp Angelina Caron, Campina Grande Do Sul, PR, Brazil.
   Univ Fed Sao Paulo, Dept Oftalmol, Curitiba, Parana, Brazil.
   PUCPR, Curitiba, Parana, Brazil.
RP Torres, RJD (corresponding author), Praca Ruy Barbosa 827,Conj 305, BR-80010030 Curitiba, Parana, Brazil.
EM rjat@terra.com.br
RI Muccioli, Cristina/C-3419-2013; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012; noronha,
   lucia/F-6339-2015
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Farah, Michel Eid E/0000-0001-5951-0193; noronha,
   lucia/0000-0003-0310-7164
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   BROEKHUYSE RM, 1975, OPHTHALMOLOGICA, V171, P82, DOI 10.1159/000307448
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   COGAN DG, 1959, ARCH OPHTHALMOL-CHIC, V61, P219
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   FISHER RF, 1987, EYE, V1, P184, DOI 10.1038/eye.1987.35
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P1126, DOI 10.1016/S0161-6420(95)30902-5
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Grunwald J, 1998, INVEST OPHTH VIS SCI, V39, P2202
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   JANES RG, 1964, AM J OPHTHALMOL, V58, P819, DOI 10.1016/0002-9394(64)90795-0
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Ramirez AI, 2006, EXP EYE RES, V83, P1423, DOI 10.1016/j.exer.2006.07.023
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Salazar JJ, 2007, EXP EYE RES, V84, P412, DOI 10.1016/j.exer.2006.10.012
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Sun YP, 2000, P SOC EXP BIOL MED, V224, P166, DOI 10.1046/j.1525-1373.2000.22416.x
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Trivino A, 2006, EXP EYE RES, V83, P357, DOI 10.1016/j.exer.2005.12.020
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
NR 32
TC 13
Z9 14
U1 0
U2 1
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD JAN-FEB
PY 2009
VL 72
IS 1
BP 68
EP 74
PG 7
WC Ophthalmology
SC Ophthalmology
GA 558OL
UT WOS:000274753700014
PM 19347126
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Wu, L
   Sanchez, JG
   Maia, M
   Saravia, MJ
   Fernandez, CF
   Evans, T
AF Arevalo, J. F.
   Wu, L.
   Sanchez, J. G.
   Maia, M.
   Saravia, M. J.
   Fernandez, C. F.
   Evans, T.
TI Intravitreal bevacizumab (avastin) for proliferative diabetic
   retinopathy: 6-months follow-up
SO EYE
LA English
DT Article; Proceedings Paper
CT 24th Annual Meeting of the American-Society-of-Retina-Specialists/6th
   Annual Meeting of the European-Vitreo-Retinal-Society
CY SEP 10, 2006
CL Cannes, FRANCE
SP Amer Soc Retina Specialists, European Vitreo Retinal Soc
DE avastin; bevacizumab; diabetic retinopathy; intravitreal injections;
   proliferative; retinal neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; SCATTER LASER PHOTOCOAGULATION; MACULAR
   EDEMA; PANRETINAL PHOTOCOAGULATION; TUMOR ANGIOGENESIS; VISUAL-LOSS;
   INJECTION; NEOVASCULARIZATION; THICKNESS; THERAPY
AB Aims To study the effects of intravitreal bevacizumab (Avastin) on retinal neovascularization (RN) in patients with proliferative diabetic retinopathy (PDR).
   Methods Retrospective study of patients with RN due to PDR who were treated with at least one intravitreal injection of 1.25 or 2.5mg of bevacizumab. Patients underwent ETDRS best-corrected visual acuity (BCVA) testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits.
   Results Forty-four eyes of 33 patients with PDR and a mean age of 57.2-years (range: 23 82 years) participated in the study. Thirty-three eyes (75%) had previous panretinal photocoagulation (PRP). Twenty-seven eyes (61.4%) showed total regression of RN on fundus examination with absence of fluorescein leakage, 15 eyes (34.1%) demonstrated partial regression of RN on fundus examination and FA. Follow-up had a mean of 28.4 weeks (range from 24 to 40 weeks). BCVA and OCT demonstrated improvement (P<0.0001). Three eyes without previous PRP ('naive' eyes) and with vitreous haemorrhage have avoided vitreo-retinal surgery. One eye (2.2%) had PDR progression to tractional retinal detachment requiring vitrectomy, and one eye (2.2%) had vitreous haemorrhage with increased intraocular pressure (ghost cell glaucoma). No systemic adverse events were observed.
   Conclusions Intravitreal bevacizumab resulted in marked regression of RN in patients with PDR and previous PRP, and rapid resolution of vitreous haemorrhage in three naive eyes. Six-months results of intravitreal bevacizumab at doses of 1.25 or 2.5mg in patients with PDR do not reveal any safety concerns.
C1 [Arevalo, J. F.; Sanchez, J. G.] Ctr Caracas, Clin Oftalmol, Retina & Vitreous Serv, Caracas 1010, Venezuela.
   [Wu, L.; Evans, T.] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Maia, M.] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Saravia, M. J.] Hosp Univ Austral, Buenos Aires, DF, Argentina.
   [Fernandez, C. F.] Oftalmolaser, Lima, Peru.
RP Arevalo, JF (corresponding author), Ctr Caracas, Clin Oftalmol, Retina & Vitreous Serv, Edif Ctr Caracas PH-1,Av Panteon, Caracas 1010, Venezuela.
EM arevalojf2020@gmail.com
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
CR Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Avery RF, 2006, OPHTHALMOLOGY, V113
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   AYLWARD GW, 1989, BRIT J OPHTHALMOL, V73, P197, DOI 10.1136/bjo.73.3.197
   Chen E, 2006, RETINA-J RET VIT DIS, V26, P699, DOI 10.1097/01.iae.0000225351.87205.69
   DOFT BH, 1982, OPHTHALMOLOGY, V89, P772
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FERRIS FL, 1987, OPHTHALMOLOGY, V94, P754
   Fong DS, 1999, AM J OPHTHALMOL, V127, P137, DOI 10.1016/S0002-9394(98)00309-2
   Friedlander SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1363
   Isaacs TW, 2006, CLIN EXP OPHTHALMOL, V34, P802, DOI 10.1111/j.1442-9071.2006.01378.x
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   KASSOFF A, 1993, OPHTHALMOLOGY, V100, P1655
   KAUFMAN SC, 1989, INVEST OPHTH VIS SCI, V30, P23
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mason JO, 2006, AM J OPHTHALMOL, V142, P685, DOI 10.1016/j.ajo.2006.04.058
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   MCDONALD HR, 1985, OPHTHALMOLOGY, V92, P388
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Nonaka A, 2002, INVEST OPHTH VIS SCI, V43, P1204
   PEER J, 1995, LAB INVEST, V72, P638
   Schachat AP, 2003, OPHTHALMOLOGY, V110, P2073, DOI 10.1016/S0161-6420(03)01004-2
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shimura M, 2003, OPHTHALMOLOGY, V110, P2386, DOI 10.1016/j.ophtha.2003.05.008
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Tsujikawa A, 1999, RETINA-J RET VIT DIS, V19, P59, DOI 10.1097/00006982-199901000-00010
   Watanabe D, 2005, AM J OPHTHALMOL, V139, P476, DOI 10.1016/j.ajo.2004.10.004
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
NR 37
TC 81
Z9 90
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2009
VL 23
IS 1
BP 117
EP 123
DI 10.1038/sj.eye.6702980
PG 7
WC Ophthalmology
SC Ophthalmology
GA 394YC
UT WOS:000262488100021
PM 17891058
OA Bronze
DA 2020-12-15
ER

PT J
AU Costa, EDF
   Rodrigues, EB
   Farah, ME
   Dib, E
   Penha, F
   Magalhaes, O
   Furlani, BA
   Lima, AAS
   de Miranda, A
   Maia, M
AF Fiod Costa, Elaine de Paula
   Rodrigues, Eduardo B.
   Farah, Michel Eid
   Dib, Eduardo
   Penha, Fernando
   Magalhaes, Octaviano, Jr.
   Furlani, Bruno Albuquerque
   Lima Filho, Acacio A. S.
   de Miranda, Antonio
   Maia, Mauricio
TI Vital Dyes and Light Sources for Chromovitrectomy: Comparative
   Assessment of Osmolarity, pH, and Spectrophotometry
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
CY APR 30, 2008
CL Ft Lauderdale, FL
SP Assoc Res Vis & Ophthalmol (ARVO)
ID INTERNAL LIMITING MEMBRANE; EXPERIMENTAL MACULAR SURGERY; PERFUSED CAT
   EYE; INDOCYANINE-GREEN; PIGMENT-EPITHELIUM; HOLE SURGERY; TRYPAN BLUE;
   DAMAGE; ACIDOSIS; RABBIT
AB PURPOSE. To investigate the in vitro pH, osmolarity, spectral, and photostability properties of nine vital dyes for vitreoretinal surgery.
   METHODS. Nine dyes-indocyanine green (ICG), trypan blue (TB), brilliant blue (BriB), bromophenol blue (BroB), Congo red (CR), light green (LG), fast green (FG), indigo carmine (IC) and Evans blue (EB)-diluted in three solvents (saline solution, glucose 5%, and water) were tested for osmolarity and pH. Spectrophotometry was used to determine absorbance properties of 27 solutions. Irradiance emission spectra of seven endoillumination light sources and fiber-optics were compared with dye absorbance curves.
   RESULTS. Dye osmolarity in saline solution and glucose 5% varied widely (257-385 mOsm) and was lower (0-54 mOsm) when dyes were dissolved in water. Dyes diluted in three solvents showed pH values varying from 2.6 to 9.85. ICG, LG, TB, BroB, CR, and IC demonstrated different absorbances, depending on the solvent. BriB and FG showed similar absorbance curves with different solvents. Spectrophometric analysis showed that all dyes except ICG had remarkable spectral overlap with the light sources. Among endoillumination fiber-optics, overlap was greatest with dual-output illumination with an integrated laser pathway and least with a mercury vapor lamp.
   CONCLUSIONS. Vital dyes showed variable osmolarity and pH, which also depended on the solvent used. Interaction of light from endoillumination source and vital dye may increase or decrease the risk for toxicity, making appropriate selection of both a desirable way to minimize the risk for phototoxic effects. (Invest Ophthalmol Vis Sci. 2009; 50: 385-391) DOI: 10.1167/iovs.08-2285
C1 [Fiod Costa, Elaine de Paula; Rodrigues, Eduardo B.; Farah, Michel Eid; Dib, Eduardo; Penha, Fernando; Magalhaes, Octaviano, Jr.; Furlani, Bruno Albuquerque; Lima Filho, Acacio A. S.; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, IPEPO, BR-04026000 Sao Paulo, Brazil.
   [de Miranda, Antonio] Univ Fed Sao Paulo, Dept Biophys, BR-04026000 Sao Paulo, Brazil.
RP Costa, EDF (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, IPEPO, Doutor Bacelar 317 Jade 191,Vila Clementino Sao P, BR-04026000 Sao Paulo, Brazil.
EM elaine68@terra.com.br
RI Miranda, Antonio/C-8855-2012; Maia, Mauricio/I-5892-2015; Maia,
   Mauricio/Z-1042-2019; Farah, Michel Eid E/F-3285-2012; Penha, Fernando
   M/G-1784-2012; de Souza Lima Filho, Acacio Alves/C-7189-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Farah, Michel Eid E/0000-0001-5951-0193; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921; Alves de Souza Lima Filho,
   Acacio/0000-0003-1802-9592
CR Gandorfer A, 2003, INVEST OPHTH VIS SCI, V44, P316, DOI 10.1167/iovs.02-0545
   GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851
   Grisanti S, 2004, INVEST OPHTH VIS SCI, V45, P282, DOI 10.1167/iovs.03-0797
   HAM WT, 1980, VISION RES, V20, P1105, DOI 10.1016/0042-6989(80)90047-4
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P1468, DOI 10.1167/iovs.04-0838
   Haritoglou C, 2003, INVEST OPHTH VIS SCI, V44, P2722, DOI 10.1167/iovs.02-1283
   Holmes JM, 1999, INVEST OPHTH VIS SCI, V40, P804
   Kadonosono K, 2003, GRAEF ARCH CLIN EXP, V241, P284, DOI 10.1007/s00417-003-0636-6
   Kwok AKH, 2005, BRIT J OPHTHALMOL, V89, P897, DOI 10.1136/bjo.2004.061093
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P178, DOI 10.1016/S0002-9394(01)00976-X
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P1016
   Maruiwa F, 1999, VISION RES, V39, P159, DOI 10.1016/S0042-6989(98)00138-2
   Narayanan R, 2005, CURR EYE RES, V30, P471, DOI 10.1080/02713680590959312
   NIEMEYER G, 1986, DOC OPHTHALMOL, V63, P113, DOI 10.1007/BF00157120
   NIEMEYER G, 1984, VISION RES, V24, P275, DOI 10.1016/0042-6989(84)90131-7
   Oberstein SYL, 2007, BRIT J OPHTHALMOL, V91, P955, DOI 10.1136/bjo.2006.112425
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   POLINER LS, 1992, OPHTHALMOLOGY, V99, P1671
   Postel EA, 1998, ARCH OPHTHALMOL-CHIC, V116, P753, DOI 10.1001/archopht.116.6.753
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2007, RETINA-J RET VIT DIS, V27, P958, DOI 10.1097/01.iae.0000253051.01194.ab
   SHIRAO Y, 1987, INVEST OPHTH VIS SCI, V28, P2015
   SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31
   Staub F, 1994, Anasthesiol Intensivmed Notfallmed Schmerzther, V29, P203, DOI 10.1055/s-2007-996719
   STAUB F, 1994, J CEREBR BLOOD F MET, V14, P1030, DOI 10.1038/jcbfm.1994.135
   Yanagi Y, 2006, BRIT J OPHTHALMOL, V90, P229, DOI 10.1136/bjo.2005.076711
NR 26
TC 28
Z9 29
U1 1
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2009
VL 50
IS 1
BP 385
EP 391
DI 10.1167/iovs.08-2285
PG 7
WC Ophthalmology
SC Ophthalmology
GA 390YP
UT WOS:000262199900050
PM 18689696
DA 2020-12-15
ER

PT J
AU Rodrigues, EB
   Maia, M
   Penha, FM
   Dib, E
   Bordon, AF
   Magalhaes, O
   Farah, ME
AF Rodrigues, Eduardo Buchele
   Maia, Mauricio
   Penha, Fernando Marcondes
   Dib, Eduardo
   Bordon, Arnaldo Furman
   Magalhaes Junior, Octaviano
   Farah, Michel Eid
TI Technique of intravitreal drug injection for therapy of vitreoretinal
   diseases
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA Portuguese
DT Article
DE Macular degeneration; Age effect; Retina; Vascular endothelial growth
   factor; Blindness; Intravitreal injection
AB Intravitreal injections are the standard technique applied in the treatment of some vitreoretinal diseases. In this paper the technique and complications of intravitreal injections are presented. In summary, the procedure involves various consecutive steps. Initially, days before the treatment topical antibiotics and acetazolamide may be prescribed for reduction of the ocular flora and intraocular pressure. Before the injection, the pupil should be dilated and topical anesthesia should be achieved. Injection shall be performed in the operating room under sterile conditions, the surgeon should wear surgical gloves and mask. The eye is then exposed with sterile blepharostat and sterile-drape thereby providing protection of the needle against the contact with contaminated lashes and lids. Injection is done 3.5 mm from the limbus through the pars plana. The needle should be inserted up to 6 mm into the vitreous cavity. Immediately after injection the patient must be examined by indirect ophthalmoscopy to verify central artery perfusion and complications as vitreous hemorrhage. Visual acuity better than light perception should be detected right after injection. If persistent central retinal artery occlusion is diagnosed, anterior chamber paracentesis should be performed. The patient may be discharged with an occlusive patch. Examination at the first postoperative day should exclude various complications such as endophthalmitis, and topical steroid and antibiotics should be prescribed for 7 days. Some complications encountered after intravitreal injections include retinal detachment, vitreous hemorrhage, cataract, uveitis, ocular hypertension, or endophthalmitis.
C1 [Rodrigues, Eduardo Buchele] Univ Fed Sao Paulo, Inst Visao, Dept Oftalmologia, UNIFESP, Sao Paulo, Brazil.
   [Maia, Mauricio; Penha, Fernando Marcondes; Dib, Eduardo; Bordon, Arnaldo Furman; Magalhaes Junior, Octaviano] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Farah, Michel Eid] Univ Fed Sao Paulo, Dept Oftalmol, Sao Paulo, Brazil.
RP Rodrigues, EB (corresponding author), Rua Almirante Barroso,45 Sunset Blvd Jade, BR-88030460 Florianopolis, SC, Brazil.
EM edubrodriguess@yahoo.com.br
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012; Maia,
   Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Buchele
   Rodrigues, Eduardo/0000-0002-4224-0921
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   APT L, 1984, ARCH OPHTHALMOL-CHIC, V102, P728, DOI 10.1001/archopht.1984.01040030584025
   Bucher RS, 2005, RETINA-J RET VIT DIS, V25, P269, DOI 10.1097/00006982-200504000-00003
   Bucher RS, 2005, ARCH OPHTHALMOL-CHIC, V123, P649, DOI 10.1001/archopht.123.5.649
   Bylsma G, 2006, CLIN EXP OPHTHALMOL, V34, P388, DOI 10.1111/j.1442-9071.2006.01231.x
   Ciulla TA, 2002, OPHTHALMOLOGY, V109, P13, DOI 10.1016/S0161-6420(01)00899-5
   Doft Bernard H, 2002, Curr Opin Ophthalmol, V13, P147, DOI 10.1097/00055735-200206000-00003
   Farah ME, 2001, ARQ BRAS OFTALMOL, V64, P583
   Hanscom TA, 2004, CLIN INFECT DIS, V38, P542, DOI 10.1086/381262
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jaissle GB, 2005, KLIN MONATSBL AUGENH, V222, P389, DOI 10.1055/s-2005-858341
   Jaissle GB, 2005, KLIN MONATSBL AUGENH, V222, P390, DOI 10.1055/s-2005-858231
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Korobelnik JF, 2006, J FR OPHTALMOL, V29, P82, DOI 10.1016/S0181-5512(06)73754-8
   Kresloff MS, 1998, SURV OPHTHALMOL, V43, P193, DOI 10.1016/S0039-6257(98)00036-8
   Kurz Daryl, 2002, Ophthalmol Clin North Am, V15, P405, DOI 10.1016/S0896-1549(02)00034-2
   Mamalis Nick, 2002, Curr Opin Ophthalmol, V13, P14, DOI 10.1097/00055735-200202000-00004
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Oliveira Neto H, 1998, ARQ BRAS OFTALMOL, V61, P312
   PERRY LD, 1977, OPHTHALMIC SURG LAS, V8, P44
   Pulido JS, 2007, EYE, V21, P1210, DOI 10.1038/sj.eye.6702577
   Pulido JS, 2007, EYE, V21, P829, DOI 10.1038/sj.eye.6702514
   Rodrigues EB, 2007, AM J OPHTHALMOL, V143, P1035, DOI 10.1016/j.ajo.2007.01.035
   Rodrigues Eduardo Büchele, 2006, Arq. Bras. Oftalmol., V69, P756, DOI 10.1590/S0004-27492006000500027
   Scott IU, 2007, ARCH OPHTHALMOL-CHIC, V125, P974, DOI 10.1001/archopht.125.7.974
   Smith JR, 2002, OPHTHALMOLOGY, V109, P1709, DOI 10.1016/S0161-6420(02)01125-9
   Song A, 2002, OPHTHALMOLOGY, V109, P985, DOI 10.1016/S0161-6420(02)00965-X
   SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P1769
   Sutter FKP, 2004, OPHTHALMOLOGY, V111, P2044, DOI 10.1016/j.ophtha.2004.05.025
   Ta CN, 2004, RETINA-J RET VIT DIS, V24, P699, DOI 10.1097/00006982-200410000-00003
   Young S, 1998, OPHTHALMOLOGY, V105, P1404, DOI 10.1016/S0161-6420(98)98020-4
NR 31
TC 7
Z9 9
U1 0
U2 0
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD NOV-DEC
PY 2008
VL 71
IS 6
BP 902
EP 907
DI 10.1590/S0004-27492008000600028
PG 6
WC Ophthalmology
SC Ophthalmology
GA V28GY
UT WOS:000208670500030
PM 19169531
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Fromow-Guerra, J
   Sanchez, JG
   Maia, M
   Berrocal, MH
   Wu, L
   Saravia, MJ
   Costa, RA
AF Arevalo, J. Fernando
   Fromow-Guerra, Jans
   Sanchez, Juan G.
   Maia, Mauricio
   Berrocal, Maria H.
   Wu, Lihteh
   Saravia, Mario J.
   Costa, Rogerio A.
TI PRIMARY INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION Results of the
   Pan-American Collaborative Retina Study Group at 12 Months Follow-up
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 111th Annual Meeting of the American-Academy-of-Ophthalmology
CY NOV 09-13, 2007
CL New Orleans, LA
SP Amer Acad Ophthalmol
DE age-related macular degeneration; Avastin; choroidal neovascularization;
   primary intravitreal bevacizumab; subfoveal
ID ENDOTHELIAL GROWTH-FACTOR; AVASTIN TREATMENT; UNITED-STATES; INJECTION;
   MACULOPATHY; PREVALENCE; SECONDARY; ANTIBODY; PROGRESS; DISEASE
AB Purpose: To report the 12-month anatomic and Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin(TM), Genentech Inc., San Francisco, CA) (1.25 mg or 2.5 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
   Methods: Sixty-three eyes of 63 consecutive patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration, a mean age of 73.7 +/- 7.5 years and a minimum of 12 months (mean 55.5 +/- 6.2 weeks) of follow-up participated in this interventional retrospective multicenter case series in 7 centers from 6 countries. Patients were treated with at least 1 intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab. Patients underwent Early Treatment Diabetic Retinopathy Study BCVA testing, ophthalmoscopic examination, optical coherence tomography, and fluorescein angiography at baseline and follow-up visits. Repeated measures analysis of variance was used to compare mean values.
   Results: The mean number of intravitreal bevacizumab injections per eye was 3.5 (range, 1-8). Mean baseline BCVA was 20/320, logarithm of the minimum angle of resolution = 1.2, and mean final BCVA was 20/200, logarithm of the minimum angle of resolution = 1.0 (P < 0.001). Central macular thickness at baseline by optical coherence tomography had a mean of 389.2 +/- 149.6 mu m which was significantly reduced to a mean of 281.0 +/- 96.1 mu m, 268.2 +/- 82.6 mu m, 262.6 +/- 92.3 mu m, and 241.3 +/- 76.7 mu m at 1, 3, 6, and 12 months after initial treatment, respectively (P < 0.0001). Ocular adverse events included transient increased intraocular pressure in 2 (3.1%) eyes, endophthalmitis in 2 (3.1%) eyes, and transient hypotony in 1 eye (1.1%). No systemic adverse events were observed.
   Conclusion: Primary intravitreal bevacizumab at doses of 1.25 mg or 2.5 mg seems to provide stability or improvement in BCVA, optical coherence tomography, and fluorescein angiography in subfoveal choroidal neovascularization secondary to age-related macular degeneration at 12 months.
C1 [Arevalo, J. Fernando; Sanchez, Juan G.] Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Caracas 1010, Venezuela.
   [Fromow-Guerra, Jans] Hosp Dr Luis Sanchez Bulnes, Asociac Para Evitar Ceguera Mexico, Mexico City, DF, Mexico.
   [Maia, Mauricio] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Berrocal, Maria H.] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Saravia, Mario J.] Hosp Univ Austral, Buenos Aires, DF, Argentina.
   [Costa, Rogerio A.] Hosp Olhos Araraquara, Araraquara, SP, Brazil.
RP Arevalo, JF (corresponding author), Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Edif Ctr Caracas PH-1,Av Panteon, Caracas 1010, Venezuela.
EM arevalojf2020@gmail.com
RI Maia, Mauricio/I-5892-2015; Costa, Rogerio A/E-6930-2013; Fromow-Guerra,
   J. Jans/A-3346-2015; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Costa, Rogerio
   A/0000-0002-0800-2233; Fromow-Guerra, J. Jans/0000-0001-5335-1275; Maia,
   Mauricio/0000-0002-7034-8091
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DAMICO DJ, 1994, NEW ENGL J MED, V331, P95, DOI 10.1056/NEJM199407143310207
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GRADOUDAS ES, 2004, NEW ENGL J MED, V351, P2805
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Husain D., 1997, Investigative Ophthalmology and Visual Science, V38, pS501
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Pieramici DJ, 2006, RETINA-J RET VIT DIS, V26, P841, DOI 10.1097/01.iae.0000234629.22614.cd
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
   2005, RETINA, V25, P815
NR 34
TC 43
Z9 48
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2008
VL 28
IS 10
BP 1387
EP 1394
DI 10.1097/IAE.0b013e3181884ff4
PG 8
WC Ophthalmology
SC Ophthalmology
GA 373LH
UT WOS:000260972600002
PM 18827735
DA 2020-12-15
ER

PT J
AU Penha, FM
   Maia, M
   Farah, ME
   Kawakami, LT
   Hoefling-Lima, AL
AF Penha, Fernando M.
   Maia, Mauricio
   Farah, Michel E.
   Kawakami, Lauro T.
   Hoefling-Lima, Ana Luisa
TI Thermal damage to a light probe using a xenon light source
SO ACTA OPHTHALMOLOGICA
LA English
DT Letter
ID ILLUMINATION; VITRECTOMY; SURGERY
C1 [Penha, Fernando M.; Maia, Mauricio; Farah, Michel E.; Kawakami, Lauro T.; Hoefling-Lima, Ana Luisa] Univ Fed Sao Paulo, Vis Inst IPEPO, Dept Ophthalmol, Sao Paulo, Brazil.
RP Farah, ME (corresponding author), Ave Ibijau 331-17 Andar, BR-04524020 Sao Paulo, Brazil.
EM mefarah@uol.com.br
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012; Penha,
   Fernando M/G-1784-2012; Maia, Mauricio/Z-1042-2019; Hofling-Lima, Ana
   Luisa/C-8865-2012; Hofling-Lima, Ana/O-7438-2019
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Hofling-Lima,
   Ana/0000-0003-0338-3951; Penha, Fernando/0000-0002-1038-5472
CR Eckardt C, 2003, RETINA-J RET VIT DIS, V23, P893, DOI 10.1097/00006982-200312000-00039
   GAYNON MW, 1986, ARCH OPHTHALMOL-CHIC, V104, P1088
   Kadonosono K, 2006, RETINA-J RET VIT DIS, V26, P708, DOI 10.1097/00006982-200607000-00025
   Shimada H, 2007, AM J OPHTHALMOL, V143, P167, DOI 10.1016/j.ajo.2006.07.049
   van den Biesen PR, 2000, BRIT J OPHTHALMOL, V84, P1372, DOI 10.1136/bjo.84.12.1372
NR 5
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2008
VL 86
IS 4
BP 461
EP 462
DI 10.1111/j.1600-0420.2007.01045.x
PG 2
WC Ophthalmology
SC Ophthalmology
GA 309YT
UT WOS:000256496800020
PM 17995977
OA Bronze
DA 2020-12-15
ER

PT J
AU Torres, RJD
   Precoma, DB
   Maia, M
   Kaiber, F
   Prim, C
   Luchini, A
   Matos, RS
   Farah, ME
AF de Almeida Torres, Rogil Jose
   Precoma, Dalton Bertolim
   Maia, Mauricio
   Kaiber, Flavia
   Prim, Camila
   Luchini, Andrea
   Matos, Rossane Serafin
   Farah, Michel Eid
TI Current concepts and perspectives in the prevention of age-related
   macular degeneration
SO REVISTA BRASILEIRA DE OFTALMOLOGIA
LA Portuguese
DT Review
DE antioxidants/adverse effects; carotenoids; lutein; zinc; vitamin D;
   fatty acids, omega-3; diet; macular degeneration; supplementary feeding;
   free radicals; clinical trials
ID 3RD NATIONAL-HEALTH; NUTRITION EXAMINATION SURVEY; VITAMIN-E
   SUPPLEMENTATION; DIETARY FATTY-ACIDS; BETA-CAROTENE; ANTIOXIDANT
   SUPPLEMENTS; RISK-FACTORS; OMEGA-3-FATTY-ACID INTAKE; SECONDARY
   PREVENTION; CIGARETTE-SMOKING
AB The authors prepare a literature review about the main antioxidants used in daily practice for the prevention of age-related macular degeneration progression (AMD), emphasizing the mechanism of action of each substance as well as the possible complications related to the overuse of such components.
C1 [de Almeida Torres, Rogil Jose; Maia, Mauricio; Farah, Michel Eid] Univ Fed Sao Paulo, Dept Oftalmol, Sao Paulo, Brazil.
   [de Almeida Torres, Rogil Jose] Hosp Angelina Caron, Curitiba, Parana, Brazil.
   [Precoma, Dalton Bertolim] Pontificia Univ Catolica Parana PUCPR, Dept Cardiol, Curitiba, Parana, Brazil.
   [Maia, Mauricio] Hosp Olhos Oeste Paulista, Serv Cirurg Vitreorretiniana, Assis, SP, Brazil.
   [Prim, Camila] PUCPR, Posgrad Ciencias Saude, Curitiba, Parana, Brazil.
   [Prim, Camila] Nutricionista Nutrimed, Curitiba, Parana, Brazil.
   [Luchini, Andrea] Ctr Oftalmol, Curitiba, Parana, Brazil.
RP Torres, RJD (corresponding author), Praca Ruy Barbosa 827,Conj 305, Curitiba, Parana, Brazil.
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
CR *AG REL EYE DIS ST, 2002, J FAM PRACTICE, V51, P105
   *AG REL EYE DIS ST, 2001, JAMA-J AM MED ASSOC, V286, P2466
   *AG REL EYE DIS ST, 2002, ARCH OPHTHALMOL-CHIC, V120, P997
   *AG REL EYE DIS ST, 2003, ARCH OPHTHALMOL-CHIC, V121, P416
   *AG REL EYE DIS ST, 2002, ARCH OPHTHALMOL-CHIC, V120, P100
   *AG REL EYE DIS ST, 2008, ARCH OPHTHALMOL-CHIC, V126, P147
   *AG REL EYE DIS ST, 2002, ARCH OPHTHALMOL-CHIC, V120, P1602
   *AG REL EYE DIS ST, 2008, ARCH OPHTHALMOL-CHIC, V126, P146
   AGGETT PJ, 1995, NUTR REV, V53, pS16
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Ames BN, 2001, MUTAT RES-FUND MOL M, V475, P7, DOI 10.1016/S0027-5107(01)00070-7
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 1995, NUTR REV, V53, P202
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Balluz LS, 2000, ARCH FAM MED, V9, P258, DOI 10.1001/archfami.9.3.258
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernardi RJ, 2002, ENDOCRINOLOGY, V143, P2508, DOI 10.1210/en.143.7.2508
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bjelakovic G, 2005, LANCET, V365, P471
   Bjelakovic G, 2004, LANCET, V364, P1219, DOI 10.1016/S0140-6736(04)17138-9
   BJELAKOVIC G, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004183.PUB2
   BJELAKOVIC G, 2007, ACP J CLUB, V147, P4
   BJELAKOVIC G, 2005, EVID BASED NURS, V8, P48
   BJELAKOVIC G, 2005, ACP J CLUB, V142, P20
   BJELAKOVIC G, 2008, JAMA-J AM MED ASSOC, V299, P765
   BJELAKOVIC G, 2007, JAMA-J AM MED ASSOC, V298, P400
   BJELAKOVIC G, 2007, JAMA-J AM MED ASSOC, V298, P402
   BJELAKOVIC G, 2007, JAMA-J AM MED ASSOC, V298, P401
   Bjelakovic G, 2007, JAMA-J AM MED ASSOC, V297, P842, DOI 10.1001/jama.297.8.842
   BJELKOVIC G, 2005, GASTROENTEROLOGY, V128, P1519
   BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BORISH ET, 1987, CARCINOGENESIS, V8, P1517, DOI 10.1093/carcin/8.10.1517
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Caraballoso M., 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002141
   Castro IA, 2007, NUTRITION, V23, P127, DOI 10.1016/j.nut.2006.11.006
   CHANDRA RK, 1984, JAMA-J AM MED ASSOC, V252, P1443, DOI 10.1001/jama.252.11.1443
   Chardigny JM, 2001, EUR J LIPID SCI TECH, V103, P478, DOI 10.1002/1438-9312(200107)103:7<478::AID-EJLT478>3.0.CO;2-A
   Chernyavsky P. V., 2006, Ukrainskii Biokhimicheskii Zhurnal, V78, P101
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   CHOW CK, 1991, FREE RADICAL BIO MED, V11, P215
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Chrysohoou C, 2007, AM J CLIN NUTR, V85, P1385
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   CRISWELL D, 1993, MED SCI SPORT EXER, V25, P1135
   De Caterina R, 2001, EUR HEART J SUPPL, V3, pD42, DOI 10.1016/S1520-765X(01)90118-X
   de Lorgeril M, 2004, REPROD NUTR DEV, V44, P283, DOI 10.1051/rnd:2004032
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   DELORGERIL, 1995, LANCET, V345, P738
   DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1
   DELORGERIL M, 1994, LANCET, V344, P893
   DELORGERIL M, 1994, LANCET, V344, P407
   DELORGERIL M, 1994, LANCET, V344, P622
   DELORGERIL M, 1994, ACP J CLUB, V121, P59
   Demmig-Adams B, 2002, SCIENCE, V298, P2149, DOI 10.1126/science.1078002
   Den Ruijter HM, 2006, J MOL CELL CARDIOL, V41, P914, DOI 10.1016/j.yjmcc.2006.08.001
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   DZIEZAK JD, 1989, FOOD TECHNOL-CHICAGO, V43, P68
   El-Agamey A, 2004, ARCH BIOCHEM BIOPHYS, V430, P37, DOI 10.1016/j.abb.2004.03.007
   Evans P, 1999, ANN NY ACAD SCI, V884, P19, DOI 10.1111/j.1749-6632.1999.tb08633.x
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Fraser PD, 2004, PROG LIPID RES, V43, P228, DOI 10.1016/j.plipres.2003.10.002
   FRIDAY KE, 1989, DIABETES CARE, V12, P276, DOI 10.2337/diacare.12.4.276
   FRIDAY KE, 1990, DIABETES CARE, V13, P80
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN DS, 2004, JAMA-J AM MED ASSOC, V291, P1900
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Gruber M, 2004, J NUTR, V134, P2387
   Guallar E, 2005, ANN INTERN MED, V143, P143, DOI 10.7326/0003-4819-143-2-200507190-00014
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Halliwell B, 1999, MUTAT RES-GEN TOX EN, V443, P37, DOI 10.1016/S1383-5742(99)00009-5
   Halliwell B, 1999, TRENDS BIOCHEM SCI, V24, P255, DOI 10.1016/S0968-0004(99)01418-8
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Harris WS, 2004, PREV MED, V39, P212, DOI 10.1016/j.ypmed.2004.02.030
   Harris WS, 2001, EUR HEART J SUPPL, V3, pD59, DOI 10.1016/S1520-765X(01)90121-X
   Hayes CE, 2003, CELL MOL BIOL, V49, P277
   Herbert V, 1997, J AM DIET ASSOC, V97, P375, DOI 10.1016/S0002-8223(97)00089-8
   HERBERT V, 1994, AM J CLIN NUTR, V60, P157
   HERBERT V, 1996, J AM DIET ASSOC, V96, P693
   HERBERT V, 1996, J AM DIET ASSOC, V96, P703
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   HOOPER PL, 1980, JAMA-J AM MED ASSOC, V244, P1960, DOI 10.1001/jama.244.17.1960
   Hu FB, 2003, CIRCULATION, V107, P1852, DOI 10.1161/01.CIR.0000062644.42133.5F
   Jacobson Terry A, 2007, Curr Atheroscler Rep, V9, P145, DOI 10.1007/s11883-007-0011-x
   Jampol LM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1533
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   JORGENSEN K, 1993, Z LEBENSM UNTERS FOR, V196, P423, DOI 10.1007/BF01190806
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KEMP CM, 1988, EXP EYE RES, V46, P185, DOI 10.1016/S0014-4835(88)80076-9
   Keys SA, 1999, EXP EYE RES, V68, P693, DOI 10.1006/exer.1999.0657
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Kim HK, 2005, J NUTR SCI VITAMINOL, V51, P8, DOI 10.3177/jnsv.51.8
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Krauss RM, 2000, CIRCULATION, V102, P2284
   KRINSKY NI, 1979, PURE APPL CHEM, V51, P649, DOI 10.1351/pac197951030649
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Lawson KA, 2007, J NATL CANCER I, V99, P754, DOI 10.1093/jnci/djk177
   LIM BP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P178
   MACHLIN LJ, 1987, FASEB J, V1, P441
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   MANOLAGAS SC, 1986, J CLIN ENDOCR METAB, V63, P394, DOI 10.1210/jcem-63-2-394
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Maxwell SRJ, 1999, DRUG SAFETY, V21, P253, DOI 10.2165/00002018-199921040-00002
   Mayne ST, 1996, FASEB J, V10, P690
   Mezzetti A, 1998, FREE RADICAL BIO MED, V25, P676, DOI 10.1016/S0891-5849(98)00109-9
   Millen AE, 2004, J AM DIET ASSOC, V104, P942, DOI 10.1016/j.jada.2004.03.022
   Miller ER, 2005, ANN INTERN MED, V143, P156, DOI 10.7326/0003-4819-143-2-200507190-00029
   Miller ER, 2005, J FAM PRACTICE, V54, P199
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   MILLER ER, EVID BASED NURS, V8, P82
   MILLER ER, 2005, ACP J CLUB, V143, P1
   MILLER ER, ANN INTERN MED, V142, P75
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nichter M, 2006, CULT MED PSYCHIAT, V30, P175, DOI 10.1007/s11013-006-9016-0
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Omenn GS, 1996, NEW ENGL J MED, V335, P1067
   OMENN GS, 1996, ACP J CLUB, V125, P40
   ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Papas AM, 1999, FOOD CHEM TOXICOL, V37, P999, DOI 10.1016/S0278-6915(99)00088-5
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   PATTERSON WP, 1985, ANN INTERN MED, V103, P385, DOI 10.7326/0003-4819-103-3-385
   PAULING L, 1970, P NATL ACAD SCI USA, V67, P1643, DOI 10.1073/pnas.67.4.1643
   PRASAD AS, 1995, NUTRITION, V11, P93
   Radimer K, 2004, AM J EPIDEMIOL, V160, P339, DOI 10.1093/aje/kwh207
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   ROE DA, 1987, FASEB J, V46, P1886
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Salganik RI, 2001, J AM COLL NUTR, V20, p464S, DOI 10.1080/07315724.2001.10719185
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schaefer EJ, 2002, AM J CLIN NUTR, V75, P191
   Seddon JM, 2004, ARCH OPHTHALMOL-CHIC, V122, P426
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   SEDDON JM, 1995, JAMA-J AM MED ASSOC, V273, P622
   Seddon JM, 2007, AM J CLIN NUTR, V85, p304S
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seifried HE, 2003, CANCER RES, V63, P4295
   SHAPIRO H, 2006, AM J CARDIOL, V98, P27
   Sickel W, 1972, Adv Exp Med Biol, V24, P101
   Simopoulos Artemis P., 1999, Annals of Nutrition and Metabolism, V43, P127, DOI 10.1159/000012777
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Stranges S, 2007, ANN INTERN MED, V147, P217, DOI 10.7326/0003-4819-147-4-200708210-00175
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Taylor HR, 2002, BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Therond P, 2000, Curr Opin Clin Nutr Metab Care, V3, P373, DOI 10.1097/00075197-200009000-00009
   Thomas SR, 2000, FREE RADICAL BIO MED, V28, P1795, DOI 10.1016/S0891-5849(00)00236-7
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thorlaksdottir AY, 2006, LIPIDS, V41, P119, DOI 10.1007/s11745-006-5079-5
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Trumbo PR, 2006, AM J CLIN NUTR, V84, P971
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Venkatraman JT, 1998, J AM COLL NUTR, V17, P586, DOI 10.1080/07315724.1998.10718807
   Vertuani S, 2004, CURR PHARM DESIGN, V10, P1677, DOI 10.2174/1381612043384655
   Visioli F, 2003, LIPIDS, V38, P415, DOI 10.1007/s11745-003-1077-x
   Vivekananthan DP, 2003, LANCET, V361, P2017, DOI 10.1016/S0140-6736(03)13637-9
   Vivekananthan DP, 2004, LANCET, V363, P662
   Vivekananthan DP, 2003, LANCET, V362, P922
   VIVEKANANTHAN DP, 2004, ACP J CLUB, V140, P45
   Vivekanathan D, 2003, LANCET, V362, P921, DOI 10.1016/S0140-6736(03)14319-X
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WHITE WS, 1988, AM J CLIN NUTR, V47, P879
   Winkler BS, 1999, MOL VIS, V5
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yessoufou A, 2006, INT J OBESITY, V30, P739, DOI 10.1038/sj.ijo.0803211
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao GX, 2007, AM J CLIN NUTR, V85, P385
   2002, VISION PROBLEMS US P
NR 191
TC 1
Z9 2
U1 0
U2 3
PU SOC BRASILEIRA OFTALMOLOGIA
PI RIO DE JANEIRO
PA RUA SAO SALVADOR 107, RIO DE JANEIRO, 22231-170, BRAZIL
SN 0034-7280
J9 REV BRAS OFTALMOL
JI Rev. Bras. Oftalmol.
PD MAY-JUN
PY 2008
VL 67
IS 3
BP 142
EP 155
DI 10.1590/S0034-72802008000300008
PG 14
WC Ophthalmology
SC Ophthalmology
GA 353XB
UT WOS:000259601200008
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Magalhaes, O
   Maia, M
   Mala, A
   Penha, F
   Dib, E
   Farah, ME
   Schor, P
AF Magalhaes, Octaviano, Jr.
   Maia, Mauricio
   Mala, Andre
   Penha, Fernando
   Dib, Eduardo
   Farah, Michel Eid
   Schor, Paulo
TI Fluid dynamics in three 25-gauge vitrectomy systems: principles for use
   in vitreoretinal surgery
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE instrumentation; retina; surgery; vitreous body; vitrectomy
ID PARS-PLANA VITRECTOMY; SELF-SEALING SCLEROTOMIES; MODIFIED SUTURELESS
   SCLEROTOMIES; INFUSION
AB Purpose: To compare infusion and extrusion fluid volumes with three 25-gauge vitrectomy systems.
   Methods: The infusion and aspiration rates of 25-gauge systems from Alcon (Fort Worth, TX, USA), Bausch & Lomb (St Louis, MO, USA), and the Dutch Ophthalmic Research Centre (DORC, Zuidland, the Netherlands) were measured in vitro using balanced saline solution with different heights (40, 609 80, 100, 120 cm) of infusion bottle, cutter velocities (800, 1100, 1500 cuts/min) and aspiration powers (100, 200, 300, 400, 500 mmHg).
   Results: The infusion flow velocities differed among the systems (p < 0.001 for all comparisons lp-values 0.0009-0.00011). The aspiration rates of the Alcon and Bausch & Lomb systems were lower than that of the DORC system (p < 0.02 for all comparisons lp-values 0.018-0.0021).
   Conclusions: Infusion and extrusion fluid rates differ among 25-gauge vitrectomy systems. These results may help to optimize ideal aspiration and infusion parameters among 25-gauge vitrectomy systems used to treat vitreoretinal diseases.
C1 [Magalhaes, Octaviano, Jr.] Univ Fed Sao Paulo, Vis Inst, Paulista Sch Med, Dept Ophthalmol, BR-04023062 Sao Paulo, Brazil.
RP Magalhaes, O (corresponding author), Univ Fed Sao Paulo, Vis Inst, Paulista Sch Med, Dept Ophthalmol, Rua Botucatu 822, BR-04023062 Sao Paulo, Brazil.
EM octavianomj@terra.com.br
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; Schor,
   Paulo/C-6555-2012; Farah, Michel Eid E/F-3285-2012; Penha, Fernando
   M/G-1784-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Schor, Paulo/0000-0002-3999-4706; Farah, Michel Eid
   E/0000-0001-5951-0193; Penha, Fernando/0000-0002-1038-5472
CR Charles S, 2004, RETINA-J RET VIT DIS, V24, P435, DOI 10.1097/00006982-200406000-00015
   Chen JC, 1996, ARCH OPHTHALMOL-CHIC, V114, P1273, DOI 10.1001/archopht.1996.01100140473024
   DEJUAN E, 1990, AM J OPHTHALMOL, V109, P218, DOI 10.1016/S0002-9394(14)75990-2
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1814, DOI 10.1016/S0161-6420(02)01119-3
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1807, DOI 10.1016/S0161-6420(02)01179-X
   Hasumura T, 2000, INVEST OPHTH VIS SCI, V41, P4300
   Hirata A, 2000, AM J OPHTHALMOL, V130, P611, DOI 10.1016/S0002-9394(00)00597-3
   Jackson T, 2000, AM J OPHTHALMOL, V129, P116, DOI 10.1016/S0002-9394(99)00377-3
   KAZUHIRO O, 2001, AM J OPHTHALMOL, V131, P814
   Kwok AKH, 1999, AM J OPHTHALMOL, V127, P731, DOI 10.1016/S0002-9394(98)00427-9
   Lam DSC, 2000, ARCH OPHTHALMOL-CHIC, V118, P850
   MINAMI M, 2007, ACTA OPHTHALMOL SCAN
   Rahman R, 2000, OPHTHALMIC SURG LAS, V31, P462
   Yonemura N, 2003, GRAEF ARCH CLIN EXP, V241, P314, DOI 10.1007/s00417-003-0629-5
NR 14
TC 21
Z9 23
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2008
VL 86
IS 2
BP 156
EP 159
DI 10.1111/j.1600-0420.2007.00988.x
PG 4
WC Ophthalmology
SC Ophthalmology
GA 307VX
UT WOS:000256348000007
PM 18373797
DA 2020-12-15
ER

PT J
AU Maia, M
   Penha, FM
   Farah, ME
   Dib, E
   Principe, A
   Lima, AAS
   Magalhaes, O
   Freymuller, E
   Rodrigues, EB
AF Maia, Mauricio
   Penha, Fernando Marcondes
   Farah, Michel Eid
   Dib, Eduardo
   Principe, Andre
   Lima Filho, Acacio A. S.
   Magalhaes, Octaviano, Jr.
   Freymueller, Edna
   Rodrigues, Eduardo B.
TI Subretinal injection of preservative-free triamcinolone acetonide and
   supernatant vehicle in rabbits: an electron microscopy study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE triamcinolone acetonide; retina pharmacotherapy; chromovitrectomy;
   toxicity; kenalog; electron microscopy; preservative; benzyl alcohol
ID INTRAVITREAL TRIAMCINOLONE; RETINAL TOXICITY; INDOCYANINE GREEN; BENZYL
   ALCOHOL; TRYPAN BLUE; PURIFICATION; CELLS; SUSPENSION; RESPONSES;
   DELIVERY
AB Background To evaluate the effect of injections of benzyl alcohol (BA)-free triamcinolone acetonide (TA) solution (MTA-PF) and the supernatant vehicle of TA (STA) containing BA into the subretinal space of rabbit eyes.
   Methods Sixteen rabbits underwent vitrectomy and subretinal injection of 0.02 ml of either 40 mg/ml MTA-PF, 40 mg/ml STA, or balanced salt solution (BSS). The animals were examined 6, 12, and 24 hours and 14 days after the procedure by fundus examination and fluorescein angiography (FA), as well as histological studies by light and transmission electron microscopy. The histological injury was classified in four stages: (1) stage 1, photoreceptor outer segment injury, (2) stage 2, stage 1 + photoreceptor inner segment injury, (3) stage 3, stage 2 + outer nuclear layer damage, and (4) stage 4, stage 3 + retinal pigment epithelium (RPE) damage.
   Results FA showed no window defects in areas where MTA-PF, STA, or BSS have been injected. Histological examination revealed that subretinal BSS-injection resulted in stage 1 damage during entire follow-up. Subretinal injection of MTA-PF resulted in damage stage 2 at 24 h and 14 days after surgery. However, at the STA position, stage 3 damage was noted 24 h and 14 days postoperatively. No RPE or choroidal damage was observed.
   Conclusions The histological lesions induced by subretinal STA were more relevant than the damage induced by MTA-PF. The vehicle BA may be involved in these abnormalities. The data indicate that care must be taken when using TA during internal limiting membrane peeling in macular hole surgery, due to the possibility of unintentional subretinal migration and for retinal pharmacotherapy.
C1 [Maia, Mauricio; Penha, Fernando Marcondes; Farah, Michel Eid; Dib, Eduardo; Principe, Andre; Lima Filho, Acacio A. S.; Magalhaes, Octaviano, Jr.; Freymueller, Edna; Rodrigues, Eduardo B.] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, IPEPO, Sao Paulo, Brazil.
RP Rodrigues, EB (corresponding author), Av Trompowsky 420-1005, BR-88015300 Florianopolis, SC, Brazil.
EM edubrodriguess@yahoo.com.br
RI Farah, Michel Eid E/F-3285-2012; Penha, Fernando M/G-1784-2012; de Souza
   Lima Filho, Acacio Alves/C-7189-2012; Maia, Mauricio/Z-1042-2019; Maia,
   Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091; Alves
   de Souza Lima Filho, Acacio/0000-0003-1802-9592
CR Albini TA, 2007, INVEST OPHTH VIS SCI, V48, P390, DOI 10.1167/iovs.06-0145
   Avci R, 2006, GRAEF ARCH CLIN EXP, V244, P28, DOI 10.1007/s00417-005-0069-5
   Beeley NRF, 2005, J BIOMED MATER RES A, V73A, P437, DOI 10.1002/jbm.a.30294
   Dierks D, 2005, ARCH OPHTHALMOL-CHIC, V123, P1563, DOI 10.1001/archopht.123.11.1563
   Felt-Baeyens O, 2006, INT J PHARMACEUT, V322, P6, DOI 10.1016/j.ijpharm.2006.05.053
   Fukukita M, 2007, RETINA-J RET VIT DIS, V27, P122, DOI 10.1097/01.iae.0000258270.98012.62
   Garcia-Arumi J, 2005, BRIT J OPHTHALMOL, V89, P1112, DOI 10.1136/bjo.2005.067744
   Hernaez-Ortega MC, 2004, OPHTHAL SURG LAS IM, V35, P350, DOI 10.3928/1542-8877-20040701-18
   HIDA T, 1986, AM J OPHTHALMOL, V101, P190, DOI 10.1016/0002-9394(86)90593-3
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Karacorlu M, 2005, GRAEF ARCH CLIN EXP, V243, P754, DOI 10.1007/s00417-005-1133-x
   Kato A, 2004, INVEST OPHTH VIS SCI, V45, P238, DOI 10.1167/iovs.02-1258
   Kertes PJ, 2005, CAN J OPHTHALMOL, V40, P573, DOI 10.1016/S0008-4182(05)80049-3
   Kim H, 2006, RETINA-J RET VIT DIS, V26, P523, DOI 10.1097/00006982-200605000-00005
   Kozak I, 2006, RETINA-J RET VIT DIS, V26, P811, DOI 10.1097/01.iae.0000244255.22406.2f
   Macky TA, 2007, GRAEF ARCH CLIN EXP, V245, P817, DOI 10.1007/s00417-006-0459-3
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Maia M, 2007, CURR EYE RES, V32, P309, DOI 10.1080/02713680701199377
   McGee DH, 2005, INT J TOXICOL, V24, P419, DOI 10.1080/10915810500366864
   Modarres M, 1998, OPHTHALMIC SURG LAS, V29, P935
   Morrison VL, 2006, RETINA-J RET VIT DIS, V26, P339, DOI 10.1097/00006982-200603000-00014
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Ramezani A, 2006, GRAEF ARCH CLIN EXP, V244, P1601, DOI 10.1007/s00417-006-0348-9
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Ruiz-Moreno JM, 2007, EXP EYE RES, V84, P342, DOI 10.1016/j.exer.2006.10.006
   Shah GK, 2004, AM J OPHTHALMOL, V138, P656, DOI 10.1016/j.ajo.2004.04.025
   Szurman P, 2007, GRAEF ARCH CLIN EXP, V245, P689, DOI 10.1007/s00417-006-0436-x
   Szurman P, 2006, EXP EYE RES, V83, P584, DOI 10.1016/j.exer.2006.02.012
   TU AH, 2004, INVEST OPHTHALMOL VI, V45
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
   Walter P, 1999, CELL MOL NEUROBIOL, V19, P87, DOI 10.1023/A:1006968608825
   Wang K, 2006, GRAEF ARCH CLIN EXP, V244, P1152, DOI 10.1007/s00417-005-0251-9
   Yeung CK, 2003, INVEST OPHTH VIS SCI, V44, P5293, DOI 10.1167/iovs.03-0490
   Yu SY, 2006, RETINA-J RET VIT DIS, V26, P531, DOI 10.1097/00006982-200605000-00006
   ZEMEL E, 1995, INVEST OPHTH VIS SCI, V36, P1875
NR 37
TC 12
Z9 15
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2008
VL 246
IS 3
BP 379
EP 388
DI 10.1007/s00417-007-0718-y
PG 10
WC Ophthalmology
SC Ophthalmology
GA 260DW
UT WOS:000252992000009
PM 18071735
DA 2020-12-15
ER

PT J
AU Dib, E
   Maia, M
   Longo-Maugeri, IM
   Martins, MC
   Mussalem, JS
   Squaiella, CC
   Penha, FM
   Magalhaes, O
   Rodrigues, EB
   Farah, ME
AF Dib, Eduardo
   Maia, Mauricio
   Longo-Maugeri, Ieda Maria
   Martins, Maria Cristina
   Mussalem, Juliana Sekeres
   Squaiella, Carla Cristina
   Penha, Fernando M.
   Magalhaes, Octaviano, Jr.
   Rodrigues, Eduardo B.
   Farah, Michel Eid
TI Subretinal bevacizumab detection after intravitreous injection in
   rabbits
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MACULAR DEGENERATION; AVASTIN; PHARMACOKINETICS; THERAPY
AB PURPOSE. To evaluate subretinal detection of bevacizumab 2 hours after intravitreous injection of 1.25 mg in rabbit eyes.
   METHODS. Anterior chamber paracentesis using a 30-gauge needle was performed in nine female Dutch-belted rabbits by removal of 0.05 mL of aqueous humor. Transscleral retinal detachment was performed with a modified 25-gauge infusion cannula connected to a bottle of physiologic saline solution (PSS). The animals were divided into experimental group 1, with intravitreous injection of 0.05 mL of (1.25 mg) with a 30-gauge needle (n = 6) and the control group 2, with intravitreous injection of 0.05 mL of PSS with a 30-gauge needle (n = 3). Two hours after the intravitreous bevacizumab or PSS injection, subretinal fluid was aspirated and immunoassayed to measure the level of bevacizumab. The rabbits were killed by intravenous pentobarbital injection. The eyes were enucleated and fixed in 10% formaldehyde. The pars plana site at which the transscleral cannula was introduced was analyzed by light microscopy, to exclude iatrogenic retinal tears. Eyes with accidental retinal tears were excluded.
   RESULTS. Subretinal bevacizumab molecules were detected in the six eyes that received an intravitreous bevacizumab injection. No subretinal bevacizumab was detected in the control eyes. Light microscopy showed no evidence of retinal tears or holes in any rabbits used for the bevacizumab detection and control group.
   CONCLUSIONS. Bevacizumab molecules were detected in the subretinal space after intravitreous injection of 1.25 mg of bevacizumab, possibly as the result of diffusion through the retina in a rabbit model.
C1 [Dib, Eduardo; Maia, Mauricio; Penha, Fernando M.; Magalhaes, Octaviano, Jr.; Rodrigues, Eduardo B.; Farah, Michel Eid] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Longo-Maugeri, Ieda Maria; Mussalem, Juliana Sekeres; Squaiella, Carla Cristina] Univ Fed Sao Paulo, Dept Immunol, Sao Paulo, Brazil.
   [Martins, Maria Cristina] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, IPEPO, Sao Paulo, Brazil.
RP Dib, E (corresponding author), 544 Pedro Toledo St,Apartment 511,Vila Clementino, BR-04039001 Sao Paulo, Brazil.
EM dibedu@gmail.com
RI Mussalem, Juliana JS/G-4084-2012; Squaiella-Baptistao, Carla
   Cristina/K-2557-2013; Longo-Maugeri, Ieda M/B-9764-2012; Maia,
   Mauricio/Z-1042-2019; Penha, Fernando M/G-1784-2012; Farah, Michel Eid
   E/F-3285-2012; Maia, Mauricio/I-5892-2015
OI Longo-Maugeri, Ieda M/0000-0003-4184-8414; Maia,
   Mauricio/0000-0002-7034-8091; Farah, Michel Eid E/0000-0001-5951-0193;
   Maia, Mauricio/0000-0002-7034-8091; Squaiella-Baptistao, Carla
   Cristina/0000-0002-4187-798X
CR Arevalo JF, 2007, OPHTHALMOLOGY, V114, P743, DOI 10.1016/j.ophtha.2006.12.028
   Arnold Jennifer, 2006, Clin Evid, P877
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   COLIGAN JE, 1995, CURRENT PROTOCOLS IM, P2
   Emmanouilides C, 2004, Tech Coloproctol, V8 Suppl 1, ps50, DOI 10.1007/s10151-004-0110-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Ivert L, 2002, GRAEF ARCH CLIN EXP, V240, P232, DOI 10.1007/s00417-001-0392-4
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moshfeghi A. A., 2002, OPHTHALMOLOGY, V113, pe1
   Schuettauf F, 2006, INVEST OPHTH VIS SCI, V47, P3573, DOI 10.1167/iovs.06-0211
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Zondor SD, 2004, ANN PHARMACOTHER, V38, P1258, DOI 10.1345/aph.1D470
NR 18
TC 29
Z9 31
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2008
VL 49
IS 3
BP 1097
EP 1100
DI 10.1167/iovs.07-1225
PG 4
WC Ophthalmology
SC Ophthalmology
GA 271TZ
UT WOS:000253812900038
PM 18326736
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Maia, M
   Flynn, HW
   Saravia, M
   Avery, RL
   Wu, L
   Farah, ME
   Pieramici, DJ
   Berrocal, MH
   Sanchez, JG
AF Arevalo, J. F.
   Maia, M.
   Flynn, H. W., Jr.
   Saravia, M.
   Avery, R. L.
   Wu, L.
   Farah, M. Eid
   Pieramici, D. J.
   Berrocal, M. H.
   Sanchez, J. G.
TI Tractional retinal detachment following intravitreal bevacizumab
   (Avastin) in patients with severe proliferative diabetic retinopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; NEOVASCULARIZATION; INJECTION
AB Aims: The aim of this study was to report the development or progression of tractional retinal detachment (TRD) after the injection of intravitreal bevacizumab (Avastin) used as an adjuvant to vitrectomy for the management of severe proliferative diabetic retinopathy (PDR).
   Methods: The clinical charts of patients who experienced the development or progression of TRD after an intravitreal injection of 1.25 mg bevacizumab before vitrectomy for the management of PDR were reviewed.
   Results: Eleven eyes (patients) out of 211 intravitreal injections (5.2%) that developed or had progression of TRD were identified. All eyes had PDR refractory to panretinal photocoagulation (PRP). Nine patients had type 1 diabetes mellitus (DM), and two patients had type 2 DM. Patients had a mean age of 39.5 years (range 22 - 62 years). In the current study, all patients used insulin administration and had poor glycaemic control (mean HbA(1c) 10.6%). Time from injection to TRD was a mean of 13 days (range 3 - 31 days). Mean best correct visual acuity (BCVA) at TRD development or progression was logarithm of the minimal angle of resolution (LogMAR) 2.2 (range 1.0 - 2.6) (mean Snellen equivalent hand motions; range 20/200 to light perception), a statistically significant worsening compared with baseline BCVA (p < 0.0001). Eight eyes underwent vitrectomy and three patients refused or were unable to undergo surgery. The final mean BCVA after surgery was LogMAR 0.9 (range 0.2 - 2.0) (mean Snellen equivalent 20/160; range 20/32 to counting fingers), a statistically significant improvement compared with TRD BCVA (p=0.002).
   Conclusions: TRD may occur or progress shortly following administration of intravitreal bevacizumab in patients with severe PDR.
C1 [Arevalo, J. F.; Sanchez, J. G.] Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Caracas 1010, Venezuela.
   [Maia, M.; Farah, M. Eid] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Flynn, H. W., Jr.] Bascom Palmer Eye Inst, Retina & Vitreous Serv, Miami, FL 33136 USA.
   [Saravia, M.] Hosp Univ Austral, Buenos Aires, DF, Argentina.
   [Avery, R. L.; Pieramici, D. J.] California Retina Consultants & Res Fdn, Santa Barbara, CA USA.
   [Wu, L.] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Berrocal, M. H.] Univ Puerto Rico, San Juan, PR 00936 USA.
RP Arevalo, JF (corresponding author), Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Edif Ctr Caracas PH 1,Av Panteon, Caracas 1010, Venezuela.
EM arevalojf2020@gmail.com
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012; Maia,
   Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091
CR Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   CHEN E, 2006, RETINA, V26, P999
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Fong DS, 1999, AM J OPHTHALMOL, V127, P137, DOI 10.1016/S0002-9394(98)00309-2
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   KAUFMAN SC, 1989, INVEST OPHTH VIS SCI, V30, P23
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   PEER J, 1995, LAB INVEST, V72, P638
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Watanabe D, 2005, AM J OPHTHALMOL, V139, P476, DOI 10.1016/j.ajo.2004.10.004
NR 19
TC 255
Z9 275
U1 1
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2008
VL 92
IS 2
BP 213
EP 216
DI 10.1136/bjo.2007.127142
PG 4
WC Ophthalmology
SC Ophthalmology
GA 256GH
UT WOS:000252715200013
PM 17965108
DA 2020-12-15
ER

PT J
AU Penha, FM
   Maia, M
   Farah, ME
   Dib, E
   Principe, AH
   Devin, F
   Rodrigues, EB
   Duprat, JP
   Freymuller, E
AF Penha, Fernando M.
   Maia, Mauricio
   Farah, Michel E.
   Dib, Eduardo
   Principe, Andre H.
   Devin, Fracois
   Rodrigues, Eduardo B.
   Duprat, Joao P.
   Freymueller, Edna
TI Morphologic and clinical effects of subretinal injection of indocyanine
   green and infracyanine green in rabbits
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology
CY APR 30-MAY 04, 2006
CL Ft Lauderdale, FL
SP Assoc Res Vis & Ophthalmol
ID INTERNAL-LIMITING MEMBRANE; RETINAL-PIGMENT EPITHELIUM; MACULAR HOLE
   SURGERY; SODIUM IODATE INJECTION; DEGENERATION; DETACHMENT; MANAGEMENT;
   TOXICITY; REMOVAL; IODINE
AB Purpose: The aim of this study was to determine the effects of subretinal injection of indocyanine green (ICG), infracyanine (IfCG), and balanced salt solution (BSS) in rabbits.
   Methods: Ten (10) animals were subjected to a subretinal injection of 0.05% ICG (279 mOsm), 0.5% IfCG (276 mOsm), and BSS (300 mOsm) used as a control. Animals were examined at 6, 12, and 24 h and 14 days following the surgical procedure by indirect binocular ophthalmoscopy, fluorescein angiography (FA), and light and transmission electron microscopy.
   Results: The subretinal injection of ICG caused damage to all retinal layers and retinal pigment epithelium (RPE) during the entire follow-up. Subretinal injection of IfCG resulted in abnormalities of the photoreceptor outer segments (POSs) during the entire follow-up; however, abnormalities of the photoreceptor inner segments (PISs) and outer nuclear layer (ONL) were observed only 24 h and 14 days after surgery; no RPE damage was observed. FA showed that window defects were more prominent in the subretinal ICG bleb position than the IfCG-related area. BSS caused only abnormalities of the POS layer and no RPE alterations.
   Conclusions: Subretinal injection of 0.05% ICG results in more significant retinal damage than 0.5% IfCG. In this model, iodine-free IfCG demonstrates a safer profile than a tenfold lower concentration of ICG, which contains iodine in its composition.
C1 [Rodrigues, Eduardo B.] Hosp Reg San Jose, Dept Ophthalmol, BR-88015300 Florianopolis, SC, Brazil.
   [Penha, Fernando M.; Maia, Mauricio; Farah, Michel E.; Dib, Eduardo; Principe, Andre H.; Duprat, Joao P.] Univ Fed Sao Paulo, Vis Inst IPEPO, Dept Ophthalmol, Sao Paulo, Brazil.
   [Penha, Fernando M.; Freymueller, Edna] Univ Fed Sao Paulo, Ctr Electron Microscopy CEME, Sao Paulo, Brazil.
   [Devin, Fracois] Ctr Paradis Monticelli, Marseille, France.
RP Dib, E (corresponding author), Hosp Reg San Jose, Dept Ophthalmol, Av Trompowsky 420-1005, BR-88015300 Florianopolis, SC, Brazil.
EM edubrodriguess@yahoo.com.br
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019; Penha, Fernando
   M/G-1784-2012; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Farah, Michel Eid E/0000-0001-5951-0193
CR BENSON RC, 1978, PHYS MED BIOL, V23, P159, DOI 10.1088/0031-9155/23/1/017
   Brooks HL, 2000, OPHTHALMOLOGY, V107, P1939, DOI 10.1016/S0161-6420(00)00331-6
   Eckardt C, 1997, OPHTHALMOLOGE, V94, P545, DOI 10.1007/s003470050156
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Gandorfer A, 2001, AM J OPHTHALMOL, V132, P431, DOI 10.1016/S0002-9394(01)01087-X
   Haritoglou C, 2004, AM J OPHTHALMOL, V137, P345, DOI 10.1016/S0002-9394(03)00845-6
   Ho JD, 2004, ARCH OPHTHALMOL-CHIC, V122, P871, DOI 10.1001/archopht.122.6.871
   Ho JD, 2003, AM J OPHTHALMOL, V135, P258, DOI 10.1016/S0002-9394(02)01976-1
   HOSODA L, 1993, ACTA OPHTHALMOL, V71, P616
   Ikagawa H, 2005, INVEST OPHTH VIS SCI, V46, P2531, DOI 10.1167/iovs.04-1521
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P3697, DOI 10.1167/iovs.04-0387
   Kadonosono K, 2000, ARCH OPHTHALMOL-CHIC, V118, P1116, DOI 10.1001/archopht.118.8.1116
   Kadonosono K, 2001, AM J OPHTHALMOL, V131, P203, DOI 10.1016/S0002-9394(00)00728-5
   KIRYU J, 1993, VISION RES, V32, P2221
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   Kodjikian L, 2005, GRAEF ARCH CLIN EXP, V243, P917, DOI 10.1007/s00417-004-1121-6
   La Heij EC, 2005, AM J OPHTHALMOL, V140, P1123, DOI 10.1016/j.ajo.2005.05.054
   Li K, 2003, BRIT J OPHTHALMOL, V87, P216, DOI 10.1136/bjo.87.2.216
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Margherio RR, 2000, ARCH OPHTHALMOL-CHIC, V118, P495
   MARMOR MF, 1979, INVEST OPHTH VIS SCI, V18, P1237
   Mester V, 2000, AM J OPHTHALMOL, V129, P769, DOI 10.1016/S0002-9394(00)00358-5
   Mizota A, 1997, VISION RES, V37, P1859, DOI 10.1016/S0042-6989(97)00015-1
   Obata R, 2005, EYE, V19, P464, DOI 10.1038/sj.eye.6701531
   Ohtaka K, 2006, CURR EYE RES, V31, P347, DOI 10.1080/02713680600629797
   OLSEN KJ, 1979, ACTA PHARMACOL TOX, V44, P241
   Park DW, 1999, OPHTHALMOLOGY, V106, P1392, DOI 10.1016/S0161-6420(99)00730-7
   RIEGER G, 1995, OPHTHALMOLOGICA, V209, P84, DOI 10.1159/000310586
   Rivett K, 2004, GRAEF ARCH CLIN EXP, V242, P393, DOI 10.1007/s00417-003-0857-8
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   RODRIGUES EB, 2007, IN PRESS OPHTHALMOLO
   Schmidt JC, 2004, OPHTHALMOLOGICA, V218, P176, DOI 10.1159/000076841
   Singalavanija A, 2000, RETINA-J RET VIT DIS, V20, P378, DOI 10.1097/00006982-200007000-00010
   Van de Moere A, 2003, AM J OPHTHALMOL, V136, P879, DOI 10.1016/S0002-9394(03)00543-9
   Vitale M, 2000, ENDOCRINOLOGY, V141, P598, DOI 10.1210/en.141.2.598
   VODE BJ, 2004, RETINA, V24, P736
   Weinberger AWA, 2001, GRAEF ARCH CLIN EXP, V239, P388, DOI 10.1007/s004170100267
   WHITACRE MM, 1990, CURR EYE RES, V9, P725, DOI 10.3109/02713689008999567
NR 40
TC 24
Z9 24
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD FEB
PY 2008
VL 24
IS 1
BP 52
EP 61
DI 10.1089/jop.2007.0047
PG 10
WC Ophthalmology; Pharmacology & Pharmacy
SC Ophthalmology; Pharmacology & Pharmacy
GA 257QS
UT WOS:000252814200007
PM 18370875
DA 2020-12-15
ER

PT J
AU Wu, LT
   Arevalo, JF
   Roca, JA
   Maia, M
   Berrocal, MH
   Rodriguez, FJ
   Evans, T
   Costa, RA
   Cardillo, J
AF Wu, Lihteh
   Arevalo, J. Fernando
   Roca, Jose A.
   Maia, Mauricio
   Berrocal, Maria H.
   Rodriguez, Francisco J.
   Evans, Teodoro
   Costa, Rogerio A.
   Cardillo, Jose
CA PACORES
TI Comparison of two doses of intravitreal bevacizumab (Avastin) for
   treatment of macular edema secondary to branch retinal vein occlusion:
   Results from the Pan-American collaborative retina study group at 6
   months of follow-up
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology
CY MAY 06-10, 2007
CL Ft Lauderdale, FL
SP Assoc Res Vis & Ophthalmol
DE bevacizumab; branch retinal vein occlusion; macular edema; vascular
   endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; CHORIORETINAL VENOUS ANASTOMOSIS;
   DIABETIC-RETINOPATHY; PERMEABILITY; BETA
AB Purpose: To report the 6-month anatomical and visual outcomes after injecting two different doses of intravitreal bevacizumab in patients with macular edema secondary to branch retinal vein occlusion (BRVO).
   Methods: An interventional, retrospective multicenter study of 45 eyes that were treated with at least one intravitreal injection (24 eyes, 1.25 mg; 21 eyes, 2.5 mg) of bevacizumab is reported. The main outcome measures were the central 1-mm macular thickness (CMT) and the change in ETDRS lines of best-corrected visual acuity (BCVA) at 6 months.
   Results: Forty-five eyes were injected on average 26.1 months (range, 3-86 months) after the diagnosis. The average follow-up was 35.2 weeks (range, 24-52 weeks). All patients completed at least 6 months of follow-up. In the 1.25-mg dose group, at 1 month, there was an average gain of 4.5 lines of BCVA; at 3 months, 5.1 lines of BCVA; and at 6 months, 5.1 lines of BCVA (P < 0.005). In the 2.5-mg dose group, at 1 month, there was an average gain of 2.3 lines of BCVA; at 3 months, 3.8 lines of BCVA; and at 6 months, 4.8 lines of BCVA (P = 0.05). In the 1.25-mg dose group, the mean CMT +/- SD decreased from 461 +/- 211 mu m at baseline to 321 +/- 152 mu m at 1 month, 273 +/- 99 mu m at 3 months, and 277 +/- 114 mu m at 6 months (P = 0.0002). In the 2.5-mg group, the mean CMT +/- SD decreased from 385 +/- 168 mu m at baseline to 279 +/- 111 mu m at 1 month, 249 +/- 97 mu m at 3 months, and 240 +/- 93 mu m at 6 months (P = 0.011).
   Conclusion: There were no statistically significant differences between the two dose groups with regard to the number of injections and anatomical and functional outcomes. Intravitreal injection of bevacizumab at doses up to 2.5 mg appears to be effective in improving BCVA and reducing CMT in BRVO in the short term. Multiple injections are needed in a large number of eyes for continued control of macular edema and preservation of visual acuity in the short term. Longer studies are needed to determine what role if any intravitreal injection of bevacizumab may play in the long-term treatment of this condition.
C1 [Wu, Lihteh; Evans, Teodoro] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Arevalo, J. Fernando] Clin Oftalmol Ctr, Retina & Vitreous Serv, Caracas, Venezuela.
   [Roca, Jose A.] Clin Ricardo Palma, Lima, Peru.
   [Maia, Mauricio] Univ Fed Sao Paulo, Inst Visao, Dept Oftalmol, Sao Paulo, Brazil.
   [Berrocal, Maria H.] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Rodriguez, Francisco J.] Univ Rosario, Fdn Oftalmol Nacl, Bogota, Colombia.
   [Costa, Rogerio A.; Cardillo, Jose] Hosp Olhos Araraquara, Retinal Diagnost & Treatment Div, Sao Paulo, Brazil.
RP Wu, L (corresponding author), Inst Cirugia Ocular, Apdo 144-1225 Plaza Mayori, San Jose, Costa Rica.
EM LW65@cornell.edu
RI Costa, Rogerio A/E-6930-2013; Maia, Mauricio/Z-1042-2019; Fromow-Guerra,
   J. Jans/A-3346-2015; Maia, Mauricio/I-5892-2015
OI Costa, Rogerio A/0000-0002-0800-2233; Maia,
   Mauricio/0000-0002-7034-8091; Fromow-Guerra, J.
   Jans/0000-0001-5335-1275; Maia, Mauricio/0000-0002-7034-8091; Cardillo,
   Jose Augusto/0000-0002-5791-3201
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Aiello LP, 1997, INVEST OPHTH VIS SCI, V38, P1647
   Aiello LP, 2002, SURV OPHTHALMOL, V47, pS263, DOI 10.1016/S0039-6257(02)00391-0
   Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1984, AM J OPHTHALMOL, V98, P271
   Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953
   Arevalo JF, 2007, OPHTHALMOLOGY, V114, P743, DOI 10.1016/j.ophtha.2006.12.028
   Cahill MT, 2003, BRIT J OPHTHALMOL, V87, P1329, DOI 10.1136/bjo.87.11.1329
   Christoffersen NLB, 1999, OPHTHALMOLOGY, V106, P2054, DOI 10.1016/S0161-6420(99)90483-9
   Fekrat S, 1998, ARCH OPHTHALMOL-CHIC, V116, P43, DOI 10.1001/archopht.116.1.43
   Figueroa MS, 2004, EUR J OPHTHALMOL, V14, P40
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Kaiser PK, 2005, AM J OPHTHALMOL, V139, P1095, DOI 10.1016/j.ajo.2005.03.035
   Lin TH, 2005, SCAND CARDIOVASC J, V39, P353, DOI 10.1080/14017430500234258
   Mason JO, 2006, RETINA-J RET VIT DIS, V26, P356, DOI 10.1097/00006982-200603000-00018
   MCALLISTER IL, 1992, BRIT J OPHTHALMOL, V76, P615, DOI 10.1136/bjo.76.10.615
   Noma H, 2006, GRAEF ARCH CLIN EXP, V244, P309, DOI 10.1007/s00417-004-1087-4
   Noma H, 2005, AM J OPHTHALMOL, V140, P256, DOI 10.1016/j.ajo.2005.03.003
   Pai SA, 2007, AM J OPHTHALMOL, V143, P601, DOI 10.1016/j.ajo.2006.12.037
   PEER J, 1995, LAB INVEST, V72, P638
   Rabena MD, 2007, RETINA-J RET VIT DIS, V27, P419, DOI 10.1097/IAE.0b013e318030e77e
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal KB, 2007, OPHTHALMOLOGE, V104, P285, DOI 10.1007/s00347-007-1509-x
   Schultz A, 1999, CIRCULATION, V100, P547, DOI 10.1161/01.CIR.100.5.547
   Spandau U, 2007, ACTA OPHTHALMOL SCAN, V85, P118, DOI 10.1111/j.1600-0420.2006.00850.x
   STAHL A, 2007, GRAEFES ARCH CLIN EX
NR 29
TC 79
Z9 81
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2008
VL 28
IS 2
BP 212
EP 219
DI 10.1097/IAE.0b013e3181619bee
PG 8
WC Ophthalmology
SC Ophthalmology
GA 266TV
UT WOS:000253460800003
PM 18301025
DA 2020-12-15
ER

PT J
AU Wu, L
   Martinez-Castellanos, MA
   Quiroz-Mercado, H
   Arevalo, JF
   Berrocal, MH
   Farah, ME
   Maia, M
   Roca, JA
   Rodriguez, FJ
AF Wu, Lihteh
   Martinez-Castellanos, Maria A.
   Quiroz-Mercado, Hugo
   Arevalo, J. Fernando
   Berrocal, Maria H.
   Farah, Michel E.
   Maia, Mauricio
   Roca, Jose A.
   Rodriguez, Francisco J.
CA Pan Amer Collaborative Retina Grp
TI Twelve-month safety of intravitreal injections of bevacizumab (Avastin
   (R)): results of the Pan-American Collaborative Retina Study Group
   (PACORES)
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article; Proceedings Paper
CT Joint Annual Meeting of the Retina-Society/Club-Jules-Gonin
CY OCT 15-20, 2006
CL Cape Town, SOUTH AFRICA
SP Retina Soc, Club Jules Gonin
DE age-related macular degeneration; angiogenesis; choroidal
   neovascularization; diabetic macular edema; intravitreal bevacizumab;
   proliferative diabetic retinopathy; safety
ID COHERENCE TOMOGRAPHY FINDINGS; GROWTH-FACTOR APTAMER; CHOROIDAL
   NEOVASCULARIZATION; PHARMACOKINETICS; PEGAPTANIB; BREAKDOWN
AB Background Vascular endothelial growth factor (VEGF) plays an important role in many diseases of the posterior pole that are characterized by macular edema and/or intraocular neovascularization. Recently anti-VEGF agents such as ranibizumab and pegaptanib sodium have been shown to be beneficial in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD). However in most parts of the world, both pegaptanib sodium and ranibizumab are not readily available. Bevacizumab, a humanized recombinant monoclonal IgG antibody that binds and inhibits all VEGF isoforms, has been proposed as an alternative treatment option.
   Methods A total of 1,265 consecutive patients were injected with bevacizumab for diseases such as proliferative diabetic retinopathy, diabetic macular edema, retinal vein occlusions, and CNV of several etiologies including ARMD at eight Latin American institutions from 1 September 2005 to 31 January 2006. Of these 1,265, 92 were excluded because they were injected once and lost to follow-up. The remaining 1,173 patients constitute the subjects of this retrospective, multicenter, open label, uncontrolled interventional case series that reports the cumulative systemic and ocular adverse events following intravitreal bevacizumab during 12 months of follow-up. Patients were examined at baseline and then monthly. If the patients were unable to attend the 12-month visit, a telephone interview was conducted to assess for possible systemic complications.
   Results A total of 4,303 intravitreal injections of bevacizumab on 1,310 eyes was reported. All 1,173 patients were accounted for at the 12-month visit. Systemic adverse events were reported in 18 (1.5%) patients. These included seven (0.59%) cases of an acute elevation of systemic blood pressure, six (0.5%) cerebrovascular accidents, five (0.4%) myocardial infarctions, two (0.17%) iliac artery aneurysms, two (0.17%) toe amputations and five (0.4%) deaths. Ocular complications included seven (0.16%) bacterial endophthalmitis, seven (0.16%) tractional retinal detachments, four (0.09%) uveitis, and a case (0.02%) each of rhegmatogenous retinal detachment and vitreous hemorrhage.
   Conclusions Despite the limited follow-up, repeated intravitreal injections of either 1.25 mg or 2.5 mg of bevacizumab appears to be safe and well tolerated during the 1st year.
C1 Inst Cirugia Ocular, San Jose, Costa Rica.
   Asociac Para Evitar Ceguera, Mexico City, DF, Mexico.
   Clin Oftalmol Caracas Ctr, Caracas, Venezuela.
   Univ Puerto Rico, Santurce, PR USA.
   Univ Fed Sao Paulo, Vis Inst, Sao Paulo, Brazil.
   Clin Ricardo Palma, Lima, Peru.
   Fdn Oftalmol Nacl, Bogota, Colombia.
RP Wu, L (corresponding author), Apdo 144-1225 Pl Mayor, San Jose, Costa Rica.
EM LW65@cornell.edu
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019; Fromow-Guerra,
   J. Jans/A-3346-2015; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Fromow-Guerra, J. Jans/0000-0001-5335-1275; Farah, Michel Eid
   E/0000-0001-5951-0193; Martinez-Castellanos, Maria/0000-0002-1265-3725
CR Adamis A P, 1999, Angiogenesis, V3, P9, DOI 10.1023/A:1009071601454
   Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   GEISS LS, 2007, MORTALITY NONINSULIN
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier J.S., 2006, OPHTHALMOLOGY, V113, P633, DOI DOI 10.1016/J.0PHTHA.2005.10.052)
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kernt M, 2007, ACTA OPHTHALMOL SCAN, V85, P119, DOI 10.1111/j.1600-0420.2006.00819.x
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   Ratner M, 2004, NAT BIOTECHNOL, V22, P1198, DOI 10.1038/nbt1004-1198
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sane David C., 2004, Angiogenesis, V7, P193, DOI 10.1007/s10456-004-2699-3
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Ziemssen F, 2006, BRIT J OPHTHALMOL, V90, P922, DOI 10.1136/bjo.2006.092262
NR 33
TC 325
Z9 346
U1 0
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2008
VL 246
IS 1
BP 81
EP 87
DI 10.1007/s00417-007-0660-z
PG 7
WC Ophthalmology
SC Ophthalmology
GA 233LQ
UT WOS:000251092800010
PM 17674014
DA 2020-12-15
ER

PT B
AU Parada, F
   Maia, M
   Pereira, J
AF Parada, F.
   Maia, M.
   Pereira, J.
GP Edizioni Minerva Medica
TI Extracorporeal shockwave therapy for chronic plantar fasciitis: a self
   controlled prospective study
SO PROCEEDINGS OF THE 16TH EUROPEAN CONGRESS OF PHYSICAL AND REHABILITATION
   MEDICINE
LA English
DT Proceedings Paper
CT 16th European Congress of Physical and Rehabilitation Medicine
CY JUN 03-06, 2008
CL Bruges, BELGIUM
ID WAVE THERAPY; PAINFUL HEEL
C1 [Parada, F.; Maia, M.; Pereira, J.] Hosp Sao Joao, Dept Phys & Rehabil Med, Oporto, Portugal.
RP Parada, F (corresponding author), Hosp Sao Joao, Dept Phys & Rehabil Med, Oporto, Portugal.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR Buchbinder R, 2004, NEW ENGL J MED, V350, P2159, DOI 10.1056/NEJMcp032745
   Crawford F, 2002, FOOT, V11, P228
   DAVIS PF, 1994, FOOT ANKLE INT, V15, P531, DOI 10.1177/107110079401501002
   DEMAIO M, 1993, ORTHOPEDICS, V16, P1153
   Gill, 1997, J Am Acad Orthop Surg, V5, P109
   Haake M, 2003, BRIT MED J, V327, P75, DOI 10.1136/bmj.327.7406.75
   Kinley S, 1993, J Foot Ankle Surg, V32, P595
   Kudo P, 2006, J ORTHOP RES, V24, P115, DOI 10.1002/jor.20008
   Malay D Scot, 2006, J Foot Ankle Surg, V45, P196, DOI 10.1053/j.jfas.2006.04.007
   Ogden JA, 2002, FOOT ANKLE INT, V23, P301, DOI 10.1177/107110070202300402
   Ogden JA, 2001, CLIN ORTHOP RELAT R, P47, DOI 10.1097/00003086-200106000-00007
   QUERISHE F, 2002, FOOT, V12, P224
   Rompe JD, 1996, ARCH ORTHOP TRAUM SU, V115, P75, DOI 10.1007/BF00573445
   SCHON LC, 1993, CURRENT PRACTICE FOO, P243
   Speed CA, 2003, J ORTHOPAED RES, V21, P937, DOI 10.1016/S0736-0266(03)00048-2
   TOMCZAK RL, 1995, J FOOD ANKLE SURG, V34, P400
NR 16
TC 0
Z9 0
U1 0
U2 4
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85, CASELLA POSTALE 491, 10126 TURIN, ITALY
BN 978-8-87711-616-1
PY 2008
BP 140
EP 143
PG 4
WC Medicine, Research & Experimental; Rehabilitation
SC Research & Experimental Medicine; Rehabilitation
GA BIK81
UT WOS:000260433300067
DA 2020-12-15
ER

PT J
AU Rodrigues, EB
   Shiroma, H
   Meyer, CH
   Maia, M
   Farah, ME
AF Rodrigues, Eduardo B.
   Shiroma, Helio
   Meyer, Carsten H.
   Maia, Mauricio
   Farah, Michel E.
TI Metrorrhagia after intravitreal injection of bevacizumab
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Letter
C1 Univ Fed Sao Paulo, IPEPO, Sao Paulo, Brazil.
RP Rodrigues, EB (corresponding author), Ave Trompowsky 420-1005, BR-88015300 Florianopolis, SC, Brazil.
EM edubrodriguess@yahoo.com.br
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019; Meyer, Carsten
   H./A-3981-2017; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Meyer, Carsten H./0000-0002-0530-5298; Farah, Michel Eid
   E/0000-0001-5951-0193; Buchele Rodrigues, Eduardo/0000-0002-4224-0921
CR *BC CANC AG, 2006, CANC MAN GUID MAN GU
   CSAKY K, 2007, SAFETY SURVEILLANCE
   Hurwitz H, 2006, SEMIN ONCOL, V33, pS26, DOI 10.1053/j.seminoncol.2006.08.001
   Nap AW, 2004, J CLIN ENDOCR METAB, V89, P1089, DOI 10.1210/jc.2003-031406
   Pai SA, 2007, AM J OPHTHALMOL, V143, P601, DOI 10.1016/j.ajo.2006.12.037
   Smith SK, 2001, TRENDS ENDOCRIN MET, V12, P147, DOI 10.1016/S1043-2760(01)00379-4
NR 6
TC 14
Z9 15
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD DEC
PY 2007
VL 85
IS 8
BP 915
EP 916
DI 10.1111/j.1600-0420.2007.00968.x
PG 3
WC Ophthalmology
SC Ophthalmology
GA 232MY
UT WOS:000251025000027
PM 17645422
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Garcia-Amaris, RA
   Roca, JA
   Sanchez, JG
   Wu, LT
   Berrocal, MH
   Maia, M
AF Arevalo, J. Fernando
   Garcia-Amaris, Rafael A.
   Roca, Jose A.
   Sanchez, Juan G.
   Wu, Lihteh
   Berrocal, Maria H.
   Maia, Mauricio
CA Pan-American Collaborat Study Grp
TI Primary intravitreal bevacizumab for the management of pseudophakic
   cystoid macular edema - Pilot study of the Pan-American Collaborative
   Retina Study Group
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article; Proceedings Paper
CT Symposium on Cataract, IOL and Refractive Surgery
CY APR, 2007
CL San Diego, CA
SP ASCRS
ID ENDOTHELIAL GROWTH-FACTOR; TRIAMCINOLONE ACETONIDE; AVASTIN TREATMENT;
   CATARACT-SURGERY; THERAPY; RETINOPATHY; VITRECTOMY
AB PURPOSE: To determine the feasibility, safety, and clinical effect of primary intravitreal bevacizumab (Avastin) in patients with cystoid macular edema (CME) after cataract surgery.
   SETTING: Five institutions in Venezuela, Costa Rica, Puerto Rico, Peru, and Brazil.
   METHODS: Twenty-eight eyes of 25 patients treated with at least 1 intravitreal injection of 1.25 mg or 2.50 mg of Avastin participated in this interventional retrospective multicenter study at 5 institutions from 5 countries. Baseline and follow-up visits included Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing, optical coherence tomography (OCT) imaging, and ophthalmoscopic examination.
   RESULTS: The mean follow-up was 32 weeks (range 24 to 52 weeks). Twenty eyes (71.4%) had improved best corrected visual acuity (BCVA) ( >= 2 ETDRS lines), and no eye had worse visual acuity ( >= 2 ETDRS lines). The BCVA remained stable in 8 eyes (28.6%). The mean baseline BCVA was 20/160 (logMAR = 0.92) and the mean final BCVA, 20/63 (logMAR = 0.50); the difference was statistically significant (P <.0001). The mean central macular thickness at baseline (466.3 mu m; range 208 to 784 mu m) decreased significantly (264.5 mu m; range 176 to 513 mu m) by the end of follow-up (P <.0001). Eight eyes (28.6%) required a second injection and 4 (14.3%), a third injection. The mean interval between injections was 13 weeks (range 5 to 26 weeks). No ocular or systemic adverse events were observed.
   CONCLUSIONS: Short-term results suggest that primary intravitreal Avastin is well tolerated in patients with pseudophakic CME. Treated eyes had a significant improvement in BCVA and decrease in macular thickness by OCT.
C1 [Arevalo, J. Fernando; Garcia-Amaris, Rafael A.] Ctr Caracas, Clin Oftalmol, Retina & Vitreous Serv, Caracas, Venezuela.
   [Roca, Jose A.] Clin Ricardo Palma, Lima, Peru.
   [Wu, Lihteh] Inst Cirugia Ocular, Retina & Vitreous Serv, San Jose, Costa Rica.
   [Berrocal, Maria H.] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Maia, Mauricio] Univ Fed Sao Paulo, Inst Visao, Dept Oftalmol, Sao Paulo, Brazil.
RP Arevalo, JF (corresponding author), Edificio Ctr Caracas PH 1, Ctr Caracas, Clin Oftalmol, Avenida Panteon, Caracas 1010A, Venezuela.
EM arevalojf@movistar.net.ve
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019; Fromow-Guerra,
   J. Jans/A-3346-2015; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Fromow-Guerra, J. Jans/0000-0001-5335-1275; Farah, Michel Eid
   E/0000-0001-5951-0193
CR Abe T, 1999, J CATARACT REFR SURG, V25, P1286, DOI 10.1016/S0886-3350(99)00159-5
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Conway MD, 2003, J CATARACT REFR SURG, V29, P27, DOI 10.1016/S0886-3350(02)01441-4
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Flach A J, 1998, Trans Am Ophthalmol Soc, V96, P557
   FUNG WE, 1985, OPHTHALMOLOGY, V92, P1102
   Grover S, 2006, AM J OPHTHALMOL, V141, P850, DOI 10.1016/j.ajo.2005.12.030
   HARBOUR JM, 1995, AM J OPHTHALMOL, V120, P302, DOI 10.1016/S0002-9394(14)72159-2
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   IRVINE SR, 1953, AM J OPHTHALMOL, V36, P599, DOI 10.1016/0002-9394(53)90302-X
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Karacorlu M, 2003, ACTA OPHTHALMOL SCAN, V81, P648, DOI 10.1046/j.1395-3907.2003.0146.x
   Levin Darrin S, 2002, Ophthalmol Clin North Am, V15, P467, DOI 10.1016/S0896-1549(02)00041-X
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mason JO, 2006, RETINA-J RET VIT DIS, V26, P356, DOI 10.1097/00006982-200603000-00018
   Mentes J, 2003, OPHTHALMOLOGICA, V217, P408, DOI 10.1159/000073070
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miyake K, 2002, SURV OPHTHALMOL, V47, pS203, DOI 10.1016/S0039-6257(02)00294-1
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Noma H, 2006, GRAEF ARCH CLIN EXP, V244, P309, DOI 10.1007/s00417-004-1087-4
   PFOFF DS, 1987, J CATARACT REFR SURG, V13, P136, DOI 10.1016/S0886-3350(87)80127-X
   Rho DS, 2003, J CATARACT REFR SURG, V29, P2378, DOI 10.1016/S0886-3350(03)00233-5
   Riley AF, 2006, CLIN EXP OPHTHALMOL, V34, P299, DOI 10.1111/j.1442-9071.2006.01213.x
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Sivaprasad S, 2005, BRIT J OPHTHALMOL, V89, P1420, DOI 10.1136/bjo.2005.073817
   SPAIDE RF, 1993, OPHTHALMIC SURG LAS, V24, P262
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   STARK WJ, 1984, SURV OPHTHALMOL, V28, P442, DOI 10.1016/0039-6257(84)90226-1
   STEINERT RF, 1989, J CATARACT REFR SURG, V15, P304, DOI 10.1016/S0886-3350(89)80089-6
   Thach AB, 1997, OPHTHALMOLOGY, V104, P2003, DOI 10.1016/S0161-6420(97)30065-7
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Tranos PG, 2004, SURV OPHTHALMOL, V49, P470, DOI 10.1016/j.survophthal.2004.06.002
   TRIPATHI RC, 1991, ANN OPHTHALMOL, V23, P127
   Ursell PG, 1999, J CATARACT REFR SURG, V25, P1492, DOI 10.1016/S0886-3350(99)00196-0
   WU L, 2007, GRAEFES ARCH CL 0803
NR 36
TC 41
Z9 45
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD DEC
PY 2007
VL 33
IS 12
BP 2098
EP 2105
DI 10.1016/j.jcrs.2007.07.046
PG 8
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA 240AJ
UT WOS:000251559100028
PM 18053911
DA 2020-12-15
ER

PT J
AU Fernandez, FAT
   Genzani, CP
   do Val, MLDM
   Maia, MLA
   Abreu, ALS
   Andrade, MC
   Andrade, ZM
   Carvalaes, JTA
AF Fernandez, F. A. T.
   Genzani, C. P.
   do Val, M. L. D. M.
   Maia, M. L. A.
   Abreu, A. L. S.
   Andrade, M. C.
   Andrade, Z. M.
   Carvalaes, J. T. A.
TI Ochoa syndrome. Two case reports
SO PEDIATRIC NEPHROLOGY
LA English
DT Meeting Abstract
C1 Univ Fed Sao Paulo, Paulista Sch Med, Dept Pediat Nephrol, Sao Paulo, Brazil.
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0931-041X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD DEC
PY 2007
VL 22
IS 12
BP 2160
EP 2160
PG 1
WC Pediatrics; Urology & Nephrology
SC Pediatrics; Urology & Nephrology
GA 228TO
UT WOS:000250755700051
DA 2020-12-15
ER

PT J
AU Genzani, CP
   Fernandes, FAT
   Maia, MLA
   Abreu, ALS
   do Val, MLDM
   Andrade, MC
   Andrade, ZM
   Carvalhaes, JTA
AF Genzani, C. P.
   Fernandes, F. A. T.
   Maia, M. L. A.
   Abreu, A. L. S.
   do Val, M. L. D. M.
   Andrade, M. C.
   Andrade, Z. M.
   Carvalhaes, J. T. A.
TI Lowe syndrome: Case reports
SO PEDIATRIC NEPHROLOGY
LA English
DT Meeting Abstract
C1 Univ Fed Sao Paulo, Paulista Sch Med, Dept Pediat Nephrol, Sao Paulo, Brazil.
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0931-041X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD DEC
PY 2007
VL 22
IS 12
BP 2164
EP 2164
PG 1
WC Pediatrics; Urology & Nephrology
SC Pediatrics; Urology & Nephrology
GA 228TO
UT WOS:000250755700067
DA 2020-12-15
ER

PT J
AU Furlani, BA
   Meyer, CH
   Rodrigues, EB
   Maia, M
   Farah, ME
   Penha, FM
   Holz, FG
AF Furlani, Bruno A.
   Meyer, Carsten H.
   Rodrigues, Eduardo B.
   Maia, Mauricio
   Farah, Michel E.
   Penha, Fernando M.
   Holz, Frank G.
TI Emerging pharmacotherapies for diabetic macular edema
SO EXPERT OPINION ON EMERGING DRUGS
LA English
DT Review
DE bevacizumab; diabetic retinopathy; macular edema; ranibizumab; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL TRIAMCINOLONE ACETONIDE;
   PROTEIN-KINASE-C; OPTICAL COHERENCE TOMOGRAPHY; UNIQUE NONSTEROIDAL
   PRODRUG; INDUCED OCULAR INFLAMMATION; RETINAL BARRIER BREAKDOWN; FACTOR
   MESSENGER-RNA; BEVACIZUMAB AVASTIN; POTENTIAL UTILITY
AB Diabetic macular edema (DME) is the most frequent cause of severe vision impairment in patients with non-proliferative diabetic retinopathy. Even though patients should achieve optimal glycemic control, normalization of blood pressure and serum lipids, as well as improvement of cardiac and renal status, these measures alone will not prevent every patient from developing visual loss caused by DME. The goal of local treatment for DME is vision improvement, usually achieved after reducing leakage on fluorescein angiography (FA) and retinal thickness on optical coherence tomography (OCT). Laser photocoagulation is still the standard treatment for clinically significant DME. However, laser photocoagulation rarely provides major visual improvement, especially in patients with diffuse DME. Thus, a therapeutic intervention that restores visual acuity impaired by DME more often remains a significant unmet medical need. This review aims to present the most important emerging drug technologies for therapy of DME at present, including corticosteroids, vascular endothelial growth factor inhibitors, protein kinase C inhibitors, small interfering RNA, hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors and non-hormonal anti-inflammatory agents. Recent progress in this field suggests that local management of DME may change rapidly in the near future. Novel emerging drugs should enable better anatomical and functional outcomes for therapy of this sight-threatening disease.
C1 Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   Univ Fed Sao Paulo, Vis Inst, Dept Ophthalmol, Sao Paulo, Brazil.
RP Meyer, CH (corresponding author), Univ Bonn, Dept Ophthalmol, Ernst-Abbe-Str 2, D-53127 Bonn, Germany.
EM meyer_eye@yahoo.com
RI Maia, Mauricio/Z-1042-2019; Meyer, Carsten H./A-3981-2017; Maia,
   Mauricio/I-5892-2015; Penha, Fernando M/G-1784-2012; Farah, Michel Eid
   E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Meyer, Carsten
   H./0000-0002-0530-5298; Maia, Mauricio/0000-0002-7034-8091; Farah,
   Michel Eid E/0000-0001-5951-0193; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921; Penha, Fernando/0000-0002-1038-5472
CR Abiko T, 2003, DIABETES, V52, P829, DOI 10.2337/diabetes.52.3.829
   Abraham P, 2006, OPHTHALMOLOGY, V113, P2221, DOI 10.1016/j.ophtha.2006.07.032
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Aiello LP, 2007, ARCH OPHTHALMOL-CHIC, V125, P318
   Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   Aiello LP, 2005, DIABETES, V54, P2188
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210
   Antcliff RJ, 2000, OPHTHALMOLOGY, V107, P593, DOI 10.1016/S0161-6420(99)00087-1
   Antonetti DA, 2002, J NEUROCHEM, V80, P667, DOI 10.1046/j.0022-3042.2001.00740.x
   Arevalo JF, 2007, OPHTHALMOLOGY, V114, P743, DOI 10.1016/j.ophtha.2006.12.028
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   Avitabile T, 2005, AM J OPHTHALMOL, V140, P695, DOI 10.1016/j.ajo.2005.05.021
   Bahadir Mehmet, 2005, International Ophthalmology, V26, P3
   Beck RW, 2001, OPHTHALMOLOGY, V108, P2266
   BRESNICK GH, 1983, OPHTHALMOLOGY, V90, P1301
   Brooks HL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1801, DOI 10.1001/archopht.122.12.1801
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bullock William H., 2002, Current Topics in Medicinal Chemistry, V2, P915, DOI 10.2174/1568026023393255
   Campochiaro PA, 2004, INVEST OPHTH VIS SCI, V45, P922, DOI 10.1167/iovs.03-0955
   Chew EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P1079, DOI 10.1001/archopht.1996.01100140281004
   Chieh JJ, 2005, RETINA-J RET VIT DIS, V25, P828, DOI 10.1097/00006982-200510000-00002
   CHRISTOFORIDIS JB, 2005, INVEST OPHTH VIS SCI, V46, pE391
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Danis RP, 1998, INVEST OPHTH VIS SCI, V39, P171
   DO DV, 2007, INVEST OPHTH VIS SCI, V48, pE1430
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Emerson MV, 2007, BIODRUGS, V21, P245, DOI 10.2165/00063030-200721040-00005
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRIS FL, 1984, SURV OPHTHALMOL, V28, P452, DOI 10.1016/0039-6257(84)90227-3
   *FLUOC AC IMPL STU, 2006, INVEST OPHTH VIS SCI, V47, pE5442
   *FLUOC AC OPHTH BA, 2005, DRUGS R&D, V6, P116
   Gamache DA, 2000, INFLAMMATION, V24, P357, DOI 10.1023/A:1007049015148
   Gao H, 2004, VISION RES, V44, P349, DOI 10.1016/j.visres.2003.09.027
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   GREWING R, 1994, BRIT J OPHTHALMOL, V78, P433, DOI 10.1136/bjo.78.6.433
   Gupta A, 2004, AM J OPHTHALMOL, V137, P675, DOI 10.1016/j.ajo.2003.11.017
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Hernaez-Ortega MC, 2004, DIABETES RES CLIN PR, V64, P71, DOI 10.1016/j.diabres.2003.10.003
   Hikichi T, 1997, OPHTHALMOLOGY, V104, P473, DOI 10.1016/S0161-6420(97)30289-9
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728
   Janoria KG, 2007, EXPERT OPIN DRUG DEL, V4, P371, DOI 10.1517/17425247.4.4.371
   Jirousek MR, 1996, J MED CHEM, V39, P2664, DOI 10.1021/jm950588y
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P57
   Kaushik S, 2004, AM J OPHTHALMOL, V137, P758, DOI 10.1016/j.ajo.2003.09.039
   Ke TL, 2000, INFLAMMATION, V24, P371, DOI 10.1023/A:1007001131987
   Kern TS, 2007, DIABETES, V56, P373, DOI 10.2337/db05-1621
   KIRKEGAARD C, 1990, ACTA ENDOCRINOL-COP, V122, P766, DOI 10.1530/acta.0.1220766
   KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464
   Koutsandrea C, 2007, RETINA-J RET VIT DIS, V27, P159, DOI 10.1097/IAE.0b013e31802e3e5c
   Kuppermann BD, 2007, ARCH OPHTHALMOL-CHIC, V125, P309, DOI 10.1001/archopht.125.3.309
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Lam DSC, 2007, BRIT J OPHTHALMOL, V91, P199, DOI 10.1136/bjo.2006.102848
   LAM RF, 2006, OPHTHALMOLOGICA, V141, P984
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Mason IG, 2006, WASTE MANAGE, V26, P3, DOI 10.1016/j.wasman.2005.01.021
   Massin P, 2004, OPHTHALMOLOGY, V111, P218, DOI 10.1016/j.ophtha.2003.05.037
   MAXWELL DP, 1991, OPHTHALMOLOGY, V98, P1370
   *MED INT LTD, 2007, WET AMD
   Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281
   Meyer CH, 2007, OPHTHALMOLOGICA, V221, P118, DOI 10.1159/000098257
   Morrison VL, 2007, OPHTHALMOLOGY, V114, P334, DOI 10.1016/j.ophtha.2006.07.013
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P1, DOI 10.1007/s10633-006-9032-y
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   NABIH M, 1991, INT OPHTHALMOL, V15, P233
   NASRALLAH FP, 1988, OPHTHALMOLOGY, V95, P1335
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Nonaka A, 2000, INVEST OPHTH VIS SCI, V41, P2702
   Oh Joo Youn, 2007, Korean J Ophthalmol, V21, P18, DOI 10.3341/kjo.2007.21.1.18
   OLK RJ, 1986, OPHTHALMOLOGY, V93, P938
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Propper DJ, 2001, J CLIN ONCOL, V19, P1485, DOI 10.1200/JCO.2001.19.5.1485
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   Quiram PA, 2006, AM J OPHTHALMOL, V141, P580, DOI 10.1016/j.ajo.2005.10.004
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rudge JS, 2005, COLD SH Q B, V70, P411, DOI 10.1101/sqb.2005.70.052
   RYAN SJ, 2007, OPHTHALMOLOGICA, V221, P118
   Schwartz SG, 2006, OPHTHAL SURG LAS IM, V37, P420, DOI 10.3928/15428877-20060901-10
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Sheetz MJ, 2002, JAMA-J AM MED ASSOC, V288, P2579, DOI 10.1001/jama.288.20.2579
   Shimonagano Y, 2007, JPN J OPHTHALMOL, V51, P204, DOI 10.1007/s10384-007-0423-8
   Simo R, 2007, DIABETES CARE, V30, P725, DOI 10.2337/dc06-1345
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Stefansson E, 2006, AM J OPHTHALMOL, V141, P984, DOI 10.1016/j.ajo.2006.01.044
   Stefansson E, 2001, ACTA OPHTHALMOL SCAN, V79, P435, DOI 10.1034/j.1600-0420.2001.790502.x
   Stellato Cristiana, 2004, Proc Am Thorac Soc, V1, P255, DOI 10.1513/pats.200402-015MS
   Stolba U, 2005, AM J OPHTHALMOL, V140, P295, DOI 10.1016/j.ajo.2005.03.045
   The Early Treatment Diabetic Retinopathy Study Research Group, 1987, INT OPHTHALMOL CLIN, V27, P254, DOI [10.1097/00004397-198702740-00005, DOI 10.1097/00004397-198702740-00005]
   Thompson JT, 2006, AM J OPHTHALMOL, V141, P629, DOI 10.1016/j.ajo.2005.11.050
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   Viola F, 2006, ARCH OPHTHALMOL-CHIC, V124, P133, DOI 10.1001/archopht.124.1.133
   Westfall AC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1075, DOI 10.1001/archopht.123.8.1075
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934
   Xu X, 2004, CURR EYE RES, V28, P251, DOI 10.1076/ceyr.28.4.251.27834
   Yanyali A, 2007, AM J OPHTHALMOL, V144, P124, DOI 10.1016/j.ajo.2007.02.048
   Yanyali A, 2007, RETINA-J RET VIT DIS, V27, P557, DOI 10.1097/01.iae.0000249390.61854.d5
   Zhou ZH, 2001, AM J PHYSIOL-CELL PH, V281, pC1118
NR 111
TC 13
Z9 13
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8214
EI 1744-7623
J9 EXPERT OPIN EMERG DR
JI Expert Opin Emerg. Drugs
PD NOV
PY 2007
VL 12
IS 4
BP 591
EP 603
DI 10.1517/14728214.12.4.591
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 237FT
UT WOS:000251360300006
PM 17979601
DA 2020-12-15
ER

PT J
AU Lowe, J
   Araujo, J
   Yang, JH
   Reich, M
   Oldendorp, A
   Shiu, V
   Quarmby, V
   Lowman, H
   Lien, S
   Gaudreault, J
   Maia, M
AF Lowe, John
   Araujo, James
   Yang, Jihong
   Reich, Mike
   Oldendorp, Amy
   Shiu, Vanessa
   Quarmby, Valerie
   Lowman, Henry
   Lien, Samantha
   Gaudreault, Jacques
   Maia, Mauricio
TI Ranibizumab inhibits multiple forms of biologically active vascular
   endothelial growth factor in vitro and in vivo
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE ranibizumab; vascular endothelial growth factor; age-related macular
   degeneration
ID MACULAR DEGENERATION; CRYSTAL-STRUCTURE; VEGF; MEMBRANES; ANTIBODY;
   AFFINITY; COMPLEX; FAB
AB Neovascular age-related macular degeneration (AMD) is the leading cause of blindness in older adults in the Western world. Ranibizumab (Lucentis (R)), a humanized antibody fragment directed against vascular endothelial growth factor (VEGF-A), was recently approved by the US Food and Drug Administration (FDA) for the treatment of neovascular AMD. The objective of this study was to characterize the binding affinity and pharmacological activity of ranibizumab for 3 biologically active forms of VEGF-A: VEGF(165), VEGF(121), and VEGF(110). The apparent equilibrium binding affinity of ranibizumab for VEGF-A molecules was determined by Biacore (R) analysis; the biological activity of VEGF-A was demonstrated in a human umbilical vein endothelial cell (HUVEC proliferation-inhibition assay. Inhibition of VEGF-A-induced vascular permeability by ranibizumab was assessed in vivo using hairless guinea pigs and a modified Miles assay. Ranibizumab was capable of binding to recombinant human VEGF(165), VEGF(121), and VEGF(110) (K-D <= 192 pM), inhibiting VEGF-A-induced HUVEC proliferation in a concentration-dependent manner. Ranibizumab also exerted potent dose-dependent inhibition IC50 of 0.4-1.2 nM) of the vascular permeability-enhancing activity of VEGF(165), VEGF(121), and VEGF(110) in the Miles assay. In conclusion, these results show that ranibizumab is capable of binding to and specifically inhibiting the activities of 3 biologically active forms of VEGF-A. As VEGF-A plays a pivotal role in the pathogenesis of neovascular AMD, ranibizumab activity, as demonstrated in this study, supports its clinical utility in the treatment of this disease. (C) 2007 Elsevier Ltd. All rights reserved.
C1 Genentech Inc, Dept BioAnalyt R&D, San Francisco, CA 94080 USA.
   Genentech Inc, In Vivo Grp, San Francisco, CA 94080 USA.
   Dept Pharmacokinet Pharmacodynam & Bioanalyt Sci, San Francisco, CA 94080 USA.
   Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA.
RP Lowe, J (corresponding author), Genentech Inc, Dept BioAnalyt R&D, MS38,1 DNA Way, San Francisco, CA 94080 USA.
EM lowe.john@gene.com
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR *AD DRUG PROF, 2002, DRUGS R D, V3, P40
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lei JX, 1998, BBA-GENE STRUCT EXPR, V1443, P400, DOI 10.1016/S0167-4781(98)00240-1
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789
   Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROSENFELD PJ, 2006, OPHTHALMOLOGY, V113
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Yang JH, 2002, THROMB HAEMOSTASIS, V87, P450
NR 18
TC 102
Z9 108
U1 0
U2 17
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2007
VL 85
IS 4
BP 425
EP 430
DI 10.1016/j.exer.2007.05.008
PG 6
WC Ophthalmology
SC Ophthalmology
GA 228FM
UT WOS:000250713000002
PM 17714704
DA 2020-12-15
ER

PT J
AU Maia, M
   Farah, ME
   Belfort, RN
   Penha, FM
   Lima, CAS
   Aggio, FB
   Belfort, R
AF Maia, Mauricio
   Farah, Michel Eid
   Belfort, Rubens N.
   Penha, Fernando Marcondes
   Lima, Cio A. S. Filho
   Aggio, Fabio Bom
   Belfort, Rubens, Jr.
TI Effects of intravitreal triamcinolone acetonide injection with and
   without preservative
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
C1 Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, BR-04023062 Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, Rua Botucatu 822, BR-04023062 Sao Paulo, Brazil.
EM maiaretina@uol.com.br
RI Maia, Mauricio/Z-1042-2019; Penha, Fernando M/G-1784-2012; Belfort,
   Rubens/E-2252-2012; de Souza Lima Filho, Acacio Alves/C-7189-2012; Maia,
   Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Belfort, Rubens/0000-0002-8422-3898;
   Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Alves de Souza Lima Filho,
   Acacio/0000-0003-1802-9592
NR 0
TC 47
Z9 49
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2007
VL 91
IS 9
BP 1122
EP 1124
DI 10.1136/bjo.2007.115386
PG 3
WC Ophthalmology
SC Ophthalmology
GA 202EN
UT WOS:000248884900011
PM 17383993
OA Green Published
DA 2020-12-15
ER

PT J
AU Maia, M
   Pieramici, DJ
   Eong, KGA
   Schachat, AP
   Rodrigues, EB
   Green, WR
AF Maia, Mauricio
   Pieramici, Dante J.
   Eong, Kah-Guan Au
   Schachat, Andrew P.
   Rodrigues, Eduardo B.
   Green, W. Richard
TI Non-contiguous recurrence or secondary choroidal melanoma following
   plaque radiotherapy
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE non-contiguous recurrence; plaque radiotherapy; Uveal melanoma;
   vitreoretinal surgery
ID POSTERIOR UVEAL MELANOMA
AB Non-contiguous local recurrence of posterior uveal melanoma occurs rarely after plaque therapy. A 50-year-old white first presented with choroidal melanoma. He underwent therapy with episcleral iodine-125 radioactive plaque therapy. Nine years later fundus evaluation revealed a new pigmented lesion in the inferotemporal equatorial area. Patient was considered to have a non-contiguous recurrent melanoma and the eye was enucleated. Histologic microscopic examination disclosed a 3 x 1.8 mm densely pigmented tumour internal to the choroid at the equator. The tumour was composed of large round cells with round nuclei, prominent nucleoli, abundant cytoplasm and spindle-shaped cells with spindle-shaped nuclei and prominent nucleoli. The tumour extended through the retina. The superior nasal area of plaque therapy had extensive chorioretinal atrophy with loss of retinal pigment epithelium, thinning of the retina and thinning and depigmentation of the choroids. Within this area of atrophy, there was a pigmented lesion composed by densely packed, spindle-shaped cells with spindle-shaped nuclei. Our patient illustrated non-contiguous recurrence of choroidal melanoma, such finding raises concerns about physiopathology and treatment of choroidal melanoma.
C1 Johns Hopkins Med Inst, Wilmer Ophthalmol Inst, Baltimore, MD 21205 USA.
RP Rodrigues, EB (corresponding author), Ave Trompowsky 420-1005, Florianopolis, SC, Brazil.
EM edubrodriguess@yahoo.com.br
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
CR DUKER JS, 1989, ARCH OPHTHALMOL-CHIC, V107, P1019, DOI 10.1001/archopht.1989.01070020081035
   Gunduz K, 1999, AM J OPHTHALMOL, V127, P579, DOI 10.1016/S0002-9394(98)00445-0
   Jampol LM, 2002, OPHTHALMOLOGY, V109, P2197, DOI 10.1016/S0161-6420(02)01277-0
   Kim JW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1659
   Lois N, 1997, AM J OPHTHALMOL, V124, P848, DOI 10.1016/S0002-9394(14)71708-8
   Robertson DM, 1999, ARCH OPHTHALMOL-CHIC, V117, P771
   SPENCER WH, 1975, AM J OPHTHALMOL, V80, P465, DOI 10.1016/0002-9394(75)90535-8
NR 7
TC 1
Z9 1
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD SEP-OCT
PY 2007
VL 35
IS 7
BP 657
EP 660
DI 10.1111/j.1442-9071.2007.01531.x
PG 4
WC Ophthalmology
SC Ophthalmology
GA 213XJ
UT WOS:000249700300012
PM 17894687
DA 2020-12-15
ER

PT J
AU Maia, M
   Farah, ME
   Aggio, FB
   Rodrigues, EB
   de Souza, EC
   Magalhaes, O
AF Maia, Mauricio
   Farah, Michel E.
   Aggio, Fabio B.
   Rodrigues, Eduardo B.
   de Souza, Eduardo C.
   Magalhaes, Octaviano, Jr.
TI Peripapillary haemorrhagic retinal pigment epithelium detachment
   following radial optic neurotomy
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Letter
DE central vein occlusion; chorioretinal anastomosis; radial optic
   neurotomy
ID VEIN OCCLUSION
AB Central retinal vein occlusion is a common vascular cause of blidness. In this paper, we first report focal haemorrhagic pigment epithelium detachment and chorioretinal anastomosis in the peripapillary area as an intraoperative complication of radial optic neurotomy (RON). A 65-year-old white man presented with ischaemic central vein occlusion OS. He underwent vitrectomy with RON, panretinal photocoagulation and intravitreal injection of triamcinolone acetonide. A circumscribed subretinal haemorrhage was noted intraoperatively at the nasal site of the RON. The haemorrhage size decreased at the seventh postoperative day when an optical coherence tomography scan disclosed a haemorrhagic pigment epithelium detachment. Fluorescein angiography and fundus photograph revealed a chorioretinal anastomosis formation nasal to the optic nerve confirmed by indocyanine green angiography. Best-correlated visual acuity improved from hand movements to 6/18 at the fourth week and it was stable until last examination. This case illustrates the role of chorioretinal anastomosis formation in the vision improvement following RON.
C1 Univ Fed Sao Paulo, Vis Inst IPEPO, Dept Ophthalmol, Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Vis Inst IPEPO, Dept Ophthalmol, Sao Paulo, Brazil.
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019; Farah, Michel
   Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Farah, Michel Eid E/0000-0001-5951-0193; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
CR Clarkson JC, 1997, ARCH OPHTHALMOL-CHIC, V115, P486
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1425
   Garcia-Arumi J, 2003, ARCH OPHTHALMOL-CHIC, V121, P1385, DOI 10.1001/archopht.121.10.1385
   Hayreh SS, 2002, RETINA-J RET VIT DIS, V22, P374
   Opremcak EM, 2001, RETINA-J RET VIT DIS, V21, P408, DOI 10.1097/00006982-200110000-00002
NR 5
TC 3
Z9 3
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD SEP-OCT
PY 2007
VL 35
IS 7
BP 672
EP 674
DI 10.1111/j.1442-9071.2007.01568.x
PG 3
WC Ophthalmology
SC Ophthalmology
GA 213XJ
UT WOS:000249700300015
PM 17894690
DA 2020-12-15
ER

PT J
AU Rodrigues, EB
   Maia, M
   Meyer, CH
   Penha, FM
   Dib, E
   Farah, ME
AF Rodrigues, Eduardo B.
   Maia, Mauricio
   Meyer, Carsten H.
   Penha, Fernando M.
   Dib, Eduardo
   Farah, Michel E.
TI Vital dyes for chromovitrectomy
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE chromovitrectomy; indocyanine green; macular hole; retina; trypan blue
ID INTERNAL LIMITING MEMBRANE; RETINAL-PIGMENT EPITHELIUM; MACULAR HOLE
   SURGERY; INTRAVITREAL TRIAMCINOLONE ACETONIDE; INDOCYANINE GREEN
   INJECTION; GLIAL-CELL CULTURES; TRYPAN BLUE; VITREORETINAL SURGERY;
   INFRACYANINE GREEN; PATENT BLUE
AB Purpose of review
   The aim of this article is to present the current state-of-the-art in regard to the application of vital dyes during vitreoretinal surgery, 'chromovitrectomy', as well as to overview the current literature regarding the properties of dyes, techniques of application, indications, and complications in chromovitrectomy.
   Recent findings
   A large body of published research has recently addressed the toxicity profile of indocyanine green for chromovitrectomy. Experimental data demonstrate dose-dependent toxicity of indocyanine green to various retinal cells. Newer generation vital dyes for chromovitrectomy include trypan blue, patent blue, triamcinolone acetonide, infracyanine green, sodium fluorescein, bromophenol blue, fluorometholone acetate and brilliant blue. Novel instruments may enable a selective painting of preretinal tissues during chromovitrectomy.
   Summary
   This review suggests that the field of chromovitrectomy represents an expanding area of research. The first line agents for internal limiting membrane staining in chromovitrectomy are indocyanine green, infracyanine green, and brilliant blue. Patent blue, bromophenol blue and trypan blue arose as outstanding biostains for visualization of epiretinal membranes. Novel dyes available for chromovitrectomy deserve further investigation.
C1 Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst OPEPO, Sao Paulo, Brazil.
   Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
RP Rodrigues, EB (corresponding author), Av Trompowsky 420-1005, BR-88015300 Florianopolis, SC, Brazil.
EM edubrodriguess@yahoo.com.br
RI Farah, Michel Eid E/F-3285-2012; Penha, Fernando M/G-1784-2012; Maia,
   Mauricio/Z-1042-2019; Meyer, Carsten H./A-3981-2017; Maia,
   Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Meyer, Carsten H./0000-0002-0530-5298;
   Maia, Mauricio/0000-0002-7034-8091; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
CR ABRAMS GW, 1978, ARCH OPHTHALMOL-CHIC, V96, P521
   Ando F, 2004, AM J OPHTHALMOL, V137, P609, DOI 10.1016/j.ajo.2003.08.038
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Burk SE, 2003, J CATARACT REFR SURG, V29, P645, DOI 10.1016/S0886-3350(03)00016-6
   Czajka MP, 2004, RETINA-J RET VIT DIS, V24, P275, DOI 10.1097/00006982-200404000-00014
   Das T, 2004, CLIN EXP OPHTHALMOL, V32, P55, DOI 10.1046/j.1442-9071.2003.00758.x
   Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P623, DOI 10.1097/00006982-200607000-00006
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Gass CA, 2003, GRAEF ARCH CLIN EXP, V241, P716, DOI 10.1007/s00417-003-0710-0
   Guo SQ, 2006, J PEDIAT OPHTH STRAB, V43, P281, DOI 10.3928/01913913-20060901-02
   Haritoglou C, 2005, INVEST OPHTH VIS SCI, V46, P3315, DOI 10.1167/iovs.04-1142
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P673, DOI 10.1097/00006982-200607000-00014
   HATA Y, 2006, GRAEFES ARCH CL 1221
   Hiebl W, 2005, KLIN MONATSBL AUGENH, V222, P309, DOI 10.1055/s-2005-858030
   HILLENKAMP J, 2006, GRAEFES ARCH CL 1221
   Hisatomi T, 2006, ARCH OPHTHALMOL-CHIC, V124, P514, DOI 10.1001/archopht.124.4.514
   Ho JD, 2004, BRIT J OPHTHALMOL, V88, P556, DOI 10.1136/bjo.2003.018523
   Ho JD, 2003, AM J OPHTHALMOL, V135, P258, DOI 10.1016/S0002-9394(02)01976-1
   Iriyama A, 2004, INVEST OPHTH VIS SCI, V45, P943, DOI 10.1167/iovs.03-1026
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P2778, DOI 10.1167/iovs.04-0320
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P3697, DOI 10.1167/iovs.04-0387
   JACKSON TL, 2006, OPHTHALMOLOGY   1120
   JAHNKE KD, 1984, MYCOLOGIA, V76, P940, DOI 10.2307/3793150
   Jin Y, 2005, EXP EYE RES, V81, P395, DOI 10.1016/j.exer.2005.02.010
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Kodjikian L, 2005, GRAEF ARCH CLIN EXP, V243, P917, DOI 10.1007/s00417-004-1121-6
   Kozak I, 2006, RETINA-J RET VIT DIS, V26, P811, DOI 10.1097/01.iae.0000244255.22406.2f
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P178, DOI 10.1016/S0002-9394(01)00976-X
   La Heij EC, 2005, AM J OPHTHALMOL, V140, P1123, DOI 10.1016/j.ajo.2005.05.054
   LARSEN M, 1993, ACTA OPHTHALMOL    S, V211, P1
   Li K, 2003, BRIT J OPHTHALMOL, V87, P216, DOI 10.1136/bjo.87.2.216
   Lochhead J, 2004, EYE, V18, P804, DOI 10.1038/sj.eye.6701328
   Luke C, 2006, GRAEF ARCH CLIN EXP, V244, P1188, DOI 10.1007/s00417-005-0239-5
   Luke C, 2005, BRIT J OPHTHALMOL, V89, P1188, DOI 10.1136/bjo.2004.062794
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   MARMOR MF, 1979, INVEST OPHTH VIS SCI, V18, P1237
   Melles GRJ, 1999, J CATARACT REFR SURG, V25, P7, DOI 10.1016/S0886-3350(99)80004-2
   Mennel S, 2006, OPHTHALMOLOGICA, V220, P190, DOI 10.1159/000091764
   Mennel S, 2006, KLIN MONATSBL AUGENH, V223, P568, DOI 10.1055/s-2006-926479
   Meyer CH, 2005, GRAEF ARCH CLIN EXP, V243, P487, DOI 10.1007/s00417-004-1054-0
   Morrison VL, 2006, RETINA-J RET VIT DIS, V26, P339, DOI 10.1097/00006982-200603000-00014
   Nakamura T, 2003, CURR EYE RES, V27, P395, DOI 10.1076/ceyr.27.6.395.18189
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   Ozawa T, 2005, NEUROSURGERY, V57, P1041, DOI 10.1227/01.NEU.0000180036.42193.f6
   Rivett K, 2004, GRAEF ARCH CLIN EXP, V242, P393, DOI 10.1007/s00417-003-0857-8
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Rodrigues EB, 2004, OPHTHALMOLOGICA, V218, P73, DOI 10.1159/000074571
   RODRIGUES EB, 2007, OPHTHALMOLOGICA, V114, P587
   Ruiz-Moreno JM, 2007, EXP EYE RES, V84, P342, DOI 10.1016/j.exer.2006.10.006
   Schuettauf F, 2006, INVEST OPHTH VIS SCI, V47, P3573, DOI 10.1167/iovs.06-0211
   Sheidow TG, 2003, OPHTHALMOLOGY, V110, P1697, DOI 10.1016/S0161-6420(03)00562-1
   Slaughter K, 2004, EYE, V18, P376, DOI 10.1038/sj.eye.6700666
   SOKOLOWSKI J, 1974, LYMPHOLOGY, V7, P28
   Stalmans P, 2002, AM J OPHTHALMOL, V134, P282, DOI 10.1016/S0002-9394(02)01468-X
   Teba FA, 2003, OPHTHALMOLOGY, V110, P2409, DOI 10.1016/S0161-6420(03)00716-4
   TSE CST, 1984, PHARMACOTHERAPY, V4, P334
   Ullern M, 2002, J FR OPHTALMOL, V25, P915
   Veckeneer M, 2001, GRAEF ARCH CLIN EXP, V239, P698, DOI 10.1007/s004170100341
   Vote BJ, 2004, RETINA-J RET VIT DIS, V24, P736, DOI 10.1097/00006982-200410000-00008
   Westermeier R, 2006, PROTEOMICS, P61
   Yu SY, 2006, RETINA-J RET VIT DIS, V26, P531, DOI 10.1097/00006982-200605000-00006
NR 66
TC 61
Z9 64
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2007
VL 18
IS 3
BP 179
EP 187
DI 10.1097/ICU.0b013e32811080b5
PG 9
WC Ophthalmology
SC Ophthalmology
GA 162BL
UT WOS:000246061200001
PM 17435423
DA 2020-12-15
ER

PT J
AU Penha, FM
   Maia, M
   Farah, ME
   Principe, AH
   Freymuller, EH
   Maia, A
   Magalhaes, O
   Smith, RL
AF Penha, Fernando M.
   Maia, Mauricio
   Farah, Michel Eid
   Principe, Andre H.
   Freymuller, Edna H.
   Maia, Andre
   Magalhaes, Octaviano, Jr.
   Smith, Ricardo L.
TI Effects of subretinal injections of indocyanine green, trypan blue, and
   glucose in rabbit eyes
SO OPHTHALMOLOGY
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology
CY APR 30-MAY 05, 2005
CL Ft Lauderdale, FL
SP Assoc Res Vis & Ophthalmol
ID INTERNAL-LIMITING MEMBRANE; MACULAR HOLE SURGERY; RETINAL-PIGMENT
   EPITHELIUM; EPIRETINAL MEMBRANE; TRIAMCINOLONE ACETONIDE; FLUID
   RESORPTION; REMOVAL; DETACHMENT; MANAGEMENT; SAFETY
AB Purpose: To evaluate the effects of subretinal injections of indocyanine green (ICG), trypan blue, glucose (GL), and balanced salt solution (BSS) in rabbits.
   Design: Experimental study.
   Participants: Twenty Dutch-belted rabbits.
   Methods: Ten animals underwent vitrectomy and subretinal injection of 0.02 ml of either 0.05% ICG (279 milliosmoles [mOsm]), 0.15% trypan blue (312 mOsm), 5% GL (280 mOsm), or BSS (300 mOsm), which was tested as a control. Ten additional animals underwent subretinal injection of 0.02 ml of 0.046% ICG (251 mOsm), 0.13% trypan blue (260 mOsm), 4.6% GL (253 mOsm), or BSS (300 mOsm). Animals were examined 6, 12, and 24 hours and 14 days after the procedure by fluorescein angiography and fundus evaluation; histologic studies were performed by light and transmission electron microscopy.
   Main Outcome Measures: Clinical outcome, fluorescein angiography, and histopathologic results.
   Results: All subretinal blebs were flat 24 hours after the procedure. Fluorescein angiography showed window defects where ICG and trypan blue had been injected. Subretinal BSS and GL resulted in minimal abnormalities of the photoreceptor outer segments (POS) during follow-up. Hypo-osmolar GL caused edema in all retinal layers; pyknosis of the outer nuclear layer (ONL) was observed 24 hours after injection. Subretinal injection of trypan blue resulted in histologic abnormalities 24 hours and 14 days after surgery. Hypo-osmolar trypan blue caused edema of the POS and the photoreceptor inner segments and pyknosis of the ONL 6 and 12 hours after surgery; the retinal pigment epithelium also was affected 24 hours and 14 days after surgery. Subretinal injection of iso-osmolar and hypo-osmolar ICG caused severe damage of all retinal layers during the entire follow-up.
   Conclusions: Subretinal injection of 0.05% ICG results in more substantial retinal damage than that associated with the 0.15% trypan blue subretinal injection. The damage induced by hypo-osmolar solutions was more important than that caused by the iso-osmolar solutions. These findings emphasize that care must be taken regarding the solution osmolarity and that subretinal migration of these substances should be avoided during macular hole surgery.
C1 Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Ctr Electron Microscopy, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Morphol, Sao Paulo, Brazil.
RP Penha, FM (corresponding author), Alameda Campinas,129,Apt 71, BR-01404000 Sao Paulo, Brazil.
EM penhaepm@yahoo.com.br
RI Penha, Fernando M/G-1784-2012; Farah, Michel Eid E/F-3285-2012; Maia,
   Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
CR Abels C, 2000, ARCH DERMATOL RES, V292, P404, DOI 10.1007/s004030000147
   Baumler W, 1999, BRIT J CANCER, V80, P360, DOI 10.1038/sj.bjc.6690363
   Berglin L, 1997, GRAEF ARCH CLIN EXP, V235, P306, DOI 10.1007/BF01739640
   Brooks HL, 2000, OPHTHALMOLOGY, V107, P1939, DOI 10.1016/S0161-6420(00)00331-6
   Costa RA, 2001, AM J OPHTHALMOL, V132, P557, DOI 10.1016/S0002-9394(01)01138-2
   Eckardt C, 1997, OPHTHALMOLOGE, V94, P545, DOI 10.1007/s003470050156
   Enaida H, 2002, GRAEF ARCH CLIN EXP, V240, P209, DOI 10.1007/s00417-002-0433-7
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   FRAMBACH DA, 1982, INVEST OPHTH VIS SCI, V22, P292
   Gandorfer A, 2001, AM J OPHTHALMOL, V132, P431, DOI 10.1016/S0002-9394(01)01087-X
   Ivert L, 2002, GRAEF ARCH CLIN EXP, V240, P232, DOI 10.1007/s00417-001-0392-4
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P3697, DOI 10.1167/iovs.04-0387
   Javid CG, 2000, INT OPHTHALMOL CLIN, V40, P225, DOI 10.1097/00004397-200040010-00021
   Kadonosono K, 2000, ARCH OPHTHALMOL-CHIC, V118, P1116, DOI 10.1001/archopht.118.8.1116
   Kadonosono K, 2001, AM J OPHTHALMOL, V131, P203, DOI 10.1016/S0002-9394(00)00728-5
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P178, DOI 10.1016/S0002-9394(01)00976-X
   Li K, 2003, BRIT J OPHTHALMOL, V87, P216, DOI 10.1136/bjo.87.2.216
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Margherio RR, 2000, ARCH OPHTHALMOL-CHIC, V118, P495
   Mester V, 2000, AM J OPHTHALMOL, V129, P769, DOI 10.1016/S0002-9394(00)00358-5
   NEGI A, 1984, INVEST OPHTH VIS SCI, V25, P616
   NEGI A, 1983, INVEST OPHTH VIS SCI, V24, P1475
   Park DW, 1999, OPHTHALMOLOGY, V106, P1392, DOI 10.1016/S0161-6420(99)00730-7
   Price N, 2000, GASTROINTEST ENDOSC, V51, P438, DOI 10.1016/S0016-5107(00)70445-7
   Shah GK, 2004, AM J OPHTHALMOL, V138, P656, DOI 10.1016/j.ajo.2004.04.025
   Sippy BD, 2001, AM J OPHTHALMOL, V132, P433, DOI 10.1016/S0002-9394(01)01061-3
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P637, DOI 10.1097/00006982-200210000-00016
   Stalmans P, 2002, AM J OPHTHALMOL, V134, P282, DOI 10.1016/S0002-9394(02)01468-X
   Uno F, 2006, RETINA-J RET VIT DIS, V26, P237, DOI 10.1097/00006982-200602000-00026
   Weinberger AWA, 2001, GRAEF ARCH CLIN EXP, V239, P388, DOI 10.1007/s004170100267
   Yamamoto N, 2004, OPHTHALMOLOGICA, V218, P248, DOI 10.1159/000078615
NR 33
TC 49
Z9 50
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2007
VL 114
IS 5
BP 899
EP 908
DI 10.1016/j.ophtha.2006.09.028
PG 10
WC Ophthalmology
SC Ophthalmology
GA 163KM
UT WOS:000246158500013
PM 17292475
DA 2020-12-15
ER

PT J
AU Maia, M
   Penha, F
   Rodrigues, EB
   Principe, A
   Dib, E
   Meyer, CH
   Freymuller, E
   Moraes, N
   Farah, ME
AF Maia, Mauricio
   Penha, Fernando
   Rodrigues, Eduardo B.
   Principe, Andre
   Dib, Eduardo
   Meyer, Carsten H.
   Freymuller, Edna
   Moraes, Nilva
   Farah, Michel Eid
TI Effects of subretinal injection of patent blue and trypan blue in
   rabbits
SO CURRENT EYE RESEARCH
LA English
DT Article
DE chromovitrectomy; macular hole; patent blue; retina; trypan blue
ID INTERNAL LIMITING MEMBRANE; INDOCYANINE GREEN INJECTION; MACULAR HOLE
   SURGERY; TOXICITY; REMOVAL; DYES
AB Purpose: To investigate the histologic and clinical effects of subretinal injection of patent blue (PB) and trypan blue (TB) in rabbits. Methods: Dutch-belted rabbits (n = 8) were vitrectomized followed by subretinal injection of 2.4 mg/ml PB (285 mOsm) and 1.5 mg/ml TB (312 mOsm); balanced salt solution (BSS) (300 mOsm) served as the control. Animals were examined 6, 12, and 24 hr and 14 days after the procedure by fluorescein angiography (FA) and indirect ophthalmoscopy; for retinal toxicity, histologic evaluation studies were performed by light and transmission electron microscopy. Results: FA examination demonstrated window defects suggestive of retinal pigment epithelium (RPE) atrophy in positions of subretinal TB injection, but this was not observed after subretinal injection of PB or BSS. Histologic evaluation disclosed only minimal abnormalities on the photoreceptor outer segment (POS) after subretinal injection of BSS during all follow-up. Subretinal injection of PB caused POS and photoreceptor inner segment (PIS) abnormalities 12 and 24 hr after surgery as well as outer nuclear layer (ONL) damage 14 days after surgery. Subretinal TB injection resulted in POS and PIS damage at 12 hr follow-up. The ONL damage was observed 24 hr after surgery; additionally, POS, PIS, ONL, and RPE abnormalities were observed 14 days after surgery after TB injection. Conclusions: Subretinal injection of TB induced more significant clinical and histologic damage of neurosensory retina/RPE than did PB or BSS. Future human studies are necessary to access the clinical relevance of these in vivo experiments.
C1 Univ Fed Sao Paulo, Vis Inst, Paulista Sch Med, Dept Ophthalmol, Sao Paulo, Brazil.
RP Farah, ME (corresponding author), Ave Ibijau,331,4th Floor, BR-04424020 Sao Paulo, Brazil.
EM mefarah@uol.com.br
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; Farah, Michel
   Eid E/F-3285-2012; Penha, Fernando M/G-1784-2012; Meyer, Carsten
   H./A-3981-2017
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Farah, Michel Eid E/0000-0001-5951-0193; Meyer, Carsten
   H./0000-0002-0530-5298; Buchele Rodrigues, Eduardo/0000-0002-4224-0921
CR Brooks HL, 2000, OPHTHALMOLOGY, V107, P1939, DOI 10.1016/S0161-6420(00)00331-6
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   CHUNG KT, 1983, MUTAT RES, V114, P269, DOI 10.1016/0165-1110(83)90035-0
   Dewachter P, 2006, ACTA ANAESTH SCAND, V50, P245, DOI 10.1111/j.1399-6576.2006.00912.x
   Eckardt C, 1997, OPHTHALMOLOGE, V94, P545, DOI 10.1007/s003470050156
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Gandorfer A, 2003, INVEST OPHTH VIS SCI, V44, P316, DOI 10.1167/iovs.02-0545
   Hiebl W, 2005, KLIN MONATSBL AUGENH, V222, P309, DOI 10.1055/s-2005-858030
   Ho JD, 2004, BRIT J OPHTHALMOL, V88, P556, DOI 10.1136/bjo.2003.018523
   Ivert L, 2002, GRAEF ARCH CLIN EXP, V240, P232, DOI 10.1007/s00417-001-0392-4
   JACKSON TL, IN PRESS OPHTHALMOLO
   Jin Y, 2005, EXP EYE RES, V81, P395, DOI 10.1016/j.exer.2005.02.010
   Kadonosono K, 2000, ARCH OPHTHALMOL-CHIC, V118, P1116, DOI 10.1001/archopht.118.8.1116
   Li K, 2003, BRIT J OPHTHALMOL, V87, P216, DOI 10.1136/bjo.87.2.216
   Lucci A, 1999, SURGERY, V126, P48, DOI 10.1067/msy.1999.99055
   Luke C, 2006, GRAEF ARCH CLIN EXP, V244, P1188, DOI 10.1007/s00417-005-0239-5
   Luke C, 2005, BRIT J OPHTHALMOL, V89, P1188, DOI 10.1136/bjo.2004.062794
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P69, DOI 10.1097/00006982-200402000-00011
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Mennel S, 2006, OPHTHALMOLOGICA, V220, P190, DOI 10.1159/000091764
   Mennel S, 2006, KLIN MONATSBL AUGENH, V223, P568, DOI 10.1055/s-2006-926479
   Meyer CH, 2002, INVEST OPHTH VIS SCI, V43, P3567
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   NEGI A, 1984, INVEST OPHTH VIS SCI, V25, P616
   Rodrigues EB, 2005, OPHTHALMOLOGICA, V219, P251, DOI 10.1159/000086107
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Stalmans P, 2001, Bull Soc Belge Ophtalmol, P21
   Stalmans P, 2002, AM J OPHTHALMOL, V134, P282, DOI 10.1016/S0002-9394(02)01468-X
   Teba FA, 2003, OPHTHALMOLOGY, V110, P2409, DOI 10.1016/S0161-6420(03)00716-4
   Uno F, 2006, RETINA-J RET VIT DIS, V26, P237, DOI 10.1097/00006982-200602000-00026
   Veckeneer M, 2001, GRAEF ARCH CLIN EXP, V239, P698, DOI 10.1007/s004170100341
NR 32
TC 28
Z9 29
U1 1
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD APR
PY 2007
VL 32
IS 4
BP 309
EP 317
DI 10.1080/02713680701199377
PG 9
WC Ophthalmology
SC Ophthalmology
GA 163IJ
UT WOS:000246153000002
PM 17453952
DA 2020-12-15
ER

PT J
AU Arevalo, JF
   Fromow-Guerra, J
   Quiroz-Mercado, H
   Sanchez, JG
   Wu, L
   Maia, M
   Berrocal, MH
   Solis-Vivancol, A
   Farah, ME
AF Arevalo, J. Fernando
   Fromow-Guerra, Jans
   Quiroz-Mercado, Hugo
   Sanchez, Juan G.
   Wu, Lihteh
   Maia, Mauricio
   Berrocal, Maria H.
   Solis-Vivancol, Adriana
   Farah, Michel E.
CA Pan Amer Collaborative Study Grp
TI Primary intravitreal bevackumab (Avastin) for diabetic macular edema -
   Results from the Pan-American Collaborative Retina Study Group at
   6-month follow-up
SO OPHTHALMOLOGY
LA English
DT Article; Proceedings Paper
CT Joint Meeting of the American-Academy-of-Ophthamology/Asia Pacific
   Academy of Ophthalmology
CY NOV, 2006
CL Las Vegas, NV
SP Amer Acad Ophthalmol
ID ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB AVASTIN; RETINOPATHY; INJECTION
AB Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME).
   Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME.
   Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7--9.3 years were included in this analysis.
   Intervention: Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated- measures analysis of variance was used to compare mean values.
   Main Outcome Measures: Changes in BCVA, OCT, and FA.
   Results: Mean follow-up was 6.31 +/- 0.81 months (range, 6-9). Sixteen (20.5%) eyes needed a second injection at a mean of 13.8 weeks (range, 4-28), and 6 eyes needed a third injection (7.7%) at a mean of 11.5 weeks (range, 5-20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of resolution), and the final mean BCVA was 0.6, a difference that was statistically significant (P < 0.0001). Final BCVA analysis by subgroups demonstrated that 32 (41.1%) eyes remained stable, 43 (55.1 %) improved >= 2 ETDRS lines of BCVA, and 3 (3.8%) decreased :2 ETDRS lines of BCVA. Mean central macular thickness at baseline by OCT was 387.0 +/- 182.8 mu m and decreased to a mean of 275.7 +/- 108.3 at end of follow-up (P < 0.0001). No ocular or systemic adverse events were observed.
   Conclusions: Primary intravitreal bevacizumab at doses of 1.25 to 2.5 mg seem to provide stability or improvement in VA, OCT, and FA in DME at 6 months. Follow-up is still short to make any specific treatment recommendations; however, the results appear promising. Evaluation in a multicenter randomized controlled clinical trial with longer follow-up is needed.
C1 Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Caracas 1010A, Venezuela.
   Hosp Dr Luis Sanchez Bulnes, Asociac Evitar Ceguera Mexico, Mexico City, DF, Mexico.
   Inst Cirugia Ocular, San Jose, Costa Rica.
   Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   Univ Puerto Rico, San Juan, PR 00936 USA.
RP Arevalo, JF (corresponding author), Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Edif Ctr Caracas PH-1,Av Panteon, Caracas 1010A, Venezuela.
EM arevalojf@movistar.net.ve
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; Farah, Michel
   Eid E/F-3285-2012; Fromow-Guerra, J. Jans/A-3346-2015
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Farah, Michel Eid E/0000-0001-5951-0193; Fromow-Guerra, J.
   Jans/0000-0001-5335-1275
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BRESNICK GH, 1983, OPHTHALMOLOGY, V90, P1301
   Campochiaro PA, 2004, INVEST OPHTH VIS SCI, V45, P922, DOI 10.1167/iovs.03-0955
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRIS FL, 1984, SURV OPHTHALMOL, V28, P452, DOI 10.1016/0039-6257(84)90227-3
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464
   LEE CM, 1991, OPHTHALMOLOGY, V98, P1594
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Nguyen QD, 2004, INVEST OPHTH VIS SCI, V45, P617, DOI 10.1167/iovs.03-0557
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Pieramici DJ, 2006, RETINA-J RET VIT DIS, V26, P841, DOI 10.1097/01.iae.0000234629.22614.cd
   Richter B, 2004, EVIDENCE BASED OPHTH, P331
   Schachat AP, 2003, OPHTHALMOLOGY, V110, P2073, DOI 10.1016/S0161-6420(03)01004-2
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Strom C, 2005, INVEST OPHTH VIS SCI, V46, P3855, DOI 10.1167/iovs.05-0096
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
NR 31
TC 239
Z9 256
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2007
VL 114
IS 4
BP 743
EP 750
DI 10.1016/j.ophtha.2006.12.028
PG 8
WC Ophthalmology
SC Ophthalmology
GA 153MU
UT WOS:000245440400021
PM 17398322
DA 2020-12-15
ER

PT J
AU Pessoa, BBGD
   Cavalcante, BBM
   Maia, MP
   Ribeiro, HH
   Koike, MK
   Pessoa, SGD
   Pinheiro, LGP
   Montero, EFD
AF Gomes De Pinho Pessoa, Breno Bezerra
   Menezes Cavalcante, Bruno Bezerra
   Maia, Munique Pinheiro
   Ribeiro Filho, Haroldo H.
   Koike, Marcia Kiyomi
   De Pinho Pessoa, Salustiano Gomes
   Porto Pinheiro, Luiz Gonzaga
   De Souza Montero, Edna Frasson
TI Effect of tamoxifen on arterial microvascular anastomosis
SO MICROSURGERY
LA English
DT Article; Proceedings Paper
CT 8th Congress of the International-Society-of-Experimental-Microsurgery
CY JUL 19, 2006
CL Montreal, CANADA
SP Int Soc Expt Micrsurg
ID BREAST-CANCER; ADJUVANT TAMOXIFEN; VENOUS THROMBOSIS; WOMEN; THERAPY;
   TRIAL; OUTCOMES; PROTEIN
AB Breast reconstruction after cancer treatment is based on the circulation of pedicle and microvascular flaps. This article aimed to verify the effect of tamoxifen (TMX) pretreatment in arterial anastomosis in rats. Twenty female Wistar rats were equally divided into two groups. TMX (0.3 mg/kg) was administered to the experimental group for 2 weeks orally. After this period, the right femoral artery was sectioned and a terminoterminal anastomosis performed. The same procedure was done in the control group, except that the animals received the vehicle without TMX. One week later, the femoral arteries were inspected for flow through the anastomosis, and the vessel near it was sent to light microscopic examination. It was observed mild vasculite in both groups. The intimal thickness and total vessel wall in the TMX-treated group was significantly higher. A real thrombotic effect upon the arterial vascular anastomosis was not observed, eventhough, TMX induced intimal hyperplasia. (C) 2007 Wiley-Liss, Inc. Microsurgery 27:286-288, 2007.
C1 Univ Fed Ceara, Div Plast Surg, Dept Surg, Fortaleza, Ceara, Brazil.
   Univ Sao Paulo, Div Clin Med, Clin Emergency Lab, BR-09500900 Sao Paulo, Brazil.
   Univ Fed Ceara, Dept Surg, Div Mastol, Fortaleza, Ceara, Brazil.
   Univ Fed Sao Paulo, Dept surg, Div Surg Tech & Expt Surg, Sao Paulo, Brazil.
RP Pessoa, BBGD (corresponding author), Rua Vicente Castro Filho,1540 Agua Fria Fortaleza, Ceara, Brazil.
EM breno_gpp@yahoo.com.br
RI Montero, Edna FS/H-9846-2014; Maia, Mauricio/I-5892-2015; Maia,
   Mauricio/Z-1042-2019; Koike, Marcia K/K-1841-2013; de Souza Montero,
   Edna Frasson/D-8930-2012
OI Montero, Edna FS/0000-0003-1437-1219; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091; Koike,
   Marcia K/0000-0002-5556-8061; de Souza Montero, Edna
   Frasson/0000-0003-1437-1219
CR Bonanni B, 2003, J THROMB HAEMOST, V1, P2149, DOI 10.1046/j.1538-7836.2003.00392.x
   Cushman M, 2003, BRIT J HAEMATOL, V120, P109, DOI 10.1046/j.1365-2141.2003.03976.x
   Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2
   DESHMUKH N, 1995, CANCER, V76, P1006, DOI 10.1002/1097-0142(19950915)76:6<1006::AID-CNCR2820760614>3.0.CO;2-K
   Freedman AN, 2003, JNCI-J NATL CANCER I, V95, P526, DOI 10.1093/jnci/95.7.526
   Garvey PB, 2006, PLAST RECONSTR SURG, V117, P1711, DOI 10.1097/01.prs.0000210679.77449.7d
   JORDAN VC, 1994, LONG TERM TAMOXIFEN, P3
   MANCOLL JS, 1996, SURG FORUM, V47, P717
   Mauriac L, 2006, BEST PRACT RES CL EN, V20, pS15, DOI 10.1016/j.beem.2006.10.003
   MCDONALD CC, 1995, BRIT MED J, V311, P977
   McNamara D A, 2003, Colorectal Dis, V5, P335, DOI 10.1046/j.1463-1318.2003.00452.x
   McNamara DA, 2001, EUR J SURG ONCOL, V27, P714, DOI 10.1053/ejso.2001.1177
   SAPHNER T, 1991, J CLIN ONCOL, V9, P286, DOI 10.1200/JCO.1991.9.2.286
   *SEER, 2003, SEER CANC STAT REV
   STEWART HJ, 1987, LANCET, V2, P171
   Weitz IC, 1997, CANCER, V79, P2024, DOI 10.1002/(SICI)1097-0142(19970515)79:10<2024::AID-CNCR25>3.0.CO;2-V
   WILSON CB, 1987, CLIN RADIOL, V38, P95, DOI 10.1016/S0009-9260(87)80425-7
NR 17
TC 7
Z9 7
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0738-1085
EI 1098-2752
J9 MICROSURG
JI Microsurgery
PY 2007
VL 27
IS 4
BP 286
EP 288
DI 10.1002/micr.20357
PG 3
WC Surgery
SC Surgery
GA 175JZ
UT WOS:000247011200019
PM 17477413
DA 2020-12-15
ER

PT J
AU Javaheri, M
   Fujii, GY
   Rossi, JV
   Panzan, CQ
   Yanai, D
   Lakhanpal, RR
   Maia, M
   Khurana, RN
   Guven, D
   De Juan, E
   Humayun, MS
AF Javaheri, Michael
   Fujii, Gildo Y.
   Rossi, Juliana V.
   Panzan, Carla Q.
   Yanai, Douglas
   Lakhanpal, Rohit R.
   Maia, Mauricio
   Khurana, Rahul N.
   Guven, Dilek
   De Juan, Eugene, Jr.
   Humayun, Mark S.
TI Effect of oxygenated intraocular irrigation solutions on the
   electroretinogram after vitrectomy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology
CY MAY 04-09, 2003
CL FT LAUDERDALE, FL
SP Assoc Res Vis & Ophthalmol
DE balanced salt solution; balanced salt solution-plus; electroretinogram;
   oxidative stress; retina; vitreoretinal surgery
ID LACTATED RINGERS SOLUTION; ISCHEMIC RETINA; BSS PLUS; BARRIER; LENS; EYE
AB Purpose: To investigate the effect of oxygenated intraocular irrigating solutions on electroretinograms (ERGs) for postvitrectomy rabbits.
   Methods: Eight groups of five rabbits each underwent pars plana vitrectomy on the right eye; the left eye of each rabbit served as control. The intraocular irrigating solutions were balanced salt solution (BSS), BSS-plus, BSS + oxygen (BSS + O-2), BSS-plus + O-2 and combinations of each with the addition of endoillumination (L). All animals were evaluated by single-flash scotopic electroretinography on the operated and nonoperated eyes before surgery and at 1 hour, 1 day, 1 week, and 1 month after surgery by an unmasked observer. The main outcome measures were dark-adapted b-wave amplitudes of operated eye/nonoperated eye ratios. The results for the different groups were compared by analysis of variance.
   Results: Mean dark-adapted b-wave amplitudes of operated eye/nonoperated eye ratios +/- SD for BSS-plus and BSS-plus + O-2 before surgery and 1 hour, 1 day, 1 week, and 1 month after surgery were 1.01 +/- 0.09, 0.50 +/- 0.11, 0.95 +/- 0.11, 0.97 +/- 0.11, and 0.99 +/- 0.08 and 0.98 +/- 0.08, 0.59 +/- 0.10, 0.92 +/- 0.06, 0.97 +/- 0.08, and 0.97 +/- 0.10, respectively. At both 1 hour and 1 day after surgery, rabbits treated with BSS-plus + O-2 had an earlier b-wave return to baseline findings, but the differences were not statistically significant (P > 0.05). Mean dark-adapted b-wave amplitudes of operated eye/nonoperated eye ratios +/- SD for BSS and BSS + O-2 before surgery and 1 hour, 1 day, 1 week, and 1 month after surgery were 1.02 +/- 0.10, 0.47 +/- 0.09, 0.77 +/- 0.07, 0.89 +/- 0.07, and 0.89 +/- 0.07 and 1.02 +/- 0.06, 0.62 +/- 0.16, 0.94 +/- 0.09, 0.97 +/- 0.08, and 0.96 +/- 0.06, respectively. One hour and 1 day after surgery, ERG readings for rabbits treated with BSS + O-2 exhibited a statistically significantly earlier return of ERG voltage to baseline values compared with both BSS and BSS + L (P = 0.05 and P = 0.02, respectively). One day after surgery, rabbits treated with BSS alone had the lowest ERG ratios. One week and 1 month after surgery, for all solutions tested other than BSS, ERG values were within normal limits.
   Conclusion: The use of oxygenated solutions appears to affect ERG readings after pars plana vitrectomy. Further studies to evaluate the role of oxygenated solutions in different vitreoretinal surgical procedures are warranted.
C1 Univ So Calif, Keck Sch Med, Doheny Eye Inst, Dohena Retina Inst,Dept Ophthalmol, Los Angeles, CA 90033 USA.
   Univ Fed Sao Paulo, Paulista Sch Med, Sao Paulo, Brazil.
RP Humayun, MS (corresponding author), Univ So Calif, Keck Sch Med, Doheny Eye Inst, Dohena Retina Inst,Dept Ophthalmol, 1355 San Pablo St,DVRC 100, Los Angeles, CA 90033 USA.
EM humayun@usc.edu
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Khurana, Rahul/0000-0001-5198-1353
FU NATIONAL EYE INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Eye
   Institute (NEI) [P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040, P30EY003040, P30EY003040, P30EY003040, P30EY003040,
   P30EY003040] Funding Source: NIH RePORTER; NEI NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Eye Institute (NEI) [EY03040] Funding Source: Medline
CR ALVAREZ MAS, 1987, CURR EYE RES, V6, P1369, DOI 10.3109/02713688709044500
   ARAIE M, 1990, ARCH OPHTHALMOL-CHIC, V108, P882, DOI 10.1001/archopht.1990.01070080126049
   Araie M, 1997, BRIT J OPHTHALMOL, V81, P150, DOI 10.1136/bjo.81.2.150
   BENNUN J, 1988, INVEST OPHTH VIS SCI, V29, P298
   Cappiello M, 2000, EXP EYE RES, V70, P795, DOI 10.1006/exer.2000.0838
   EDELHAUSER HF, 1978, ARCH OPHTHALMOL-CHIC, V96, P516, DOI 10.1001/archopht.1978.03910050284021
   EDELHAUSER HF, 1976, AM J OPHTHALMOL, V81, P473, DOI 10.1016/0002-9394(76)90304-4
   Giblin FJ, 2000, J OCUL PHARMACOL TH, V16, P121, DOI 10.1089/jop.2000.16.121
   KHURANA RN, 2006, IN PRESS RETINA
   Kitamura K, 1998, JPN J OPHTHALMOL, V42, P275, DOI 10.1016/S0021-5155(98)00019-7
   Lu Lin, 2003, Yan Ke Xue Bao, V19, P33
   MANZANAS LL, 1992, OPHTHALMIC RES, V24, P61, DOI 10.1159/000267148
   MOORHEAD LC, 1979, AM J OPHTHALMOL, V88, P239, DOI 10.1016/0002-9394(79)90472-0
   NEGI A, 1982, ARCH OPHTHALMOL-CHIC, V100, P1839
   NIEMEYER G, 1977, A GRAEF ARCH KLIN EX, V203, P209, DOI 10.1007/BF00409827
   NUYTS RMMA, 1995, GRAEF ARCH CLIN EXP, V233, P655, DOI 10.1007/BF00185287
   PUCKETT TR, 1995, OPHTHALMOLOGY, V102, P291
   RINKOFF J, 1986, AM J OPHTHALMOL, V102, P452, DOI 10.1016/0002-9394(86)90073-5
   ROSENFELD SI, 1986, OPHTHALMOLOGY, V93, P109
   TEXTORIUS O, 1986, DOC OPHTHALMOL, V63, P349
   WILSON CA, 1995, INVEST OPHTH VIS SCI, V36, P131
   WILSON CA, 1994, ARCH OPHTHALMOL-CHIC, V112, P839, DOI 10.1001/archopht.1994.01090180139048
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Yusifov, 2000, Pathophysiology, V7, P203, DOI 10.1016/S0928-4680(00)00051-1
NR 24
TC 11
Z9 11
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2007
VL 27
IS 1
BP 87
EP 94
DI 10.1097/01.iae.0000256665.79487.a4
PG 8
WC Ophthalmology
SC Ophthalmology
GA 175AS
UT WOS:000246985000015
PM 17218921
DA 2020-12-15
ER

PT J
AU O'Hearn, TM
   Sadda, SR
   Weiland, JD
   Maia, M
   Margalit, E
   Humayun, MS
AF O'Hearn, Thomas M.
   Sadda, Srinivas R.
   Weiland, James D.
   Maia, Mauricio
   Margalit, Eyal
   Humayun, Mark S.
TI Electrical stimulation in normal and retinal degeneration (rd1) isolated
   mouse retina
SO VISION RESEARCH
LA English
DT Article
DE electrophysiology; rd1; mouse
ID GANGLION-CELLS; MICE; PHOTORECEPTORS; PRESERVATION; PROSTHESIS;
   PIGMENTOSA; NEURONS
AB Stimulus threshold and response latencies were measured for electrically elicited retinal ganglion cell responses in retina isolated from the eyes of normal and retinal degenerate (rd1) mice. Stimulation of the ganglion cell-side in normal retina yielded a significantly lower mean threshold and shorter latency when compared with stimulation of the photoreceptor side in normal retina. The latency of the ganglion cell-side stimulation in normal retina also proved to be significantly shorter than the latency for stimulation of the ganglion cell side in rd1 retina. Thus both the electrode positioning as well as the health of the retinal tissue play a role in the stimulating current required to elicit a retinal response. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90089 USA.
   Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD 21218 USA.
RP O'Hearn, TM (corresponding author), Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90089 USA.
EM ohearn@usc.edu
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Weiland, James/0000-0003-3453-9074
CR BEEBE X, 1988, IEEE T BIO-MED ENG, V35, P494, DOI 10.1109/10.2122
   BRUCKNER R, 1951, Doc Ophthalmol, V5-6, P452, DOI 10.1007/BF00143667
   CALEY DW, 1972, AM J ANAT, V133, P179, DOI 10.1002/aja.1001330205
   CARTERDAWSON LD, 1978, INVEST OPHTH VIS SCI, V17, P489
   Chow AY, 1997, NEUROSCI LETT, V225, P13, DOI 10.1016/S0304-3940(97)00185-7
   DRAGER UC, 1978, J COMP NEUROL, V180, P85, DOI 10.1002/cne.901800107
   Eckmiller R, 1997, OPHTHALMIC RES, V29, P281, DOI 10.1159/000268026
   GRAFSTEI.B, 1972, BRAIN RES, V44, P37, DOI 10.1016/0006-8993(72)90364-2
   Grumet AE, 2000, J NEUROSCI METH, V101, P31, DOI 10.1016/S0165-0270(00)00246-6
   HAMPTON R, 1992, AGE RELATED MACULAR
   HECKENLIVELY J, 1998, DIAGNOSIS CLASSIFICA
   Humayun MS, 1998, EYE, V12, P605, DOI 10.1038/eye.1998.151
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Jensen RJ, 2005, J NEURAL ENG, V2, pS16, DOI 10.1088/1741-2560/2/1/003
   KUFFLER SW, 1953, J NEUROPHYSIOL, V16, P37
   Mahadevappa M, 2005, IEEE T NEUR SYS REH, V13, P201, DOI 10.1109/TNSRE.2005.848687
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Northmore DPM, 1998, J PHYSIOL-LONDON, V506, P207, DOI 10.1111/j.1469-7793.1998.207bx.x
   Radner W, 2002, INVEST OPHTH VIS SCI, V43, P3053
   Rizzo JF, 1997, NEUROSCIENTIST, V3, P251, DOI 10.1177/107385849700300413
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Soucy E, 1998, NEURON, V21, P481, DOI 10.1016/S0896-6273(00)80560-7
   Strettoi E, 2000, P NATL ACAD SCI USA, V97, P11020, DOI 10.1073/pnas.190291097
   TANSLEY K, 1951, BRIT J OPHTHALMOL, V35, P573, DOI 10.1136/bjo.35.10.573
   WARD R, 1982, REV CAN BIOL EXPTL, V41, P115
   Yazulla S, 1997, VISION RES, V37, P3471, DOI 10.1016/S0042-6989(96)00223-4
   Zrenner E, 1999, VISION RES, V39, P2555, DOI 10.1016/S0042-6989(98)00312-5
NR 30
TC 48
Z9 48
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
J9 VISION RES
JI Vision Res.
PD OCT
PY 2006
VL 46
IS 19
BP 3198
EP 3204
DI 10.1016/j.visres.2006.03.031
PG 7
WC Neurosciences; Ophthalmology; Psychology
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 082PM
UT WOS:000240398800012
PM 16723150
DA 2020-12-15
ER

PT J
AU Scaranelo, AM
   Maia, MDR
AF Scaranelo, Anabel Medeiros
   Ribeiro Maia, Maria de Fatima
TI Sonographic and mammographic findings of breast liquid silicone
   injection
SO JOURNAL OF CLINICAL ULTRASOUND
LA English
DT Article
DE breast; silicone; sonography; mammography; foreign bodies
ID IMPLANT RUPTURE; US
AB Purpose. To describe the sonographic and mammographic features of patients whose breasts have been injected with silicone.
   Methods. Between July 1997 and August 1999, 14 patients with a history of breast injection of liquid silicone underwent physical, mammographic, and sonographic examination. Mammographic findings were classified as macronodular, micronodular, or mixed striated patterns. Sonographic appearances were classified as macronodular, micronodular, mixed, or snowstorm patterns.
   Results. Eighty-six percent of the patients had abnormal physical examination. Well-defined nodules were palpable in 4 patients, 6 patients had diffusely heterogeneous breasts on palpation, and 2 patients had a combination of heterogeneous texture with dominant nodules. Sonographic examination revealed the presence of marked echogenicity (i.e., snowstorm pattern) in all 14 patients; in 11 patients it was associated with macronodules and/or micronodules, whereas in 3 patients only snowstorm appearance was noted. Mammographic patterns were macronodular in 7 patients and mixed macronodular and micronodular in 6 patients.
   Conclusions. Both mammography and sonography can help identify free silicone injected directly into the breast. (C) 2006 Wiley Periodicals, Inc.
C1 Univ Fed Sao Paulo, UNIFESP, EPM Paulista Sch Med, Dept Diagnost Imaging, BR-04024002 Sao Paulo, Brazil.
   Univ Fed Rio de Janeiro, Gynecol Inst, BR-20211340 Rio De Janeiro, Brazil.
RP Scaranelo, AM (corresponding author), Univ Fed Sao Paulo, UNIFESP, EPM Paulista Sch Med, Dept Diagnost Imaging, Rua Napoleao de Barros 800, BR-04024002 Sao Paulo, Brazil.
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; Scaranelo,
   Anabel/J-4993-2013
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Scaranelo, Anabel/0000-0002-0326-412X
CR COLEBEUGLET C, 1983, RADIOLOGY, V146, P737, DOI 10.1148/radiology.146.3.6828690
   Elia L, 1989, Minerva Chir, V44, P2013
   FORNAGE BD, 2000, ANATOMIC VARIANTS DI, P153
   Fox LP, 2004, J AM ACAD DERMATOL, V50, P450, DOI 10.1016/j.jaad.2003.09.008
   Gutierrez L, 2002, REV MED CHILE, V130, P793, DOI 10.4067/S0034-98872002000700012
   HABAL MB, 1984, ARCH SURG-CHICAGO, V119, P843
   HARRIS KM, 1993, RADIOLOGY, V187, P761, DOI 10.1148/radiology.187.3.8497626
   LEIBMAN AJ, 1994, ANN PLAS SURG, V33, P412, DOI 10.1097/00000637-199410000-00009
   LETTERMAN G, 1976, PLASTIC RECONSTRUCTI, P3
   LEVINE RA, 1991, PLAST RECONSTR SURG, V87, P1126, DOI 10.1097/00006534-199106000-00019
   ROSCULET KA, 1992, AM J ROENTGENOL, V159, P711, DOI 10.2214/ajr.159.4.1529833
   RUBIN JM, 1994, RADIOLOGY, V190, P583, DOI 10.1148/radiology.190.2.8284424
   Scaranelo Anabel Medeiros, 2004, Sao Paulo Med. J., V122, P41, DOI 10.1590/S1516-31802004000200002
   TEIMOURIAN B, 1983, PLAST RECONSTR SURG, V72, P905, DOI 10.1097/00006534-198312000-00037
   Wang J, 2002, ANN PLAS SURG, V48, P617, DOI 10.1097/00000637-200206000-00009
NR 15
TC 18
Z9 18
U1 1
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0091-2751
J9 J CLIN ULTRASOUND
JI J. Clin. Ultrasound
PD JUL-AUG
PY 2006
VL 34
IS 6
BP 273
EP 277
DI 10.1002/jcu.20235
PG 5
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 061QI
UT WOS:000238887000002
PM 16788958
DA 2020-12-15
ER

PT J
AU Uno, F
   Malerbi, F
   Maia, M
   Farah, ME
   Maia, A
   Magalhaes, O
AF Uno, Fausto
   Malerbi, Fernando
   Maia, Mauricio
   Farah, Michel Eid
   Maia, Andre
   Magalhaes, Octaviano, Jr.
TI Subretinal trypan blue migration during epiretinal membrane peeling
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE trypan blue; epiretinal membrane; macular hole; retinal pigment
   epithelium; vitreoretinal surgery; toxicity; subretinal drug delivery
ID INTERNAL LIMITING MEMBRANE
C1 Univ Fed Sao Paulo, Paulista Sch Med, Vis Inst, BR-04023062 Sao Paulo, Brazil.
RP Maia, M (corresponding author), Univ Fed Sao Paulo, Paulista Sch Med, Vis Inst, Rua Botucatu 862, BR-04023062 Sao Paulo, Brazil.
EM retina@femanet.com.br
RI Maia, Mauricio/Z-1042-2019; Farah, Michel Eid E/F-3285-2012; Malerbi,
   Fernando/AAD-3827-2019; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091
CR Hirata A, 2003, AM J OPHTHALMOL, V136, P353, DOI 10.1016/S0002-9394(03)00121-1
   Li K, 2003, BRIT J OPHTHALMOL, V87, P216, DOI 10.1136/bjo.87.2.216
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P157, DOI 10.1097/00006982-200402000-00024
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Veckeneer M, 2001, GRAEF ARCH CLIN EXP, V239, P698, DOI 10.1007/s004170100341
NR 5
TC 15
Z9 18
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2006
VL 26
IS 2
BP 237
EP 239
DI 10.1097/00006982-200602000-00026
PG 3
WC Ophthalmology
SC Ophthalmology
GA 050KS
UT WOS:000238086900026
PM 16467691
DA 2020-12-15
ER

PT J
AU Magalhaes, O
   Maia, M
   Farah, ME
   Principe, AH
   Penha, FM
   Maia, A
   Freymuller, E
AF Magalhaes, O
   Maia, M
   Farah, ME
   Principe, AH
   Penha, FM
   Maia, A
   Freymuller, E
TI Effects of subretinal injection of hyposmolar solutions of indocyanine
   green 0.05%, trypan blue 0.15% and glucose 5% in rabbits
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Meeting of the Association-for-Research-in-Vision-and-Ophthalmology
   (ARVO 2005)
CY MAY 01-05, 2005
CL Ft Lauderdale, FL
SP Assoc Res Vision Ophthalmol
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012; Penha,
   Fernando M/G-1784-2012
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PY 2005
VL 46
SU S
MA 5364
PG 1
WC Ophthalmology
SC Ophthalmology
GA 911CZ
UT WOS:000227980405674
DA 2020-12-15
ER

PT J
AU Maia, M
   Malerbi, FK
   Farah, ME
   Maia, A
   Bardal, AEC
   Penha, FM
   Magalhaes, O
   Meirelles, R
AF Maia, M
   Malerbi, FK
   Farah, ME
   Maia, A
   Bardal, AEC
   Penha, FM
   Magalhaes, O
   Meirelles, R
TI Radial optic neurotomy associated with intravitreous triamcinolone
   injection: An alternative approach for central retinal vein occlusion
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Meeting of the Association-for-Research-in-Vision-and-Ophthalmology
   (ARVO 2005)
CY MAY 01-05, 2005
CL Ft Lauderdale, FL
SP Assoc Res Vision Ophthalmol
C1 Escola Paulista Med, Sao Paulo, Brazil.
RI Malerbi, Fernando/AAD-3827-2019; Maia, Mauricio/I-5892-2015; Farah,
   Michel Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PY 2005
VL 46
SU S
MA 4029
PG 1
WC Ophthalmology
SC Ophthalmology
GA 911CZ
UT WOS:000227980404322
DA 2020-12-15
ER

PT J
AU Penha, FM
   Maia, M
   Principe, AH
   Farah, ME
   Maia, A
   Magalhaes, O
   Freymuller, E
AF Penha, FM
   Maia, M
   Principe, AH
   Farah, ME
   Maia, A
   Magalhaes, O
   Freymuller, E
TI Effects of subretinal injection of indocyanine green 0.05%, trypan blue
   0.15% and glucose 0.5% in rabbits
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Meeting of the Association-for-Research-in-Vision-and-Ophthalmology
   (ARVO 2005)
CY MAY 01-05, 2005
CL Ft Lauderdale, FL
SP Assoc Res Vision Ophthalmol
RI Farah, Michel Eid E/F-3285-2012; Penha, Fernando M/G-1784-2012; Maia,
   Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PY 2005
VL 46
SU S
MA 5359
PG 1
WC Ophthalmology
SC Ophthalmology
GA 911CZ
UT WOS:000227980405669
DA 2020-12-15
ER

PT J
AU Mire-Sluis, AR
   Barrett, YC
   Devanarayan, V
   Koren, E
   Liu, H
   Maia, M
   Parish, T
   Scott, G
   Shankar, G
   Shores, E
   Swanson, SJ
   Taniguchi, G
   Wierda, D
   Zuckerman, LA
AF Mire-Sluis, AR
   Barrett, YC
   Devanarayan, V
   Koren, E
   Liu, H
   Maia, M
   Parish, T
   Scott, G
   Shankar, G
   Shores, E
   Swanson, SJ
   Taniguchi, G
   Wierda, D
   Zuckerman, LA
TI Recommendations for the design and optimization of immunoassays used in
   the detection of host antibodies against biotechnology products
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE assays; antibody; immunogenicity
AB Most biopharmaceutical therapeutics elicit some level of antibody response against the product. This antibody response can, in some cases, lead to potentially serious side effects and/or loss of efficacy. Therefore, the immunogenicity of therapeutic proteins is a concern for clinicians, manufacturers and regulatory agencies. In order to assess immunogenicity of these molecules, appropriate detection, quantitation and characterization of antibody responses are necessary. Inadequately designed antibody assays have led to the hampering of product development or, during licensure, post-marketing commitments. This document provides scientific recommendations based on the experience of the authors for the development of anti-product antibody immunoassays intended for preclinical or clinical studies. While the main focus of this document is assay design considerations, we provide scientific focus and background to the various assay performance parameters necessary for developing a valid assay. Sections on assay performance parameters, including those that appear in regulatory guidances, are contained in this manuscript. (C) 2004 Elsevier B.V. All rights reserved.
C1 US FDA, Ctr Drug Evaluat & Res, Off Biotechnol Prod, Rockville, MD 20852 USA.
   Bristol Myers Squibb Co, Princeton, NJ 08543 USA.
   Lilly Corp Ctr, Lilly Res Labs, Global Stat Sci, Indianapolis, IN 46285 USA.
   Amgen Inc, Clin Immunol, Thousand Oaks, CA 91320 USA.
   Wyeth Pharmaceut, Pearl River, NY 10965 USA.
   Proctor & Gamble Pharmaceut, Norwich, NY 13346 USA.
   MDS Pharma Sci, Ligand Binding Serv, St Laurent, PQ, Canada.
   Centocor Inc, Dept Clin Pharmacol, Malvern, PA 19355 USA.
   US FDA, Div Therapeut Prot, CDER, Bethesda, MD 20892 USA.
   Biomarin Pharmaceut Inc, Clin Lab Operat, Novato, CA 94949 USA.
   Eli Lilly & Co, Dept Immunotoxicol, Greenfield, IN 46140 USA.
   ZymoGenet Inc, BioAnalyt Res & Dev, Seattle, WA 98102 USA.
RP Mire-Sluis, AR (corresponding author), US FDA, Ctr Drug Evaluat & Res, Off Biotechnol Prod, 5515 Secur Lane,HFD-3,Rm 1011, Rockville, MD 20852 USA.
EM mire-sluisa@cder.fda.gov
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR Findlay JWA, 2000, J PHARMACEUT BIOMED, V21, P1249, DOI 10.1016/S0731-7085(99)00244-7
   Finney D. J., 1978, STAT METHOD BIOL ASS
   *INT COMM HARM, Q2A TEXT VAL AN PROC
   *INT COMM HARM, Q2B TEXT VAL AN PROC
   LEE JW, 2003, BIOMARKERS CLIN DRUG, P119
   US Food and Drug Administration, 2001, GUID IND BIOAN METH
NR 6
TC 418
Z9 432
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD JUN
PY 2004
VL 289
IS 1-2
BP 1
EP 16
DI 10.1016/j.jim.2004.06.002
PG 16
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 842MV
UT WOS:000223009400001
PM 15251407
DA 2020-12-15
ER

PT J
AU Maia, M
   Margalit, E
   Lakhanpal, R
   Tso, MOM
   Grebe, R
   Torres, G
   Eong, KGA
   Farah, ME
   Fujii, GY
   Weiland, J
   De Juan, E
   D'Anna, SA
   Humayun, MS
AF Maia, M
   Margalit, E
   Lakhanpal, R
   Tso, MOM
   Grebe, R
   Torres, G
   Eong, KGA
   Farah, ME
   Fujii, GY
   Weiland, J
   De Juan, E
   D'Anna, SA
   Humayun, MS
TI Effects of intravitreal indocyanine green injection in rabbits
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID INTERNAL LIMITING MEMBRANE; MACULAR HOLE SURGERY; PHOTODYNAMIC THERAPY;
   RETINAL-DETACHMENT; NEOVASCULARIZATION; TOXICITY; REMOVAL; ICG
AB Purpose: To report the clinical, electrophysiologic, and histologic findings of different concentrations of indocyanine green (ICG) injected into the vitreous cavity of rabbit eyes.
   Methods: Forty-two rabbits underwent intravitreal injection of 0.1 mL of ICG in three different concentrations: 0.5 mg/mL (250 mOsm), 5 mg/mL (270 mOsm), and 25 mg/mL (170 mOsm). Fellow eyes were injected with 0.1 mL of balanced salt solution. Biomicroscopy, ophthalmoscopy, electroretinography, fluorescein angiography, and histologic evaluation were performed.
   Results: Eyes injected with 0.5 mg/mL of ICG showed b-wave latency delay on the first day after injection. Eyes injected with 5 mg/mL of ICG showed b-wave latency delay and decreased b-wave amplitude on the first and seventh days after injection; delayed a-wave latency on the first day after injection was also observed. Eyes injected with 25 mg/mL of ICG showed b- and a-wave amplitude and latency abnormalities during the entire followup. Direct correlation of increasing retinal edema proportional to the progressively increasing ICG concentrations was shown on histologic evaluation.
   Conclusion: Intravitreal ICG injection in rabbit eyes may impair retinal function and morphology proportional to the progressively increasing ICG dosages.
C1 Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Retina Inst, Los Angeles, CA 90033 USA.
   Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD 21205 USA.
   Univ Fed Sao Paulo, Paulista Sch Med, Sao Paulo, Brazil.
RP Humayun, MS (corresponding author), Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Retina Inst, 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM humayun@usc.edu
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Weiland, James/0000-0003-3453-9074
CR Abels C, 2000, ARCH DERMATOL RES, V292, P404, DOI 10.1007/s004030000147
   Baumler W, 1999, BRIT J CANCER, V80, P360, DOI 10.1038/sj.bjc.6690363
   Costa RA, 2001, CURR EYE RES, V23, P271, DOI 10.1076/ceyr.23.4.271.5449
   Costa RA, 2001, AM J OPHTHALMOL, V132, P557, DOI 10.1016/S0002-9394(01)01138-2
   DOWLING JE, 1970, INVEST OPHTH VISUAL, V9, P655
   Enaida H, 2002, GRAEF ARCH CLIN EXP, V240, P209, DOI 10.1007/s00417-002-0433-7
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Gandorfer A, 2001, AM J OPHTHALMOL, V132, P431, DOI 10.1016/S0002-9394(01)01087-X
   GUYTON AC, 1971, PHYSIOL REV, V51, P527
   Hanitzsch R, 1999, DOC OPHTHALMOL, V97, P57
   Hikichi T, 1999, RETINA-J RET VIT DIS, V19, P55, DOI 10.1097/00006982-199901000-00009
   IMAI M, 1995, JPN J OPHTHALMOL, V39, P120
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Kadonosono K, 2000, ARCH OPHTHALMOL-CHIC, V118, P1116, DOI 10.1001/archopht.118.8.1116
   Kadonosono K, 2001, AM J OPHTHALMOL, V131, P203, DOI 10.1016/S0002-9394(00)00728-5
   Kurihara K, 1999, GRAEF ARCH CLIN EXP, V237, P648, DOI 10.1007/s004170050292
   Kusaka S, 2001, AM J OPHTHALMOL, V131, P388, DOI 10.1016/S0002-9394(00)00848-5
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P178, DOI 10.1016/S0002-9394(01)00976-X
   Lam DSC, 1999, RETINA-J RET VIT DIS, V19, P478, DOI 10.1097/00006982-199919050-00030
   Liang CP, 1998, AM J OPHTHALMOL, V125, P191, DOI 10.1016/S0002-9394(99)80091-9
   MARMOR MF, 1979, INVEST OPHTH VIS SCI, V18, P1237
   Mester V, 2000, AM J OPHTHALMOL, V129, P769, DOI 10.1016/S0002-9394(00)00358-5
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   Price N, 2000, GASTROINTEST ENDOSC, V51, P438, DOI 10.1016/S0016-5107(00)70445-7
   Weinberger AWA, 2001, GRAEF ARCH CLIN EXP, V239, P388, DOI 10.1007/s004170100267
   WHITANACRE MM, 2001, CURR EYE RES, V9, P725
   Wiechens B, 1998, INT OPHTHALMOL, V22, P133, DOI 10.1023/A:1006137100444
NR 27
TC 57
Z9 61
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2004
VL 24
IS 1
BP 69
EP 79
DI 10.1097/00006982-200402000-00011
PG 11
WC Ophthalmology
SC Ophthalmology
GA 778HU
UT WOS:000189234200011
PM 15076947
DA 2020-12-15
ER

PT J
AU Maia, M
   Kellner, L
   De Juan, E
   Smith, R
   Farah, ME
   Margalit, E
   Lakhanpal, RR
   Grebe, L
   Eong, KGA
   Humayun, MS
AF Maia, M
   Kellner, L
   De Juan, E
   Smith, R
   Farah, ME
   Margalit, E
   Lakhanpal, RR
   Grebe, L
   Eong, KGA
   Humayun, MS
TI Effects of indocyanine green injection on the retinal surface and into
   the subretinal space in rabbits
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID INTERNAL LIMITING MEMBRANE; MACULAR HOLE SURGERY; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL INJECTION; PHOTODYNAMIC THERAPY;
   DETACHMENT; REMOVAL; LIGHT; EYES; STABILIZATION
AB Purpose: To evaluate the effects of indocyanine green (ICG) injection on the retinal surface and into the subretinal space of rabbit eyes.
   Methods: Twenty-two Dutch-belted rabbits underwent two-port vitrectomy followed by injection of ICG (5 mg/mL) on the retinal surface and into the subretinal space. Balanced salt solution (BSS) was also injected subretinally. The locations where ICG was delivered (both epiretinal and subretinal) were exposed to light from an endoilluminator for 7 minutes. The animals were examined at 1, 7, and 14 days after surgery. The eyes were studied by fluorescein angiography as well as light and electron microscopy.
   Results: No damage was observed after epiretinal ICG injection, but subretinal ICG injection resulted in damage to the outer nuclear layer, photoreceptor inner and outer segments, and retinal pigment epithelium. This damage was more severe with longer follow-up. Control experiments without ICG, in which balanced salt solution was injected into the subretinal space or light was delivered on the epiretinal surface, demonstrated only damage to the photoreceptor outer segments.
   Conclusion: Subretinal delivery of ICG (5 mg/mL) in rabbits induces retinal pigment epithelium, photoreceptor inner and outer segment, and outer nuclear layer damage. These mechanisms of damage may explain the retinal pigment epithelium changes that are sometimes seen after ICG-assisted internal limiting membrane peeling in humans.
C1 Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Retina Inst, Los Angeles, CA 90033 USA.
   Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD 21218 USA.
   Univ Fed Sao Paulo, Paulista Sch Med, Sao Paulo, Brazil.
RP Humayun, MS (corresponding author), Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Retina Inst, 1450 San Pablo St,DEI-3620, Los Angeles, CA 90033 USA.
EM humayun@usc.edu
RI Maia, Mauricio/I-5892-2015; Farah, Michel Eid E/F-3285-2012; Maia,
   Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091
CR Abels C, 2000, ARCH DERMATOL RES, V292, P404, DOI 10.1007/s004030000147
   Baumler W, 1999, BRIT J CANCER, V80, P360, DOI 10.1038/sj.bjc.6690363
   Berglin L, 1997, GRAEF ARCH CLIN EXP, V235, P306, DOI 10.1007/BF01739640
   CHANG CJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P880, DOI 10.1001/archopht.1995.01100070054025
   Costa RA, 2001, CURR EYE RES, V23, P271, DOI 10.1076/ceyr.23.4.271.5449
   Costa RA, 2001, AM J OPHTHALMOL, V132, P557, DOI 10.1016/S0002-9394(01)01138-2
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   FULLER D, 1978, AM J OPHTHALMOL, V85, P519, DOI 10.1016/S0002-9394(14)75250-X
   Gandorfer A, 2001, AM J OPHTHALMOL, V132, P431, DOI 10.1016/S0002-9394(01)01087-X
   Imai K, 1998, AM J OPHTHALMOL, V125, P627, DOI 10.1016/S0002-9394(98)00023-3
   Javid CG, 2000, INT OPHTHALMOL CLIN, V40, P225, DOI 10.1097/00004397-200040010-00021
   Kadonosono K, 2000, ARCH OPHTHALMOL-CHIC, V118, P1116, DOI 10.1001/archopht.118.8.1116
   Kadonosono K, 2001, AM J OPHTHALMOL, V131, P203, DOI 10.1016/S0002-9394(00)00728-5
   Kurihara K, 1999, GRAEF ARCH CLIN EXP, V237, P648, DOI 10.1007/s004170050292
   Kusaka S, 2001, AM J OPHTHALMOL, V131, P388, DOI 10.1016/S0002-9394(00)00848-5
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P178, DOI 10.1016/S0002-9394(01)00976-X
   Lam DSC, 1999, RETINA-J RET VIT DIS, V19, P478, DOI 10.1097/00006982-199919050-00030
   LANDSMAN MLJ, 1976, J APPL PHYSIOL, V40, P575
   MAIA M, 2003, ARVO ABSTR
   MARMOR MF, 1979, INVEST OPHTH VIS SCI, V18, P1237
   Mester V, 2000, AM J OPHTHALMOL, V129, P769, DOI 10.1016/S0002-9394(00)00358-5
   MICHELS M, 1995, INT OPHTHALMOL CLIN, V35, P157, DOI 10.1097/00004397-199503540-00013
   Park D W, 1998, Korean J Ophthalmol, V12, P92
   Rajagopalan R, 2000, PHOTOCHEM PHOTOBIOL, V71, P347, DOI 10.1562/0031-8655(2000)071<0347:SOTOTA>2.0.CO;2
   Weinberger AWA, 2001, GRAEF ARCH CLIN EXP, V239, P388, DOI 10.1007/s004170100267
   WHITACRE MM, 1990, CURR EYE RES, V9, P725, DOI 10.3109/02713689008999567
   Wiechens B, 1998, INT OPHTHALMOL, V22, P133, DOI 10.1023/A:1006137100444
NR 27
TC 78
Z9 82
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2004
VL 24
IS 1
BP 80
EP 91
DI 10.1097/00006982-200402000-00012
PG 12
WC Ophthalmology
SC Ophthalmology
GA 778HU
UT WOS:000189234200012
PM 15076948
DA 2020-12-15
ER

PT J
AU Maia, M
   Haller, JA
   Pieramici, DJ
   Margalit, E
   De Juan, E
   Farah, M
   Lakhanpal, RR
   Eong, KGA
   Guven, D
   Humayun, MS
AF Maia, M
   Haller, JA
   Pieramici, DJ
   Margalit, E
   De Juan, E
   Farah, M
   Lakhanpal, RR
   Eong, KGA
   Guven, D
   Humayun, MS
TI Retinal pigment epithelial abnormalities after internal limiting
   membrane peeling guided by indocyanine green staining
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE indocyanine green; internal limiting membrane; macular hole; retinal
   pigment epithelium; vitreoretinal surgery
ID MACULAR HOLE SURGERY
C1 Univ So Calif, Doheny Retina Inst, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD USA.
   Univ Fed Sao Paulo, Paulista Sch Med, Sao Paulo, Brazil.
RP Humayun, MS (corresponding author), Univ So Calif, Doheny Retina Inst, Keck Sch Med, Doheny Eye Inst, 1450 San Pablo St,DEI 3620, Los Angeles, CA 90033 USA.
EM humayun@usc.edu
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019; Farah, Michel
   Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Farah, Michel Eid E/0000-0001-5951-0193
CR Costa RA, 2001, CURR EYE RES, V23, P271, DOI 10.1076/ceyr.23.4.271.5449
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Haritoglou C, 2002, AM J OPHTHALMOL, V134, P661, DOI 10.1016/S0002-9394(02)01751-8
   Javid CG, 2000, INT OPHTHALMOL CLIN, V40, P225, DOI 10.1097/00004397-200040010-00021
   MAIA M, 2003, EFFECTS INTRAVITREAL
   Weinberger AWA, 2001, GRAEF ARCH CLIN EXP, V239, P388, DOI 10.1007/s004170100267
NR 6
TC 43
Z9 45
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2004
VL 24
IS 1
BP 157
EP 160
DI 10.1097/00006982-200402000-00024
PG 4
WC Ophthalmology
SC Ophthalmology
GA 778HU
UT WOS:000189234200024
PM 15076960
DA 2020-12-15
ER

PT J
AU Javaheri, M
   Fujii, GY
   Rossi, JV
   Panzan, CQ
   Yanai, D
   Guven, D
   Maia, M
   de Juan, E
   Humayun, MS
AF Javaheri, M
   Fujii, GY
   Rossi, JV
   Panzan, CQ
   Yanai, D
   Guven, D
   Maia, M
   de Juan, E
   Humayun, MS
TI The effects of various intraocular irrigating solutions on the rabbit
   electroretinogram
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology
CY MAY, 2003
CL FT LAUDERDALE, FLORIDA
SP Assoc Res Vis & Ophthalmol
C1 Univ So Calif, Doheny Eye Inst, Doheny Retina Inst, Keck Sch Med, Los Angeles, CA 90089 USA.
   Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2003
VL 44
SU 1
MA 1905
BP U304
EP U304
PG 1
WC Ophthalmology
SC Ophthalmology
GA 709CH
UT WOS:000184606801855
DA 2020-12-15
ER

PT J
AU Maia, M
   Margalit, E
   Grebe, R
   de Juan, E
   Eong, KGA
   Farah, ME
   Tso, MOM
   Weiland, J
   Fujii, G
   Humayun, MS
AF Maia, M
   Margalit, E
   Grebe, R
   de Juan, E
   Eong, KGA
   Farah, ME
   Tso, MOM
   Weiland, J
   Fujii, G
   Humayun, MS
TI Effects of intravitreal indocyanine green injection in rabbits
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology
CY MAY   04, 2003
CL FT LAUDERDALE, FLORIDA
SP Assoc Res Vis & Ophthalmol
C1 Wilmer Eye Inst, Baltimore, MD USA.
   Doheny Eye Inst, Los Angeles, CA 90033 USA.
   Escola Paulista Med, Sao Paulo, Brazil.
RI Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019; Farah, Michel
   Eid E/F-3285-2012
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Farah, Michel Eid E/0000-0001-5951-0193
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2003
VL 44
SU 2
MA 4445
BP U526
EP U526
PG 1
WC Ophthalmology
SC Ophthalmology
GA 709CK
UT WOS:000184607001905
DA 2020-12-15
ER

PT J
AU Palacio, GL
   Maia, M
   Kellner, L
   de Juan, E
   Smith, R
   Farah, ME
   Margalit, E
   Grebe, L
   Kong, KGA
   Humayun, MS
AF Palacio, GL
   Maia, M
   Kellner, L
   de Juan, E
   Smith, R
   Farah, ME
   Margalit, E
   Grebe, L
   Kong, KGA
   Humayun, MS
TI Effects of indocyanine green delivery over the retinal surface and into
   the subretinal space of rabbits
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology
CY MAY   04, 2003
CL FT LAUDERDALE, FLORIDA
SP Assoc Res Vis & Ophthalmol
C1 Univ Fed Sao Paulo, Sao Paulo, Brazil.
   Wilmer Eye Inst, Baltimore, MD USA.
   Doheny Eye Inst, Los Angeles, CA 90033 USA.
RI Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/I-5892-2015; Maia,
   Mauricio/Z-1042-2019
OI Farah, Michel Eid E/0000-0001-5951-0193; Maia,
   Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2003
VL 44
SU 2
MA 4066
BP U434
EP U434
PG 1
WC Ophthalmology
SC Ophthalmology
GA 709CK
UT WOS:000184607001528
DA 2020-12-15
ER

PT J
AU Margalit, E
   Maia, M
   Weiland, JD
   Greenberg, RJ
   Fujii, GY
   Torres, G
   Piyathaisere, DV
   O'Hearn, TM
   Liu, WT
   Lazzi, G
   Dagnelie, G
   Scribner, DA
   de Juan, E
   Humayun, MS
AF Margalit, E
   Maia, M
   Weiland, JD
   Greenberg, RJ
   Fujii, GY
   Torres, G
   Piyathaisere, DV
   O'Hearn, TM
   Liu, WT
   Lazzi, G
   Dagnelie, G
   Scribner, DA
   de Juan, E
   Humayun, MS
TI Retinal prosthesis for the blind
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE artificial vision; blindness; cortical prosthesis; electrical
   stimulation; electronic implants; macular degeneration; optic nerve;
   optic nerve prosthesis; retina; retinal prosthesis; retinitis
   pigmentosa; visual cortex; visual prosthesis
ID ELECTRICALLY-EVOKED RESPONSE; CENTRAL-NERVOUS-SYSTEM; VISUAL-SYSTEM;
   STIMULUS PARAMETERS; INTRACORTICAL MICROSTIMULATION; SUBRETINAL
   MICROPHOTODIODES; MORPHOMETRIC-ANALYSIS; RETINITIS-PIGMENTOSA; CHARGE
   INJECTION; ELECTRODE ARRAY
AB Most of current concepts for a visual prosthesis are based on neuronal electrical stimulation at different locations along the visual pathways within the central nervous system. The different designs of Visual prostheses are named according to their locations (i.e., cortical, optic nerve, subretinal, and epiretinal). Visual loss caused by outer retinal degeneration in diseases such as retinitis pigmentosa or age-related macular degeneration can be reversed by electrical Stimulation of the retina or the optic nerve (retinal or optic nerve prostheses, respectively). On the other hand, Visual loss caused by inner or whole thickness retinal diseases, eye loss, optic nerve diseases (tumors, ischemia, inflammatory processes etc.), or diseases of the central nervous system (not including diseases of the primary and secondary visual cortices) can be reversed by a cortical visual prosthesis. The intent of this article is to provide an overview of current and future concepts of retinal and optic nerve prostheses. This article will begin with general considerations that are related to all Or most Of visual prostheses and then concentrate on the retinal and optic nerve designs. The authors believe that the field has grown beyond the scope of a single article so cortical prostheses will be described only because of their direct effect oil the concept and technical development of the other prostheses, and this will be done in a more general and historic perspective.. (C) 2002 by Elsevier Science Inc. All rights reserved.
C1 Wilmer Eye Inst, Intraocular Prosthesis Grp, Baltimore, MD USA.
   Second Sight LLC, Valencia, CA USA.
   N Carolina State Univ, Dept Elect & Comp Engn, Raleigh, NC 27695 USA.
   USN, Res Lab, Washington, DC 20375 USA.
RP Humayun, MS (corresponding author), Wilmer Ophthalmol Inst, Maumenee 738,600 N Wolf St, Baltimore, MD 21287 USA.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Weiland, James/0000-0003-3453-9074
FU NEI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Eye Institute (NEI)
   [R24EY12893-01, R209EY11888, R01 EY012843] Funding Source: Medline;
   NATIONAL EYE INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Eye
   Institute (NEI) [R24EY012893, R01EY012843, R24EY012893, R01EY012843,
   R24EY012893, R24EY012893, R01EY012843, R29EY011888, R29EY011888,
   R24EY012893, R01EY012843, R24EY012893, R29EY011888, R29EY011888,
   R29EY011888, R24EY012893, R01EY012843] Funding Source: NIH RePORTER
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   AGNEW WF, 1986, EXP NEUROL, V92, P162, DOI 10.1016/0014-4886(86)90132-9
   ANDERSON DJ, 1989, IEEE T BIO-MED ENG, V36, P693, DOI 10.1109/10.32101
   App E, 1998, ERGONOMICS, V41, P689, DOI 10.1080/001401398186856
   Bach-y-Rita P, 1998, J REHABIL RES DEV, V35, P427
   BAK M, 1990, MED BIOL ENG COMPUT, V28, P257, DOI 10.1007/BF02442682
   BARD AJ, 1980, ELECTROCHEMICAL METH, P213
   BEEBE X, 1988, IEEE T BIO-MED ENG, V35, P494, DOI 10.1109/10.2122
   BEMENT SL, 1969, EXP NEUROL, V24, P171, DOI 10.1016/0014-4886(69)90013-2
   BEMENT SL, 1986, IEEE T BIO-MED ENG, V33, P230, DOI 10.1109/TBME.1986.325895
   BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BOSTOCK H, 1983, J PHYSIOL-LONDON, V341, P59, DOI 10.1113/jphysiol.1983.sp014792
   BRABYN JA, 1982, IEEE T BIO-MED ENG, V29, P285, DOI 10.1109/TBME.1982.324945
   Brindley G., 1965, J PHYSL, V177, P44
   BRINDLEY GS, 1968, J PHYSIOL-LONDON, V196, P479, DOI 10.1113/jphysiol.1968.sp008519
   BRINDLEY GS, 1974, T AM ACAD OPHTHALMOL, V78, pO741
   BRINDLEY GS, 1968, J PHYSIOL-LONDON, V194, pP54
   BROWN WJ, 1977, J NEUROSURG, V47, P366, DOI 10.3171/jns.1977.47.3.0366
   BRUMMER SB, 1977, IEEE T BIO-MED ENG, V24, P59, DOI 10.1109/TBME.1977.326218
   BRUMMER SB, 1975, BIOELECTROCH BIOENER, V2, P13, DOI 10.1016/0302-4598(75)80002-X
   BUCKETT JR, 1988, IEEE T BIO-MED ENG, V35, P897, DOI 10.1109/10.8669
   BUFFET J, 1975, MED PROG TECHNOL, V3, P133
   BULLARA LA, 1983, J NEUROSCI METH, V9, P15, DOI 10.1016/0165-0270(83)90104-8
   BUNKER CH, 1984, AM J OPHTHALMOL, V97, P357, DOI 10.1016/0002-9394(84)90636-6
   BUTTON JOHN, 1962, JOUR IOWA MED SOC, V52, P17
   CHA K, 1992, VISION RES, V32, P1367, DOI 10.1016/0042-6989(92)90229-C
   CHA K, 1992, J OPT SOC AM A, V9, P673, DOI 10.1364/JOSAA.9.000673
   CHA KH, 1992, ANN BIOMED ENG, V20, P439, DOI 10.1007/BF02368135
   CHENG YT, 2000, INT MEMS C, P757
   Chow AY, 1998, OPHTHALMIC RES, V30, P195, DOI 10.1159/000055474
   Chow AY, 1997, NEUROSCI LETT, V225, P13, DOI 10.1016/S0304-3940(97)00185-7
   CHOW AY, 1907, VITRORETINAL SURG TE, P576
   CHOW AY, 2001, SILICON CHIP IMPLANT
   Clark G M, 1995, Ann Otol Rhinol Laryngol Suppl, V166, P111
   Clark GM, 1996, CLIN EXP PHARMACOL P, V23, P766, DOI 10.1111/j.1440-1681.1996.tb01178.x
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DAGNELIE G, IN PRESS OSA TECHNIC
   DAWSON WW, 1977, INVEST OPHTH VIS SCI, V16, P249
   DELCERRO M, 1987, NEUROSCIENCE, V21, P707, DOI 10.1016/0306-4522(87)90032-7
   DINEEN P, 1973, LANCET, V2, P1157
   DJOURNO A, 1957, PRESSE MED, V35, P14
   DOBELLE WH, 1974, J PHYSIOL-LONDON, V243, P553, DOI 10.1113/jphysiol.1974.sp010766
   DOBELLE WH, 1976, NATURE, V259, P111, DOI 10.1038/259111a0
   Dobelle WH, 2000, ASAIO J, V46, P3, DOI 10.1097/00002480-200001000-00002
   Dougherty S H, 1982, Curr Probl Surg, V19, P265
   DOWLING JE, 1987, RETINA APPROACHABLE, P81
   Eckmiller R, 1997, OPHTHALMIC RES, V29, P281, DOI 10.1159/000268026
   Evans D., 1979, APPL OCEAN RES, V1, P3, DOI [DOI 10.1016/0141-1187(79)90003-8), 10.1016/0141-1187(79)90003-8]
   Foerster O., 1929, J PSYCHOL NEUROL, V39, P435
   GEKELER F, 2001, VISION SENSATIONS EN, P77
   Gerding H, 2001, INVEST OPHTH VIS SCI, V42, pS814
   GIRVIN JP, 1979, SENS PROCESS, V3, P66
   GORMAN PH, 1983, IEEE T BIO-MED ENG, V30, P407, DOI 10.1109/TBME.1983.325041
   Greenberg RJ, 1999, IEEE T BIO-MED ENG, V46, P505, DOI 10.1109/10.759051
   GREENBERG RJ, 1998, ANAL ELECT SIMULATIO
   Grill W M, 1998, IEEE Trans Rehabil Eng, V6, P364, DOI 10.1109/86.736150
   Grill WM, 1996, IEEE T BIO-MED ENG, V43, P161, DOI 10.1109/10.481985
   GRILL WM, 1994, ANN BIOMED ENG, V22, P23, DOI 10.1007/BF02368219
   Grumet AE, 2000, J NEUROSCI METH, V101, P31, DOI 10.1016/S0165-0270(00)00246-6
   Guenther E, 1999, VISION RES, V39, P3988, DOI 10.1016/S0042-6989(99)00128-5
   HARPSTER H, 2000, IEEE 13 ANN INT C MI, P335
   HARRIS HI, 1961, PLAST RECONSTR SURG, V28, P81, DOI 10.1097/00006534-196107000-00007
   HEETDERKS WJ, 1988, IEEE T BIO-MED ENG, V35, P323, DOI 10.1109/10.1388
   HENDERSON DC, 1979, T AM SOC ART INT ORG, V25, P367
   Hesse L, 2000, GRAEF ARCH CLIN EXP, V238, P840, DOI 10.1007/s004170000197
   HETKE JF, 1994, IEEE T BIO-MED ENG, V41, P314, DOI 10.1109/10.284959
   HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764
   HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P473, DOI 10.1113/jphysiol.1952.sp004718
   HUMAYUN M, 1994, ARCH OPHTHALMOL-CHIC, V112, P110, DOI 10.1001/archopht.1994.01090130120028
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Humayun MS, 1999, INVEST OPHTH VIS SCI, V40, P143
   JANDERS M, 1996, IEEE 19 INT C EMBS, P1191
   JANSEN B, 1991, ZBL BAKT-INT J MED M, V276, P36
   Jones KE, 1997, IEEE T BIO-MED ENG, V44, P1210, DOI 10.1109/10.649992
   JONES KE, 1992, ANN BIOMED ENG, V20, P423, DOI 10.1007/BF02368134
   Karny H, 1975, Surv Ophthalmol, V20, P47, DOI 10.1016/0039-6257(75)90038-7
   KNIGHTON RW, 1975, J NEUROPHYSIOL, V38, P198
   KNIGHTON RW, 1975, J NEUROPHYSIOL, V38, P185
   KO WH, 1977, MED BIOL ENG COMPUT, V15, P634, DOI 10.1007/BF02457921
   KOVACS GTA, 1992, IEEE T BIO-MED ENG, V39, P893, DOI 10.1109/10.256422
   LILLY JC, 1961, ELECTRICAL STIMULATI, P60
   Liu WT, 2000, IEEE J SOLID-ST CIRC, V35, P1487, DOI 10.1109/4.871327
   Liu WT, 1997, P ANN INT IEEE EMBS, V19, P2303, DOI 10.1109/IEMBS.1997.758824
   Majji AB, 1999, INVEST OPHTH VIS SCI, V40, P2073
   Margalit E, 2000, RETINA-J RET VIT DIS, V20, P469, DOI 10.1097/00006982-200009000-00007
   Margalit E, 2001, INVEST OPHTH VIS SCI, V42, pS814
   MARSHALL SV, 1987, ELECTROMAGNETIC CONC, P58
   Maynard EM, 2001, ANNU REV BIOMED ENG, V3, P145, DOI 10.1146/annurev.bioeng.3.1.145
   Maynard EM, 1997, ELECTROEN CLIN NEURO, V102, P228, DOI 10.1016/S0013-4694(96)95176-0
   MCCREERY DB, 1986, EXP NEUROL, V92, P147, DOI 10.1016/0014-4886(86)90131-7
   MCCREERY DB, 1990, IEEE T BIO-MED ENG, V37, P996, DOI 10.1109/10.102812
   McCreery DB, 1997, IEEE T BIO-MED ENG, V44, P931, DOI 10.1109/10.634645
   MCCREERY DB, 1988, ANN BIOMED ENG, V16, P463, DOI 10.1007/BF02368010
   McCreery DB, 1990, NEURAL PROSTHESES FU, P297
   MCHARDY J, 1980, BIOMATERIALS, V1, P129, DOI 10.1016/0142-9612(80)90034-4
   MEACHIM G, 1982, BIOMATERIALS, V3, P213, DOI 10.1016/0142-9612(82)90022-9
   MONROE R, 2000, EYENET, V4, P14
   MOTZ H, 1986, NEUROSCIENCE, V18, P699, DOI 10.1016/0306-4522(86)90064-3
   NAJAFI K, 1990, IEEE T BIO-MED ENG, V37, P474, DOI 10.1109/10.55638
   Nordhausen CT, 1996, BRAIN RES, V726, P129
   Normann RA, 1999, VISION RES, V39, P2577, DOI 10.1016/S0042-6989(99)00040-1
   OEHMICHEN M, 1983, PROG NEUROPATH, V5, P277
   Peyman G, 1998, OPHTHALMIC SURG LAS, V29, P234
   Piyathaisere DV, 2001, INVEST OPHTH VIS SCI, V42, pS814
   POLLEN DA, 1977, BRAIN BEHAV EVOLUT, V14, P67, DOI 10.1159/000125576
   POTTS AM, 1968, INVEST OPHTH VISUAL, V7, P269
   POTTS AM, 1969, INVEST OPHTH VISUAL, V8, P605
   POTTS AM, 1970, INVEST OPHTH VISUAL, V9, P814
   Pudenz R H, 1975, Surg Neurol, V4, P389
   PUDENZ R H, 1975, Surgical Neurology, V4, P265
   Pudenz R H, 1975, Surg Neurol, V4, P37
   RANCK JB, 1975, BRAIN RES, V98, P417, DOI 10.1016/0006-8993(75)90364-9
   Rattay F, 1998, IEEE T BIO-MED ENG, V45, P766, DOI 10.1109/10.678611
   RITT PJ, 1999, IEEE T BIOMED ENG, V46, P911
   Rizzo JF, 1997, NEUROSCIENTIST, V3, P251, DOI 10.1177/107385849700300413
   Robblee L. S., 1985, MATER RES SOC S P, V55, P303
   ROBBLEE LS, 1980, BIOMATERIALS, V1, P135, DOI 10.1016/0142-9612(80)90035-6
   ROBBLEE LS, 1998, NEURAL PROSTHESIS FU, P25
   ROCHA G, 1992, CRIT REV IMMUNOL, V12, P81
   RONNER SF, 1990, NEURAL PROSTHESES FU, P169
   ROSE TL, 1985, J NEUROSCI METH, V12, P181, DOI 10.1016/0165-0270(85)90001-9
   Ross RD, 1998, ARCH OPHTHALMOL-CHIC, V116, P236
   ROUSCHE PJ, 1992, ANN BIOMED ENG, V20, P413, DOI 10.1007/BF02368133
   RUBINSTEIN JT, 1987, IEEE T BIO-MED ENG, V34, P864, DOI 10.1109/TBME.1987.326007
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   SCHEINBERG LC, 1965, ARCH NEUROL-CHICAGO, V13, P283, DOI 10.1001/archneur.1965.00470030063005
   SCHIERHOLZ J, 1994, BIOMATERIALS, V15, P996, DOI 10.1016/0142-9612(94)90080-9
   Schmidt EM, 1996, BRAIN, V119, P507, DOI 10.1093/brain/119.2.507
   Schubert M. B., 1999, IEEE SMC'99 Conference Proceedings. 1999 IEEE International Conference on Systems, Man, and Cybernetics (Cat. No.99CH37028), P376, DOI 10.1109/ICSMC.1999.812431
   Schubert MB, 1999, SENSOR ACTUAT A-PHYS, V74, P193, DOI 10.1016/S0924-4247(98)00313-6
   Shandurina A. N., 1995, Fiziologiya Cheloveka, V21, P25
   Shandurina A N, 1996, Neurosci Behav Physiol, V26, P137, DOI 10.1007/BF02359417
   Sharma RK, 1999, SURV OPHTHALMOL, V43, P427, DOI 10.1016/S0039-6257(99)00006-5
   SHEPHERD RK, 1993, HEARING RES, V66, P108, DOI 10.1016/0378-5955(93)90265-3
   Shimazu K, 1999, VISION RES, V39, P2251, DOI 10.1016/S0042-6989(98)00331-9
   Shimazu K, 1996, JPN J OPHTHALMOL, V40, P469
   STERLING TD, 1971, VISUAL PROSTHESIS IN, P1
   Stett A, 1999, INVEST OPHTH VIS SCI, V40, pS736
   Stett A, 2000, VISION RES, V40, P1785, DOI 10.1016/S0042-6989(00)00005-5
   STONE JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1634, DOI 10.1001/archopht.1992.01080230134038
   Szlavik RB, 2000, IEEE T BIO-MED ENG, V47, P1202, DOI 10.1109/10.867947
   TANGHE SJ, 1992, IEEE J SOLID-ST CIRC, V27, P1819, DOI 10.1109/4.173111
   TASSIKER GE, 1956, Patent No. 2760483
   Tehovnik EJ, 1996, J NEUROSCI METH, V65, P1, DOI 10.1016/0165-0270(95)00131-X
   TOYODA J, 1984, J GEN PHYSIOL, V84, P915, DOI 10.1085/jgp.84.6.915
   TROYK PR, 1992, IEEE T BIO-MED ENG, V39, P589, DOI 10.1109/10.141197
   Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983
   UEMATSU S, 1974, CONFIN NEUROL, V36, P113
   Veraart C, 1998, BRAIN RES, V813, P181, DOI 10.1016/S0006-8993(98)00977-9
   VERAART C, 1993, IEEE T BIO-MED ENG, V40, P640, DOI 10.1109/10.237694
   Veraart CG, 2001, INVEST OPHTH VIS SCI, V42, pS942
   Von Arx J., 1995, 8th International Conference on Solid-State Sensors and Actuators and Eurosensors IX. Digest of Technical Papers (IEEE Cat. No.95TH8173), P244
   Walter P, 1999, RETINA-J RET VIT DIS, V19, P546, DOI 10.1097/00006982-199911000-00012
   Weiland JD, 1999, GRAEF ARCH CLIN EXP, V237, P1007, DOI 10.1007/s004170050337
   Weiland JD, 2000, IEEE T BIO-MED ENG, V47, P911, DOI 10.1109/10.846685
   WEST DC, 1983, J PHYSIOL-LONDON, V337, P37, DOI 10.1113/jphysiol.1983.sp014610
   WILEY JD, 1982, IEEE T BIO-MED ENG, V29, P381, DOI 10.1109/TBME.1982.324910
   WILSON BS, 1993, J REHABIL RES DEV, V30, P110
   WINTER G, 1980, EVALUATION BIOMATERI
   WISE KD, 1970, IEEE T BIO-MED ENG, VBM17, P238, DOI 10.1109/TBME.1970.4502738
   WISE KD, 1991, SCIENCE, V254, P1335, DOI 10.1126/science.1962192
   Wyatt J, 1996, IEEE SPECTRUM, V33, P47, DOI 10.1109/6.490056
   Yagi T, 1999, Nihon Rinsho, V57, P1208
   YAGI T, 1998, P 1998 IEEE INT JOIN, P780
   YUEN TGH, 1990, NEURAL PROSTHESES FU, P197
   ZAUBERMAN H, 1969, EXP EYE RES, V8, P276, DOI 10.1016/S0014-4835(69)80039-4
   Ziaie B, 1997, IEEE T BIO-MED ENG, V44, P909, DOI 10.1109/10.634643
   Zrenner E, 1999, VISION RES, V39, P2555, DOI 10.1016/S0042-6989(98)00312-5
   Zrenner E, 1997, OPHTHALMIC RES, V29, P269, DOI 10.1159/000268025
NR 171
TC 293
Z9 314
U1 1
U2 78
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JUL-AUG
PY 2002
VL 47
IS 4
BP 335
EP 356
AR PII S0039-6257(02)00311-9
DI 10.1016/S0039-6257(02)00311-9
PG 22
WC Ophthalmology
SC Ophthalmology
GA 581MN
UT WOS:000177296300002
PM 12161210
DA 2020-12-15
ER

PT J
AU Shi, J
   Maia, M
   Efros, L
   Chang, C
   Rice, T
   Li, JM
   Thein, C
   Wang, H
   Woo, J
   Keller, S
   Chen, S
   Bullock, C
   Vexler, V
   Klingbeil, C
AF Shi, J
   Maia, M
   Efros, L
   Chang, C
   Rice, T
   Li, JM
   Thein, C
   Wang, H
   Woo, J
   Keller, S
   Chen, S
   Bullock, C
   Vexler, V
   Klingbeil, C
TI Evaluation of multiple intravenous administration of daclizumab, a SMART
   humanized anti-CD25 antibody, on lymphocyte function in cynomolgus
   monkeys.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Prot Design Labs Inc, Fremont, CA USA.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JUN
PY 2002
VL 103
IS 3
SU S
MA 158
BP S52
EP S52
PN 2
PG 1
WC Immunology
SC Immunology
GA 566QK
UT WOS:000176439600159
DA 2020-12-15
ER

PT J
AU Margalit, E
   Weiland, JD
   Clatterbuck, R
   Fujii, GY
   Maia, M
   Torres, G
   D'anna, SA
   Piyathaisere, DV
   Tameesh, M
   Humayun, MS
AF Margalit, E
   Weiland, JD
   Clatterbuck, R
   Fujii, GY
   Maia, M
   Torres, G
   D'anna, SA
   Piyathaisere, DV
   Tameesh, M
   Humayun, MS
TI Visual and electrical evoked response (VER. EER) recorded from subdural
   or epidural electrodes implanted above the visual cortex in normal dogs
   under two methods of anesthesia
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology
CY MAY 05-10, 2002
CL FT LAUDERDALE, FLORIDA
SP Assoc Res Vis & Ophthalmol
C1 Wilmer Eye Inst, Baltimore, MD USA.
   Doheny Eye Inst, Los Angeles, CA 90033 USA.
   Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2002
VL 43
SU 2
MA 4487
BP U1284
EP U1284
PG 1
WC Ophthalmology
SC Ophthalmology
GA 709CG
UT WOS:000184606701637
DA 2020-12-15
ER

PT J
AU O'Hearn, TM
   Weiland, JD
   Humayun, MS
   Maia, M
   Margalit, E
   Sadda, SR
AF O'Hearn, TM
   Weiland, JD
   Humayun, MS
   Maia, M
   Margalit, E
   Sadda, SR
TI Electrical stimulation of normal and retinal degenerate (rd) isolated
   mouse retina
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology
CY MAY 05-10, 2002
CL FT LAUDERDALE, FLORIDA
SP Assoc Res Vis & Ophthalmol
C1 Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   USC, Doheny Eye Inst, Los Angeles, CA USA.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 1
Z9 1
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2002
VL 43
SU 2
MA 4467
BP U1281
EP U1281
PG 1
WC Ophthalmology
SC Ophthalmology
GA 709CG
UT WOS:000184606701618
DA 2020-12-15
ER

PT J
AU Weiland, JD
   Fujii, GY
   Tameesh, MK
   Margalit, E
   Maia, M
   D'Anna, SA
   Piyathaisere, DV
   de Juan, E
   Greenberg, RJ
   Humayun, MS
AF Weiland, JD
   Fujii, GY
   Tameesh, MK
   Margalit, E
   Maia, M
   D'Anna, SA
   Piyathaisere, DV
   de Juan, E
   Greenberg, RJ
   Humayun, MS
TI Chronic electrical stimulation of the canine retina
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology
CY MAY 05-10, 2002
CL FT LAUDERDALE, FLORIDA
SP Assoc Res Vis & Ophthalmol
C1 Doheny Eye Inst, Los Angeles, CA 90033 USA.
   Wilmer Eye Inst, Baltimore, MD USA.
   Second Sight LLC, Santa Clarita, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2002
VL 43
SU 2
MA 2847
BP U803
EP U803
PG 1
WC Ophthalmology
SC Ophthalmology
GA 709CG
UT WOS:000184606700011
DA 2020-12-15
ER

PT J
AU Eong, KGA
   Fujii, GY
   de Juan, E
   Jensen, PS
   Sommerville, DN
   Shelley, TH
   Barnes, AC
   Maia, M
AF Eong, KGA
   Fujii, GY
   de Juan, E
   Jensen, PS
   Sommerville, DN
   Shelley, TH
   Barnes, AC
   Maia, M
TI A new three-port cannular system for closed pars plana vitrectomy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
C1 Univ So Calif, Keck Sch Med, Los Angeles, CA USA.
RP de Juan, E (corresponding author), Doheny Eye Inst, Doheny Retina Inst, Microsurg Adv Design Lab, 1450 San Pablo St,DEI 3600, Los Angeles, CA 90033 USA.
EM dejuan@usc.edu
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR AUEONG KG, 2001, AGE RELATED MACULAR, P37
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Eong KGA, 2001, AM J OPHTHALMOL, V131, P244, DOI 10.1016/S0002-9394(00)00788-1
   Loewenstein A, 1997, OPHTHALMIC SURG LAS, V28, P774
   MACHEMER R, 1985, AM J OPHTHALMOL, V100, P590, DOI 10.1016/0002-9394(85)90687-7
NR 5
TC 9
Z9 10
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2002
VL 22
IS 1
BP 130
EP 132
DI 10.1097/00006982-200202000-00032
PG 3
WC Ophthalmology
SC Ophthalmology
GA 529BF
UT WOS:000174279600032
PM 11884900
DA 2020-12-15
ER

PT J
AU Maia, M
   Vivier, J
   Hue, D
   Durand, P
   Feige, JJ
   Defaye, G
AF Maia, M
   Vivier, J
   Hue, D
   Durand, P
   Feige, JJ
   Defaye, G
TI Expression of the melanocortin receptors MC2-R (ACTH-receptor) and MC5-R
   during embryonic development of ovine adrenals
SO ENDOCRINE RESEARCH
LA English
DT Article; Proceedings Paper
CT 10th Conference on the Adrenal Cortex
CY JUN 15-18, 2002
CL SAN FRANCISCO, CALIFORNIA
SP Marcel Dekker Inc, Dekker Fdn, Eli Lilly Corp, Invitrogen Life Technol, Adrenal 2000, Univ toronto, Univ Buffalo, Dept Biochem, Univ Cal San Francisco, Dept Biochem
ID MELANOCYTE-STIMULATING HORMONE; ADRENOCORTICOTROPIN; CLONING; FAMILY
AB Two melanocortin receptors MC2-R (ACTH-receptor) and MC5-R are expressed in the adult lamb adrenal cortex. In this work, we have studied the time-course of expression of these two receptors during ovine fetal development. MC2-R expression progressively increases from day 60 to day 140 of gestation (x 3), then more rapidly before parturition and remains constant in the newborn. In contrast, the pattern of MC5-R expression is totally different. A strong increase is observed between days 60 and 120 (x 7) then followed by a decrease until parturition and after birth. This peak of MC5-R expression precedes that of MC2-R, suggesting that MC5-R might be involved in alpha-MSH- and/or ACTH-stimulated corticosteroid synthesis during early embryonic life.
C1 CEA, INSERM EMI 105, Grenoble, France.
   Fac Med Porto, Inst Histol, Oporto, Portugal.
   INRA, Unite PRMD, F-37380 Nouzilly, France.
   Hop Debrousse, INSERM, U418, Lyon, France.
RP Defaye, G (corresponding author), CEA, INSERM EMI 105, Grenoble, France.
RI Feige, Jean-Jacques/M-8905-2017; Maia, Mauricio/I-5892-2015
OI Feige, Jean-Jacques/0000-0002-1354-7692; Maia,
   Mauricio/0000-0002-7034-8091
CR BARRETT P, 1994, J MOL ENDOCRINOL, V12, P203, DOI 10.1677/jme.0.0120203
   Cone RD, 1996, RECENT PROG HORM RES, V51, P287
   DURAND P, 1981, ENDOCRINOLOGY, V108, P2114, DOI 10.1210/endo-108-6-2114
   Liakos P, 2000, MOL CELL ENDOCRINOL, V159, P99, DOI 10.1016/S0303-7207(99)00196-3
   LLANOS AJ, 1979, ENDOCRINOLOGY, V105, P613, DOI 10.1210/endo-105-3-613
   MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670
   RUDMAN D, 1980, J CLIN INVEST, V65, P822, DOI 10.1172/JCI109733
   WEBB P D, 1980, Journal of Developmental Physiology (Eynsham), V2, P161
NR 8
TC 4
Z9 4
U1 0
U2 1
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 0743-5800
J9 ENDOCR RES
JI Endocr. Res.
PY 2002
VL 28
IS 4
BP 631
EP 635
DI 10.1081/ERC-120016977
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 632FU
UT WOS:000180213900057
PM 12530674
DA 2020-12-15
ER

PT J
AU Guimaraes, J
   Maia, M
   Monteiro, E
   Ferraro, A
AF Guimaraes, J
   Maia, M
   Monteiro, E
   Ferraro, A
TI Aesthetic correction of mild pectus excavatum with autologous tissue
   during mastopexy
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID SILICONE IMPLANT CORRECTION; CONGENITAL HEART-DISEASE; FUNNEL CHEST;
   REPAIR; DEFORMITY
C1 Hosp Prelada, Dept Plast Reconstruct & Aesthet Surg, P-4251901 Oporto, Portugal.
RP Maia, M (corresponding author), Hosp Prelada, Dept Plast Reconstruct & Aesthet Surg, Rua Sarmento Beires 153,POB 52857, P-4251901 Oporto, Portugal.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR BAUCHINUS J, 1594, ONSERVATIONIUM MEDIC, V264, P516
   Chen YBT, 1999, MICROSURG, V19, P296
   DeLeon MM, 1997, ANN THORAC SURG, V64, P557, DOI 10.1016/S0003-4975(97)00556-0
   Ehrenhaft J L, 1966, Ann Thorac Surg, V2, P384
   Einsiedel E, 1999, J CARDIOVASC SURG, V40, P733
   Gittes GK, 1999, J PEDIATR SURG, V34, P1282, DOI 10.1016/S0022-3468(99)90170-7
   Hodgkinson DJ, 1997, AESTHET PLAST SURG, V21, P7, DOI 10.1007/s002669900074
   HOUGAARD G, 1995, SCAND J PLAST RECONS, V29, P227, DOI 10.3109/02844319509050131
   Johnson PE, 1996, PLAST RECONSTR SURG, V97, P445, DOI 10.1097/00006534-199602000-00027
   Kowalewski J, 1999, J THORAC CARDIOV SUR, V118, P87, DOI 10.1016/S0022-5223(99)70145-5
   MARKS MW, 1984, PLAST RECONSTR SURG, V74, P52, DOI 10.1097/00006534-198407000-00007
   MORSHUIS W, 1994, CHEST, V105, P1646, DOI 10.1378/chest.105.6.1646
   MURRAY JF, 1965, ANN M AM SOC PLAST R
   OCHSNER A, 1939, J THORACIC SURG, V8, P469
   Paolini A, 1996, Riv Eur Sci Med Farmacol, V18, P11
   RAVITCH MM, 1949, ANN SURG, V129, P429, DOI 10.1097/00000658-194904000-00002
   SAUERBRUCH DF, 1928, CHIRURG BRUSTORGANE, P735
   SHAW WW, 1990, PLASTIC SURG, V6
   Willekes CL, 1999, ANN THORAC SURG, V67, P511, DOI 10.1016/S0003-4975(99)00015-6
   Yamamoto Y, 1997, PLAST RECONSTR SURG, V99, P892, DOI 10.1097/00006534-199703000-00047
NR 20
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0032-1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD SEP 1
PY 2001
VL 108
IS 3
BP 757
EP 761
DI 10.1097/00006534-200109010-00025
PG 5
WC Surgery
SC Surgery
GA 465PG
UT WOS:000170598700025
PM 11698853
DA 2020-12-15
ER

PT J
AU Maia, M
   Haller, JA
   Eong, KGA
   Fujii, G
   Pieramici, D
   Torres, GD
   Margalit, E
   De Juan, E
   Humayun, MS
AF Maia, M
   Haller, JA
   Eong, KGA
   Fujii, G
   Pieramici, D
   Torres, GD
   Margalit, E
   De Juan, E
   Humayun, MS
TI Intravitreal injection of indocyanine green dye during vitreous surgery:
   A technique to aid peeling of the internal limiting membrane and
   epiretinal membrane.
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
C1 Wilmer Eye Inst, Baltimore, MD USA.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR 15
PY 2001
VL 42
IS 4
SU S
MA 922
BP S172
EP S172
PG 1
WC Ophthalmology
SC Ophthalmology
GA 427EP
UT WOS:000168392100913
DA 2020-12-15
ER

PT J
AU Margalit, E
   Weiland, JD
   Clatterbuck, R
   Olivi, A
   D'Anna, SA
   Maia, M
   Fujii, GY
   Torres, G
   Piyathaisere, DV
   de Juan, E
   Humayun, MS
AF Margalit, E
   Weiland, JD
   Clatterbuck, R
   Olivi, A
   D'Anna, SA
   Maia, M
   Fujii, GY
   Torres, G
   Piyathaisere, DV
   de Juan, E
   Humayun, MS
TI Light and electrically evoked response (VER, EER) recorded from
   sub-dural epileptic electrodes implanted above the visual cortex in
   normal dogs.
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
C1 Wilmer Eye Inst, Baltimore, MD USA.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 2
Z9 2
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR 15
PY 2001
VL 42
IS 4
SU S
MA 4367
BP S814
EP S814
PG 1
WC Ophthalmology
SC Ophthalmology
GA 427EP
UT WOS:000168392104330
DA 2020-12-15
ER

PT J
AU Sadda, SR
   Torres, GD
   Maia, M
   Fujii, G
   Grebe, R
   Humayun, M
   de Juan, E
AF Sadda, SR
   Torres, GD
   Maia, M
   Fujii, G
   Grebe, R
   Humayun, M
   de Juan, E
TI Neural retinal transplantation in homozygous CRX-knockout mice.
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
C1 Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD 21218 USA.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR 15
PY 2001
VL 42
IS 4
SU S
MA 4180
BP S780
EP S780
PG 1
WC Ophthalmology
SC Ophthalmology
GA 427EP
UT WOS:000168392104143
DA 2020-12-15
ER

PT J
AU Torres, GD
   Maia, M
   Sadda, SR
   Fujii, G
   Grebe, RR
   Margalit, E
   Weiland, J
   Humayun, M
   de Juan, E
AF Torres, GD
   Maia, M
   Sadda, SR
   Fujii, G
   Grebe, RR
   Margalit, E
   Weiland, J
   Humayun, M
   de Juan, E
TI Long-term preservation of light-responsiveness following neural retinal
   transplantation in rd mice.
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
C1 Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR 15
PY 2001
VL 42
IS 4
SU S
MA 4171
BP S779
EP S779
PG 1
WC Ophthalmology
SC Ophthalmology
GA 427EP
UT WOS:000168392104134
DA 2020-12-15
ER

PT J
AU Weiland, JD
   Maia, M
   Shyu, JS
   O'Hearn, TH
   Margalit, E
   Piyathaisere, DV
   Torres, G
   Humayun, MS
   de Juan, E
AF Weiland, JD
   Maia, M
   Shyu, JS
   O'Hearn, TH
   Margalit, E
   Piyathaisere, DV
   Torres, G
   Humayun, MS
   de Juan, E
TI Parameters of electrical stimulation in isolated rabbit retina
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
C1 Johns Hopkins Univ, Baltimore, MD USA.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 1
Z9 1
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR 15
PY 2001
VL 42
IS 4
SU S
MA 4359
BP S813
EP S813
PG 1
WC Ophthalmology
SC Ophthalmology
GA 427EP
UT WOS:000168392104322
DA 2020-12-15
ER

PT J
AU Golomb, MR
   Durand, ML
   Schaefer, PW
   McDonald, CT
   Maia, M
   Schwamm, LH
AF Golomb, MR
   Durand, ML
   Schaefer, PW
   McDonald, CT
   Maia, M
   Schwamm, LH
TI A case of immunotherapy-responsive eastern equine encephalitis with
   diffusion-weighted imaging
SO NEUROLOGY
LA English
DT Article
ID DISEASES
C1 Massachusetts Gen Hosp, Massachusetts Eye & Ear Infirm, Infect Dis Serv, Boston, MA 02114 USA.
   Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
   Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
   Div Infect Dis Lab, Boston, MA USA.
   Prot Design Labs Inc, Fremont, CA USA.
RP Schwamm, LH (corresponding author), Massachusetts Gen Hosp, Massachusetts Eye & Ear Infirm, Infect Dis Serv, 55 Fruit St,VBK 915, Boston, MA 02114 USA.
RI Schaefer, Pamela/AAA-1323-2019; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Schwamm, Lee/0000-0003-0592-9145;
   Golomb, Meredith/0000-0002-9707-6735
CR Ay H, 1998, NEUROLOGY, V51, P1369, DOI 10.1212/WNL.51.5.1369
   Dalakas MC, 1997, ANN INTERN MED, V126, P721, DOI 10.7326/0003-4819-126-9-199705010-00008
   Deresiewicz RL, 1997, NEW ENGL J MED, V336, P1867, DOI 10.1056/NEJM199706263362604
   FINBERG RW, 1984, NEW ENGL J MED, V311, P1559, DOI 10.1056/NEJM198412133112408
   PRZELOMSKI MM, 1988, NEUROLOGY, V38, P736, DOI 10.1212/WNL.38.5.736
   Sorensen AG, 1996, RADIOLOGY, V199, P391, DOI 10.1148/radiology.199.2.8668784
   Stangel M, 1999, ARCH NEUROL-CHICAGO, V56, P661, DOI 10.1001/archneur.56.6.661
NR 7
TC 17
Z9 17
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD FEB 13
PY 2001
VL 56
IS 3
BP 420
EP 421
DI 10.1212/WNL.56.3.420
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 401DK
UT WOS:000166911700032
PM 11171919
DA 2020-12-15
ER

PT J
AU Eong, KGA
   Pieramici, DJ
   Fujii, GY
   Ng, EWM
   Humayun, MS
   Maia, M
   Harland, JB
   Schachat, AP
   Beatty, S
   Toth, CA
   Thomas, MA
   Lewis, H
   Eckardt, C
   Tano, Y
   de Juan, E
AF Eong, KGA
   Pieramici, DJ
   Fujii, GY
   Ng, EWM
   Humayun, MS
   Maia, M
   Harland, JB
   Schachat, AP
   Beatty, S
   Toth, CA
   Thomas, MA
   Lewis, H
   Eckardt, C
   Tano, Y
   de Juan, E
TI Macular translocation: Unifying concepts, terminology, and
   classification
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RETINAL-PIGMENT EPITHELIUM;
   FOVEAL TRANSLOCATION; SURGICAL-MANAGEMENT; SCLERAL IMBRICATION; RABBIT
   EYE; DEGENERATION; RETINOTOMY; MEMBRANES; SURGERY
AB PURPOSE: To describe some unifying concepts, terminology, and classification of macular translocation so as to facilitate communication within the scientific community.
   METHODS: A panel of ophthalmologists with expertise in macular translocation reviewed available data and developed some unifying concepts, terminology, and classification of macular translocation.
   RESULTS: Macular translocation may be defined as any surgery that has a primary goal of relocating the central neurosensory retina or fovea intraoperatively or postoperatively specifically for the management of macular disease. It may be classified according to the size of the retinotomy and, where applicable, the technique of chorioscleral shortening used. The direction of macular translocation is denoted by the movement of the neurosensory macula relative to the underlying tissues. Effective macular translocation may be defined as successful intraoperative or postoperative relocation of the fovea overlying a subfoveal lesion to an area outside the border of the lesion. The concepts of minimum desired translocation and median postoperative foveal displacement can give some useful idea of the likelihood of effective macular translocation before surgery.
   CONCLUSIONS: Use of a common standardized terminology for macular translocation will facilitate communication within the scientific community and enhance further research in this area. However, the definitions, terms, classification, and concepts concerning macular translocation are likely to continue to evolve as macular translocation undergoes further modifications and refinements. (Am J Ophthalmol 2001; 131:244-253. (C) 2001 by Elsevier Science Inc. All rights reserved).
C1 Johns Hopkins Univ, Johns Hopkins Hosp, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD 21287 USA.
   Moorfields Eye Hosp, London, England.
   Duke Univ, Ctr Eye, Durham, NC USA.
   Barnes Retina Inst, St Louis, MO USA.
   Cleveland Clin Fdn, Div Ophthalmol, Cleveland, OH 44195 USA.
   Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   Frankfurt Hoechst Municipal Hosp, Dept Ophthalmol, Frankfurt, Germany.
   Osaka Univ, Sch Med, Dept Ophthalmol, Osaka, Japan.
RP de Juan, E (corresponding author), Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Bldg Room 719,600 N Wolfe St, Baltimore, MD 21287 USA.
EM edejuan@jhmi.edu
RI toth, cynthia/F-5614-2011; Maia, Mauricio/I-5892-2015; Toth,
   Cynthia/L-5534-2019
OI Maia, Mauricio/0000-0002-7034-8091; Toth, Cynthia/0000-0002-2324-0854
CR Akduman L, 1999, RETINA-J RET VIT DIS, V19, P418, DOI 10.1097/00006982-199909000-00009
   *AM AC OPHTH, 2000, OPHTHALMOLOGY, V107, P1015
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cekic O, 1999, LANCET, V354, P340, DOI 10.1016/S0140-6736(05)75249-1
   de Juan E, 1999, AM J OPHTHALMOL, V128, P380, DOI 10.1016/S0002-9394(99)00142-7
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   EONG KGA, IN PRESS AGE RELATED
   FAUDE F, 1999, RETINA, V12, P173
   FUJII GY, IN PRESS AM J OPHTHA
   Fujikado T, 1998, AM J OPHTHALMOL, V125, P647, DOI 10.1016/S0002-9394(98)00021-X
   Fujikado T, 1998, AM J OPHTHALMOL, V126, P839, DOI 10.1016/S0002-9394(98)00201-3
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HARLAN JB, 1999, WILMER RETINA UPDATE, V5, P3
   HEMELIN NN, 2000, INVEST OPHTHALMOL  S, V41, pS541
   Imai K, 1998, AM J OPHTHALMOL, V125, P627, DOI 10.1016/S0002-9394(98)00023-3
   Imai K., 1996, Investigative Ophthalmology and Visual Science, V37, pS116
   Kamei M, 2000, INVEST OPHTH VIS SCI, V41, pS540
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   LINDSEY P, 1983, INVEST OPHTHALMOL  S, V24, P242
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   Machemer R, 1998, AM J OPHTHALMOL, V125, P698, DOI 10.1016/S0002-9394(98)00020-8
   Meyer CH, 2000, INVEST OPHTH VIS SCI, V41, pS540
   Ng EW, 2000, INVEST OPHTH VIS SCI, V41, pS540
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Ohji M, 1998, Semin Ophthalmol, V13, P52, DOI 10.3109/08820539809066082
   Phillips SJ, 2000, INVEST OPHTH VIS SCI, V41, pS541
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Roider J, 2000, INVEST OPHTH VIS SCI, V41, pS540
   Seaber JH, 1997, GRAEF ARCH CLIN EXP, V235, P76, DOI 10.1007/BF00941733
   Tano Y, 2000, INVEST OPHTH VIS SCI, V41, pS540
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   TIEDEMAN J, 1985, INVEST OPHTHALMOL  S, V26, P59
   TOTH CA, 1999, 15 BIENN EYE RES SEM, P30
   TOTH CA, 1999, AGE RELATED MACULAR, P353
   TSO MOM, 1967, ARCH OPHTHALMOL-CHIC, V78, P641, DOI 10.1001/archopht.1967.00980030643016
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   YONEYA S, 1987, ARCH OPHTHALMOL-CHIC, V105, P681
NR 41
TC 25
Z9 26
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2001
VL 131
IS 2
BP 244
EP 253
DI 10.1016/S0002-9394(00)00788-1
PG 10
WC Ophthalmology
SC Ophthalmology
GA 400KK
UT WOS:000166870600014
PM 11228303
DA 2020-12-15
ER

PT J
AU Pignatelli, D
   Maia, M
   Castro, AR
   Magalhaes, MD
   Vivier, J
   Defaye, G
AF Pignatelli, D
   Maia, M
   Castro, AR
   Magalhaes, MD
   Vivier, J
   Defaye, G
TI Chronic stress effects on the rat adrenal cortex
SO ENDOCRINE RESEARCH
LA English
DT Article; Proceedings Paper
CT 9th Conference on the Adrenal Cortex
CY JUN 17-20, 2000
CL UNIV TORONTO, ST MICHAELS COLL, TORONTO, CANADA
SP Canadian Life Technologies Inc, Hoffman La Roche Ltd, Marcel Dekker Inc, Nikon, Qiagen Inc, Roche Diagnost, VWR Canlab
HO UNIV TORONTO, ST MICHAELS COLL
ID RECEPTOR; AXIS; ADRENOCORTICOTROPIN; GLOMERULOSA; EXPRESSION; CYTOKINES;
   HORMONE; RELEASE; CELLS
AB Under the influence of a chronic permanent stress, the adrenal function as well as the entire hypothalamic-pituitary-adrenal axis (HPAA) suffered an adaptation process that resulted in the normalization of the studied stress hormones (ACTH, corticosterone and aldosterone) with the exception of plasma renin activity which first diminished and at the end increased. ACTH receptors exhibited a dual response since after 14 days of permanent stress MC2-R showed a slight reduction while MC5-R was stilt up-regulated.
C1 Fac Med Porto, Inst Histol, Porto, Portugal.
   IBMC, Porto, Portugal.
   CEA, INSERM, U244, Dept Biol Cellulaire & Struct, Grenoble, France.
RP Pignatelli, D (corresponding author), Fac Med Porto, Inst Histol, Porto, Portugal.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Pignatelli,
   Duarte/0000-0002-5555-7004; Castro, Ana Rita/0000-0003-0524-156X
CR AGUILERA G, 1994, FRONT NEUROENDOCRIN, V15, P321, DOI 10.1006/frne.1994.1013
   AGUILERA G, 1995, J CLIN INVEST, V96, P1512, DOI 10.1172/JCI118189
   Aguilera G, 1996, ENDOCR RES, V22, P433, DOI 10.1080/07435809609043729
   Buggy JJ, 1998, BIOCHEM J, V331, P211, DOI 10.1042/bj3310211
   DALLMAN MF, 1992, J NEUROENDOCRINOL, V4, P517, DOI 10.1111/j.1365-2826.1992.tb00200.x
   GALLOPAYET N, 1985, ENDOCRINOLOGY, V117, P38, DOI 10.1210/endo-117-1-38
   GRIFFON N, 1994, BIOCHEM BIOPH RES CO, V200, P1007, DOI 10.1006/bbrc.1994.1550
   HERMUS ARMM, 1990, J STEROID BIOCHEM, V37, P867, DOI 10.1016/0960-0760(90)90434-M
   LEBRETHON MC, 1994, J CLIN INVEST, V93, P1828, DOI 10.1172/JCI117168
   Liakos P, 1998, ENDOCR RES, V24, P427, DOI 10.3109/07435809809032628
   MAKARA GB, 1971, ENDOCRINOLOGY, V88, P412, DOI 10.1210/endo-88-2-412
   MORITA TM, 1995, ENDOCR J, V42, P475, DOI 10.1507/endocrj.42.475
   PENHOAT A, 1989, P NATL ACAD SCI USA, V86, P4978, DOI 10.1073/pnas.86.13.4978
   PNEHOAT A, 1994, MOL CELL ENDOCRINOL, V103, pR7
   RIVIER C, 1989, ENDOCRINOLOGY, V125, P3096, DOI 10.1210/endo-125-6-3096
   RIVIER C, 1993, ANN NY ACAD SCI, V697, P97, DOI 10.1111/j.1749-6632.1993.tb49926.x
   SAPOLSKY R, 1987, SCIENCE, V238, P524
   VANDEKRAAN M, 1998, ENDOCRINOLOGY, V139, P2384
NR 18
TC 28
Z9 29
U1 0
U2 1
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 0743-5800
J9 ENDOCR RES
JI Endocr. Res.
PY 2000
VL 26
IS 4
BP 537
EP 544
DI 10.3109/07435800009048567
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 386MC
UT WOS:000166064600010
PM 11196426
DA 2020-12-15
ER

PT J
AU Pignatelli, D
   Maia, M
   Bento, MJ
   Sousa, S
   Azevedo, ME
   Magalhaes, MM
   Magalhaes, MC
   Vinson, GP
AF Pignatelli, D
   Maia, M
   Bento, MJ
   Sousa, S
   Azevedo, ME
   Magalhaes, MM
   Magalhaes, MC
   Vinson, GP
TI Captopril effects on the rat adrenal cortex
SO ENDOCRINE RESEARCH
LA English
DT Article; Proceedings Paper
CT 9th Conference on the Adrenal Cortex
CY JUN 17-20, 2000
CL UNIV TORONTO, ST MICHAELS COLL, TORONTO, CANADA
SP Canadian Life Technologies Inc, Hoffman La Roche Ltd, Marcel Dekker Inc, Nikon, Qiagen Inc, Roche Diagnost, VWR Canlab
HO UNIV TORONTO, ST MICHAELS COLL
ID ANGIOTENSIN-CONVERTING ENZYME; PIG ADRENOCORTICAL-CELLS; ALDOSTERONE
   SYNTHASE; OUTER CORTICES; INHIBITORS; RECEPTOR; INVITRO; SYSTEM; SODIUM;
   INNER
C1 Fac Med Porto, Inst Histol, Porto, Portugal.
   IBMC, Porto, Portugal.
   IPATIMUP, Porto, Portugal.
   Royal London Sch Med, Biochem QMW Coll, London, England.
RP Pignatelli, D (corresponding author), Fac Med Porto, Inst Histol, Porto, Portugal.
RI Maia, Mauricio/I-5892-2015; sousa, susana/D-8567-2013
OI Maia, Mauricio/0000-0002-7034-8091; sousa, susana/0000-0003-3891-3924;
   Pignatelli, Duarte/0000-0002-5555-7004
CR BLACK VH, 1987, ENDOCRINOLOGY, V120, P640, DOI 10.1210/endo-120-2-640
   Esther CR, 1996, LAB INVEST, V74, P953
   GOLDBERG MR, 1995, HYPERTENSION, V25, P37, DOI 10.1161/01.HYP.25.1.37
   HINSON JP, 1989, CONTROL HYPOTHALAMO, P147
   Kalyns'ka L. M., 1992, Fiziologicheskii Zhurnal (Kiev), V38, P3
   KEUNEKE C, 1995, CLIN EXP HYPERTENS, V17, P551, DOI 10.3109/10641969509037424
   LAIRD SM, 1988, ACTA ENDOCRINOL-COP, V119, P420, DOI 10.1530/acta.0.1190420
   LEHOUX JG, 1994, ENDOCRINOLOGY, V134, P776, DOI 10.1210/en.134.2.776
   LONN EM, 1994, CIRCULATION, V90, P2056, DOI 10.1161/01.CIR.90.4.2056
   MARTIN KO, 1982, ENDOCRINOLOGY, V110, P1749, DOI 10.1210/endo-110-5-1749
   MARTIN KO, 1983, ENDOCRINOLOGY, V112, P573
   McEwan PE, 1996, AM J PHYSIOL-ENDOC M, V271, pE192
   MCEWAN PE, 1995, ENDOCR RES, V21, P91, DOI 10.3109/07435809509030424
   MIAO P, 1982, J CELL BIOL, V94, P241, DOI 10.1083/jcb.94.2.241
   Okubo S, 1997, J CLIN INVEST, V99, P855, DOI 10.1172/JCI119249
   TREMBLAY A, 1992, ENDOCRINOLOGY, V130, P3152, DOI 10.1210/en.130.6.3152
   VINSON GP, 1995, J ENDOCRINOL, V144, P359, DOI 10.1677/joe.0.1440359
   VINSON GP, 1976, ACTA ENDOCRINOL-COP, V81, P340, DOI 10.1530/acta.0.0810340
NR 18
TC 4
Z9 4
U1 0
U2 1
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 0743-5800
J9 ENDOCR RES
JI Endocr. Res.
PY 2000
VL 26
IS 4
BP 965
EP 972
DI 10.3109/07435800009048624
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 386MC
UT WOS:000166064600067
PM 11196477
DA 2020-12-15
ER

PT J
AU Vilarinho, L
   Santorelli, FM
   Coelho, I
   Rodrigues, L
   Maia, M
   Barata, I
   Cabral, P
   Dionisio, A
   Costa, A
   Guimaraes, A
   DiMauro, S
AF Vilarinho, L
   Santorelli, FM
   Coelho, I
   Rodrigues, L
   Maia, M
   Barata, I
   Cabral, P
   Dionisio, A
   Costa, A
   Guimaraes, A
   DiMauro, S
TI The mitochondrial DNA A3243G mutation in Portugal: clinical and
   molecular studies in 5 families
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE mitochondrial DNA; A3243G; MELAS
ID LEIGH-SYNDROME; LACTIC-ACIDOSIS; EPISODES MELAS; GENE; MYOPATHY;
   ENCEPHALOMYOPATHIES; ENCEPHALOPATHY; FEATURES
AB Out of 90 Portuguese patients with mitochondrial cytopathy, six harbored the A3243G mutation in the mtDNA tRNA(Leu(UUR)) gene ('MELAS mutation'). They had heterogeneous clinical features, including myopathy with stroke-like episodes, progressive external ophthalmoparesis, diabetes mellitus, and subacute encephalopathy. Histochemical and biochemical analyses of muscle biopsies showed abundant ragged-red fibers reacting positively with the cytochrome oxidase stain, and decreased respiratory chain enzyme activities. On average, the proportion of mutated mtDNA was 67% (20-88%) in tissues from patients and 21% (0-49%) in blood from 20 maternal relatives. The proportion of mutated mitochondrial genomes in muscle did not correlate with clinical presentation or duration of disease. This study, the first in Portuguese patients, confirms the frequent occurrence of the A3243G mutation in patients with mitochondrial diseases, and emphasises the usefulness of genetic testing in reaching a correct diagnosis. (C) 1999 Elsevier Science BN. All rights reserved.
C1 Inst Med Genet, Dept Biol Clin, P-4050 Oporto, Portugal.
   Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
   Hosp Senhora Oliveria, Dept Neurol, Guimaraes, Portugal.
   Hosp S Januario, Dept Neuropediat, Macao, Portugal.
   Hosp D Estefania, Dept Neuropediat, Lisbon, Portugal.
   Cent Hosp Coimbra, Dept Neurol, Coimbra, Portugal.
   Hosp S Antonio, Div Neuropathol, Oporto, Portugal.
   Univ Roma La Sapienza, Inst Malattie Nervose & Mentali, Rome, Italy.
   Univ Pavia, UCADH, I-27100 Pavia, Italy.
   Univ Pavia, Neurol Inst C Mondino, Mol Neurobiol Lab, I-27100 Pavia, Italy.
   Neuromed IRCCS, Pozzilli, IS, Italy.
RP Vilarinho, L (corresponding author), Inst Med Genet, Dept Biol Clin, Pr Pedro Nunes,88, P-4050 Oporto, Portugal.
EM laura.vilarinho@igmjm.pt
RI Maia, Mauricio/I-5892-2015; Costa, Alfredo/J-8366-2016; Santorelli,
   Filippo M/A-2205-2014
OI Maia, Mauricio/0000-0002-7034-8091; Costa, Alfredo/0000-0001-7312-8011;
   Vilarinho, Laura/0000-0001-6186-779X; Santorelli, Filippo
   M/0000-0002-1359-9062
CR CAMPOS Y, 1995, PEDIATR NEUROL, V13, P1945
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   DiMauro S, 1998, NEUROSCIENTIST, V4, P53, DOI 10.1177/107385849800400113
   DiMauro S, 1996, ANN NEUROL, V40, P5, DOI 10.1002/ana.410400104
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   KOGA Y, 1995, AM J HUM GENET, V57, P338
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Vilarinho L, 1998, EUR NEUROL, V39, P148, DOI 10.1159/000007925
   Vilarinho L, 1997, J INHERIT METAB DIS, V20, P704, DOI 10.1023/A:1005330611147
   Vilarinho L, 1997, J MED GENET, V34, P607, DOI 10.1136/jmg.34.7.607
   Zeviani M, 1998, NEUROLOGY, V51, P1339
NR 22
TC 15
Z9 16
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAR 1
PY 1999
VL 163
IS 2
BP 168
EP 174
DI 10.1016/S0022-510X(99)00030-1
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 196DJ
UT WOS:000080293500010
PM 10371079
DA 2020-12-15
ER

PT J
AU Pignatelli, D
   Bento, MJ
   Maia, M
   Magalhaes, MM
   Magalhaes, MC
   Mason, JI
AF Pignatelli, D
   Bento, MJ
   Maia, M
   Magalhaes, MM
   Magalhaes, MC
   Mason, JI
TI Ontogeny of 3 beta-hydroxysteroid dehydrogenase expression in the rat
   adrenal gland as studied by immunohistochemistry.
SO ENDOCRINE RESEARCH
LA English
DT Article
ID ADRENOCORTICAL-CELLS; STRESS RESPONSE; ANGIOTENSIN-II; ISOMERASE;
   PITUITARY; PERIOD
AB The enzyme 3 beta-hydroxysteroid dehydrogenase plays a crucial role in the steroidogenic process in the adrenal gland. In the present study we tried to characterize its localization and developmental changes in the rat adrenal cortex during the postnatal period, using immunohistochemical methods. The development of the different zones evidenced specific particularities: the zona glomerulosa almost lacked 3 beta-HSD in the first days after birth; then, 3 beta-HSD increased, attaining a maximum around day 20 and afterwards it decreased again and remained less intense than the neighbouring zona fasciculata up until adulthood (65 days of age). The zona fasciculata was already intensely stained at birth and the expression of 3 beta-HSD increased rapidly reaching a maximum after 2 weeks of life and that level was maintained from then on. The inner part of the zona fasciculata and the zona reticularis both pf which develop postnatally were faintly immunostained before day 20. The expression of 3 beta-HSD increased after that age to become approximately as intense as in the outer zona fasciculata and so remaining until day 90. The development of the zona glomerulosa was parallel to the secretion of aldosterone. The same did not occur with the zona fasciculata as the intensity of staining during the first 14 postnatal days was accompanied by very low levels of corticosterone.
C1 Fac Med Porto, Inst Histol & Embryol, Porto, Portugal.
   IBMC, Porto, Portugal.
   IPATIMUP, Porto, Portugal.
   Univ Porto, P-4100 Porto, Portugal.
   Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland.
RP Pignatelli, D (corresponding author), Fac Med Porto, Inst Histol & Embryol, Porto, Portugal.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Pignatelli,
   Duarte/0000-0002-5555-7004
CR DOERING CH, 1969, ENDOCRINOLOGY, V85, P500, DOI 10.1210/endo-85-3-500
   DOODY KM, 1990, ENDOCRINOLOGY, V126, P2487, DOI 10.1210/endo-126-5-2487
   DUPONT E, 1990, MOL CELL ENDOCRINOL, V74, pR7, DOI 10.1016/0303-7207(90)90120-W
   LEBRETHON MC, 1994, J CLIN ENDOCR METAB, V79, P1033, DOI 10.1210/jc.79.4.1033
   NAVILLE D, 1991, ENDOCRINOLOGY, V128, P139, DOI 10.1210/endo-128-1-139
   PARKER CR, 1995, ENDOCR RES, V21, P69, DOI 10.3109/07435809509030422
   PARKER LN, 1991, ENDOCRIN METAB CLIN, V20, P71, DOI 10.1016/S0889-8529(18)30282-2
   Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281
   PIGNATELLI D, 1995, ENDOCR RES, V21, P129, DOI 10.3109/07435809509030429
   PIGNATELLI D, 1994, BIOCH STUDIES PATHOP, P129
   RAINEY WE, 1991, ENDOCR RES, V17, P281, DOI 10.1080/07435809109027202
   RAINEY WE, 1992, J STEROID BIOCHEM, V43, P847, DOI 10.1016/0960-0760(92)90311-6
   RICH BH, 1981, J CLIN ENDOCR METAB, V52, P1129, DOI 10.1210/jcem-52-6-1129
   SAPOLSKY RM, 1986, BRAIN RES REV, V11, P65, DOI 10.1016/0165-0173(86)90010-X
   SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235
   TRUDEL C, 1991, ENDOCRINOLOGY, V129, P2077, DOI 10.1210/endo-129-4-2077
   Vianello S, 1997, ENDOCRINOLOGY, V138, P3166, DOI 10.1210/en.138.8.3166
   WALKER CD, 1986, ENDOCRINOLOGY, V118, P1445, DOI 10.1210/endo-118-4-1445
   WALKER CD, 1986, ENDOCRINOLOGY, V119, P1816, DOI 10.1210/endo-119-4-1816
NR 19
TC 6
Z9 6
U1 0
U2 2
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 0743-5800
J9 ENDOCR RES
JI Endocr. Res.
PY 1999
VL 25
IS 1
BP 21
EP 27
DI 10.1080/07435809909066126
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 173RR
UT WOS:000078994000003
PM 10098590
DA 2020-12-15
ER

PT J
AU Pignatelli, D
   Bento, MJ
   Maia, M
   Magalhaes, MM
   Magalhaes, MC
   Mason, JI
AF Pignatelli, D
   Bento, MJ
   Maia, M
   Magalhaes, MM
   Magalhaes, MC
   Mason, JI
TI Ontogeny of 3 beta-hydroxysteroid dehydrogenase expression in the rat
   adrenal gland as studied by immunohistochemistry.
SO ENDOCRINE RESEARCH
LA English
DT Article; Proceedings Paper
CT 8th Conference on the Adrenal Cortex
CY JUN 13-16, 1998
CL ORFORD, CANADA
SP Univ Laval, Univ Montreal, McGill Univ, Univ Sherbrooke, Univ Toronto, Univ Sherbrooke, Ctr Res, Univ Montreal, Ctr Res, Univ Laval, Ctr Res, Duglas Hosp Res Ctr, Med Res Council Canada, Merck Frosst, Bayer, BiochemPharma
ID ADRENOCORTICAL-CELLS; ANGIOTENSIN-II
C1 Fac Med Porto, Inst Histol & Embryol, Porto, Portugal.
   Univ Porto, IPATIMUP, P-4100 Porto, Portugal.
   Univ Edinburgh, Edinburgh, Midlothian, Scotland.
   IBMC, Porto, Portugal.
RP Pignatelli, D (corresponding author), Fac Med Porto, Inst Histol & Embryol, Porto, Portugal.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Pignatelli,
   Duarte/0000-0002-5555-7004
CR NAVILLE D, 1991, ENDOCRINOLOGY, V128, P139, DOI 10.1210/endo-128-1-139
   PIGNATELLI D, 1995, ENDOCR RES, V21, P129, DOI 10.3109/07435809509030429
   PIGNATELLI D, 1994, ADV T ADDISONS DISEA, P129
   RAINEY WE, 1991, ENDOCR RES, V17, P281, DOI 10.1080/07435809109027202
   RAINEY WE, 1992, J STEROID BIOCHEM, V43, P847, DOI 10.1016/0960-0760(92)90311-6
   SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235
   TRUDEL C, 1991, ENDOCRINOLOGY, V129, P2077, DOI 10.1210/endo-129-4-2077
NR 7
TC 2
Z9 2
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 0743-5800
J9 ENDOCR RES
JI Endocr. Res.
PY 1998
VL 24
IS 3-4
BP 613
EP 614
DI 10.3109/07435809809032655
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 150ZW
UT WOS:000077697300049
PM 9888547
DA 2020-12-15
ER

PT J
AU Pignatelli, D
   Leitao, D
   Maia, M
   Schmidt, F
AF Pignatelli, D
   Leitao, D
   Maia, M
   Schmidt, F
TI DNA quantification and ploidy patterns in human adrenocortical
   neoplasms.
SO ENDOCRINE RESEARCH
LA English
DT Article; Proceedings Paper
CT 8th Conference on the Adrenal Cortex
CY JUN 13-16, 1998
CL ORFORD, CANADA
SP Univ Laval, Univ Montreal, McGill Univ, Univ Sherbrooke, Univ Toronto, Univ Sherbrooke, Ctr Res, Univ Montreal, Ctr Res, Univ Laval, Ctr Res, Duglas Hosp Res Ctr, Med Res Council Canada, Merck Frosst, Bayer, BiochemPharma
ID ADRENAL-CORTICAL CARCINOMA; FLOW CYTOMETRIC ANALYSIS; CELLULAR DNA;
   NUCLEAR-DNA; TUMORS
AB The determination of DNA ploidy and the study of the cell cycle in adrenocortical tumoral cells could help in the distinction between benign and malignant lesions and also in the prediction of the biological behaviour of these tumors. We analysed 32 cases of adrenal tissue (8 normal adrenals - N, 12 benign adenomas - A and 12 carcinomas - C). DNA was quantified by image analysis of Feulgen stained sections (Ahrens System) employing ACAS3 software. The DNA content was considered to be diploid in 70% of the N and in 67% of the A groups and in none of C. In this latter group nearly 90% were triploid or tetraploid while this did not occur in any of the A cases. The percentage of cases with a 5c-exceeding rate (5cER) above 5% was nil in the N and A groups and 100% in C. In what concerns the distribution in the cell cycle we found a very distinctive pattern between the groups as the percentage of cases in which the S-phase fraction exceeded 33% was nil in the normals, 8% in A and 83% in the C cases. In conclusion, there was a good correlation between the analysed parameters and the clinically defined groups of adrenal cortex tumors.
C1 Fac Med Porto, Dept Endocrinol, Porto, Portugal.
   Fac Med Porto, Dept Cellular Biol, Porto, Portugal.
   Univ Porto, IPATIMUP, P-4100 Porto, Portugal.
RP Pignatelli, D (corresponding author), Fac Med Porto, Dept Endocrinol, Porto, Portugal.
RI Schmitt, Fernando/A-5270-2008; Maia, Mauricio/I-5892-2015
OI Schmitt, Fernando/0000-0002-3711-8681; Maia,
   Mauricio/0000-0002-7034-8091; Pignatelli, Duarte/0000-0002-5555-7004
CR AMBERSON JB, 1987, CANCER, V59, P2091, DOI 10.1002/1097-0142(19870615)59:12<2091::AID-CNCR2820591221>3.0.CO;2-U
   BARLOGIE B, 1984, EUR J CANCER CLIN ON, V20, P1123, DOI 10.1016/0277-5379(84)90119-6
   BOWLBY LS, 1986, CANCER, V58, P1499, DOI 10.1002/1097-0142(19861001)58:7<1499::AID-CNCR2820580721>3.0.CO;2-V
   CAMUTO P, 1991, UROLOGY, V37, P380, DOI 10.1016/0090-4295(91)80273-A
   CAMUTO P M, 1989, Pediatric Pathology, V9, P551
   CIBAS ES, 1990, AM J SURG PATHOL, V14, P948, DOI 10.1097/00000478-199010000-00008
   FAVARA B E, 1991, Pediatric Pathology, V11, P521
   GICQUEL C, 1994, CLIN ENDOCRINOL, V40, P465, DOI 10.1111/j.1365-2265.1994.tb02485.x
   HAAK HR, 1993, BRIT J CANCER, V68, P151, DOI 10.1038/bjc.1993.304
   HOSAKA Y, 1987, SURGERY, V102, P1027
   SCHULTE EKW, 1991, ANAL CELL PATHOL, V3, P167
   SUZUKI T, 1992, MODERN PATHOL, V5, P224
   TAYLOR SR, 1987, CANCER, V59, P2059, DOI 10.1002/1097-0142(19870615)59:12<2059::AID-CNCR2820591216>3.0.CO;2-X
   TOMASI T, 1986, INT ACAD PATHOLOGY M, V27, P59
   WOOTEN MD, 1993, CANCER, V72, P3145, DOI 10.1002/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N
NR 15
TC 2
Z9 2
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 0743-5800
J9 ENDOCR RES
JI Endocr. Res.
PY 1998
VL 24
IS 3-4
BP 869
EP 874
DI 10.3109/07435809809032700
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 150ZW
UT WOS:000077697300093
PM 9888590
DA 2020-12-15
ER

PT J
AU Barbot, C
   Fineza, I
   Diogo, L
   Maia, M
   Melo, J
   Guimaraes, A
   Pires, MM
   Cardoso, ML
   Vilarinho, L
AF Barbot, C
   Fineza, I
   Diogo, L
   Maia, M
   Melo, J
   Guimaraes, A
   Pires, MM
   Cardoso, ML
   Vilarinho, L
TI L-2-hydroxyglutaric aciduria: Clinical, biochemical and magnetic
   resonance imaging in six Portuguese pediatric patients
SO BRAIN & DEVELOPMENT
LA English
DT Article
DE L-2-hydroxyglutaric aciduria; magnetic resonance image; ataxia; mental
   retardation; macrocephaly; neuropathology; cerebral tumor
ID ACIDEMIA; DEHYDROGENASE
AB We present clinical, biochemical and cranial magnetic resonance imaging data of six pediatric patients with L-2-hydroxyglutaric aciduria. All the children have the same ethnic origin and lived in the northern area of Portugal. Our findings reinforce the described phenotype of this rare metabolic disease with mental deficiency, severe cerebellar dysfunction, mild extrapyramidal and pyramidal symptoms, progressive macrocephaly and seizures. Magnetic resonance imaging revealed subcortical leukoencephalopathy, cerebellar atrophy and signal changes in the putamina and dentate nuclei. These were similar to those of the previous reports in all patients. The urinary excretion of L-2-hydroxyglutaric acid was variably increased in all patients. The other persistent biochemical abnormality was hyperlysinemia. We have found a strong correlation between the severity of the clinical manifestations and the extension of the lesions in the neuroimaging studies. There was no correlation between the clinical findings and the amount of urinary excretion of L-2-hydroxyglutaric acid. We report the second case in the literature of a cerebral thalamic tumor in L-2-hydroxyglutaric aciduria;neuropathological examination of the surgical biopsy demonstrated a diffuse fibrillary astrocytoma. (C) 1997 Elsevier Science B.V.
C1 HOSP PEDIAT,SERV NEUROPEDIAT,COIMBRA,PORTUGAL.
   HOSP SANTO ANTONIO,SERV NEURORADIOL,OPORTO,PORTUGAL.
   HOSP SANTO ANTONIO,SERV NEUROPATOL,OPORTO,PORTUGAL.
   INST MED GENET,OPORTO,PORTUGAL.
RP Barbot, C (corresponding author), HOSP CRIANCAS MARIA PIA,SERV NEUROPEDIAT,RUA BOAVISTA 827,P-4000 OPORTO,PORTUGAL.
RI Maia, Mauricio/I-5892-2015; Barbot, Clara/K-6378-2013
OI Maia, Mauricio/0000-0002-7034-8091; Barbot, Clara/0000-0002-5597-107X;
   Pires, Manuel/0000-0002-0046-6455; Vilarinho, Laura/0000-0001-6186-779X;
   Diogo, Luisa/0000-0003-3821-6643
CR BARTH PG, 1993, J INHERIT METAB DIS, V16, P753, DOI 10.1007/BF00711907
   BARTH PG, 1992, ANN NEUROL, V32, P66, DOI 10.1002/ana.410320111
   BARTH PG, 1995, BRAIN DEV-JPN, V17, P144, DOI 10.1016/0387-7604(95)00004-U
   Chen E, 1996, J INHERIT METAB DIS, V19, P335, DOI 10.1007/BF01799264
   DASNEVES HJC, 1996, J HIGH RES CHROMATOG, V19, P161
   DIVRY P, 1993, J INHERIT METAB DIS, V16, P505, DOI 10.1007/BF00711666
   DURAN M, 1980, J INHERIT METAB DIS, V3, P11
   JANSEN GA, 1993, BIOCHIM BIOPHYS ACTA, V1225, P53, DOI 10.1016/0925-4439(93)90121-G
   LARNAOUT A, 1994, ACTA NEUROPATHOL, V88, P367, DOI 10.1007/BF00310381
   WILCKEN B, 1993, J INHERIT METAB DIS, V16, P501, DOI 10.1007/BF00711665
NR 10
TC 61
Z9 63
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0387-7604
J9 BRAIN DEV-JPN
JI Brain Dev.
PD JUN
PY 1997
VL 19
IS 4
BP 268
EP 273
DI 10.1016/S0387-7604(97)00574-3
PG 6
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA XC342
UT WOS:A1997XC34200007
PM 9187477
DA 2020-12-15
ER

PT J
AU MAIA, M
   TAKAHASHI, H
   ADLER, K
   GARLICK, RK
   WANDS, JR
AF MAIA, M
   TAKAHASHI, H
   ADLER, K
   GARLICK, RK
   WANDS, JR
TI DEVELOPMENT OF A 2-SITE IMMUNO-PCR ASSAY FOR HEPATITIS-B SURFACE-ANTIGEN
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE 2-SITE; SENSITIVE; IMMUNO-PCR; DETECTION; HBV; ANTIGEN
ID POLYMERASE CHAIN-REACTION; MONOCLONAL-ANTIBODIES; VIRUS-DNA;
   IDENTIFICATION; TRANSMISSION; SYSTEM; SERUM
AB Hepatitis B virus (HBV) gene transcription may occur at very low levels resulting in HBsAg concentrations in serum and liver below the limit of detection by currently available immunoassays. An assay has been developed that combines the specificity of two high affinity anti-HBs monoclonal antibodies (MAb) directed against distinct and separate determinants in the 'a' domain of HBsAg with the highly sensitive polymerase chain reaction (PCR) detection method. Following capture of HBsAg present in serum samples, the second anti-HBs MAb, which is biotinylated, is added. Binding of the second antibody allows the subsequent specific binding of streptavidin and a biotinylated linear DNA molecule derived from a bluetongue virus (BTV) gene. Presence of this DNA is then detected by PCR using BTV-specific primers. The PCR product is quantified by a liquid-phase oligonucleotide enzymatic assay, which further increases the sensitivity of the technique. The use of a two-site MAb capture and PCR detection system for HBsAg was shown to greatly enhance the specificity and sensitivity of the assay and detect as little as 0.5 pg of HBsAg in serum samples. It is suggested that the principles of this technique could be applied to measure other low level viral antigens in serum and biological samples.
C1 HARVARD UNIV, SCH MED, MASSACHUSETTS GEN HOSP CANC CTR, MOLEC HEPATOL LAB, BOSTON, MA 02129 USA.
   HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, GASTROINTESTINAL UNIT, BOSTON, MA 02129 USA.
   DUPONT CO INC, BOSTON, MA 02118 USA.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
FU NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R37CA035711, R01CA035711, R37CA035711, R01CA035711,
   R01CA035711, R01CA035711, R37CA035711, R01CA035711, R37CA035711,
   R01CA035711, R01CA035711, R01CA035711, R37CA035711, R01CA035711,
   R01CA035711, R01CA035711, R37CA035711, R01CA035711, R01CA035711,
   R37CA035711, R01CA035711, R01CA035711, R37CA035711, R37CA035711] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND
   ALCOHOLISMUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse
   & Alcoholism (NIAAA) [R01AA008169, R01AA008169, R01AA008169,
   R01AA008169, R01AA008169, R01AA008169, R01AA008169, R01AA008169,
   R01AA008169, R01AA008169, R01AA008169, R01AA008169, R01AA008169,
   R01AA008169, R01AA008169, R01AA008169, R01AA008169, R01AA008169,
   R01AA008169, R01AA008169, R01AA008169, R01AA008169, R01AA008169,
   R01AA008169] Funding Source: NIH RePORTER; NCI NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [CA-35711] Funding Source:
   Medline; NIAAA NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Alcohol Abuse & Alcoholism (NIAAA) [AA-08169, AA-00048] Funding
   Source: Medline
CR ADLER K, 1992, ADAPTABLE MICROPLATE
   BENPORATH E, 1985, J CLIN INVEST, V76, P1338, DOI 10.1172/JCI112108
   BENPORATH E, 1986, PROGR LIVER DISEASES, V8, P403
   BORTOLOTTI F, 1990, GASTROENTEROLOGY, V99, P805, DOI 10.1016/0016-5085(90)90972-4
   BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503
   DIENES HP, 1990, GASTROENTEROLOGY, V98, P1017, DOI 10.1016/0016-5085(90)90028-Y
   HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424
   KANEKO S, 1990, GASTROENTEROLOGY, V99, P799
   LIANG TJ, 1989, J CLIN INVEST, V84, P1367, DOI 10.1172/JCI114308
   LIANG TJ, 1990, HEPATOLOGY, V12, P204, DOI 10.1002/hep.1840120205
   LIANG TJ, 1994, J MED VIROL, V42, P151, DOI 10.1002/jmv.1890420210
   PARKER CW, 1990, METHOD ENZYMOL, V182, P700
   PARKER CW, 1976, RADIOIMMUNOASSAY BIO
   PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q
   PORATH EB, 1985, TRANSFUSION, V25, P10, DOI 10.1046/j.1537-2995.1985.25185116491.x
   RUZICKA V, 1993, SCIENCE, V260, P698, DOI 10.1126/science.8480182
   SANO T, 1992, SCIENCE, V258, P120, DOI 10.1126/science.1439758
   SHOREY J, 1981, HEPATOLOGY, V1, P546
   SUTER M, 1986, IMMUNOL LETT, V13, P313, DOI 10.1016/0165-2478(86)90064-7
   TAKAHASHI H, 1988, J IMMUNOL METHODS, V112, P191, DOI 10.1016/0022-1759(88)90357-2
   THIERS V, 1988, LANCET, V2, P1273
   WANDS JR, 1981, GASTROENTEROLOGY, V80, P225
   WANDS JR, 1986, P NATL ACAD SCI USA, V83, P6608, DOI 10.1073/pnas.83.17.6608
   WHETSELL AJ, 1992, J CLIN MICROBIOL, V30, P845, DOI 10.1128/JCM.30.4.845-853.1992
NR 24
TC 43
Z9 49
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD APR
PY 1995
VL 52
IS 3
BP 273
EP 286
DI 10.1016/0166-0934(94)00145-7
PG 14
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA QR246
UT WOS:A1995QR24600004
PM 7601903
DA 2020-12-15
ER

PT J
AU HE, XS
   WANG, LF
   DOI, RH
   MAIA, M
   OSBURN, BI
   CHUANG, RY
AF HE, XS
   WANG, LF
   DOI, RH
   MAIA, M
   OSBURN, BI
   CHUANG, RY
TI EXPRESSION OF A FULL-LENGTH NONSTRUCTURAL PROTEIN NS1 OF BLUETONGUE
   VIRUS SEROTYPE-17 IN ESCHERICHIA-COLI
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
ID UNITED-STATES; RECOMBINANT BACULOVIRUSES; GENOME SEGMENTS; INFECTED
   CELLS; INSECT CELLS; RNA; NS1-GENE; SEQUENCE; TUBULES
C1 UNIV CALIF DAVIS,DEPT BIOCHEM & BIOPHYS,DAVIS,CA 95616.
   UNIV CALIF DAVIS,DEPT VET PATHOL,DAVIS,CA 95616.
   UNIV CALIF DAVIS,DEPT PHARMACOL & TOXICOL,DAVIS,CA 95616.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR BARBER TL, 1979, AM J VET RES, V40, P1654
   Ben-Bassat A., 1987, NATURE, V326, P315
   EATON BT, 1988, VIROLOGY, V163, P527, DOI 10.1016/0042-6822(88)90293-0
   GIBBS EPJ, 1983, AM J VET RES, V44, P2226
   HARLOW E, 1988, ANTIBODIES LABORATOR
   HUISMANS H, 1987, VIROLOGY, V158, P373, DOI 10.1016/0042-6822(87)90209-1
   HUISMANS H, 1987, J VIROL, V61, P3589, DOI 10.1128/JVI.61.11.3589-3595.1987
   HUISMANS H, 1979, VIROLOGY, V92, P385, DOI 10.1016/0042-6822(79)90143-0
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035
   MECHAM JO, 1986, J GEN VIROL, V67, P2617, DOI 10.1099/0022-1317-67-12-2617
   MERTENS PPC, 1984, VIROLOGY, V135, P207, DOI 10.1016/0042-6822(84)90131-4
   ROY P, 1989, VIRUS RES, V13, P179, DOI 10.1016/0168-1702(89)90015-4
   STUDIER FW, 1990, METHOD ENZYMOL, V185, P60
   UNGER RE, 1988, VIROLOGY, V167, P296, DOI 10.1016/0042-6822(88)90083-9
   URAKAWA T, 1988, J VIROL, V62, P3919, DOI 10.1128/JVI.62.11.3919-3927.1988
   VERWOERD DW, 1970, J VIROL, V5, P1
   VERWOERD DW, 1972, J VIROL, V10, P783, DOI 10.1128/JVI.10.4.783-794.1972
   WANG LF, 1989, BIOCHEM BIOPH RES CO, V162, P892, DOI 10.1016/0006-291X(89)92393-0
   WANG LF, 1989, NUCLEIC ACIDS RES, V17, P8002, DOI 10.1093/nar/17.19.8002
NR 20
TC 3
Z9 3
U1 0
U2 2
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 31
PY 1991
VL 180
IS 2
BP 994
EP 1001
DI 10.1016/S0006-291X(05)81164-7
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA GM638
UT WOS:A1991GM63800078
PM 1659409
DA 2020-12-15
ER

PT J
AU DOSSANTOS, MR
   TANAKA, A
   MIRANDA, MCS
   RIBEIRO, MG
   MAIA, M
   SUZUKI, K
AF DOSSANTOS, MR
   TANAKA, A
   MIRANDA, MCS
   RIBEIRO, MG
   MAIA, M
   SUZUKI, K
TI GM2-GANGLIOSIDOSIS-B1 VARIANT - ANALYSIS OF BETA-HEXOSAMINIDASE
   ALPHA-GENE MUTATIONS IN 11 PATIENTS FROM A DEFINED REGION IN PORTUGAL
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
AB The G(M2)-gangliosidosis B1 variant occurs at an exceptionally high frequency in the northern part of Portugal.  In most patients, the disease manifests itself as a juvenile form, as opposed to the late-infantile form described for many patients from other parts of the world.  We have analyzed the beta-hexosaminidase alpha-gene in 11 patients, as well as in some relatives, in order to characterize the underlying abnormalities.  They were screened for the two previously identified mutations responsible for the B1 variant phenotype (G533 --> A, also designated as the "DN allele," and C532 --> T) by PCR amplification of an 800-bp DNA fragment and subsequent dot-blot hybridization with allele-specific oligonucleotides. The fragment amplified from one patient was also subcloned and sequenced.   Ten patients, constituting a clinically and biochemically homogeneous group, were found to be homozygous for the DN allele.  The other, whose clinical profile more resembled the late-infantile phenotype often described in the literature, was a compound heterozygote carrying the DN allele and another, as yet unidentified, abnormal allele.  Our results, corroborated by previously published data, suggest that homozygotes and compound heterozygotes for the DN allele may be distinguishable at the phenotypic level, depending on the nature of the abnormality in the other allele.  A common ancestral origin for the DN allele can also be postulated.
C1 UNIV N CAROLINA,SCH MED,BRAIN & DEV RES CTR,CB 7250,CHAPEL HILL,NC 27599.
RI sa Miranda, Maria Clara/K-3920-2013; Maia, Mauricio/I-5892-2015;
   Ribeiro, Maria Gil/B-6467-2013
OI sa Miranda, Maria Clara/0000-0003-0123-5525; Maia,
   Mauricio/0000-0002-7034-8091; Ribeiro, Maria Gil/0000-0001-9365-6057;
   Santos, Rosario/0000-0002-8594-6377
FU NICHD NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [HD-03110] Funding
   Source: Medline; NINDS NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [NS-24289, NS-28997] Funding
   Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD
   HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110, P30HD003110,
   P30HD003110, P30HD003110, P30HD003110, P30HD003110] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [R01NS024289, R01NS024289, R01NS024289, R01NS028997,
   R01NS024289, R01NS028997, R01NS024289, R01NS024289, R01NS024289,
   R01NS024289, R01NS024289, R01NS024289, R01NS024289, R01NS028997,
   R01NS024289, R01NS024289, R01NS024289, R01NS024289, R01NS024289,
   R01NS028997] Funding Source: NIH RePORTER
CR BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963
   DOSSANTOS MR, 1990, DEC INT WORKSH LAT O
   KYTZIA HJ, 1983, EMBO J, V2, P1201, DOI 10.1002/j.1460-2075.1983.tb01567.x
   MAIA M, 1990, NEUROPEDIATRICS, V21, P18, DOI 10.1055/s-2008-1071451
   MANIATIS T, 1982, MOL CLONING
   NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094
   OHNO K, 1988, J NEUROCHEM, V50, P316, DOI 10.1111/j.1471-4159.1988.tb13266.x
   RIBEIRO MG, UNPUB BIOCH CHARACTE
   Sandhoff K., 1989, METABOLIC BASIS INHE, P1807
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SUZUKI K, IN PRESS DEV NEUROSC
   TANAKA A, 1990, AM J HUM GENET, V46, P329
   TANAKA A, 1988, BIOCHEM BIOPH RES CO, V156, P1015, DOI 10.1016/S0006-291X(88)80945-8
NR 13
TC 38
Z9 40
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD OCT
PY 1991
VL 49
IS 4
BP 886
EP 890
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA GG665
UT WOS:A1991GG66500021
PM 1832817
DA 2020-12-15
ER

PT J
AU RIBEIRO, MG
   PINTO, RA
   DOSSANTOS, MR
   MAIA, M
   MIRANDA, MCS
AF RIBEIRO, MG
   PINTO, RA
   DOSSANTOS, MR
   MAIA, M
   MIRANDA, MCS
TI BIOCHEMICAL-CHARACTERIZATION OF BETA-HEXOSAMINIDASE IN DIFFERENT
   BIOLOGICAL SPECIMENS FROM 11 PATIENTS WITH GM2-GANGLIOSIDOSIS-B1 VARIANT
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID GM2 GANGLIOSIDOSIS; SUBSTRATE
AB GM2-gangliosidosis B1 variant is thought to be a rare disorder with a wide geographical and ethnic distribution.  We report the biochemical findings obtained in different specimens from a group of 11 B1 variant patients originating from the north of Portugal.  The biochemical data obtained seem to indicate that only one of these patients is a genetic compound presenting a clinical and biochemical pattern similar to the majority of B1 variant patients described in the literature, but somewhat different from the profile presented by the other patients reported here, who are homozygous for the 'DN-allele'.
C1 HOSP MARIA PIA,OPORTO,PORTUGAL.
RP RIBEIRO, MG (corresponding author), INST GENET MED JACINTO MAGALHAES,OPORTO,PORTUGAL.
RI Maia, Mauricio/I-5892-2015; Ribeiro, Maria Gil/B-6467-2013; sa Miranda,
   Maria Clara/K-3920-2013; Santos, Rosario/AAZ-7103-2020
OI Maia, Mauricio/0000-0002-7034-8091; Ribeiro, Maria
   Gil/0000-0001-9365-6057; sa Miranda, Maria Clara/0000-0003-0123-5525;
   Santos, Rosario/0000-0002-8594-6377
CR BECCARI T, 1987, BIOCHEM J, V244, P801, DOI 10.1042/bj2440801
   GOEBEL HH, 1989, PEDIATR RES, V25, P89, DOI 10.1203/00006450-198901000-00019
   JONSSON LMV, 1987, EUR J BIOCHEM, V164, P171, DOI 10.1111/j.1432-1033.1987.tb11008.x
   KYTZIA HJ, 1983, EMBO J, V2, P1201, DOI 10.1002/j.1460-2075.1983.tb01567.x
   KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MAGALHAES J, 1984, CLIN CHIM ACTA, V141, P111, DOI 10.1016/0009-8981(84)90003-2
   MAIA M, 1990, NEUROPEDIATRICS, V21, P18, DOI 10.1055/s-2008-1071451
   NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094
   OHNO K, 1988, J NEUROCHEM, V50, P316, DOI 10.1111/j.1471-4159.1988.tb13266.x
   POENARU L, 1973, CLIN CHIM ACTA, V43, P439
   Sandhoff K., 1989, METABOLIC BASIS INHE, P1807
   TANAKA A, 1990, AM J HUM GENET, V46, P329
NR 13
TC 9
Z9 9
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0141-8955
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PY 1991
VL 14
IS 5
BP 715
EP 720
DI 10.1007/BF01799940
PG 6
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA GD652
UT WOS:A1991GD65200010
PM 1838125
DA 2020-12-15
ER

PT J
AU MAIA, M
   ALVES, D
   RIBEIRO, G
   PINTO, R
   MIRANDA, MCS
AF MAIA, M
   ALVES, D
   RIBEIRO, G
   PINTO, R
   MIRANDA, MCS
TI JUVENILE GM2 GANGLIOSIDOSIS VARIANT-B1 - CLINICAL AND BIOCHEMICAL-STUDY
   IN 7 PATIENTS
SO NEUROPEDIATRICS
LA English
DT Article
C1 INST GENET MED,OPORTO,PORTUGAL.
RP MAIA, M (corresponding author), HOSP CRIANCAS MARIA PIA,R BOAVISTA 827,P-4000 OPORTO,PORTUGAL.
RI Maia, Mauricio/I-5892-2015; sa Miranda, Maria Clara/K-3920-2013;
   Ribeiro, Maria Gil/B-6467-2013
OI Maia, Mauricio/0000-0002-7034-8091; sa Miranda, Maria
   Clara/0000-0003-0123-5525; Ribeiro, Maria Gil/0000-0001-9365-6057
CR BECCARI T, 1987, BIOCHEM J, V244, P801, DOI 10.1042/bj2440801
   BESLEY GTN, 1987, J INHERIT METAB DIS, V10, P403, DOI 10.1007/BF01799987
   CHARROW J, 1985, CLIN GENET, V27, P78
   CONZELMANN E, 1985, PEDIATR RES, V19, P1220, DOI 10.1203/00006450-198511000-00022
   GOLDIE WD, 1977, ANN NEUROL, V2, P156, DOI 10.1002/ana.410020212
   GOLDMAN JE, 1980, ACTA NEUROPATHOL, V52, P189, DOI 10.1007/BF00705807
   INUI K, 1983, AM J HUM GENET, V35, P551
   INUI K, 1984, CLIN GENET, V26, P318
   JOHNSON WG, 1980, AM J HUM GENET, V32, P508
   KYTZIA HJ, 1983, EMBO J, V2, P1201, DOI 10.1002/j.1460-2075.1983.tb01567.x
   LI SC, 1981, BIOCHEM BIOPH RES CO, V101, P479, DOI 10.1016/0006-291X(81)91285-7
   LI YT, 1983, AM J HUM GENET, V35, P520
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MAIA M, 1985, NEUROPEDIATRICS, V16, P180
   NAKAGAWA S, 1977, CLIN CHIM ACTA, V75, P181, DOI 10.1016/0009-8981(77)90189-9
   OBRIEN JS, 1978, AM J HUM GENET, V30, P602
   OBRIEN JS, 1983, METABOLIC BASIS INHE, P945
   OHNO K, 1988, J NEUROCHEM, V50, P316, DOI 10.1111/j.1471-4159.1988.tb13266.x
   POENARU L, 1973, CLIN CHIM ACTA, V43, P439
   SANDHOFF K, 1979, HUM GENET, V50, P107, DOI 10.1007/BF00390234
   SKOOG WA, 1956, BLOOD, V11, P436, DOI 10.1182/blood.V11.5.436.436
   STIRLING JL, 1984, METHODS ENZYMATIC AN, V4
   SUZUKI K, 1970, NEUROLOGY, V20, P190, DOI 10.1212/WNL.20.2.190
   TANAKA A, 1988, BIOCHEM BIOPH RES CO, V156, P1015, DOI 10.1016/S0006-291X(88)80945-8
NR 24
TC 23
Z9 24
U1 0
U2 0
PU HIPPOKRATES VERLAG GMBH
PI STITTGART
PA PO BOX 30 05 04 RUDIGERSTRASSE 14, 70469 STITTGART, GERMANY
SN 0174-304X
J9 NEUROPEDIATRICS
JI Neuropediatrics
PD FEB
PY 1990
VL 21
IS 1
BP 18
EP 23
DI 10.1055/s-2008-1071451
PG 6
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA CR630
UT WOS:A1990CR63000004
PM 2138256
DA 2020-12-15
ER

PT J
AU MAIA, M
   PIRES, MM
   GUIMARAES, A
AF MAIA, M
   PIRES, MM
   GUIMARAES, A
TI GIANT AXONAL DISEASE - REPORT OF 3 CASES AND REVIEW OF THE LITERATURE
SO NEUROPEDIATRICS
LA English
DT Article
C1 HOSP GERAL SANTO ANTONIO,SERV NEUROL,PORTO,PORTUGAL.
RP MAIA, M (corresponding author), HOSP CRIANCAS MARIA PIA,SERV NEUROPEDIAT,R BOAVISTA 827,P-4000 PORTO,PORTUGAL.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Pires, Manuel/0000-0002-0046-6455
CR ASBURY AK, 1972, ACTA NEUROPATHOL, V20, P237, DOI 10.1007/BF00686905
   BERG BO, 1972, PEDIATRICS, V49, P894
   BOLTSHAUSER E, 1977, J NEUROL SCI, V31, P269, DOI 10.1016/0022-510X(77)90112-5
   CARPENTE.S, 1974, ARCH NEUROL-CHICAGO, V31, P312, DOI 10.1001/archneur.1974.00490410060005
   CARPENTER S, 1974, NEUROLOGY MINN, V23, P429
   DOLLEY JM, 1981, CAN J NEUROL SCI, V8, P321
   FOIS A, 1985, EUR J PEDIATR, V144, P274, DOI 10.1007/BF00451961
   GAMBARELLI D, 1977, ACTA NEUROPATHOL, V39, P261, DOI 10.1007/BF00691706
   IGISU H, 1975, NEUROLOGY, V25, P717, DOI 10.1212/WNL.25.8.717
   JEDRZEJOWSKA H, 1977, ACTA NEUROPATHOL, V37, P213
   JONES Z, 1979, J NEUROPATHOL EXP NE, V38, P324
   KINNEY RB, 1985, ARCH PATHOL LAB MED, V109, P639
   KOCH T, 1977, ANN NEUROL, V1, P438, DOI 10.1002/ana.410010507
   LARBRISSEAU A, 1979, NEUROPADIATRIE, V10, P76, DOI 10.1055/s-0028-1085316
   MIZUNO Y, 1979, ARCH NEUROL-CHICAGO, V36, P107, DOI 10.1001/archneur.1979.00500380077010
   OUVRIER RA, 1974, P AUST ASS NEUROL, V2, P137
   PEIFFER J, 1977, ACTA NEUROPATHOL, V40, P213, DOI 10.1007/BF00691956
   PENA SDJ, 1982, MUSCLE NERVE, V5, P166, DOI 10.1002/mus.880050215
   PRINEAS JW, 1976, J NEUROPATH EXP NEUR, V35, P458, DOI 10.1097/00005072-197607000-00006
   Spencer P S, 1975, Trans Am Neurol Assoc, V100, P148
   Spencer P S, 1974, Can J Neurol Sci, V1, P152
   SPENCER PS, 1975, ARCH NEUROL-CHICAGO, V32, P219, DOI 10.1001/archneur.1975.00490460035002
   TAKEBE Y, 1981, NEUROPEDIATRICS, V12, P392, DOI 10.1055/s-2008-1059670
   WATTERS G, 1978, CAN J NEUROL SCI, V5, P340
NR 24
TC 19
Z9 19
U1 1
U2 1
PU HIPPOKRATES VERLAG GMBH
PI STITTGART
PA PO BOX 30 05 04 RUDIGERSTRASSE 14, 70469 STITTGART, GERMANY
SN 0174-304X
J9 NEUROPEDIATRICS
JI Neuropediatrics
PD FEB
PY 1988
VL 19
IS 1
BP 10
EP 15
DI 10.1055/s-2008-1052394
PG 6
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA M3869
UT WOS:A1988M386900003
PM 3283594
DA 2020-12-15
ER

PT J
AU PIRES, MM
   GUIMARAES
   MAIA, M
AF PIRES, MM
   GUIMARAES
   MAIA, M
TI GIANT AXONAL DISEASE - A GENERALIZED AND GENETICALLY-DETERMINED DISORDER
SO NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
LA English
DT Meeting Abstract
C1 HOSP ST ANTONIO,SERV NEUROL,P-4000 PORTO,PORTUGAL.
   HOSP MARIA PIA,SERV NEUROPEDIAT,P-4000 PORTO,PORTUGAL.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR ASBURY, 1972, ACTA NEUROPATHOL, V40, P237
   PEIFFER J, 1977, ACTA NEUROPATHOL, V40, P213, DOI 10.1007/BF00691956
NR 2
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0305-1846
J9 NEUROPATH APPL NEURO
JI Neuropathol. Appl. Neurobiol.
PD NOV-DEC
PY 1987
VL 13
IS 6
BP 495
EP 495
PG 1
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA M0945
UT WOS:A1987M094500024
DA 2020-12-15
ER

PT J
AU MAIA, M
   GUIMARAES, A
AF MAIA, M
   GUIMARAES, A
TI FLOPPY BABY, EARLY FITS, GLOBAL REGRESSION WITH PYRAMIDAL AND EYE SIGNS
   AND A MITOCHONDRIAL MYOPATHY - A NEW SYNDROME
SO NEUROPEDIATRICS
LA English
DT Meeting Abstract
C1 HOSP MARIA PIA,PORTO,PORTUGAL.
   HOSP ST ANTONIO,PORTO,PORTUGAL.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU HIPPOKRATES VERLAG GMBH
PI STITTGART
PA PO BOX 30 05 04 RUDIGERSTRASSE 14, 70469 STITTGART, GERMANY
SN 0174-304X
J9 NEUROPEDIATRICS
JI Neuropediatrics
PD MAY
PY 1987
VL 18
IS 2
BP 115
EP 115
PG 1
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA H4618
UT WOS:A1987H461800020
DA 2020-12-15
ER

PT J
AU MAIA, M
   BARBOT, C
   BARBOSA, C
   ALVES, D
   BOTELHO, B
AF MAIA, M
   BARBOT, C
   BARBOSA, C
   ALVES, D
   BOTELHO, B
TI RETT SYNDROME AND ITS LIMITS - STUDY OF 15 CASES
SO REVUE NEUROLOGIQUE
LA French
DT Meeting Abstract
C1 HOSP MARIA PIA,PORTO,PORTUGAL.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MASSON EDITEUR
PI PARIS 06
PA 120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE
SN 0035-3787
J9 REV NEUROL
JI Rev. Neurol.
PY 1987
VL 143
IS 4
BP 318
EP 318
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA J2959
UT WOS:A1987J295900032
DA 2020-12-15
ER

PT J
AU MAIA, M
   BARBOT, C
AF MAIA, M
   BARBOT, C
TI PANORAMA OF CNS DEGENERATIVE DISEASES OF NORTHERN AREA OF PORTUGAL
SO NEUROPEDIATRICS
LA English
DT Meeting Abstract
C1 HOSP CRIANCAS MARIA PIA,PORTO,PORTUGAL.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR DYKEN P, 1983, ANN NEUROL, V13, P351, DOI 10.1002/ana.410130402
   HAGBERG B, 1983, JUN EFCNS NOORDW M
NR 2
TC 1
Z9 1
U1 0
U2 0
PU HIPPOKRATES VERLAG GMBH
PI STITTGART
PA PO BOX 30 05 04 RUDIGERSTRASSE 14, 70469 STITTGART, GERMANY
SN 0174-304X
J9 NEUROPEDIATRICS
JI Neuropediatrics
PY 1985
VL 16
IS 3
BP 180
EP 180
PG 1
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA APL81
UT WOS:A1985APL8100060
DA 2020-12-15
ER

PT J
AU BEHAN, WMH
   MAIA, M
AF BEHAN, WMH
   MAIA, M
TI STRUMPELLS FAMILIAL SPASTIC PARAPLEGIA - GENETICS AND NEUROPATHOLOGY
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
C1 RADCLIFFE INFIRM, DEPT NEUROPATHOL, OXFORD, ENGLAND.
   MRC, POPULATION GENET UNIT, OXFORD, ENGLAND.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR APPEL L, 1952, Acta Neurol Psychiatr Belg, V52, P129
   Aring CD, 1942, BRAIN, V65, P34, DOI 10.1093/brain/65.1.34
   BAAR HS, 1966, AM J MENT DEF, V71, P13
   BELL J, 1939, TREASURY HUMAN INHER, V4
   BICKERSTAFF ER, 1950, J NEUROL NEUROSUR PS, V13, P134, DOI 10.1136/jnnp.13.2.134
   BISCHOFF E, 1902, JB PSYCHIATRIE NEURO, V22, P109
   CAVANAGH JB, 1954, J NEUROL NEUROSUR PS, V17, P163, DOI 10.1136/jnnp.17.3.163
   DICK AP, 1953, LANCET, V264, P921
   Farago I, 1947, MON PSYCHIATR NEUROL, V114, P161
   FENTON JCB, 1955, J PATHOL BACTERIOL, V69, P181, DOI 10.1002/path.1700690124
   FONTAINE G, 1969, J NEUROL SCI, V8, P183, DOI 10.1016/0022-510X(69)90049-5
   GARLAND HG, 1950, J NEUROL NEUROSUR PS, V13, P130, DOI 10.1136/jnnp.13.2.130
   Greenfield JG, 1954, SPINO CEREBELLAR DEG
   GREENFIELD JG, 1963, NEUROPATHOLOGY
   JAKOB C, 1909, RIV SOC MED ARGENT, V17, P665
   JATZKEWITZ H, 1968, SOME RECENT ADV INBO
   JEQUIER M, 1947, Arch Julius Klaus Stift Vererbungsforsch Sozialanthropol Rassenhyg, V22, P129
   JOHNSTON AW, 1962, AM J HUM GENET, V14, P83
   Kahlstorf A, 1937, Z GESAMTE NEUROL PSY, V159, P774, DOI 10.1007/BF02870699
   KIRIKAE T, 1968, Clinical Neurology (Tokyo), V8, P589
   NEWMARK L, 1904, DTSCH Z NERVENHEILK, V27, P1
   NEWMARK L, 1911, DTSCH Z NERVENH, V42, P419
   NEWMARK L, 1906, DTSCH Z NERVENHEILK, V31, P224
   Ozsvath K, 1968, Dtsch Z Nervenheilkd, V193, P287
   POSER CM, 1957, J NEUROPATH EXP NEUR, V16, P209, DOI 10.1097/00005072-195704000-00002
   Raymond F, 1908, LANCET, V1, P1859
   RAYMOND F, 1909, REV NEUROL, V17, P781
   Rhein JHW, 1916, J NERV MENT DIS, V44, P224, DOI 10.1097/00005053-191609000-00004
   Rhein JHW, 1916, J NERV MENT DIS, V44, P115, DOI 10.1097/00005053-191608000-00004
   SCHUT J W, 1951, J Neuropathol Clin Neurol, V1, P183
   SCHUT JW, 1950, ARCH NEURO PSYCHIATR, V63, P535, DOI 10.1001/archneurpsyc.1950.02310220002001
   SCHWARZ GA, 1952, AMA ARCH NEUROL PSY, V68, P655, DOI 10.1001/archneurpsyc.1952.02320230081010
   SCHWARZ GA, 1956, ARCH NEURO PSYCHIATR, V75, P144, DOI 10.1001/archneurpsyc.1956.02330200038005
   SILVER JR, 1966, J NEUROL NEUROSUR PS, V29, P135, DOI 10.1136/jnnp.29.2.135
   STRUMPELL A, 1886, ARCH PSYCHIAT NERVEN, V17, P227
   Strumpell A., 1880, ARCH PSYCHIAT NERVEN, V10, P676, DOI [DOI 10.1007/BF02224539, 10.1007/bf02054821]
   Strumpell A., 1904, DTSCH Z NERVENHEILK, V27, P291, DOI 10.1007/bf01667115
   VAN BOGAERT L, 1952, Acta Neurol Psychiatr Belg, V52, P795
NR 38
TC 166
Z9 169
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
EI 1468-330X
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PY 1974
VL 37
IS 1
BP 8
EP 20
DI 10.1136/jnnp.37.1.8
PG 13
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA S1770
UT WOS:A1974S177000002
PM 4813430
OA Green Published, Bronze
DA 2020-12-15
ER

PT J
AU MAIA, M
AF MAIA, M
TI SJOGREN-LARSSON SYNDROME IN 2 SIBS WITH PERIPHERAL-NERVE INVOLVEMENT AND
   BISALBUMINEMIA
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
C1 HOSP ST ANTONIO,DEPT NEUROL,OPORTO,PORTUGAL.
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR BAAR H S, 1960, J Maine Med Assoc, V51, P189
   BLUMEL J, 1958, AMA J DIS CHILD, V96, P724, DOI 10.1001/archpedi.1958.02060060726013
   FRANCESCHETTI A, 1963, CONFIN NEUROL, V23, P334
   FRANGLEN G, 1960, LANCET, V1, P307
   FRASER GR, 1959, LANCET, V1, P1023
   GOMESDACOSTA MG, 1963, REV PORT PEDIAT PUER, V26, P6
   HEIJER A, 1965, ARCH DERMATOL, V92, P545, DOI 10.1001/archderm.92.5.545
   LINK JK, 1958, J PEDIATR-US, V52, P712, DOI 10.1016/S0022-3476(58)80271-1
   RICHARDS BW, 1960, BRIT MED J, V2, P714, DOI 10.1136/bmj.2.5200.714
   RICHARDS BW, 1972, HDB CLINICAL NEUROLO, V13, P466
   SANDOR G, 1965, NATURE, V208, P1222, DOI 10.1038/2081222a0
   SCHNYDER UW, 1970, ARCH DERMATOL, V102, P240, DOI 10.1001/archderm.102.3.240
   SELMANOWITZ VJ, 1967, AM J MED, V42, P412, DOI 10.1016/0002-9343(67)90269-0
   SJOGREN T, 1956, Acta Genet Stat Med, V6, P80
   SJOGREN T, 1957, ACTA PSYCHIATRI S113, V32
   SYLVESTER PE, 1969, J MENT DEFIC RES, V13, P267
   TARNOKY AL, 1970, NATURE, V225, P742, DOI 10.1038/225742a0
   WEITKAMP LR, 1967, ACTA GENET STAT MED, V17, P399
   WELLS RS, 1965, ARCH DERMATOL, V92, P1, DOI 10.1001/archderm.92.1.1
   ZALESKI WA, 1962, CAN MED ASSOC J, V86, P951
NR 20
TC 8
Z9 8
U1 0
U2 0
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PY 1974
VL 37
IS 12
BP 1306
EP 1315
DI 10.1136/jnnp.37.12.1306
PG 10
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA V6416
UT WOS:A1974V641600003
PM 4448995
OA Green Published, Bronze
DA 2020-12-15
ER

PT J
AU MAIA, MO
   GUEDESDECARVALH.RA
AF MAIA, MO
   GUEDESDECARVALH.RA
TI CHROMATOGRAPHIE SUR PAPIER DE LANTHANIDES
SO JOURNAL OF CHROMATOGRAPHY
LA English
DT Article
RI Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
CR DUKE FR, 1951, J AM CHEM SOC, V73, P5179, DOI 10.1021/ja01155a051
   GUEDESDECARVA. R, 1960, J CHROMATOGRAPHY, V4, P353
   GUEDESDECARVALH.R, 1957, ANAL CHIM ACTA, V16, P555
   LEDERER M, 1956, ANAL CHIM ACTA, V15, P122, DOI 10.1016/0003-2670(56)80024-X
   LEDERER M, 1956, ANAL CHIM ACTA, V15, P46, DOI 10.1016/0003-2670(56)80009-3
   LEDERER M, 1953, CR HEBD ACAD SCI, V236, P1557
   POLLARD FH, 1951, J CHEM SOC, P1863, DOI 10.1039/jr9510001863
   POLLARD FH, 1954, J CHEM SOC, P3435, DOI 10.1039/jr9540003435
   POLLARD FH, 1952, J CHEM SOC, P4730, DOI 10.1039/jr9520004730
   WENDLANDT WW, 1960, TEXAS J SCI, V12, P61
NR 10
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0021-9673
J9 J CHROMATOGR
PY 1962
VL 8
IS 2
BP 245
EP &
DI 10.1016/S0021-9673(01)99255-6
PG 0
WC Chemistry, Analytical
SC Chemistry
GA 4271B
UT WOS:A19624271B00012
PM 14468481
DA 2020-12-15
ER

EF